FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Wahlster, S
Williamson, C
Shafi, M
Westover, M
AF Wahlster, Sarah
Williamson, Craig
Shafi, Mouhsin
Westover, M.
TI Sensitivity of Compressed Spectral Array Displays for Seizures and Other
Critical Patterns in Adult Long Term EEG Monitoring
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Wahlster, Sarah; Williamson, Craig; Westover, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Shafi, Mouhsin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P01021
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600178
ER
PT J
AU Wahlster, S
Berkowitz, A
Zepeda, R
Sagar, V
Lyons, J
Klein, J
Mejia, N
AF Wahlster, Sarah
Berkowitz, Aaron
Zepeda, Rodrigo
Sagar, Vanya
Lyons, Jennifer
Klein, Joshua
Mejia, Nicte
TI Neurology and Global Health: Initiatives Led by Residents and Staff from
the Partners Neurology Program
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Wahlster, Sarah; Berkowitz, Aaron; Sagar, Vanya] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wahlster, Sarah; Berkowitz, Aaron; Sagar, Vanya; Lyons, Jennifer; Klein, Joshua] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Zepeda, Rodrigo] Massachusetts Gen Hosp, Cambridge, MA USA.
[Zepeda, Rodrigo] Brigham & Womens Hosp, Cambridge, MA USA.
[Mejia, Nicte] Massachusetts Gen Hosp, Somerville, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN61010
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600081
ER
PT J
AU Wells, R
Yeh, G
Kerr, C
Wolkin, J
Davis, R
Dossett, M
Tan, Y
Wall, R
Walsh, J
Kaptchuk, T
Press, D
Phillips, R
Kong, J
AF Wells, Rebecca
Yeh, Gloria
Kerr, Catherine
Wolkin, Jennifer
Davis, Roger
Dossett, Michelle
Tan, Ying
Wall, Robert
Walsh, Jacquelyn
Kaptchuk, Ted
Press, Daniel
Phillips, Russell
Kong, Jian
TI Impact of Meditation on Default Mode Network & Hippocampus in Mild
Cognitive Impairment: A Randomized Trial
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Wells, Rebecca] Wake Forest Baptist Hlth, Winston Salem, NC USA.
[Yeh, Gloria; Davis, Roger; Dossett, Michelle; Kaptchuk, Ted; Phillips, Russell] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Kerr, Catherine] Brown Univ, Sch Med, Pawtucket, RI USA.
[Wolkin, Jennifer] NYU, Langone Med Ctr, New York, NY USA.
[Tan, Ying] Massachusetts Gen Hosp, Charlestown, MA USA.
[Wall, Robert] Commonwealth Care Alliance, Boston, MA USA.
[Walsh, Jacquelyn] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Press, Daniel] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Winchester, MA USA.
[Kong, Jian] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P01014
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600171
ER
PT J
AU Wigman, S
Papp, K
Bamfo, R
Becker, A
Johnson, K
Sperling, R
Rentz, D
AF Wigman, Sarah
Papp, Kathryn
Bamfo, Rose
Becker, Alex
Johnson, Keith
Sperling, Reisa
Rentz, Dorene
TI Are Problems Retrieving Proper Names a Harbinger of Disease in Older
Adults?
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Wigman, Sarah] Brigham & Womens Hosp, Charlestown, MA USA.
[Papp, Kathryn; Sperling, Reisa; Rentz, Dorene] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bamfo, Rose] Massachusetts Gen Hosp, Charlestown, MA USA.
[Becker, Alex; Johnson, Keith] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P07146
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605128
ER
PT J
AU Wilson, M
Bogoch, I
Venna, N
AF Wilson, Michael
Bogoch, Isaac
Venna, Nagagopal
TI Subacute Segmental Lower Motor Neuron Syndrome Associated with Spinal
Cord Gray Matter T2-Hyperintensities in 2 Patients with Well-Controlled
HIV Infection
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Wilson, Michael] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Bogoch, Isaac] Univ Toronto, Toronto, ON, Canada.
[Venna, Nagagopal] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P03250
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068602218
ER
PT J
AU Baggett, TP
Hwang, SW
O'Connell, JJ
Porneala, BC
Stringfellow, EJ
Orav, EJ
Singer, DE
Rigotti, NA
AF Baggett, Travis P.
Hwang, Stephen W.
O'Connell, James J.
Porneala, Bianca C.
Stringfellow, Erin J.
Orav, E. John
Singer, Daniel E.
Rigotti, Nancy A.
TI Mortality Among Homeless Adults in Boston Shifts in Causes of Death Over
a 15-Year Period
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID UNITED-STATES; DEATH CERTIFICATES; COHORT; WOMEN; MEN; SHELTERS; HEALTH;
RESIDENTS; ACCURACY; PROGRAMS
AB Background: Homeless persons experience excess mortality, but US-based studies on this topic are outdated or lack information about causes of death. To our knowledge, no studies have examined shifts in causes of death for this population over time.
Methods: We assessed all-cause and cause-specific mortality rates in a cohort of 28 033 adults 18 years or older who were seen at Boston Health Care for the Homeless Program from January 1, 2003, through December 31, 2008. Deaths were identified through probabilistic linkage to the Massachusetts death occurrence files. We compared mortality rates in this cohort with rates in the 2003-2008 Massachusetts population and a 1988-1993 cohort of homeless adults in Boston using standardized rate ratios with 95% confidence intervals.
Results: A total of 1302 deaths occurred during 90 450 person-years of observation. Drug overdose (n=219), cancer (n=206), and heart disease (n=203) were the major causes of death. Drug overdose accounted for one-third of deaths among adults younger than 45 years. Opioids were implicated in 81% of overdose deaths. Mortality rates were higher among whites than nonwhites. Compared with Massachusetts adults, mortality disparities were most pronounced among younger individuals, with rates about 9-fold higher in 25- to 44-year-olds and 4.5-fold higher in 45- to 64-year-olds. In comparison with 1988-1993 rates, reductions in deaths from human immunodeficiency virus (HIV) were offset by 3- and 2-fold increases in deaths owing to drug overdose and psychoactive substance use disorders, resulting in no significant difference in overall mortality.
Conclusions: The all-cause mortality rate among homeless adults in Boston remains high and unchanged since 1988 to 1993 despite a major interim expansion in clinical services. Drug overdose has replaced HIV as the emerging epidemic. Interventions to reduce mortality in this population should include behavioral health integration into primary medical care, public health initiatives to prevent and reverse drug overdose, and social policy measures to end homelessness. JAMA Intern Med. 2013;173(3):189-195. Published online January 14, 2013. doi:10.1001/jamainternmed.2013.1604
C1 [Baggett, Travis P.; O'Connell, James J.; Porneala, Bianca C.; Singer, Daniel E.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Div Gen Med, Dept Med, Boston, MA 02114 USA.
[Baggett, Travis P.; O'Connell, James J.; Orav, E. John; Singer, Daniel E.; Rigotti, Nancy A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Baggett, Travis P.; O'Connell, James J.; Stringfellow, Erin J.] Boston Hlth Care Homeless Program, Boston, MA USA.
[Hwang, Stephen W.] Univ Toronto, St Michaels Hosp, Dept Med, Div Gen Internal Med, Toronto, ON M5B 1W8, Canada.
[Stringfellow, Erin J.] Washington Univ, George Warren Brown Sch Social Work, St Louis, MO 63130 USA.
[Orav, E. John] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA.
RP Baggett, TP (reprint author), Massachusetts Gen Hosp, Div Gen Med, Dept Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM tbaggett@partners.org
RI Hwang, Stephen/D-2297-2011
OI Hwang, Stephen/0000-0002-1276-1101
FU General Medicine Division at Massachusetts General Hospital, Boston;
BHCHP, Boston; National Institute on Drug Abuse of the National
Institutes of Health [K23DA034008]; American Cancer Society
[122269-IRG-12-070-01-IRG]; BHCHP
FX Drs Baggett and O'Connell are staff physicians at BHCHP, where they
receive financial compensation for rendering patient care services. At
the time of the study, Ms Stringfellow was employed by BHCHP as a
research coordinator.; Funding for this study was provided by the
General Medicine Division at Massachusetts General Hospital and by
BHCHP, both in Boston. Dr Baggett also receives funding from the
National Institute on Drug Abuse of the National Institutes of Health
under Award Number K23DA034008 and from the American Cancer Society
under award No. 122269-IRG-12-070-01-IRG.
NR 47
TC 70
Z9 70
U1 6
U2 40
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 11
PY 2013
VL 173
IS 3
BP 189
EP 195
DI 10.1001/jamainternmed.2013.1604
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 121JV
UT WOS:000317240400010
PM 23318302
ER
PT J
AU Vijayaraghavan, M
Penko, J
Bangsberg, DR
Miaskowski, C
Kushel, MB
AF Vijayaraghavan, Maya
Penko, Joanne
Bangsberg, David R.
Miaskowski, Christine
Kushel, Margot B.
TI Opioid Analgesic Misuse in a Community-Based Cohort of HIV-Infected
Indigent Adults
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID CHRONIC NONCANCER PAIN; INDIVIDUALS
C1 [Vijayaraghavan, Maya] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA.
[Penko, Joanne; Kushel, Margot B.] San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94110 USA.
[Penko, Joanne; Kushel, Margot B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Miaskowski, Christine] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA.
[Bangsberg, David R.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Ctr Global Hlth, Boston, MA 02114 USA.
[Bangsberg, David R.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Charlestown, MA USA.
[Bangsberg, David R.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Bangsberg, David R.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
RP Kushel, MB (reprint author), Univ Calif San Francisco, Div Gen Internal Med, San Francisco Gen Hosp, POB 1364, San Francisco, CA 94143 USA.
EM margot.kushel@ucsf.edu
FU NCRR NIH HHS [UL1RR024131]; NIDA NIH HHS [R01DA022550]; NIMH NIH HHS
[R01MH54907]
NR 9
TC 7
Z9 7
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 11
PY 2013
VL 173
IS 3
BP 235
EP 237
DI 10.1001/jamainternmed.2013.1576
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 121JV
UT WOS:000317240400021
PM 23319013
ER
PT J
AU Campbell, EG
Pham-Kanter, G
Vogeli, C
Iezzoni, LI
AF Campbell, Eric G.
Pham-Kanter, Genevieve
Vogeli, Christine
Iezzoni, Lisa I.
TI Physician Acquiescence to Patient Demands for Brand-Name Drugs: Results
of a National Survey of Physicians
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Campbell, Eric G.; Vogeli, Christine; Iezzoni, Lisa I.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA.
[Campbell, Eric G.; Pham-Kanter, Genevieve; Vogeli, Christine; Iezzoni, Lisa I.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Pham-Kanter, Genevieve] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA.
[Pham-Kanter, Genevieve] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA.
RP Campbell, EG (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM ecampbell@partners.org
OI Pham-Kanter, Genevieve/0000-0002-3044-7829
NR 7
TC 12
Z9 12
U1 1
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 11
PY 2013
VL 173
IS 3
BP 237
EP 239
DI 10.1001/jamainternmed.2013.1539
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 121JV
UT WOS:000317240400022
PM 23303297
ER
PT J
AU Demichelis, F
Garraway, LA
Rubin, MA
AF Demichelis, Francesca
Garraway, Levi A.
Rubin, Mark A.
TI Molecular Archeology: Unearthing Androgen-Induced Structural
Rearrangements in Prostate Cancer Genomes
SO CANCER CELL
LA English
DT Editorial Material
ID TMPRSS2; FUSION
AB In this issue of Cancer Cell, Weischenfeldt and colleagues report on the whole genome sequencing of 11 early-onset prostate cancers. Compared to elderly onset prostate cancer, these tumors demonstrate enrichment for androgen-driven structural rearrangements involving ETS family genes. This study confirms observations that prostate cancer manifests discrete genomic subclasses.
C1 [Demichelis, Francesca] Univ Trent, Ctr Integrat Biol, I-38123 Povo, Trento, Italy.
[Garraway, Levi A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Garraway, Levi A.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Garraway, Levi A.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA.
[Demichelis, Francesca] Cornell Univ, Weill Cornell Med Coll, Inst Computat Biomed, Dept Physiol & Biophys, New York, NY 10065 USA.
[Rubin, Mark A.] Cornell Univ, Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
[Rubin, Mark A.] Cornell Univ, Weill Cornell Med Coll, Brady Fdn, Dept Urol, New York, NY 10065 USA.
[Rubin, Mark A.] Cornell Univ, Weill Cornell Med Coll, Inst Precis Med, New York, NY 10065 USA.
[Rubin, Mark A.] New York Presbyterian Hosp, New York, NY 10065 USA.
RP Rubin, MA (reprint author), Cornell Univ, Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
EM rubinma@med.cornell.edu
OI Rubin, Mark/0000-0002-8321-9950; Demichelis,
Francesca/0000-0002-8266-8631
FU NCI NIH HHS [R01 CA125612, U01 CA111275, U01CA111275]
NR 10
TC 1
Z9 1
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD FEB 11
PY 2013
VL 23
IS 2
BP 133
EP 135
DI 10.1016/j.ccr.2013.01.019
PG 3
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 091RO
UT WOS:000315067700002
PM 23410968
ER
PT J
AU Davids, MS
Letai, A
AF Davids, Matthew S.
Letai, Anthony
TI ABT-199: Taking Dead Aim at BCL-2
SO CANCER CELL
LA English
DT Editorial Material
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; FAMILY; ABT-737
AB ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer therapies.
C1 [Davids, Matthew S.; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP Letai, A (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM anthony_letai@dfci.harvard.edu
RI Jones, Jeffrey/E-9827-2013
FU NCI NIH HHS [R01 CA129974, T32 CA009172]
NR 10
TC 35
Z9 35
U1 2
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD FEB 11
PY 2013
VL 23
IS 2
BP 139
EP 141
DI 10.1016/j.ccr.2013.01.018
PG 3
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 091RO
UT WOS:000315067700005
PM 23410971
ER
PT J
AU Malin, JL
Weeks, JC
Potosky, AL
Hornbrook, MC
Keating, NL
AF Malin, Jennifer L.
Weeks, Jane C.
Potosky, Arnold L.
Hornbrook, Mark C.
Keating, Nancy L.
TI Medical Oncologists' Perceptions of Financial Incentives in Cancer Care
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID COST SAVINGS; CHEMOTHERAPY; TRENDS; LIFE; END; AGGRESSIVENESS; PATTERNS;
SERVICES; OUTCOMES; PROGRAM
AB Purpose
The cost of cancer care continues to increase at an unprecedented rate. Concerns have been raised about financial incentives associated with the chemotherapy concession in oncology practices and their impact on treatment recommendations.
Methods
The objective of this study was to measure the physician-reported effects of prescribing chemotherapy or growth factors or making referrals to other cancer specialists, hospice, or hospital admissions on medical oncologists' income. US medical oncologists involved in the care of a population-based cohort of patients with lung or colorectal cancer from the Cancer Care Outcomes Research and Surveillance (CanCORS) study were surveyed regarding their perceptions of the impact of prescribing practices or referrals on their income.
Results
Although most oncologists reported that their incomes would be unaffected, compared with salaried oncologists, physicians in fee-for-service practice, and those paid a salary with productivity incentives were more likely to report that their income would increase from administering chemotherapy (odds ratios [ORs], 7.05 and 7.52, respectively; both P < .001) or administering growth factors (ORs, 5.60 and 6.03, respectively; both P < .001).
Conclusion
A substantial proportion of oncologists who are not paid a fixed salary report that their incomes increase when they administer chemotherapy and growth factors. Further research is needed to understand the impact of these financial incentives on both the quality and cost of care. J Clin Oncol 31:530-535. (C) 2012 by American Society of Clinical Oncology
C1 [Malin, Jennifer L.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[Malin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Malin, Jennifer L.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Weeks, Jane C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Keating, Nancy L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Keating, Nancy L.] Harvard Univ, Sch Med, Boston, MA USA.
[Potosky, Arnold L.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
[Hornbrook, Mark C.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA.
RP Malin, JL (reprint author), WellPoint, 1 WellPoint Way, Thousand Oaks, CA 91362 USA.
EM jennifer.malin@wellpoint.com
FU National Cancer Institute (NCI) [U01 CA093344]; Dana-Farber Cancer
Institute/Cancer Research Network [U01 CA093332]; Harvard Medical
School/Northern California Cancer Center [U01 CA093324]; RAND/University
of California, Los Angeles [U01 CA093348]; University of Alabama at
Birmingham [U01 CA093329]; University of Iowa [U01 CA01013]; University
of North Carolina [U01 CA093326]; Department of Veterans Affairs (VA)
[CRS 02-164]
FX Supported by Grants No. U01 CA093344 from the National Cancer Institute
(NCI) to the Statistical Coordinating Center, U01 CA093332 from the
Dana-Farber Cancer Institute/Cancer Research Network, U01 CA093324 from
Harvard Medical School/Northern California Cancer Center, U01 CA093348
from RAND/University of California, Los Angeles, U01 CA093329 from the
University of Alabama at Birmingham, U01 CA01013 from the University of
Iowa, U01 CA093326 from the University of North Carolina, and CRS 02-164
from the Department of Veterans Affairs (VA) to the Durham VA Medical
Center.
NR 27
TC 17
Z9 17
U1 0
U2 8
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 10
PY 2013
VL 31
IS 5
BP 530
EP 535
DI 10.1200/JCO.2012.43.6063
PG 6
WC Oncology
SC Oncology
GA 088FY
UT WOS:000314820400009
PM 23269996
ER
PT J
AU Chen, AB
Cronin, A
Weeks, JC
Chrischilles, EA
Malin, J
Hayman, JA
Schrag, D
AF Chen, Aileen B.
Cronin, Angel
Weeks, Jane C.
Chrischilles, Elizabeth A.
Malin, Jennifer
Hayman, James A.
Schrag, Deborah
TI Palliative Radiation Therapy Practice in Patients With Metastatic
Non-Small-Cell Lung Cancer: A Cancer Care Outcomes Research and
Surveillance Consortium (CanCORS) Study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT 53rd Annual Meeting of the American-Society-of-Radiation-Oncology
(ASTRO)
CY OCT 01-06, 2011
CL Miami Beach, FL
SP Amer Soc Radiat Oncol (ASTRO)
ID PAINFUL BONE METASTASES; SINGLE-FRACTION; THORACIC RADIOTHERAPY;
MULTIPLE IMPUTATION; SURVIVAL; TRIALS; GY; PREFERENCES; SCHEDULE;
ONCOLOGY
AB Purpose
Randomized data suggest that single-fraction or short-course palliative radiation therapy (RT) is sufficient in the majority of patients with metastatic cancer. We investigated population-based patterns in the use of palliative RT among patients with metastatic non-small-cell lung cancer (NSCLC).
Patients and Methods
From patients diagnosed with lung cancer from 2003 to 2005 at a participating geographic or organizational site and who consented to the Cancer Care Outcomes Research and Surveillance Consortium study, we identified patients with metastatic NSCLC who had complete medical records abstractions. Patient characteristics and clinical factors associated with receipt of palliative RT and RT intensity (total dose and number of treatments) were evaluated with multivariable regression.
Results
Of 1,574 patients with metastatic NSCLC, 780 (50%) received at least one course of RT, and 21% and 12% received RT to the chest and bone, respectively. Use of palliative RT was associated with younger age at diagnosis and receipt of chemotherapy and surgery to metastatic sites. Among patients receiving palliative bone RT, only 6% received single-fraction treatment. Among patients receiving palliative chest RT, 42% received more than 20 fractions. Patients treated in integrated networks were more likely to receive lower doses and fewer fractions to the bone and chest.
Conclusion
When palliative RT is used in patients with metastatic NSCLC, a substantial proportion of patients receive a greater number of treatments and higher doses than supported by current evidence, suggesting an opportunity to improve care delivery. J Clin Oncol 31:558-564. (C) 2013 by American Society of Clinical Oncology
C1 [Chen, Aileen B.; Cronin, Angel; Weeks, Jane C.; Schrag, Deborah] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Chen, Aileen B.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chrischilles, Elizabeth A.] Univ Iowa, Iowa City, IA USA.
[Malin, Jennifer] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[Hayman, James A.] Univ Michigan Hlth Syst, Ann Arbor, MI USA.
RP Chen, AB (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,D1111, Boston, MA 02215 USA.
EM achen7@partners.org
OI Chen, Aileen/0000-0002-5385-3360
FU NCI NIH HHS [U01 CA093324, U01 CA093326, U01 CA093348, U01 CA093332, K05
CA166208, U01 CA093339, U01 CA093329, P30 CA086862, U01 CA093344]
NR 42
TC 30
Z9 31
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 10
PY 2013
VL 31
IS 5
BP 558
EP 564
DI 10.1200/JCO.2012.43.7954
PG 7
WC Oncology
SC Oncology
GA 088FY
UT WOS:000314820400013
PM 23295799
ER
PT J
AU Unguru, Y
Joffe, S
Fernandez, CV
Yu, AL
AF Unguru, Yoram
Joffe, Steven
Fernandez, Conrad V.
Yu, Alice L.
TI Ethical Issues for Control-Arm Patients After Revelation of Benefits of
Experimental Therapy: A Framework Modeled in Neuroblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID COLONY-STIMULATING FACTOR; CHILDRENS ONCOLOGY GROUP; PHASE-I;
CLINICAL-RESEARCH; POSTTRIAL ACCESS; UNITED-STATES; ANTIBODY; CH14.18;
TRIAL; DRUGS
AB In 2009, the Children's Oncology Group (COG) phase III randomized controlled trial, ANBL0032, found that adding immunotherapy (Ch14.18) to standard therapy significantly improved outcomes in patients with high-risk neuroblastoma when administered within 110 days after autologous stem-cell transplantation (SCT). After careful deliberation and consultation, the COG Neuroblastoma Committee decided to offer Ch14.18 to prior trial participants who had been randomly assigned to the control arm (no immunotherapy), regardless of the time that had elapsed since SCT. This decision occurred in the context of a limited supply of Ch14.18 and no data regarding its role when administered beyond 110 days. In this article, we analyze the numerous ethical challenges highlighted by the ANBL0032 trial, including the limits of researchers' reciprocity-based obligations to study participants, post-trial access to beneficial therapies, and the balance between scientific knowledge and parental hope. These deliberations may be useful to other researchers when considering their ethical obligations to control-arm participants in the wake of a positive randomized trial. J Clin Oncol 31:641-646. (C) 2013 by American Society of Clinical Oncology
C1 [Unguru, Yoram] Herman & Walter Samuelson Childrens Hosp Sinai, Baltimore, MD 21215 USA.
[Unguru, Yoram] Johns Hopkins Berman Inst Bioeth, Baltimore, MD USA.
[Joffe, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Joffe, Steven] Boston Childrens Hosp, Boston, MA USA.
[Fernandez, Conrad V.] Dalhousie Univ, Halifax, NS, Canada.
[Yu, Alice L.] Univ Calif San Diego, San Diego, CA 92103 USA.
RP Unguru, Y (reprint author), Herman & Walter Samuelson Childrens Hosp Sinai, Div Pediat Hematol Oncol, 2401 W Belvedere Ave, Baltimore, MD 21215 USA.
EM yunguru@lifebridgehealth.org
OI Joffe, Steven/0000-0002-0667-7384
FU National Cancer Institute [UA CA098543-06]
FX Supported by Grant No. UA CA098543-06 from the National Cancer Institute
to the Children's Oncology Group.
NR 31
TC 5
Z9 5
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 10
PY 2013
VL 31
IS 5
BP 641
EP 646
DI 10.1200/JCO.2012.47.1227
PG 6
WC Oncology
SC Oncology
GA 088FY
UT WOS:000314820400023
PM 23295797
ER
PT J
AU Corrales-Medina, VF
Musher, DM
Shachkina, S
Chirinos, JA
AF Corrales-Medina, Vicente F.
Musher, Daniel M.
Shachkina, Svetlana
Chirinos, Julio A.
TI Acute pneumonia and the cardiovascular system
SO LANCET
LA English
DT Review
ID COMMUNITY-ACQUIRED PNEUMONIA; ANGIOTENSIN-CONVERTING ENZYME; ACUTE
CORONARY SYNDROMES; THROMBOSIS-INDUCING ACTIVITY; SHORT-TERM MORTALITY;
ACUTE KIDNEY INJURY; RISK-FACTORS; BACTERIAL PNEUMONIA; NATRIURETIC
PEPTIDE; PNEUMOCOCCAL PNEUMONIA
AB Although traditionally regarded as a disease confined to the lungs, acute pneumonia has important effects on the cardiovascular system at all severities of infection. Pneumonia tends to affect individuals who are also at high cardiovascular risk. Results of recent studies show that about a quarter of adults admitted to hospital with pneumonia develop a major acute cardiac complication during their hospital stay, which is associated with a 60% increase in short-term mortality. These findings suggest that outcomes of patients with pneumonia can be improved by prevention of the development and progression of associated cardiac complications. Before this hypothesis can be tested, however, an adequate mechanistic understanding of the cardiovascular changes that occur during pneumonia, and their role in the trigger of various cardiac complications, is needed. In this Review, we summarise knowledge about the burden of cardiac complications in adults with acute pneumonia, the cardiovascular response to this infection, the potential effects of commonly used cardiovascular and anti-infective drugs on these associations, and possible directions for future research.
C1 [Corrales-Medina, Vicente F.; Shachkina, Svetlana] Univ Ottawa, Dept Med, Ottawa, ON K1Y 4E9, Canada.
[Corrales-Medina, Vicente F.; Shachkina, Svetlana] Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
[Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
[Musher, Daniel M.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA.
[Chirinos, Julio A.] Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA.
[Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Corrales-Medina, VF (reprint author), Univ Ottawa, Dept Med, 1053 Carling Ave,CPC 470, Ottawa, ON K1Y 4E9, Canada.
EM vcorrales@toh.on.ca
OI Corrales-Medina, Vicente/0000-0002-9691-491X
FU Research Priority Grant from the Department of Medicine of The Ottawa
Hospital; Junior Investigator Award of the Ottawa Hospital Research
Institute
FX We thank Alexandra Davis, librarian at The Ottawa Hospital, for her
assistance in the design of our search strategies and the retrieval of
selected articles. We also acknowledge Yoko S Schreiber and Bing Wang,
from the Division of Infectious Diseases at the University of Ottawa,
for their assistance with the translation of articles in French, German,
and Chinese; and Waheed Raja and Zubair A Khan, from the Divisions of
Internal Medicine at Texas Tech University Health Sciences Center and
Cooper University Hospital, respectively, for their helpful assistance
during the literature search process. VFC-M is supported by a Research
Priority Grant from the Department of Medicine of The Ottawa Hospital,
and a Junior Investigator Award of the Ottawa Hospital Research
Institute.
NR 100
TC 58
Z9 60
U1 2
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD FEB 9
PY 2013
VL 381
IS 9865
BP 496
EP 505
DI 10.1016/S0140-6736(12)61266-5
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 088CH
UT WOS:000314810900035
PM 23332146
ER
PT J
AU Koch, MR
Jagannathan, JP
Shinagare, AB
Krajewski, KM
Raut, CP
Hornick, JL
Ramaiya, NH
AF Koch, M. R.
Jagannathan, J. P.
Shinagare, A. B.
Krajewski, K. M.
Raut, C. P.
Hornick, J. L.
Ramaiya, N. H.
TI Imaging features of primary anorectal gastrointestinal stromal tumors
with clinical and pathologic correlation
SO CANCER IMAGING
LA English
DT Article
DE Gastrointestinal stromal tumor; anorectal; CT; MRI; FDG-PET/CT
ID TERM-FOLLOW-UP; INTERSTITIAL-CELLS; IMATINIB MESYLATE; RECTUM;
PROGNOSIS; BIOLOGY; COLON; CAJAL
AB Purpose: To evaluate the imaging features of anorectal gastrointestinal stromal tumors (GISTs) with clinical and histopathologic correlation. Materials and methods: In this Institutional Review Board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study, 16 patients (12 men; mean age 66 years (30-89 years)) with pathologically proven anorectal GISTs seen at our institution from January 2001 to July 2011 were identified. Electronic medical records were reviewed to obtain clinical data. Pretreatment imaging studies (computed tomography (CT) in 16 patients, magnetic resonance imaging (MRI) in 9 patients and fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT in 8 patients) were evaluated by 2 radiologists until consensus. The location, size and imaging features of the primary tumor and metastases at presentation, if any, were recorded, and correlated with clinical data and pathologic features (histologic type, presence of necrosis, mitotic activity, risk category, immunohistochemical profile). Results: The mean tumor size was 6.9 x 6.0 cm. Of the 16 tumors, 11 (68.7%) were infralevator, 4 (25%) supra and infralevator and 1 (6.3%) supralevator; 9 (56.2%) were exophytic, 6 (37.5%) both exophytic and intraluminal, and 1 (6.3%) was intraluminal. The tumors were iso- to minimally hypoattenuating to muscle on CT, iso-to minimally hypointense on T1-weighted images, hyperintense on T2-weighted images and showed variable enhancement. Necrosis was seen in 4 (25%), and hemorrhage and calcification in 2 (12.5%) patients each. The tumors were FDG avid with a mean maximum standardized uptake value of 11 (8.4-16.8). All tumors were positive for KIT and CD34. Distant metastasis to liver was seen in 1 patient (6.3%) at presentation. Conclusion: Anorectal GISTs are well-circumscribed, non-circumferential, predominantly infralevator, intramural or exophytic, FDG-avid, hypoattenuating masses, and present without lymphadenopathy or intestinal obstruction.
C1 [Koch, M. R.; Jagannathan, J. P.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Jagannathan, J. P.; Shinagare, A. B.; Krajewski, K. M.; Ramaiya, N. H.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
[Raut, C. P.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Hornick, J. L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Shinagare, AB (reprint author), Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA.
EM ashinagare@partners.org
NR 21
TC 4
Z9 4
U1 0
U2 1
PU E-MED
PI LONDON
PA PO BOX 29761, LONDON, NW3 7ZS, ENGLAND
SN 1470-7330
J9 CANCER IMAGING
JI Cancer Imaging
PD FEB 8
PY 2013
VL 12
IS 3
BP 557
EP 565
DI 10.1102/1470-7330.2012.0048
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 172MZ
UT WOS:000321009500004
PM 23400107
ER
PT J
AU Liu, N
Yu, ZY
Li, YD
Yuan, J
Zhang, J
Xiang, SL
Wang, XY
AF Liu, Ning
Yu, Zhanyang
Li, Yadan
Yuan, Jing
Zhang, Jian
Xiang, Shuanglin
Wang, Xiaoying
TI Transcriptional regulation of mouse neuroglobin gene by cyclic AMP
responsive element binding protein (CREB) in N2a cells
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Neuroglobin; CREB; Transcriptional regulation; Mouse; N2a cells
ID NEURONAL CELLS; EXPRESSION; PROMOTER; HYPOXIA; INDUCTION; INJURY;
REGION; BRAIN
AB Neuroglobin (Ngb) has been demonstrated to be a novel neuroprotective protein that protects against hypoxia/ischemia and oxidative stress-induced injury in the nervous system. However, the regulation mechanisms of Ngb gene expression under both normal resting and stress conditions have not been fully elucidated. The cyclic AMP response element binding protein (CREB) is a key transcription factor that regulates a variety of pro-survival genes, but its role in regulating the neuroprotective gene Ngb has not been studied. In this study we investigated the transcriptional regulation of mouse Ngb gene by CREB in mouse neuroblastoma cell line N2a. Our results showed that CREB knockdown decreased Ngb gene expression, and overexpression of the wild-type CREB, but not the mutant CREB, significantly increased Ngb gene expression in N2a cells. Moreover, a CAMP response element (CRE) site located at -854 in the promoter region of mouse Ngb gene was found to be responsible for both basal and CREB-induced Ngb promoter activity. Using chromatin immunopreciptation (ChIP) assays, we found that CREB could bind to the Ngb promoter region spanning from -1016 to -793 that harbors the CRE site. Taken together, our results suggested that transcription factor CREB participates in the transcriptional regulation of mouse Ngb gene. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Liu, Ning; Yu, Zhanyang; Li, Yadan; Wang, Xiaoying] Harvard Univ, Sch Med, Neuroprotect Res Lab, Dept Neurol,Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Liu, Ning; Yu, Zhanyang; Li, Yadan; Wang, Xiaoying] Harvard Univ, Sch Med, Neuroprotect Res Lab, Dept Radiol,Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Liu, Ning; Yuan, Jing; Zhang, Jian; Xiang, Shuanglin] Hunan Normal Univ, Key Lab Prot Chem & Dev Biol, State Educ Minist China, Coll Life Sci, Changsha 410081, Hunan, Peoples R China.
RP Wang, XY (reprint author), Harvard Univ, Sch Med, Neuroprotect Res Lab, Dept Neurol,Massachusetts Gen Hosp, 149 13th St,Room 2411A, Charlestown, MA 02129 USA.
EM xshlin@hunnu.edu.cn; wangxi@helix.mgh.harvard.edu
FU NIH [R01-NS049476]; American Heart Association [12POST9720007]
FX This work was supported in part by NIH grant R01-NS049476 (to X.W.) and
postdoctoral fellowship (12POST9720007) from American Heart Association
(to Z.Y.). We appreciate Dr. Eng H. Lo for his very helpful discussion.
The authors declare no conflict of interest.
NR 23
TC 13
Z9 14
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD FEB 8
PY 2013
VL 534
BP 333
EP 337
DI 10.1016/j.neulet.2012.11.025
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 160AL
UT WOS:000320088300062
PM 23182882
ER
PT J
AU Kashiwagi, S
Atochin, DN
Li, Q
Schleicher, M
Pong, T
Sessa, WC
Huang, PL
AF Kashiwagi, Satoshi
Atochin, Dmitriy N.
Li, Qian
Schleicher, Michael
Pong, Terrence
Sessa, William C.
Huang, Paul L.
TI eNOS phosphorylation on serine 1176 affects insulin sensitivity and
adiposity
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Nitric oxide; Endothelium; Insulin resistance; Diabetes; Metabolism;
Obesity
ID NITRIC-OXIDE SYNTHASE; VASCULAR ENDOTHELIAL-CELLS; ACTIVATED
PROTEIN-KINASE; SKELETAL-MUSCLE; GLUCOSE-UPTAKE; MICE LACKING;
MITOCHONDRIAL BIOGENESIS; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME;
DIABETES-MELLITUS
AB Phosphoxylation of endothelial nitric oxide synthase (eNOS) is an important regulator of its enzymatic activity. We generated knockin mice expressing phosphomimetic (SD) and unphosphorylatable (SA) eNOS mutations at S1176 to study the role of eNOS phosphorylation. The single amino acid SA mutation is associated with hypertension and decreased vascular reactivity, while the SD mutation results in increased basal and stimulated endothelial NO production. In addition to these vascular effects, modulation of the S1176 phosphorylation site resulted in unanticipated effects on metabolism. The eNOS SA mutation results in insulin resistance, hyperinsulinemia, adiposity, and increased weight gain on high fat. In contrast, the eNOS SD mutation is associated with decreased insulin levels and resistance to high fat-induced weight gain. These results demonstrate the importance of eNOS in regulation of insulin sensitivity, energy metabolism, and bodyweight regulation, and suggest eNOS phosphorylation as a novel target for the treatment of obesity and insulin resistance. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Kashiwagi, Satoshi; Atochin, Dmitriy N.; Li, Qian; Pong, Terrence; Huang, Paul L.] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Kashiwagi, Satoshi; Atochin, Dmitriy N.; Li, Qian; Pong, Terrence; Huang, Paul L.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Schleicher, Michael; Sessa, William C.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA.
[Schleicher, Michael; Sessa, William C.] Yale Univ, Sch Med, Vasc Biol & Therapeut Program, New Haven, CT 06536 USA.
RP Huang, PL (reprint author), Harvard Univ, Sch Med, Cardiovasc Res Ctr, Massachusetts Gen Hosp,Cardiol Div, 149 13th St, Charlestown, MA 02129 USA.
EM phuang1@partners.org
RI Atochin, Dmitriy/Q-3150-2016
FU NHLBI NIH HHS [R01 HL057818]; NINDS NIH HHS [R01 NS033335, R01 NS048426]
NR 47
TC 12
Z9 13
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 8
PY 2013
VL 431
IS 2
BP 284
EP 290
DI 10.1016/j.bbrc.2012.12.110
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 095HM
UT WOS:000315325300030
PM 23291238
ER
PT J
AU Martin, LS
Castano, A
Bravo, M
Tavares, M
Niederman, R
Ogunbodede, EO
AF San Martin, Laura
Castano, Antonio
Bravo, Manuel
Tavares, Mary
Niederman, Richard
Ogunbodede, Eyitope O.
TI Dental sealant knowledge, opinion, values and practice of Spanish
dentists
SO BMC ORAL HEALTH
LA English
DT Article
DE Fissure sealants; Dental; Prevention; Children; Oral health
ID FLUORIDE VARNISH; FISSURE SEALANTS; ORAL-HEALTH; CARIES;
RECOMMENDATIONS; CHILDREN; ADOLESCENTS; STRATEGIES; BEHAVIOR; TRIAL
AB Background: Multiple guidelines and systematic reviews recommend sealant use to reduce caries risk. Yet, multiple reports also indicate that sealants are significantly underutilized. This study examined the knowledge, opinions, values, and practice (KOVP) of dentists concerning sealant use in the southwest region of Andalusia, Spain. This is a prelude to the generation of a regional plan for improving children's oral health in Andalusia.
Methods: The survey's target population was dentists working in western Andalusia, equally distributed in the provinces of Seville, Cadiz, and Huelva (N=2,047). A convenience sample of meeting participants and meeting participant email lists (N=400) were solicited from the annual course on Community and Pediatric Dentistry. This course is required for all public health sector dentists, and is open to all private sector dentists. Information on the dentist's KOVP of sealants was collected using four-part questionnaire with 31, 5-point Likert-scaled questions.
Results: The survey population demographics included 190 men (48%) and 206 women (52%) with an average clinical experience of 10.6 (+/- 8.4) years and 9.3 (+/- 7.5) years, respectively. A significant sex difference was observed in the distribution of place of work (urban/suburb) (p=0.001), but no sex differences between working sector (public/private). The mean +/- SD values for each of the four KOVP sections for pit and fissure sealants were: knowledge = 3.57 +/- 0.47; opinion = 2.48 +/- 0.47; value = 2.74 +/- 0.52; and practice = 3.48 +/- 0.50. No sex differences were found in KOVP (all p > 0.4). Independent of sex: knowledge statistically differed by years of experience and place of work; opinion statistically differed by years of experience and sector; and practice statistically differed by years of experience and sector. Less experienced dentists tended to have slightly higher scores (similar to 0.25 on a Likert 1-5 scale). Statistically significant correlations were found between knowledge and practice (r=0.44, p=0.00) and between opinion and value (r=0.35, p=0.00).
Conclusions: The results suggest that, similar to other countries, Andalusian dentists know that sealants are effective, have neutral to positive attitudes toward sealants; though, based on epidemiological studies, underuse sealants. Therefore, methods other than classical behavior change (eg: financial or legal mechanisms) will be required to change practice patterns aimed at improving children's oral health.
C1 [San Martin, Laura; Castano, Antonio] Univ Seville, Sch Dent, Seville, Spain.
[San Martin, Laura; Tavares, Mary; Niederman, Richard] Forsyth Inst, Cambridge, MA USA.
[San Martin, Laura] Harvard Univ, Sch Dent Med Boston, Boston, MA 02115 USA.
[Bravo, Manuel] Univ Granada, Sch Dent, Granada, Spain.
[Tavares, Mary] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
[Ogunbodede, Eyitope O.] Obafemi Awolowo Univ, Fac Dent, Ife, Nigeria.
RP Martin, LS (reprint author), Univ Seville, Sch Dent, Avicena S-N, Seville, Spain.
EM LSanMartin@us.es
OI niederman, richard/0000-0001-6674-1774
FU NIMHD [1 R34 DE022272 (NIH2385)]; NIDCR [1 U24 MD006964]
FX The authors would like to thank the Vicerrectorado de Investigacion of
the University of Seville, Harvard School of Dental Medicine, and the
Forsyth Institute. We would also like to thank the following clinicians
who participated in the validation of the survey: Drs. Anibal Gonzalez,
Rafael Llamas, Maria del Aguila Cordero, David Ribas, Emilio Lledo,
Manuel Poyato, Antonio Fernandez. We acknowledge the following sources
for invaluable financial support NIMHD 1 R34 DE022272 (NIH2385) and
NIDCR 1 U24 MD006964. We are grateful to Dr. Javier Gil for assistance
with the statistical analysis.
NR 40
TC 1
Z9 1
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD FEB 8
PY 2013
VL 13
AR 12
DI 10.1186/1472-6831-13-12
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 099BK
UT WOS:000315593700001
ER
PT J
AU Paintlia, MK
Paintlia, AS
Singh, AK
Singh, I
AF Paintlia, Manjeet K.
Paintlia, Ajaib S.
Singh, Avtar K.
Singh, Inderjit
TI S-Nitrosoglutathione Induces Ciliary Neurotrophic Factor Expression in
Astrocytes, Which Has Implications to Protect the Central Nervous System
under Pathological Conditions
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID FIBRILLARY ACIDIC PROTEIN; ACTIVATED-RECEPTOR-GAMMA; TRAUMATIC
BRAIN-INJURY; NITRIC-OXIDE ACTIVATION; IN-VITRO; SIGNALING PATHWAY;
GLIAL-CELLS; CYCLOOXYGENASE-2 EXPRESSION; OLIGODENDROCYTE PROGENITORS;
DEMYELINATING DISEASES
AB Accumulating evidence suggests that reactive astrogliosis has beneficial and detrimental outcomes in various CNS disorders, but the mechanism behind this dichotomy is unclear. Recent advances in this direction suggested that NO signaling is critical to regulate the outcomes of reactive astrogliosis in vivo. Using biochemical and genetic approaches, we here investigated the effect of S-nitrosoglutathione (GSNO; a physiological NO donor) in astrocytes in vitro settings. GSNO enhanced the expressions of glial fibrillary acidic protein and neurotrophic factors including ciliary neurotrophic factor (CNTF) in astrocytes in a dose-dependent manner. The enhanced CNTF expression in GSNO-treated astrocytes was ascribed to NO-mediated sGC/cGMP/PKG signaling. It was associated with p38 MAPK-dependent increased peroxisome proliferator-activated receptor-gamma transactivation. In addition, the chromatin accessibility of peroxisome proliferator-activated receptor-gamma accompanied with ATF2 and CREB (cAMP-response element-binding protein) was enhanced across the CNTF gene promoter in GSNO treated astrocytes. Interestingly, secreted CNTF was responsible for increased expression of glial fibrillary acidic protein in GSNO-treated astrocytes in an autocrine manner via a JAK2- and STAT3-dependent mechanism. In addition, CNTF secreted by GSNO-treated astrocytes enhanced the differentiation of immature oligodendrocytes in vitro. These effects of GSNO were consistent with an endogenously produced NO in astrocytes stimulated with proinflammatory cytokines in vitro. We conclude that NO signaling induces CNTF expression in astrocytes that favors the beneficial outcomes of reactive astrogliosis in vivo. Our data suggest that the endogenously produced NO or its exogenous source has potential to modulate the outcomes of reactive astrogliosis to protect CNS under pathological conditions.
C1 [Paintlia, Manjeet K.; Paintlia, Ajaib S.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA.
EM singhi@musc.edu
FU National Institutes of Health [NS-22576, NS-37766, VA-1BX001072,
VA-BX001999, C06 RR018823, C06 RR015455]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants NS-22576, NS-37766, VA-1BX001072, VA-BX001999, C06
RR018823, and C06 RR015455.
NR 69
TC 11
Z9 11
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 8
PY 2013
VL 288
IS 6
BP 3831
EP 3843
DI 10.1074/jbc.M112.405654
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 088OP
UT WOS:000314845000015
PM 23264628
ER
PT J
AU Foerch, C
Rosidi, NL
Schlunk, F
Lauer, A
Cianchetti, FA
Mandeville, E
Arai, K
Yigitkanli, K
Fan, X
Wang, X
van Leyen, K
Steinmetz, H
Schaffer, CB
Lo, EH
AF Foerch, Christian
Rosidi, Nathanael L.
Schlunk, Frieder
Lauer, Arne
Cianchetti, Flor A.
Mandeville, Emiri
Arai, Ken
Yigitkanli, Kazim
Fan, Xiang
Wang, Xiaoying
van Leyen, Klaus
Steinmetz, Helmuth
Schaffer, Chris B.
Lo, Eng H.
TI Intravenous tPA Therapy Does Not Worsen Acute Intracerebral Hemorrhage
in Mice
SO PLOS ONE
LA English
DT Article
ID TISSUE-PLASMINOGEN-ACTIVATOR; FOCAL CEREBRAL-ISCHEMIA;
BLOOD-BRAIN-BARRIER; SUBARACHNOID HEMORRHAGE; RAT MODEL; STROKE;
THROMBOLYSIS; INHIBITION; PROTEIN; INJURY
AB Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH). Surprisingly, however, the assumption that tPA will worsen ICH has never been biologically tested. Here, we assessed the effects of tPA in two models of ICH. In a mouse model of collagenase-induced ICH, hemorrhage volumes and neurological deficits after 24 hrs were similar in saline controls and tPA-treated mice, whereas heparin-treated mice had 3-fold larger hematomas. In a model of laser-induced vessel rupture, tPA also did not worsen hemorrhage volumes, while heparin did. tPA is known to worsen neurovascular injury by amplifying matrix metalloproteinases during cerebral ischemia. In contrast, tPA did not upregulate matrix metalloproteinases in our mouse ICH models. In summary, our experimental data do not support the assumption that intravenous tPA has a deleterious effect in acute ICH. However, due to potential species differences and the inability of models to fully capture the dynamics of human ICH, caution is warranted when considering the implications of these findings for human therapy.
C1 [Foerch, Christian; Schlunk, Frieder; Lauer, Arne; Mandeville, Emiri; Arai, Ken; Yigitkanli, Kazim; Fan, Xiang; Wang, Xiaoying; van Leyen, Klaus; Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroprotect Res Lab, Boston, MA 02114 USA.
[Foerch, Christian; Schlunk, Frieder; Lauer, Arne; Steinmetz, Helmuth] Goethe Univ Frankfurt, Dept Neurol, D-60054 Frankfurt, Germany.
[Rosidi, Nathanael L.; Cianchetti, Flor A.; Schaffer, Chris B.] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA.
RP Foerch, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroprotect Res Lab, Boston, MA 02114 USA.
EM foerch@em.uni-frankfurt.de
RI van Leyen, Klaus/C-9126-2013; Schaffer, Chris/A-7409-2008
OI Schaffer, Chris/0000-0002-7800-9596
FU National Institutes of Health [R37-NS37074, R01-NS56458, P01-NS55104]
FX This work was supported in part by National Institutes of Health grants
R37-NS37074, R01-NS56458 and P01-NS55104. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 31
TC 8
Z9 8
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 8
PY 2013
VL 8
IS 2
AR e54203
DI 10.1371/journal.pone.0054203
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 086CJ
UT WOS:000314660300005
PM 23408937
ER
PT J
AU Ding, QR
Lee, YK
Schaefer, EAK
Peters, DT
Veres, A
Kim, K
Kuperwasser, N
Motola, DL
Meissner, TB
Hendriks, WT
Trevisan, M
Gupta, RM
Moisan, A
Banks, E
Friesen, M
Schinzel, RT
Xia, F
Tang, A
Xia, YL
Figueroa, E
Wann, A
Ahfeldt, T
Daheron, L
Zhang, F
Rubin, LL
Peng, LF
Chung, RT
Musunuru, K
Cowan, CA
AF Ding, Qiurong
Lee, Youn-Kyoung
Schaefer, Esperance A. K.
Peters, Derek T.
Veres, Adrian
Kim, Kevin
Kuperwasser, Nicolas
Motola, Daniel L.
Meissner, Torsten B.
Hendriks, William T.
Trevisan, Marta
Gupta, Rajat M.
Moisan, Annie
Banks, Eric
Friesen, Max
Schinzel, Robert T.
Xia, Fang
Tang, Alexander
Xia, Yulei
Figueroa, Emmanuel
Wann, Amy
Ahfeldt, Tim
Daheron, Laurence
Zhang, Feng
Rubin, Lee L.
Peng, Lee F.
Chung, Raymond T.
Musunuru, Kiran
Cowan, Chad A.
TI A TALEN Genome-Editing System for Generating Human Stem Cell-Based
Disease Models
SO CELL STEM CELL
LA English
DT Article
ID INSULIN-RESISTANCE; ADIPOSE-TISSUE; MICE LACKING; DNA; EFFECTORS;
PERILIPIN; NUCLEASES; SORTILIN; MUTATION; AKT2
AB Transcription activator-like effector nucleases (TALENs) are a new class of engineered nucleases that are easier to design to cleave at desired sites in a genome than previous types of nucleases. We report here the use of TALENs to rapidly and efficiently generate mutant alleles of 15 genes in cultured somatic cells or human pluripotent stem cells, the latter for which we differentiated both the targeted lines and isogenic control lines into various metabolic cell types. We demonstrate cell-autonomous phenotypes directly linked to disease-dyslipidemia, insulin resistance, hypoglycemia, lipodystrophy, motor-neuron death, and hepatitis C infection. We found little evidence of TALEN off-target effects, but each clonal line nevertheless harbors a significant number of unique mutations. Given the speed and ease with which we were able to derive and characterize these cell lines, we anticipate TALEN-mediated genome editing of human cells becoming a mainstay for the investigation of human biology and disease.
C1 [Ding, Qiurong; Lee, Youn-Kyoung; Peters, Derek T.; Veres, Adrian; Kim, Kevin; Kuperwasser, Nicolas; Meissner, Torsten B.; Hendriks, William T.; Trevisan, Marta; Gupta, Rajat M.; Friesen, Max; Schinzel, Robert T.; Xia, Fang; Tang, Alexander; Xia, Yulei; Figueroa, Emmanuel; Wann, Amy; Ahfeldt, Tim; Daheron, Laurence; Rubin, Lee L.; Musunuru, Kiran; Cowan, Chad A.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Hendriks, William T.; Trevisan, Marta; Daheron, Laurence; Rubin, Lee L.; Musunuru, Kiran; Cowan, Chad A.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Schaefer, Esperance A. K.; Motola, Daniel L.; Rubin, Lee L.; Peng, Lee F.] Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Boston, MA 02114 USA.
[Cowan, Chad A.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Schaefer, Esperance A. K.; Peters, Derek T.; Veres, Adrian; Motola, Daniel L.; Gupta, Rajat M.; Peng, Lee F.; Chung, Raymond T.; Musunuru, Kiran; Cowan, Chad A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Kuperwasser, Nicolas; Gupta, Rajat M.; Musunuru, Kiran] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
[Moisan, Annie] Roche Pharmaceut, Metab Discovery & Translat Area, CH-4070 Basel, Switzerland.
[Banks, Eric; Zhang, Feng; Musunuru, Kiran; Cowan, Chad A.] Broad Inst, Cambridge, MA 02142 USA.
[Zhang, Feng] MIT, McGovern Inst Brain Res, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
RP Musunuru, K (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
EM kiranmusunuru@gmail.com; ccowan@fas.harvard.edu
RI Ahfeldt, Tim/E-2935-2017;
OI Kim, Kevin/0000-0002-7015-5871
FU Roche Postdoctoral Fellowship; Harvard Stem Cell Institute; Harvard
Presidential Scholars Fund of the Harvard Medical School MD/PhD Program;
United States National Institutes of Health [T32-DK007191, T32-HL007604,
K08-DK088951, K24-DK078772, P01-NS066888, R00-HL098364, U01-HL107440,
R01-DK097768]; New York Stem Cell Foundation; Broad Institute's Lawrence
H. Summers Fellowship; Carlos Slim Foundation; Harvard University
FX This work was supported in part by a Roche Postdoctoral Fellowship (Q.
D.); the Sternlicht Director's Fund Award for Graduate Students from the
Harvard Stem Cell Institute (D. T. P.); the Harvard Presidential
Scholars Fund of the Harvard Medical School MD/PhD Program (A. V.);
grants T32-DK007191 (E. A. K. S. and D. L. M.), T32-HL007604 (R. M. G.),
K08-DK088951 (L. F. P.), K24-DK078772 (R. T. C.), P01-NS066888 (L. L.
R.), R00-HL098364 (K. M.), U01-HL107440 (C. A. C.), and R01-DK097768
(F.Z., K. M., and C. A. C.) from the United States National Institutes
of Health; the New York Stem Cell Foundation (L. L. R.); the Broad
Institute's Lawrence H. Summers Fellowship and the Carlos Slim
Foundation (K. M.); the Harvard Stem Cell Institute (T. B. M., L. L. R.,
K. M., and C. A. C.); and Harvard University (L. L. R., K. M., and C. A.
C.). A. M. is a full-time employee of Roche Pharmaceuticals. We thank
David Altshuler, Noel Burtt, Guillermo del Angel, Mark DePristo, Stacey
Gabriel, Namrata Gupta, J. Keith Joung, Adam Kaplan, Ami Levy-Moonshine,
Heng Li, Elyse Macksoud, Khalid Shakir, Alanna Strong, Kristin Thompson,
Jayaraj Rajagopal, Stephanie Regan, Jennifer Shay, and the staffs of the
HSCRB-HSCI Flow Cytometry Core and the Broad Institute's Genomics
Platform for assistance and suggestions.
NR 46
TC 227
Z9 250
U1 13
U2 92
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD FEB 7
PY 2013
VL 12
IS 2
BP 238
EP 251
DI 10.1016/j.stem.2012.11.011
PG 14
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VB
UT WOS:000329569300014
PM 23246482
ER
PT J
AU Wang, S
Bates, J
Li, XJ
Schanz, S
Chandler-Militello, D
Levine, C
Maherali, N
Studer, L
Hochedlinger, K
Windrem, M
Goldman, SA
AF Wang, Su
Bates, Janna
Li, Xiaojie
Schanz, Steven
Chandler-Militello, Devin
Levine, Corri
Maherali, Nimet
Studer, Lorenz
Hochedlinger, Konrad
Windrem, Martha
Goldman, Steven A.
TI Human iPSC-Derived Oligodendrocyte Progenitor Cells Can Myelinate and
Rescue a Mouse Model of Congenital Hypomyelination
SO CELL STEM CELL
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; TRANSCRIPTION FACTOR; HUMAN ES; DIFFERENTIATION;
DISEASE; LINEAGE; BRAIN; FETAL; IDENTIFICATION; REMYELINATE
AB Neonatal engraftment by oligodendrocyte progenitor cells (OPCs) permits the myelination of the congenitally dysmyelinated brain. To establish a potential autologous source of these cells, we developed a strategy by which to differentiate human induced pluripotent stem cells (hiPSCs) into OPCs. From three hiPSC lines, as well as from human embryonic stem cells (hESCs), we generated highly enriched OLIG2(+)/PDGFR alpha(+)/NKX2.2(+)/SOX10(+) human OPCs, which could be further purified using fluorescence-activated cell sorting. hiPSC OPCs efficiently differentiated into both myelinogenic oligodendrocytes and astrocytes, in vitro and in vivo. Neonatally engrafted hiPSC OPCs robustly myelinated the brains of myelin-deficient shiverer mice and substantially increased their survival. The speed and efficiency of myelination by hiPSC OPCs was higher than that previously observed using fetal-tissue-derived OPCs, and no tumors from these grafts were noted as long as 9 months after transplant. These results suggest the potential utility of hiPSC-derived OPCs in treating disorders of myelin loss.
C1 [Wang, Su; Bates, Janna; Li, Xiaojie; Schanz, Steven; Chandler-Militello, Devin; Levine, Corri; Windrem, Martha; Goldman, Steven A.] Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA.
[Wang, Su; Bates, Janna; Li, Xiaojie; Schanz, Steven; Chandler-Militello, Devin; Levine, Corri; Windrem, Martha; Goldman, Steven A.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
[Maherali, Nimet; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Regenerat Med, Cambridge, MA 02138 USA.
[Maherali, Nimet; Hochedlinger, Konrad] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Studer, Lorenz] Sloan Kettering Inst, Dev Biol Program, New York, NY 10065 USA.
RP Goldman, SA (reprint author), Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA.
EM steven_goldman@urmc.rochester.edu
OI Levine, Corri/0000-0003-0405-5191
FU New York State Stem Cell Science (NYSTEM); National Multiple Sclerosis
Society; NIH [R01NS75345, R01NS39559]; G. Harold and Leila Y. Mathers
Charitable Foundation; Dr. Miriam and Sheldon G. Adelson Medical
Research Foundation
FX This work was supported by New York State Stem Cell Science (NYSTEM);
the National Multiple Sclerosis Society; NIH grants R01NS75345 and
R01NS39559; the G. Harold and Leila Y. Mathers Charitable Foundation;
and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.
We thank Karen Bentley and Gayle Schneider for their assistance in
electron microscopy.
NR 29
TC 155
Z9 159
U1 9
U2 43
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD FEB 7
PY 2013
VL 12
IS 2
BP 252
EP 264
DI 10.1016/j.stem.2012.12.002
PG 13
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VB
UT WOS:000329569300015
PM 23395447
ER
PT J
AU Paccez, JD
Vasques, GJ
Correa, RG
Vasconcellos, JF
Duncan, K
Gu, X
Bhasin, M
Libermann, TA
Zerbini, LF
AF Paccez, J. D.
Vasques, G. J.
Correa, R. G.
Vasconcellos, J. F.
Duncan, K.
Gu, X.
Bhasin, M.
Libermann, T. A.
Zerbini, L. F.
TI The receptor tyrosine kinase Ax1 is an essential regulator of prostate
cancer proliferation and tumor growth and represents a new therapeutic
target
SO ONCOGENE
LA English
DT Article
DE tyrosine kinase receptor; Ax1; prostate cancer; proliferation; NF-kappa
B; IL-6
ID NF-KAPPA-B; ARREST-SPECIFIC GENE-6; BREAST-CANCER; PROLONGS SURVIVAL;
ENDOTHELIAL-CELLS; CARCINOMA CELLS; ACTIVATION; PATHWAY; EXPRESSION;
GAS6
AB Deregulation of the receptor tyrosine kinase Ax1 has been implicated in the progression of several human cancers. However, the role of Ax1 in prostate cancer remains poorly understood, and the therapeutic efficacy of Ax1 targeting remains untested. In this report we identified Ax1 as a new therapeutic target for prostate cancer. Ax1 is consistently overexpressed in prostate cancer cell lines and human prostate tumors. Interestingly, the blockage of Ax1 gene expression strongly inhibits proliferation, migration, invasion and tumor growth. Furthermore, inhibition of Ax1 expression by small interfering RNA regulates a transcriptional program of genes involved in cell survival, strikingly all connected to the nuclear factor-kappa B pathway. Additionally, blockage of Ax1 expression leads to inhibition of Akt, IKK alpha and I kappa B alpha phosphorylation, increasing I kappa B alpha expression and stability. Furthermore, induction of Akt phosphorylation by insulin-like growth factor 1 in Ax1 knockdown cells restores Akt activity and proliferation. Taken together, our results establish an unambiguous role for Ax1 in prostate cancer tumorigenesis with implications for prostate cancer treatment. Oncogene (2013) 32, 689-698; doi:10.1038/onc.2012.89; published online 12 March 2012
C1 [Paccez, J. D.; Vasques, G. J.; Duncan, K.; Zerbini, L. F.] Int Ctr Genet Engn & Biotechnol, Canc Genom Grp, Cape Town, South Africa.
[Paccez, J. D.; Zerbini, L. F.] Univ Cape Town, Div Med Biochem, ZA-7925 Cape Town, South Africa.
[Correa, R. G.] Sanford Burnham Med Res Inst, La Jolla, CA USA.
[Vasconcellos, J. F.; Gu, X.; Bhasin, M.; Libermann, T. A.] Beth Israel Deaconess Med Ctr, BIDMC Genom & Prote Ctr, Boston, MA 02215 USA.
[Vasconcellos, J. F.; Gu, X.; Bhasin, M.; Libermann, T. A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Zerbini, LF (reprint author), Int Ctr Genet Engn & Biotechnol, Canc Genom Grp, Cape Town, South Africa.
EM luiz.zerbini@uct.ac.za
RI Correa, Ricardo/G-7613-2012; Zerbini, Luiz /B-7720-2015; Paccez,
Juliano/K-8560-2012
OI Correa, Ricardo/0000-0001-6940-7034; Paccez, Juliano/0000-0002-1086-4588
FU ICGEB post-doctoral fellowship; CAPES international fellowship;
Department of Defense [PC051217]; NIH [1RO1 CA85467]; Prostate Cancer
Foundation
FX JDP is recipient of the ICGEB post-doctoral fellowship. JFV is recipient
of CAPES international fellowship. This study was supported by the
Department of Defense grant PC051217 (LFZ), NIH grants 1RO1 CA85467
(TAL) and the Prostate Cancer Foundation (TAL).
NR 50
TC 36
Z9 39
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD FEB 7
PY 2013
VL 32
IS 6
BP 689
EP 698
DI 10.1038/onc.2012.89
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 101AF
UT WOS:000315746700003
PM 22410775
ER
PT J
AU Beunders, G
Voorhoeve, E
Golzio, C
Pardo, LM
Rosenfeld, JA
Talkowski, ME
Simonic, I
Lionel, AC
Vergult, S
Pyatt, RE
van de Kamp, J
Nieuwint, A
Weiss, MM
Rizzu, P
Verwer, LENI
van Spaendonk, RML
Shen, YP
Wu, BL
Yu, TT
Yu, YG
Chiang, C
Gusella, JF
Lindgren, AM
Morton, CC
van Binsbergen, E
Bulk, S
van Rossem, E
Vanakker, O
Armstrong, R
Park, SM
Greenhalgh, L
Maye, U
Neill, NJ
Abbott, KM
Sell, S
Ladda, R
Farber, DM
Bader, PI
Cushing, T
Drautz, JM
Konczal, L
Nash, P
de Los Reyes, E
Carter, MT
Hopkins, E
Marshall, CR
Osborne, LR
Gripp, KW
Thrush, DL
Hashimoto, S
Gastier-Foster, JM
Astbury, C
Ylstra, B
Meijers-Heijboer, H
Posthuma, D
Menten, B
Mortier, G
Scherer, SW
Eichler, EE
Girirajan, S
Katsanis, N
Groffen, AJ
Sistermans, EA
AF Beunders, Gea
Voorhoeve, Els
Golzio, Christelle
Pardo, Luba M.
Rosenfeld, Jill A.
Talkowski, Michael E.
Simonic, Ingrid
Lionel, Anath C.
Vergult, Sarah
Pyatt, Robert E.
van de Kamp, Jiddeke
Nieuwint, Aggie
Weiss, Marjan M.
Rizzu, Patrizia
Verwer, Lucilla E. N. I.
van Spaendonk, Rosalina M. L.
Shen, Yiping
Wu, Bai-lin
Yu, Tingting
Yu, Yongguo
Chiang, Colby
Gusella, James F.
Lindgren, Amelia M.
Morton, Cynthia C.
van Binsbergen, Ellen
Bulk, Saskia
van Rossem, Els
Vanakker, Olivier
Armstrong, Ruth
Park, Soo-Mi
Greenhalgh, Lynn
Maye, Una
Neill, Nicholas J.
Abbott, Kristin M.
Sell, Susan
Ladda, Roger
Farber, Darren M.
Bader, Patricia I.
Cushing, Tom
Drautz, Joanne M.
Konczal, Laura
Nash, Patricia
de Los Reyes, Emily
Carter, Melissa T.
Hopkins, Elizabeth
Marshall, Christian R.
Osborne, Lucy R.
Gripp, Karen W.
Thrush, Devon Lamb
Hashimoto, Sayaka
Gastier-Foster, Julie M.
Astbury, Caroline
Ylstra, Bauke
Meijers-Heijboer, Hanne
Posthuma, Danielle
Menten, Bjoern
Mortier, Geert
Scherer, Stephen W.
Eichler, Evan E.
Girirajan, Santhosh
Katsanis, Nicholas
Groffen, Alexander J.
Sistermans, Erik A.
TI Exonic Deletions in AUTS2 Cause a Syndromic Form of Intellectual
Disability and Suggest a Critical Role for the C Terminus
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID TRANSLOCATION BREAKPOINT; MUTATIONS; AUTISM; ABNORMALITIES; GENERATION;
PHENOTYPE; DATABASE; GENES
AB Genomic rearrangements involving AUTS2 (7q11.22) are associated with autism and intellectual disability (ID), although evidence for causality is limited. By combining the results of diagnostic testing of 49,684 individuals, we identified 24 microdeletions that affect at least one exon of AUTS2, as well as one translocation and one inversion each with a breakpoint within the AUTS2 locus. Comparison of 17 well-characterized individuals enabled identification of a variable syndromic phenotype including ID, autism, short stature, microcephaly, cerebral palsy, and facial dysmorphisms. The dysmorphic features were more pronounced in persons with 3' AUTS2 deletions. This part of the gene is shown to encode a C-terminal isoform (with an alternative transcription start site) expressed in the human brain. Consistent with our genetic data, suppression of auts2 in zebrafish embryos caused microcephaly that could be rescued by either the full-length or the C-terminal isoform of AUTS2. Our observations demonstrate a causal role of AUTS2 in neurocognitive disorders, establish a hitherto unappreciated syndromic phenotype at this locus, and show how transcriptional complexity can underpin human pathology. The zebrafish model provides a valuable tool for investigating the etiology of AUTS2 syndrome and facilitating gene-function analysis in the future.
C1 [Beunders, Gea; Voorhoeve, Els; Pardo, Luba M.; van de Kamp, Jiddeke; Nieuwint, Aggie; Weiss, Marjan M.; Rizzu, Patrizia; Verwer, Lucilla E. N. I.; van Spaendonk, Rosalina M. L.; Meijers-Heijboer, Hanne; Posthuma, Danielle; Groffen, Alexander J.; Sistermans, Erik A.] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, NL-1007 MB Amsterdam, Netherlands.
[Golzio, Christelle; Katsanis, Nicholas] Duke Univ, Med Ctr, Dept Cell Biol, Ctr Human Dis Modeling, Durham, NC 27710 USA.
[Rosenfeld, Jill A.; Neill, Nicholas J.] Perkin Elmer, Signature Genom Labs, Spokane, WA 99207 USA.
[Talkowski, Michael E.; Shen, Yiping; Chiang, Colby; Gusella, James F.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Human Genet Res,Dept Genet, Boston, MA 02114 USA.
[Talkowski, Michael E.; Shen, Yiping; Chiang, Colby; Gusella, James F.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Human Genet Res,Dept Neurol, Boston, MA 02114 USA.
[Talkowski, Michael E.; Gusella, James F.; Morton, Cynthia C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Simonic, Ingrid; Armstrong, Ruth; Park, Soo-Mi; Abbott, Kristin M.] Natl Hlth Serv Fdn Trust, Cambridge Univ Hosp, Addenbrookes Hosp, E Anglian Med Genet Serv, Cambridge CB2 0QQ, England.
[Lionel, Anath C.; Marshall, Christian R.] Hosp Sick Children, Ctr Appl Genom, Toronto, ON M5G 1L7, Canada.
[Lionel, Anath C.; Marshall, Christian R.] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1L7, Canada.
[Lionel, Anath C.; Marshall, Christian R.; Scherer, Stephen W.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A1, Canada.
[Lionel, Anath C.; Marshall, Christian R.; Scherer, Stephen W.] Univ Toronto, McLaughlin Ctr, Toronto, ON M5S 1A1, Canada.
[Vergult, Sarah; Vanakker, Olivier; Menten, Bjoern] Univ Hosp Ghent, Ctr Med Genet, B-9000 Ghent, Belgium.
[Pyatt, Robert E.; Thrush, Devon Lamb; Hashimoto, Sayaka; Gastier-Foster, Julie M.; Astbury, Caroline] Nationwide Childrens Hosp, Columbus, OH 43205 USA.
[Pyatt, Robert E.; Gastier-Foster, Julie M.; Astbury, Caroline] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
[Shen, Yiping; Wu, Bai-lin; Yu, Tingting] Boston Childrens Hosp, Dept Lab Med, Boston, MA 02114 USA.
[Shen, Yiping; Yu, Tingting; Yu, Yongguo] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Shanghai 200025, Peoples R China.
[Wu, Bai-lin] Fudan Univ, Childrens Hosp, Shanghai 200032, Peoples R China.
[Wu, Bai-lin] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
[Lindgren, Amelia M.; Morton, Cynthia C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Lindgren, Amelia M.; Morton, Cynthia C.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
[van Binsbergen, Ellen; Bulk, Saskia] Univ Med Ctr Utrecht, Dept Med Genet, NL-3508 AB Utrecht, Netherlands.
[van Rossem, Els] Onze Lieve Vrouwe Ziekenhuis, B-9300 Aalst, Belgium.
[Greenhalgh, Lynn; Maye, Una] Royal Liverpool Childrens Hosp, Liverpool L12 2AP, Merseyside, England.
[Sell, Susan; Ladda, Roger] Penn State Milton S Hershey Med Ctr, Hershey, PA 17033 USA.
[Farber, Darren M.] Univ Louisville, Dept Neurol, Louisville, KY 40222 USA.
[Bader, Patricia I.] NE Indiana Genet Counseling Ctr, Ft Wayne, IN 46804 USA.
[Cushing, Tom; Drautz, Joanne M.] Univ New Mexico, Dept Pediat, Pediat Genet Div, Albuquerque, NM 87131 USA.
[Konczal, Laura] Case Western Reserve Univ, Univ Hosp, Cleveland, OH 44106 USA.
[Nash, Patricia] Nationwide Childrens Hosp, Dept Behav Pediat, Columbus, OH 43205 USA.
[de Los Reyes, Emily] Ohio State Univ, Dept Pediat & Neurol, Columbus, OH 43210 USA.
[Carter, Melissa T.] Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada.
[Hopkins, Elizabeth; Gripp, Karen W.] Alfred I duPont Hosp Children, Div Med Genet, Wilmington, DE 19803 USA.
[Osborne, Lucy R.] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada.
[Osborne, Lucy R.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada.
[Thrush, Devon Lamb] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.
[Ylstra, Bauke] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands.
[Posthuma, Danielle; Groffen, Alexander J.] Vrije Univ Amsterdam, Ctr Neurogenom & Cognit Res, Dept Funct Genom, NL-1081 HV Amsterdam, Netherlands.
[Posthuma, Danielle] Erasmus Univ, Dept Child & Adolescent Psychiat, NL-3000 CB Rotterdam, Netherlands.
[Mortier, Geert] Univ Antwerp, Dept Med Genet, B-2650 Edegem, Belgium.
[Eichler, Evan E.; Girirajan, Santhosh] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Eichler, Evan E.; Girirajan, Santhosh] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA.
[Girirajan, Santhosh] Penn State Univ, Dept Biochem & Mol Biol, Dept Anthropol, University Pk, PA 16803 USA.
RP Sistermans, EA (reprint author), Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, NL-1007 MB Amsterdam, Netherlands.
EM e.sistermans@vumc.nl
RI Mortier, Geert/D-2542-2012; Scherer, Stephen /B-3785-2013; Katsanis,
Nicholas/E-1837-2012; Groffen, Alexander/C-1118-2009; Astbury,
Caroline/E-2665-2011; Ylstra, Bauke/D-2906-2012;
OI yu, yongguo/0000-0002-4472-0910; Katsanis, Nicholas/0000-0002-2480-0171;
Scherer, Stephen /0000-0002-8326-1999; Groffen,
Alexander/0000-0003-0046-4027; Ylstra, Bauke/0000-0001-9479-3010;
Menten, Bjorn/0000-0001-8182-659X; Golzio,
Christelle/0000-0002-4420-3921; Sistermans, Erik/0000-0001-7187-4563;
Chiang, Colby/0000-0002-4113-6065
FU Wellcome Trust [076113, 085475]; National Institutes of Health
[GM061354, HD065286, MH095867]; American Heart Association
[11POST7160006]; Distinguished Brumley Professorship
FX The authors would like to thank all patients and their families for
their major contribution; without them, we would not have been able to
describe this syndrome. We thank Marjolein van de Mespel, Desiree
Linders, Stefan Strijbis, Amanda Clarkson, and Carrie Hanscom for their
contribution to the laboratory work in this project and Shahrin Pereira
for clinical coordination. This study made use of data generated by the
Wellcome Trust Case Control Consortium. A full list of the investigators
who contributed to the generation of the data is available at
www.wtccc.org.uk. Funding for this project was provided by the Wellcome
Trust under awards 076113 and 085475, as well as by the National
Institutes of Health (GM061354, HD065286, and MH095867), the American
Heart Association (11POST7160006), and a Distinguished Brumley
Professorship to N.K. Evan Eichler is a Howards Hughes Medical Institute
investigator. The authors thank Klaas Kok for making available the
control data of The Low-Lands Consortium for this study and for
developing the custom design of the 180K Agilent oligo array used in The
Netherlands. We acknowledge Soheil Shams from Bio-Discovery for his help
with processing the different array data files. J.A.R. and N.J.N. are
employees of Signature Genomic Laboratories, a subsidiary of
PerkinElmer, and E.E.E. is on the scientific advisory boards for Pacific
Biosciences, SynapDx, and DNAnexus.
NR 24
TC 46
Z9 47
U1 0
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD FEB 7
PY 2013
VL 92
IS 2
BP 210
EP 220
DI 10.1016/j.ajhg.2012.12.011
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 093GL
UT WOS:000315179600005
PM 23332918
ER
PT J
AU Borissoff, JI
Otten, JJT
Heeneman, S
Leenders, P
van Oerle, R
Soehnlein, O
Loubele, STBG
Hamulyak, K
Hackeng, TM
Daemen, MJAP
Degen, JL
Weiler, H
Esmon, CT
van Ryn, J
Biessen, EAL
Spronk, HMH
ten Cate, H
AF Borissoff, Julian I.
Otten, Jeroen J. T.
Heeneman, Sylvia
Leenders, Peter
van Oerle, Rene
Soehnlein, Oliver
Loubele, Sarah T. B. G.
Hamulyak, Karly
Hackeng, Tilman M.
Daemen, Mat J. A. P.
Degen, Jay L.
Weiler, Hartmut
Esmon, Charles T.
van Ryn, Joanne
Biessen, Erik A. L.
Spronk, Henri M. H.
ten Cate, Hugo
TI Genetic and Pharmacological Modifications of Thrombin Formation in
Apolipoprotein E-deficient Mice Determine Atherosclerosis Severity and
Atherothrombosis Onset in a Neutrophil-Dependent Manner
SO PLOS ONE
LA English
DT Article
ID SUDDEN CORONARY DEATH; COLONY-STIMULATING FACTOR; PLAQUE STABILITY;
P-SELECTIN; INFLAMMATION; ATHEROGENESIS; COAGULATION; MECHANISMS;
DISEASE; ACTIVATION
AB Background: Variations in the blood coagulation activity, determined genetically or by medication, may alter atherosclerotic plaque progression, by influencing pleiotropic effects of coagulation proteases. Published experimental studies have yielded contradictory findings on the role of hypercoagulability in atherogenesis. We therefore sought to address this matter by extensively investigating the in vivo significance of genetic alterations and pharmacologic inhibition of thrombin formation for the onset and progression of atherosclerosis, and plaque phenotype determination.
Methodology/Principal Findings: We generated transgenic atherosclerosis-prone mice with diminished coagulant or hypercoagulable phenotype and employed two distinct models of atherosclerosis. Gene-targeted 50% reduction in prothrombin (FII-/WT:ApoE(-/-)) was remarkably effective in limiting disease compared to control ApoE(-/-) mice, associated with significant qualitative benefits, including diminished leukocyte infiltration, altered collagen and vascular smooth muscle cell content. Genetically-imposed hypercoagulability in TMPro/Pro:ApoE(-/-) mice resulted in severe atherosclerosis, plaque vulnerability and spontaneous atherothrombosis. Hypercoagulability was associated with a pronounced neutrophilia, neutrophil hyper-reactivity, markedly increased oxidative stress, neutrophil intraplaque infiltration and apoptosis. Administration of either the synthetic specific thrombin inhibitor Dabigatran etexilate, or recombinant activated protein C (APC), counteracted the pro-inflammatory and pro-atherogenic phenotype of pro-thrombotic TMPro/Pro:ApoE(-/-) mice.
Conclusions/Significance: We provide new evidence highlighting the importance of neutrophils in the coagulation-inflammation interplay during atherogenesis. Our findings reveal that thrombin-mediated proteolysis is an unexpectedly powerful determinant of atherosclerosis in multiple distinct settings. These studies suggest that selective anticoagulants employed to prevent thrombotic events may also be remarkably effective in clinically impeding the onset and progression of cardiovascular disease.
C1 [Borissoff, Julian I.; Leenders, Peter; van Oerle, Rene; Loubele, Sarah T. B. G.; Hamulyak, Karly; Spronk, Henri M. H.; ten Cate, Hugo] Maastricht Univ, Med Ctr, Lab Clin Thrombosis & Hemostasis, Dept Internal Med,Cardiovasc Res Inst Maastricht, Maastricht, Netherlands.
[Borissoff, Julian I.] Harvard Univ, Sch Med, Program Cellular & Mol Med, Boston Childrens Hosp, Boston, MA USA.
[Borissoff, Julian I.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Otten, Jeroen J. T.; Heeneman, Sylvia; Daemen, Mat J. A. P.; Biessen, Erik A. L.] Maastricht Univ, Cardiovasc Res Inst Maastricht, Expt Vasc Pathol Res Grp, Dept Pathol, Maastricht, Netherlands.
[Soehnlein, Oliver] Rhein Westfal TH Aachen, Fac Med, Inst Cardiovasc Mol Res, Aachen, Germany.
[Hackeng, Tilman M.] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Biochem, Med Ctr, Maastricht, Netherlands.
[Degen, Jay L.] Univ Cincinnati, Coll Med, Childrens Hosp Res Fdn, Cincinnati, OH USA.
[Weiler, Hartmut] Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53233 USA.
[Esmon, Charles T.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Esmon, Charles T.] Howard Hughes Med Inst, Oklahoma City, OK USA.
[van Ryn, Joanne] Boehringer Ingelheim Pharma GmbH & Co KG, Dept CardioMetab Dis Res, Biberach, Germany.
RP Borissoff, JI (reprint author), Maastricht Univ, Med Ctr, Lab Clin Thrombosis & Hemostasis, Dept Internal Med,Cardiovasc Res Inst Maastricht, Maastricht, Netherlands.
EM j.ilcheff@maastrichtuniversity.nl
OI ten Cate, Hugo/0000-0001-7796-4463
FU European Commission [MEST-CT-2005-020706]; SenterNovem grant; Maastricht
University; Netherlands Organization for Scientific Research (NWO)
[825.11.019]; Deutsche Forschungsgemeinschaft [SO876/3-1, SO876/4-1];
Gutenberg Research College Fellowship (Gutenberg University, Mainz,
Germany); Bayer; Boehringer Ingelheim; GlaxoSmithKline; Leo Pharma
FX Boehringer Ingelheim GmbH provided Dabigatran etexilate-supplemented and
placebo diets. This study was supported by a Marie Curie fellowship
(MEST-CT-2005-020706) from the European Commission (to Dr. J.I.
Borissoff) and a SenterNovem grant (to Cardiovascular Research Institute
Maastricht (CARIM)). Dr. J.I. Borissoff is a recipient of a Kootstra
Talent Fellowship (2011) from Maastricht University and is supported by
a Rubicon fellowship (825.11.019), granted by the Netherlands
Organization for Scientific Research (NWO). Dr. Oliver Soehnlein is
supported by the Deutsche Forschungsgemeinschaft (SO876/3-1 and
SO876/4-1). Dr. Hugo ten Cate is sponsored by a Gutenberg Research
College Fellowship (Gutenberg University, Mainz, Germany). The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.; The authors have the
following interests. Boehringer Ingelheim GmbH provided Dabigatran
etexilate-supplemented and placebo diets for this study and is the
employer of Joanne van Ryn. Dr. ten Cate has received speaker fees from
Bayer, Boehringer Ingelheim, GlaxoSmithKline and Leo Pharma. There are
no further patents, products in development or marketed products to
declare. This does not alter the authors' adherence to all the PLOS ONE
policies on sharing data and materials.
NR 55
TC 36
Z9 36
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 7
PY 2013
VL 8
IS 2
AR e55784
DI 10.1371/journal.pone.0055784
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092XV
UT WOS:000315157200063
PM 23409043
ER
PT J
AU Plovanich, M
Bogorad, RL
Sancak, Y
Kamer, KJ
Strittmatter, L
Li, AA
Girgis, HS
Kuchimanchi, S
De Groot, J
Speciner, L
Taneja, N
Oshea, J
Koteliansky, V
Mootha, VK
AF Plovanich, Molly
Bogorad, Roman L.
Sancak, Yasemin
Kamer, Kimberli J.
Strittmatter, Laura
Li, Andrew A.
Girgis, Hany S.
Kuchimanchi, Satya
De Groot, Jack
Speciner, Lauren
Taneja, Nathan
Oshea, Jonathan
Koteliansky, Victor
Mootha, Vamsi K.
TI MICU2, a Paralog of MICU1, Resides within the Mitochondrial Uniporter
Complex to Regulate Calcium Handling
SO PLOS ONE
LA English
DT Article
ID RAT KIDNEY MITOCHONDRIA; CA2+ UPTAKE; ESSENTIAL COMPONENT; RNAI
THERAPEUTICS; RESPIRATION; METABOLISM; DELIVERY; PROTEIN; MCU;
OSCILLATIONS
AB Mitochondrial calcium uptake is present in nearly all vertebrate tissues and is believed to be critical in shaping calcium signaling, regulating ATP synthesis and controlling cell death. Calcium uptake occurs through a channel called the uniporter that resides in the inner mitochondrial membrane. Recently, we used comparative genomics to identify MICU1 and MCU as the key regulatory and putative pore-forming subunits of this channel, respectively. Using bioinformatics, we now report that the human genome encodes two additional paralogs of MICU1, which we call MICU2 and MICU3, each of which likely arose by gene duplication and exhibits distinct patterns of organ expression. We demonstrate that MICU1 and MICU2 are expressed in HeLa and HEK293T cells, and provide multiple lines of biochemical evidence that MCU, MICU1 and MICU2 reside within a complex and cross-stabilize each other's protein expression in a cell-type dependent manner. Using in vivo RNAi technology to silence MICU1, MICU2 or both proteins in mouse liver, we observe an additive impairment in calcium handling without adversely impacting mitochondrial respiration or membrane potential. The results identify MICU2 as a new component of the uniporter complex that may contribute to the tissue-specific regulation of this channel.
C1 [Plovanich, Molly; Sancak, Yasemin; Kamer, Kimberli J.; Strittmatter, Laura; Li, Andrew A.; Girgis, Hany S.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Plovanich, Molly; Sancak, Yasemin; Kamer, Kimberli J.; Strittmatter, Laura; Li, Andrew A.; Girgis, Hany S.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Plovanich, Molly; Sancak, Yasemin; Kamer, Kimberli J.; Strittmatter, Laura; Li, Andrew A.; Girgis, Hany S.; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
[Plovanich, Molly; Sancak, Yasemin; Kamer, Kimberli J.; Strittmatter, Laura; Li, Andrew A.; Girgis, Hany S.; Mootha, Vamsi K.] Broad Inst, Cambridge, MA USA.
[Bogorad, Roman L.; Koteliansky, Victor] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Kuchimanchi, Satya; De Groot, Jack; Speciner, Lauren; Taneja, Nathan; Oshea, Jonathan] Alnylam Pharmaceut Inc, Cambridge, MA USA.
RP Mootha, VK (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM vamsi@hms.harvard.edu
OI Kamer, Kimberli/0000-0001-8728-7793
FU National Institutes of Health [GM0077465, DK080261]; Alnylam
FX This work was supported by grants from the National Institutes of Health
(GM0077465, DK080261) awarded to VKM. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.; Please note that in this paper, the
authors' academic laboratory (based at Massachusetts General
Hospital/Harvard Medical School) collaborated with Alnylam
Pharmaceuticals (co-authors include JDG, L. Speciner, NT, JO, VK). As
employees, they received compensation/stock from Alnylam. The authors do
not believe that the fact that they are employees of a company,
receiving salary/equity from this company, represents a competing
interest that compromises the objectivity of the work. This does not
alter the authors' adherence to all the PLOS ONE policies on data
sharing and materials.
NR 32
TC 89
Z9 97
U1 1
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 7
PY 2013
VL 8
IS 2
AR e55785
DI 10.1371/journal.pone.0055785
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092XV
UT WOS:000315157200064
PM 23409044
ER
PT J
AU Fulzele, K
Krause, DS
Panaroni, C
Saini, V
Barry, KJ
Liu, XL
Lotinun, S
Baron, R
Bonewald, L
Feng, JQ
Chen, M
Weinstein, LS
Wu, JY
Kronenberg, HM
Scadden, DT
Pajevic, PD
AF Fulzele, Keertik
Krause, Daniela S.
Panaroni, Cristina
Saini, Vaibhav
Barry, Kevin J.
Liu, Xiaolong
Lotinun, Sutada
Baron, Roland
Bonewald, Lynda
Feng, Jian Q.
Chen, Min
Weinstein, Lee S.
Wu, Joy Y.
Kronenberg, Henry M.
Scadden, David T.
Pajevic, Paola Divieti
TI Myelopoiesis is regulated by osteocytes through Gs alpha-dependent
signaling
SO BLOOD
LA English
DT Article
ID STEM-CELL NICHE; HEMATOPOIETIC STEM; BONE-FORMATION; G-PROTEIN;
PROGENITOR CELLS; RECEPTOR; OSTEOBLASTS; SCLEROSTIN; MARROW;
DIFFERENTIATION
AB Hematopoietic progenitors are regulated in their respective niches by cells of the bone marrow microenvironment. The bone marrow microenvironment is composed of a variety of cell types, and the relative contribution of each of these cells for hematopoietic lineage maintenance has remained largely unclear. Osteocytes, the most abundant yet least understood cells in bone, are thought to initiate adaptive bone remodeling responses via osteoblasts and osteoclasts. Here we report that these cells regulate hematopoiesis, constraining myelopoiesis through a Gs alpha-mediated mechanism that affects G-CSF production. Mice lacking Gs alpha in osteocytes showed a dramatic increase in myeloid cells in bone marrow, spleen, and peripheral blood. This hematopoietic phenomenon was neither intrinsic to the hematopoietic cells nor dependent on osteoblasts but was a consequence of an altered bone marrow microenvironment imposed by Gs alpha deficiency in osteocytes. Conditioned media from osteocyte-enriched bone explants significantly increased myeloid colony formation in vitro, which was blocked by G-CSF-neutralizing antibody, indicating a critical role of osteocyte-derived G-CSF in the myeloid expansion. (Blood. 2013;121(6):930-939)
C1 [Fulzele, Keertik; Panaroni, Cristina; Saini, Vaibhav; Barry, Kevin J.; Liu, Xiaolong; Baron, Roland; Wu, Joy Y.; Kronenberg, Henry M.; Pajevic, Paola Divieti] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA USA.
[Krause, Daniela S.; Scadden, David T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA USA.
[Lotinun, Sutada; Baron, Roland] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
[Bonewald, Lynda] Univ Missouri, Dept Oral Biol, Kansas City, MO 64110 USA.
[Feng, Jian Q.] Baylor Coll Dent, Dept Biomed Sci, Texas A&M Hlth Sci Ctr, Dallas, TX 75246 USA.
[Chen, Min; Weinstein, Lee S.] NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Pajevic, PD (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,Thier 1101, Boston, MA 02114 USA.
EM divieti@helix.mgh.harvard.edu
FU National Institutes of Health [AR060221, DK079161, K08CA138916];
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health; Harvard Stem Cell Institute
FX This work was supported by the National Institutes of Health (grants
AR060221 and DK079161, P. D. P.; grant K08CA138916, D. S. K.), the
Intramural Research Program of National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health (L. S. W.),
and the Harvard Stem Cell Institute (J.Y.W.).
NR 33
TC 46
Z9 46
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 7
PY 2013
VL 121
IS 6
BP 930
EP 939
DI 10.1182/blood-2012-06-437160
PG 10
WC Hematology
SC Hematology
GA 088WO
UT WOS:000314868800014
PM 23160461
ER
PT J
AU Duerschmied, D
Suidan, GL
Demers, M
Herr, N
Carbo, C
Brill, A
Cifuni, SM
Mauler, M
Cicko, S
Bader, M
Idzko, M
Bode, C
Wagner, DD
AF Duerschmied, Daniel
Suidan, Georgette L.
Demers, Melanie
Herr, Nadine
Carbo, Carla
Brill, Alexander
Cifuni, Stephen M.
Mauler, Maximilian
Cicko, Sanja
Bader, Michael
Idzko, Marco
Bode, Christoph
Wagner, Denisa D.
TI Platelet serotonin promotes the recruitment of neutrophils to sites of
acute inflammation in mice
SO BLOOD
LA English
DT Article
ID VON-WILLEBRAND-FACTOR; SELECTIN-DEFICIENT MICE; SMOOTH-MUSCLE-CELLS;
P-SELECTIN; PULMONARY-HYPERTENSION; ENDOTHELIAL-CELLS; MAST-CELLS;
RECEPTOR; 5-HYDROXYTRYPTAMINE; PERMEABILITY
AB The majority of peripheral serotonin is stored in platelets, which secrete it on activation. Serotonin releases Weibel-Palade bodies (WPBs) and we asked whether absence of platelet serotonin affects neutrophil recruitment in inflammatory responses. Tryptophan hydroxylase (Tph)1-deficient mice, lacking non-neuronal serotonin, showed mild leukocytosis compared with wild-type (WT), primarily driven by an elevated neutrophil count. Despite this, 50% fewer leukocytes rolled on unstimulated mesenteric venous endothelium of Tph1(-/-) mice. The velocity of rolling leukocytes was higher in Tph1(-/-) mice, indicating fewer selectin-mediated interactions with endothelium. Stimulation of endothelium with histamine, a secretagogue of WPBs, or injection of serotonin normalized the rolling in Tph1(-/-) mice. Diminished rolling in Tph1(-/-) mice resulted in reduced firm adhesion of leukocytes after lipopolysaccharide treatment. Blocking platelet serotonin uptake with fluoxetine in WT mice reduced serum serotonin by > 80% and similarly reduced leukocyte rolling and adhesion. Four hours after inflammatory stimulation, neutrophil extravasation into lung, peritoneum, and skin wounds was reduced in Tph1(-/-) mice, whereas in vitro neutrophil chemotaxis was independent of serotonin. Survival of lipopolysaccharide-induced endotoxic shock was improved in Tph1(-/-) mice. In conclusion, platelet serotonin promotes the recruitment of neutrophils in acute inflammation, supporting an important role for platelet serotonin in innate immunity. (Blood. 2013;121(6):1008-1015)
C1 [Duerschmied, Daniel; Suidan, Georgette L.; Demers, Melanie; Carbo, Carla; Brill, Alexander; Cifuni, Stephen M.; Wagner, Denisa D.] Immune Dis Inst, Boston, MA 02115 USA.
[Duerschmied, Daniel; Suidan, Georgette L.; Demers, Melanie; Carbo, Carla; Brill, Alexander; Cifuni, Stephen M.; Wagner, Denisa D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Duerschmied, Daniel; Suidan, Georgette L.; Demers, Melanie; Carbo, Carla; Brill, Alexander; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Duerschmied, Daniel; Herr, Nadine; Mauler, Maximilian; Bode, Christoph] Univ Freiburg, Ctr Heart, Dept Cardiol & Angiol 1, D-79106 Freiburg, Germany.
[Cicko, Sanja; Idzko, Marco] Univ Med Ctr Freiburg, Dept Pneumol, Freiburg, Germany.
[Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany.
RP Wagner, DD (reprint author), Immune Dis Inst, 3 Blackfan Cir,3rd Fl, Boston, MA 02115 USA.
EM daniel.duerschmied@uniklinik-freiburg.de;
denisa.wagner@childrens.harvard.edu
OI Bader, Michael/0000-0003-4780-4164
FU National Heart, Lung, and Blood Institute of the National Institutes of
Health [R01 HL095091, R01 HL041002]; Deutsche Forschungsgemeinschaft [DU
1190/3-1]
FX This work was supported by the National Heart, Lung, and Blood Institute
of the National Institutes of Health grants R01 HL095091 (D. D. W.) and
R01 HL041002 (D. D. W.). D. D. was supported by a fellowship of the
Deutsche Forschungsgemeinschaft (DU 1190/3-1).
NR 50
TC 54
Z9 54
U1 1
U2 26
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 7
PY 2013
VL 121
IS 6
BP 1008
EP 1015
DI 10.1182/blood-2012-06-437392
PG 8
WC Hematology
SC Hematology
GA 088WO
UT WOS:000314868800022
PM 23243271
ER
PT J
AU Metallo, CM
Vander Heiden, MG
AF Metallo, Christian M.
Vander Heiden, Matthew G.
TI Understanding Metabolic Regulation and Its Influence on Cell Physiology
SO MOLECULAR CELL
LA English
DT Review
ID MITOCHONDRIAL PYRUVATE CARRIER; C-13 MAGNETIC-RESONANCE; PROTEIN-KINASE;
GLUTAMINE-METABOLISM; GLUCOSE-METABOLISM; FLUX ANALYSIS; ONCOMETABOLITE
2-HYDROXYGLUTARATE; REDUCTIVE CARBOXYLATION; HISTONE DEMETHYLATION;
DEHYDROGENASE KINASE
AB Metabolism impacts all cellular functions and plays a fundamental role in biology. In the last century, our knowledge of metabolic pathway architecture and the genomic landscape of disease has increased exponentially. Combined with these insights, advances in analytical methods for quantifying metabolites and systems approaches to analyze these data now provide powerful tools to study metabolic regulation. Here we review the diverse mechanisms cells use to adapt metabolism to specific physiological states and discuss how metabolic flux analyses can be applied to identify important regulatory nodes to understand normal and pathological cell physiology.
C1 [Metallo, Christian M.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
[Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Vander Heiden, Matthew G.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Vander Heiden, Matthew G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Metallo, CM (reprint author), Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
EM cmetallo@ucsd.edu; mvh@mit.edu
FU American Cancer Society Institutional Research Grant [70-002]; Burroughs
Wellcome Fund; Damon Runyon Cancer Research Foundation; Smith Family
Foundation; National Cancer Institute
FX We thank members of the Metallo and Vander Heiden laboratories for
comments and Brooke Bevis for help generating the figures. C.M.M. is
supported by the American Cancer Society Institutional Research Grant
70-002. M.G.V.H. is supported by the Burroughs Wellcome Fund, the Damon
Runyon Cancer Research Foundation, the Smith Family Foundation, and the
National Cancer Institute.
NR 98
TC 66
Z9 68
U1 6
U2 70
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD FEB 7
PY 2013
VL 49
IS 3
BP 388
EP 398
DI 10.1016/j.molcel.2013.01.018
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 087VO
UT WOS:000314792500002
PM 23395269
ER
PT J
AU Fang, R
Chen, F
Dong, ZH
Hu, D
Barbera, AJ
Clark, EA
Fang, J
Yang, Y
Mei, PC
Rutenberg, M
Li, Z
Zhang, Y
Xu, YW
Yang, HR
Wang, P
Simon, MD
Zhou, QJ
Li, J
Marynick, MP
Li, XT
Lu, HJ
Kaiser, UB
Kingston, RE
Xu, YH
Shi, YJG
AF Fang, Rui
Chen, Fei
Dong, Zhenghong
Hu, Di
Barbera, Andrew J.
Clark, Erin A.
Fang, Jian
Yang, Ying
Mei, Pinchao
Rutenberg, Michael
Li, Ze
Zhang, Ying
Xu, Youwei
Yang, Huirong
Wang, Ping
Simon, Matthew D.
Zhou, Qiongjie
Li, Jing
Marynick, Mark P.
Li, Xiaotian
Lu, Haojie
Kaiser, Ursula B.
Kingston, Robert E.
Xu, Yanhui
Shi, Yujiang Geno
TI LSD2/KDM1B and Its Cofactor NPAC/GLYR1 Endow a Structural and Molecular
Model for Regulation of H3K4 Demethylation
SO MOLECULAR CELL
LA English
DT Article
ID HISTONE LYSINE DEMETHYLASES; LSD1; RECOGNITION; DISEASE; CANCER; DOMAIN;
MARKS; TRANSCRIPTION; METHYLATION; EPIGENETICS
AB Dynamic regulation of histone methylation represents a fundamental epigenetic mechanism underlying eukaryotic gene regulation, yet little is known about how the catalytic activities of histone demethylases are regulated. Here, we identify and characterize NPAC/GLYR1 as an LSD2/KDM1b-specific cofactor that stimulates H3K4me1 and H3K4me2 demethylation. We determine the crystal structures of LSD2 alone and LSD2 in complex with the NPAC linker region in the absence or presence of histone H3 peptide, at resolutions of 2.9, 2.0, and 2.25 angstrom, respectively. These crystal structures and further biochemical characterization define a dodecapeptide of NPAC (residues 214-225) as the minimal functional unit for its cofactor activity and provide structural determinants and a molecular mechanism underlying the intrinsic cofactor activity of NPAC in stimulating LSD2-catalyzed H3K4 demethylation. Thus, these findings establish a model for how a cofactor directly regulates histone demethylation and will have a significant impact on our understanding of catalytic-activity-based epigenetic regulation.
C1 [Fang, Rui; Hu, Di; Barbera, Andrew J.; Clark, Erin A.; Mei, Pinchao; Rutenberg, Michael; Zhou, Qiongjie; Li, Jing; Marynick, Mark P.; Kaiser, Ursula B.; Shi, Yujiang Geno] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, Boston, MA 02115 USA.
[Fang, Rui; Hu, Di; Barbera, Andrew J.; Clark, Erin A.; Mei, Pinchao; Rutenberg, Michael; Zhou, Qiongjie; Li, Jing; Marynick, Mark P.; Kaiser, Ursula B.; Shi, Yujiang Geno] Brigham & Womens Hosp, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Fang, Rui; Hu, Di; Barbera, Andrew J.; Clark, Erin A.; Mei, Pinchao; Rutenberg, Michael; Zhou, Qiongjie; Li, Jing; Marynick, Mark P.; Kaiser, Ursula B.; Shi, Yujiang Geno] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Chen, Fei; Dong, Zhenghong; Hu, Di; Fang, Jian; Yang, Ying; Li, Ze; Zhang, Ying; Xu, Youwei; Yang, Huirong; Wang, Ping; Lu, Haojie; Xu, Yanhui; Shi, Yujiang Geno] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
[Zhang, Ying; Lu, Haojie] Fudan Univ, Dept Chem, Shanghai 200032, Peoples R China.
[Chen, Fei; Dong, Zhenghong; Fang, Jian; Yang, Ying; Li, Ze; Xu, Youwei; Yang, Huirong; Wang, Ping; Xu, Yanhui] Fudan Univ, State Key Lab Genet Engn, Shanghai 200032, Peoples R China.
[Zhou, Qiongjie; Li, Xiaotian] Fudan Univ, Obstet & Gynecol Hosp, Shanghai 200032, Peoples R China.
[Shi, Yujiang Geno] Fudan Univ, Childrens Hosp, Shanghai 200032, Peoples R China.
[Simon, Matthew D.; Kingston, Robert E.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
RP Xu, YH (reprint author), Fudan Univ, Inst Biomed Sci, 130 Dong An Rd, Shanghai 200032, Peoples R China.
EM xuyh@fudan.edu.cn; yujiang_shi@hms.harvard.edu
OI Mei, Pinchao/0000-0002-1564-0372; Li, Jing/0000-0001-7699-4249
FU National Institutes of Health [5R01GM078458]; Brigham and Women's
Hospital Funds to Sustain Research Excellence; National Basic Research
Program of China [2011CB965300, 2009CB918600]; National Natural Science
Foundation of China [81130047, 31270779, 31030019, 11079016, 30870493];
Fok Ying Tung Education Foundation [20090071220012]
FX We thank staff members of beamline BL17U at SSRF for assistance in data
collection and staff members of the Biomedical Core Facility, Fudan
University for mass spectrometry analyses. We thank James Chou, Paco
Kang, and Lisa Schwartz for critical reading of the manuscript. This
work was supported by grants from the National Institutes of Health
(5R01GM078458) and Brigham and Women's Hospital Funds to Sustain
Research Excellence to Y.G.S., and the National Basic Research Program
of China (2011CB965300 and 2009CB918600), the National Natural Science
Foundation of China (81130047, 31270779, 31030019, 11079016, and
30870493), and the Fok Ying Tung Education Foundation (20090071220012).
NR 47
TC 28
Z9 28
U1 1
U2 41
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD FEB 7
PY 2013
VL 49
IS 3
BP 558
EP 570
DI 10.1016/j.molcel.2012.11.019
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 087VO
UT WOS:000314792500018
PM 23260659
ER
PT J
AU Kesselheim, JC
Cassel, CK
AF Kesselheim, Jennifer C.
Cassel, Christine K.
TI Service: An Essential Component of Graduate Medical Education
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Kesselheim, Jennifer C.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Kesselheim, Jennifer C.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Cassel, Christine K.] Amer Board Internal Med, Philadelphia, PA USA.
RP Kesselheim, JC (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
NR 5
TC 8
Z9 9
U1 0
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 7
PY 2013
VL 368
IS 6
BP 500
EP 501
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 083VU
UT WOS:000314494100014
PM 23388001
ER
PT J
AU Thanassoulis, G
Campbell, CY
Owens, DS
Smith, JG
Smith, AV
Peloso, GM
Kerr, KF
Pechlivanis, S
Budoff, MJ
Harris, TB
Malhotra, R
O'Brien, KD
Kamstrup, PR
Nordestgaard, BG
Tybjaerg-Hansen, A
Allison, MA
Aspelund, T
Criqui, MH
Heckbert, SR
Hwang, SJ
Liu, YM
Sjogren, M
van der Pals, J
Kalsch, H
Muhleisen, TW
Nothen, MM
Cupples, LA
Caslake, M
Di Angelantonio, E
Danesh, J
Rotter, JI
Sigurdsson, S
Wong, Q
Erbel, R
Kathiresan, S
Melander, O
Gudnason, V
O'Donnell, CJ
Post, WS
AF Thanassoulis, George
Campbell, Catherine Y.
Owens, David S.
Smith, J. Gustav
Smith, Albert V.
Peloso, Gina M.
Kerr, Kathleen F.
Pechlivanis, Sonali
Budoff, Matthew J.
Harris, Tamara B.
Malhotra, Rajeev
O'Brien, Kevin D.
Kamstrup, Pia R.
Nordestgaard, Borge G.
Tybjaerg-Hansen, Anne
Allison, Matthew A.
Aspelund, Thor
Criqui, Michael H.
Heckbert, Susan R.
Hwang, Shih-Jen
Liu, Yongmei
Sjogren, Marketa
van der Pals, Jesper
Kaelsch, Hagen
Muehleisen, Thomas W.
Noethen, Markus M.
Cupples, L. Adrienne
Caslake, Muriel
Di Angelantonio, Emanuele
Danesh, John
Rotter, Jerome I.
Sigurdsson, Sigurdur
Wong, Quenna
Erbel, Raimund
Kathiresan, Sekar
Melander, Olle
Gudnason, Vilmundur
O'Donnell, Christopher J.
Post, Wendy S.
CA CHARGE Extracoronary Calcium Worki
TI Genetic Associations with Valvular Calcification and Aortic Stenosis
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; CORONARY-ARTERY CALCIUM; RISK-FACTORS; VALVE
CALCIFICATION; MYOCARDIAL-INFARCTION; LP(A) LIPOPROTEIN; HEART-DISEASE;
LONG-TERM; DESIGN; ATHEROSCLEROSIS
AB Background
Limited information is available regarding genetic contributions to valvular calcification, which is an important precursor of clinical valve disease.
Methods
We determined genomewide associations with the presence of aortic-valve calcification (among 6942 participants) and mitral annular calcification (among 3795 participants), as detected by computed tomographic (CT) scanning; the study population for this analysis included persons of white European ancestry from three cohorts participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (discovery population). Findings were replicated in independent cohorts of persons with either CT-detected valvular calcification or clinical aortic stenosis.
Results
One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification (odds ratio per allele, 2.05; P = 9.0x10(-10)), a finding that was replicated in additional white European, African-American, and Hispanic-American cohorts (P<0.05 for all comparisons). Genetically determined Lp(a) levels, as predicted by LPA genotype, were also associated with aortic-valve calcification, supporting a causal role for Lp(a). In prospective analyses, LPA genotype was associated with incident aortic stenosis (hazard ratio per allele, 1.68; 95% confidence interval [CI], 1.32 to 2.15) and aortic-valve replacement (hazard ratio, 1.54; 95% CI, 1.05 to 2.27) in a large Swedish cohort; the association with incident aortic stenosis was also replicated in an independent Danish cohort. Two SNPs (rs17659543 and rs13415097) near the proinflammatory gene IL1F9 achieved genomewide significance for mitral annular calcification (P = 1.5x10(-8) and P = 1.8x10(-8), respectively), but the findings were not replicated consistently.
Conclusions
Genetic variation in the LPA locus, mediated by Lp(a) levels, is associated with aortic-valve calcification across multiple ethnic groups and with incident clinical aortic stenosis. (Funded by the National Heart, Lung, and Blood Institute and others.)
C1 [Thanassoulis, George] McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ, Canada.
[Thanassoulis, George] McGill Univ, Res Inst, Ctr Hlth, Montreal, PQ, Canada.
[Hwang, Shih-Jen; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Framingham, MA USA.
[Thanassoulis, George; Peloso, Gina M.; Hwang, Shih-Jen; Cupples, L. Adrienne; Kathiresan, Sekar; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Peloso, Gina M.; Malhotra, Rajeev; Kathiresan, Sekar; O'Donnell, Christopher J.] Boston Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA 02118 USA.
[Campbell, Catherine Y.; Post, Wendy S.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
[Rotter, Jerome I.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Budoff, Matthew J.] Harbor UCLA, Los Angeles Biomed Res Inst, Los Angeles, CA USA.
[Liu, Yongmei] Wake Forest Sch Med, Winston Salem, NC USA.
[Kerr, Kathleen F.; Wong, Quenna] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
[Heckbert, Susan R.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Allison, Matthew A.; Criqui, Michael H.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Owens, David S.; O'Brien, Kevin D.] Univ Washington, Dept Med, Seattle, WA USA.
[Smith, Albert V.; Aspelund, Thor; Sigurdsson, Sigurdur; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
[Smith, Albert V.; Aspelund, Thor; Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland.
[Harris, Tamara B.] NIA, Bethesda, MD 20892 USA.
[Caslake, Muriel] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
[Di Angelantonio, Emanuele; Danesh, John] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
[Smith, J. Gustav] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Smith, J. Gustav; van der Pals, Jesper] Lund Univ, Dept Cardiol, Lund, Sweden.
[Sjogren, Marketa; Melander, Olle] Lund Univ, Dept Clin Sci, Malmo, Sweden.
[Pechlivanis, Sonali] Univ Essen Gesamthsch, Inst Med Informat Biometry & Epidemiol, Essen, Germany.
[Kaelsch, Hagen; Erbel, Raimund] W German Heart Ctr, Dept Cardiol, Essen, Germany.
[Muehleisen, Thomas W.; Noethen, Markus M.] Univ Bonn, Life & Brain Ctr, Dept Genom, Bonn, Germany.
[Muehleisen, Thomas W.; Noethen, Markus M.] Univ Bonn, Inst Human Genet, Bonn, Germany.
[Noethen, Markus M.] Univ Bonn, German Ctr Neurodegenerat Dis, Bonn, Germany.
[Kamstrup, Pia R.; Tybjaerg-Hansen, Anne] Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, Copenhagen, Denmark.
[Nordestgaard, Borge G.] Copenhagen Univ Hosp, Herlev Hosp, Dept Clin Biochem, Copenhagen, Denmark.
[Nordestgaard, Borge G.; Tybjaerg-Hansen, Anne] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
RP Post, WS (reprint author), Carnegie 568,600 N Wolfe St, Baltimore, MD 21287 USA.
EM wpost@jhmi.edu
RI Aspelund, Thor/C-5983-2008; Gudnason, Vilmundur/K-6885-2015; Smith,
Albert/K-5150-2015; Kerr, Kathleen/A-2893-2013;
OI Aspelund, Thor/0000-0002-7998-5433; Gudnason,
Vilmundur/0000-0001-5696-0084; Smith, Albert/0000-0003-1942-5845;
Cupples, L. Adrienne/0000-0003-0273-7965; Di Angelantonio,
Emanuele/0000-0001-8776-6719; Owens, David/0000-0002-7293-9688; Nothen,
Markus/0000-0002-8770-2464; Allison, Matthew/0000-0003-0777-8272
FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-25195,
N02-HL-6-4278, N01-HC-95159, 95169, RR-024156, R01-HL-071739,
R01-HL-071051, R01-HL-071205, R01-HL-071250, R01-HL-071251,
R01-HL-071252, R01-HL-071258, R01-HL-071259, N01-HC-65226]; Affymetrix
for genotyping services; National Institute on Aging [N01-AG-12100];
National Eye Institute; National Institute on Deafness and Other
Communication Disorders; National Institute on Aging Intramural Research
Program, Hjartavernd (the Icelandic Heart Association); Althingi
(Icelandic parliament); MESA; MESA Family; MESA CARe; MESA SHARe
project; Heinz Nixdorf Recall Study; Heinz Nixdorf Foundation; German
Foundation of Research (DFG); Malmo Diet and Cancer study; Swedish
Cancer Society; Swedish Medical Research Council; Swedish Dairy
Association; Albert Pahlsson Foundation; Gunnar Nilsson Foundation;
Malmo city council; Copenhagen City Heart Study; Danish Heart Foundation
FX The Framingham Heart Study was supported by a grant (N01-HC-25195) from
the National Heart, Lung, and Blood Institute (NHLBI) and an NHLBI
contract (N02-HL-6-4278) with Affymetrix for genotyping services; the
Age, Gene/Environment Susceptibility-Reykjavik Study, by a grant from
the National Institute on Aging (N01-AG-12100) and by the National Eye
Institute, the National Institute on Deafness and Other Communication
Disorders, the NHLBI, the National Institute on Aging Intramural
Research Program, Hjartavernd (the Icelandic Heart Association), and the
Althingi (Icelandic parliament); the MESA, MESA Family, MESA CARe, and
the MESA SHARe project, by grants (N01-HC-95159 through 95169,
RR-024156, R01-HL-071739, R01-HL-071051, R01-HL-071205, R01-HL-071250,
R01-HL-071251, R01-HL-071252, R01-HL-071258, R01-HL-071259,
N02-HL-6-4278, and N01-HC-65226) from the NHLBI; the Heinz Nixdorf
Recall Study, by the Heinz Nixdorf Foundation and the German Foundation
of Research (DFG); the Malmo Diet and Cancer study, by the Swedish
Cancer Society, the Swedish Medical Research Council, the Swedish Dairy
Association, the Albert Pahlsson and Gunnar Nilsson Foundations, and the
Malmo city council; and the Copenhagen City Heart Study, by the Danish
Heart Foundation. Detailed information on support for individual authors
and analyses is available in the Supplementary Appendix.
NR 47
TC 164
Z9 170
U1 2
U2 30
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 7
PY 2013
VL 368
IS 6
BP 503
EP 512
DI 10.1056/NEJMoa1109034
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 083VU
UT WOS:000314494100001
PM 23388002
ER
PT J
AU Tsiamas, P
Liu, B
Cifter, F
Ngwa, WF
Berbeco, RI
Kappas, C
Theodorou, K
Marcus, K
Makrigiorgos, MG
Sajo, E
Zygmanski, P
AF Tsiamas, Panagiotis
Liu, Bo
Cifter, Fulya
Ngwa, Wilfred F.
Berbeco, Ross I.
Kappas, Constantin
Theodorou, Kiriaki
Marcus, Karen
Makrigiorgos, Mike G.
Sajo, Erno
Zygmanski, Piotr
TI Impact of beam quality on megavoltage radiotherapy treatment techniques
utilizing gold nanoparticles for dose enhancement
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID MONTE-CARLO-SIMULATION; RADIATION-THERAPY; X-RAYS; ENERGY;
BRACHYTHERAPY; ELECTRONS; RADIOSENSITIZATION; DNA
AB This study determines the optimal clinical scenarios for gold nanoparticle dose enhancement as a function of irradiation conditions and potential biological targets using megavoltage x-ray beams. Four hundred and eighty clinical beams were studied for different potential cellular or sub-cellular targets. Beam quality was determined based on a 6 MV linac with and without a flattening filter for various delivery conditions. Dose enhancement ratios DER = D-GNP/D-water were calculated for all cases using the GEANT4 Monte Carlo code and the CEPXS/ONEDANT radiation transport deterministic code. Dose enhancement using GEANT4 agreed with CEPXS/ONEDANT. DER for unflattened beams is similar to 2 times larger than for flattened beams. The maximum DER values were calculated for split-IMRT fields (similar to 6) and for out-of-field areas of an unflattened linac (similar to 17). In-field DER values, at the surface of gold nanoparticles, ranged from 2.2 to 4.2 (flattened beam) and from 3 to 4.7 (unflattened beams). For a GNP cluster with thicknesses of 10 and 100 nm, the DER ranges from 14% to 287%. DER is the greatest for split-IMRT, larger depths, out-of-field areas and/or unflattened linac. Mapping of a GNP location in tumor and normal tissue is essential for efficient and safe delivery of nanoparticle-enhanced radiotherapy.
C1 [Tsiamas, Panagiotis; Liu, Bo; Ngwa, Wilfred F.; Berbeco, Ross I.; Marcus, Karen; Makrigiorgos, Mike G.; Zygmanski, Piotr] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA.
[Tsiamas, Panagiotis; Liu, Bo; Ngwa, Wilfred F.; Berbeco, Ross I.; Marcus, Karen; Makrigiorgos, Mike G.; Zygmanski, Piotr] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Tsiamas, Panagiotis; Kappas, Constantin; Theodorou, Kiriaki] Univ Thessaly, Sch Med, Dept Med Phys, Larisa 4100, Greece.
[Liu, Bo] Heidelberg Univ, Med Fac Mannheim, D-68167 Mannheim, Germany.
[Cifter, Fulya; Sajo, Erno] Univ Massachusetts Lowell, Dept Phys & Appl Phys, Lowell, MA 01854 USA.
RP Sajo, E (reprint author), Univ Massachusetts Lowell, Dept Phys & Appl Phys, Lowell, MA 01854 USA.
EM erno_sajo@uml.edu; pzygmanski@lroc.harvard.edu
NR 28
TC 27
Z9 27
U1 1
U2 38
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD FEB 7
PY 2013
VL 58
IS 3
BP 451
EP 464
DI 10.1088/0031-9155/58/3/451
PG 14
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 071CV
UT WOS:000313564200006
PM 23302438
ER
PT J
AU Salari, E
Unkelbach, J
AF Salari, Ehsan
Unkelbach, Jan
TI A column-generation-based method for multi-criteria direct aperture
optimization
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID INTENSITY-MODULATED RADIOTHERAPY; FLUENCE MAP OPTIMIZATION;
RADIATION-THERAPY; PARETO SURFACES; IMRT; ALGORITHMS
AB Navigation-based multi-criteria optimization has been introduced to radiotherapy planning in order to allow the interactive exploration of trade-offs between conflicting clinical goals. However, this has been mainly applied to fluence map optimization. The subsequent leaf sequencing step may cause dose discrepancy, leading to human iteration loops in the treatment planning process that multi-criteria methods were meant to avoid. To circumvent this issue, this paper investigates the application of direct aperture optimization methods in the context of multi-criteria optimization. We develop a solution method to directly obtain a collection of apertures that can adequately span the entire Pareto surface. To that end, we extend the column generation method for direct aperture optimization to a multi-criteria setting in which apertures that can improve the entire Pareto surface are sequentially identified and added to the treatment plan. Our proposed solution method can be embedded in a navigation-based multi-criteria optimization framework, in which the treatment planner explores the trade-off between treatment objectives directly in the space of deliverable apertures. Our solution method is demonstrated for a paraspinal case where the trade-off between target coverage and spinal-cord sparing is studied. The computational results validate that our proposed method obtains a balanced approximation of the Pareto surface over a wide range of clinically relevant plans.
C1 [Salari, Ehsan] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Salari, E (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
EM salari.ehsan@mgh.harvard.edu
FU National Cancer Institute [R01 CA118200-01]
FX The project described was supported by Award No R01 CA118200-01 from the
National Cancer Institute. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
National Cancer Institute or the National Institutes of Health. The
authors would like to thank David Craft for providing feedback on the
manuscript.
NR 30
TC 7
Z9 7
U1 0
U2 7
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD FEB 7
PY 2013
VL 58
IS 3
BP 621
EP 639
DI 10.1088/0031-9155/58/3/621
PG 19
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 071CV
UT WOS:000313564200016
PM 23318527
ER
PT J
AU Dhabangi, A
Mworozi, E
Lubega, IR
Cserti-Gazdewich, CM
Maganda, A
Dzik, WH
AF Dhabangi, Aggrey
Mworozi, Edison
Lubega, Irene R.
Cserti-Gazdewich, Christine M.
Maganda, Albert
Dzik, Walter H.
TI The effect of blood storage age on treatment of lactic acidosis by
transfusion in children with severe malarial anaemia: a pilot,
randomized, controlled trial
SO MALARIA JOURNAL
LA English
DT Article
DE Severe malarial anaemia; Lactic acidosis; Blood storage age; Blood
transfusion; Children
ID AFRICAN CHILDREN; CELLS
AB Background: Severe malarial anaemia requiring blood transfusion is a life-threatening condition affecting millions of children in sub-Saharan Africa. Up to 40% of children with severe malarial anaemia have associated lactic acidosis. Lactic acidosis in these children is strongly associated with fatal outcomes and is corrected by blood transfusion. However, it is not known whether the storage age of blood for transfusion affects resolution of lactic acidosis. The objective of this pilot study was to evaluate the effect of blood storage age on resolution of lactic acidosis in children with severe malarial anaemia and demonstrate feasibility of conducting a large trial.
Methods: Children aged six to 59 months admitted to Acute Care Unit of Mulago Hospital (Kampala, Uganda) with severe malarial anaemia (haemoglobin <= 5 g/dL) and lactic acidosis (blood lactate >= 5 mmol/L), were randomly assigned to receive either blood of short storage age (one to 10 days) or long storage age (21-35 days) by gravity infusion. Seventy-four patients were enrolled and randomized to two equal-sized study arms. Physiological measurements, including blood lactate, oxygen saturation, haemoglobin, and vital signs, were taken at baseline, during and after transfusion. The primary outcome variable was the proportion of children whose lactic acidosis resolved by four hours after transfusion.
Results: Thirty-four of 37 (92%) of the children in the short storage treatment arm compared to 30/37 (81%) in the long storage arm achieved a blood lactate <5 mmol/L by four hours post transfusion (p value = 0.308). The mean time to lactic acidosis resolution was 2.65 hours (95% CI; 2.25-3.05) in the short storage arm, compared to 3.35 hours (95% CI; 2.60-4.10) in the long storage arm (p value = 0.264).
Conclusion: Pilot data suggest that among children with severe malarial anaemia and lactic acidosis transfused with packed red blood cells, the storage age of blood does not affect resolution of lactic acidosis. The results support a larger and well-powered study which is under way.
C1 [Dhabangi, Aggrey] Makerere Univ, Child Hlth & Dev Ctr, Kampala, Uganda.
[Mworozi, Edison; Lubega, Irene R.] Minist Hlth Kampala, Mulago Hosp, Dept Paediat & Child Hlth, Kampala, Uganda.
[Cserti-Gazdewich, Christine M.] Univ Toronto, Dept Hematol, Toronto, ON, Canada.
[Maganda, Albert] Baylor Coll Med Childrens Fdn, Kampala, Uganda.
[Dzik, Walter H.] Massachusetts Gen Hosp, Blood Transfus Serv, Boston, MA 02114 USA.
RP Dhabangi, A (reprint author), Makerere Univ, Child Hlth & Dev Ctr, Kampala, Uganda.
EM adhabangi@gmail.com
FU Belgian Technical Co-operation (BTC); Carnegie next generation of
academics project
FX This research was supported in part by scholarship grants from the
Belgian Technical Co-operation (BTC) and the Carnegie next generation of
academics project 2010 - 2012. The Cytoadherence in Paediatric Malaria
(CPM) project provided kind donations of all the study equipment used.
The authors wish to thank the research assistants (Josephine Badaru and
Victor Tumukunde), the laboratory technicians of ACU (Edson Sabuni,
Rehema Namwanje, Timothy Pande and Josephine Birungi), Dr Dorothy
Kyeyune, Director of the Uganda National Blood Transfusion Service, all
the paediatricians (particularly Dr Ezekiel Mupere, Dr Eric Wobudeya and
Prof Heather A Hume) in the Department of Paediatrics and Child Health
at Makerere University for all their respective support. We thank the
caretakers and the children who participated in this study. We do
appreciate Uganda Society for Health Scientists (USHS) for the
manuscript-writing workshop.
NR 14
TC 9
Z9 9
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD FEB 6
PY 2013
VL 12
AR 55
DI 10.1186/1475-2875-12-55
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 118ZI
UT WOS:000317065700001
PM 23388470
ER
PT J
AU Mueller, S
Wang, DH
Fox, MD
Yeo, BTT
Sepulcre, J
Sabuncu, MR
Shafee, R
Lu, J
Liu, HS
AF Mueller, Sophia
Wang, Danhong
Fox, Michael D.
Yeo, B. T. Thomas
Sepulcre, Jorge
Sabuncu, Mert R.
Shafee, Rebecca
Lu, Jie
Liu, Hesheng
TI Individual Variability in Functional Connectivity Architecture of the
Human Brain
SO NEURON
LA English
DT Article
ID HUMAN CEREBRAL-CORTEX; SURFACE-BASED ANALYSIS; INTERSUBJECT VARIABILITY;
PREFRONTAL CORTEX; GENETIC INFLUENCES; EVOLUTION; NETWORKS; SYSTEM;
CYTOARCHITECTURE; MORPHOMETRY
AB The fact that people think or behave differently from one another is rooted in individual differences in brain anatomy and connectivity. Here, we used repeated-measurement resting-state functional MRI to explore intersubject variability in connectivity. Individual differences in functional connectivity were heterogeneous across the cortex, with significantly higher variability in heteromodal association cortex and lower variability in unimodal cortices. Intersubject variability in connectivity was significantly correlated with the degree of evolutionary cortical expansion, suggesting a potential evolutionary root of functional variability. The connectivity variability was also related to variability in sulcal depth but not cortical thickness, positively correlated with the degree of long-range connectivity but negatively correlated with local connectivity. A meta-analysis further revealed that regions predicting individual differences in cognitive domains are predominantly located in regions of high connectivity variability. Our findings have potential implications for understanding brain evolution and development, guiding intervention, and interpreting statistical maps in neuroimaging.
C1 [Mueller, Sophia; Wang, Danhong; Yeo, B. T. Thomas; Sepulcre, Jorge; Sabuncu, Mert R.; Liu, Hesheng] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Mueller, Sophia; Sepulcre, Jorge; Shafee, Rebecca] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Mueller, Sophia] Univ Munich, Inst Clin Radiol, D-81377 Munich, Germany.
[Fox, Michael D.] Brigham & Womens Hosp, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Yeo, B. T. Thomas] Duke NUS Grad Med Sch, Neurosci & Behav Disorders Program, Singapore 169857, Singapore.
[Sepulcre, Jorge] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Sepulcre, Jorge] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Lu, Jie] Capital Med Univ, Xuanwu Hosp, Dept Radiol, Beijing 100053, Peoples R China.
RP Lu, J (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Radiol, Beijing 100053, Peoples R China.
EM jielu@nmr.mgh.harvard.edu; hesheng@nmr.mgh.harvard.edu
OI Liu, Hesheng/0000-0002-7233-1509; Yeo, B.T. Thomas/0000-0002-0119-3276
FU NINDS [K25NS069805]; NARSAD; German Research Foundation [MU 3222/2-1]
FX This work was supported by NINDS grant K25NS069805, NARSAD Young
Investigator Grant, and a research grant from the German Research
Foundation (MU 3222/2-1). The authors would like to thank Drs. Randy L.
Buckner and Bruce Fischl for discussions and comments on the manuscript.
NR 64
TC 124
Z9 128
U1 7
U2 52
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
J9 NEURON
JI Neuron
PD FEB 6
PY 2013
VL 77
IS 3
BP 586
EP 595
DI 10.1016/j.neuron.2012.12.028
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 118MY
UT WOS:000317030800018
PM 23395382
ER
PT J
AU Zeliadt, SB
Hannon, PA
Trivedi, RB
Bonner, LM
Vu, TT
Simons, C
Kimmie, CA
Hu, EY
Zipperer, C
Lin, DW
AF Zeliadt, Steven B.
Hannon, Peggy A.
Trivedi, Ranak B.
Bonner, Laura M.
Vu, Thuy T.
Simons, Carol
Kimmie, Crystal A.
Hu, Elaine Y.
Zipperer, Chris
Lin, Daniel W.
TI A preliminary exploration of the feasibility of offering men information
about potential prostate cancer treatment options before they know their
biopsy results
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
DE Prostate cancer; Biopsy; Decision aid; Prostate biopsy; Treatment
decision making
ID DECISION-MAKING; AIDS
AB Background: A small pre-test study was conducted to ascertain potential harm and anxiety associated with distributing information about possible cancer treatment options at the time of biopsy, prior to knowledge about a definitive cancer diagnosis. Priming men about the availability of multiple options before they have a confirmed diagnosis may be an opportunity to engage patients in more informed decision-making.
Methods: Men with an elevated PSA test or suspicious Digital Rectal Examination (DRE) who were referred to a urology clinic for a biopsy were randomized to receive either the clinic's usual care (UC) biopsy instruction sheet (n = 11) or a pre-biopsy educational (ED) packet containing the biopsy instruction sheet along with a booklet about the biopsy procedure and a prostate cancer treatment decision aid originally written for newly diagnosed men that described in detail possible treatment options (n = 18).
Results: A total of 62% of men who were approached agreed to be randomized, and 83% of the ED group confirmed they used the materials. Anxiety scores were similar for both groups while awaiting the biopsy procedure, with anxiety scores trending lower in the ED group: 41.2 on a prostate-specific anxiety instrument compared to 51.7 in the UC group (p = 0.13). ED participants reported better overall quality of life while awaiting biopsy compared to the UC group (76.4 vs. 48.5, p = 0.01). The small number of men in the ED group who went on to be diagnosed with cancer reported being better informed about the risks and side effects of each option compared to men diagnosed with cancer in the UC group (p = 0.07). In qualitative discussions, men generally reported they found the pre-biopsy materials to be helpful and indicated having information about possible treatment options reduced their anxiety. However, 2 of 18 men reported they did not want to think about treatment options until after they knew their biopsy results.
Conclusions: In this small sample offering pre-biopsy education about potential treatment options was generally well received by patients, appeared to be beneficial to men who went on to be diagnosed, and did not appear to increase anxiety unnecessarily among those who had a negative biopsy.
C1 [Zeliadt, Steven B.; Trivedi, Ranak B.; Bonner, Laura M.; Simons, Carol; Hu, Elaine Y.] VA Puget Sound Hlth Care Syst, Northwest HSR&D Ctr Excellence, Seattle, WA 98101 USA.
[Zeliadt, Steven B.; Hannon, Peggy A.; Trivedi, Ranak B.; Vu, Thuy T.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Kimmie, Crystal A.] Seattle Inst Biomed & Clin Res, Seattle, WA USA.
[Zipperer, Chris] Washington State Dept Hlth, Canc Prevent & Control Unit, Olympia, WA USA.
[Kimmie, Crystal A.; Lin, Daniel W.] Dept Vet Affairs Med Ctr, Urol Serv, Seattle, WA USA.
[Lin, Daniel W.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA.
RP Zeliadt, SB (reprint author), VA Puget Sound Hlth Care Syst, Northwest HSR&D Ctr Excellence, Metropolitan Pk West,1100 Olive Way 1400, Seattle, WA 98101 USA.
EM szeliadt@uw.edu
FU Washington State Department of Health [N17493]; Centers for Disease
Control and Prevention; National Cancer Institute through the Cancer
Prevention and Control Research Network [1-U48-DP-000050]; Department of
Veterans Affairs [HFP 83-027]
FX This work was conducted at the VA Puget Sound Healthcare System.
Financial support for this study was provided in part by a contract with
the Washington State Department of Health (Contract Number N17493; CK),
the Centers for Disease Control and Prevention and the National Cancer
Institute through the Cancer Prevention and Control Research Network
(Grant 1-U48-DP-000050; PAH; TV), and by the Department of Veterans
Affairs (HFP 83-027; SBZ). The funding agreement ensured the authors'
independence in designing the study, interpreting the data, writing, and
publishing the report. The views expressed in this article are those of
the authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or of the United States government.
NR 29
TC 3
Z9 3
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD FEB 6
PY 2013
VL 13
AR 19
DI 10.1186/1472-6947-13-19
PG 9
WC Medical Informatics
SC Medical Informatics
GA 107NL
UT WOS:000316224400001
PM 23388205
ER
PT J
AU Jeon, JY
Jeong, DH
Park, MG
Lee, JW
Chu, SH
Park, JH
Lee, MK
Sato, K
Ligibel, JA
Meyerhardt, JA
Kim, NK
AF Jeon, Justin Y.
Jeong, Duck Hyoun
Park, Min Geun
Lee, Ji-Won
Chu, Sang Hui
Park, Ji-Hye
Lee, Mi Kyung
Sato, Kaori
Ligibel, Jennifer A.
Meyerhardt, Jeffrey A.
Kim, Nam Kyu
TI Impact of Diabetes on Oncologic Outcome of Colorectal Cancer Patients:
Colon vs. Rectal Cancer
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; INDEPENDENT RISK-FACTOR; IGF-BINDING-PROTEINS; IOWA
WOMENS HEALTH; SERUM C-PEPTIDE; MELLITUS; INSULIN; TYPE-2; METAANALYSIS;
MORTALITY
AB Background: To evaluate the impact of diabetes on outcomes in colorectal cancer patients and to examine whether this association varies by the location of tumor (colon vs. rectum).
Patients and methods: This study includes 4,131 stage I-III colorectal cancer patients, treated between 1995 and 2007 (12.5% diabetic, 53% colon, 47% rectal) in South Korea. Cox proportional hazards modeling was used to determine the prognostic influence of DM on survival endpoints.
Results: Colorectal cancer patients with DM had significantly worse disease-free survival (DFS) [hazard ratio (HR) 1.17, 95% confidence interval (CI): 1.00-1.37] compared with patients without DM. When considering colon and rectal cancer independently, DM was significantly associated with worse overall survival (OS) (HR: 1.46, 95% CI: 1.11-1.92), DFS (HR: 1.45, 95% CI: 1.15-1.84) and recurrence-free survival (RFS) (HR: 1.32, 95% CI: 0.98-1.76) in colon cancer patients. No association for OS, DFS or RFS was observed in rectal cancer patients. There was significant interaction of location of tumor (colon vs. rectal cancer) with DM on OS (P = 0.009) and DFS (P = 0.007).
Conclusions: This study suggests that DM negatively impacts survival outcomes of patients with colon cancer but not rectal cancer.
C1 [Jeong, Duck Hyoun; Park, Min Geun; Kim, Nam Kyu] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea.
[Jeon, Justin Y.; Sato, Kaori; Ligibel, Jennifer A.; Meyerhardt, Jeffrey A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Jeon, Justin Y.; Park, Ji-Hye; Lee, Mi Kyung] Yonsei Univ, Sports Med Lab, Seoul 120749, South Korea.
[Lee, Ji-Won] Yonsei Univ, Coll Med, Dept Family Med, Seoul, South Korea.
[Chu, Sang Hui] Yonsei Univ, Coll Nursing, Biobehav Res Ctr, Dept Clin Nursing Sci, Seoul 120749, South Korea.
[Chu, Sang Hui] Yonsei Univ, Coll Nursing, Biobehav Res Ctr, Nursing Policy & Res Inst, Seoul 120749, South Korea.
RP Meyerhardt, JA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM jmeyerhardt@partners.org; namkyuk@yuhs.ac
OI Kim, Nam-Kyu/0000-0003-0639-5632
FU NCI NIH HHS [R01 CA149222]
NR 51
TC 14
Z9 14
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 6
PY 2013
VL 8
IS 2
AR e55196
DI 10.1371/journal.pone.0055196
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092WJ
UT WOS:000315153400068
PM 23405123
ER
PT J
AU Liu, Y
Yang, XS
Guo, CY
Nie, P
Liu, Y
Ma, J
AF Liu, Yong
Yang, Xuesen
Guo, Chenying
Nie, Pan
Liu, Yan
Ma, Jie
TI Essential Role of MFG-E8 for Phagocytic Properties of Microglial Cells
SO PLOS ONE
LA English
DT Article
ID GLOBULE-EGF FACTOR-8; SYSTEMIC-LUPUS-ERYTHEMATOSUS; APOPTOTIC CELLS;
NEURONAL DEATH; MACROPHAGE CLEARANCE; LENTIVIRUS VECTOR; VIABLE NEURONS;
PHOSPHATIDYLSERINE; DISEASE; IDENTIFICATION
AB Milk fat globule factor-E8 (MFG-E8) has been regarded as a key factor involved in the phagocytosis of apoptotic cells. We induced a lentivirus into the microglial cells for the augmentation or abrogation of MFG-E8 expression in mouse microglial cells, and investigated phagocytosis of phosphatidylserine tagged human red blood cells (hRBCs) in co-cultures. Increased MFG-E8 levels were associated with a significant increase in phagocytic activity compared to the controls. Conversely, phagocytosis dramitically decreased due to the abrogation of MFG-E8. In addition, the expression of the inflammatory cytokines, TNF-alpha and IL-1 beta, also increased or decreased in the microglial cells with the augmentation or abrogation of MFG-E8, respectively. Our findings indicate that the enhanced expression of MFG-E8 could increase phagocytosis of apoptotic cells; conversely, the rate of phagocytosis and the expression of inflammatory cytokines decreased when MFG-E8 expression was knocked down. Our results confirm that MFG-E8 plays an important role in phagocytosis, and possibly serves as an essential signal molecule for microglial cells.
C1 [Liu, Yong] Third Mil Med Univ, SW Eye Hosp, Southwest Hosp, Chongqing, Peoples R China.
[Yang, Xuesen] Third Mil Med Univ, Inst Trop Med, Chongqing, Peoples R China.
[Guo, Chenying; Ma, Jie] Harvard Univ, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Dept Ophthalmol,Med Sch, Boston, MA USA.
[Nie, Pan; Liu, Yan] Southwest Univ, Coll Life Sci, Chongqing, Peoples R China.
RP Liu, Y (reprint author), Third Mil Med Univ, SW Eye Hosp, Southwest Hosp, Chongqing, Peoples R China.
EM liu_yong2012@yahoo.com
FU National Natural Science Foundation of China [30700931, 30970672]
FX This study was supported by the National Natural Science Foundation of
China (No. 30700931 to Yong Liu and No. 30970672 to Xuesen Yang). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 38
TC 8
Z9 9
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 6
PY 2013
VL 8
IS 2
AR e55754
DI 10.1371/journal.pone.0055754
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092WJ
UT WOS:000315153400154
PM 23405209
ER
PT J
AU Gallagher, TQ
Brigger, MT
Hartnick, CJ
AF Gallagher, Thomas Q.
Brigger, Matthew T.
Hartnick, Christopher J.
TI Bleeding Risk and Dexamethasone Use in Children Undergoing Tonsillectomy
Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Gallagher, Thomas Q.] USN, Med Ctr Portsmouth, Dept Otolaryngol, Portsmouth, VA USA.
[Brigger, Matthew T.] USN, San Diego Med Ctr, Dept Otolaryngol, San Diego, CA 92152 USA.
[Hartnick, Christopher J.] Massachusetts Eye & Ear Infirm, Dept Pediat Otolaryngol, Boston, MA 02114 USA.
RP Gallagher, TQ (reprint author), USN, Med Ctr Portsmouth, Dept Otolaryngol, Portsmouth, VA USA.
EM christopher_hartnick@meei.harvard.edu
NR 2
TC 1
Z9 1
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 6
PY 2013
VL 309
IS 5
BP 437
EP 438
DI 10.1001/jama.2012.113521
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 083LY
UT WOS:000314466900012
PM 23385257
ER
PT J
AU Bangalore, S
Steg, PG
Bhatt, DL
AF Bangalore, Sripal
Steg, P. Gabriel
Bhatt, Deepak L.
TI beta-Blocker Use for Patients With or at Risk for Coronary Artery
Disease Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID MYOCARDIAL-INFARCTION; ATENOLOL
C1 [Bangalore, Sripal] NYU, Sch Med, New York, NY USA.
[Steg, P. Gabriel] Univ Paris Diderot, Paris, France.
[Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA.
RP Bangalore, S (reprint author), NYU, Sch Med, New York, NY USA.
EM sripalbangalore@gmail.com
RI Bangalore, Sripal/B-6246-2013;
OI Bangalore, Sripal/0000-0001-9485-0652
NR 6
TC 1
Z9 1
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 6
PY 2013
VL 309
IS 5
BP 439
EP 440
DI 10.1001/jama.2012.128872
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 083LY
UT WOS:000314466900016
PM 23385261
ER
PT J
AU Axelrod, L
Shah, DJ
Jena, AB
AF Axelrod, Lloyd
Shah, Deep J.
Jena, Anupam B.
TI The European Working Time Directive An Uncontrolled Experiment in
Medical Care and Education
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
C1 [Axelrod, Lloyd; Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Axelrod, Lloyd] Massachusetts Gen Hosp, Div Endocrine, Boston, MA 02114 USA.
[Shah, Deep J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Jena, Anupam B.] Hlth Care Policy, Boston, MA USA.
[Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA.
RP Axelrod, L (reprint author), Massachusetts Gen Hosp, Dept Med, Div Endocrine, Boston, MA 02114 USA.
EM laxelrod@partners.org
NR 8
TC 15
Z9 15
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 6
PY 2013
VL 309
IS 5
BP 447
EP 448
DI 10.1001/jama.2012.148065
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 083LY
UT WOS:000314466900023
PM 23385268
ER
PT J
AU Inouye, SK
O'Connell, JJ
Puelle, MR
AF Inouye, Sharon K.
O'Connell, James J.
Puelle, Margaret R.
TI Falling Off the Edge
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID HOMELESS ADULTS; MENTAL-ILLNESS
C1 [Inouye, Sharon K.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Cambridge, MA 02138 USA.
[O'Connell, James J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Cambridge, MA 02138 USA.
[Inouye, Sharon K.; O'Connell, James J.] Boston Healthcare Homeless Program, Boston, MA USA.
RP Inouye, SK (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Cambridge, MA 02138 USA.
EM agingbraincenter@hsl.harvard.edu
NR 9
TC 0
Z9 0
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 6
PY 2013
VL 309
IS 5
BP 451
EP 452
DI 10.1001/jama.2012.214089
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 083LY
UT WOS:000314466900025
PM 23385270
ER
PT J
AU Sano, M
AF Sano, Mary
TI Never Too Fit for Body and Mind
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID PHYSICAL-ACTIVITY; CARDIORESPIRATORY FITNESS; MORTALITY; MEN;
IMPAIRMENT; EXERCISE; ADULTS; WOMEN; RISK
C1 [Sano, Mary] Mt Sinai Sch Med, New York, NY USA.
[Sano, Mary] James J Peters Vet Affairs Med Ctr, New York, NY USA.
[Sano, Mary] Mt Sinai Sch Med, Bronx, NY USA.
[Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
RP Sano, M (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM mary.sano@mssm.edu
FU NIA NIH HHS [P50 AG005138]
NR 11
TC 0
Z9 0
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 5
PY 2013
VL 158
IS 3
BP 213
EP 214
DI 10.7326/0003-4819-158-3-201302050-00013
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 087JP
UT WOS:000314757900010
PM 23381042
ER
PT J
AU Rueda, BR
Davis, JS
AF Rueda, Bo R.
Davis, John S.
TI No REST for fibroids
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Editorial Material
ID UTERINE LEIOMYOMA; PATHWAY; MYOMETRIUM
C1 [Rueda, Bo R.] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Davis, John S.] VA Nebraska Western Iowa Hlth Care Syst, Res Serv, Omaha, NE 68105 USA.
[Davis, John S.] Univ Nebraska Med Ctr, Olson Ctr Womens Hlth, Dept Obstet & Gynecol, Omaha, NE 68198 USA.
RP Davis, JS (reprint author), VA Nebraska Western Iowa Hlth Care Syst, Res Serv, Omaha, NE 68105 USA.
EM jsdavis@unmc.edu
NR 18
TC 0
Z9 0
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 5
PY 2013
VL 110
IS 6
BP 1980
EP 1981
DI 10.1073/pnas.1222730110
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093RQ
UT WOS:000315209800016
PM 23355686
ER
PT J
AU Tomasetti, C
Vogelstein, B
Parmigiani, G
AF Tomasetti, Cristian
Vogelstein, Bert
Parmigiani, Giovanni
TI Half or more of the somatic mutations in cancers of self-renewing
tissues originate prior to tumor initiation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE cancer evolution; mathematical modeling; stochastic processes; driver
mutation; passenger mutation
ID STEM-CELLS; EVOLUTION; PROGRESSION; GENES; LANDSCAPE; LEUKEMIA; GENOME;
TIME
AB Although it has been hypothesized that some of the somatic mutations found in tumors may occur before tumor initiation, there is little experimental or conceptual data on this topic. To gain insights into this fundamental issue, we formulated a mathematical model for the evolution of somatic mutations in which all relevant phases of a tissue's history are considered. The model makes the prediction, validated by our empirical findings, that the number of somatic mutations in tumors of self-renewing tissues is positively correlated with the age of the patient at diagnosis. Importantly, our analysis indicates that half or more of the somatic mutations in certain tumors of self-renewing tissues occur before the onset of neoplasia. The model also provides a unique way to estimate the in vivo tissue-specific somatic mutation rates in normal tissues directly from the sequencing data of tumors. Our results have substantial implications for the interpretation of the large number of genome-wide cancer studies now being undertaken.
C1 [Tomasetti, Cristian; Parmigiani, Giovanni] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Tomasetti, Cristian; Parmigiani, Giovanni] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Vogelstein, Bert] Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA.
[Vogelstein, Bert] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA.
RP Tomasetti, C (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
EM cristian@jimmy.harvard.edu; bertvog@gmail.com; gp@jimmy.harvard.edu
OI Tomasetti, Cristian/0000-0003-3277-4804
FU National Institutes of Health (NIH) [T32 CA009337]; NIH/National Cancer
Institute [5P30 CA006516-46]
FX C.T. was supported in part by the National Institutes of Health (NIH)
under Grant T32 CA009337. G. P. was supported in part by the
NIH/National Cancer Institute Grant 5P30 CA006516-46.
NR 26
TC 110
Z9 113
U1 1
U2 31
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 5
PY 2013
VL 110
IS 6
BP 1999
EP 2004
DI 10.1073/pnas.1221068110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093RQ
UT WOS:000315209800019
PM 23345422
ER
PT J
AU Liu, SZ
Ho, CK
Ouyang, J
Zou, L
AF Liu, Shizhou
Ho, Chu Kwen
Ouyang, Jian
Zou, Lee
TI Nek1 kinase associates with ATR-ATRIP and primes ATR for efficient DNA
damage signaling
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID REPLICATION CHECKPOINT RESPONSE; CELL-CYCLE ARREST; 2-DEPENDENT
PHOSPHORYLATION; G2/M CHECKPOINT; CHK1 ACTIVATION; PROTEIN-KINASE;
KIDNEY FAILURE; CLASPIN; MUTATIONS; DEGRADATION
AB The master checkpoint kinase ATR (ATM and Rad3-related) and its partner ATRIP (ATR-interacting protein) exist as a complex and function together in the DNA damage response. Unexpectedly, we found that the stability of the ATR-ATRIP complex is regulated by an unknown kinase independently of DNA damage. In search for this regulator of ATR-ATRIP, we found that a single member of the NIMA (never in mitosis A)-related kinase family, Nek1, is critical for initiating the ATR response. Upon DNA damage, cells lacking Nek1 failed to efficiently phosphorylate multiple ATR substrates and support ATR autophosphorylation at threnine 1989, one of the earliest events during the ATR response. The ability of Nek1 to promote ATR activation relies on the kinase activity of Nek1 and its interaction with ATR-ATRIP. Importantly, even in undamaged cells, Nek1 is required for maintaining the levels of ATRIP, the association between ATR and ATRIP, and the basal kinase activity of ATR. Thus, as an ATR-associated kinase, Nek1, enhances the stability and activity of ATR-ATRIP before DNA damage, priming ATR-ATRIP for a robust DNA damage response.
C1 [Liu, Shizhou; Ho, Chu Kwen; Ouyang, Jian; Zou, Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Charlestown, MA 02129 USA.
[Zou, Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Zou, Lee] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Liu, Shizhou] China Med Univ, Affiliated Hosp 1, Dept Med Oncol, Shenyang 110001, Peoples R China.
RP Liu, SZ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Charlestown, MA 02129 USA.
EM Liu_shizhou@hotmail.com; zou.lee@mgh.harvard.edu
FU National Institutes of Health [GM076388]; Federal Share of Proton Income
FX We thank members of the Zou laboratory for helpful discussions. This
work was supported by the National Institutes of Health Grant GM076388
and a grant funded by the Federal Share of Proton Income (to L.Z.). L.Z.
is a Jim and Ann Orr Massachusetts General Hospital Research Scholar.
NR 46
TC 14
Z9 14
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 5
PY 2013
VL 110
IS 6
BP 2175
EP 2180
DI 10.1073/pnas.1217781110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093RQ
UT WOS:000315209800049
PM 23345434
ER
PT J
AU Yan, D
Zhu, Y
Walsh, T
Xie, DH
Yuan, HJ
Sirmaci, A
Fujikawa, T
Wong, ACY
Loh, TL
Du, LL
Grati, M
Vlajkovic, SM
Blanton, S
Ryan, AF
Chen, ZY
Thorne, PR
Kachar, B
Tekin, M
Zhao, HB
Housley, GD
King, MC
Liu, XZ
AF Yan, Denise
Zhu, Yan
Walsh, Tom
Xie, Dinghua
Yuan, Huijun
Sirmaci, Asli
Fujikawa, Taro
Wong, Ann Chi Yan
Loh, Tze L.
Du, Lilin
Grati, M'hamed
Vlajkovic, Srdjan M.
Blanton, Susan
Ryan, Allen F.
Chen, Zheng-Yi
Thorne, Peter R.
Kachar, Bechara
Tekin, Mustafa
Zhao, Hong-Bo
Housley, Gary D.
King, Mary-Claire
Liu, Xue Z.
TI Mutation of the ATP-gated P2X(2) receptor leads to progressive hearing
loss and increased susceptibility to noise
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE channel; deafness; genomics; presbycusis
ID ION CHANNELS; AUDITORY NEUROTRANSMISSION; SOUND TRANSDUCTION; COCHLEAR
FUNCTION; RAT COCHLEA; SUBUNIT; MOUSE; LOCALIZATION; STEREOCILIA;
EXPRESSION
AB Age-related hearing loss and noise-induced hearing loss are major causes of human morbidity. Here we used genetics and functional studies to showthat a shared cause of these disordersmay be loss of function of the ATP-gated P2X(2) receptor (ligand-gated ion channel, purinergic receptor 2) that is expressed in sensory and supporting cells of the cochlea. Genomic analysis of dominantly inherited, progressive sensorineural hearing loss DFNA41 in a six-generation kindred revealed a rare heterozygous allele, P2RX2 c.178G > T (p.V60L), at chr12: 133,196,029, which cosegregated with fully penetrant hearing loss in the index family, and also appeared in a second family with the same phenotype. The mutation was absent from more than 7,000 controls. P2RX2 p.V60L abolishes two hallmark features of P2X(2) receptors: ATP-evoked inward current response and ATP-stimulated macropore permeability, measured as loss of ATP-activated FM1-43 fluorescence labeling. Coexpression of mutant and WT P2X(2) receptor subunits significantly reduced ATP-activated membrane permeability. P2RX2-null mice developed severe progressive hearing loss, and their early exposure to continuous moderate noise led to high-frequency hearing loss as young adults. Similarly, among family members heterozygous for P2RX2 p.V60L, noise exposure exacerbated high-frequency hearing loss in young adulthood. Our results suggest that P2X(2) function is required for life-long normal hearing and for protection from exposure to noise.
C1 [Yan, Denise; Du, Lilin; Grati, M'hamed; Liu, Xue Z.] Univ Miami, Sch Med, Dept Otolaryngol, Miami, FL 33136 USA.
[Zhu, Yan; Zhao, Hong-Bo] Univ Kentucky, Med Ctr, Dept Otolaryngol, Lexington, KY 40536 USA.
[Walsh, Tom; King, Mary-Claire] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Walsh, Tom; King, Mary-Claire] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Xie, Dinghua; Liu, Xue Z.] Cent S Univ, Dept Otolaryngol Head & Neck Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
[Yuan, Huijun] Chinese Peoples Liberat Army Gen Hosp, Inst Otolaryngol, Beijing 100853, Peoples R China.
[Sirmaci, Asli; Blanton, Susan; Tekin, Mustafa; Liu, Xue Z.] Univ Miami, Sch Med, Dept Human Genet, Miami, FL 33136 USA.
[Fujikawa, Taro; Grati, M'hamed; Kachar, Bechara] Natl Inst Deafness & Other Commun Disorders, Lab Cell Struct & Dynam, Sect Struct Cell Biol, NIH, Bethesda, MD 20892 USA.
[Wong, Ann Chi Yan; Loh, Tze L.; Housley, Gary D.] Univ New S Wales, Sch Med Sci, Translat Neurosci Facil, Sydney, NSW 2052, Australia.
[Wong, Ann Chi Yan; Loh, Tze L.; Housley, Gary D.] Univ New S Wales, Sch Med Sci, Dept Physiol, Sydney, NSW 2052, Australia.
[Vlajkovic, Srdjan M.; Thorne, Peter R.] Univ Auckland, Sch Med Sci, Dept Physiol, Auckland 1, New Zealand.
[Vlajkovic, Srdjan M.; Thorne, Peter R.] Univ Auckland, Sch Med Sci, Ctr Brain Res, Auckland 1, New Zealand.
[Vlajkovic, Srdjan M.; Thorne, Peter R.] Univ Auckland, Sch Populat Hlth, Sect Audiol, Auckland 1, New Zealand.
[Ryan, Allen F.] Univ Calif San Diego, Dept Otolaryngol, La Jolla, CA 92093 USA.
[Ryan, Allen F.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Chen, Zheng-Yi] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Eaton Peabody Lab,Dept Otol & Laryngol, Boston, MA 02114 USA.
RP King, MC (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA.
EM mcking@u.washington.edu; xliu@med.miami.edu
OI Walsh, Tom/0000-0002-8875-0310; Wong, Ann CY/0000-0001-7011-0369;
Housley, Gary/0000-0002-8413-588X; Vlajkovic, Srdjan/0000-0001-8548-6844
FU National Institutes of Health, National Institute on Deafness and Other
Communication Disorders [R01 DC012546, R01 DC005575, R01 DC005989, R01
HL105631, R01 DC009645, R01 DC000139, R01 DC005641]; Veterans'
Administration; Australia National Health and Medical Research Council
[630618]; New Zealand Marsden Fund; Health Research Council and Deafness
Research Foundation; People's Republic of China National Natural Science
Foundation [30528025]
FX We thank the families for their participation in the study. We thank
Menwei Cai, Pu Dai, Dongyi Han, Kaisun Li, Chunyu Liang, Zian Xiao, and
Shiming Yang for contributions to the fieldwork in China; Anne Thornton,
Ming Lee, Xiaomai Ouyang, and Suleyman Gulsuner for contributions to
genomics and bioinformatics; Kwang Pak, Eduardo Chavez, Jeremy Pinyon,
Rachel Morton-Jones, Sherif Tadros, and Yogeesan Sivakumaran for
contributions to the mouse experiments; Debra Cockayne for supporting
the establishment of the mouse model; Edward Crawford for designing and
engineering the environmental chambers; and Karen B. Avraham, Walter
Nance, Yanbin Zhang, and Jianxin Bao for helpful discussions. This work
was supported by the National Institutes of Health, National Institute
on Deafness and Other Communication Disorders [Grants R01 DC012546 (to
X.Z.L.), R01 DC005575 (to X.Z.L.), R01 DC005989 (to H.-B.Z.), R01
HL105631 (to Y.Z.), R01 DC009645 (to M. T.), R01 DC000139 (to A. F. R.),
and R01 DC005641 (to M.-C. K. and T. W.), and the intramural program (B.
K.)], the Veterans' Administration (A. F. R.), the Australia National
Health and Medical Research Council [Grant 630618 (to G. D. H. and A. F.
R.)], the New Zealand Marsden Fund (G. D. H.) and Health Research
Council and Deafness Research Foundation (P. R. T., G. D. H., and S. M.
V.), and the People's Republic of China National Natural Science
Foundation [Grant 30528025 (to X.Z.L.)].
NR 40
TC 31
Z9 36
U1 3
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 5
PY 2013
VL 110
IS 6
BP 2228
EP 2233
DI 10.1073/pnas.1222285110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093RQ
UT WOS:000315209800058
PM 23345450
ER
PT J
AU Oksenych, V
Kumar, V
Liu, XY
Guo, CG
Schwer, B
Zha, S
Alt, FW
AF Oksenych, Valentyn
Kumar, Vipul
Liu, Xiangyu
Guo, Chunguang
Schwer, Bjoern
Zha, Shan
Alt, Frederick W.
TI Functional redundancy between the XLF and DNA-PKcs DNA repair factors in
V(D)J recombination and nonhomologous DNA end joining
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE Cernunnos; nej1; nhej1; SCID; T-FISH
ID CLASS SWITCH RECOMBINATION; DEPENDENT PROTEIN-KINASE; LEAKY SCID
PHENOTYPE; DOUBLE-STRAND BREAKS; SIGNAL JOINT; LYMPHOCYTE DEVELOPMENT;
CATALYTIC SUBUNIT; B-CELLS; ATM; TRANSLOCATIONS
AB Classical nonhomologous end joining (C-NHEJ) is a major mammalian DNA double-strand break (DSB) repair pathway that is required for assembly of antigen receptor variable region gene segments by V(D)J recombination. Recombination activating gene endonuclease initiates V(D)J recombination by generating DSBs between two V (D) J coding gene segments and flanking recombination signal sequences (RS), with the two coding ends and two RS ends joined by C-NHEJ to form coding joins and signal joins, respectively. During C-NHEJ, recombination activating gene factor generates two coding ends as covalently sealed hairpins and RS ends as blunt 5'-phosphorylated DSBs. Opening and processing of coding end hairpins before joining by C-NHEJ requires the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). However, C-NHEJ of RS ends, which do not require processing, occurs relatively normally in the absence of DNA-PKcs. The XRCC4-like factor (XLF) is a C-NHEJ component that is not required for C-NHEJ of chromosomal signal joins or coding joins because of functional redundancy with ataxia telangiectasia mutated kinase, a protein that also has some functional overlap with DNA-PKcs in this process. Here, we show that XLF has dramatic functional redundancy with DNA-PKcs in the V(D)J SJ joining process, which is nearly abrogated in their combined absence. Moreover, we show that XLF functionally overlaps with DNA-PKcs in normal mouse development, promotion of genomic stability in mouse fibroblasts, and in IgH class switch recombination in mature B cells. Our findings suggest that DNA-PKcs has fundamental roles in C-NHEJ processes beyond end processing that have been masked by functional overlaps with XLF.
C1 [Oksenych, Valentyn; Kumar, Vipul; Guo, Chunguang; Schwer, Bjoern; Alt, Frederick W.] Boston Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Oksenych, Valentyn; Kumar, Vipul; Guo, Chunguang; Schwer, Bjoern; Alt, Frederick W.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Oksenych, Valentyn; Kumar, Vipul; Guo, Chunguang; Schwer, Bjoern; Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Liu, Xiangyu; Zha, Shan] Columbia Univ, Coll Phys & Surg, Inst Canc Genet, Dept Pathol & Cell Biol, New York, NY 10032 USA.
[Liu, Xiangyu; Zha, Shan] Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA.
RP Alt, FW (reprint author), Boston Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
EM alt@enders.tch.harvard.edu
RI liu, xiangyu/D-8213-2014;
OI Oksenych, Valentyn/0000-0002-5088-3791
FU National Institutes of Health (NIH) [AI076210]; NIH/National Cancer
Institute Grant [NCI 5R01CA158073]; National Institute of Aging/NIH [K01
AG043630]
FX This work is supported by National Institutes of Health (NIH) Grant
AI076210 (to F. W. A.) and NIH/National Cancer Institute Grant NCI
5R01CA158073 (to S.Z). B. S. is supported by the National Institute of
Aging/NIH under Award K01 AG043630. F. W. A. is an investigator of the
Howard Hughes Medical Institute. C.G. is a fellow of Cancer Research
Institute.
NR 44
TC 14
Z9 17
U1 1
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 5
PY 2013
VL 110
IS 6
BP 2234
EP 2239
DI 10.1073/pnas.1222573110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093RQ
UT WOS:000315209800059
PM 23345432
ER
PT J
AU Chang, J
Burkett, PR
Borges, CM
Kuchroo, VK
Turka, LA
Chang, CH
AF Chang, JiHoon
Burkett, Patrick R.
Borges, Christopher M.
Kuchroo, Vijay K.
Turka, Laurence A.
Chang, Cheong-Hee
TI MyD88 is essential to sustain mTOR activation necessary to promote T
helper 17 cell proliferation by linking IL-1 and IL-23 signaling
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID ROR-GAMMA-T; TGF-BETA; AUTOIMMUNE INFLAMMATION; TOXOPLASMA-GONDII;
DIFFERENTIATION; RECEPTOR; T(H)17; EXPRESSION; EFFECTOR; GENERATION
AB Myeloid differentiation primary response protein 88 (MyD88) is classically known as an adaptor, linking TLR and IL-1R to downstream signaling pathways in the innate immune system. In addition to its role in innate immune cells, MyD88 has been shown to play an important role in T cells. How MyD88 regulates helper T-cell differentiation remains largely unknown, however. Here we demonstrate that MyD88 is an important regulator of IL-17-producing CD4(+) T helper cells (Th17) cell proliferation. MyD88-deficient CD4(+) T cells showed a defect in Th17 cell differentiation, but not in Th1 cell or Th2 cell differentiation. The impaired IL-17 production from MyD88-deficient CD4(+) T cells is not a result of defective RAR-related orphan receptor gamma t (ROR gamma t) expression. Instead, MyD88 is essential for sustaining the mammalian target of rapamycin (mTOR) activation necessary to promote Th17 cell proliferation by linking IL-1 and IL-23 signaling. MyD88-deficient CD4(+) T cells showed impaired mTOR activation and, consequently, reduced Th17 cell proliferation. Importantly, the absence of MyD88 in T cells ameliorated disease in the experimental autoimmune encephalomyelitis model. Taken together, our results demonstrate that MyD88 has a dual function in Th17 cells by delivering IL-1 signaling during the early differentiation stage and integrating IL-23 signaling to the mTOR complex to expand committed Th17 cells.
C1 [Chang, JiHoon; Chang, Cheong-Hee] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.
[Burkett, Patrick R.; Kuchroo, Vijay K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.
[Burkett, Patrick R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Pulm & Crit Care Div,Dept Med, Boston, MA 02115 USA.
[Borges, Christopher M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Transplant Inst, Sch Med, Boston, MA 02215 USA.
[Turka, Laurence A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Transplantat Biol Res Ctr, Boston, MA 02129 USA.
RP Turka, LA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Transplantat Biol Res Ctr, Boston, MA 02129 USA.
EM lturka@partners.org; heechang@umich.edu
FU National Institutes of Health [AI062789, AI073677]
FX We thank Sang-Won V. Kim and Dan R. Littman (New York University, New
York, NY) for the IL-23R retroviral vectors, Sei Yoshida and Ken Inoki
(University of Michigan, Ann Arbor, MI) for helpful comments on mTOR
signaling, and Ryan H. Newton (Beth Israel Deaconess Medical Center) for
a critical reading of the manuscript. This work was supported by
National Institutes of Health Grants AI062789 (to L. A. T.) and AI073677
(to C.-H.C.).
NR 39
TC 27
Z9 30
U1 0
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 5
PY 2013
VL 110
IS 6
BP 2270
EP 2275
DI 10.1073/pnas.1206048110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093RQ
UT WOS:000315209800065
PM 23341605
ER
PT J
AU Windahl, SH
Borjesson, AE
Farman, HH
Engdahl, C
Moverare-Skrtic, S
Sjogren, K
Lagerquist, MK
Kindblom, JM
Koskela, A
Tuukkanen, J
Pajevic, PD
Feng, JQ
Dahlman-Wright, K
Antonson, P
Gustafsson, JA
Ohlsson, C
AF Windahl, Sara H.
Borjesson, Anna E.
Farman, Helen H.
Engdahl, Cecilia
Moverare-Skrtic, Sofia
Sjogren, Klara
Lagerquist, Marie K.
Kindblom, Jenny M.
Koskela, Antti
Tuukkanen, Juha
Pajevic, Paola Divieti
Feng, Jian Q.
Dahlman-Wright, Karin
Antonson, Per
Gustafsson, Jan-Ake
Ohlsson, Claes
TI Estrogen receptor-alpha in osteocytes is important for trabecular bone
formation in male mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID OSTEOBLAST-LIKE CELLS; ANDROGEN RECEPTOR; KNOCKOUT MICE; FAS LIGAND;
OLDER MEN; ER-ALPHA; BETA; DEFICIENT; ESTRADIOL; HEALTH
AB The bone-sparing effect of estrogen in both males and females is primarily mediated via estrogen receptor-alpha (ER alpha), encoded by the Esr1 gene. ER alpha in osteoclasts is crucial for the trabecular bone-sparing effect of estrogen in females, but it is dispensable for trabecular bone in male mice and for cortical bone in both genders. We hypothesized that ER alpha in osteocytes is important for trabecular bone in male mice and for cortical bone in both males and females. Dmp1-Cre mice were crossed with ER alpha(flox/flox) mice to generate mice lacking ER alpha protein expression specifically in osteocytes (Dmp1-ER alpha(-/-)). Male Dmp1-ER alpha(-/-) mice displayed a substantial reduction in trabecular bone volume (-20%, P < 0.01) compared with controls. Dynamic histomorphometry revealed reduced bone formation rate (-45%, P < 0.01) but the number of osteoclasts per bone surface was unaffected in the male Dmp1-ER alpha(-/-) mice. The male Dmp1-ER alpha(-/-) mice had reduced expression of several osteoblast/osteocyte markers in bone, including Runx2, Sp7, and Dmp1 (P < 0.05). Gonadal intact Dmp1-ER alpha(-/-) female mice had no significant reduction in trabecular bone volume but ovariectomized Dmp1-ER alpha(-/-) female mice displayed an attenuated trabecular bone response to supraphysiological E2 treatment. Dmp1-ER alpha(-/-) mice of both genders had unaffected cortical bone. In conclusion, ER alpha in osteocytes regulates trabecular bone formation and thereby trabecular bone volume in male mice but it is dispensable for the trabecular bone in female mice and the cortical bone in both genders. We propose that the physiological trabecular bone-sparing effect of estrogen is mediated via ER alpha in osteocytes in males, but via ER alpha in osteoclasts in females.
C1 [Windahl, Sara H.; Borjesson, Anna E.; Farman, Helen H.; Engdahl, Cecilia; Moverare-Skrtic, Sofia; Sjogren, Klara; Lagerquist, Marie K.; Kindblom, Jenny M.; Ohlsson, Claes] Univ Gothenburg, Dept Internal Med & Clin Nutr, Ctr Bone & Arthrit Res, Inst Med,Sahlgrenska Acad, S-41345 Gothenburg, Sweden.
[Koskela, Antti; Tuukkanen, Juha] Univ Oulu, Dept Anat & Cell Biol, Inst Biomed, Oulu 90014, Finland.
[Pajevic, Paola Divieti] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA.
[Feng, Jian Q.] Texas A&M Hlth Sci Ctr, Baylor Coll Dent, Dept Biomed Sci, Dallas, TX 75246 USA.
[Dahlman-Wright, Karin; Antonson, Per; Gustafsson, Jan-Ake] Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden.
[Dahlman-Wright, Karin; Antonson, Per; Gustafsson, Jan-Ake] Karolinska Inst, Ctr Biosci Novum, S-14183 Huddinge, Sweden.
[Gustafsson, Jan-Ake] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Dept Cell Biol & Biochem, Houston, TX 77204 USA.
RP Gustafsson, JA (reprint author), Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden.
EM jgustafsson@uh.edu; Claes.Ohlsson@medic.gu.se
OI Lagerquist, Marie/0000-0002-9089-8605
FU Swedish Research Council; Swedish Cancer Fund; Swedish Foundation for
Strategic Research; Swedish Combine Project; Avtal om Lakarutbildning
och Forskning/Lakarutbildningsavtalet research grant in Gothenburg;
Lundberg Foundation; Torsten and Ragnar Soderberg's Foundation; Novo
Nordisk Foundation; National Institutes of Health (National Institute of
Diabetes and Digestive and Kidney Diseases) [DK071122]; Robert A. Welch
Foundation [E-0004]
FX This study was supported by the Swedish Research Council, the Swedish
Cancer Fund, the Swedish Foundation for Strategic Research, the Swedish
Combine Project, the Avtal om Lakarutbildning och
Forskning/Lakarutbildningsavtalet research grant in Gothenburg, the
Lundberg Foundation, the Torsten and Ragnar Soderberg's Foundation, the
Novo Nordisk Foundation, the National Institutes of Health (National
Institute of Diabetes and Digestive and Kidney Diseases Grant DK071122),
and the Robert A. Welch Foundation (E-0004).
NR 34
TC 33
Z9 35
U1 2
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 5
PY 2013
VL 110
IS 6
BP 2294
EP 2299
DI 10.1073/pnas.1220811110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093RQ
UT WOS:000315209800069
PM 23345419
ER
PT J
AU Yang, ZF
Zhang, HJ
Ma, LY
Peng, C
Chen, YY
Wang, JL
Green, MR
Li, SG
Rosmarin, AG
AF Yang, Zhong-Fa
Zhang, Haojian
Ma, Leyuan
Peng, Cong
Chen, Yaoyu
Wang, Junling
Green, Michael R.
Li, Shaoguang
Rosmarin, Alan G.
TI GABP transcription factor is required for development of chronic
myelogenous leukemia via its control of PRKD2
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE LSC; cell cycle control; signal transduction; imatinib
ID CHRONIC MYELOID-LEUKEMIA; STEM-CELLS; GENE-EXPRESSION; MICE;
PROGRESSION; ALPHA
AB Hematopoietic stem cells (HSCs) are the source of all blood lineages, and HSCs must balance quiescence, self-renewal, and differentiation to meet lifelong needs for blood cell development. Transformation of HSCs by the breakpoint cluster region-ABL tyrosine kinase (BCR-ABL) oncogene causes chronic myelogenous leukemia (CML). The E-twenty six (ets) transcription factor GA binding protein (GABP) is a tetrameric transcription factor complex that contains GABP alpha and GABP beta proteins. Deletion in bone marrow of Gabpa, the gene that encodes the DNA-binding component, caused cell cycle arrest in HSCs and profound loss of hematopoietic progenitor cells. Loss of Gabp alpha prevented development of CML, although mice continued to generate BCR-ABL-expressing Gabp alpha-null cells for months that were serially transplantable and contributed to all lineages in secondary recipients. A bioinformatic screen identified the serine-threonine kinase protein kinase D2 (PRKD2) as a potential effector of GABP in HSCs. Prkd2 expression was markedly reduced in Gabp alpha-null HSCs and progenitor cells. Reduced expression of PRKD2 or pharmacologic inhibition decreased cell cycling, and PRKD2 rescued growth of Gabp alpha-null BCR-ABL-expressing cells. Thus, GABP is required for HSC cell cycle entry and CML development through its control of PRKD2. This offers a potential therapeutic target in leukemia.
C1 [Yang, Zhong-Fa; Zhang, Haojian; Peng, Cong; Chen, Yaoyu; Wang, Junling; Li, Shaoguang; Rosmarin, Alan G.] Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA 01655 USA.
[Yang, Zhong-Fa] TaiShan Med Univ, Sch Basic Med Sci, Tai An 271016, Shandong, Peoples R China.
[Zhang, Haojian] Dana Farber Canc Inst, Div Genom Stabil & DNA Repair, Dept Radiat Oncol, Boston, MA 02215 USA.
[Ma, Leyuan; Green, Michael R.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01655 USA.
[Ma, Leyuan; Green, Michael R.] Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01655 USA.
[Ma, Leyuan; Green, Michael R.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01655 USA.
[Peng, Cong] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Peng, Cong] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Chen, Yaoyu] Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
RP Rosmarin, AG (reprint author), Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA 01655 USA.
EM alan.rosmarin@umassmed.edu
FU National Institutes of Health [R01 HL073945, R01 CA122142, CA 114199, GM
033977]
FX We thank Xuejun Zhu, Karen Drumea, and James Cormier for technical
assistance and Jonathan Licht, Lucio Castilla, and Glen Raffel for
helpful discussions. We thank Cancer Research Technology Discovery
Laboratories, Wolfson Institute for Biomedical Research, London WC1E
6BT, United Kingdom, for providing CRT0066101. This work was supported
by National Institutes of Health Grants R01 HL073945 (to A. G. R.), R01
CA122142 (to S. L.), CA 114199 (to S. L.), and GM 033977 (to M. R. G.).
M. R. G. is an investigator of the Howard Hughes Medical Institute.
NR 20
TC 8
Z9 9
U1 0
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 5
PY 2013
VL 110
IS 6
BP 2312
EP 2317
DI 10.1073/pnas.1212904110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093RQ
UT WOS:000315209800072
PM 23345428
ER
PT J
AU Jensen, RA
Sim, XL
Li, XH
Cotch, MF
Ikram, MK
Holliday, EG
Eiriksdottir, G
Harris, TB
Jonasson, F
Klein, BEK
Launer, LJ
Smith, AV
Boerwinkle, E
Cheung, N
Hewitt, AW
Liew, G
Mitchell, P
Wang, JJ
Attia, J
Scott, R
Glazer, NL
Lumley, T
McKnight, B
Psaty, BM
Taylor, K
Hofman, A
de Jong, PTVM
Rivadeneira, F
Uitterlinden, AG
Tay, WT
Teo, YY
Seielstad, M
Liu, JJ
Cheng, CY
Saw, SM
Aung, T
Ganesh, SK
O'Donnell, CJ
Nalls, MA
Wiggins, KL
Kuo, JZ
van Duijn, CM
Gudnason, V
Klein, R
Siscovick, DS
Rotter, JI
Tai, ES
Vingerling, J
Wong, TY
AF Jensen, Richard A.
Sim, Xueling
Li, Xiaohui
Cotch, Mary Frances
Ikram, M. Kamran
Holliday, Elizabeth G.
Eiriksdottir, Gudny
Harris, Tamara B.
Jonasson, Fridbert
Klein, Barbara E. K.
Launer, Lenore J.
Smith, Albert Vernon
Boerwinkle, Eric
Cheung, Ning
Hewitt, Alex W.
Liew, Gerald
Mitchell, Paul
Wang, Jie Jin
Attia, John
Scott, Rodney
Glazer, Nicole L.
Lumley, Thomas
McKnight, Barbara
Psaty, Bruce M.
Taylor, Kent
Hofman, Albert
de Jong, Paulus T. V. M.
Rivadeneira, Fernando
Uitterlinden, Andre G.
Tay, Wan-Ting
Teo, Yik Ying
Seielstad, Mark
Liu, Jianjun
Cheng, Ching-Yu
Saw, Seang-Mei
Aung, Tin
Ganesh, Santhi K.
O'Donnell, Christopher J.
Nalls, Mike A.
Wiggins, Kerri L.
Kuo, Jane Z.
van Duijn, Cornelia M.
Gudnason, Vilmundur
Klein, Ronald
Siscovick, David S.
Rotter, Jerome I.
Tai, E. Shong
Vingerling, Johannes
Wong, Tien Y.
CA Blue Mt Eye Study GWAS Team
CKDGen Consortium
TI Genome-Wide Association Study of Retinopathy in Individuals without
Diabetes
SO PLOS ONE
LA English
DT Article
ID RETINAL MICROVASCULAR ABNORMALITIES; ANTIHYPERTENSIVE DRUG THERAPIES;
ATHEROSCLEROSIS RISK; BLOOD-PRESSURE; CARDIOVASCULAR HEALTH;
HYPERTENSION; COMMUNITIES; MORTALITY; DESIGN; STROKE
AB Background: Mild retinopathy (microaneurysms or dot-blot hemorrhages) is observed in persons without diabetes or hypertension and may reflect microvascular disease in other organs. We conducted a genome-wide association study (GWAS) of mild retinopathy in persons without diabetes.
Methods: A working group agreed on phenotype harmonization, covariate selection and analytic plans for within-cohort GWAS. An inverse-variance weighted fixed effects meta-analysis was performed with GWAS results from six cohorts of 19,411 Caucasians. The primary analysis included individuals without diabetes and secondary analyses were stratified by hypertension status. We also singled out the results from single nucleotide polymorphisms (SNPs) previously shown to be associated with diabetes and hypertension, the two most common causes of retinopathy.
Results: No SNPs reached genome-wide significance in the primary analysis or the secondary analysis of participants with hypertension. SNP, rs12155400, in the histone deacetylase 9 gene (HDAC9) on chromosome 7, was associated with retinopathy in analysis of participants without hypertension, -1.3 +/- 0.23 (beta +/- standard error), p=6.6x10(-9). Evidence suggests this was a false positive finding. The minor allele frequency was low (similar to 2%), the quality of the imputation was moderate (r(2) similar to 0.7), and no other common variants in the HDAC9 gene were associated with the outcome. SNPs found to be associated with diabetes and hypertension in other GWAS were not associated with retinopathy in persons without diabetes or in subgroups with or without hypertension.
Conclusions: This GWAS of retinopathy in individuals without diabetes showed little evidence of genetic associations. Further studies are needed to identify genes associated with these signs in order to help unravel novel pathways and determinants of microvascular diseases.
C1 [Jensen, Richard A.; Lumley, Thomas; McKnight, Barbara; Psaty, Bruce M.; Wiggins, Kerri L.; Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Jensen, Richard A.; Psaty, Bruce M.; Wiggins, Kerri L.; Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA.
[Sim, Xueling; Teo, Yik Ying] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore.
[Li, Xiaohui; Taylor, Kent; Kuo, Jane Z.; Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Ikram, M. Kamran; Tay, Wan-Ting; Cheng, Ching-Yu; Saw, Seang-Mei; Aung, Tin; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
[Ikram, M. Kamran; Vingerling, Johannes] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
[Holliday, Elizabeth G.; Attia, John] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia.
[Eiriksdottir, Gudny; Smith, Albert Vernon; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
[Harris, Tamara B.; Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Jonasson, Fridbert; Smith, Albert Vernon; Gudnason, Vilmundur] Univ Iceland, Dept Med, Reykjavik, Iceland.
[Jonasson, Fridbert] Landspitalinn Univ Hosp, Dept Ophthalmol, Reykjavik, Iceland.
[Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX USA.
[Cheung, Ning; Hewitt, Alex W.; Liew, Gerald; Wang, Jie Jin; Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
[Liew, Gerald; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
[Liew, Gerald; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
[Attia, John] John Hunter Hosp, Dept Med, Newcastle, NSW, Australia.
[Attia, John] Hunter Med Res Inst, Newcastle, NSW, Australia.
[Scott, Rodney] Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2300, Australia.
[Glazer, Nicole L.] Boston Univ, Sch Med, Sect Prevent Med & Epidemiol, Boston, MA 02118 USA.
[Lumley, Thomas] Univ Auckland, Dept Stat, Auckland 1, New Zealand.
[McKnight, Barbara] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Psaty, Bruce M.; Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Hofman, Albert; Rivadeneira, Fernando; Uitterlinden, Andre G.; van Duijn, Cornelia M.; Vingerling, Johannes] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[de Jong, Paulus T. V. M.] Netherlands Inst Neurosci, Amsterdam, Netherlands.
[de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
[Rivadeneira, Fernando; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Uitterlinden, Andre G.] Erasmus MC, Dept Clin Chem, Rotterdam, Netherlands.
[Teo, Yik Ying; Cheng, Ching-Yu; Saw, Seang-Mei; Tai, E. Shong] Natl Univ Singapore, Dept Epidemiol & Publ Hlth, Singapore 117548, Singapore.
[Teo, Yik Ying] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore.
[Teo, Yik Ying] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore.
[Teo, Yik Ying; Liu, Jianjun] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore, Singapore.
[Seielstad, Mark] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
[Cheng, Ching-Yu; Saw, Seang-Mei; Aung, Tin; Wong, Tien Y.] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
[Ganesh, Santhi K.] Univ Michigan, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.
[O'Donnell, Christopher J.] Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA.
[O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA.
[O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Nalls, Mike A.] NIA, Neurogenet Lab, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Tai, E. Shong] Natl Univ Singapore, Singapore 117548, Singapore.
[Tai, E. Shong] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
RP Jensen, RA (reprint author), Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
EM richaj@uw.edu
RI Cheng, Ching-Yu/K-7017-2013; Attia, John/F-5376-2013; Wang, Jie
Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; Hewitt, Alex/D-1936-2013;
Cheung, Ning Danny/F-2043-2013; Gudnason, Vilmundur/K-6885-2015;
Rivadeneira, Fernando/O-5385-2015; Smith, Albert/K-5150-2015;
OI Klein, Ronald/0000-0002-4428-6237; Ikram, Mohammad
Kamran/0000-0003-0173-9571; Tai, E Shyong/0000-0003-2929-8966; Cheng,
Ching-Yu/0000-0003-0655-885X; Attia, John/0000-0001-9800-1308; Wang, Jie
Jin/0000-0001-9491-4898; Hewitt, Alex/0000-0002-5123-5999; Gudnason,
Vilmundur/0000-0001-5696-0084; Rivadeneira,
Fernando/0000-0001-9435-9441; Smith, Albert/0000-0003-1942-5845; Cotch,
Mary Frances/0000-0002-2046-4350; Seielstad, Mark/0000-0001-5783-1401
FU National Institutes of Health (NIH) [N01-AG-12100]; National Institute
on Aging Intramural Research Program at the NIH [ZIAAG007380,
ZIAEY000401]; National Eye Institute Intramural Research Program at the
NIH [ZIAAG007380, ZIAEY000401]; Hjartavernd (the Icelandic Heart
Association); Althingi (the Icelandic Parliament); National Heart, Lung,
and Blood Institute [HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641,
R01HL59367, R01HL086694]; National Human Genome Research Institute
[U01HG004402]; National Institutes of Health [HHSN268200625226C];
National Institutes of Health and NIH Roadmap for Medical Research
[UL1RR025005]; Australian National Health & Medical Research Council
(NHMRC) [974159, 991407, 211069, 457349]; NHMRC [512423, 475604, 529912,
590204]; Wellcome Trust, UK as part of Wellcome Trust Case Control
Consortium; genotyping costs of the entire BMES population
[085475/B/08/Z, 085475/08/Z]; National Heart, Lung, and Blood Institute
(NHLBI) [N01-HC-85239, N01-HC-85079, N01-HC-85086, N01-HC-35129, N01
HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133]; NHLBI [HL080295,
HL075366, HL087652, HL105756, N02-HL-6-4278]; National Institute on
Aging [AG-023629, AG-15928, AG-20098, AG-027058]; Clinical Translational
Science Institute [UL1RR033176]; National Institute of Diabetes and
Digestive and Kidney Diseases [DK063491]; Cedars-Sinai Board of
Governors' Chair in Medical Genetics (JIR); Netherlands Organization of
Scientific Research NWO [175.010.2005.011]; Erasmus Medical Center,
Rotterdam; Erasmus University, Rotterdam; Netherlands Organization for
Scientific Research; Netherlands Organization for Health Research and
Development; Research Institute for Diseases in the Elderly; Ministry of
Education, Culture and Science; Ministry for Health, Welfare and Sports;
European Commission (DG XII) the Netherlands; Municipality of Rotterdam;
Lijf en Leven, Krimpen a/d Lek the Netherlands; MD Fonds, Utrecht the
Netherlands; Oogfonds Nederland, Utrecht the Netherlands; Stichting
Nederlands Oogheelkundig Onderzoek, Nijmegen/Rotterdam the Netherlands;
Swart van Essen, Rotterdam the Netherlands; Netherlands Organisation for
Scientific Research the Netherlands; Bevordering van Volkskracht,
Rotterdam the Netherlands; Blindenhulp, The Hague the Netherlands;
Rotterdamse Vereniging Blindenbelangen, Rotterdam the Netherlands; OOG,
The Hague the Netherlands; Algemene Nederlandse Vereniging ter
Voorkoming van Blindheid, Doorn the Netherlands; Blinden-Penning,
Amsterdam the Netherlands; Blindenhulp, 's Gravenzande the Netherlands;
Henkes Stichting, Rotterdam the Netherlands; Topcon Europe BV, Capelle
aan de IJssel the Netherlands; Medical Workshop BV, Groningen the
Netherlands; [N01 HC-95159]; [N01-HC-95169]; [RR-024156]
FX The authors declare that they have no relevant financial interests. Age,
Gene/Environment Susceptibility-Reykjavik Study has been funded by
National Institutes of Health (NIH) contract N01-AG-12100, the National
Institute on Aging and National Eye Institute Intramural Research
Programs at the NIH (ZIAAG007380 and ZIAEY000401), Hjartavernd (the
Icelandic Heart Association), and the Althingi (the Icelandic
Parliament). The Atherosclerosis Risk in Communities Study is carried
out as a collaborative study supported by National Heart, Lung, and
Blood Institute contracts HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641,
R01HL59367 and R01HL086694; National Human Genome Research Institute
contract U01HG004402; and National Institutes of Health contract
HHSN268200625226C. Infrastructure was partly supported by Grant Number
UL1RR025005, a component of the National Institutes of Health and NIH
Roadmap for Medical Research. The Blue Mountains Eye Study (BMES) was
supported by the Australian National Health & Medical Research Council
(NHMRC) grants (IDs 974159, 991407, 211069 and 457349). The genome-wide
association study was supported by the following grants: NHMRC project
grants IDs 512423, 475604, 529912 and 590204, and funding by the
Wellcome Trust, UK as part of Wellcome Trust Case Control Consortium 2
(A Viswanathan, P McGuffin, P Mitchell, F Topouzis, P Foster), which
supported the genotyping costs of the entire BMES population (Grant
numbers 085475/B/08/Z and 085475/08/Z). The Cardiovascular Health Study
research was supported by National Heart, Lung, and Blood Institute
(NHLBI) contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086;
N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133 and
NHLBI grants HL080295, HL075366, HL087652, HL105756 with additional
contribution from the National Institute of Neurological Disorders and
Stroke. Additional support was provided through AG-023629, AG-15928,
AG-20098, and AG-027058 from the National Institute on Aging. See also
http://www.chs-nhlbi.org/pi.htm. DNA handling and genotyping was
supported in part by the Clinical Translational Science Institute grant
UL1RR033176 to the Cedars-Sinai General Clinical Research Center
Genotyping core and National Institute of Diabetes and Digestive and
Kidney Diseases grant DK063491 to the Southern California Diabetes
Endocrinology Research Center. Additional funding was provided by the
Cedars-Sinai Board of Governors' Chair in Medical Genetics (JIR). The
Multi-Ethnic Study of Atherosclerosis (MESA) and MESA SNP Health
Association Resource (SHARe) are conducted and supported by the National
Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA
investigators. Support is provided by grants and contracts N01 HC-95159
through N01-HC-95169 and RR-024156. Funding for SHARe genotyping was
provided by NHLBI Contract N02-HL-6-4278. The authors thank the other
investigators, the staff, and the participants of the MESA study for
their valuable contributions. A full list of participating MESA
investigators and institutions can be found at
http://www.mesa-nhlbi.org. The GWA database of the Rotterdam Study was
funded through the Netherlands Organization of Scientific Research NWO
(nr. 175.010.2005.011).; The Rotterdam Study is supported by the Erasmus
Medical Center and Erasmus University, Rotterdam; the Netherlands
Organization for Scientific Research, the Netherlands Organization for
Health Research and Development, the Research Institute for Diseases in
the Elderly, the Ministry of Education, Culture and Science, the
Ministry for Health, Welfare and Sports, the European Commission (DG
XII), and the Municipality of Rotterdam. The ophthalmologic part of the
Rotterdam Study was supported by Lijf en Leven, Krimpen a/d Lek; MD
Fonds, Utrecht. Oogfonds Nederland, Utrecht; Stichting Nederlands
Oogheelkundig Onderzoek, Nijmegen/Rotterdam; Swart van Essen, Rotterdam;
Netherlands Organisation for Scientific Research; Bevordering van
Volkskracht, Rotterdam; Blindenhulp, The Hague; Rotterdamse Vereniging
Blindenbelangen, Rotterdam; OOG, The Hague; Algemene Nederlandse
Vereniging ter Voorkoming van Blindheid, Doorn; Blinden-Penning,
Amsterdam; Blindenhulp, 's Gravenzande; Henkes Stichting, Rotterdam;
Topcon Europe BV, Capelle aan de IJssel; Medical Workshop BV, Groningen;
all in the Netherlands; Heidelberg Engineering, Dossenheim, Germany. The
Singapore Indian Eye Study was funded by grants from the Biomedical
Research Council of Singapore (BMRC 09/1/35/19/616 and BMRC
08/1/35/19/550) and the National Medical Research Council of Singapore
(NMRC/STaR/0003/2008). The Singapore BioBank and the Genome Institute of
Singapore, Agency for Science, Technology and Research, Singapore
provided services for tissue archival and genotyping. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 52
TC 5
Z9 5
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 5
PY 2013
VL 8
IS 2
AR e54232
DI 10.1371/journal.pone.0054232
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 086NV
UT WOS:000314692800009
PM 23393555
ER
PT J
AU Raeder, MB
Birkeland, E
Trovik, J
Krakstad, C
Shehata, S
Schumacher, S
Zack, TI
Krohn, A
Werner, HMJ
Moody, SE
Wik, E
Stefansson, IM
Holst, F
Oyan, AM
Tamayo, P
Mesirov, JP
Kalland, KH
Akslen, LA
Simon, R
Beroukhim, R
Salvesen, HB
AF Raeder, Maria B.
Birkeland, Even
Trovik, Jone
Krakstad, Camilla
Shehata, Shyemaa
Schumacher, Steven
Zack, Travis I.
Krohn, Antje
Werner, Henrica M. J.
Moody, Susan E.
Wik, Elisabeth
Stefansson, Ingunn M.
Holst, Frederik
Oyan, Anne M.
Tamayo, Pablo
Mesirov, Jill P.
Kalland, Karl H.
Akslen, Lars A.
Simon, Ronald
Beroukhim, Rameen
Salvesen, Helga B.
TI Integrated Genomic Analysis of the 8q24 Amplification in Endometrial
Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers
SO PLOS ONE
LA English
DT Article
ID PROGNOSTIC IMPACT; BREAST-CANCER; CARCINOMA; METASTASIS; MARKERS; GENE;
INHIBITION; EXPRESSION; STRATEGY; TARGETS
AB Chromosome 8q24 is the most commonly amplified region across multiple cancer types, and the typical length of the amplification suggests that it may target additional genes to MYC. To explore the roles of the genes most frequently included in 8q24 amplifications, we analyzed the relation between copy number alterations and gene expression in three sets of endometrial cancers (N = 252); and in glioblastoma, ovarian, and breast cancers profiled by TCGA. Among the genes neighbouring MYC, expression of the bromodomain-containing gene ATAD2 was the most associated with amplification. Bromodomain-containing genes have been implicated as mediators of MYC transcriptional function, and indeed ATAD2 expression was more closely associated with expression of genes known to be upregulated by MYC than was MYC itself. Amplifications of 8q24, expression of genes downstream from MYC, and overexpression of ATAD2 predicted poor outcome and increased from primary to metastatic lesions. Knockdown of ATAD2 and MYC in seven endometrial and 21 breast cancer cell lines demonstrated that cell lines that were dependent on MYC also depended upon ATAD2. These same cell lines were also the most sensitive to the histone deacetylase (HDAC) inhibitor Trichostatin-A, consistent with prior studies identifying bromodomain-containing proteins as targets of inhibition by HDAC inhibitors. Our data indicate high ATAD2 expression is a marker of aggressive endometrial cancers, and suggest specific inhibitors of ATAD2 may have therapeutic utility in these and other MYC-dependent cancers.
C1 [Raeder, Maria B.; Birkeland, Even; Trovik, Jone; Krakstad, Camilla; Werner, Henrica M. J.; Wik, Elisabeth; Salvesen, Helga B.] Haukeland Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway.
[Raeder, Maria B.; Birkeland, Even; Trovik, Jone; Krakstad, Camilla; Werner, Henrica M. J.; Wik, Elisabeth; Salvesen, Helga B.] Univ Bergen, Dept Clin Med, Bergen, Norway.
[Raeder, Maria B.; Shehata, Shyemaa; Schumacher, Steven; Zack, Travis I.; Moody, Susan E.; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Raeder, Maria B.; Shehata, Shyemaa; Schumacher, Steven; Zack, Travis I.; Moody, Susan E.; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Schumacher, Steven; Zack, Travis I.; Moody, Susan E.; Tamayo, Pablo; Mesirov, Jill P.; Beroukhim, Rameen] Broad Inst, Cambridge, MA USA.
[Zack, Travis I.] Harvard Univ, Dept Biophys, Boston, MA 02115 USA.
[Krohn, Antje; Holst, Frederik; Simon, Ronald] Univ Med Ctr Hamburg Eppendorf, Dept Pathol, Hamburg, Germany.
[Stefansson, Ingunn M.; Oyan, Anne M.; Kalland, Karl H.; Akslen, Lars A.] Univ Bergen, Gade Inst, Bergen, Norway.
[Stefansson, Ingunn M.; Akslen, Lars A.] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway.
[Oyan, Anne M.; Kalland, Karl H.] Haukeland Hosp, Dept Microbiol & Immunol, N-5021 Bergen, Norway.
[Beroukhim, Rameen] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Beroukhim, Rameen] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Raeder, MB (reprint author), Haukeland Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway.
EM Maria.Rader@uib.no
RI Schumacher, Steven/E-9821-2013; Kalland, Karl-Henning/B-9445-2017;
Akslen, Lars /C-1202-2017; salvesen, Helga/C-1187-2017;
OI Schumacher, Steven/0000-0002-6819-5647; Kalland,
Karl-Henning/0000-0003-4486-2334; Akslen, Lars /0000-0003-2710-9543;
salvesen, Helga/0000-0002-4438-8831; Holst,
Frederik/0000-0002-5928-2175; Simon, Ronald/0000-0003-0158-4258;
Krakstad, Camilla/0000-0002-0174-8139
FU Helse Vest [990172, 911351, 911624, 911626]; University of Bergen;
Norwegian Cancer Society; Research Council of Norway [205404, 193373];
National Cancer Institute [K08CA122833, U54CA143798]; V Foundation
Scholarship
FX Financial support: Helse Vest Grants 990172 (MBR), 911351, 911624, and
911626 (HBS); the University of Bergen; the Norwegian Cancer Society;
the Research Council of Norway Grants 205404 and 193373 (HBS); the
National Cancer Institute (K08CA122833 and U54CA143798); and a V
Foundation Scholarship (RB). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 30
TC 35
Z9 37
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 5
PY 2013
VL 8
IS 2
AR e54873
DI 10.1371/journal.pone.0054873
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 086NV
UT WOS:000314692800014
PM 23393560
ER
PT J
AU Wang, X
Zhang, L
O'Neill, A
Bahamon, B
Alsop, DC
Mier, JW
Goldberg, SN
Signoretti, S
Atkins, MB
Wood, CG
Bhatt, RS
AF Wang, X.
Zhang, L.
O'Neill, A.
Bahamon, B.
Alsop, D. C.
Mier, J. W.
Goldberg, S. N.
Signoretti, S.
Atkins, M. B.
Wood, C. G.
Bhatt, R. S.
TI Cox-2 inhibition enhances the activity of sunitinib in human renal cell
carcinoma xenografts
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE renal cell carcinoma; anti-angiogenic therapy; COX-2 inhibitor;
sunitinib
ID CYCLOOXYGENASE-2 INHIBITOR; INTERFERON-ALPHA; LUNG-CANCER; PHASE-II;
SELECTIVE CYCLOOXYGENASE-2; ANTIANGIOGENIC THERAPY; EXPRESSION;
CELECOXIB; RESISTANCE; APOPTOSIS
AB Background: Sunitinib (Su), a tyrosine kinase inhibitor of VEGFR, is effective at producing tumour response in clear cell renal cell carcinoma (cRCC), but resistance to therapy is inevitable. As COX-2 is a known mediator of tumour growth, we explored the potential benefit of COX-2 inhibition in combination with VEGFR inhibition in attempts at delaying tumour progression on Su.
Methods: COX-2 expression was compared with areas of hypoxia in tumours that progressed on Su vs untreated tumours. Mice bearing human cRCC xenografts were treated with Su and the COX-2 inhibitor, celecoxib, and the effects on tumour growth were assessed. Sequential vs concurrent regimens were compared.
Results: COX-2 expression was increased in cRCC xenografts in areas of tumour hypoxia. The combination of Su and celecoxib achieved longer times to tumour progression compared to treatment with either agent alone or to untreated control animals in four models. This effect was seen with concurrent but not with sequential therapy.
Conclusion: COX-2 inhibition can extend the effectiveness of VEGFR inhibition. This effect is dependent on the timing of therapy. Clinical trials combining Su and COX-2 inhibitors should be considered as a means delaying time to progression on sunitinib in patients with metastatic cRCC.
C1 [Wang, X.; Alsop, D. C.; Goldberg, S. N.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
[Wang, X.; Zhang, L.; Mier, J. W.; Bhatt, R. S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol & Canc Biol, Boston, MA 02215 USA.
[O'Neill, A.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Bahamon, B.; Signoretti, S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA.
[Goldberg, S. N.] Hadassah Hebrew Univ, Dept Radiol, Med Ctr, IL-91120 Jerusalem, Israel.
[Atkins, M. B.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA.
[Wood, C. G.] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Urol, Houston, TX 77030 USA.
RP Bhatt, RS (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol & Canc Biol, 330 Brookline Ave, Boston, MA 02215 USA.
EM rbhatt@bidmc.harvard.edu
RI Alsop, David/J-5764-2013
OI Alsop, David/0000-0002-8206-1995
FU National Institutes of Health/National Cancer Institute [5 K08
CA138900]; Dana-Farber/Harvard Cancer Centre Kidney SPORE National
Cancer Institute [P50CA101942]
FX This work was supported by research grants awarded to RB from the
National Institutes of Health/National Cancer Institute (5 K08 CA138900)
and the Dana-Farber/Harvard Cancer Centre Kidney SPORE National Cancer
Institute (P50CA101942).
NR 39
TC 15
Z9 16
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD FEB 5
PY 2013
VL 108
IS 2
BP 319
EP 326
DI 10.1038/bjc.2012.591
PG 8
WC Oncology
SC Oncology
GA 087YP
UT WOS:000314800900011
PM 23322198
ER
PT J
AU Butler, J
Subacius, H
Vaduganathan, M
Fonarow, GC
Ambrosy, AP
Konstam, MA
Maggioni, A
Mentz, RJ
Swedberg, K
Zannad, F
Gheorghiade, M
AF Butler, Javed
Subacius, Haris
Vaduganathan, Muthiah
Fonarow, Gregg C.
Ambrosy, Andrew P.
Konstam, Marvin A.
Maggioni, Aldo
Mentz, Robert J.
Swedberg, Karl
Zannad, Faiez
Gheorghiade, Mihai
CA EVEREST Investigators
TI Relationship Between Clinical Trial Site Enrollment With Participant
Characteristics, Protocol Completion, and Outcomes Insights From the
EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome
Study with Tolvaptan) Trial
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE acute heart failure; clinical trials; outcomes assessment; quality of
care
AB Objectives The study investigated whether the number of participants enrolled per site in an acute heart failure trial is associated with participant characteristics and outcomes.
Background Whether and how site enrollment volume affects clinical trials is not known.
Methods A total of 4,133 participants enrolled among 359 sites were grouped on the basis of total enrollment into 1 to 10, 11 to 30, and >30 participants per site and were compared for outcomes (cardiovascular mortality or heart failure hospitalization).
Results Per-site enrollment ranged from 0 to 75 (median 6; 77 sites had no enrollment). Regional differences in enrollment were noted between North and South America, and Western and Eastern Europe (p < 0.001). Participants from sites with fewer enrollments were more likely to be older and male, have lower ejection fraction and blood pressure as well as worse comorbidity and laboratory profile, and were less likely to be on angiotensin-converting enzyme inhibitors or aldosterone antagonists. During a median follow-up of 9.9 months, 1,700 (41%) participants had an outcome event. Compared to event rate at sites with >30 participants (32%), those with 1 to 10 (51%, hazard ratio [HR]: 1.77, 95% confidence interval [CI]: 1.56 to 2.02) and 11 to 30 (42%, HR: 1.44, 95% CI: 1.28 to 1.62) participants per site groups had worse outcomes. This relationship was comparable across regions (p = 0.43). After adjustment for risk factors, participants enrolled at sites with fewer enrollees were at higher risk for adverse outcomes (HR: 1.26, 95% CI: 1.08 to 1.46 for 1 to 10; HR: 1.22, 95% CI: 1.07 to 1.38 for 11 to 30 vs. >30 participant sites). Higher proportion of participants from site with >30 participants completed the protocol (45.5% for <10, 61.7% for 11 to 30, and 68.4% for sites enrolling >30 participants; p < 0.001).
Conclusions Baseline characteristics, protocol completion, and outcomes differed significantly among higher versus lower enrolling sites. These data imply that the number of participant enrolled per site may influence trials beyond logistics. (J Am Coll Cardiol 2013; 61: 571-9) (C) 2013 by the American College of Cardiology Foundation
C1 [Butler, Javed] Emory Univ, Atlanta, GA 30322 USA.
[Subacius, Haris; Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Vaduganathan, Muthiah] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Fonarow, Gregg C.] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Ambrosy, Andrew P.] Stanford Univ, Palo Alto, CA 94304 USA.
[Konstam, Marvin A.] Tufts Med Ctr, Boston, MA USA.
[Konstam, Marvin A.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Maggioni, Aldo] ANMCO Res Ctr, Florence, Italy.
[Mentz, Robert J.] Duke Univ, Durham, NC USA.
[Swedberg, Karl] Univ Gothenburg, Gothenburg, Sweden.
[Zannad, Faiez] INSERM, CIC 9501, Nancy, France.
[Zannad, Faiez] CHU Nancy, Inst Lorrain Coeur & Vaisseaux, U961, Nancy, France.
[Zannad, Faiez] Univ Lorraine, Nancy, France.
RP Gheorghiade, M (reprint author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA.
EM m-gheorghiade@northwestern.edu
OI Subacius, Haris/0000-0003-4061-1220; Maggioni, Aldo
Pietro/0000-0003-2764-6779
FU Agency for Healthcare Research and Quality; Merck; Otsuka; Johnson
Johnson; Amgen; Novartis; Cardiokine; Medtronic; Gilead Sciences;
AstraZeneca; Servier; Bayer Schering Pharma AG; DebioPharm S.A.;
Novartis Pharma AG; Otsuka Pharmaceuticals; Sigma Tau; Solvay
Pharmaceuticals; Sticares InterACT; Takeda Pharmaceuticals North
America, Inc.
FX Dr. Fonarow receives research support from the Agency for Healthcare
Research and Quality and serves as a consultant for Medtronic and
Novartis. Dr. Konstam has received research support and/or served as a
consultant for Merck, Otsuka, Johnson & Johnson, Amgen, Novartis, and
Cardiokine. Dr. Maggioni receives honoraria from Otsuka. Dr. Mentz has
received grants from Medtronic and research funding from Gilead
Sciences. Dr. Swedberg receives research grants from AstraZeneca,
Servier, and Amgen; honoraria from AstraZeneca, Otsuka, Servier, and
Amgen; and is a consultant for Cytokinetics, Servier, and Novartis. Dr.
Zannad has received honoraria from and served on advisory boards for
Pfizer Inc. Dr. Gheorghiade has a relationship with Abbott Laboratories,
Astellas, AstraZeneca, Bayer Schering Pharma AG, Cardiorentis Ltd,
Corthera, Cytokinetics, CytoPherx, Inc., DebioPharm S.A., Errekappa
Terapeutici, GlaxoSmithKline, Ikaria, Intersection Medical, Inc.,
Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Ono
Pharmaceuticals USA, Otsuka Pharmaceuticals, Palatin Technologies,
PeriCor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma
Tau, Solvay Pharmaceuticals, Sticares InterACT, Takeda Pharmaceuticals
North America, Inc., and Trevena Therapeutics; and has received support
from Bayer Schering Pharma AG, DebioPharm S.A., Medtronic, Novartis
Pharma AG, Otsuka Pharmaceuticals, Sigma Tau, Solvay Pharmaceuticals,
Sticares InterACT, and Takeda Pharmaceuticals North America, Inc. All
other authors have reported that they have no relationships relevant to
the contents of this paper to disclose.
NR 25
TC 32
Z9 32
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD FEB 5
PY 2013
VL 61
IS 5
BP 571
EP 579
DI 10.1016/j.jacc.2012.10.025
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 086BZ
UT WOS:000314659300010
PM 23246389
ER
PT J
AU Bhatt, DL
Cavender, MA
AF Bhatt, Deepak L.
Cavender, Matthew A.
TI Are All Clinical Trial Sites Created Equal?
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE acute heart failure; clinical trials; quality of care and outcomes
assessment
ID ELEVATION MYOCARDIAL-INFARCTION; HEART-FAILURE; OUTCOMES; TOLVAPTAN;
EVEREST
C1 [Bhatt, Deepak L.] Vet Affairs Boston Healthcare Syst, Boston, MA USA.
[Bhatt, Deepak L.; Cavender, Matthew A.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA.
[Bhatt, Deepak L.; Cavender, Matthew A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Bhatt, DL (reprint author), Brigham & Womens Hosp, 75 Francis St,PBB 146, Boston, MA 02115 USA.
EM DLBHATTMD@post.harvard.edu
NR 14
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD FEB 5
PY 2013
VL 61
IS 5
BP 580
EP 581
DI 10.1016/j.jacc.2012.10.024
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 086BZ
UT WOS:000314659300011
PM 23246386
ER
PT J
AU Wynn, JK
Mathis, KI
Ford, J
Breitmeyer, BG
Green, MF
AF Wynn, Jonathan K.
Mathis, Kristopher I.
Ford, Judith
Breitmeyer, Bruno G.
Green, Michael F.
TI Object substitution masking in schizophrenia: an event-related potential
analysis
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE visual processing; schizophrenia; ERP; visual backward masking;
reentrant processing
ID PSYCHIATRIC RATING-SCALE; BACKWARD VISUAL MASKING; PROCESSING DEFICITS;
SENSORY CONTRIBUTIONS; RECOGNITION AREAS; QUALITY-ASSURANCE; AWARENESS;
PERCEPTION; ATTENTION; ERP
AB Schizophrenia patients exhibit deficits on visual processing tasks, including visual backward masking, and these impairments are related to deficits in higher-level processes. In the current study we used electroencephalography techniques to examine successive stages and pathways of visual processing in a specialized masking paradigm, four-dot masking, which involves masking by object substitution. Seventy-six schizophrenia patients and 66 healthy controls had event-related potentials (ERPs) recorded during four-dot masking. Target visibility was manipulated by changing stimulus onset asynchrony (SOA) between the target and mask, such that performance decreased with increasing SOA. Three SOAs were used: 0, 50, and 100 ms. The P100 and N100 perceptual ERPs were examined. Additionally, the visual awareness negativity (VAN) to correct vs. incorrect responses, an index of reentrant processing, was examined for SOAs 50 and 100 ms. Results showed that patients performed worse than controls on the behavioral task across all SOAs. The ERP results revealed that patients had significantly smaller P100 and N100 amplitudes, though there was no effect of SOA on either component in either group. In healthy controls, but not patients, N100 amplitude correlated significantly with behavioral performance at SOAs where masking occurred, such that higher accuracy correlated with a larger N100. Healthy controls, but not patients, exhibited a larger VAN to correct vs. incorrect responses. The results indicate that the N100 appears to be related to attentional effort in the task in controls, but not patients. Considering that the VAN is thought to reflect reentrant processing, one interpretation of the findings is that patients' lack of VAN response and poorer performance may be related to dysfunctional reentrant processing.
C1 [Wynn, Jonathan K.; Mathis, Kristopher I.; Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Ford, Judith] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ford, Judith] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Breitmeyer, Bruno G.] Univ Houston, Dept Psychol, Houston, TX USA.
RP Wynn, JK (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jkwynn@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU NIMH NIH HHS [R01 MH043292, R01 MH065707, R29 MH043292]
NR 64
TC 2
Z9 2
U1 0
U2 5
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD FEB 4
PY 2013
VL 4
AR 30
DI 10.3389/fpsyg.2013.00030
PG 9
WC Psychology, Multidisciplinary
SC Psychology
GA AA0KW
UT WOS:000330785000001
PM 23382723
ER
PT J
AU Magge, R
Lau, BC
Soares, BP
Fischette, S
Arora, S
Tong, E
Cheng, S
Wintermark, M
AF Magge, R.
Lau, B. C.
Soares, B. P.
Fischette, S.
Arora, S.
Tong, E.
Cheng, S.
Wintermark, M.
TI Clinical Risk Factors and CT Imaging Features of Carotid Atherosclerotic
Plaques as Predictors of New Incident Carotid Ischemic Stroke: A
Retrospective Cohort Study
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID INTIMA-MEDIA THICKNESS; MULTIDETECTOR COMPUTED-TOMOGRAPHY;
HIGH-RESOLUTION MRI; ARTERY STENOSIS; CARDIOVASCULAR HEALTH;
SURFACE-MORPHOLOGY; CEREBRAL-ISCHEMIA; VIVO MRI; ENDARTERECTOMY;
BIFURCATION
AB BACKGROUND AND PURPOSE: Parameters other than luminal narrowing are needed to predict the risk of stroke more reliably, particularly in patients with <70% stenosis. The goal of our study was to identify clinical risk factors and CT features of carotid atherosclerotic plaques, in a retrospective cohort of patients free of stroke at baseline, that are independent predictors of incident stroke on follow-up.
MATERIALS AND METHODS: We identified a retrospective cohort of patients admitted to our emergency department with suspected stroke between 2001-2007 who underwent a stroke work-up including a CTA of the carotid arteries that was subsequently negative for acute stroke. All patients also had to receive a follow-up brain study at least 2 weeks later. From a random sample, we reviewed charts and imaging studies of patients with subsequent new stroke on follow-up as well as those who remained stroke-free. All patients were classified either as new carotid infarct patients or no-new carotid infarct patients based on the Causative Classification for Stroke. Independently, the baseline CTA studies were processed using a custom, CT-based automated computer classifier algorithm that quantitatively assesses a set of carotid CT features (wall thickness, plaque ulcerations, fibrous cap thickness, lipid-rich necrotic core, and calcifications). Univariate and multivariate statistical analyses were used to identify any significant differences in CT features between the patient groups in the sample. Subsequent ROC analysis allowed comparison to the classic NASCET stenosis rule in identifying patients with incident stroke on follow-up.
RESULTS: We identified a total of 315 patients without a new carotid stroke between baseline and follow-up, and 14 with a new carotid stroke between baseline and follow-up, creating the main comparison groups for the study. Statistical analysis showed age and use of antihypertensive drugs to be the most significant clinical variables, and maximal carotid wall thickness was the most relevant imaging variable. The use of age 75 years, antihypertensive medication use, and a maximal carotid wall thickness of at least 4 mm was able to successfully identify 10 of the 14 patients who developed a new incident infarct on follow-up. ROC analysis showed an area under the ROC curve of 0.706 for prediction of new stroke with this new model.
CONCLUSIONS: Our new paradigm of using age 75 years, history of hypertension, and carotid maximal wall thickness of >4 mm identified most of the patients with subsequent new carotid stroke in our study. It is simple and may help clinicians choose the patients at greatest risk of developing a carotid infarct, warranting validation with a prospective observational study.
C1 [Magge, R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Magge, R.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Lau, B. C.; Tong, E.; Wintermark, M.] Univ Virginia, Dept Radiol, Neuroradiol Div, Charlottesville, VA USA.
[Soares, B. P.; Wintermark, M.] Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, San Francisco, CA 94143 USA.
[Fischette, S.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA.
[Cheng, S.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Arora, S.] Univ Louisville, Dept Radiol, Louisville, KY 40292 USA.
RP Wintermark, M (reprint author), Univ Virginia, Hlth Sci Ctr, Dept Radiol, Neuroradiol Div, Box 800170, Charlottesville, VA 22908 USA.
EM Max.Wintermark@virginia.edu
OI Wintermark, Max/0000-0002-6726-3951; Soares, Bruno/0000-0003-4185-6940
FU Doris Duke Clinical Research Fellowship; UCSF; Dana; NIH; Doris Duke;
Dana Foundation; National Center for Research Resources (NCRR), a
component of the National Institutes of Health (NIH) [KL2 RR024130]; NIH
Roadmap for Medical Research; National Institute of Neurological
Disorders and Stroke, at the NIH [NS045085]; GE Healthcare
FX Rajiv Magge-RELATED: Grant: Doris Duke Clinical Research Fellowship,
Comments: Received financial support as clinical research fellow (during
medical school; Support for Travel to Meetings for the Study or Other
Purposes: Doris Duke Clinical Research Fellowship, Comments: Received
travel support as clinical research fellow (during medical school). W.
Scott Fischette-RELATED: Grant: UCSF Dean's Research Grant, Comments:
Research grant provided by UCSF to medical students for summer research.
Max Wintermark-RELATED: Grant: Dana,* NIH,* Doris Duke,* Comments: This
research project was conducted with the support of a grant from the Dana
Foundation (http://www.dana.org/). Max Wintermark was supported by Grant
KL2 RR024130 from the National Center for Research Resources (NCRR), a
component of the National Institutes of Health (NIH) and the NIH Roadmap
for Medical Research, and by Grant NS045085 from the National Institute
of Neurological Disorders and Stroke, at the NIH. Information on NCRR is
available at http://www.ncrr.nih.gov/. The contents of this article are
solely the responsibility of the authors and do not necessarily
represent the official view of the Dana Foundation, Doris Duke
Charitable Foundation, NCRR or NIH; UNRELATED: Grant: GE Healthcare.*
(*Money paid to institution)
NR 43
TC 7
Z9 9
U1 0
U2 2
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD FEB
PY 2013
VL 34
IS 2
BP 402
EP 409
DI 10.3174/ajnr.A3228
PG 8
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 282YH
UT WOS:000329210300029
PM 22859283
ER
PT J
AU Vishwas, MS
Healy, BC
Pienaar, R
Gorman, MP
Grant, PE
Chitnis, T
AF Vishwas, M. S.
Healy, B. C.
Pienaar, R.
Gorman, M. P.
Grant, P. E.
Chitnis, T.
TI Diffusion Tensor Analysis of Pediatric Multiple Sclerosis and Clinically
Isolated Syndromes
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID APPEARING WHITE-MATTER; FRACTIONAL ANISOTROPY; PROGNOSTIC-FACTORS;
CORPUS-CALLOSUM; MRI CRITERIA; ONSET; CHILDHOOD; MS; DEMYELINATION;
CHILDREN
AB BACKGROUND AND PURPOSE: DTI has shown focal and diffuse white matter abnormalities in adults and children with MS. Here we explore whether DTI abnormalities are present at the time of a first attack or CIS in children and whether early DTI features can predict the development of MS.
MATERIALS AND METHODS: We assessed region-of-interest and tract-based mean ADC and mean FA values for 3 major white matter pathways and NAWM in 20 children with MS, 27 children with forms of CIS, and controls. Tracts were selected by using standard region-of-interest placements on color FA maps. Identical ROIs were placed in the NAWM on b = 0 T2-weighted images to ensure that both ROIs and resulting tracts passed through NAWM. Conventional MR imaging characteristics were assessed by visual inspection. Statistical analysis compared FA and ADC values between groups by a t test. Logistic regression assessed the predictive value of DTI measures and published conventional MR imaging measures for conversion from CIS to MS.
RESULTS: In pediatric patients with MS, all white matter pathways and analysis confined to the NAWM demonstrated higher mean ADC values and lower mean FA than in controls. In contrast, there were no significant differences in mean ADC and mean FA of white matter pathways in all CIS cohorts compared with controls. In the CIS cohort, none of the DTI measures in white matter pathways or in NAWM were significantly associated with conversion to RRMS in univariate or multivariate models (P > .05 in all models).
CONCLUSIONS: There are significant anisotropic abnormalities in the NAWM of major tracts in children with MS. In contrast, there were no significant changes in pediatric patients with CIS compared with controls at baseline. DTI measures did not predict conversion to MS. The period between CIS and conversion to pediatric MS may represent a window of opportunity for the prevention of diffuse damage in the CNS and potentially progressive disability.
C1 [Vishwas, M. S.; Gorman, M. P.; Chitnis, T.] Massachusetts Gen Hosp Children, Partners Pediat Multiple Sclerosis Ctr, Boston, MA USA.
[Vishwas, M. S.; Pienaar, R.; Grant, P. E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA.
[Healy, B. C.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
RP Chitnis, T (reprint author), Massachusetts Gen Hosp, Partners Pediat Multiple Sclerosis Ctr, ACC 708,55 Fruit St, Boston, MA 02114 USA.
EM tchitnis@partners.org
FU Pediatric Multiple Sclerosis Centers of Excellence Grant from the
National Multiple Sclerosis Society
FX This work was supported by the Pediatric Multiple Sclerosis Centers of
Excellence Grant from the National Multiple Sclerosis Society to T.C.
NR 29
TC 11
Z9 11
U1 0
U2 3
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD FEB
PY 2013
VL 34
IS 2
BP 417
EP 423
DI 10.3174/ajnr.A3216
PG 7
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 282YH
UT WOS:000329210300031
PM 22859275
ER
PT J
AU Silverman, MA
Misasi, J
Smole, S
Feldman, HA
Cohen, AB
Santagata, S
McManus, M
Ahmed, AA
AF Silverman, Michael A.
Misasi, John
Smole, Sandra
Feldman, Henry A.
Cohen, Adam B.
Santagata, Sandro
McManus, Michael
Ahmed, Asim A.
TI Eastern Equine Encephalitis in Children, Massachusetts and New
Hampshire, USA, 1970-2010
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID INTRACRANIAL-PRESSURE; VIRUS; ENCEPHALOMYELITIS; CRANIECTOMY; OUTBREAK;
VARIETY
AB We describe the clinical, laboratory, and radiographic characteristics of 15 cases of eastern equine encephalitis in children during 1970-2010. The most common clinical and laboratory features were fever, headache, seizures, peripheral leukocytosis, and cerebrospinal fluid neutrophilic pleocytosis. Radiographic lesions were found in the basal ganglia, thalami, and cerebral cortex: Clinical outcomes included severe neurologic deficits in 5 (33%) patients, death of 4 (27%), full recovery of 4 (27%), and mild neurologic deficits in 2 (13%). We identify an association between a short prodrome and an increased risk for death or for severe disease.
C1 [Silverman, Michael A.; Misasi, John; Feldman, Henry A.; Santagata, Sandro; McManus, Michael; Ahmed, Asim A.] Boston Childrens Hosp, Boston, MA USA.
[Smole, Sandra] Dept Publ Hlth, Boston, MA USA.
[Cohen, Adam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Santagata, Sandro] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Ahmed, AA (reprint author), Dept Med, Div Infect Dis, 300 Longwood Ave, Boston, MA 02115 USA.
EM asim.ahmed@childrens.harvard.edu
FU Fred Lovejoy Resident Research and Education Award; Child Health
Research Center Fellowship; Boston Children's Hospital Faculty
Development Award
FX This work was supported by the Fred Lovejoy Resident Research and
Education Award (M.A.S.) and by the Child Health Research Center
Fellowship and the Boston Children's Hospital Faculty Development Award
(A.A.A.).
NR 25
TC 20
Z9 20
U1 0
U2 4
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD FEB
PY 2013
VL 19
IS 2
BP 194
EP 201
DI 10.3201/eid1902.120039
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 268LT
UT WOS:000328172900002
PM 23343480
ER
PT J
AU Elbogen, EB
Wagner, HR
Johnson, SC
Kinneer, P
Kang, H
Vasterling, JJ
Timko, C
Beckham, JC
AF Elbogen, Eric B.
Wagner, H. Ryan
Johnson, Sally C.
Kinneer, Patricia
Kang, Han
Vasterling, Jennifer J.
Timko, Christine
Beckham, Jean C.
TI Are Iraq and Afghanistan Veterans Using Mental Health Services? New Data
From a National Random-Sample Survey
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; WOMEN VETERANS; PERCEIVED BARRIERS; GUARD
SOLDIERS; UNITED-STATES; PRIMARY-CARE; ACTIVE-DUTY; COMBAT; PREVALENCE;
STIGMA
AB Objective: This study analyzed data from a national survey of Iraq and Afghanistan veterans to improve understanding of mental health services use and perceived barriers. Methods: The National Post-Deployment Adjustment Survey randomly sampled post-9/11 veterans separated from active duty or in the Reserves or National Guard. The corrected response rate was 56% (N=1,388). Results: Forty-three percent screened positive for posttraumatic stress disorder (PTSD), major depression, or alcohol misuse. Past-year psychiatric treatment was reported by 69% of the PTSD group, 67% of the depression group, and 45% of those with alcohol misuse. Most received care at Veterans Affairs (VA) facilities, although women were more likely than men to seek non-VA services. Veterans with more severe symptoms reported greater treatment utilization. Eighteen percent saw a pastoral counselor (chaplain) in the past year. Veterans with mental health needs who did not access treatment were more likely to believe that they had to solve problems themselves and that medications would not help. Those who had accessed treatment were more likely to express concern about being seen as weak by others. Conclusions: Veterans in greatest need were more likely to access services. More than two-thirds with probable PTSD obtained past-year treatment, mostly at VA facilities. Treatment for veterans may be improved by increasing awareness of gender differences, integrating mental health and pastoral services, and recognizing that alcohol misuse may reduce utilization. Veterans who had and had not used services endorsed different perceptions about treatment, indicating that barriers to accessing care may be distinct from barriers to engaging in care.
C1 [Elbogen, Eric B.; Johnson, Sally C.; Kinneer, Patricia] Univ North Carolina Chapel Hill, Dept Psychiat, Durham, NC 27599 USA.
[Elbogen, Eric B.] Durham Vet Affairs VA Med Ctr, Durham, NC USA.
[Wagner, H. Ryan; Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA.
[Kang, Han] Environm Epidemiol Serv, US Dept Vet Affairs, Washington, DC USA.
[Vasterling, Jennifer J.] VA Boston Healthcare Syst, Psychol Serv, Boston, MA USA.
[Vasterling, Jennifer J.] Boston Univ, Dept Psychiat, Med Ctr, Boston, MA 02215 USA.
[Timko, Christine] VA Palo Alto Healthcare Syst, Palo Alto, CA USA.
[Timko, Christine] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
RP Elbogen, EB (reprint author), Univ North Carolina Chapel Hill, Dept Psychiat, CB 7167, Durham, NC 27599 USA.
EM eric.elbogen@unc.edu
FU National Institute of Mental Health [R01MH080988]; Office of Research
and Development Clinical Science and Health Services and Health
Services, U.S. Department of Veterans Affairs (VA); VA's Mid-Atlantic
Mental Illness Research, Education and Clinical Center
FX Preparation of this report was supported by grant R01MH080988 from the
National Institute of Mental Health and by the Office of Research and
Development Clinical Science and Health Services, U.S. Department of
Veterans Affairs (VA), and the VA's Mid-Atlantic Mental Illness
Research, Education and Clinical Center. The authors extend sincere
thanks to the participants who volunteered for this study. The views
expressed in this article are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs or
the National Institutes of Health.
NR 43
TC 54
Z9 54
U1 0
U2 10
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD FEB
PY 2013
VL 64
IS 2
BP 134
EP 141
DI 10.1176/appi.ps.004792011
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255SP
UT WOS:000327260400012
PM 23475498
ER
PT J
AU Amin, ST
Morrow, DA
Braunwald, E
Sloan, S
Contant, C
Murphy, S
Antman, EM
AF Amin, Sameer T.
Morrow, David A.
Braunwald, Eugene
Sloan, Sarah
Contant, Charles
Murphy, Sabina
Antman, Elliott M.
TI Dynamic TIMI Risk Score for STEMI
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE coronary artery disease; mortality; myocardial infarction; prognosis
ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES;
ATRIAL-FIBRILLATION; HEART-FAILURE; VENTRICULAR-TACHYCARDIA;
CARDIOVASCULAR MEDICINE; PROGNOSTIC-SIGNIFICANCE; RECURRENT ISCHEMIA;
GLOBAL REGISTRY; II TRIAL
AB Background-Although there are multiple methods of risk stratification for ST-elevation myocardial infarction (STEMI), this study presents a prospectively validated method for reclassification of patients based on in-hospital events. A dynamic risk score provides an initial risk stratification and reassessment at discharge.
Methods and Results-The dynamic TIMI risk score for STEMI was derived in ExTRACT-TIMI 25 and validated in TRITON-TIMI 38. Baseline variables were from the original TIMI risk score for STEMI. New variables were major clinical events occurring during the index hospitalization. Each variable was tested individually in a univariate Cox proportional hazards regression. Variables with P<0.05 were incorporated into a full multivariable Cox model to assess the risk of death at 1 year. Each variable was assigned an integer value based on the odds ratio, and the final score was the sum of these values. The dynamic score included the development of in-hospital MI, arrhythmia, major bleed, stroke, congestive heart failure, recurrent ischemia, and renal failure. The C-statistic produced by the dynamic score in the derivation database was 0.76, with a net reclassification improvement (NRI) of 0.33 (P<0.0001) from the inclusion of dynamic events to the original TIMI risk score. In the validation database, the C-statistic was 0.81, with a NRI of 0.35 (P=0.01).
Conclusions-This score is a prospectively derived, validated means of estimating 1-year mortality of STEMI at hospital discharge and can serve as a clinically useful tool. By incorporating events during the index hospitalization, it can better define risk and help to guide treatment decisions.
C1 [Amin, Sameer T.] Univ Calif Los Angeles, Dept Cardiol, Los Angeles, CA USA.
[Morrow, David A.; Braunwald, Eugene; Sloan, Sarah; Murphy, Sabina; Antman, Elliott M.] Brigham & Womens Hosp, Dept Cardiol, TIMI Study Grp, Boston, MA 02115 USA.
[Morrow, David A.; Braunwald, Eugene; Sloan, Sarah; Murphy, Sabina; Antman, Elliott M.] Harvard Univ, Boston, MA 02115 USA.
[Contant, Charles] Tufts Clin & Translat Res Ctr, Boston, MA USA.
RP Antman, EM (reprint author), Brigham & Womens Hosp, TIMI Study Grp, 350 Longwood Ave,1st Off Floor, Boston, MA 02115 USA.
EM eantman@partners.org
FU Sanofi-Aventis; Daicchi Sankyo; Eli Lilly
FX ExTRACT-TIMI 25 was supported by a research grant from Sanofi-Aventis,
and TRITON-TIMI 38 was supported by research grants from Daicchi Sankyo
and Eli Lilly.
NR 41
TC 12
Z9 12
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD FEB
PY 2013
VL 2
IS 1
AR UNSP e003269
DI 10.1161/JAHA.112.003269
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243SF
UT WOS:000326336800002
PM 23525425
ER
PT J
AU Singer, DE
Hellkamp, AS
Piccini, JP
Mahaffey, KW
Lokhnygina, Y
Pan, G
Halperin, JL
Becker, RC
Breithardt, G
Hankey, GJ
Hacke, W
Nessel, CC
Patel, MR
Califf, RM
Fox, KAA
AF Singer, Daniel E.
Hellkamp, Anne S.
Piccini, Jonathan P.
Mahaffey, Kenneth W.
Lokhnygina, Yuliya
Pan, Guohua
Halperin, Jonathan L.
Becker, Richard C.
Breithardt, Guenter
Hankey, Graeme J.
Hacke, Werner
Nessel, Christopher C.
Patel, Manesh R.
Califf, Robert M.
Fox, Keith A. A.
CA ROCKET AF Investigators
TI Impact of Global Geographic Region on Time in Therapeutic Range on
Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE anticoagulants; arrhythmia; embolism; prevention; risk factors
ID NONVALVULAR ATRIAL-FIBRILLATION; NORMALIZED RATIO CONTROL; STROKE
PREVENTION; ORAL ANTICOAGULATION; INTENSITY; QUALITY; RIVAROXABAN;
DABIGATRAN; REGISTRY; VALUES
AB Background-Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial.
Methods and Results-TTR (international normalized ratio [INR] 2.0 to 3.0) was determined using standard linear interpolation in patients randomized to warfarin in the ROCKET AF trial. Factors associated with TTR at the individual patient level (i-TTR) were determined via multivariable linear regression. Among 6983 patients taking warfarin, recruited from 45 countries grouped into 7 regions, the mean i-TTR was 55.2% (SD 21.3%) and the median i-TTR was 57.9% (interquartile range 43.0% to 70.6%). The mean time with INR <2 was 29.1% and the mean time with an INR >3 was 15.7%. While multiple clinical features were associated with i-TTR, dominant determinants were previous warfarin use (mean i-TTR of 61.1% for warfarin-experienced versus 47.4% in VKA-naive patients) and geographic region where patients were managed (mean i-TTR varied from 64.1% to 35.9%). These effects persisted in multivariable analysis. Regions with the lowest i-TTRs had INR distributions shifted toward lower INR values and had longer inter-INR test intervals.
Conclusions-Independent of patient clinical features, the regional location of medical care is a dominant determinant of variation in i-TTR in global studies of warfarin. Regional differences in mean i-TTR are heavily influenced by subtherapeutic INR values and are associated with reduced frequency of INR testing.
C1 [Singer, Daniel E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Hellkamp, Anne S.; Piccini, Jonathan P.; Mahaffey, Kenneth W.; Lokhnygina, Yuliya; Becker, Richard C.; Patel, Manesh R.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Piccini, Jonathan P.; Mahaffey, Kenneth W.; Becker, Richard C.; Patel, Manesh R.; Califf, Robert M.] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA.
[Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC 27710 USA.
[Pan, Guohua; Nessel, Christopher C.] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
[Halperin, Jonathan L.] Mt Sinai Sch Med, Cardiovasc Inst, New York, NY USA.
[Breithardt, Guenter] Univ Hosp, Dept Cardiol & Angiol, Munster, Germany.
[Hankey, Graeme J.] Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6001, Australia.
[Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany.
[Fox, Keith A. A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
[Fox, Keith A. A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
RP Singer, DE (reprint author), Massachusetts Gen Hosp, Div Gen Med, Clin Epidemiol Unit, S50-9, Boston, MA 02114 USA.
EM dsinger@partners.org
RI Hankey, Graeme /H-4968-2014
OI Hankey, Graeme /0000-0002-6044-7328
FU Johnson & Johnson Pharmaceutical Research & Development (Raritan, NJ);
Bayer HealthCare AG (Leverkusen, Germany); Massachusetts General
Hospital (Boston, MA)
FX The ROCKET AF trial was supported by research grants from Johnson &
Johnson Pharmaceutical Research & Development (Raritan, NJ) and Bayer
HealthCare AG (Leverkusen, Germany). The Duke Clinical Research
Institute (Durham, NC) coordinated the trial and performed the
statistical analyses for this manuscript, independent of the sponsors.
Dr Singer was supported, in part, by the Eliot B. and Edith C. Shoolman
fund of Massachusetts General Hospital (Boston, MA).
NR 25
TC 57
Z9 59
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD FEB
PY 2013
VL 2
IS 1
AR UNSP e000067
DI 10.1161/JAHA.112.000067
PG 18
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243SF
UT WOS:000326336800033
PM 23525418
ER
PT J
AU Smith, EE
Shobha, N
Dai, D
Olson, DM
Reeves, MJ
Saver, JL
Hernandez, AF
Peterson, ED
Fonarow, GC
Schwamm, LH
AF Smith, Eric E.
Shobha, Nandavar
Dai, David
Olson, DaiWai M.
Reeves, Mathew J.
Saver, Jeffrey L.
Hernandez, Adrian F.
Peterson, Eric D.
Fonarow, Gregg C.
Schwamm, Lee H.
TI A Risk Score for In-Hospital Death in Patients Admitted With Ischemic or
Hemorrhagic Stroke
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE intracerebral hemorrhage; ischemic stroke; mortality; subarachnoid
hemorrhage
ID QUALITY-OF-CARE; AMERICAN-HEART-ASSOCIATION; INTRACEREBRAL HEMORRHAGE;
GUIDELINES-STROKE; SUBARACHNOID HEMORRHAGE; EXTERNAL VALIDATION; PREDICT
MORTALITY; PROGNOSTIC MODELS; 30-DAY MORTALITY; GRADING SCALE
AB Background-We aimed to derive and validate a single risk score for predicting death from ischemic stroke (IS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH).
Methods and Results-Data from 333 865 stroke patients (IS, 82.4%; ICH, 11.2%; SAH, 2.6%; uncertain type, 3.8%) in the Get With The Guidelines-Stroke database were used. In-hospital mortality varied greatly according to stroke type (IS, 5.5%; ICH, 27.2%; SAH, 25.1%; unknown type, 6.0%; P<0.001). The patients were randomly divided into derivation (60%) and validation (40%) samples. Logistic regression was used to determine the independent predictors of mortality and to assign point scores for a prediction model in the overall population and in the subset with the National Institutes of Health Stroke Scale (NIHSS) recorded (37.1%). The c statistic, a measure of how well the models discriminate the risk of death, was 0.78 in the overall validation sample and 0.86 in the model including NIHSS. The model with NIHSS performed nearly as well in each stroke type as in the overall model including all types (c statistics for IS alone, 0.85; for ICH alone, 0.83; for SAH alone, 0.83; uncertain type alone, 0.86). The calibration of the model was excellent, as demonstrated by plots of observed versus predicted mortality.
Conclusions-A single prediction score for all stroke types can be used to predict risk of in-hospital death following stroke admission. Incorporation of NIHSS information substantially improves this predictive accuracy.
C1 [Smith, Eric E.; Shobha, Nandavar] Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB, Canada.
[Dai, David; Olson, DaiWai M.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA.
[Reeves, Mathew J.] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.
[Saver, Jeffrey L.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Schwamm, Lee H.] Massachusetts Gen Hosp, Stroke Serv, Boston, MA 02114 USA.
RP Smith, EE (reprint author), Foothills Med Ctr, Room C1212,1403 29th St NW, Calgary, AB T2N 2T9, Canada.
EM eesmith@ucalgary.ca
RI Hernandez, Adrian F./A-7818-2016
OI Saver, Jeffrey/0000-0001-9141-2251; Schwamm, Lee/0000-0003-0592-9145;
Hernandez, Adrian F./0000-0003-3387-9616
FU Boeringher-Ingelheim; Merck
FX The GWTG-Stroke program is provided by the American Heart
Association/American Stroke Association. The GWTG-Stroke program is
currently supported in part by a charitable contribution from
Bristol-Myers Squib/Sanofi Pharmaceutical Partnership and the American
Heart Association Pharmaceutical Roundtable. GWTG-Stroke has been funded
in the past through support from Boeringher-Ingelheim and Merck.
NR 38
TC 16
Z9 19
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD FEB
PY 2013
VL 2
IS 1
AR UNSP e005207
DI 10.1161/JAHA.112.005207
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243SF
UT WOS:000326336800034
PM 23525444
ER
PT J
AU Zamani, P
Schwartz, GG
Olsson, AG
Rifai, N
Bao, WH
Libby, P
Ganz, P
Kinlay, S
AF Zamani, Payman
Schwartz, Gregory G.
Olsson, Anders G.
Rifai, Nader
Bao, Weihang
Libby, Peter
Ganz, Peter
Kinlay, Scott
CA Myocardial Ischemia Reduction Aggr
TI Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events
After an Acute Coronary Syndrome in the MIRACL Study
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE acute coronary syndromes; biomarkers; CRP; death; nonfatal events; risk
ID C-REACTIVE PROTEIN; ACUTE MYOCARDIAL-INFARCTION; ACUTE-PHASE PROTEINS;
LONG-TERM MORTALITY; UNSTABLE ANGINA; ARTERY-DISEASE; PROGNOSTIC VALUE;
TROPONIN-T; RISK; ELEVATION
AB Background-In acute coronary syndromes, C-reactive protein (CRP) strongly relates to subsequent death, but surprisingly not to recurrent myocardial infarction. Other biomarkers may reflect different processes related to these outcomes. We assessed 8 inflammatory and vascular biomarkers and the risk of death and recurrent nonfatal cardiovascular events in the 16 weeks after an acute coronary syndrome.
Methods and Results-We measured blood concentrations of CRP, serum amyloid A (SAA), interleukin-6 (IL-6), soluble intercellular adhesion molecule (ICAM), soluble vascular cell adhesion molecule (VCAM), E-selectin, P-selectin, and tissue plasminogen activator antigen (tPA) 24 to 96 hours after presentation with acute coronary syndrome in 2925 subjects participating in a multicenter study. Biomarkers were related to the risk of death, and recurrent nonfatal acute coronary syndromes (myocardial infarction or unstable angina) over 16 weeks using Cox proportional hazard models. On univariate analyses, baseline CRP (P=0.006), SAA (P=0.012), and IL-6 (P<0.001) were related to death, but not to recurrent nonfatal acute coronary syndromes. VCAM and tPA related to the risk of death (P<0.001, P=0.021, respectively) and to nonfatal acute coronary syndromes (P=0.021, P=0.049, respectively). Adjusting for significant covariates reduced the strength of the associations; however, CRP and SAA continued to relate to death.
Conclusions-In acute coronary syndromes, the CRP inflammatory axis relates to the risk of death and may reflect myocardial injury. VCAM and tPA may have greater specificity for processes reflecting inflammation and thrombosis in the epicardial arteries, which determine recurrent coronary events.
C1 [Zamani, Payman] Hosp Univ Penn, Div Cardiovasc, Philadelphia, PA 19104 USA.
[Schwartz, Gregory G.] Univ Colorado, Vet Affairs Med Ctr, Div Cardiol, Denver, CO 80202 USA.
[Olsson, Anders G.] Linkoping Univ, Fac Hlth Sci, Linkoping, Sweden.
[Rifai, Nader] Childrens Hosp, Boston, MA 02115 USA.
[Bao, Weihang] Pfizer Pharmaceut Grp, New York, NY USA.
[Ganz, Peter] San Francisco Gen Hosp, Div Cardiovasc, San Francisco, CA 94110 USA.
[Ganz, Peter] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Libby, Peter; Kinlay, Scott] VA Boston Healthcare Syst, Brigham & Womens Hosp, Div Cardiovasc, West Roxbury, MA 02132 USA.
[Rifai, Nader; Libby, Peter; Kinlay, Scott] Harvard Univ, Sch Med, Boston, MA USA.
RP Kinlay, S (reprint author), VA Boston Healthcare Syst, Div Cardiovasc, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM scott.kinlay@va.gov
FU Pfizer, Inc.
FX This study was supported by an unrestricted grant from Pfizer, Inc.
NR 32
TC 21
Z9 26
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD FEB
PY 2013
VL 2
IS 1
AR UNSP e003103
DI 10.1161/JAHA.112.003103
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243SF
UT WOS:000326336800041
PM 23525424
ER
PT J
AU Garcia-Godoy, F
Kao, LM
Flaitz, CM
Hicks, J
AF Garcia-Godoy, Franklin
Kao, Lisa Marie
Flaitz, Catherine M.
Hicks, John
TI Fluoride dentifrice containing xylitol: In vitro root caries formation
SO AMERICAN JOURNAL OF DENTISTRY
LA English
DT Article
ID 0.243-PERCENT SODIUM-FLUORIDE; MUTANS STREPTOCOCCI; LASER IRRADIATION;
DENTAL ENAMEL; BIOCHEMICAL-MECHANISM; ANTICARIES EFFICACY; 10-PERCENT
XYLITOL; SURFACE CARIES; ORAL BACTERIA; REMINERALIZATION
AB Purpose: To evaluate the effects of experimental xylitol dentifrices with and without fluoride on in vitro root caries formation. Methods: Root surfaces from caries-free human permanent teeth (n=10) underwent debridement and a fluoride-free prophylaxis. The tooth roots were sectioned into quarters, and acid-resistant varnish was placed with two sound root surface windows exposed on each tooth quarter. Each quarter from a single tooth was assigned to a treatment group: (1) No treatment control; (2) Aquafresh Advanced (0.15% F = 1,150 ppm F); (3) Experimental xylitol dentifrice without fluoride (0.45% xylitol); and (4) Diamynt fluoride dentifrice with xylitol (0.83% sodium monofluorophosphate = 1,100 ppm F and 0.20% xylitol). Tooth root quarters were treated with fresh dentifrice twice daily (3 minutes) followed by fresh synthetic saliva rinsing over a 7-day period. Controls were exposed twice daily to fresh synthetic saliva rinsing daily over a 7-day period. In vitro root caries were created using an acidified gel (pH 4.25, 21 days). Longitudinal sections (three sections/tooth quarter, 60/group) were evaluated for mean lesion depths (water inhibition, polarized light, ANOVA, DMR). Results: Mean lesion depths were 359 +/- 37 mu m for the control Group; 280 +/- 28 mu m for Aquafresh Advanced; 342 +/- 41 mu m for the experimental xylitol dentifrice without fluoride; and 261 +/- 34 pm for Diamynt. Aquafresh Advanced and Diamynt had mean lesion depths significantly less than those for the no treatment control and the experimental xylitol without fluoride dentifrice (P< 0.05). There were minimal non-significant differences in mean lesion depths between Aquafresh Advanced and Diamynt (P> 0.05).
C1 [Garcia-Godoy, Franklin] Univ Tennessee, Coll Dent, Hlth Sci Ctr, Memphis, TN 38163 USA.
[Garcia-Godoy, Franklin] Forsyth Inst, Cambridge, MA USA.
[Kao, Lisa Marie] LMKao LLC, New York, NY USA.
[Flaitz, Catherine M.] Univ Texas Houston, Sch Dent, Dept Diagnost & Biomed Sci, Houston, TX USA.
[Flaitz, Catherine M.] Univ Texas Houston, Dept Pediat Dent, Sch Dent, Houston, TX USA.
[Flaitz, Catherine M.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Oncol, Houston, TX 77030 USA.
[Hicks, John] Texas Childrens Hosp, Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Hicks, John] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat Hematol & Oncol, Houston, TX 77030 USA.
[Hicks, John] Univ Texas Hlth Sci Ctr Houston, Sch Dent, Dept Pediat Dent, Houston, TX 77030 USA.
RP Garcia-Godoy, F (reprint author), Univ Tennessee, Coll Dent, Biosci Res Ctr, Hlth Sci Ctr, 875 Union Ave, Memphis, TN 38163 USA.
EM fgarciagodoy@gmail.com
NR 61
TC 0
Z9 0
U1 1
U2 4
PU MOSHER & LINDER, INC
PI WESTON
PA 318 INDIAN TRACE SUITE 500, WESTON, FL 33326 USA
SN 0894-8275
J9 AM J DENT
JI Am. J. Dent.
PD FEB
PY 2013
VL 26
IS 1
BP 56
EP 60
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 233UX
UT WOS:000325596100010
PM 23724551
ER
PT J
AU Shyti, R
Eikermann-Haerter, K
Meijer, OC
van Heiningen, SH
De Groote, L
Ferrari, MD
Ayata, C
van den Maagdenberg, AMJ
Tolner, EA
AF Shyti, R.
Eikermann-Haerter, K.
Meijer, O. C.
van Heiningen, S. H.
De Groote, L.
Ferrari, M. D.
Ayata, C.
van den Maagdenberg, A. M. J.
Tolner, E. A.
TI Corticosterone enhances CSD susceptibility via glucocorticoid receptor
activation in familial hemiplegic migraine 1 Cacna1a knock-in mice
SO JOURNAL OF HEADACHE AND PAIN
LA English
DT Meeting Abstract
ID SPREADING DEPRESSION
C1 [Shyti, R.; van Heiningen, S. H.; van den Maagdenberg, A. M. J.] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands.
[Eikermann-Haerter, K.; Ayata, C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurovasc Res Lab,Dept Neurol, Boston, MA USA.
[Meijer, O. C.] Leiden Univ, Dept Endocrinol, Med Ctr, Leiden, Netherlands.
[De Groote, L.; Tolner, E. A.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands.
[Ferrari, M. D.] Dept Neurol, Leiden, Netherlands.
NR 2
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1129-2369
EI 1129-2377
J9 J HEADACHE PAIN
JI J. Headache Pain
PD FEB
PY 2013
VL 14
SU 1
AR P85
DI 10.1186/1129-2377-14-S1-P85
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 232WR
UT WOS:000325525600103
ER
PT J
AU Singh, JA
AF Singh, Jasvinder A.
TI Racial and Gender Disparities Among Patients with Gout
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Gout; Hyperuricemia; Race; Ethnicity; Gender; Disparity; Epidemiology;
Prevalence; Genetic risk factors; Adverse effects
ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; ACUTE MYOCARDIAL-INFARCTION;
QUALITY-OF-LIFE; UNITED-STATES; URIC-ACID; AFRICAN-AMERICAN;
SEX-DIFFERENCES; HEALTH-CARE; PHYSICIAN COMMUNICATION; RACE/ETHNIC
DISPARITY
AB Gout affects 8.3 million Americans according to NHANES 2007-2008, approximately 3.9 % of the US population. Gout has substantial effect on physical function, productivity, health-related quality of life (HRQOL), and health care costs. Uncontrolled gout is also associated with significant use of emergency care services. Women are less likely to have gout than men, but in the postmenopausal years the gender difference in disease incidence decreases. Compared with whites, racial and/or ethnic minorities, especially blacks, have higher prevalence of gout. Blacks are also less likely to receive quality gout care, leading to disproportionate morbidity. Women are less likely than men to receive allopurinol, and less likely to undergo joint aspirations for crystal analysis to establish diagnosis, but those on urate-lowering therapy are as likely as, or more likely than, men to undergo serum urate check within six months of initiation. Although a few studies provide the knowledge related to gender and race and/or ethnicity disparities for gout, several knowledge gaps exist in gout epidemiology and outcomes differences by gender and race and/or ethnicity. These should be investigated in future studies.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Div Rheumatol, Sch Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU National Institute of Aging; National Cancer Institute; National
Institute of Arthritis and Musculoskeletal Diseases; Agency for Health
Quality; Research Center for Education and Research on Therapeutics
FX Dr Singh is supported by research grants from the National Institute of
Aging, the National Cancer Institute, the National Institute of
Arthritis and Musculoskeletal Diseases, the Agency for Health Quality,
and the Research Center for Education and Research on Therapeutics, and
by the resources and facilities at the Birmingham VA Medical Center,
Alabama, USA. The views expressed in this article are those of the
author and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States government.
NR 79
TC 21
Z9 21
U1 2
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3774
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD FEB
PY 2013
VL 15
IS 2
AR 307
DI 10.1007/s11926-012-0307-x
PG 9
WC Rheumatology
SC Rheumatology
GA 225VT
UT WOS:000324993800004
PM 23315156
ER
PT J
AU Bhuvaneswar, CG
Stern, TA
AF Bhuvaneswar, Chaya G.
Stern, Theodore A.
TI Teaching cross-cultural aspects of mourning: A Hindu perspective on
death and dying
SO PALLIATIVE & SUPPORTIVE CARE
LA English
DT Editorial Material
ID SUICIDE
C1 [Bhuvaneswar, Chaya G.] Covance Inc, Dept Neurosci, Princeton, NJ USA.
[Bhuvaneswar, Chaya G.; Stern, Theodore A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Bhuvaneswar, CG (reprint author), Covance Inc, Dept Neurosci, Princeton, NJ USA.
EM chayab77@gmail.com
NR 26
TC 0
Z9 0
U1 1
U2 10
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1478-9515
J9 PALLIAT SUPPORT CARE
JI Palliat. Support Care
PD FEB
PY 2013
VL 11
IS 1
BP 79
EP 84
DI 10.1017/S1478951512000946
PG 6
WC Health Policy & Services
SC Health Care Sciences & Services
GA 219VP
UT WOS:000324539500009
PM 23171885
ER
PT J
AU Courtwright, A
AF Courtwright, Andrew
TI From Unregulated Practice to Credentialed Profession: Implementing
Ethics Consultation Competencies
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Editorial Material
C1 [Courtwright, Andrew] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Courtwright, A (reprint author), Massachusetts Gen Hosp, Inst Patient Care, 55 Fruit St, Boston, MA 02114 USA.
EM acourt1500@gmail.com
NR 4
TC 1
Z9 1
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1526-5161
EI 1536-0075
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PD FEB 1
PY 2013
VL 13
IS 2
BP 16
EP 17
DI 10.1080/15265161.2012.750389
PG 2
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
Biomedical Social Sciences
GA 189YG
UT WOS:000322303600004
PM 23391051
ER
PT J
AU Fox, MD
Liu, HS
Pascual-Leone, A
AF Fox, Michael D.
Liu, Hesheng
Pascual-Leone, Alvaro
TI Identification of reproducible individualized targets for treatment of
depression with TMS based on intrinsic connectivity
SO NEUROIMAGE
LA English
DT Article
DE Transcranial magnetic stimulation; TMS; Intrinsic connectivity; Resting
state functional connectivity; MRI; Subgenual; Dorsolateral prefrontal
cortex; Depression; Individual differences; Variability; Seed map
ID TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT-RESISTANT DEPRESSION;
DORSOLATERAL PREFRONTAL CORTEX; TEST-RETEST RELIABILITY; HUMAN
CEREBRAL-CORTEX; FUNCTIONAL CONNECTIVITY; BRAIN CONNECTIVITY; ANTERIOR
CINGULATE; MAJOR DEPRESSION; MOTOR CORTEX
AB Transcranial magnetic stimulation (TMS) to the left dorsolateral prefrontal cortex (DLPFC) is used clinically for the treatment of depression however outcomes vary greatly between patients. We have shown that average clinical efficacy of different left DLPFC TMS sites is related to intrinsic functional connectivity with remote regions including the subgenual cingulate and suggested that functional connectivity with these remote regions might be used to identify optimized left DLPFC targets for TMS. However it remains unclear if and how this connectivity-based targeting approach should be applied at the single-subject level to potentially individualize therapy to specific patients. In this article we show that individual differences in DLPFC connectivity are large, reproducible across sessions, and can be used to generate individualized DLPFC TMS targets that may prove clinically superior to those selected on the basis of group-average connectivity. Factors likely to improve individualized targeting including the use of seed maps and the focality of stimulation are investigated and discussed. The techniques presented here may be applicable to individualized targeting of focal brain stimulation across a range of diseases and stimulation modalities and can be experimentally tested in clinical trials. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Fox, Michael D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Fox, Michael D.; Pascual-Leone, Alvaro] Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA.
[Fox, Michael D.; Pascual-Leone, Alvaro] Harvard Univ, Sch Med, Boston, MA USA.
[Fox, Michael D.; Liu, Hesheng] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA.
[Pascual-Leone, Alvaro] Univ Autonoma Barcelona, Hosp Neurorehabil, Inst Guttmann, E-08193 Barcelona, Spain.
RP Fox, MD (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM foxmdphd@gmail.com
OI Liu, Hesheng/0000-0002-7233-1509
FU National Institutes of Health [R25NS065743, K25NS069805]; National
Center for Research Resources: Harvard Clinical and Translational
Science Center [UL1 RR025758]
FX We thank the Brain Genomics Superstruct Project for contributing data
and David Alsop for assistance with MRI acquisition and sequence
optimization for the depression patients. MDF was supported by NIH grant
R25NS065743 and HL by NIH grant K25NS069805. APL serves on the
scientific advisory boards for Nexstim, Neuronix, Starlab Neuroscience,
Neuroelectrics, Neosync, and Novavision, and is listed as inventor in
issued patents and patent applications on the real-time integration of
transcranial magnetic stimulation (TMS) with electroencephalography
(EEG) and magnetic resonance imaging (MRI). Work on this study was also
supported by grants from the National Institutes of Health and National
Center for Research Resources: Harvard Clinical and Translational
Science Center (UL1 RR025758).
NR 64
TC 32
Z9 34
U1 1
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2013
VL 66
BP 151
EP 160
DI 10.1016/j.neuroimage.2012.10.082
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 190QR
UT WOS:000322355800016
PM 23142067
ER
PT J
AU Bernal-Rusiel, JL
Greve, DN
Reuter, M
Fischl, B
Sabuncu, MR
AF Bernal-Rusiel, Jorge L.
Greve, Douglas N.
Reuter, Martin
Fischl, Bruce
Sabuncu, Mert R.
CA Alzheimer's Dis Neuroimaging Initi
TI Statistical analysis of longitudinal neuroimage data with Linear Mixed
Effects models
SO NEUROIMAGE
LA English
DT Article
DE Longitudinal studies; Linear Mixed Effects models; Statistical analysis
ID MILD COGNITIVE IMPAIRMENT; BRAIN VOLUME CHANGES; SURFACE-BASED ANALYSIS;
GRAY-MATTER VOLUME; ALZHEIMERS-DISEASE; HIPPOCAMPAL ATROPHY; CORTICAL
THICKNESS; 1ST-EPISODE SCHIZOPHRENIA; MAXIMUM-LIKELIHOOD; COORDINATE
SYSTEM
AB Longitudinal neuroimaging (LNI) studies are rapidly becoming more prevalent and growing in size. Today, no standardized computational tools exist for the analysis of LNI data and widely used methods are sub-optimal for the types of data encountered in real-life studies. Linear Mixed Effects (LME) modeling, a mature approach well known in the statistics community, offers a powerful and versatile framework for analyzing real-life LNI data. This article presents the theory behind LME models, contrasts it with other popular approaches in the context of LNI, and is accompanied with an array of computational tools that will be made freely available through FreeSurfer - a popular Magnetic Resonance Image (MRI) analysis software package.
Our core contribution is to provide a quantitative empirical evaluation of the performance of LME and competing alternatives popularly used in prior longitudinal structural MRI studies, namely repeated measures ANOVA and the analysis of annualized longitudinal change measures (e.g. atrophy rate). In our experiments, we analyzed MRI-derived longitudinal hippocampal volume and entorhinal cortex thickness measurements from a public dataset consisting of Alzheimer's patients, subjects with mild cognitive impairment and healthy controls. Our results suggest that the LME approach offers superior statistical power in detecting longitudinal group differences. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Bernal-Rusiel, Jorge L.; Greve, Douglas N.; Reuter, Martin; Fischl, Bruce; Sabuncu, Mert R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Reuter, Martin] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Fischl, Bruce; Sabuncu, Mert R.] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
RP Sabuncu, MR (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St,Room 2301, Charlestown, MA 02129 USA.
EM msabuncu@nmr.mgh.harvard.edu
RI Reuter, Martin/B-3456-2010
OI Reuter, Martin/0000-0002-2665-9693
FU Alzheimer's Disease Neuroimaging Initiative (ADNI); National Institutes
of Health (NIH) [U01 AG024904]; National Institute on Aging (NIA), the
National Institute of Biomedical Imaging and Bioengineering; National
Center for Research Resources [P41-RR14075]; National Institute for
Biomedical Imaging and Bioengineering [R01EB006758]; National Institute
on Aging [AG022381]; National Center for Alternative Medicine [RC1
AT005728-01]; National Institute for Neurological Disorders and Stroke
[R01 N5052585-01, 1R21NS072652-01, 1R01NS070963, 2R01NS042861-06A1,
5P01NS058793-03]; National Institute of Child Health and Human
Development [R01-HD071664]; Shared Instrumentation Grants [1S10RR023401,
1S10RR019307, 1S10RR023043]; Autism & Dyslexia Project; Ellison Medical
Foundation; NIH [5R01AG008122-22]; NIH Blueprint for Neuroscience
Research, part of the multi-institutional Human Connectome Project
[5U01-MH093765]; KL2 Medical Research Investigator Training (MeRIT)
grant awarded via Harvard Catalyst, The Harvard Clinical and
Translational Science Center (NIH) [1KL2RR025757-01]; Harvard
University; AHAF Alzheimer's Disease pilot grant [AHAF A2012333]; NIH
K25 grant [NIBIB 1K25EB013649-01]
FX Data collection and sharing for this project was funded by the
Alzheimer's Disease Neuroimaging Initiative (ADNI) and the National
Institutes of Health (NIH) (grant U01 AG024904). The ADNI is funded by
the National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering, and through generous
contributions from the following: Abbott Laboratories, AstraZeneca AB,
Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical
Development, Elan Corporation Plc, Genentech Inc, GE Healthcare,
GlaxoSmithKline, Innogenetics, Johnson and Johnson Services Inc, Eli
Lilly and Company, Medpace Inc, Merck and Co Inc, Novartis International
AG, Pfizer Inc, F. Hoffman-La Roche Ltd, Schering-Plough Corporation,
CCBR-SYNARC Inc, and Wyeth Pharmaceuticals, as well as nonprofit
partners the Alzheimer's Association and Alzheimer's Drug Discovery
Foundation, with participation from the US Food and Drug Administration.
Private sector contributions to the ADNI are facilitated by the
Foundation for the NIH. The grantee organization is the Northern
California Institute for Research and Education Inc, and the study is
coordinated by the Alzheimer's Disease Cooperative Study at the
University of California, San Diego. The ADNI data are disseminated by
the Laboratory for NeuroImaging at the University of California, Los
Angeles.; Support for this research was provided in part by the National
Center for Research Resources (P41-RR14075), the National Institute for
Biomedical Imaging and Bioengineering (R01EB006758), the National
Institute on Aging (AG022381), the National Center for Alternative
Medicine (RC1 AT005728-01), the National Institute for Neurological
Disorders and Stroke (R01 N5052585-01, 1R21NS072652-01, 1R01NS070963,
2R01NS042861-06A1, 5P01NS058793-03), the National Institute of Child
Health and Human Development (R01-HD071664), and was made possible by
the resources provided by Shared Instrumentation Grants 1S10RR023401,
1S10RR019307, and 1S10RR023043. Additional support was provided by The
Autism & Dyslexia Project funded by the Ellison Medical Foundation, by
the NIH 5R01AG008122-22 grant, and by the NIH Blueprint for Neuroscience
Research (5U01-MH093765), part of the multi-institutional Human
Connectome Project. Dr. Sabuncu received support from a KL2 Medical
Research Investigator Training (MeRIT) grant awarded via Harvard
Catalyst, The Harvard Clinical and Translational Science Center (NIH
grant #1KL2RR025757-01 and financial contributions from Harvard
University and its affiliated academic health care centers), an AHAF
Alzheimer's Disease pilot grant (AHAF A2012333), and an NIH K25 grant
(NIBIB 1K25EB013649-01).
NR 76
TC 51
Z9 51
U1 2
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2013
VL 66
BP 249
EP 260
DI 10.1016/j.neuroimage.2012.10.065
PG 12
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 190QR
UT WOS:000322355800027
PM 23123680
ER
PT J
AU Zhu, Q
Nelissen, K
Van den Stock, J
De Winter, FL
Pauwels, K
de Gelder, B
Vanduffel, W
Vandenbulcke, M
AF Zhu, Qi
Nelissen, Koen
Van den Stock, Jan
De Winter, Francois-Laurent
Pauwels, Karl
de Gelder, Beatrice
Vanduffel, Wim
Vandenbulcke, Mathieu
TI Dissimilar processing of emotional facial expressions in human and
monkey temporal cortex
SO NEUROIMAGE
LA English
DT Article
DE fMRI; Emotions; Facial expressions; Monkey; Human; STS
ID CORTICAL AREAS TE; VISUAL-CORTEX; HUMAN BRAIN; NEURAL REPRESENTATIONS;
SELECTIVE RESPONSES; SOCIAL-PERCEPTION; RHESUS MACAQUES; CONTRAST AGENT;
FACE PATCH; FMRI
AB Emotional facial expressions play an important role in social communication across primates. Despite major progress made in our understanding of categorical information processing such as for objects and faces, little is known, however, about how the primate brain evolved to process emotional cues. In this study, we used functional magnetic resonance imaging (fMRI) to compare the processing of emotional facial expressions between monkeys and humans. We used a 2 x 2 x 2 factorial design with species (human and monkey), expression (fear and chewing) and configuration (intact versus scrambled) as factors. At the whole brain level, neural responses to conspecific emotional expressions were anatomically confined to the superior temporal sulcus (STS) in humans. Within the human STS, we found functional subdivisions with a face-selective right posterior STS area that also responded to emotional expressions of other species and a more anterior area in the right middle STS that responded specifically to human emotions. Hence, we argue that the latter region does not show a mere emotion-dependent modulation of activity but is primarily driven by human emotional facial expressions. Conversely, in monkeys, emotional responses appeared in earlier visual cortex and outside face-selective regions in inferior temporal cortex that responded also to multiple visual categories. Within monkey IT, we also found areas that were more responsive to conspecific than to non-conspecific emotional expressions but these responses were not as specific as in human middle STS. Overall, our results indicate that human STS may have developed unique properties to deal with social cues such as emotional expressions. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Zhu, Qi; Nelissen, Koen; Pauwels, Karl; Vanduffel, Wim] Katholieke Univ Leuven, Lab Neuro & Psychophysiol, Louvain, Belgium.
[Nelissen, Koen; de Gelder, Beatrice; Vanduffel, Wim] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Van den Stock, Jan; de Gelder, Beatrice] Tilburg Univ, Cognit & Affect Neurosci Lab, NL-5000 LE Tilburg, Netherlands.
[Van den Stock, Jan; De Winter, Francois-Laurent; de Gelder, Beatrice; Vandenbulcke, Mathieu] Katholieke Univ Leuven, Dept Neurosci, Div Psychiat, BELL, Louvain, Belgium.
RP Vanduffel, W (reprint author), Bldg 149,13th St, Charlestown, MA 02129 USA.
EM wim@nmr.mgh.harvard.edu
RI Van den Stock, Jan/F-1906-2014; Pauwels, Karl/B-1074-2013
OI Van den Stock, Jan/0000-0001-5756-3195; Pauwels,
Karl/0000-0003-3731-0582
FU Fund for Scientific Research (Flanders) [G.0746.09, G.0622.08,
G.0831.11]; Hercules II funding; Inter University Attraction Pole
[6/29]; National Institute of Neurological Disorders and Stroke
[R21NS064432]; National Science Foundation in the USA [BCS-0745436];
Geconcerteerde Onderzoeks Actie [10/19]; [PFV/10/008]
FX We thank C. Fransen, C. Van Eupen and A. Coeman for animal training and
care; H. Kolster, W. Depuydt G. Meulemans, P. Kayenbergh, M. De Paep, S.
Verstraeten, M. Docx, and I. Puttemans for technical assistance. In
addition, we thank I. Popivanov, R. Vogels, J. Jastorff and N. Caspari
for their help with the localizer experiment. This work was supported by
the Fund for Scientific Research (Flanders) G.0746.09, G.0622.08, and
G.0831.11, Hercules II funding, Inter University Attraction Pole 6/29,
the National Institute of Neurological Disorders and Stroke
(R21NS064432), and the National Science Foundation (BCS-0745436) in the
USA, Programme Financing PFV/10/008, and Geconcerteerde Onderzoeks Actie
10/19. Q.Z., K.N. and J.V.d.S. are postdoctoral fellows of the FWO
Vlaanderen.
NR 77
TC 10
Z9 10
U1 5
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2013
VL 66
BP 402
EP 411
DI 10.1016/j.neuroimage.2012.10.083
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 190QR
UT WOS:000322355800043
PM 23142071
ER
PT J
AU Carmichael, O
McLaren, DG
Tommet, D
Mungas, D
Jones, RN
AF Carmichael, Owen
McLaren, Donald G.
Tommet, Douglas
Mungas, Dan
Jones, Richard N.
CA Alzheimer's Dis Neuroimaging Initi
TI Coevolution of brain structures in amnestic mild cognitive impairment
SO NEUROIMAGE
LA English
DT Article
DE MRI parcellation; Longitudinal cortical change; Alzheimer's disease;
Exploratory factor analysis; Distributed networks
ID HUMAN CEREBRAL-CORTEX; NEUROIMAGING INITIATIVE ADNI; MAGNETIC-RESONANCE
IMAGES; MIDLIFE BLOOD-PRESSURE; SURFACE-BASED ANALYSIS; DEFAULT-MODE
NETWORK; ALZHEIMERS-DISEASE; COORDINATE SYSTEM; CORTICAL SURFACE;
INDIVIDUAL-DIFFERENCES
AB Network accounts of the progression of Alzheimer's disease (AD), based on cross-sectional brain imaging observations, postulate that the biological course of the disease is characterized by coordinated spatial patterns of brain change to distributed cognitive networks. This study tests this conjecture by quantifying inter-regional covariance in cortical gray matter atrophy rates in 317 Alzheimer's Disease Neuroimaging Initiative participants who were clinically diagnosed with amnestic mild cognitive impairment at baseline and underwent serial MRI at 6-month intervals over the course of 2 years. A factor analysis model identified five factors (i.e. groupings of regions) that exhibited highly correlated rates of atrophy. Four groupings approximately corresponded to coordinated change within the posterior default mode network, prefrontal cortex, medial temporal lobe, and regions largely spared by the early pathological course of AD (i.e., sensorimotor and occipital cortex), while the fifth grouping represented diffuse, global atrophy. The data-driven observation of "frontal aging" superimposed upon medial temporal atrophy typical of early AD and default mode network changes supports the view that in individuals at high risk of eventual clinical AD, multiple patterns of distributed neuronal death corresponding to multiple biological substrates may be active. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Carmichael, Owen; Mungas, Dan] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA.
[McLaren, Donald G.] ENRM Vet Hosp, Geriatr Res Educ & Clin Ctr, Bedford, MA USA.
[McLaren, Donald G.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA.
[McLaren, Donald G.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[McLaren, Donald G.] Harvard Univ, Sch Med, Boston, MA USA.
[Tommet, Douglas; Jones, Richard N.] Hebrew SeniorLife, Inst Aging Res, Roslindale, MA USA.
[Jones, Richard N.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA.
RP Carmichael, O (reprint author), Ctr Neurosci, 1544 Newton Court, Davis, CA 95618 USA.
EM ocarmichael@ucdavis.edu; mclaren@nmr.mgh.harvard.edu;
DougTommet@hsl.harvard.edu; jones@hsl.harvard.edu
RI Jones, Richard/J-3488-2013;
OI Jones, Richard/0000-0002-1049-218X; McLaren, Donald/0000-0002-0566-4610
FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes
of Health) [U01 AG024904]; National Institute on Aging, the National
Institute of Biomedical Imaging and Bioengineering; Canadian Institutes
of Health Research; National Institutes of Health [AG010129, AG030514,
AG030995, AG036694, AG027171]; Edward Fein Foundation (Nevada)
FX Data collection and sharing for this project was funded by the
Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes
of Health Grant U01 AG024904). ADNI is funded by the National Institute
on Aging, the National Institute of Biomedical Imaging and
Bioengineering, and through generous contributions from the following:
Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation;
Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica,
Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan
Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd
and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics,
N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &
Development, LLC.; Johnson & Johnson Pharmaceutical Research &
Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale
Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.;
Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian
Institutes of Health Research is providing funds to support ADNI
clinical sites in Canada. Private sector contributions are facilitated
by the Foundation for the National Institutes of Health (www.fnih.org).
The grantee organization is the Northern California Institute for
Research and Education, and the study is coordinated by the Alzheimer's
Disease Cooperative Study at the University of California, San Diego.
ADNI data are disseminated by the Laboratory for Neuro Imaging at the
University of California, Los Angeles. This research was also supported
by National Institutes of Health grants AG010129, AG030514, AG030995,
AG036694, and AG027171. Drs. Jones was supported in part by the Edward
Fein Foundation (Nevada) and through the generosity of Vicki and Arthur
Loring (Massachusetts). The contents do not represent the views of the
Dept. of Veterans Affairs, the United States Government, or any other
funding entities.
NR 64
TC 5
Z9 5
U1 2
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2013
VL 66
BP 449
EP 456
DI 10.1016/j.neuroimage.2012.10.029
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 190QR
UT WOS:000322355800047
PM 23103689
ER
PT J
AU Brown, K
Xie, S
Qiu, XL
Mohrin, M
Shin, JY
Liu, YF
Zhang, D
Scadden, DT
Chen, D
AF Brown, Katharine
Xie, Stephanie
Qiu, Xiaolei
Mohrin, Mary
Shin, Jiyung
Liu, Yufei
Zhang, Dan
Scadden, David T.
Chen, Danica
TI SIRT3 Reverses Aging-Associated Degeneration
SO CELL REPORTS
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; REGULATES LIFE-SPAN; OXIDATIVE STRESS;
HOMEOSTASIS; DEACETYLATION; MITOCHONDRIA; RESTRICTION; ACETYLATION;
PATHWAYS; SIRTUINS
AB Despite recent controversy about their function in some organisms, sirtuins are thought to play evolutionarily conserved roles in lifespan extension. Whether sirtuins can reverse aging-associated degeneration is unknown. Tissue-specific stem cells persist throughout the entire lifespan to repair and maintain tissues, but their self-renewal and differentiation potential become dysregulated with aging. We show that SIRT3, a mammalian sirtuin that regulates the global acetylation landscape of mitochondrial proteins and reduces oxidative stress, is highly enriched in hematopoietic stem cells (HSCs) where it regulates a stress response. SIRT3 is dispensable for HSC maintenance and tissue homeostasis at a young age under homeostatic conditions but is essential under stress or at an old age. Importantly, SIRT3 is suppressed with aging, and SIRT3 upregulation in aged HSCs improves their regenerative capacity. Our study illuminates the plasticity of mitochondrial homeostasis controlling stem cell and tissue maintenance during the aging process and shows that aging-associated degeneration can be reversed by a sirtuin.
C1 [Brown, Katharine; Qiu, Xiaolei; Mohrin, Mary; Shin, Jiyung; Zhang, Dan; Chen, Danica] Univ Calif Berkeley, Program Metab Biol Nutr Sci & Toxicol, Berkeley, CA 94720 USA.
[Liu, Yufei] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
[Xie, Stephanie; Scadden, David T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med,Canc Ctr, Boston, MA 02114 USA.
[Xie, Stephanie; Scadden, David T.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Scadden, DT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med,Canc Ctr, 185 Cambridge St, Boston, MA 02114 USA.
EM dscadden@mgh.harvard.edu; danicac@berkeley.edu
FU Searle Scholars Program; Hellman Family Faculty Funds; Ellison Medical
Foundation; NIH [R01AG040990]; UCOP TRDRP; American Heart Association;
Siebel Stem Cell Institute; CIRM; NSF
FX We thank F. Alt and H. Cheng for reagents. This work was supported by
Searle Scholars Program (to D.C.), the Hellman Family Faculty Funds (to
D.C.), the Ellison Medical Foundation (to D.C.), the NIH (R01AG040990;
to D.C.), UCOP TRDRP (to D.C.), American Heart Association (to D.C.),
the Siebel Stem Cell Institute (to D.C., X.Q., and M.M.), the CIRM (to
X.Q.), and the NSF (to J.S.).
NR 26
TC 86
Z9 91
U1 3
U2 29
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD FEB
PY 2013
VL 3
IS 2
BP 319
EP 327
DI 10.1016/j.celrep.2013.01.005
PG 9
WC Cell Biology
SC Cell Biology
GA 184MS
UT WOS:000321895200007
PM 23375372
ER
PT J
AU El Ouaamari, A
Kawamori, D
Dirice, E
Liew, CW
Shadrach, JL
Hu, J
Katsuta, H
Hollister-Lock, J
Qian, WJ
Wagers, AJ
Kulkarni, RN
AF El Ouaamari, Abdelfattah
Kawamori, Dan
Dirice, Ercument
Liew, Chong Wee
Shadrach, Jennifer L.
Hu, Jiang
Katsuta, Hitoshi
Hollister-Lock, Jennifer
Qian, Wei-Jun
Wagers, Amy J.
Kulkarni, Rohit N.
TI Liver-Derived Systemic Factors Drive beta Cell Hyperplasia in
Insulin-Resistant States
SO CELL REPORTS
LA English
DT Article
ID GROWTH-FACTOR; COMPENSATORY GROWTH; GLUCOSE-INTOLERANCE; RECEPTOR;
PROLIFERATION; MICE; MASS; ACTIVATION; EXPANSION; PANCREAS
AB Integrative organ crosstalk regulates key aspects of energy homeostasis, and its dysregulation may underlie metabolic disorders such as obesity and diabetes. To test the hypothesis that crosstalk between the liver and pancreatic islets modulates beta cell growth in response to insulin resistance, we used the liver-specific insulin receptor knockout (LIRKO) mouse, a unique model that exhibits dramatic islet hyperplasia. Using complementary in vivo parabiosis and transplantation assays, as well as in vitro islet culture approaches, we demonstrate that humoral, nonneural, non-cell-autonomous factor(s) induces beta cell proliferation in LIRKO mice. Furthermore, we report that a hepatocyte-derived factor(s) stimulates mouse and human beta cell proliferation in ex vivo assays, independent of ambient glucose and insulin levels. These data implicate the liver as a critical source of beta cell growth factor(s) in insulin-resistant states.
C1 [El Ouaamari, Abdelfattah; Kawamori, Dan; Dirice, Ercument; Liew, Chong Wee; Shadrach, Jennifer L.; Hu, Jiang; Wagers, Amy J.; Kulkarni, Rohit N.] Joslin Diabet Ctr, Sect Islet Cell Biol & Regenerat Med, Boston, MA 02115 USA.
[Katsuta, Hitoshi; Hollister-Lock, Jennifer] Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02115 USA.
[Katsuta, Hitoshi; Hollister-Lock, Jennifer] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Shadrach, Jennifer L.; Wagers, Amy J.] Harvard Univ, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Shadrach, Jennifer L.; Wagers, Amy J.] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.
[Qian, Wei-Jun] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA.
[Qian, Wei-Jun] Pacific NW Natl Lab, Environm Mol Sci Lab, Richland, WA 99352 USA.
RP Kulkarni, RN (reprint author), Joslin Diabet Ctr, Sect Islet Cell Biol & Regenerat Med, Boston, MA 02115 USA.
EM rohit.kulkarni@joslin.harvard.edu
RI Dirice, Ercument/B-2825-2017
FU NIH [RO1 DK 067536]; Societe Francophone du Diabete; Association
Francaise des Diabetiques; American Diabetes Association; Burroughs
Wellcome Fund [NIH 5 P30 DK36836-20, NIH 1 DP2 OD004345]; Harvard Stem
Cell Institute Seed Grant; Juvenile Diabetes Research Foundation/Sanofi
Aventis Strategic Alliance [17-2011-644]; [R01 DK 074795]
FX We are grateful to C. Ronald Kahn for sharing the LIRKO model. We thank
the laboratory of Gordon Weir for assistance in transplantation
experiments, T. Roderick Bronson for assistance with histology, and
Amarnath Kurpad, Marta Robledo, Samantha Haring, Rachael Martinez, and
Ben Hambro for technical assistance. This work is supported by NIH RO1
DK 067536 (to R.N.K.); Societe Francophone du Diabete, Association
Francaise des Diabetiques, and American Diabetes Association (to
A.E.O.); R01 DK 074795 (to W.-J.Q.); and the Burroughs Wellcome Fund,
NIH 5 P30 DK36836-20, and NIH 1 DP2 OD004345 (to A.J.W.). A.J.W. is an
Early Career Scientist of the Howard Hughes Medical Institute. Part of
the study was supported by a Harvard Stem Cell Institute Seed Grant (to
R.N.K.) and by a grant from the Juvenile Diabetes Research
Foundation/Sanofi Aventis Strategic Alliance (17-2011-644) (to R.N.K.).
NR 40
TC 51
Z9 52
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD FEB
PY 2013
VL 3
IS 2
BP 401
EP 410
DI 10.1016/j.celrep.2013.01.007
PG 10
WC Cell Biology
SC Cell Biology
GA 184MS
UT WOS:000321895200015
PM 23375376
ER
PT J
AU Price, M
Davidson, TM
Andrews, JO
Ruggiero, KJ
AF Price, Matthew
Davidson, Tatiana M.
Andrews, Jeannette O.
Ruggiero, Kenneth J.
TI Access, use and completion of a brief disaster mental health
intervention among Hispanics, African-Americans and Whites affected by
Hurricane Ike
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Article
ID RECRUITMENT
AB African-Americans and Hispanics are disproportionally affected by disasters. We evaluated differences in the use and completion of a web-based mental health intervention, Disaster Recovery Web (DRW), by White, African-American and Hispanic adults in the aftermath of Hurricane Ike. Approximately one year after the hurricane, a telephone survey was carried out with adults from Galveston and Chambers counties. A total of 1249 adults participated in the survey (80% White, 14% African-American and 6% Hispanic). Mental health and mental health service utilization were assessed. Whites were more likely to have previously used the Internet to obtain general health information than African-Americans or Hispanics (P < 0.001). A logistic regression was used to identify differences in the use of the Internet intervention after controlling for covariates. There were no differences in rates of non-use and dropout attrition between Whites, African-Americans and Hispanics. Thus the findings suggest that web-based mental health interventions can be used to reach African-American, Hispanic and White adults at similar rates after a disaster.
C1 [Price, Matthew; Davidson, Tatiana M.; Andrews, Jeannette O.; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Price, M (reprint author), Natl Crime Victims Res & Treatment Ctr, 67 President St,2 South MSC 861, Charleston, SC 29425 USA.
EM prima@musc.edu
FU National Institute of Mental Health [R34 MH77149, R01 MH081056-03S2];
South Carolina Clinical and Translational Research Institute [NCRR/NIH
UL1 RR029882]; [T32 MH018869]; [P60 MH082598]
FX The study was supported by National Institute of Mental Health grant R34
MH77149. Dr Price was supported by T32 MH018869. Dr Davidson was
supported by National Institute of Mental Health grant R01
MH081056-03S2. Dr Ruggiero was supported by P60 MH082598. Dr Andrews was
supported by the South Carolina Clinical and Translational Research
Institute (NCRR/NIH UL1 RR029882).
NR 17
TC 8
Z9 8
U1 1
U2 6
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 1357-633X
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PD FEB
PY 2013
VL 19
IS 2
BP 70
EP 74
DI 10.1177/1357633X13476230
PG 5
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 184OO
UT WOS:000321901300002
PM 23514936
ER
PT J
AU Magnani, JW
Wang, N
Nelson, KP
Connelly, S
Deo, R
Rodondi, N
Schelbert, EB
Garcia, ME
Phillips, CL
Shlipak, MG
Harris, TB
Ellinor, PT
Benjamin, EJ
AF Magnani, Jared W.
Wang, Na
Nelson, Kerrie P.
Connelly, Stephanie
Deo, Rajat
Rodondi, Nicolas
Schelbert, Erik B.
Garcia, Melissa E.
Phillips, Caroline L.
Shlipak, Michael G.
Harris, Tamara B.
Ellinor, Patrick T.
Benjamin, Emelia J.
CA Hlth Aging Body Composition Study
TI Electrocardiographic PR Interval and Adverse Outcomes in Older Adults
The Health, Aging, and Body Composition Study
SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
LA English
DT Article
DE atrial fibrillation; ECG; epidemiology; heart failure; risk factors
ID CONGESTIVE-HEART-FAILURE; MIDDLE-AGED MEN; ATRIAL-FIBRILLATION;
METABOLIC SYNDROME; ATHEROSCLEROSIS RISK; ATRIOVENTRICULAR-BLOCK;
CARDIOVASCULAR-DISEASE; COMMUNITIES; OBESITY; SCORE
AB Background- The electrocardiographic PR interval increases with aging, differs by race, and is associated with atrial fibrillation (AF), pacemaker implantation, and all-cause mortality. We sought to determine the associations between PR interval and heart failure, AF, and mortality in a biracial cohort of older adults.
Methods and Results- The Health, Aging, and Body Composition (Health ABC) Study is a prospective, biracial cohort. We used multivariable Cox proportional hazards models to examine PR interval (hazard ratios expressed per SD increase) and 10-year risks of heart failure, AF, and all-cause mortality. Multivariable models included demographic, anthropometric, and clinical variables in addition to established cardiovascular risk factors. We examined 2722 Health ABC participants (aged 74 +/- 3 years, 51.9% women, and 41% black). We did not identify significant effect modification by race for the outcomes studied. After multivariable adjustment, every SD increase (29 ms) in PR interval was associated with a 13% greater 10-year risk of heart failure (95% confidence interval, 1.02-1.25) and a 13% increased risk of incident AF (95% confidence interval, 1.04-1.23). PR interval >200 ms was associated with a 46% increased risk of incident heart failure (95% confidence interval, 1.11-1.93). PR interval was not associated with increased all-cause mortality.
Conclusions- We identified significant relationships of PR interval to heart failure and AF in older adults. Our findings extend prior investigations by examining PR interval and associations with adverse outcomes in a biracial cohort of older men and women.
C1 [Magnani, Jared W.; Benjamin, Emelia J.] Boston Univ, Sch Med, Evans Dept Med, Cardiol Sect,Whitaker Cardiovasc Inst, Boston, MA 02118 USA.
[Magnani, Jared W.; Benjamin, Emelia J.] NHLBI, Framingham, MA USA.
[Magnani, Jared W.; Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA 02118 USA.
[Wang, Na] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA.
[Nelson, Kerrie P.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA.
[Connelly, Stephanie] Univ Tennessee, Dept Med, Memphis, TN 38104 USA.
[Deo, Rajat] Univ Penn, Div Cardiovasc Med, Sect Electrophysiol, Philadelphia, PA 19104 USA.
[Rodondi, Nicolas] Univ Bern, Dept Gen Internal Med, Bern, Switzerland.
[Schelbert, Erik B.] Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA USA.
[Garcia, Melissa E.; Phillips, Caroline L.; Harris, Tamara B.] NIA, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94143 USA.
[Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown & Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
RP Magnani, JW (reprint author), Boston Univ, Sch Med, 88 E Newton St, Boston, MA 02118 USA.
EM jmagnani@bu.edu
OI Benjamin, Emelia/0000-0003-4076-2336
FU Intramural Research Program of the National Institutes of Health,
National Institute on Aging; American Heart Association Award
[09FTF2190028]; National Institute on Aging (NIA) [N01-AG-6-2101,
N01-AG-6-2103, N01-AG-6-2106]; NIA grant [R01-AG028050]; National
Institute of Nursing Research grant [R01-NR012459]; National Institutes
of Health [1RC1HL101056, 1RO1HL092577, 5R21DA027021, 1RO1HL104156,
1K24HL105780, K23DK089118]
FX This research was supported, in part, by the Intramural Research Program
of the National Institutes of Health, National Institute on Aging.; This
research was funded by American Heart Association Award 09FTF2190028
(J.W.M.); by National Institute on Aging (NIA) Contracts N01-AG-6-2101,
N01-AG-6-2103, and N01-AG-6-2106; NIA grant R01-AG028050; National
Institute of Nursing Research grant R01-NR012459, and by National
Institutes of Health grants 1RC1HL101056 (E.J.B.), 1RO1HL092577 (E.J.B.
and P.T.E.), 5R21DA027021, 1RO1HL104156, 1K24HL105780 (P.T.E.), and
K23DK089118 (R.D.).
NR 31
TC 32
Z9 33
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3149
J9 CIRC-ARRHYTHMIA ELEC
JI Circ.-Arrhythmia Electrophysiol.
PD FEB
PY 2013
VL 6
IS 1
BP 84
EP 90
DI 10.1161/CIRCEP.112.975342
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 167YE
UT WOS:000320670700016
PM 23243193
ER
PT J
AU Lakdawala, NK
Winterfield, JR
Funke, BH
AF Lakdawala, Neal K.
Winterfield, Jeffery R.
Funke, Birgit H.
TI Dilated Cardiomyopathy
SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
LA English
DT Article
DE arrhythmia (heart rhythm disorders); cardiomyopathy, dilated; genetics;
heart failure
ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; LAMIN A/C GENE;
CARDIAC-RESYNCHRONIZATION THERAPY; SENSORINEURAL HEARING-LOSS;
MUSCULAR-DYSTROPHY; MAGNETIC-RESONANCE; PRIMARY PREVENTION;
SUDDEN-DEATH; VENTRICULAR-ARRHYTHMIAS; ATRIOVENTRICULAR-BLOCK
C1 [Lakdawala, Neal K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Lakdawala, Neal K.] Harvard Univ, Sch Med, Boston VA Hosp, Boston, MA USA.
[Winterfield, Jeffery R.] Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA.
[Funke, Birgit H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners Healthcare Ctr Personalized Genet Med,De, Boston, MA USA.
RP Lakdawala, NK (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM nlakdawala@partners.org
FU NHLBI NIH HHS [U01 HL084877]
NR 88
TC 22
Z9 27
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3149
J9 CIRC-ARRHYTHMIA ELEC
JI Circ.-Arrhythmia Electrophysiol.
PD FEB
PY 2013
VL 6
IS 1
BP 228
EP 237
DI 10.1161/CIRCEP.111.962050
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 167YE
UT WOS:000320670700033
PM 23022708
ER
PT J
AU Chen, CC
Kasper, EM
Zinn, PO
Warnke, PC
AF Chen, Clark C.
Kasper, Ekkehard M.
Zinn, Pascal O.
Warnke, Peter C.
TI Management of Entrapped Temporal Horn by Temporal Horn to Prepontine
Cistern Shunting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Entrapped temporal horn; Prepontine cistern; Shunting
ID HYDROCEPHALUS; ENTRAPMENT
AB BACKGROUND: Entrapped temporal horn syndrome secondary to obstructive neoplastic lesions is most frequently treated by surgical excision of the offending lesion. Here we describe an alternate approach involving temporal horn to prepontine cistern shunting followed by radiosurgery of the offending lesion.
METHODS: A 41-year-old woman with a history of meningiomatosis presented with progressive, incapacitating headache. Magnetic resonance imaging (MRI) showed growth of a right trigone meningioma, causing entrapment of the right temporal horn. A ventricular catheter was placed using frame-based stereotaxy and image fusion computed tomography/MRI to connect the entrapped lateral ventricle to the prepontine cistern. The patient reported complete resolution of her symptoms after the procedure.
RESULTS: Postoperative MRI revealed decompression of the temporal horn. The trigonal meningioma was treated with stereotactic radiosurgery. The patient remained asymptomatic at the 2-year follow-up.
CONCLUSIONS: Trapped temporal horn syndrome secondary to obstructive neoplastic lesions can be treated by internal shunting followed by radiosurgery.
C1 [Chen, Clark C.; Kasper, Ekkehard M.; Zinn, Pascal O.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Neurosurg, Boston, MA 02215 USA.
[Chen, Clark C.; Zinn, Pascal O.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Warnke, Peter C.] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA.
RP Chen, CC (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Neurosurg, Boston, MA 02215 USA.
EM cchen1@partners.org
NR 13
TC 3
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2013
VL 79
IS 2
AR 404.e7
DI 10.1016/j.wneu.2011.02.025
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 165VL
UT WOS:000320513600002
PM 22120406
ER
PT J
AU Kapoor, R
Piris, A
Saavedra, AP
Duncan, LM
Nazarian, RM
AF Kapoor, Roger
Piris, Adriano
Saavedra, Arturo P.
Duncan, Lyn M.
Nazarian, Rosalynn M.
TI Wolf Isotopic Response Manifesting as Postherpetic Granuloma Annulare A
Case Series
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Article
ID HEALED HERPES-ZOSTER; OF-THE-LITERATURE; LICHEN-PLANUS; CUTANEOUS
REACTIONS; SITE; INFECTION; VASCULITIS; KOEBNER; SCARS
AB Context.-Wolf isotopic response has infrequently been reported in the literature, mainly as isolated case reports.
Objective.-To aid in recognition of the occurrence of postherpetic granuloma annulare for accurate histologic interpretation of granulomatous dermatitides.
Design.-We report 5 cases of patients with Wolf isotopic response manifesting as granuloma annulare, developing in a site of previous herpes zoster, and discuss the clinicopathologic findings.
Results.-Previous infection with herpes zoster or herpes simplex virus was found in 5 of 5 cases reported. The differential diagnosis of a dermal lymphohistiocytic infiltrate with multinucleated giant cells includes postherpetic granuloma annulare.
Conclusions.-All cases of postherpetic Wolf isotopic response reported in this series revealed granuloma annulare, with a perineurovascular or perifollicular pattern of lymphohistiocytic infiltration including multinucleated giant cells, and occurred following herpes zoster or herpes simplex infection, although herpes viral infection was not always associated with a subsequent isotopic eruption. Awareness of this entity can aid in the clinicopathologic diagnosis of granuloma annulare occurring at the site of prior herpes viral infection.
C1 [Kapoor, Roger; Nazarian, Rosalynn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
[Piris, Adriano; Duncan, Lyn M.; Nazarian, Rosalynn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dermatopathol Unit,Pathol Serv, Boston, MA 02114 USA.
[Saavedra, Arturo P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol & Pathol, Boston, MA 02114 USA.
RP Nazarian, RM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, 50 Staniford St,Suite 200, Boston, MA 02114 USA.
EM rmnazarian@partners.org
OI Nazarian, Rosalynn/0000-0003-4003-7193
NR 22
TC 10
Z9 10
U1 0
U2 0
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD FEB
PY 2013
VL 137
IS 2
BP 255
EP 258
DI 10.5858/arpa.2011-0643-OA
PG 4
WC Medical Laboratory Technology; Medicine, Research & Experimental;
Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine;
Pathology
GA 155VH
UT WOS:000319776000017
PM 23368868
ER
PT J
AU Kong, JY
Hou, JB
Ma, LJ
Xing, L
Jia, HB
Liu, HM
Zhang, SS
Yu, B
Jang, IK
AF Kong, Junying
Hou, Jingbo
Ma, Lijia
Xing, Lei
Jia, Haibo
Liu, Huimin
Zhang, Shaosong
Yu, Bo
Jang, Ik-Kyung
TI Cutting balloon combined with paclitaxel-eluting balloon for treatment
of in-stent restenosis
SO ARCHIVES OF CARDIOVASCULAR DISEASES
LA English
DT Article
DE In-stent restenosis; Angioplasty; Animal model; Apoptosis
ID LASER CORONARY ANGIOPLASTY; LONG-TERM OUTCOMES; ROTATIONAL ATHERECTOMY;
RADIATION-THERAPY; ARTERY INJURY; FOLLOW-UP; TRIAL; INTERVENTIONS;
IMPLANTATION; MECHANISMS
AB Background. - The optimal therapy for in-stent restenosis (ISR) is controversial. We evaluated three different strategies for the treatment of in-stent restenosis: cutting balloon angioplasty (CBA), paclitaxel-eluting balloon angioplasty (PEBA) and cutting balloon followed by paclitaxel-eluting balloon angioplasty (CB + PEBA).
Methods. - Forty-five coronary arteries in 45 mini-pigs underwent oversized bare-metal stent (stent-to-artery ratio, 1.2:1) implantation to induce in-stent restenosis. After 28 days, vessels with in-stent restenosis (>= 50% diameter stenosis) were randomly divided into three groups: CBA, PEBA and CB + PEBA. In vivo angiography was performed before intervention, immediately after intervention and at 28-day follow-up. Stented arteries were harvested for pathological analyses. The proliferation and apoptosis of vascular smooth muscle cells were evaluated by imunohistochemical staining and the terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay, respectively.
Results. - Acute lumen gain was not different between the three groups. Late lumen loss and neointimal area at follow-up were lower for CB + PEBA compared with CBA but similar for CB + PEBA compared with PEBA. There were no significant differences in proliferating cell nuclear antigen-positive vascular smooth muscle cells and TUNEL-positive vascular smooth muscle cells between the CB + PEBA and PEBA groups.
Conclusions. - PEBA with or without cutting balloon was superior to CBA alone for in-stent restenosis. The underlying mechanism was probably related to inhibition of smooth muscle cell proliferation and increased apoptosis. In this porcine coronary artery restenosis model, PEBA with or without cutting balloon was superior. (c) 2013 Elsevier Masson SAS. All rights reserved.
C1 [Kong, Junying; Hou, Jingbo; Ma, Lijia; Xing, Lei; Jia, Haibo; Liu, Huimin; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Minist Myocardial Ischaemia Mech & Treatment, Dept Cardiol,Key Labs Educ, Harbin 150086, Heilongjiang, Peoples R China.
[Zhang, Shaosong] St Jude Med, LightLab Imaging, Westford, MA USA.
[Zhang, Shaosong] Harbin Med Univ, Harbin 150086, Heilongjiang, Peoples R China.
[Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP Yu, B (reprint author), Harbin Med Univ, Affiliated Hosp 2, Minist Myocardial Ischaemia Mech & Treatment, Dept Cardiol,Key Labs Educ, Harbin 150086, Heilongjiang, Peoples R China.
EM yuboteacher@163.com
NR 28
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 1875-2136
J9 ARCH CARDIOVASC DIS
JI Arch. Cardiovasc. Dis.
PD FEB
PY 2013
VL 106
IS 2
BP 79
EP 85
DI 10.1016/j.acvd.2012.10.004
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 141WL
UT WOS:000318757100003
PM 23527911
ER
PT J
AU Laden, F
Chiu, YH
Garshick, E
Hammond, SK
Hart, JE
AF Laden, Francine
Chiu, Yueh-Hsiu
Garshick, Eric
Hammond, S. Katharine
Hart, Jaime E.
TI A cross-sectional study of secondhand smoke exposure and respiratory
symptoms in non-current smokers in the US trucking industry: SHS
exposure and respiratory symptoms
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Occupational health; Secondhand smoke; Respiratory symptoms
ID ENVIRONMENTAL TOBACCO-SMOKE; PASSIVE SMOKING; LUNG-FUNCTION; BRONCHIAL
RESPONSIVENESS; CHRONIC RHINOSINUSITIS; GENERAL-POPULATION;
CIGARETTE-SMOKING; 2ND-HAND SMOKE; HEALTH SURVEY; WOMEN
AB Background: Previous studies have suggested associations of adult exposures to secondhand smoke (SHS) with respiratory symptoms, but no study has focused on blue-collar industrial environments. We assessed the association between SHS and respiratory symptoms in 1,562 non-current smoking U.S. trucking industry workers.
Methods: Information on SHS exposure and respiratory health was obtained by questionnaire. Multiple logistic regression analyses were used to assess the associations of recent and lifetime exposures to SHS with chronic phlegm, chronic cough, and any wheeze, defined by American Thoracic Society criteria.
Results: In analyses adjusted for age, gender, race, childhood SHS exposure, former smoking, pack-years of smoking and years since quitting, body mass index, job title, region of the country, and urban residence, recent exposures to SHS were associated with all three respiratory symptoms (odds ratio (OR) = 1.46; 95% confidence interval (CI) = 1.00-2.13) for chronic cough, 1.55 (95% CI = 1.08-2.21) for chronic phlegm, and 1.76 (95% CI = 1.41-2.21) for any wheeze). Workplace exposure was the most important recent exposure. Childhood exposure to SHS was also associated with all three symptoms, but only statistically significantly for chronic phlegm (OR = 1.84; 95% CI = 1.24-2.75). Additional years of living with a smoker were associated with an increased risk, but there was no evidence of a dose-response, except for chronic phlegm.
Conclusions: In this group of trucking industry workers, childhood and recent exposures to SHS were related to respiratory symptoms.
C1 [Laden, Francine; Chiu, Yueh-Hsiu; Hart, Jaime E.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Laden, Francine] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Laden, Francine; Garshick, Eric; Hart, Jaime E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Laden, Francine; Garshick, Eric; Hart, Jaime E.] Harvard Univ, Sch Med, Boston, MA USA.
[Garshick, Eric] VA Boston Healthcare Syst, Med Serv, Pulm & Crit Care Med Sect, Boston, MA USA.
[Hammond, S. Katharine] Univ Calif Berkeley, Sch Publ Hlth, Environm Hlth Sci Div, Berkeley, CA 94720 USA.
RP Laden, F (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
EM francine.laden@channing.harvard.edu
FU Flight Attendants Medical Research Institute (FAMRI) Young Investigators
Award; NIH/NCI [R01 CA90792]
FX This study was supported by the Flight Attendants Medical Research
Institute (FAMRI) Young Investigators Award and NIH/NCI R01 CA90792.
NR 40
TC 1
Z9 2
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD FEB 1
PY 2013
VL 13
AR 93
DI 10.1186/1471-2458-13-93
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 145WN
UT WOS:000319050100001
PM 23368999
ER
PT J
AU Kraybill, ML
Thorgusen, SR
Suchy, Y
AF Kraybill, Matthew L.
Thorgusen, Sommer R.
Suchy, Yana
TI The Push-Turn-Taptap Task Outperforms Measures of Executive Functioning
in Predicting Declines in Functionality: Evidence-Based Approach to Test
Validation
SO CLINICAL NEUROPSYCHOLOGIST
LA English
DT Article
DE Executive functioning; Motor programming; Functional independence;
Geriatrics; Evidence-based practice
ID BEHAVIORAL DYSCONTROL SCALE; MILD COGNITIVE IMPAIRMENT; LOWER-EXTREMITY
FUNCTION; DEMENTIA RATING-SCALE; ADULT AGE-DIFFERENCES; INSTRUMENTAL
ACTIVITIES; OLDER-ADULTS; ECOLOGICAL VALIDITY; ELECTRONIC VERSION;
ALZHEIMERS-DISEASE
AB Performance on the Push-Turn-Taptap (PTT) task has been shown to be a strong predictor of concurrent everyday functioning. This study utilized a prospective, longitudinal design to evaluate the PTT task for predicting future performance on a behavioral assessment of everyday functioning. The PTT task was compared to other measures of executive functioning as well as general cognition in terms of administration time and ability to identify participants who evidenced functional decline. A total of 50 community-dwelling older adults (ages 5887) completed the PTT task, Mattis Dementia Rating Scale, Geriatric Depression Scale, Behavioral Dyscontrol Scale, Delis-Kaplan Executive Function System, and Timed Instrumental Activities of Daily Living. Baseline PTT performance (a) was highly correlated with an objective measure of everyday functioning after approximately one year (r=.497, p<.001), (b) was associated with changes in follow-up functioning, F(3, 46)=3.15, p=.03, (c) was a better predictor of future functional status than a longer battery of EF, and (d) reliably identified individuals with the greatest magnitude of functional decline. The PTT tasks may provide a particularly advantageous method of predicting future changes in everyday functioning in older adults.
C1 [Kraybill, Matthew L.; Thorgusen, Sommer R.; Suchy, Yana] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA.
RP Kraybill, ML (reprint author), San Francisco VA Med Ctr, 4150 Clement St,S-116, San Francisco, CA 94121 USA.
EM mkraybill@gmail.com
OI Suchy, Yana/0000-0001-6513-565X
NR 73
TC 8
Z9 8
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1385-4046
J9 CLIN NEUROPSYCHOL
JI Clin. Neuropsychol.
PD FEB 1
PY 2013
VL 27
IS 2
BP 238
EP 255
DI 10.1080/13854046.2012.735702
PG 18
WC Psychology, Clinical; Clinical Neurology; Psychology
SC Psychology; Neurosciences & Neurology
GA 146MH
UT WOS:000319094700004
PM 23116212
ER
PT J
AU Choi, YJ
Sicinski, P
AF Choi, Yoon Jong
Sicinski, Piotr
TI Unexpected Outcomes of CDK4/6 Inhibition
SO ONCOTARGET
LA English
DT Editorial Material
ID CYCLIN D; THERAPY; CANCER
C1 [Choi, Yoon Jong; Sicinski, Piotr] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Choi, Yoon Jong; Sicinski, Piotr] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
RP Sicinski, P (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
EM peter_sicinski@dfci.harvard.edu
FU NCI NIH HHS [R01 CA083688]
NR 10
TC 6
Z9 6
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB
PY 2013
VL 4
IS 2
BP 176
EP 177
PG 2
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 142FO
UT WOS:000318782500002
PM 23563596
ER
PT J
AU Falchook, GS
Trent, JC
Heinrich, MC
Beadling, C
Patterson, J
Bastida, CC
Blackman, SC
Kurzrock, R
AF Falchook, G. S.
Trent, J. C.
Heinrich, M. C.
Beadling, C.
Patterson, J.
Bastida, C. C.
Blackman, S. C.
Kurzrock, R.
TI BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression
with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing
for analysis of acquired resistance
SO ONCOTARGET
LA English
DT Article
DE Gastrointestinal stromal tumor; Dabrafenib; GSK2118436; BRAF mutation;
BRAF inhibition; V600E
ID IMATINIB MESYLATE; PHASE-II; MUTATIONS; MELANOMA; GENE; CANCER; PDGFRA;
GIST
AB Activating oncogenic mutations of BRAF have been described in patients with gastrointestinal stromal tumor (GIST), but treatment of GIST with BRAF inhibitors and mechanisms of mediating the emergence of resistance in GIST have not been reported. Dabrafenib is a potent ATP-competitive inhibitor of BRAF kinase and is highly selective for mutant BRAF in kinase panel screening, cell lines, and xenografts. We report prolonged antitumor activity in the first patient with V600E BRAF-mutated GIST who was treated with a BRAF inhibitor. Whole exome sequencing performed in tumor tissue obtained at the time of progressive disease demonstrated a somatic gain-of-function PIK3CA mutation (H1047R) as well as a CDKN2A aberration, which may have contributed to eventual resistance to treatment.
C1 [Falchook, G. S.; Bastida, C. C.] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA.
[Trent, J. C.] Univ Miami, Sarcoma Med Oncol Program, Sylvester Comprehens Canc Ctr, Miami, FL USA.
[Heinrich, M. C.; Beadling, C.; Patterson, J.] Portland VA Med Ctr, Portland, OR USA.
[Heinrich, M. C.; Beadling, C.; Patterson, J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Oncol, Portland, OR 97201 USA.
[Blackman, S. C.] GlaxoSmithKline, Collegeville, PA USA.
[Kurzrock, R.] Univ Calif San Diego, Dept Med, Hematol Oncol Div, Moores Canc Ctr, San Diego, CA 92103 USA.
RP Falchook, GS (reprint author), Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA.
EM gfalchoo@mdanderson.org
FU Center for Clinical and Translational Sciences; National Institutes of
Health Clinical and Translational Science Award [UL1 RR024148]; National
Institutes of Health Cancer Center Support Grant (CCSG) [CA016672]; GIST
Cancer Research Fund; Life Raft Group; VA Merit Review Grant;
GlaxoSmithKline; Novartis; Pfizer
FX This work was performed in the U.T. MD Anderson Cancer Center Clinical
and Translational Research Center (CTRC) and was supported by the Center
for Clinical and Translational Sciences, which is funded by National
Institutes of Health Clinical and Translational Science Award UL1
RR024148 and by the National Institutes of Health Cancer Center Support
Grant (CCSG) award CA016672 to MD Anderson Cancer Center. Short read
sequencing assays were performed by the Oregon Health & Science
University Massively Parallel Sequencing Shared Resource. Funded in part
by philanthropic donations from the GIST Cancer Research Fund and the
Life Raft Group (MCH) and a VA Merit Review Grant (MCH). We would like
to thank Dr. Vicki Goodman of GlaxoSmithKline for her comments on this
manuscript.; Gerald Falchook received research funding and travel
reimbursement for conference attendance from GlaxoSmithKline. Razelle
Kurzrock received research funding from GlaxoSmithKline, Novartis, and
Pfizer. Samuel Blackman was an employee of GlaxoSmithKline at the time
of the study. The other coauthors report no conflicts of interest.
NR 25
TC 40
Z9 41
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB
PY 2013
VL 4
IS 2
BP 310
EP 315
PG 6
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 142FO
UT WOS:000318782500017
PM 23470635
ER
PT J
AU Yamanaka, YJ
Gierahn, TM
Love, JC
AF Yamanaka, Yvonne J.
Gierahn, Todd M.
Love, J. Christopher
TI The dynamic lives of T cells: new approaches and themes
SO TRENDS IN IMMUNOLOGY
LA English
DT Review
DE T cells; dynamics; heterogeneity; multiparameter measurements;
single-cell analysis
ID IN-VIVO REVEALS; DENDRITIC CELLS; IMMUNOLOGICAL SYNAPSES; SINGLE-CELL;
CUTTING EDGE; LYMPH-NODES; HISTONE ACETYLATION; FLOW-CYTOMETRY; TH2
CELLS; ANTIGEN PRESENTATION
AB Activated T cells have classically been thought to progress unidirectionally through discrete phenotypic states and differentiate into static lineages. It is increasingly evident, however, that T cells exhibit much more,complex and flexible dynamic behaviors than initially appreciated, and that these behaviors influence the efficacy of T cell responses to immunological challenges. In this review, we discuss how new technologies for monitoring the dynamics of T cells are enhancing the resolution of the fine phenotypic and functional heterogeneity within populations of T cells and revealing how individual T cells transition among a continuum of states. Such insights into the dynamic properties of T cells should improve immune monitoring and inform strategies for therapeutic interventions.
C1 [Yamanaka, Yvonne J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Gierahn, Todd M.; Love, J. Christopher] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Love, J. Christopher] Massachusetts Gen Hosp, MIT, Ragon Inst, Boston, MA 02129 USA.
[Love, J. Christopher] Harvard Univ, Boston, MA 02129 USA.
[Love, J. Christopher] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
RP Love, JC (reprint author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM clove@mit.edu
FU Charles A. Dana Foundation; W.M. Keck Foundation; NIH/NIAID
[4U19AI089992, 5P01AI045757, UMI AI068618]; National Science Foundation;
Collamore-Rogers Fellowship; Ragon Institute of MGH, MIT and Harvard
FX We thank Qing Han, Rita Lucia Content, and Alexis Torres for helpful
discussions and comments on the manuscript. This work was supported in
part by funding from the Charles A. Dana Foundation, the W.M. Keck
Foundation, and NIH/NIAID (4U19AI089992, 5P01AI045757, UMI AI068618).
Y.J.Y is supported in part by a fellowship from the National Science
Foundation and the Collamore-Rogers Fellowship. T.M.G. was supported in
part by a postdoctoral fellowship from the Ragon Institute of MGH, MIT
and Harvard. J.C.L. is a Latham Family Career Development Professor and
Camille Dreyfus Teacher-Scholar.
NR 95
TC 7
Z9 7
U1 2
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4906
J9 TRENDS IMMUNOL
JI Trends Immunol.
PD FEB
PY 2013
VL 34
IS 2
BP 59
EP 66
DI 10.1016/j.it.2012.10.006
PG 8
WC Immunology
SC Immunology
GA 145QG
UT WOS:000319031300003
PM 23200626
ER
PT J
AU Lagares, D
Kapoor, M
AF Lagares, David
Kapoor, Mohit
TI Targeting Focal Adhesion Kinase in Fibrotic Diseases
SO BIODRUGS
LA English
DT Article
ID IDIOPATHIC PULMONARY-FIBROSIS; I COLLAGEN EXPRESSION; GROWTH-FACTOR
BETA-1; SMOOTH MUSCLE ACTIN; MYOFIBROBLAST DIFFERENTIATION; TYROSINE
PHOSPHORYLATION; TGF-BETA; CARDIAC-HYPERTROPHY; TRANSFORMING
GROWTH-FACTOR-BETA-1; CELL-PROLIFERATION
AB Fibrotic diseases such as idiopathic pulmonary fibrosis or scleroderma (systemic sclerosis) are chronic fibroproliferative disorders for which there are currently no effective treatments. Dysregulated normal tissue repair process is considered to cause a fibrotic response culminating in compromised organ function due to excess extracellular matrix deposition. The mechanisms underlying the pathophysiology of fibrosis are poorly understood. Recent findings suggest that focal adhesion kinase (FAK) plays a key role in development of fibrotic disorders, and it appears to be an attractive target for antifibrotic therapy. Here, we review the emerging role of FAK as a key regulator of fibrotic signaling and its potential as a future therapeutic target to counteract fibrosis.
C1 [Lagares, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med Pulm & Crit Care Unit, Boston, MA USA.
[Kapoor, Mohit] Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada.
RP Kapoor, M (reprint author), Univ Montreal, Dept Med, 1560 Sherbrooke St East,Pavillon DeSeve,Room Y262, Montreal, PQ H2L 4M1, Canada.
EM mohit.kapoor.chum@ssss.gouv.qc.ca
NR 79
TC 10
Z9 12
U1 0
U2 8
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
ZEALAND
SN 1173-8804
J9 BIODRUGS
JI Biodrugs
PD FEB
PY 2013
VL 27
IS 1
BP 15
EP 23
DI 10.1007/s40259-012-0003-4
PG 9
WC Oncology; Immunology; Pharmacology & Pharmacy
SC Oncology; Immunology; Pharmacology & Pharmacy
GA 138MH
UT WOS:000318512200002
PM 23329396
ER
PT J
AU Aloia, TA
Haynes, AB
Vauthey, J
Ferrone, C
Crane, C
Krishnan, S
Wo, JY
Hong, TS
Yoon, SS
AF Aloia, T. A.
Haynes, A. B.
Vauthey, J.
Ferrone, C.
Crane, C.
Krishnan, S.
Wo, J. Y.
Hong, T. S.
Yoon, S. S.
TI Laparoscopic Placement of Biologic Spacers to Facilitate Dose Intense
Radiotherapy for Unresectable Hepatic Malignancy
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Aloia, T. A.; Haynes, A. B.; Vauthey, J.; Crane, C.; Krishnan, S.] UT MD Anderson Canc Ctr, Houston, TX USA.
[Ferrone, C.; Wo, J. Y.; Hong, T. S.; Yoon, S. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S36
EP S36
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700088
ER
PT J
AU Carson, WE
Otteson, RA
Hughes, ME
Neumayer, L
Hwang, ES
Laronga, C
Breslin, T
Chen, SL
Khan, S
Edge, SB
Farrar, WB
Weeks, JC
AF Carson, W. E.
Otteson, R. A.
Hughes, M. E.
Neumayer, L.
Hwang, E. S.
Laronga, C.
Breslin, T.
Chen, S. L.
Khan, S.
Edge, S. B.
Farrar, W. B.
Weeks, J. C.
TI Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer: A
Review of the National Comprehensive Cancer Network (NCCN) Database
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Carson, W. E.; Farrar, W. B.] Ohio State Univ, Columbus, OH 43210 USA.
[Otteson, R. A.; Chen, S. L.] City Hope Natl Med Ctr, Duarte, CA USA.
[Hughes, M. E.; Weeks, J. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Neumayer, L.] Univ Utah HSC, Salt Lake City, UT USA.
[Hwang, E. S.] Duke Univ, Durham, NC USA.
[Laronga, C.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Breslin, T.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Khan, S.] Northwestern Univ, Chicago, IL 60611 USA.
[Edge, S. B.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
RI Carson, William/E-2846-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S10
EP S10
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700014
ER
PT J
AU Conrad, C
Nedelcu, M
Camerlo, A
Simvathirtan, N
Tanabe, KK
Gayet, B
AF Conrad, C.
Nedelcu, M.
Camerlo, A.
Simvathirtan, N.
Tanabe, K. K.
Gayet, B.
TI Single Incision Intragastric Surgery for T1a Gastric Cancer
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Conrad, C.] Dana Farber Partners CancerCare Surg Oncol Progra, Boston, MA USA.
[Nedelcu, M.; Camerlo, A.; Simvathirtan, N.; Gayet, B.] Inst Mutualiste Montsouris, Paris, France.
[Tanabe, K. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S36
EP S36
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700089
ER
PT J
AU Conrad, C
Nedelcu, M
Camerlo, A
Simvathirtan, N
Tanabe, KK
Gayet, B
AF Conrad, C.
Nedelcu, M.
Camerlo, A.
Simvathirtan, N.
Tanabe, K. K.
Gayet, B.
TI Thoracoscopic Access Facilitates Safe Exposure of Posterior/Superior
Liver Lesions in Patients Ineligible for Laparoscopy
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Conrad, C.] Dana Farber Partners CancerCare Surg Oncol Fellow, Boston, MA USA.
[Nedelcu, M.; Camerlo, A.; Simvathirtan, N.; Gayet, B.] Inst Mutualiste Montsouris, Paris, France.
[Tanabe, K. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S35
EP S36
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700087
ER
PT J
AU Erstad, D
Feng, Y
Ready, J
Abraham, J
Ferrone, ML
Bertagnolli, MM
Baldini, EH
Raut, C
AF Erstad, D.
Feng, Y.
Ready, J.
Abraham, J.
Ferrone, M. L.
Bertagnolli, M. M.
Baldini, E. H.
Raut, C.
TI Amputation for Extremity Sarcoma: Indications and Outcomes in the Modern
Era
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Erstad, D.] Harvard Univ, Sch Med, Boston, MA USA.
[Feng, Y.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Ready, J.; Ferrone, M. L.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Ready, J.; Ferrone, M. L.] Dana Farber Canc Inst Hosp, Ctr Sarcoma & Bone Oncol, Boston, MA USA.
[Abraham, J.] Thomas Jefferson Univ, Dept Orthoped Surg, Philadelphia, PA 19107 USA.
[Bertagnolli, M. M.; Raut, C.] Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA.
[Bertagnolli, M. M.; Baldini, E. H.; Raut, C.] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA.
[Baldini, E. H.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S124
EP S124
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700365
ER
PT J
AU Fragomeni, RAS
Cusack, JC
AF Fragomeni, R. A. Salas
Cusack, J. C.
TI XPO1 and BRAF Inhibition Synergize and Modulate pRb, Survivin and ERK in
Melanoma
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Fragomeni, R. A. Salas; Cusack, J. C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S91
EP S91
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700259
ER
PT J
AU Greenup, RA
Breslin, T
Edge, SB
Hughes, ME
Hwang, ES
Laronga, C
Marcom, P
Moy, B
Otteson, RA
Rugo, H
Wilson, JL
Wong, Y
Weeks, JC
AF Greenup, R. A.
Breslin, T.
Edge, S. B.
Hughes, M. E.
Hwang, E. S.
Laronga, C.
Marcom, P.
Moy, B.
Otteson, R. A.
Rugo, H.
Wilson, J. L.
Wong, Y.
Weeks, J. C.
TI Outcomes after Mastectomy for Node-positive Breast Cancer: Comparison of
Women Treated With and Without Completion Axillary Dissection at NCCN
Cancer Centers
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Greenup, R. A.; Hwang, E. S.; Marcom, P.] Duke Univ, Med Ctr, Durham, NC USA.
[Breslin, T.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Edge, S. B.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Hughes, M. E.; Weeks, J. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Laronga, C.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Moy, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Otteson, R. A.] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Rugo, H.] UCSF, San Francisco, CA USA.
[Wilson, J. L.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Wong, Y.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S9
EP S9
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700011
ER
PT J
AU Haynes, AB
Aloia, TA
Vauthey, J
Ferrone, C
Crane, C
Wo, JY
Hong, TS
Yoon, SS
AF Haynes, A. B.
Aloia, T. A.
Vauthey, J.
Ferrone, C.
Crane, C.
Wo, J. Y.
Hong, T. S.
Yoon, S. S.
TI Surgical Placement of Biological Mesh Spacers to Displace Bowel from
Unresectable Liver Tumors Facilitates Safe Delivery of Dose-intense
Radiation Therapy
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Haynes, A. B.; Aloia, T. A.; Vauthey, J.; Crane, C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Ferrone, C.; Wo, J. Y.; Hong, T. S.; Yoon, S. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S86
EP S86
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700243
ER
PT J
AU Hyder, O
Cosgrove, D
Liapi, E
Zhu, A
Sofocleous, C
Petre, E
Neal, D
Kalva, S
Marsh, JW
Geschwind, J
Pawlik, T
AF Hyder, O.
Cosgrove, D.
Liapi, E.
Zhu, A.
Sofocleous, C.
Petre, E.
Neal, D.
Kalva, S.
Marsh, J. W.
Geschwind, J.
Pawlik, T.
TI Intra-arterial Therapy for Advanced Intrahepatic Cholangiocarcinoma - A
Multi-Institutional Analysis
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Hyder, O.; Cosgrove, D.; Liapi, E.; Geschwind, J.; Pawlik, T.] Johns Hopkins Univ, Baltimore, MD USA.
[Neal, D.; Marsh, J. W.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Zhu, A.; Kalva, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sofocleous, C.; Petre, E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RI Liapi, Eleni/B-5195-2013
OI Liapi, Eleni/0000-0001-5864-4448
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S7
EP S7
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700006
ER
PT J
AU Kane, JM
Zhang, Q
Klimowicz, A
Magliocco, A
George, A
Simko, J
DeLaney, T
Kraybill, W
AF Kane, J. M.
Zhang, Q.
Klimowicz, A.
Magliocco, A.
George, A.
Simko, J.
DeLaney, T.
Kraybill, W.
TI High Risk Soft Tissue Sarcoma Biomarker Expression Patterns and Outcome
Following Neoadjuvant Chemoradiation
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Kane, J. M.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Zhang, Q.; George, A.; Kraybill, W.] Radiat Therapy Oncol Grp, Philadelphia, PA USA.
[DeLaney, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Klimowicz, A.] Tom Baker Canc Clin, Calgary, AB, Canada.
[Magliocco, A.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Simko, J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S28
EP S28
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700065
ER
PT J
AU Kwon, S
Mann, GN
Wu, P
Drake, F
Gow, K
AF Kwon, S.
Mann, G. N.
Wu, P.
Drake, F.
Gow, K.
TI General Surgery Resident Operative Experience in Surgical Oncology Over
Two Decades
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Kwon, S.; Mann, G. N.; Drake, F.] Univ Washington, Seattle, WA 98195 USA.
[Wu, P.] Vet Affairs Puget Sound, Seattle, WA USA.
[Gow, K.] Seattle Childrens Hosp, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S113
EP S114
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700333
ER
PT J
AU Merkow, RP
Bilimoria, KY
Tomlinson, JS
Paruch, JL
Stewart, A
Winchester, D
Ko, CY
Bentrem, DJ
AF Merkow, R. P.
Bilimoria, K. Y.
Tomlinson, J. S.
Paruch, J. L.
Stewart, A.
Winchester, D.
Ko, C. Y.
Bentrem, D. J.
TI Postoperative Complications Reduce Adjuvant Chemotherapy Use in
Resectable Pancreatic Cancer
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Merkow, R. P.; Bilimoria, K. Y.; Paruch, J. L.; Stewart, A.; Winchester, D.; Ko, C. Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Bentrem, D. J.] Northwestern Univ, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA.
[Bentrem, D. J.] Northwestern Univ, Northwestern Inst Comparat Effectiveness Res NICE, Chicago, IL 60611 USA.
[Tomlinson, J. S.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Tomlinson, J. S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S27
EP S28
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700063
ER
PT J
AU Miller, CL
Skolny, MN
Jammallo, LS
O'Toole, J
Horick, N
Shenouda, M
Sadek, B
Smith, BL
Taghian, A
Specht, MC
AF Miller, C. L.
Skolny, M. N.
Jammallo, L. S.
O'Toole, J.
Horick, N.
Shenouda, M.
Sadek, B.
Smith, B. L.
Taghian, A.
Specht, M. C.
TI Risk of Lymphedema after Mastectomy - Potential Benefit of Applying Z11
Protocol to Mastectomy Patients
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Miller, C. L.; Skolny, M. N.; Jammallo, L. S.; O'Toole, J.; Horick, N.; Shenouda, M.; Sadek, B.; Smith, B. L.; Taghian, A.; Specht, M. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S55
EP S56
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700146
ER
PT J
AU Schmidt, B
Chang, KK
Maduekwe, UN
Look-Hong, N
Yang, H
Rattner, DW
Lauwers, GY
Mullen, JT
Yoon, SS
AF Schmidt, B.
Chang, K. K.
Maduekwe, U. N.
Look-Hong, N.
Yang, H.
Rattner, D. W.
Lauwers, G. Y.
Mullen, J. T.
Yoon, S. S.
TI D2 Lymphadenectomy and Ex Vivo Dissection into Node Stations for Gastric
Adenocarcinoma Ensures Optimal Staging
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Schmidt, B.; Chang, K. K.; Maduekwe, U. N.; Look-Hong, N.; Rattner, D. W.; Lauwers, G. Y.; Mullen, J. T.; Yoon, S. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Yang, H.] Seoul Natl Univ Hosp, Seoul 110744, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S133
EP S134
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700391
ER
PT J
AU Tang, R
Kansal, KJ
Lei, L
Coopey, S
Colwell, AS
Gadd, MA
Specht, MC
Taghian, A
Austen, WG
Smith, BL
AF Tang, R.
Kansal, K. J.
Lei, L.
Coopey, S.
Colwell, A. S.
Gadd, M. A.
Specht, M. C.
Taghian, A.
Austen, W. G., Jr.
Smith, B. L.
TI Impact of Prior Radiation Therapy on Post-operative Complications in
Nipple Sparing Mastectomy and Immediate Reconstruction: A Case-Matched,
Risk-Adjusted Cohort Study
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Tang, R.; Kansal, K. J.; Lei, L.; Coopey, S.; Colwell, A. S.; Gadd, M. A.; Specht, M. C.; Taghian, A.; Austen, W. G., Jr.; Smith, B. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S39
EP S39
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700095
ER
PT J
AU Webb, ML
Cady, B
Michaelson, JS
Bush, DM
Calvillo, KZ
Kopans, DB
Smith, BL
AF Webb, M. L.
Cady, B.
Michaelson, J. S.
Bush, D. M.
Calvillo, K. Zabicki
Kopans, D. B.
Smith, B. L.
TI A Failure Analysis of Invasive Breast Cancer: Most Deaths from Disease
Occur in Women Not Regularly Screened
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Webb, M. L.; Cady, B.; Michaelson, J. S.; Bush, D. M.; Smith, B. L.] Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Breast Program, Boston, MA 02114 USA.
[Calvillo, K. Zabicki] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kopans, D. B.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S53
EP S53
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700138
ER
PT J
AU Yoon, CH
Le, J
Ibrahim, N
Gold, J
Bertagnolli, MM
Hodi, FS
AF Yoon, C. H.
Le, J.
Ibrahim, N.
Gold, J.
Bertagnolli, M. M.
Hodi, F. S.
TI Tumor Heterogeneity in Metastatic Melanoma Patients with BRAF/NRAS
Mutations
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO)
CY MAR 06-09, 2013
CL National Harbor, MD
SP Soc Surg Oncol (SSO)
C1 [Yoon, C. H.; Le, J.; Gold, J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Ibrahim, N.; Bertagnolli, M. M.; Hodi, F. S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD FEB
PY 2013
VL 20
SU 1
BP S23
EP S23
PG 1
WC Oncology; Surgery
SC Oncology; Surgery
GA 133XR
UT WOS:000318174700052
ER
PT J
AU Elfiky, AA
Jiang, ZY
AF Elfiky, Aymen A.
Jiang, Zhenyang
TI The PI3 Kinase Signaling Pathway in Prostate Cancer
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Androgen receptor; mammalian target of rapamycin; phosphatidylinositol
3-kinase; prostate cancer; PTEN
ID ANDROGEN RECEPTOR FUNCTION; PTEN GENOMIC DELETION; 4-PHOSPHATASE
TYPE-II; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; HORMONAL-THERAPY;
CELL-POPULATIONS; FISH ANALYSIS; MTOR COMPLEX; GENE FUSIONS
AB Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway is increasingly implicated in a number of malignancies, including prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the therapeutic implications of targeting it.
C1 [Elfiky, Aymen A.; Jiang, Zhenyang] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
RP Elfiky, AA (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM Aymen_Elfiky@dfci.harvard.edu
NR 93
TC 8
Z9 8
U1 0
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD FEB
PY 2013
VL 13
IS 2
BP 157
EP 164
PG 8
WC Oncology
SC Oncology
GA 130MW
UT WOS:000317923100005
PM 23215719
ER
PT J
AU Sikora, D
Moran, E
Orlich, F
Hall, TA
Kovacs, EA
Delahaye, J
Clemons, TE
Kuhlthau, K
AF Sikora, Darryn
Moran, Erin
Orlich, Felice
Hall, Trevor A.
Kovacs, Erica A.
Delahaye, Jennifer
Clemons, Traci E.
Kuhlthau, Karen
TI The relationship between family functioning and behavior problems in
children with autism spectrum disorders
SO RESEARCH IN AUTISM SPECTRUM DISORDERS
LA English
DT Article
DE Family functioning; Behavior problems; Impact on parents; Marriage;
Siblings
ID QUALITY-OF-LIFE; DEVELOPMENTAL DELAY; PRESCHOOL-CHILDREN;
YOUNG-CHILDREN; MENTAL-HEALTH; PARENTING STRESS; MOTHERS; IMPACT;
DISABILITIES; ADJUSTMENT
AB Although it is well known that families of children with an autism spectrum disorder (ASD) are at risk for increased stress and other problems, little is known about what child characteristics may mediate that risk. To address the impact of child behavior problems on family health, we examined data collected from 136 families raising children with ASD. Children were divided into groups based on parent responses to the Child Behavior Checklist (CBCL): low versus high internalizing and low versus high externalizing behavior problems. Family functioning was measured using the Family Impact Questionnaire, Revised (FIQ-R). Results of ANCOVA analyses indicated significant group differences in FIQ-R domains of Negative Attitudes About Parenting, Social Relationships, Sibling Impact, and Impact to Marriage when comparing externalizing behaviors. None of the FIQ-R domains demonstrated group differences when comparing internalizing behaviors. Correlation coefficients indicated moderately strong associations between higher externalizing behaviors and poorer family functioning, with the most significant associations among child behavior and increased negativity in parenting perceptions and poorer social functioning. This study provides information regarding co-occurring behaviors that have the strongest negative association with family functioning and the domains of family functioning most vulnerable to the severity of such behaviors. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Sikora, Darryn; Moran, Erin] Oregon Hlth & Sci Univ, Child Dev & Rehabil Ctr, Portland, OR 97201 USA.
[Orlich, Felice] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA.
[Orlich, Felice] Seattle Childrens Hosp, Autism Program, CAC Autism Ctr, Seattle, WA 98105 USA.
[Hall, Trevor A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Kovacs, Erica A.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Delahaye, Jennifer] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA 02114 USA.
[Clemons, Traci E.] EMMES Corp, Rockville, MD 20850 USA.
[Kuhlthau, Karen] Harvard Univ, Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, Dept Pediat,Med Sch, Boston, MA 02114 USA.
RP Sikora, D (reprint author), Providence Hlth & Serv, 814 NE 47th Ave, Portland, OR 97213 USA.
EM darryn.sikora@providence.org
NR 65
TC 11
Z9 11
U1 13
U2 54
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1750-9467
J9 RES AUTISM SPECT DIS
JI Res. Autism Spectr. Disord.
PD FEB
PY 2013
VL 7
IS 2
BP 307
EP 315
DI 10.1016/j.rasd.2012.09.006
PG 9
WC Education, Special; Psychology, Developmental; Psychiatry;
Rehabilitation
SC Education & Educational Research; Psychology; Psychiatry; Rehabilitation
GA 134FD
UT WOS:000318194700011
ER
PT J
AU McLaughlin, VV
Langer, A
Tan, M
Clements, PJ
Oudiz, RJ
Tapson, VF
Channick, RN
Rubin, LJ
AF McLaughlin, Vallerie V.
Langer, Anatoly
Tan, Mary
Clements, Philip J.
Oudiz, Ronald J.
Tapson, Victor F.
Channick, Richard N.
Rubin, Lewis J.
CA Pulm Arterial Hypertension-Quality
TI Contemporary Trends in the Diagnosis and Management of Pulmonary
Arterial Hypertension An Initiative to Close the Care Gap
SO CHEST
LA English
DT Article
ID CONTINUOUS INTRAVENOUS EPOPROSTENOL; CLINICAL-PRACTICE GUIDELINES;
CONTROLLED-TRIAL; REGISTRY; THERAPY; SURVIVAL; DISEASE; PROSTACYCLIN;
REVEAL
AB Background: The Pulmonary Arterial Hypertension-Quality Enhancement Research Initiative (PAH-QuERI) was created to help clinicians to implement a guidelines-based approach to the diagnosis and management of pulmonary arterial hypertension (PAR). Patients with PAR represent a heterogeneous population, and physician evaluation and treatment paradigms may vary considerably.
Methods: Using an electronic data management system, participating physicians recorded data on diagnostic workup, disease management, and outcomes of patients with PAH. Queries were generated automatically following each follow-up visit if the tests recommended by the American College of Chest Physicians (ACCP) were not performed at least once.
Results: Of 791 patients enrolled in PAH-QuERI, 77% were women; 64% received a diagnosis >3 months prior to enrollment; 9% were in New York Heart Association functional class I, 39% in II, 48% in III, and 5% in IV; and the median age was 55 years (interquartile range, 45-66 years). At enrollment, all ACCP-recommended tests had been performed in only 6% of patients. The automated program generated 1,530 reminders for 642 patients (81%) with validated enrollment data. The proportion of recommended tests performed was 91% for CBC count, 91% for liver function test, 50% for connective tissue disease screen, 29% for HIV screen, 88% for chest radiograph, 82% for ECG, 97% for two-dimensional echocardiogram, 83% for pulmonary function tests, 41% for oximetry, 57% for ventilation/perfusion scan, 79% for 6-min walk distance, and 90% for right-sided heart catheterization. Regarding management, 78% of patients were on disease-specific therapy, and the use of these therapies tended to increase with the functional disability of the patient. One hundred seventy patients were taking calcium channel blockers, 91 specifically for PAR. Only six of 91 patients (7%) who received calcium channel blockers specifically for PAH had met the current guideline for acute vasoreactivity.
Conclusions: When comparing reported clinical practice with ACCP guidelines-recommended strategies, a diagnostic care gap is apparent such that certain essential and recommended diagnostic tests may be underused despite the availability of detailed guidelines and reminders. CHEST 2013; 143(2):324-332
C1 [McLaughlin, Vallerie V.] Univ Michigan Hlth Syst, Pulm Hypertens Program, Ann Arbor, MI USA.
[Langer, Anatoly; Tan, Mary] Canadian Heart Res Ctr, Toronto, ON, Canada.
[Clements, Philip J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Oudiz, Ronald J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA.
[Tapson, Victor F.] Duke Univ, Med Ctr, Durham, NC USA.
[Channick, Richard N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rubin, Lewis J.] Univ Calif San Diego, La Jolla, CA USA.
RP McLaughlin, VV (reprint author), Univ Michigan, Ctr Cardiovasc, Pulm Hypertens Program, 1500 E Med Ctr Dr,SPC 5853, Ann Arbor, MI 48109 USA.
EM vmclaugh@umich.edu
FU Actelion Pharmaceuticals US, Inc; Gilead; Novartis AG; United
Therapeutics Corporation; Lung LLC; Pfizer, Inc; GlaxoSimithKline plc;
Ikaria, Inc; Bayer AG
FX The authors have reported to CHEST the following conflicts of interest:
Dr McLaughlin has served as a consultant and speaker for Actelion
Pharmaceuticals US, Inc; Bayer AG; Gilead; and United Therapeutics
Corporation. She has also received research funding for multicenter
trials from Actelion Pharmaceuticals US, Inc; Gilead; Novartis AG; and
United Therapeutics Corporation. Dr Langer has received research and
educational grants from Actelion Pharmaceuticals US, Inc, and United
Therapeutics Corporation. Dr Clements has served as a consultant for
Gilead. Dr Oudiz has served as a consultant and speaker and received
research funding for multicenter trials from Actelion Pharmaceuticals
US, Inc; Bayer AG; Gilead; Lung LLC; Pfizer, Inc; and United
Therapeutics Corporation. Dr Tapson has served as a consultant for and
received research funding from Actelion Pharmaceuticals US, Inc; Gilead;
GlaxoSimithKline plc; Lung LLC; Novartis AG; and United Therapeutics
Corporation. Dr Channick has served as a consultant for Actelion
Pharmaceuticals US, Inc; Gilead; and Ikaria, Inc. He has also received
research grants from Actelion Pharmaceuticals US, Inc; Bayer AG; Gilead;
Pfizer, Inc; and United Therapeutics Corporation. Dr Rubin has served as
a consultant for Actelion Pharmaceuticals US, Inc; Pfizer, Inc; United
Therapeutics Corporation; Lung LLC; National Heart, Lung, and Blood
Institute; Gilead; Aires Pharmaceuticals, Inc; GlaxoSmithKline plc;
Bayer AG; Geno Pharmaceuticals Ltd; Cytokinetics, Inc; and mondoBIOTECH
Holding AG. He has served on the scientific advisory committee for
United Therapeutics Corporation. He is a stock shareholder for United
Therapeutics Corporation; Geno Pharmaceuticals Ltd; and Aires
Pharmaceuticals, Inc. Ms Tan has reported that no potential conflicts of
interest exist with any companies/organizations whose products or
services may be discussed in this article.
NR 24
TC 31
Z9 32
U1 0
U2 6
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD FEB
PY 2013
VL 143
IS 2
BP 324
EP 332
DI 10.1378/chest.11-3060
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 129VC
UT WOS:000317871100011
PM 22910999
ER
PT J
AU Jalian, HR
Jalian, CA
Avram, MM
AF Jalian, H. Ray
Jalian, Chris A.
Avram, Mathew M.
TI Common Causes of Injury and Legal Action in Laser Surgery
SO JAMA DERMATOLOGY
LA English
DT Article
ID Q-SWITCHED RUBY; CARBON-DIOXIDE; HAIR REMOVAL; MALPRACTICE
AB Objective: To identify common causes of legal action, injuries, claims, and decisions related to medical professional liability claims stemming from cutaneous laser surgery.
Design: Search of online public legal documents using a national database.
Main Outcome Measures: Frequency and nature of cases, including year of litigation, location and certification of provider, injury sustained, cause of legal action, verdict, and indemnity payment.
Results: From 1985 to 2012, the authors identified 174 cases related to injury stemming from cutaneous laser surgery. The incidence of litigation related to laser surgery shows an increasing trend, with peak occurrence in 2010. Laser hair removal was the most common litigated procedure. Nonphysician operators accounted for a substantial subset of these cases, with their physician supervisors named as defendants, despite not performing the procedure. Plastic surgery was the specialty most frequently litigated against. Of the preventable causes of action, the most common was failure to obtain an informed consent. Of the 120 cases with public decisions, 61 (50.8%) resulted in decisions in favor of the plaintiff. The mean indemnity payment was $380 719.
Conclusions: Claims related to cutaneous laser surgery are increasing and result in indemnity payments that exceed the previously reported average across all medical specialties. Nonphysicians performing these procedures will be held to a standard of care corresponding to an individual with appropriate training; thus, physicians are ultimately responsible for the actions of their nonphysician agents. JAMA Dermatol. 2013;149(2):188-193
C1 [Jalian, H. Ray; Avram, Mathew M.] Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Jalian, Chris A.] Columbia Law Sch, New York, NY USA.
RP Jalian, HR (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 40 Blossom St,Thier 2,Room 204, Boston, MA 02114 USA.
EM HJalian@partners.org
NR 13
TC 19
Z9 19
U1 2
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD FEB
PY 2013
VL 149
IS 2
BP 188
EP 193
DI 10.1001/jamadermatol.2013.1384
PG 6
WC Dermatology
SC Dermatology
GA 127CH
UT WOS:000317672300011
PM 23426473
ER
PT J
AU Hausauer, AK
Maurer, T
Leslie, KS
Parvataneni, R
Stuart, SE
Chren, MM
AF Hausauer, Amelia K.
Maurer, Toby
Leslie, Kieron S.
Parvataneni, Rupa
Stuart, Sarah E.
Chren, Mary-Margaret
TI Recurrence After Treatment of Cutaneous Basal Cell and Squamous Cell
Carcinomas in Patients Infected With Human Immunodeficiency Virus
SO JAMA DERMATOLOGY
LA English
DT Letter
ID MALIGNANCIES
C1 [Hausauer, Amelia K.; Maurer, Toby; Leslie, Kieron S.; Parvataneni, Rupa; Stuart, Sarah E.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Maurer, Toby; Leslie, Kieron S.] San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94110 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Chren, MM (reprint author), Mt Zion Canc Res Bldg,2340 Sutter St,Room N412,Ma, San Francisco, CA 94143 USA.
EM chrenm@derm.ucsf.edu
FU NIAMS NIH HHS [K24 AR052667, R01 AR054983]
NR 5
TC 3
Z9 3
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD FEB
PY 2013
VL 149
IS 2
BP 239
EP 241
DI 10.1001/2013.jamadermatol.245
PG 4
WC Dermatology
SC Dermatology
GA 127CH
UT WOS:000317672300029
PM 23426494
ER
PT J
AU Ibrahimi, OA
Sakamoto, FH
Anderson, RR
AF Ibrahimi, Omar A.
Sakamoto, Fernanda H.
Anderson, R. Rox
TI Picosecond Laser Pulses for Tattoo Removal: A Good, Old Idea
SO JAMA DERMATOLOGY
LA English
DT Letter
ID PIGMENT
C1 [Ibrahimi, Omar A.] Connecticut Skin Inst, Stamford, CT USA.
[Ibrahimi, Omar A.; Sakamoto, Fernanda H.; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
RP Ibrahimi, OA (reprint author), Univ Connecticut, Ctr Hlth, 21 South Rd,2nd Flr, Farmington, CT 06032 USA.
EM omar.ibrahimi@gmail.com
NR 5
TC 6
Z9 6
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD FEB
PY 2013
VL 149
IS 2
BP 241
EP 241
DI 10.1001/jamadermatol.2013.2136
PG 1
WC Dermatology
SC Dermatology
GA 127CH
UT WOS:000317672300030
PM 23426495
ER
PT J
AU Bosley, JC
Zhao, NW
Hill, S
Shofer, FS
Asch, DA
Becker, LB
Merchant, RM
AF Bosley, Justin C.
Zhao, Nina W.
Hill, Shawndra
Shofer, Frances S.
Asch, David A.
Becker, Lance B.
Merchant, Raina M.
TI Decoding twitter: Surveillance and trends for cardiac arrest and
resuscitation communication
SO RESUSCITATION
LA English
DT Article
DE Cardiopulmonary resuscitation; Heart arrest; Defibrillation;
Resuscitation; Social media
ID AMERICAN-HEART-ASSOCIATION; EMERGENCY CARDIOVASCULAR CARE;
CARDIOPULMONARY-RESUSCITATION; SOCIAL MEDIA; SURVIVAL
AB Aim of the study: Twitter has over 500 million subscribers but little is known about how it is used to communicate health information. We sought to characterize how Twitter users seek and share information related to cardiac arrest, a time-sensitive cardiovascular condition where initial treatment often relies on public knowledge and response.
Methods: Tweets published April-May 2011 with keywords cardiac arrest, CPR, AED, resuscitation, heart arrest, sudden death and defib were identified. Tweets were characterized by content, dissemination, and temporal trends. Tweet authors were further characterized by: self-identified background, tweet volume, and followers.
Results: Of 62,163 tweets (15,324, 25%) included resuscitation/cardiac arrest-specific information. These tweets referenced specific cardiac arrest events (1130, 7%), CPR performance or AED use (6896, 44%), resuscitation-related education, research, or news media (7449, 48%), or specific questions about cardiac arrest/resuscitation (270, 2%). Regarding dissemination (1980, 13%) of messages were retweeted. Resuscitation specific tweets primarily occurred on weekdays. Most users (10,282, 93%) contributed three or fewer tweets during the study time frame. Users with more than 15 resuscitation-specific tweets in the study time frame had a mean 1787 followers and most self-identified as having a healthcare affiliation.
Conclusion: Despite a large volume of tweets, Twitter can be filtered to identify public knowledge and information seeking and sharing about cardiac arrest. To better engage via social media, healthcare providers can distil tweets by user, content, temporal trends, and message dissemination. Further understanding of information shared by the public in this forum could suggest new approaches for improving resuscitation related education. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Bosley, Justin C.; Zhao, Nina W.; Shofer, Frances S.; Becker, Lance B.; Merchant, Raina M.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Hill, Shawndra] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Asch, David A.; Merchant, Raina M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Merchant, RM (reprint author), Univ Penn, 423 Guardian St,Blockley Hall, Philadelphia, PA 19104 USA.
EM raina.merchant@uphs.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU NIH [10714038]; Physio-Control Seattle, Washington; Zoll Medical, Boston
MA; Cardiac Science, Bothell, Washington; Philips Medical Seattle,
Washington; Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger,
Norway; NIH, Bethesda, MD
FX Merchant: Grant/research support: NIH, K23 grant 10714038, Pilot
funding: Physio-Control Seattle, Washington; Zoll Medical, Boston MA;
Cardiac Science, Bothell, Washington; Philips Medical Seattle,
Washington.; Becker: Speaker honoraria/consultant fees: Philips
Healthcare, Seattle, WA. Institutional grant/research support: Philips
Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH,
Bethesda, MD; Cardiac Science, Bothell, Washington.
NR 28
TC 22
Z9 23
U1 2
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0300-9572
J9 RESUSCITATION
JI Resuscitation
PD FEB
PY 2013
VL 84
IS 2
BP 206
EP 212
DI 10.1016/j.resuscitation.2012.10.017
PG 7
WC Critical Care Medicine; Emergency Medicine
SC General & Internal Medicine; Emergency Medicine
GA 123UH
UT WOS:000317416100029
PM 23108239
ER
PT J
AU Lazaridou, A
Kalogianni, C
AF Lazaridou, Asimina
Kalogianni, Christina
TI Mindfulness and sexuality
SO SEXUAL AND RELATIONSHIP THERAPY
LA English
DT Article
DE mindfulness; sexuality; behavior
ID STRESS REDUCTION; METAANALYSIS; HEALTH; MEDITATION; MEDICINE; ANXIETY;
WOMEN
AB Mindfulness seems to associate with positive effects on health and overall wellbeing. However, little research has indicated association between mindfulness and sexuality. The goal of this study was to test the hypothesis that mindfulness correlates with sexuality in healthy people. We conducted a cross-sectional study with people who practice yoga or meditation (n = 51), people who have done a sport for over 10years (n = 21) and people who have done none of the above (n = 145) by studying correlations between mindfulness and sexuality. A total of 215 men and women participated in this study (M = 31.61, SD = 9.24). We measured mindfulness and sexuality by distri-buting the Langer's Mindfulness Scale and the Multidimensional Sexuality Questionnaire. We explored whether mindfulness subscales correlate with any of the sexuality subscales in these three study groups, irrespectively. People in the meditation/yoga group had been practicing mindfulness and different meditative practices (including vipassana and yoga) for over 10years. We found significant higher scores in the novelty-seeking component in people who meditate compared to athletes. Even though our results showed that the group of people who do a sport have less sexual anxiety and sexual depression compared to the meditators, these results were not at a statistically significant level. Additionally, no significant differences were found between the other groups. We found positive correlations between all mindfulness subscales (engagement, novelty seeking, novelty producing and flexibility) and sexual motivation, and between novelty seeking and sexual consciousness. Our findings seem to indicate that mindfulness correlates positively with sexual motivation and sexual consiousness. In particular, people who practice meditation or yoga showed higher levels in novelty seeking (mindfulness subscale) compared to people who play sport. Novelty seeking might be an important component in affecting sexuality.
C1 [Lazaridou, Asimina] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
[Kalogianni, Christina] Catholic Univ Louvain, Louvain, Belgium.
RP Lazaridou, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
EM asilaz@nmr.mgh.harvard.edu
NR 41
TC 7
Z9 7
U1 3
U2 25
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1468-1994
J9 SEX RELATSH THER
JI Sex. Relatsh. Ther.
PD FEB 1
PY 2013
VL 28
IS 1-2
BP 29
EP 38
DI 10.1080/14681994.2013.773398
PG 10
WC Psychology, Clinical
SC Psychology
GA 122HE
UT WOS:000317308400004
ER
PT J
AU Elder, JB
Chiocce, EA
AF Elder, J. Bradley
Chiocce, E. Antonio
TI Molecular and Genetic Characterization of Meningiomas: Future Predictive
Assays and "Personalized" Treatment
SO WORLD NEUROSURGERY
LA English
DT Editorial Material
DE Atypical meningioma; Copy number; Copy number gains; Gene amplification;
Meningioma; Multiplex ligation-dependent probe amplification; Oncogene
C1 [Elder, J. Bradley] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA.
[Chiocce, E. Antonio] Harvard Univ, Sch Med, Dept Neurosurg, Inst Neurosci,Brigham & Womens Faulkner Hosp, Boston, MA USA.
[Chiocce, E. Antonio] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA.
RP Chiocce, EA (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
EM EAChiocca@partners.org
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2013
VL 79
IS 2
BP 247
EP 248
DI 10.1016/j.wneu.2011.10.005
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 125JV
UT WOS:000317537000009
PM 22120235
ER
PT J
AU Wang, Y
Wang, H
Xia, JX
Liang, TT
Wang, GJ
Li, XK
Yang, YG
AF Wang, Yi
Wang, Hui
Xia, Jinxing
Liang, Tingting
Wang, Guanjun
Li, Xiaokun
Yang, Yong-Guang
TI Activated CD8 T cells acquire NK1.1 expression and preferentially locate
in the liver in mice after allogeneic hematopoietic cell transplantation
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE CD8 T cells; NK1.1(+)CD8(+) T cells; Allogeneic hematopoietic cell
transplantation; Liver
ID IFN-GAMMA; NKT CELLS; DISEASE; EXPANSION; RECEPTORS; MOLECULES
AB Immune cells expressing both NK and T cell markers include CD1d-dependent NKT cells and CD1d-independent NKT-like cells. We now describe the presence of NK1.1(+)CD8(+) T cells in the liver, but not other tissues (spleen, bone marrow, thymus or peripheral blood) in mice receiving allogeneic hematopoietic cell transplantation (allo-HCT). These cells are CD1d-independent TCR alpha beta(+) T cells with an effector/memory CD44(hi)CD62L(-) phenotype, and do not express Ly49 receptors. Furthermore, these cells were derived from donor splenocytes, but not bone marrow cells. Depletion of CD8(+), but not NK1.1(+), cells from donor splenocytes prior to transplantation prevented the generation of NK1.1(+)CD8(+) T cells, indicating that these cells arose from donor NK1.1(-)CD8(+) splenic T cells. These results provide direct evidence that donor CD8(+) T cells can acquire NK1.1 expression upon activation in allo-HCT recipients and that these NK1.1(+)CD8(+) NKT-like cells maintain an effector/memory phenotype and persist in the recipients with preferential localization in the liver. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Wang, Yi; Li, Xiaokun] Wenzhou Med Coll, Sch Pharmaceut Sci, Key Lab Biotechnol Pharmaceut Engn Zhejiang Prov, Wenzhou 325035, Peoples R China.
[Wang, Yi; Wang, Hui; Yang, Yong-Guang] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02129 USA.
[Wang, Hui; Xia, Jinxing; Yang, Yong-Guang] Columbia Univ, Med Ctr, Columbia Ctr Translat Immunol, New York, NY USA.
[Liang, Tingting; Wang, Guanjun; Yang, Yong-Guang] Jilin Univ, Hosp 1, Changchun 130023, Peoples R China.
RP Yang, YG (reprint author), Columbia Univ Coll Phys & Surg, Columbia Ctr Translat Immunol, 630 W 168th St, New York, NY 10032 USA.
EM yy2324@columbia.edu
RI Xia, Jinxing/E-5658-2015
FU NIH [CA111519, AI064569]; Zhejiang Province Extremely Key Subject
Building Funding [2012R10042-11]; Natural Science Funding of China
[81102452]
FX We thank Drs. Haowei Li and Ben Sprangers for critical review of the
manuscript, Ms. Shumei Wang for technical support, and Mr. Orlando
Moreno for outstanding animal husbandry. This study was supported by
grants from NIH (CA111519 and AI064569), Zhejiang Province Extremely Key
Subject Building Funding (2012R10042-11), and Natural Science Funding of
China (81102452).
NR 12
TC 1
Z9 1
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD FEB
PY 2013
VL 150
IS 1-2
BP 75
EP 78
DI 10.1016/j.imlet.2012.12.009
PG 4
WC Immunology
SC Immunology
GA 122JW
UT WOS:000317315400010
PM 23291124
ER
PT J
AU Yan, QS
Xu, R
Zhu, LY
Cheng, X
Wang, Z
Manis, J
Shipp, MA
AF Yan, Qingsheng
Xu, Rong
Zhu, Liya
Cheng, Xin
Wang, Zhe
Manis, John
Shipp, Margaret A.
TI BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation,
Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1,
and RNF8
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID B-CELL LYMPHOMAS; DAMAGE RESPONSE; PARP INHIBITORS; PROTEINS; CHROMATIN;
BREAKS; BRCA1; SURVIVAL; TARGETS; CANCER
AB The BAL1 macrodomain-containing protein and its partner E3 ligase, BBAP, are overexpressed in chemotherapy-resistant lymphomas. BBAP selectively ubiquitylates histone H4 and indirectly promotes early 53BP1 recruitment to DNA damage sites. However, neither BBAP nor BAL1 has been directly associated with a DNA damage response (DDR), and the function of BAL1 remains undefined. Herein, we describe a direct link between rapid and short-lived poly(ADP-ribose) (PAR) polymerase 1 (PARP1) activation and PARylation at DNA damage sites, PAR-dependent recruitment of the BAL1 macrodomain-containing protein and its partner E3 ligase, local BBAP-mediated ubiquitylation, and subsequent recruitment of the checkpoint mediators 53BP1 and BRCA1. The PARP1-dependent localization of BAL1-BBAP functionally limits both early and delayed DNA damage and enhances cellular viability independent of ATM, MDC1, and RNF8. These data establish that BAL1 and BBAP are bona fide members of a DNA damage response pathway and are directly associated with PARP1 activation, BRCA1 recruitment, and double-strand break repair.
C1 [Yan, Qingsheng; Xu, Rong; Zhu, Liya; Cheng, Xin; Wang, Zhe; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Manis, John] Childrens Hosp Boston, Boston, MA USA.
[Manis, John] Harvard Univ, Sch Med, Joint Program Transfus Med, Boston, MA USA.
RP Shipp, MA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM margaret_shipp@dfci.harvard.edu
FU NIH [PO1CA092625, CA133781]
FX We acknowledge support from NIH grants PO1CA092625 (M.A.S.) and CA133781
(J.M.).
NR 31
TC 26
Z9 29
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD FEB
PY 2013
VL 33
IS 4
BP 845
EP 857
DI 10.1128/MCB.00990-12
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 121TK
UT WOS:000317267000016
PM 23230272
ER
PT J
AU Demers, M
Wagner, DD
AF Demers, Melanie
Wagner, Denisa D.
TI Neutrophil extracellular traps A new link to cancer-associated
thrombosis and potential implications for tumor progression
SO ONCOIMMUNOLOGY
LA English
DT Editorial Material
DE cancer; NETs; metastasis; neutrophils; thrombosis; tumor progression
ID INNATE IMMUNITY; LUNG METASTASIS; DNA TRAPS
AB Cancers prime neutrophils to release extracellular DNA traps through the systemic release of granulocyte colony-stimulating factor (G-CSF). We recently showed that these circulating neutrophil extracellular traps (NETs) promote the establishment of a pro-thrombotic state. The role of NETs in cancer biology and tumor progression may prove much more than an unfortunate side effect of cancer.
C1 [Wagner, Denisa D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Wagner, DD (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
EM Denisa.Wagner@childrens.harvard.edu
FU NHLBI NIH HHS [R01 HL102101]
NR 10
TC 31
Z9 32
U1 2
U2 11
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD FEB
PY 2013
VL 2
IS 2
AR e22946
DI 10.4161/onci.22946
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA 121SF
UT WOS:000317263800025
PM 23526174
ER
PT J
AU Villablanca, EJ
AF Villablanca, Eduardo J.
TI Retinoic acid-producing DCs and gut-tropic FOXP3(+) regulatory T cells
in the induction of oral tolerance
SO ONCOIMMUNOLOGY
LA English
DT Editorial Material
DE dendritic cells; FOXP3; gut homing; oral tolerance; retinoic acid
ID MICROBIOTA
AB The systemic unresponsiveness of the immune system to orally administered antigens is known as oral tolerance. Recent findings describe a new step for the induction of oral tolerance, consisting in the homing of FOXP3(+) regulatory T cells to the small bowel and the local acquisition of full immunosuppressive capacities, a process in which retinoic acid-producing dendritic cells might play a crucial role.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02215 USA.
RP Villablanca, EJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02215 USA.
EM Villablanca.Eduardo@mgh.harvard.edu
RI Villablanca, Eduardo/E-1380-2016
OI Villablanca, Eduardo/0000-0001-9522-9729
NR 8
TC 4
Z9 4
U1 0
U2 3
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD FEB
PY 2013
VL 2
IS 2
AR e22987
DI 10.4161/onci.22987
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA 121SF
UT WOS:000317263800030
ER
PT J
AU Reis, JP
Loria, CM
Launer, LJ
Sidney, S
Liu, K
Jacobs, DR
Zhu, N
Lloyd-Jones, DM
He, K
Yaffe, K
AF Reis, Jared P.
Loria, Catherine M.
Launer, Lenore J.
Sidney, Stephen
Liu, Kiang
Jacobs, David R., Jr.
Zhu, Na
Lloyd-Jones, Donald M.
He, Ka
Yaffe, Kristine
TI Cardiovascular health through young adulthood and cognitive functioning
in midlife
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID RISK-FACTORS; METABOLIC SYNDROME; INCIDENT DEMENTIA; BLOOD-PRESSURE; US
ADULTS; IMPAIRMENT; LIFE; DECLINE; CARDIA; ASSOCIATION
AB Objective A study was undertaken to examine the association between overall cardiovascular health as recently defined by the American Heart Association in young adulthood to middle age and cognitive function in midlife. Overall ideal cardiovascular health incorporates 7 metrics, including the avoidance of overweight or obesity, a healthful diet, nonsmoking, and physical activity, total cholesterol, blood pressure, and fasting glucose at goal levels. Methods This analysis of the Coronary Artery Risk Development in Young Adults study, a multicenter community-based study with 25 years of follow-up, included 2,932 participants aged 18 to 30 years at baseline (year 0) who attended follow-up examinations at years 7 and 25. Cardiovascular health metrics were measured at each examination. The Digit Symbol Substitution Test (DSST), modified Stroop test, and Rey Auditory Verbal Learning Test (RAVLT) were completed at year 25. Results A greater number of ideal cardiovascular metrics in young adulthood and middle age were independently associated with better cognitive function in midlife (p for trend < 0.01, for all). Specifically, each additional ideal metric was associated with 1.32 more symbols on the DSST (95% confidence interval [CI] = 0.93 1.71), a 0.77-point lower interference score on the Stroop test (95% CI=1.03 to 0.45), and 0.12 more words on the RAVLT (95% CI = 0.04 to 0.20). Participants who had 5 ideal metrics at a greater number of the 3 examinations over the 25-year period exhibited better performance on each cognitive test in middle age (p for trend < 0.01, for all). Interpretation Ideal cardiovascular health in young adulthood and its maintenance to middle age is associated with better psychomotor speed, executive function, and verbal memory in midlife. ANN NEUROL 2013;73:170179
C1 [Reis, Jared P.; Loria, Catherine M.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
[Sidney, Stephen] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA.
[Liu, Kiang; Lloyd-Jones, Donald M.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
[Jacobs, David R., Jr.; Zhu, Na] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway.
[He, Ka] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA.
[He, Ka] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Reis, JP (reprint author), NHLBI, Div Cardiovasc Sci, 6701 Rockledge Dr,Suite 10197, Bethesda, MD 20892 USA.
EM reisjp@mail.nih.gov
FU National Heart, Lung, and Blood Institute; University of Alabama at
Birmingham [N01-HC95095, N01-HC48047]; Kaiser Foundation Research
Institute [N01-HC48050]; Northwestern University [N01-HC48049];
University of Minnesota [N01-HC48048]
FX CARDIA is conducted and supported by the National Heart, Lung, and Blood
Institute in collaboration with the University of Alabama at Birmingham
(N01-HC95095, N01-HC48047), Kaiser Foundation Research Institute
(N01-HC48050), Northwestern University (N01-HC48049), and University of
Minnesota (N01-HC48048).
NR 38
TC 40
Z9 41
U1 0
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD FEB
PY 2013
VL 73
IS 2
BP 170
EP 179
DI 10.1002/ana.23836
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 113UA
UT WOS:000316693200006
PM 23443990
ER
PT J
AU Fitzgerald, KC
O'Reilly, EJ
Fondell, E
Falcone, GJ
McCullough, ML
Park, Y
Kolonel, LN
Ascherio, A
AF Fitzgerald, Kathryn C.
O'Reilly, Eilis J.
Fondell, Elinor
Falcone, Guido J.
McCullough, Marjorie L.
Park, Yikyung
Kolonel, Laurence N.
Ascherio, Alberto
TI Intakes of vitamin C and carotenoids and risk of amyotrophic lateral
sclerosis: Pooled results from 5 cohort studies
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID FOOD-FREQUENCY QUESTIONNAIRE; HEALTH-AMERICAN-ASSOCIATION; SOCIETY
CANCER PREVENTION; BASE-LINE CHARACTERISTICS; RETIRED-PERSONS DIET;
MOTOR-NEURON DISEASE; NATIONAL-INSTITUTES; OXIDATIVE STRESS; SURVIVAL;
WOMEN
AB Objective Prior research has suggested the possible role of oxidative stress in the pathogenesis of amyotrophic lateral sclerosis (ALS). Prospective data examining dietary antioxidants such carotenoids and vitamin C are limited. Methods Risk of ALS associated with carotenoid and vitamin C intake was investigated in 5 prospective cohorts: the National Institutes of HealthAssociation of American Retired Persons Diet and Health Study, the Cancer Prevention Study II Nutrition Cohort, the Multiethnic Cohort, the Health Professionals Follow-up Study (HPFS), and the Nurses Health Study (NHS). ALS deaths were documented using the National Death Index, and confirmed nonfatal ALS cases were included from HPFS and NHS. A total of 1,153 ALS deaths occurred among 1,100,910 participants (562,942 men; 537,968 women). Participants were categorized into cohort-specific quintiles of intake for dietary variables. We applied Cox proportional hazards regression to calculate cohort-specific risk ratios (RRs), and pooled results using random-effects methods. Results A greater total major carotenoids intake was associated with a reduced risk of ALS (pooled, multivariate-adjusted RR for the highest to the lowest quintile = 0.75, 95% confidence interval [CI] = 0.610.91, p for trend = 0.004). Individually, higher dietary intakes of -carotene and lutein were inversely associated with ALS risk. The pooled multivariate RRs comparing the highest to the lowest quintile for -carotene and lutein were 0.85 (95% CI = 0.641.13, p for trend = 0.03) and 0.79 (95% CI = 0.640.96, p for trend = 0.01), respectively. Lycopene, -cryptoxanthin, and vitamin C were not associated with reduced risk of ALS. Interpretation Consumption of foods high in carotenoids may help prevent or delay onset of ALS. ANN NEUROL 2013;73:236245
C1 [Fitzgerald, Kathryn C.; O'Reilly, Eilis J.; Fondell, Elinor; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[O'Reilly, Eilis J.; Ascherio, Alberto] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[O'Reilly, Eilis J.; Ascherio, Alberto] Harvard Univ, Sch Med, Boston, MA USA.
[Falcone, Guido J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Falcone, Guido J.; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[McCullough, Marjorie L.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Park, Yikyung] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Kolonel, Laurence N.] Univ Hawaii, Program Epidemiol, Ctr Canc, Honolulu, HI 96822 USA.
RP Fitzgerald, KC (reprint author), 665 Huntington Ave, Boston, MA 02115 USA.
EM hpkcf@channing.harvard.edu
RI Falcone, Guido/L-2287-2016;
OI Falcone, Guido/0000-0002-6407-0302; Park, Yikyung/0000-0002-6281-489X
FU NIH/National Institute of Neurological Diseases and Stroke [R01
NS045893]; NIH/NCI [R37 CA54281]; neurological diseases and stroke (NIH)
[P01 CA87969]; NIH [P01 CA055075]; Blanceflor Foundation (Stockholm,
Sweden); Michael J Fox Foundation; Accelerated Cure Project; F.
Hoffmann-La Roche; Merck Serono
FX This work was supported by grant R01 NS045893 from the NIH/National
Institute of Neurological Diseases and Stroke. The multiethnic cohort
study was supported by NIH/NCI R37 CA54281. Nurses Health Study is
funded by neurological diseases and stroke (NIH) program project P01
CA87969 and Health Professional Follow-up Study by NIH program project
P01 CA055075. E.F. received a postdoctoral scholarship from the
Blanceflor Foundation (Stockholm, Sweden).; K.C.F.: grants/grants
pending, NIH. E.J.O.: grants/grants pending, NIH. A.A.: grants/grants
pending, National Institutes of Health, Michael J Fox Foundation,
Accelerated Cure Project; speaking fees, F. Hoffmann-La Roche, Merck
Serono.
NR 39
TC 19
Z9 21
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD FEB
PY 2013
VL 73
IS 2
BP 236
EP 245
DI 10.1002/ana.23820
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 113UA
UT WOS:000316693200012
PM 23362045
ER
PT J
AU Cea, M
Cagnetta, A
Gobbi, M
Patrone, F
Richardson, PG
Hideshima, T
Anderson, KC
AF Cea, Michele
Cagnetta, Antonia
Gobbi, Marco
Patrone, Franco
Richardson, Paul G.
Hideshima, Teru
Anderson, Kenneth C.
TI New Insights into the Treatment of Multiple Myeloma with Histone
Deacetylase Inhibitors
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Multiple myeloma; HDACIs; apoptosis; proteasome inhibitor; novel therapy
ID SUBEROYLANILIDE HYDROXAMIC ACID; T-CELL LYMPHOMA; DNA-DAMAGE;
LEUKEMIA-CELLS; HEMATOLOGIC MALIGNANCIES; ANTILEUKEMIA ACTIVITY;
DEPENDENT APOPTOSIS; CLINICAL-RESPONSES; TUMOR ANGIOGENESIS;
TRANSFORMED-CELLS
AB Multiple Myeloma (MM) is a common hematologic malignancy of plasma cells representing an excellent model of epigenomics dysregulation in human disease. Importantly, these findings, in addition to providing a better understanding of the underlying molecular changes leading to this malignance, furnish the basis for an innovative therapeutic approach. Histone deacetylase inhibitors (HDACIs), including Vorinostat and Panobinostat, represent a novel class of drugs targeting enzymes involved in epigenetic regulation of gene expression, which have been evaluated also for the treatment of multiple myeloma. Although the clinical role in this setting is evolving and their precise utility remains to be determined, to date that single-agent anti-MM activity is modest. More importantly, HDACIs appear to be synergistic both in vitro and in vivo when combined with other anti-MM agents, mainly proteasome inhibitors including bortezomib. The molecular basis underlying this synergism seems to be multifactorial and involves interference with protein degradation as well as the interaction of myeloma cells with microenvironment. Here we review molecular events underling antitumor effects of HDACIs and the most recent results of clinical trials in relapsed and refractory MM.
C1 [Cea, Michele; Cagnetta, Antonia; Richardson, Paul G.; Hideshima, Teru; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Cea, Michele; Cagnetta, Antonia; Richardson, Paul G.; Hideshima, Teru; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA.
[Cea, Michele; Patrone, Franco] IRCCS AOU San Martino IST, Dept Internal Med, Genoa, Italy.
[Cagnetta, Antonia; Gobbi, Marco] IRCCS AOU San Martino IST, Dept Hematol & Oncol, Genoa, Italy.
RP Cea, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, M551,450 Brookline Ave, Boston, MA 02115 USA.
EM michele_cea@dfci.harvard.edu; anderson@dfci.harvard.edu
FU National Institutes of Health [RO-1 CA-50947, RO-1 CA-73878]; DF/HCC
SPORE in Multiple Myeloma [PO-50100707]; American Italian Cancer
Foundation; Fondazione Italiana per la Ricerca sul Cancro; International
Multiple Myeloma Foundation; Associazione Italiana per la Ricerca sul
Cancro
FX This study is supported by National Institutes of Health (grants RO-1
CA-50947, RO-1 CA-73878), DF/HCC SPORE in Multiple Myeloma
(PO-50100707); American Italian Cancer Foundation (M.C.), Fondazione
Italiana per la Ricerca sul Cancro (M.C.) and International Multiple
Myeloma Foundation (A.C.). K.C.A. is an American Cancer Society Council
Research Professor.
NR 97
TC 18
Z9 19
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD FEB
PY 2013
VL 19
IS 4
BP 734
EP 744
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 110MS
UT WOS:000316448200012
PM 23016853
ER
PT J
AU Alexeeff, SE
Baccarelli, AA
Halonen, J
Coull, BA
Wright, RO
Tarantini, L
Bollati, V
Sparrow, D
Vokonas, P
Schwartz, J
AF Alexeeff, Stacey E.
Baccarelli, Andrea A.
Halonen, Jaana
Coull, Brent A.
Wright, Robert O.
Tarantini, Letizia
Bollati, Valentina
Sparrow, David
Vokonas, Pantel
Schwartz, Joel
TI Association between blood pressure and DNA methylation of
retrotransposons and pro-inflammatory genes
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Epigenetics; DNA methylation; blood pressure; inflammation; Bayesian
model
ID CARDIOVASCULAR-DISEASE RISK; CORONARY-HEART-DISEASE; PROMOTER
METHYLATION; RHEUMATOID-ARTHRITIS; L1 RETROTRANSPOSONS; METABOLIC
SYNDROME; HUMAN GENOME; EXPRESSION; HYPOMETHYLATION; ATHEROSCLEROSIS
AB Background Methylation of deoxyribonucleic acid (DNA) is an epigenetic regulator of gene expression that changes with age, but its contribution to aging-related disorders, including high blood pressure (BP), is still largely unknown. We examined the relation of BP to the methylation of retrotransposon sequences of DNA and of selected candidate genes.
Methods This investigation included 789 elderly participants in the Normative Aging Study, ranging in age from 55 to 100 years, who had longitudinal measurements of DNA methylation. In these subjects' DNA we measured the proportion of methylated sites in retrotransposable sequences and in pro-inflammatory genes, expressed as the percent of 5-methylated cytosines (%5mC) among all cytosines. From one to four methylation measurements were made for each subject between 1999 and 2009. We fit mixed-effects models, using repeated measures of BP as the outcome and DNA methylation as the explanatory variable, adjusting for confounding variables. We also fit a Bayesian mixed-effects structural equation model to account for heterogeneity in the effects of methylation sites within each gene.
Results An increase in inter-quartile range (IQR) in the methylation of Alu elements was associated with an increase of 0.97 mm Hg in diastolic blood pressure (DBP) (95% CI 0.32-1.57), but no such association was observed for long interspersed nuclear element-1 (LINE-1). We also found positive associations between DBP and methylation of the genes for toll-like receptor 2 (TLR2) and inducible nitric oxide synthase (iNOS), and a negative association between DBP and methylation of the gene for interferon-gamma (IFN-gamma). Associations between methylation and systolic blood pressure (SBP) were weaker than those between methylation and DBP. Bayesian mixed-effects structural equation model results were similar for both DBP and SBP models.
Conclusions The results of our study suggest that changes in DNA methylation of some pro-inflammatory genes and retrotransposable elements are related to small changes in BP.
C1 [Alexeeff, Stacey E.; Baccarelli, Andrea A.; Halonen, Jaana; Wright, Robert O.; Schwartz, Joel] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02215 USA.
[Alexeeff, Stacey E.; Coull, Brent A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
[Baccarelli, Andrea A.; Tarantini, Letizia; Bollati, Valentina] Ca Granda Osped Maggiore Policlin IRCCS Fdn, Lab Environm Epigenet, Dept Occupat & Environm Hlth, Milan, Italy.
[Baccarelli, Andrea A.; Tarantini, Letizia; Bollati, Valentina] Univ Milan, Milan, Italy.
[Halonen, Jaana] Finnish Inst Occupat Hlth, Kuopio, Finland.
[Wright, Robert O.] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Sch Med, Boston, MA 02215 USA.
[Sparrow, David; Vokonas, Pantel] VA Boston Healthcare Syst, VA Normat Aging Study, Boston, MA USA.
[Sparrow, David; Vokonas, Pantel] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
RP Alexeeff, SE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 401 Pk Dr, Boston, MA 02215 USA.
EM salexeeff@fas.harvard.edu
OI Baccarelli, Andrea/0000-0002-3436-0640; Bollati,
Valentina/0000-0002-0370-9598
FU National Institute of Environmental Health Sciences [R01 ES015172]; US
Department of Veterans Affairs is a component of the Massachusetts
Veterans Epidemiology Research and Information Center (MAVERIC), Boston,
MA; VA Research Career Scientist award
FX This research was supported by National Institute of Environmental
Health Sciences grant R01 ES015172. The Normative Aging Study is
supported by the Cooperative Studies Program/Epidemiology Research and
Information Center of the US Department of Veterans Affairs and is a
component of the Massachusetts Veterans Epidemiology Research and
Information Center (MAVERIC), Boston, MA. This research was also
supported by a VA Research Career Scientist award to D.S.
NR 66
TC 17
Z9 19
U1 2
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD FEB
PY 2013
VL 42
IS 1
BP 270
EP 280
DI 10.1093/ije/dys220
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 113WE
UT WOS:000316699300034
PM 23508416
ER
PT J
AU Littman, AJ
Jacobson, IG
Boyko, EJ
Powell, TM
Smith, TC
AF Littman, A. J.
Jacobson, I. G.
Boyko, E. J.
Powell, T. M.
Smith, T. C.
CA Millennium Cohort Study Team
TI Weight change following US military service
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE military veterans; weight gain; prospective; cohort; posttraumatic
stress disorder; military deployment
ID VETERANS; OBESITY; COHORT; OVERWEIGHT; VALIDITY; BURDEN
AB BACKGROUND: Although overweight and obesity are less prevalent among active-duty military personnel compared with similar persons not serving in the military, no such differences have been observed between veterans and non-veterans.
OBJECTIVES: To assess the magnitude of weight changes before, concurrent with and following discharge from the military, relative to weight during service, and to determine the demographic, service-related and psychological characteristics associated with clinically important weight gain among those who were discharged from military service during follow-up.
METHODS: Eligible Millennium Cohort Study participants (n = 38 686) completed the questionnaires approximately every 3 years (2001, 2004 and 2007) that were used to estimate annual weight changes, as well as the percentage experiencing clinically important weight gain, defined as >= 10%. Analyses were stratified by sex.
RESULTS: Weight gain was greatest around the time of discharge from service and in the 3 years before discharge (1.0-1.3 kg per year), while it was nearly half as much during service (0.6-0.7 kg per year) and >= 3 years after service ended (0.7 kg per year). Consequently, 6-year weight gain was over 2 kg greater in those who were discharged compared with those who remained in the military during follow-up (5.7 vs 3.5 kg in men; 6.3 vs 4.0 kg in women). In those who were discharged, younger age, less education, being overweight at baseline, being in the active-duty component (vs Reserve/National Guard) and having experienced deployment with combat exposures (vs non-deployment) were associated with increased risks of clinically important weight gain.
CONCLUSIONS: This study provides the first prospectively collected evidence for an increased rate of weight gain around the time of military discharge that may explain previously reported higher rates of obesity in veterans, and identifies characteristics of higher-risk groups. Discharge from military service presents a window of risk and opportunity to prevent unhealthy weight gain in military personnel and veterans. International Journal of Obesity (2013) 37, 244-253; doi:10.1038/ijo.2012.46; published online 10 April 2012
C1 [Littman, A. J.; Boyko, E. J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Littman, A. J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Jacobson, I. G.; Powell, T. M.; Smith, T. C.] USN, Dept Deployment Hlth Res, Hlth Res Ctr, San Diego, CA 92152 USA.
RP Littman, AJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst 152E, Seattle Epidemiol Res & Informat Ctr, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM alyson@u.washington.edu
FU Henry M Jackson Foundation for the Advancement of Military Medicine,
Rockville, MD; VA Rehabilitation Research and Development Career
Development Award [6982]; Cooperative Studies Program, Department of
Veterans; Puget Sound VA Medical Center; Department of Defense [60002]
FX We are indebted to the Millennium Cohort Study participants, without
whom these analyses would not be possible. In addition to the authors,
the Millennium Cohort Study Team includes Paul J Amoroso, MD; Gary D
Gackstetter, MD, from the Analytic Services, Inc., Arlington, VA;
Gregory C Gray, MD, MPH, from the College of Public Health and Health
Professions, University of Florida, Gainesville, FL; Tomoko Hooper, MD,
from the Departments of Preventive Medicine and Biometrics, Uniformed
Services University of Health Sciences, Bethesda, MD; James R Riddle,
DVM, MPH, from the Air Force Research Laboratory, Wright-Patterson Air
Force Base, OH; Margaret AK Ryan, MD, MPH, from Naval Hospital Camp
Pendleton, Occupational Health Department; Melissa Bagnell, MPH; Nancy
Crum-Cianflone, MD, MPH; Gia Gumbs, MPH; Nisara Granado, MPH, PhD; Jaime
Horton; Kelly Jones, MPH; Cynthia LeardMann, MPH; William Lee; Travis
Leleu; Michelle Linfesty; Gordon Lynch; Jamie McGrew; Hope McMaster,
PhD; Sheila Medina-Torne, MPH; Amanda Pietrucha, MPH; Donald Sandweiss,
MD; Amber Seelig, MPH; Beverly Sheppard; Katherine Snell; Steven
Speigle; Kari Sausedo, MA; Donald Slymen, PhD; Besa Smith, MPH, PhD;
Jennifer Walstrom; Timothy S Wells, DVM, MPH, PhD; Martin White, MPH;
James Whitmer; and Charlene Wong, MPH; from the Department of Deployment
Health Research, Naval Health Research Center, San Diego, CA. We thank
Scott L Seggerman and Greg D Boyd from the Management Information
Division, Defense Manpower Data Center, Monterey, CA. Additionally, we
thank Michelle LeWark from the Naval Health Research Center. We also
thank all the professionals from the US Army Medical Research and
Materiel Command, especially those from the Military Operational
Medicine Research Program, Fort Detrick, MD. We appreciate the support
of the Henry M Jackson Foundation for the Advancement of Military
Medicine, Rockville, MD. Dr Littman was supported by a VA Rehabilitation
Research and Development Career Development Award (#6982).; The views
expressed in this article are those of the authors and do not reflect
the official policy or position of the Department of the Navy,
Department of the Army, Department of the Air Force, Department of
Defense, Department of Veterans Affairs or the US Government. This
material is the result of work partly supported with resources and the
use of facilities from the Cooperative Studies Program, Department of
Veterans and the Puget Sound VA Medical Center. This work represents
report 0934, supported by the Department of Defense, under work unit no.
60002. This research has been conducted in compliance with all
applicable federal regulations governing the protection of human
subjects in research (Protocol NHRC.2000.007).
NR 21
TC 12
Z9 12
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
J9 INT J OBESITY
JI Int. J. Obes.
PD FEB
PY 2013
VL 37
IS 2
BP 244
EP 253
DI 10.1038/ijo.2012.46
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 117DK
UT WOS:000316932100014
PM 22491091
ER
PT J
AU Winer, L
Srinivasan, D
Chun, S
Lacomis, D
Jaffa, M
Fagan, A
Holtzman, DM
Wancewicz, E
Bennett, CF
Bowser, R
Cudkowicz, M
Miller, TM
AF Winer, Leah
Srinivasan, Dushyanth
Chun, Seung
Lacomis, David
Jaffa, Matthew
Fagan, Anne
Holtzman, David M.
Wancewicz, Ed
Bennett, C. Frank
Bowser, Robert
Cudkowicz, Merit
Miller, Timothy M.
TI SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense
Oligonucleotide Therapy
SO JAMA NEUROLOGY
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE;
SUPEROXIDE-DISMUTASE; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; IN-VIVO;
ALS; PROTEIN; MODEL; BIOMARKER
AB Background: Therapies designed to decrease the level of SOD1 are currently in a clinical trial for patients with superoxide dismutase (SOD1)-linked familial amyotrophic lateral sclerosis (ALS).
Objective: To determine whether the SOD1 protein in cerebral spinal fluid (CSF) may be a pharmacodynamic marker for antisense oligonucleotide therapy and a disease marker for ALS.
Design: Antisense oligonucleotides targeting human SOD1 were administered to rats expressing SOD1(G93A). The human SOD1 protein levels were measured in the rats' brain and CSF samples. In human CSF samples, the following proteins were measured: SOD1, tau, phosphorylated tau, VILIP-1, and YKL-40.
Participants: Ninety-three participants with ALS, 88 healthy controls, and 89 controls with a neurological disease (55 with dementia of the Alzheimer type, 19 with multiple sclerosis, and 15 with peripheral neuropathy).
Results: Antisense oligonucleotide-treated SOD1(G93A) rats had decreased human SOD1 messenger RNA levels (mean [SD] decrease of 69% [4%]) and decreased protein levels (mean [SD] decrease of 48% [14%]) in the brain. The rats' CSF samples showed a similar decrease in hSOD1 levels (mean [SD] decrease of 42% [14%]). In human CSF samples, the SOD1 levels varied a mean (SD) 7.1% (5.7%) after additional measurements, separated by months, were performed. The CSF SOD1 levels were higher in the participants with ALS (mean [SE] level, 172 [8] ng/mL; P < .05) and the controls with a neurological disease (mean [SE] level, 172 [6] ng/mL; P < .05) than in the healthy controls (mean [SE] level, 134 [4] ng/mL). Elevated CSF SOD1 levels did not correlate with disease characteristics in participants with ALS or controls with dementia of the Alzheimer type, but they did correlate with tau, phosphorylated tau, VILIP-1 and YKL-40 levels in controls with dementia of the Alzheimer type.
Conclusions: SOD1 in CSF may be an excellent pharmacodynamic marker for SOD1-lowering therapies because antisense oligonucleotide therapy lowers protein levels in the rat brain and rat CSF samples and because SOD1 levels in CSF samples from humans are stable over time. JAMA Neurol. 2013;70(2):201-207. Published online November 12, 2012. doi:10.1001/jamaneurol.2013.593
C1 [Winer, Leah; Srinivasan, Dushyanth; Chun, Seung; Fagan, Anne; Holtzman, David M.; Miller, Timothy M.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA.
[Lacomis, David] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Bowser, Robert] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA.
[Jaffa, Matthew; Cudkowicz, Merit] Massachusetts Gen Hosp, Dept Neurol, Neurol Clin Trials Unit, Boston, MA 02114 USA.
[Wancewicz, Ed; Bennett, C. Frank] ISIS Pharmaceut, Carlsbad, CA 92008 USA.
RP Miller, TM (reprint author), Washington Univ, Dept Neurol, 115 Biotech Bldg,660 S Euclid,POB 8111, St Louis, MO 63110 USA.
EM millert@neuro.wustl.edu
FU National Institute of Aging of the National Institutes of Health [P01
AG03991, P01 AG026276, U01 AG032438]; Hope Center for Neurological
Disorders; ALS Association pilot grant; Clinical and Translation Science
Award [UL1 RR024992, K08NS074194]; Washington University Knight
Alzheimer's Disease Research Center [P50-AG05681, P01-AG03991,
P01-AG26276, P30-NS057105]; University of Pittsburgh [RO1 NS061867-01,
RC1 NS068179-01]
FX Dr Fagan is supported by grants P01 AG03991, P01 AG026276, and U01
AG032438 from the National Institute of Aging of the National Institutes
of Health and by the Hope Center for Neurological Disorders. She is a
member of the Alzheimer's Disease CSF Biomarker Development Advisory
Board for Roche and the US Alzheimer's Disease Advisory Board for Lilly
USA. Isis Pharmaceuticals provided the antisense oligonucleotides used
in this study.; This work was supported by an ALS Association pilot
grant (to Dr Miller) and Clinical and Translation Science Award grants
UL1 RR024992 (to Dr Miller) and K08NS074194 (to Dr Miller). The CSF
samples were from Northeast ALS Consortium and the Washington University
Knight Alzheimer's Disease Research Center (grants P50-AG05681 [to Dr
Morris], P01-AG03991 [to Dr Morris], P01-AG26276 [to Dr Morris], and
P30-NS057105 [to Dr Holtzman]), the Charles and Joanne Knight
Alzheimer's Disease Research Initiative (to Dr Morris), and the
University of Pittsburgh (grants RO1 NS061867-01 [to Dr Bowser] and RC1
NS068179-01 [to Dr Bowser])
NR 29
TC 27
Z9 27
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6149
J9 JAMA NEUROL
JI JAMA Neurol.
PD FEB
PY 2013
VL 70
IS 2
BP 201
EP 207
DI 10.1001/jamaneurol.2013.593
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 115GT
UT WOS:000316801300007
PM 23147550
ER
PT J
AU Tsuang, D
Leverenz, JB
Lopez, OL
Hamilton, RL
Bennett, DA
Schneider, JA
Buchman, AS
Larson, EB
Crane, PK
Kaye, JA
Kramer, P
Woltjer, R
Trojanowski, JQ
Weintraub, D
Chen-Plotkin, AS
Irwin, DJ
Rick, J
Schellenberg, GD
Watson, GS
Kukull, W
Nelson, PT
Jicha, GA
Neltner, JH
Galasko, D
Masliah, E
Quinn, JF
Chung, KA
Yearout, D
Mata, IF
Wan, JY
Edwards, KL
Montine, TJ
Zabetian, CP
AF Tsuang, Debby
Leverenz, James B.
Lopez, Oscar L.
Hamilton, Ronald L.
Bennett, David A.
Schneider, Julie A.
Buchman, Aron S.
Larson, Eric B.
Crane, Paul K.
Kaye, Jeffrey A.
Kramer, Patricia
Woltjer, Randy
Trojanowski, John Q.
Weintraub, Daniel
Chen-Plotkin, Alice S.
Irwin, David J.
Rick, Jacqueline
Schellenberg, Gerard D.
Watson, G. Stennis
Kukull, Walter
Nelson, Peter T.
Jicha, Gregory A.
Neltner, Janna H.
Galasko, Doug
Masliah, Eliezer
Quinn, Joseph F.
Chung, Kathryn A.
Yearout, Dora
Mata, Ignacio F.
Wan, Jia Y.
Edwards, Karen L.
Montine, Thomas J.
Zabetian, Cyrus P.
TI APOE epsilon 4 Increases Risk for Dementia in Pure Synucleinopathies
SO JAMA NEUROLOGY
LA English
DT Article
ID APOLIPOPROTEIN-E GENOTYPE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; LEWY
BODIES; COGNITIVE DECLINE; BODY; ALLELE; ASSOCIATION; METAANALYSIS;
CONSORTIUM
AB Objective: To test for an association between the apolipoprotein E (APOE) epsilon 4 allele and dementias with synucleinopathy.
Design: Genetic case-control association study.
Setting: Academic research.
Patients: Autopsied subjects were classified into 5 categories: dementia with high-level Alzheimer disease (AD) neuropathologic changes (NCs) but without Lewy body disease (LBD) NCs (AD group; n = 244), dementia with LBDNCs and high-level ADNCs (LBD-AD group; n = 224), dementia with LBDNCs and no or low levels of ADNCs (pure DLB [pDLB] group; n = 91), Parkinson disease dementia (PDD) with no or low levels of ADNCs (n = 81), and control group (n = 269).
Main Outcome Measure: The APOE allele frequencies.
Results: The APOE e4 allele frequency was significantly higher in the AD (38.1%), LBD-AD (40.6%), pDLB (31.9%), and PDD (19.1%) groups compared with the control group (7.2%; overall chi(2)(4) = 185.25; P = 5.56 X 10(-39)), and it was higher in the pDLB group than the PDD group (P = . 01). In an age-adjusted and sex-adjusted dominant model, epsilon 4 was strongly associated with AD (odds ratio, 9.9; 95% CI, 6.4-15.3), LBD-AD (odds ratio, 12.6; 95% CI, 8.1-19.8), pDLB (odds ratio, 6.1; 95% CI, 3.5-10.5), and PDD (odds ratio, 3.1; 95% CI, 1.7-5.6).
Conclusions: The APOE epsilon 4 allele is a strong risk factor across the LBD spectrum and occurs at an increased frequency in pDLB relative to PDD. This suggests that epsilon 4 increases the likelihood of presenting with dementia in the context of a pure synucleinopathy. The elevated epsilon 4 frequency in the pDLB and PDD groups, in which the overall brain neuritic plaque burden was low, indicates that apoE might contribute to neurodegeneration through mechanisms unrelated to amyloid processing. JAMA Neurol. 2013;70(2):223-228. Published online November 19, 2012. doi:10.1001/jamaneurol.2013.600
C1 [Tsuang, Debby; Leverenz, James B.; Watson, G. Stennis; Yearout, Dora; Mata, Ignacio F.; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Tsuang, Debby; Leverenz, James B.; Watson, G. Stennis] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Leverenz, James B.; Yearout, Dora; Mata, Ignacio F.; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Larson, Eric B.; Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Kukull, Walter; Wan, Jia Y.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA.
[Lopez, Oscar L.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Hamilton, Ronald L.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA.
[Trojanowski, John Q.; Irwin, David J.; Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
[Weintraub, Daniel; Chen-Plotkin, Alice S.; Irwin, David J.; Rick, Jacqueline] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Bennett, David A.; Buchman, Aron S.] Rush Univ, Dept Neurol Sci, Chicago, IL 60612 USA.
[Schneider, Julie A.] Rush Univ, Dept Pathol, Chicago, IL 60612 USA.
[Kaye, Jeffrey A.; Kramer, Patricia; Quinn, Joseph F.; Chung, Kathryn A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Woltjer, Randy] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA.
[Quinn, Joseph F.; Chung, Kathryn A.] Portland VA Med Ctr, Portland, OR USA.
[Nelson, Peter T.; Neltner, Janna H.] Univ Kentucky, Dept Pathol, Lexington, KY 40506 USA.
[Jicha, Gregory A.] Univ Kentucky, Dept Neurol, Lexington, KY 40506 USA.
[Galasko, Doug] Univ Calif San Diego, Dept Neurol, San Diego, CA 92103 USA.
[Masliah, Eliezer] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA.
RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, GRECC S-182,1660 S Columbian Way, Seattle, WA 98108 USA.
EM zabetian@u.washington.edu
RI Crane, Paul/C-8623-2014; Tsuang, Debby/L-7234-2016
OI Tsuang, Debby/0000-0002-4716-1894
FU National Institutes of Health [P30 AG008017, P30 AG028383, P30 AG010124,
P30 AG010161, P50 NS053488, P50 AG005131, P50 NS062684, P50 AG005136,
P50 AG005133, R01 NS048595, R01 NS065070, R01 AG010845, U01 AG006781];
Department of Veterans Affairs [1I01BX000531]
FX Dr Schneider's work was funded by grants from the National Institutes of
Health.; This work was supported by grant 1I01BX000531 from the
Department of Veterans Affairs and grants P30 AG008017, P30 AG028383,
P30 AG010124, P30 AG010161, P50 NS053488, P50 AG005131, P50 NS062684,
P50 AG005136, P50 AG005133, R01 NS048595, R01 NS065070, R01 AG010845,
and U01 AG006781 from the National Institutes of Health.
NR 37
TC 60
Z9 61
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6149
J9 JAMA NEUROL
JI JAMA Neurol.
PD FEB
PY 2013
VL 70
IS 2
BP 223
EP 228
DI 10.1001/jamaneurol.2013.600
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 115GT
UT WOS:000316801300010
PM 23407718
ER
PT J
AU Ziegler, DA
Wonderlick, JS
Ashourian, P
Hansen, LA
Young, JC
Murphy, AJ
Koppuzha, CK
Growdon, JH
Corkin, S
AF Ziegler, David A.
Wonderlick, Julien S.
Ashourian, Paymon
Hansen, Leslie A.
Young, Jeremy C.
Murphy, Alex J.
Koppuzha, Cecily K.
Growdon, John H.
Corkin, Suzanne
TI Substantia Nigra Volume Loss Before Basal Forebrain Degeneration in
Early Parkinson Disease
SO JAMA NEUROLOGY
LA English
DT Article
ID COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; NUCLEUS BASALIS; MR FINDINGS;
SPIN-ECHO; INNOMINATA; BRAIN; ACETYLCHOLINESTERASE; PATHOGENESIS;
PATHOLOGY
AB Objective: To test the hypothesis that degeneration of the substantia nigra pars compacta (SNc) precedes that of the cholinergic basal forebrain (BF) in Parkinson disease (PD) using new multispectral structural magnetic resonance (MR) imaging tools to measure the volumes of the SNc and BF.
Design: Matched case-control study.
Setting: The Athinoula A. Martinos Imaging Center at the McGovern Institute for Brain Research, Massachusetts Institute of Technology (MIT), and the Massachusetts General Hospital/MIT Morris Udall Center of Excellence in Parkinson Disease Research.
Patients: Participants included 29 patients with PD (Hoehn and Yahr [H&Y] stages 1-3) and 27 matched healthy control subjects.
Main Outcome Measures: We acquired multiecho T1-weighted, multiecho proton density, T2-weighted, and T2-weighted fluid-attenuated inversion recovery (FLAIR) sequences from each participant. For the SNc, we created a weighted mean of the multiple echoes, yielding a single volume with a high ratio of contrast to noise. We visualized the BF using T2-weighted FLAIR images. For each participant, we manually labeled the 2 structures and calculated their volumes.
Results: Relative to the controls, 13 patients with H&Y stage 1 PD had significantly decreased SNc volumes. Sixteen patients with H&Y stage 2 or 3 PD showed little additional volume loss. In contrast, the BF volume loss occurred later in the disease, with a significant decrease apparent in patients having H&Y stage 2 or 3 PD compared with the controls and the patients having H&Y stage 1 PD. The latter group did not differ significantly from the controls.
Conclusion: Our results support the proposed neuropathological trajectory in PD and establish novel multispectral methods as MR imaging biomarkers for tracking the degeneration of the SNc and BF. JAMA Neurol. 2013;70(2):241-247. Published online November 26, 2012. doi:10.1001/jamaneurol.2013.597-
C1 [Ziegler, David A.; Wonderlick, Julien S.; Ashourian, Paymon; Hansen, Leslie A.; Young, Jeremy C.; Murphy, Alex J.; Koppuzha, Cecily K.; Corkin, Suzanne] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Growdon, John H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Growdon, John H.] Massachusetts Gen Hosp, Morris Udall Ctr Excellence Parkinson Dis Res, Boston, MA 02114 USA.
RP Ziegler, DA (reprint author), MIT, Dept Brain & Cognit Sci, 43 Vassar St,Room 46-5121, Cambridge, MA 02139 USA.
EM daz@mit.edu
FU National Institutes of Health [AG021525, DA022759-03, GM0007484,,
K23-AG22509, T32 GM007484, T32 MH082718, T90 DA022759]; Health Sciences
and Technology Martinos Catalyst Fund
FX This research was supported by grants AG021525, DA022759-03, GM0007484,
K23-AG22509, T32 GM007484, T32 MH082718, and T90 DA022759 from the
National Institutes of Health and by the Health Sciences and Technology
Martinos Catalyst Fund. The Athinoula A. Martinos Imaging Center at
Massachusetts Institute of Technology's McGovern Institute for Brain
Research is supported in part by a generous gift from Pat and Lore
McGovern.
NR 46
TC 20
Z9 21
U1 1
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6149
J9 JAMA NEUROL
JI JAMA Neurol.
PD FEB
PY 2013
VL 70
IS 2
BP 241
EP 247
DI 10.1001/jamaneurol.2013.597
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 115GT
UT WOS:000316801300013
PM 23183921
ER
PT J
AU Gabrielian, A
MacCumber, MM
Kukuyev, A
Mitsuyasu, R
Holland, GN
Sarraf, D
AF Gabrielian, Anna
MacCumber, Mathew M.
Kukuyev, Alla
Mitsuyasu, Ronald
Holland, Gary N.
Sarraf, David
TI Didanosine-Associated Retinal Toxicity in Adults Infected With Human
Immunodeficiency Virus
SO JAMA OPHTHALMOLOGY
LA English
DT Editorial Material
ID ZIDOVUDINE; THERAPY
C1 [Gabrielian, Anna; MacCumber, Mathew M.] Rush Univ, Med Ctr, Dept Ophthalmol, Chicago, IL 60612 USA.
[Kukuyev, Alla; Holland, Gary N.] Univ Calif Los Angeles, Jules Stein Eye Inst, Ocular Inflammatory Dis Ctr, Los Angeles, CA 90095 USA.
[Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA.
[Kukuyev, Alla; Holland, Gary N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
[Mitsuyasu, Ronald] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90095 USA.
[Sarraf, David] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
OI Kukuyev, Alla/0000-0003-3472-6523
NR 8
TC 3
Z9 3
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6165
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB
PY 2013
VL 131
IS 2
BP 255
EP 259
PG 6
WC Ophthalmology
SC Ophthalmology
GA 113RB
UT WOS:000316684400029
PM 23411900
ER
PT J
AU Berson, EL
Rosner, B
Sandberg, MA
Weigel-DiFranco, C
Willett, WC
AF Berson, Eliot L.
Rosner, Bernard
Sandberg, Michael A.
Weigel-DiFranco, Carol
Willett, Walter C.
TI omega-3 Intake in Patients With Retinitis Pigmentosa Receiving Vitamin A
reply
SO JAMA OPHTHALMOLOGY
LA English
DT Letter
ID DOCOSAHEXAENOIC ACID; CLINICAL-TRIAL
C1 [Berson, Eliot L.; Rosner, Bernard; Sandberg, Michael A.; Weigel-DiFranco, Carol] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA USA.
[Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
RP Berson, EL (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Berman Gund Lab Study Retinal Degenerat, 243 Charles St, Boston, MA 02114 USA.
EM linda_berard@meei.harvard.edu
NR 11
TC 0
Z9 0
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6165
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB
PY 2013
VL 131
IS 2
BP 268
EP 268
PG 1
WC Ophthalmology
SC Ophthalmology
GA 113RB
UT WOS:000316684400035
ER
PT J
AU Thompson, CF
Nabili, V
Wang, MB
AF Thompson, Christopher F.
Nabili, Vishad
Wang, Marilene B.
TI Pathology Quiz Case 2 Diagnosis
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Editorial Material
ID SOLITARY EXTRAMEDULLARY PLASMACYTOMA; NECK REGION; HEAD
C1 [Thompson, Christopher F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Thompson, CF (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 9
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6181
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD FEB
PY 2013
VL 139
IS 2
BP 197
EP 198
DI 10.1001/jamaoto.2013.1280a
PG 2
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 114HS
UT WOS:000316732300016
PM 23429957
ER
PT J
AU Ginat, DT
Schatz, CJ
AF Ginat, Daniel T.
Schatz, Charles J.
TI Imaging of Silastic Cheek Implant Penetration Into the Maxillary Sinus
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
AB Importance: Silastic implants are popular for cosmetic cheek augmentation. We describe the computed tomographic (CT) and magnetic resonance imaging (MRI) findings in 5 cases (4 patients) with penetration of the medial aspect of Silastic cheek implants through the anterior maxillary sinus wall.
Observations: Three cases demonstrated associated sinus mucosal thickening, and 3 cases demonstrated infection surrounding the implant. In 3 cases, the implants migrated into the maxillary sinus, and in 1 case the implant also eroded through the nasoantral wall and extended into the nasal cavity.
Conclusions and Relevance: Maxillary sinus penetration is a potential complication of Silastic cheek implants. The extent of this complication can be characterized by CT and MRI. JAMA Otolaryngol Head Neck Surg. 2013; 139(2): 199-201
C1 [Ginat, Daniel T.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Ginat, Daniel T.] Harvard Univ, Sch Med, Boston, MA USA.
[Schatz, Charles J.] Beverly Tower Wilshire Adv Imaging, Beverly Hills, CA USA.
[Schatz, Charles J.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
RP Ginat, DT (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM ginatd01@gmail.com
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6181
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD FEB
PY 2013
VL 139
IS 2
BP 199
EP 201
DI 10.1001/jamaoto.2013.1618
PG 3
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 114HS
UT WOS:000316732300017
PM 23429959
ER
PT J
AU Wen, Y
Feng, J
Sachs, G
AF Wen, Yi
Feng, Jing
Sachs, George
TI Helicobacter pylori 5 ' ureB-sRNA, a cis-Encoded Antisense Small RNA,
Negatively Regulates ureAB Expression by Transcription Termination
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID 2-COMPONENT SYSTEM; ALLELIC EXCHANGE; ACID ADAPTATION; PEPTIC-ULCER; PH;
COLONIZATION; ATTENUATION; MECHANISMS; LEVEL; GENE
AB Urease is an essential component of gastric acid acclimation by Helicobacter pylori. The increased level of urease in gastric acidity is due, in part, to acid activation of the two-component system consisting of the membrane sensor HP0165 (ArsS) and its response regulator HP0166 (ArsR), which regulates transcription of the seven genes in two separate operons (ureAB and ureIEFGH) of the urease gene cluster. Recently, we identified a novel cis-encoded antisense small RNA, 5' ureB-sRNA, targeted at the 5' end of ureB, which downregulates ureAB expression by truncation of the ureAB transcript at neutral pH. It is not known whether the truncated transcript is due to transcription termination or processing of the full-length mRNA by codegradation of a ureAB mRNA-sRNA hybrid complex. S1 nuclease mapping assays show that the truncated transcript is due to transcription termination. Further studies using an in vitro transcription assay found that 5' ureB-sRNA promotes premature termination of transcription of ureAB mRNA. These results suggest that the antisense small RNA 5' ureB-sRNA downregulates ureAB expression by enhancing transcription termination 5' of ureB. With this mechanism, a limited amount of 5' ureB-sRNA is sufficient to regulate the relatively high level of ureAB transcript.
C1 [Wen, Yi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Membrane Biol Lab, Los Angeles, CA 90095 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Wen, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Membrane Biol Lab, Los Angeles, CA 90095 USA.
EM ywen@ucla.edu
FU U.S. Veterans Administration; NIH [DK46917, 53462, 58333]
FX This work was supported by U.S. Veterans Administration and NIH grants
DK46917, 53462, and 58333.
NR 44
TC 7
Z9 8
U1 1
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD FEB
PY 2013
VL 195
IS 3
BP 444
EP 452
DI 10.1128/JB.01022-12
PG 9
WC Microbiology
SC Microbiology
GA 117NS
UT WOS:000316960800006
PM 23104809
ER
PT J
AU Yen, YT
Cameron, TA
Bensing, BA
Seepersaud, R
Zambryski, PC
Sullam, PM
AF Yen, Yihfen T.
Cameron, Todd A.
Bensing, Barbara A.
Seepersaud, Ravin
Zambryski, Patricia C.
Sullam, Paul M.
TI Differential Localization of the Streptococcal Accessory Sec Components
and Implications for Substrate Export
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article
ID BINDING PROTEIN-GSPB; SURFACE GLYCOPROTEIN GSPB; RICH REPEAT
GLYCOPROTEIN; SIGNAL PEPTIDE; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI;
HUMAN PLATELETS; GORDONII; SYSTEM; BIOGENESIS
AB The accessory Sec system of Streptococcus gordonii is comprised of SecY2, SecA2, and five proteins (Asp1 through -5) that are required for the export of a serine-rich glycoprotein, GspB. We have previously shown that a number of the Asps interact with GspB, SecA2, or each other. To further define the roles of these Asps in export, we examined their subcellular localization in S. gordonii and in Escherichia coli expressing the streptococcal accessory Sec system. In particular, we assessed how the locations of these accessory Sec proteins were altered by the presence of other components. Using fluorescence microscopy, we found in E. coli that SecA2 localized within multiple foci at the cell membrane, regardless of whether other accessory Sec proteins were expressed. Asp2 alone localized to the cell poles but formed a similar punctate pattern at the membrane when SecA2 was present. Asp1 and Asp3 localized diffusely in the cytosol when expressed alone or with SecA2. However, these proteins redistributed to the membrane in a punctate arrangement when all of the accessory Sec components were present. Cell fractionation studies with S. gordonii further corroborated these microscopy results. Collectively, these findings indicate that Asp1 to -3 are not integral membrane proteins that form structural parts of the translocation channel. Instead, SecA2 serves as a docking site for Asp2, which in turn attracts a complex of Asp1 and Asp3 to the membrane. These protein interactions may be important for the trafficking of GspB to the cell membrane and its subsequent translocation.
C1 [Yen, Yihfen T.; Bensing, Barbara A.; Seepersaud, Ravin; Sullam, Paul M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Yen, Yihfen T.; Bensing, Barbara A.; Seepersaud, Ravin; Sullam, Paul M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Cameron, Todd A.; Zambryski, Patricia C.] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.
RP Sullam, PM (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
EM paul.sullam@ucsf.edu
OI Cameron, Todd/0000-0002-6608-6551
FU Department of Veterans Affairs; VA Merit Review program; Northern
California Institute for Research and Education; American Heart
Association [10POST3010018, 12POST11040013]; National Institutes of
Health [R01 AI41513, R01 AI057433]; National Science Foundation
[MCB-0343566]
FX This work was supported by the Department of Veterans Affairs, the VA
Merit Review program, the Northern California Institute for Research and
Education, grants 10POST3010018 and 12POST11040013 (to Y.T.Y.) from the
American Heart Association, grants R01 AI41513 and R01 AI057433 (to
P.M.S.) from the National Institutes of Health, and grant MCB-0343566
(to P.C.Z.) from the National Science Foundation.
NR 44
TC 6
Z9 6
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD FEB
PY 2013
VL 195
IS 4
BP 682
EP 695
DI 10.1128/JB.01742-12
PG 14
WC Microbiology
SC Microbiology
GA 117NW
UT WOS:000316961200006
PM 23204472
ER
PT J
AU Chen, LY
Reisner, AT
Chen, XX
Gribok, A
Reifman, J
AF Chen, Liangyou
Reisner, Andrew T.
Chen, Xiaoxiao
Gribok, Andrei
Reifman, Jaques
TI Are Standard Diagnostic Test Characteristics Sufficient for the
Assessment of Continual Patient Monitoring?
SO MEDICAL DECISION MAKING
LA English
DT Article
DE continual patient monitoring; decision-support algorithm; sequential
probability ratio test; physiological data
ID INTENSIVE-CARE-UNIT; TRAUMA PATIENTS; PREHOSPITAL HYPOTENSION;
EMERGENCY-DEPARTMENT; SCORING SYSTEMS; FALSE ALARMS; VITAL SIGN;
MORTALITY; EPIDEMIOLOGY; PROBABILITY
AB Background. For diagnostic processes involving continual measurements from a single patient, conventional test characteristics, such as sensitivity and specificity, do not consider decision consistency, which might be a distinct, clinically relevant test characteristic. Objective. The authors investigated the performance of a decision-support classifier for the diagnosis of traumatic injury with blood loss, implemented with three different data-processing methods. For each method, they computed standard diagnostic test characteristics and novel metrics related to decision consistency and latency. Setting. Prehospital air ambulance transport. Patients. A total of 557 trauma patients. Design. Continually monitored vital-sign data from 279 patients (50%) were randomly selected for classifier development, and the remaining were used for testing. Three data-processing methods were evaluated over 16 min of patient monitoring: a 2-min moving window, time averaging, and postprocessing with the sequential probability ratio test (SPRT). Measurements. Sensitivity and specificity were computed. Consistency was quantified through cumulative counts of decision changes over time and the fraction of patients affected by false alarms. Latency was evaluated by the fraction of patients without a decision. Results. All 3 methods showed very similar final sensitivities and specificities. Yet, there were significant differences in terms of the fraction of patients affected by false alarms, decision changes through time, and latency. For instance, use of the SPRT led to a 75% reduction in the number of decision changes and a 36% reduction in the number of patients affected by false alarms, at the expense of 3% unresolved final decisions. Conclusion. The proposed metrics of decision consistency and decision latency provided additional information beyond what could be obtained from test sensitivity and specificity and are likely to be clinically relevant in some applications involving temporal decision making.
C1 [Chen, Liangyou; Reisner, Andrew T.; Chen, Xiaoxiao; Gribok, Andrei; Reifman, Jaques] Telemed & Adv Technol Res Ctr TATRC, DoD Biotechnol HPC Software Applicat Inst BHSAI, Ft Detrick, MD USA.
[Reisner, Andrew T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
RP Reifman, J (reprint author), ATTN MCMR TT, TATRC, BHSAI, 504 Scott St, Ft Detrick, MD 21702 USA.
EM jaques.reifman@us.army.mil
FU Combat Casualty Care Research Area Directorate of the USAMRMC, Fort
Detrick, MD
FX Received 10 August 2011 from DoD Biotechnology HPC Software Applications
Institute (BHSAI), Telemedicine and Advanced Technology Research Center
(TATRC), Fort Detrick, MD (LC, ATR, XC, AG, JR), and Massachusetts
General Hospital Department of Emergency Medicine, Boston, MA (ATR).
This work was performed at BHSAI, TATRC, US Army Medical Research and
Materiel Command (USAMRMC), Fort Detrick, MD 21702. This work was
partially supported by the Combat Casualty Care Research Area
Directorate of the USAMRMC, Fort Detrick, MD. The funding agreement
ensured the authors' independence in designing the study, interpreting
the data, writing, and publishing the report. The following author is
employed by the sponsor: Jaques Reifman is a U.S. Department of the Army
Senior Research Scientist. The opinions and assertions contained herein
are the private views of the authors and are not to be construed as
official or as reflecting the views of the U.S. Army or of the U.S.
Department of Defense. This article has been approved for public release
with unlimited distribution. Revision accepted for publication 24 March
2012.
NR 36
TC 5
Z9 5
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0272-989X
J9 MED DECIS MAKING
JI Med. Decis. Mak.
PD FEB
PY 2013
VL 33
IS 2
BP 225
EP 234
DI 10.1177/0272989X12451059
PG 10
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 113QZ
UT WOS:000316684200010
PM 22753421
ER
PT J
AU Thurber, GM
Yang, KS
Reiner, T
Kohler, RH
Sorger, P
Mitchison, T
Weissleder, R
AF Thurber, Greg M.
Yang, Katy S.
Reiner, Thomas
Kohler, Rainer H.
Sorger, Peter
Mitchison, Tim
Weissleder, Ralph
TI Single-cell and subcellular pharmacokinetic imaging allows insight into
drug action in vivo
SO NATURE COMMUNICATIONS
LA English
DT Article
ID OPEN-LABEL; CANCER; INHIBITOR; KINASE; TUMORS; MOUSE; OLAPARIB; MODELS;
PARP; PENETRATION
AB Pharmacokinetic analysis at the organ level provides insight into how drugs distribute throughout the body, but cannot explain how drugs work at the cellular level. Here we demonstrate in vivo single-cell pharmacokinetic imaging of PARP-1 inhibitors and model drug behaviour under varying conditions. We visualize intracellular kinetics of the PARP-1 inhibitor distribution in real time, showing that PARP-1 inhibitors reach their cellular target compartment, the nucleus, within minutes in vivo both in cancer and normal cells in various cancer models. We also use these data to validate predictive finite element modelling. Our theoretical and experimental data indicate that tumour cells are exposed to sufficiently high PARP-1 inhibitor concentrations in vivo and suggest that drug inefficiency is likely related to proteomic heterogeneity or insensitivity of cancer cells to DNA-repair inhibition. This suggests that single-cell pharmacokinetic imaging and derived modelling improve our understanding of drug action at single-cell resolution in vivo.
C1 [Thurber, Greg M.; Yang, Katy S.; Reiner, Thomas; Kohler, Rainer H.; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Reiner, Thomas] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA.
[Sorger, Peter; Mitchison, Tim; Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA.
EM rweissleder@mgh.harvard.edu
OI Reiner, Thomas/0000-0002-7819-5480; Thurber, Greg/0000-0001-7570-2080
FU [1R01CA164448]; [PO1CA139980]; [P50CA086355]; [K01DK093766]; [T32
CA079443]
FX We thank Yoshiko Iwamoto for expert histopathological analysis, Dr
Claudio Vinegoni for intravital imaging, Dr Michael Birrer for cell
lines, Dr Gaudenz Danuser for many helpful discussions, Drs Mikael
Pittet, John Higgins, Yvonna Fisher-Jeffes, Filip Swirski and Matthias
Nahrendorf for critical review, and Edmund Keliher for help with NMR
analysis. The work was funded in parts by 1R01CA164448 (R. W., P. S., T.
M.), PO1CA139980 (T. M., P. S., R. W.) and P50CA086355 (R. W.). G. T.
was supported by K01DK093766. K.Y. was supported by T32 CA079443.
NR 52
TC 57
Z9 57
U1 5
U2 62
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB
PY 2013
VL 4
AR 1504
DI 10.1038/ncomms2506
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 112TL
UT WOS:000316616400074
PM 23422672
ER
PT J
AU Spindler, MA
Galifianakis, NB
Wilkinson, JR
Duda, JE
AF Spindler, Meredith A.
Galifianakis, Nicholas B.
Wilkinson, Jayne R.
Duda, John E.
TI Globus pallidus interna deep brain stimulation for tardive dyskinesia:
Case report and review of the literature
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Review
DE Tardive dyskinesia; Tardive dystonia; Deep brain stimulation; Pallidal
stimulation; Globus pallidus
ID SECONDARY DYSTONIA; PARKINSONS-DISEASE; PATHOPHYSIOLOGY; MECHANISMS;
NEURONS; HYPOTHESIS; OUTCOMES; PATIENT; MOOD
AB Tardive dyskinesia (TD) can be a disabling condition and is frequently refractory to medical therapy. Over the past decade there have been many reports of TD patients experiencing significant benefit with deep brain stimulation (DBS) of the globus pallidus interna (GPi). The growing literature on this treatment option for TD consists predominantly of case reports and series. The reported benefit ranges widely, but the majority of cases experienced at least a 50% improvement in symptoms. The anatomical distribution of dyskinesias has not clearly influenced outcome, though fixed postures appear less likely to improve than phasic movements. Onset of benefit can be immediate or take months, and benefit is sustained in most cases, for at least 6 months and up to several years. A wide variety of voltages, frequencies, and pulse widths have demonstrated efficacy. A small number of reports which examined psychiatric symptoms before and after surgery did not find any decline, and in some cases revealed improvement in mood. However, these overall positive results should be interpreted with caution, as the majority of reports lacked blinded assessments, control groups, or standardized therapy parameters. Finally, we present an illustrative case of refractory tardive dyskinesia treated with GPi-DBS with 5 years of follow-up and 4 accompanying video segments. Published by Elsevier Ltd.
C1 [Spindler, Meredith A.; Wilkinson, Jayne R.; Duda, John E.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA 19104 USA.
[Spindler, Meredith A.; Wilkinson, Jayne R.; Duda, John E.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Galifianakis, Nicholas B.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA.
RP Duda, JE (reprint author), Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM John.duda@va.gov
NR 45
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD FEB
PY 2013
VL 19
IS 2
BP 141
EP 147
DI 10.1016/j.parkreldis.2012.09.016
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 115RG
UT WOS:000316829000001
PM 23099106
ER
PT J
AU Barry, W
St Andre, JR
Evans, CT
Sabharwal, S
Miskevics, S
Weaver, FM
Smith, BM
AF Barry, W.
St Andre, J. R.
Evans, C. T.
Sabharwal, S.
Miskevics, S.
Weaver, F. M.
Smith, B. M.
TI Hypertension and antihypertensive treatment in veterans with spinal cord
injury and disorders
SO SPINAL CORD
LA English
DT Article
DE spinal cord injury; hypertension; blood pressure; antihypertensive;
cardiovascular disease; veterans
ID CARDIOVASCULAR-DISEASE RISK; CORONARY-HEART-DISEASE; HIGH
BLOOD-PRESSURE; PREVALENCE; PREVENTION; MORTALITY; IMPACT
AB Hypertension (HTN) is an important risk factor for cardiovascular disease, a major cause of morbidity and mortality among people with spinal cord injury and disorders (SCI/D). Our study examined prevalence, associated factors, and pharmacological treatment of HTN in Veterans with SCI/D compared with a matched control group.
Methods: A retrospective review was conducted of Veterans with traumatic SCI/D (TSCI/D; n=6672), non-traumatic SCI/D (NTSCI/D; n=3566) and a matched, non-injured cohort.
Results: Over half of patients with TSCI/D (56.6%) had HTN, compared with 68.4% of matched controls (P<0.001). Paraplegic and tetraplegic Veterans with TSCI/D had significantly lower odds of having a HTN diagnosis compared with control (odds ratios (OR) 0.84 (0.77-0.91); OR=0.38 (0.35-0.42)). About 71.8% of patients with NTSCI/D had HTN compared with 72.3% of matched controls (P>0.05). Paraplegic and tetraplegic Veterans with NTSCI/D did not have significantly different odds of a HTN diagnosis compared with control (OR 0.92 (0.79-1.05); OR 0.85 (0.71-1.01)). Adjusted analysis indicates that Veterans with tetraplegia and HTN were less likely to receive antihypertensive therapy (TSCI/D, OR 0.62 (0.53-0.71); NTSCI/D, OR 0.81 (0.66-0.99)).
Conclusion: HTN appears to be more prevalent in SCI/D Veterans than previously reported. TSCI/D Veterans have a significantly lower prevalence of HTN whereas NTSCI/D Veterans have a comparable prevalence of HTN to those without SCI/D. The level of injury (tetraplegia vs paraplegia) has a large impact on the prevalence of HTN in the traumatic cohort. Subsequent antihypertensive therapy is used less in both TSCI/D and NTSCI/D Veterans with tetraplegia and more in TSCI/D Veterans with paraplegia. Spinal Cord (2013) 51, 109-115; doi:10.1038/sc.2012.122; published online 13 November 2012
C1 [Barry, W.; Evans, C. T.; Miskevics, S.; Weaver, F. M.; Smith, B. M.] Edward Hines Jr VA Hosp, Dept Vet Affairs VA, Ctr Management Complex Chron Care CMC3, Spinal Cord Injury Qual Enhancement Res Initiat S, Hines, IL USA.
[Barry, W.; Weaver, F. M.; Smith, B. M.] Loyola Univ Chicago, Med Ctr, Stritch Sch Med, Loyola Univ, Maywood, IL 60153 USA.
[St Andre, J. R.] Hlth Res & Educ Trust, Chicago, IL USA.
[Evans, C. T.] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA.
[Sabharwal, S.] VA Boston Healthcare Syst, Dept Vet Affairs, Boston, MA USA.
[Sabharwal, S.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
RP Barry, W (reprint author), Loyola Univ Chicago, Med Ctr, Stritch Sch Med, Loyola Univ, 2160 South 1st Ave,SSOM DePorres 315, Maywood, IL 60153 USA.
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, the Department of Veterans Affairs Spinal
Cord Injury Quality Enhancement Research Initiative (SCI QUERI); PVA
Research Foundation [2618]
FX This material is based upon work supported in part by the Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development, the Department of Veterans Affairs Spinal Cord Injury
Quality Enhancement Research Initiative (SCI QUERI) and by grant # 2618
from the PVA Research Foundation. The views expressed in this article
are those of the authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs or the United States
government.
NR 20
TC 4
Z9 4
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD FEB
PY 2013
VL 51
IS 2
BP 109
EP 115
DI 10.1038/sc.2012.122
PG 7
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 114DG
UT WOS:000316720500006
PM 23147130
ER
PT J
AU Liu, G
Chen, YH
Kolesar, J
Huang, W
DiPaola, R
Pins, M
Carducci, M
Stein, M
Bubley, GJ
Wilding, G
AF Liu, Glenn
Chen, Yu-Hui
Kolesar, Jill
Huang, Wei
DiPaola, Robert
Pins, Michael
Carducci, Michael
Stein, Mark
Bubley, Glenn J.
Wilding, George
TI Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men
with biochemically relapsed, androgen dependent prostate cancer
SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE Epidermal growth factor receptor; Tyrosine kinase inhibitors; Clinical
trial
ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; RADICAL
PROSTATECTOMY; CLINICAL-TRIALS; BREAST-CANCER; WORKING GROUP;
ACTIVATION; GEFITINIB; RECOMMENDATIONS; TRASTUZUMAB
AB Purpose: Activation of the epidermal growth factor pathway is important in prostate cancer development and the transcription of androgen receptor regulated genes. This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage DO) prostate cancer.
Patients and methods: Patients with a rising PSA after primary therapy for prostate cancer were enrolled. A PSA doubling time (PSADT) <12 months was required. Lapatinib was administered at 1,500 mg orally daily. Outcome measures were changes in PSA kinetics. Primary tumor blocks were obtained and assessed for EGFR expression, EGFR Q787Q polymorphism, and Kras 38 mutational status.
Results: Forty-nine patients were enrolled (14 ineligible), resulting in 35 patients for analysis. No PSA response was observed; best response was stable disease (n = 28, 80.0%). Pretreatment average slope was 0.19 log (PSA)/month (PSADT = 3.70 months), in contrast to on-treatment average slope of 0.13 log (PSA)/month (PSADT = 5.44 months) using linear mixed effects models (P = 0.006). Median progression-free survival (PFS) was 17.4 months for the high EGFR group and 6.0 months for the low EGER group (P = 0.50). Patients with Kras 38 mutation had shorter PFS than those without Kras 38 mutation (P = 0.09).
Conclusion: Although no PSA responses (primary endpoint) was observed, lapatinib may have biologic activity in men with stage DO prostate cancer as evidenced by a decrease in PSA slope in this non-randomized study. Additional trials assessing the role of EGFR overexpression and Kras wild type status in prostate cancer should be investigated. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Liu, Glenn; Kolesar, Jill; Huang, Wei; Wilding, George] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA.
[Chen, Yu-Hui] Dana Farber Canc Inst, Boston, MA 02115 USA.
[DiPaola, Robert; Stein, Mark] Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
[Pins, Michael] Univ Illinois, Coll Med, Chicago, IL 60612 USA.
[Carducci, Michael] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD 21231 USA.
[Bubley, Glenn J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Liu, G (reprint author), Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA.
EM gxl@medicine.wisc.edu
FU Frontier Science and Technology Research [UWMO33JK-00]; Public Health
Service [CA23318, CA66636, CA21115, CA21076, CA107868, CA16116,
CA80775]; National Cancer Institute, National Institutes of Health;
Department of Health and Human Services
FX Research Support: UWMO33JK-00, Frontier Science and Technology Research.
This study was conducted by the Eastern Cooperative Oncology Group
(Robert L. Comis, M.D., Chair) and supported in part by Public Health
Service grants CA23318, CA66636, CA21115, CA21076, CA107868, CA16116,
CA80775, and from the National Cancer Institute, National Institutes of
Health and the Department of Health and Human Services. Its contents are
solely the responsibility of the authors and do not necessarily
represent the official views of the National Cancer Institute.
NR 38
TC 7
Z9 7
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1078-1439
EI 1873-2496
J9 UROL ONCOL-SEMIN ORI
JI Urol. Oncol.-Semin. Orig. Investig.
PD FEB
PY 2013
VL 31
IS 2
BP 211
EP 218
DI 10.1016/j.urolonc.2011.01.002
PG 8
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 114XY
UT WOS:000316777500013
PM 21784672
ER
PT J
AU Levitt, JM
Jian, WG
Lerner, SP
Sonpavde, G
AF Levitt, Jonathan M.
Jian, Weiguo
Lerner, Seth P.
Sonpavde, Guru
TI A conventional preclinical schedule of cisplatin is more effective than
a metronomic frequent bolus schedule for urothelial carcinoma
SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE Cisplatin; Transitional cell carcinoma; Standard; Metronomic
ID TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; GEMCITABINE PLUS CISPLATIN;
COOPERATIVE-ONCOLOGY-GROUP; METASTATIC BLADDER-CANCER; 5-DAY
CONTINUOUS-INFUSION; LONG-TERM-SURVIVAL; RANDOMIZED-TRIAL;
BREAST-CANCER; CHEMOTHERAPY
AB Objectives: Given the frequent inability to administer a conventional 3-weekly schedule of cisplatin to human subjects with urothelial carcinoma, we evaluated a frequent bolus metronomic schedule in a preclinical system of transitional cell carcinoma (TCC) of the urothelium. We hypothesized that the anti-angiogenic and anti-cell-migratory activity of lower concentrations of cisplatin may confer similar anti-tumor activity and demonstrate less nephrotoxicity than conventional cytotoxic concentrations.
Materials and methods: We evaluated the activity of cisplatin in vitro against human urothelial carcinoma (5637) and endothelial cells (human umbilical vein endothelial cells, HUVECs). The MIT assay was employed to assess viability, and flow cytometry with Annexin-FITC labeling was employed to assess apoptosis. Cell migration in monolayer culture was assessed by scratch assay. Murine xenografts (n = 12 per group) bearing measurable subcutaneous tumors of 5637 cells were administered either no therapy, cisplatin 2 mg/kg/3 days a week (metronomic) or 6 mg/kg/ once a week (standard) intraperitoneal (i.p.) for 4 weeks. Blood was collected from 5 mice per group at baseline and at the end of therapy to measure changes in serum creatinine.
Results: Significant antiproliferative activity, but poor pro-apoptotic activity, was observed against 5637 urothelial carcinoma cells in vitro by MIT assay with cisplatin at concentrations lower than those attainable in vivo. Anti-proliferative activity against HUVECs required higher concentrations than attainable in vivo. Anti-migratory activity was observed against 5637 and HUVECs at earlier time points and with concentrations lower than anti-proliferative concentrations. In murine 5637 xenografts, standard cisplatin was significantly better at inhibiting tumor growth than the no treatment control (P = 0.005), while metronomic therapy was not better than control (P = 0.22). Standard cisplatin was also significantly nephrotoxic (P = 0.016), while metronomic cisplatin (P = 0.374) or no therapy (P = 0.178) did not demonstrate significant nephrotoxicity compared with baseline.
Conclusions: Cisplatin exhibited anti-cell-migratory activity against urothelial carcinoma and endothelial cells at lower than cytotoxic concentrations. However, a standard preclinical schedule was better than control in vivo for inhibiting tumor growth, while a metronomic schedule was not better. Despite the lower nephrotoxicity of the metronomic schedule, its lower anti-tumor activity suggests that a standard clinical schedule of cisplatin should not be routinely substituted by a split schedule without definitive clinical data. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Levitt, Jonathan M.; Jian, Weiguo; Lerner, Seth P.; Sonpavde, Guru] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
[Levitt, Jonathan M.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA.
[Sonpavde, Guru] Texas Oncol Canc Ctr, Webster, TX 77598 USA.
[Sonpavde, Guru] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Med Oncol, Dept Med, Houston, TX 77030 USA.
RP Sonpavde, G (reprint author), Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
EM gurus@bcm.edu
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1078-1439
J9 UROL ONCOL-SEMIN ORI
JI Urol. Oncol.-Semin. Orig. Investig.
PD FEB
PY 2013
VL 31
IS 2
BP 234
EP 240
DI 10.1016/j.urolonc.2010.11.004
PG 7
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 114XY
UT WOS:000316777500016
PM 21723160
ER
PT J
AU Sonnenberg, A
Boardman, CR
AF Sonnenberg, Amnon
Boardman, Charles R.
TI Costs of Fear
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Editorial Material
ID AMERICAN-SURGEONS; PRACTICE PATTERNS
C1 [Sonnenberg, Amnon; Boardman, Charles R.] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon; Boardman, Charles R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 13
TC 2
Z9 2
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD FEB
PY 2013
VL 108
IS 2
BP 173
EP 175
DI 10.1038/ajg.2012.192
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 112NZ
UT WOS:000316600300003
PM 23381065
ER
PT J
AU Sonnenberg, A
Genta, RM
AF Sonnenberg, Amnon
Genta, Robert M.
TI Helicobacter pylori is a Risk Factor for Colonic Neoplasms
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID COLORECTAL-CANCER RISK; INTESTINAL METAPLASIA; GASTROINTESTINAL-TRACT;
GASTRITIS; INFECTION; DISEASE; IMMUNOHISTOCHEMISTRY; CLASSIFICATION;
METAANALYSIS; PATHOLOGY
AB OBJECTIVES: It has been suggested that Helicobacter pylori (H. pylori) constitutes a risk for the development of adenomatous polyps and adenocarcinoma of the colon. Our aim was to study the association between H. pylori-positive gastritis and the occurrence of any colonic neoplasm.
METHODS: From a computerized database of surgical pathology reports, we selected 156,000 subjects who underwent colonoscopy and esophago-gastro-duodenoscopy with biopsy results from both procedures.
RESULTS: Compared with normal gastric mucosa, H. pylori gastritis occurred more frequently among patients with hyperplastic polyps (OR = 1.24, 95 % CI: 1.18-1.30), adenomatous polyps (1.52, 1.46-1.57), advanced adenomas (1.80, 1.69-1.92), villous adenomas or adenomas with high-grade dysplasia (1.97, 1.82-2.14), and adenocarcinomas (2.35, 1.98-2.80). Similarly, the strength of the association between H. pylori-positive gastritis and colonic neoplasm increased with size and number of the adenomas. The association between H. pylori gastritis and the occurrence of colonic neoplasm was similar for different locations of the large bowel. Other gastric conditions etiologically associated with H. pylori, such as intestinal metaplasia, adenoma, lymphoma, and adenocarcinoma, were also significantly associated with an increased risk of colonic neoplasm.
CONCLUSIONS: Various forms of gastritis related to H. pylori infection confer an increased risk for colonic neoplasm. In the past, when H. pylori infection was more prevalent, its attributable risk to the occurrence of colorectal neoplasm may have been quite substantial. Am J Gastroenterol 2013; 108: 208-215; doi: 10.1038/ajg.2012.407; published online 4 December 2012
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Genta, Robert M.] Miraca Life Sci, Irving, TX USA.
[Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Genta, Robert M.] Dallas VA Med Ctr, Dallas, TX USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
FU Takeda Pharmaceuticals
FX Amnon Sonnenberg is supported by a grant from Takeda Pharmaceuticals.
Robert M. Genta is employed by Miraca Life Sciences, Irving, TX.
NR 32
TC 52
Z9 57
U1 2
U2 14
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD FEB
PY 2013
VL 108
IS 2
BP 208
EP 215
DI 10.1038/ajg.2012.407
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 112NZ
UT WOS:000316600300009
PM 23208272
ER
PT J
AU Markman, B
Tao, JJ
Scaltriti, M
AF Markman, Ben
Tao, Jessica J.
Scaltriti, Maurizio
TI PI3K Pathway Inhibitors: Better Not Left Alone
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE PI3K; PIK3CA; PTEN; mTOR; Akt; PI3K inhibitor; therapeutic combination;
clinical trial
ID VIVO ANTITUMOR-ACTIVITY; POSITIVE BREAST-CANCER; ADVANCED SOLID TUMORS;
PHOSPHOINOSITIDE 3-KINASE PATHWAY; RENAL-CELL CARCINOMA;
PHOSPHATIDYLINOSITOL 3-KINASE; ESTROGEN DEPRIVATION; KINASE INHIBITOR;
PHASE-I; TRASTUZUMAB RESISTANCE
AB The PI3K/Akt/mTOR signaling pathway plays a key role in diverse physiologic processes. It is also central to many aspects of the malignant process. Genetic phenomena that lead to constitutive pathway activation are common in human cancer; the most relevant are mutations affecting the catalytic subunit of PI3K and loss of function of the PTEN tumor suppressor. These factors have made this important cascade attractive as a potential target for cancer therapeutics. A host of inhibitors are now in various stages of development that target key nodes within the PI3K pathway. To date, however, the efficacy of these agents has fallen short of expectation, with at least one possible explanation being the presence of feedback loops and cross-talk that exists within and between PI3K and other signaling pathways. Accordingly, enthusiasm is again high as strategies employing therapeutic combinations are gaining pace, with encouraging results documented in both preclinical studies and emerging clinical trials. Here, we review the agents that have reached evaluation in early phase clinical studies of human subjects with cancer, and discuss the rationale for and use of novel drug combinations.
C1 [Markman, Ben] So Hlth, Monash Med Ctr, Melbourne, Vic 3165, Australia.
[Markman, Ben] Monash Univ, Monash Inst Med Res, Melbourne, Vic 3168, Australia.
[Tao, Jessica J.; Scaltriti, Maurizio] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.
[Tao, Jessica J.; Scaltriti, Maurizio] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Scaltriti, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, CNY 149,13th St, Charlestown, MA 02129 USA.
EM mscaltriti@partners.org
NR 114
TC 20
Z9 21
U1 1
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD FEB
PY 2013
VL 19
IS 5
BP 895
EP 906
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 110NE
UT WOS:000316449900008
PM 22973958
ER
PT J
AU Drakaki, A
Hatziapostolou, M
Iliopoulos, D
AF Drakaki, Alexandra
Hatziapostolou, Maria
Iliopoulos, Dimitrios
TI Therapeutically Targeting MicroRNAs in Liver Cancer
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Liver cancer; microRNAs; networks; delivery technologies
ID HUMAN HEPATOCELLULAR-CARCINOMA; HEPATITIS-B-VIRUS; GROWTH-FACTOR-BETA;
TUMOR-SUPPRESSOR GENE; HUMAN HEPATOMA-CELLS; DOWN-REGULATION; C-MYC;
PROGNOSTIC-SIGNIFICANCE; REGULATES EXPRESSION; UNITED-STATES
AB MicroRNAs are small non-coding RNAs that negatively regulate gene expression through binding on the 3' untranslated region (UTR) of genes. Although microRNAs constitute a small fraction of the human genome, multiple studies have indicated their involvement in the pathogenesis of different types of cancer. Hepatocellular carcinoma (liver) is one of the most aggressive types of cancer with very few therapeutic options. Several studies have revealed that microRNAs are deregulated during liver cancer development and affect central oncogenic and anti-apoptotic liver cancer signaling pathways. Furthermore, the expression levels of specific microRNAs have been identified to be correlated with clinicopathological parameters and treatment responses in liver cancer patients. Here, we review how different epidemiological and liver cancer risk factors, such as the hepatitis B and C viruses, deregulate microRNA-gene circuits in the liver, contributing to liver cancer development. Furthermore, we describe how the most frequently deregulated microRNAs identified in liver cancer patients control their down-stream signaling pathways in liver cancer cells. In addition, we provide examples of microRNAs or microRNA inhibitors that have been used as liver cancer therapeutics and describe novel delivery technologies that could be potentially used in order to optimize the delivery of microRNAs in the liver without having any toxicity or side effects in other major organs. Taken together, there is ample evidence suggesting the deregulation of microRNA-gene circuits in liver, promising that the development of microRNA-based therapeutics could be a clinically viable approach for liver cancer patients.
C1 [Drakaki, Alexandra] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Dept Med, Boston, MA 02215 USA.
[Hatziapostolou, Maria; Iliopoulos, Dimitrios] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
[Hatziapostolou, Maria; Iliopoulos, Dimitrios] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Syst Biomed, Los Angeles, CA 90095 USA.
RP Iliopoulos, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, 650 Charles E Young Dr South,CHS 33-315, Los Angeles, CA 90095 USA.
EM diliopoulos@mednet.ucla.edu
RI Hatziapostolou, Maria/N-1820-2015
OI Hatziapostolou, Maria/0000-0003-2493-7028
NR 139
TC 14
Z9 14
U1 1
U2 18
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD FEB
PY 2013
VL 19
IS 7
BP 1180
EP 1191
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 110NV
UT WOS:000316451800002
PM 23092338
ER
PT J
AU Desai, A
Zator, ZA
de Silva, P
Nguyen, DD
Korzenik, J
Yajnik, V
Ananthakrishnan, AN
AF Desai, Amit
Zator, Zachary A.
de Silva, Punyanganie
Nguyen, Deanna D.
Korzenik, Joshua
Yajnik, Vijay
Ananthakrishnan, Ashwin N.
TI Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF
Therapy in Patients with Inflammatory Bowel Disease
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE Crohn's disease; ulcerative colitis; age; anti-TNF; infections
ID CROHNS-DISEASE; CERTOLIZUMAB PEGOL; MAINTENANCE; INFLIXIMAB; TRIAL;
ADALIMUMAB; RISK; IMMUNOMODULATORS; INFECTIONS; REMISSION
AB Background: In increasingly aging populations, awareness of outcomes of older patients treated with biologics is becoming more important. However, few studies to date have investigated the safety and durability of anti-tumor necrosis factor (TNF) therapy in this subgroup.
Methods: This was a retrospective single-center study with cases comprising all IBD patients who began anti-TNF treatment at age >60 years. Cases of Crohn's disease (CD) and ulcerative colitis (UC) were identified from medical record review. Our controls consisted of patients younger than age 60 years on anti-TNF treatment and patients >60 years on treatment with immunomodulators. Kaplan-Meier survival estimates were used to calculate the probability of remaining on anti-TNF therapy.
Results: We identified a total of 54 IBD patients who initiated anti-TNF therapy over the age of 60 years (mean 73, range 61-97 years). Among these, a total of 38 patients (70%) discontinued anti-TNF therapy after a mean of 24.1 months. At 12 months after initiation, 75% of patients older than age 60 years were still on anti-TNF agents compared to 93% among younger users and 82% among older AZA users (P<0.05). Compared to older AZA users, older anti-TNF users remained more likely to require early therapy cessation (hazard ratio 2.21, 95% confidence interval 1.29-3.78).
Conclusions: The IBD population older than age 60 at the time of initiation of anti-TNF therapy is at higher risk for discontinuation of therapy. They may also be particularly vulnerable to infectious complications requiring hospitalization, suggesting the need for careful monitoring during therapy. (Inflamm Bowel Dis 2013; 19: 309-315)
C1 [Desai, Amit; Zator, Zachary A.; de Silva, Punyanganie; Nguyen, Deanna D.; Korzenik, Joshua; Yajnik, Vijay; Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[de Silva, Punyanganie; Nguyen, Deanna D.; Korzenik, Joshua; Yajnik, Vijay; Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Gastrointestinal Unit, Crohns & Colitis Ctr, Boston, MA 02114 USA.
RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Crohns & Colitis Ctr, 165 Cambridge St,9th Fl, Boston, MA 02114 USA.
EM aananthakrishnan@partners.org
FU Procter and Gamble; Warner Chilcott
FX Potential conflict of interest: Joshua Korzenik has been a consultant
for Procter and Gamble, Shire Pharmaceuticals, CytokinePharma, and
receives research support from Procter and Gamble and Warner Chilcott.
The other authors declare no conflicts of interest. Author
contributions: Amit Desai - study design, data collection, analysis and
interpretation of data, drafting of the article, critical revision of
the article for important intellectual content; Zachary Zator - study
design, data collection, analysis and interpretation of data, drafting
of the article, critical revision of the article for important
intellectual content; P. de Silva-data collection, analysis and
interpretation of data, critical revision of the article for important
intellectual content. D. Nguyen - data, collection, critical revision of
the article for important intellectual content; V. Yajnik - data,
collection, critical revision of the article for important intellectual
content; J. Korzenik - data, collection, critical revision of the
article for important intellectual content; A. Ananthakrishnan - study
design, data collection, analysis and interpretation of data, drafting
of the article, critical revision of the article for important
intellectual content.
NR 28
TC 24
Z9 26
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD FEB
PY 2013
VL 19
IS 2
BP 309
EP 315
DI 10.1002/ibd.23026
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 110MM
UT WOS:000316447300027
PM 22605668
ER
PT J
AU Lye-Barthel, M
Sun, D
Jakobs, TC
AF Lye-Barthel, Ming
Sun, Daniel
Jakobs, Tatjana C.
TI Morphology of Astrocytes in a Glaucomatous Optic Nerve
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ELEVATED INTRAOCULAR-PRESSURE; RETROGRADE AXOPLASMIC-TRANSPORT; RETINAL
GANGLION-CELLS; DBA/2J MICE; AXONAL-TRANSPORT; HEAD; TISSUE; DAMAGE;
MOUSE; DEGENERATION
AB PURPOSE. To establish the morphologic changes of astrocytes in the glial lamina of glaucomatous mice.
METHODS. A strain of mice that expresses GFP in individual astrocytes (hGFAPpr-GFP) was crossed into the DBA/2J strain that develops glaucoma. In the resulting strain (D2.hGFAPpr-GFP) we assessed the severity of glaucoma by staining the retina for neurofilaments and counting the neurons of the retinal ganglion cell layer. We observed the morphology of astrocytes in the glial lamina of the optic nerves.
RESULTS. D2.hGFAPpr-GFP mice developed glaucoma in an age-dependent manner. Astrocytes in the glial lamina showed morphologic changes that correlated with the severity of glaucoma. The cells showed thickening of processes from 1.3 +/- 0.28 mu m in nondiseased animals to 1.71 +/- 0.46 mu m in eyes with moderate glaucoma and 2.1 +/- 0.42 mu m in those with severe glaucoma. Their spatial coverage, as determined by their convex polygon area, was reduced in eyes with severe glaucoma. The astrocytes in severely glaucomatous optic nerves also showed simplification of their processes. In 6-month-old mice with no obvious signs of degeneration in the retina, we found astrocytes with appendages growing out of primary astrocyte processes into the axon bundles. This localized hypertrophy of processes was never observed in the hGFAPpr-GFP strain.
CONCLUSIONS. Confirming results after optic nerve crush, astrocytes in glaucomatous optic nerves had thickened and simplified processes, and reduced spatial coverage. We also found evidence of localized sprouting of new processes in early stages of the disease, before detectable changes in ganglion cell number. (Invest Ophthalmol Vis Sci. 2013; 54:909-917) DOI: 10.1167/iovs.12-10109
C1 [Lye-Barthel, Ming; Sun, Daniel; Jakobs, Tatjana C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Jakobs, TC (reprint author), Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM Tatjana_Jakobs@meei.harvard.edu
OI Jakobs, Tatjana/0000-0002-8104-9206
FU NIH Grant [EY019703]; Glaucoma Foundation; American Health Assistance
Foundation; Research to Prevent Blindness; Massachusetts Lions Eye
Research Fund; [EY14104]
FX Supported by NIH Grant EY019703 and by grants from the Glaucoma
Foundation and the American Health Assistance Foundation, by the Core
Grant EY14104 (to Massachusetts Eye and Ear Infirmary), and by grants
from Research to Prevent Blindness and the Massachusetts Lions Eye
Research Fund.
NR 33
TC 35
Z9 35
U1 2
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2013
VL 54
IS 2
BP 909
EP 917
DI 10.1167/iovs.12-10109
PG 9
WC Ophthalmology
SC Ophthalmology
GA 100BS
UT WOS:000315670300001
PM 23322566
ER
PT J
AU Darabad, RR
Suzuki, T
Richards, SM
Jensen, RV
Jakobiec, FA
Zakka, FR
Liu, SH
Sullivan, DA
AF Darabad, Raheleh Rahimi
Suzuki, Tomo
Richards, Stephen M.
Jensen, Roderick V.
Jakobiec, Frederick A.
Zakka, Fouad R.
Liu, Shaohui
Sullivan, David A.
TI Influence of Aromatase Absence on the Gene Expression and Histology of
the Mouse Meibomian Gland
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID DRY EYE SYNDROME; SEBACEOUS GLAND; SJOGRENS-SYNDROME; KNOCKOUT MOUSE;
LIPID PROFILES; SEX STEROIDS; MICROARRAY PLATFORMS; ESTROGEN
REPLACEMENT; ANDROGEN DEFICIENCY; GENDER-DIFFERENCES
AB PURPOSE. We hypothesize that aromatase, an enzyme that controls estrogen biosynthesis, plays a major role in the sex-related differences of the meibomian gland. To begin to test this hypothesis, we examined the influence of aromatase absence, which completely eliminates estrogen production, on glandular gene expression and histology in male and female mice.
METHODS. Meibomian glands were obtained from adult, age-matched wild-type (WT) and aromatase knockout (ArKO) mice. Tissues were processed for histology or the isolation of total RNA, which was analyzed for differentially expressed mRNAs by using microarrays.
RESULTS. Our results show that aromatase significantly influences the expression of more than a thousand genes in the meibomian gland. The nature of this effect is primarily sex-dependent. In addition, the influence of aromatase on sex-related differences in gene expression is predominantly genotype-specific. However, many of the sex-related variations in biological process, molecular function, and cellular component ontologies, as well as in KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways, are remarkably similar between WT and ArKO mice. The loss of aromatase activity has no obvious effect on the histology of meibomian glands in male or female mice.
CONCLUSIONS. Our findings demonstrate that aromatase has a significant impact on gene expression in the meibomian gland. The nature of this influence is sex-dependent and genotype-specific; however, many of the sex-related variations in gene ontologies and KEGG pathways are similar between WT and ArKO mice. Consequently, it appears that aromatase, and by extension estrogen, do not play a major role in the sex-related differences of the mouse meibomian gland. (Invest Ophthalmol Vis Sci. 2013;54:987-998) DOI:10.1167/iovs.12-10992
C1 [Darabad, Raheleh Rahimi; Suzuki, Tomo; Richards, Stephen M.; Liu, Shaohui; Sullivan, David A.] Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA.
[Darabad, Raheleh Rahimi; Suzuki, Tomo; Richards, Stephen M.; Jakobiec, Frederick A.; Zakka, Fouad R.; Liu, Shaohui; Sullivan, David A.] Harvard Univ, Sch Med, Boston, MA USA.
[Jensen, Roderick V.] Virginia Tech, Dept Biol Sci, Blacksburg, VA USA.
[Jakobiec, Frederick A.; Zakka, Fouad R.; Sullivan, David A.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Sullivan, DA (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM david.sullivan@schepens.harvard.edu
FU National Institutes of Health [R01EY05612]; Margaret S. Sinon Scholar in
Ocular Surface Research fund; Allergan, Japan; Bausch Lomb; Japan Eye
Bank Association
FX Supported by National Institutes of Health Grant R01EY05612, the
Margaret S. Sinon Scholar in Ocular Surface Research fund, and
postdoctoral fellowship awards from Allergan, Japan, Bausch & Lomb, and
the Japan Eye Bank Association.
NR 69
TC 6
Z9 6
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2013
VL 54
IS 2
BP 987
EP 998
DI 10.1167/iovs.12-10992
PG 12
WC Ophthalmology
SC Ophthalmology
GA 100BS
UT WOS:000315670300010
PM 23233261
ER
PT J
AU Liu, J
Clermont, AC
Gao, BB
Feener, EP
AF Liu, Jia
Clermont, Allen C.
Gao, Ben-Bo
Feener, Edward P.
TI Intraocular Hemorrhage Causes Retinal Vascular Dysfunction via Plasma
Kallikrein
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BLOOD-BRAIN-BARRIER; INTRACEREBRAL HEMORRHAGE; DIABETIC-RATS; IN-VIVO;
KININ SYSTEM; FACTOR-XII; PERMEABILITY; ACTIVATION; PERICYTES; COL4A1
AB PURPOSE. Retinal hemorrhages occur in a variety of sight-threatening conditions including ocular trauma, high altitude retinopathy, and chronic diseases such as diabetic and hypertensive retinopathies. The goal of this study is to investigate the effects of blood in the vitreous on retinal vascular function in rats.
METHODS. Intravitreal injections of autologous blood, plasma kallikrein (PK), bradykinin, and collagenase were performed in Sprague-Dawley and Long-Evans rats. Retinal vascular permeability was measured using vitreous fluorophotometry and Evans blue dye permeation. Leukostasis was measured by fluorescein isothiocyanate-coupled concanavalin A lectin and acridine orange labeling. Retinal hemorrhage was examined on retinal flatmounts. Primary cultures of bovine retinal pericytes were cultured in the presence of 25 nM PK for 24 hours. The pericyte-conditioned medium was collected and the collagen proteome was analyzed by tandem mass spectrometry.
RESULTS. Intravitreal injection of autologous blood induced retinal vascular permeability and retinal leukostasis, and these responses were ameliorated by PK inhibition. Intravitreal injections of exogenous PK induced retinal vascular permeability, leukostasis, and retinal hemorrhage. Proteomic analyses showed that PK increased collagen degradation in pericyte-conditioned medium and purified type IV collagen. Intravitreal injection of collagenase mimicked PK's effect on retinal hemorrhage.
CONCLUSIONS. Intraocular hemorrhage increases retinal vascular permeability and leukostasis, and these responses are mediated, in part, via PK. Intravitreal injections of either PK or collagenase, but not bradykinin, induce retinal hemorrhage in rats. PK exerts collagenase-like activity that may contribute to blood-retinal barrier dysfunction. (Invest Ophthalmol Vis Sci. 2013;54:1086-1094) DOI:10.1167/iovs.12-10537
C1 [Liu, Jia; Clermont, Allen C.; Gao, Ben-Bo; Feener, Edward P.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Res Div,Dept Med, Boston, MA 02115 USA.
RP Feener, EP (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM edward.feener@joslin.harvard.edu
FU US National Institutes of Health [EY 19029, DK36836]; Juvenile Diabetes
Research Foundation (JDRF) [17-2011-251]
FX Supported in part by the US National Institutes of Health Grants EY
19029 and DK36836, and Juvenile Diabetes Research Foundation (JDRF)
Grant 17-2011-251.
NR 48
TC 8
Z9 8
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2013
VL 54
IS 2
BP 1086
EP 1094
DI 10.1167/iovs.12-10537
PG 9
WC Ophthalmology
SC Ophthalmology
GA 100BS
UT WOS:000315670300022
PM 23299478
ER
PT J
AU Velez, G
Weingarden, AR
Lei, HT
Kazlauskas, A
Gao, GP
AF Velez, Gisela
Weingarden, Alexa R.
Lei, Hetian
Kazlauskas, Andrius
Gao, Guangping
TI SU9518 Inhibits Proliferative Vitreoretinopathy in Fibroblast and
Genetically Modified Muller Cell-Induced Rabbit Models
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; EXPERIMENTAL RETINAL-DETACHMENT; TYROSINE KINASE
INHIBITOR; ACIDIC PROTEIN; EXPRESSION; VIMENTIN; ALPHA
AB PURPOSE. Proliferative vitreoretinopathy (PVR) is a complication of retinal detachment that can lead to surgical failure and vision loss. Previous studies suggest that a variety of retinal cells, including RPE and Muller glia, may be responsible. Platelet-derived growth factor receptor alpha (PDGFR alpha) has been strongly implicated in the pathogenesis, and found to be intrinsic to the development of PVR in rabbit models. We examine whether SU9518, a tyrosine kinase inhibitor with PDGFR alpha specificity, can inhibit the development of PVR in fibroblast and Muller cell rabbit models of PVR.
METHODS. SU9518 was injected in rabbit eyes along with fibroblasts, Muller cells (MIO-M1), or Muller cells transfected to increase their expression of PDGFR alpha (MIO-M1 alpha). Indirect ophthalmoscopy and histopathology were used to assess efficacy and toxicity.
RESULTS. SU9518 was an effective inhibitor of PVR in both fibroblast and Muller cell models of PVR. No toxic effects were identified by indirect ophthalmoscopy or histopathology.
CONCLUSIONS. SU9518 is an effective and safe inhibitor of PVR in rabbit models, and could potentially be used in humans for the treatment of this and other proliferative diseases of the retina involving fibrosis and gliosis. Further animal studies need to be performed to examine retinal toxicity and sustained delivery mechanisms. (Invest Ophthalmol Vis Sci. 2013; 54: 1392-1397) DOI: 10.1167/iovs.12-10320
C1 [Velez, Gisela] Univ Massachusetts, Sch Med, Dept Ophthalmol, Worcester, MA 01605 USA.
[Velez, Gisela; Gao, Guangping] Univ Massachusetts, Sch Med, Gene Therapy Ctr, Worcester, MA 01605 USA.
[Weingarden, Alexa R.; Lei, Hetian; Kazlauskas, Andrius] Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02114 USA.
[Lei, Hetian; Kazlauskas, Andrius] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Velez, G (reprint author), Univ Massachusetts, Sch Med, Dept Ophthalmol, 381 Plantat St,Suite 250, Worcester, MA 01605 USA.
EM Gisela.velez@umassmed.edu
FU National Eye Institute [K08EY17383]
FX Supported by National Eye Institute Grant K08EY17383.
NR 24
TC 8
Z9 8
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2013
VL 54
IS 2
BP 1392
EP 1397
DI 10.1167/iovs.12-10320
PG 6
WC Ophthalmology
SC Ophthalmology
GA 100BS
UT WOS:000315670300061
PM 23341018
ER
PT J
AU Scarcelli, G
Kling, S
Quijano, E
Pineda, R
Marcos, S
Yun, SH
AF Scarcelli, Giuliano
Kling, Sabine
Quijano, Elena
Pineda, Roberto
Marcos, Susana
Yun, Seok Hyun
TI Brillouin Microscopy of Collagen Crosslinking: Noncontact
Depth-Dependent Analysis of Corneal Elastic Modulus
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OCULAR RESPONSE ANALYZER; ULTRAVIOLET-A LIGHT; BIOMECHANICAL PROPERTIES;
EPITHELIAL DEBRIDEMENT; OPTICAL MICROSCOPY; PROGRESSIVE KERATOCONUS;
BENZALKONIUM CHLORIDE; RIBOFLAVIN; EYES; SPECTROSCOPY
AB PURPOSE. Corneal collagen crosslinking (CXL) is designed to halt the progression of keratoconus and corneal ectasia by inducing corneal stiffening. However, it currently is difficult to monitor and evaluate CXL outcome objectively due to the lack of suitable methods to characterize corneal mechanical properties. We validated noncontact Brillouin microscopy to quantify corneal mechanical properties before and after CXL.
METHODS. CXL was performed on fresh porcine eyes using various presoaking times and light doses, with or without epithelial debridement. From Brillouin maps of corneal elastic modulus, stiffness and average modulus of anterior, middle, and posterior stroma were analyzed. Corneal stiffening index (CSI) was introduced as a metric to compare the mechanical efficacy of a given CXL protocol with respect to the standard protocol (30-minute riboflavin presoak, 3 mW/cm(2) ultraviolet illumination for 30 minutes).
RESULTS. Brillouin corneal stiffness increased significantly (P < 0.001) by epi-off and epi-on CXL. The increase of Brillouin modulus was depth-dependent, indicating that anterior stromal stiffening contributes the most to mechanical outcome. The increase of anterior Brillouin modulus was linearly proportional to the light dose (R-2 > 0.98). Compared to the standard epi-off procedure, a typical epi-on procedure resulted in a third of stiffness increase in porcine corneas (CSI = 33).
CONCLUSIONS. Brillouin microscopy allowed imaging and quantifying CXL-induced mechanical changes without contact in a depth-dependent manner at high spatial resolution. This technique may be useful to evaluate the mechanical outcomes of CXL procedures, to compare different crosslinking agents, and for real-time monitoring of CXL in clinical and experimental settings. (Invest Ophthalmol Vis Sci. 2013; 54: 1418-1425) DOI:10.1167/iovs.12-11387
C1 [Scarcelli, Giuliano; Quijano, Elena; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA USA.
[Scarcelli, Giuliano; Yun, Seok Hyun] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Kling, Sabine; Marcos, Susana] CSIC, Inst Opt, E-28006 Madrid, Spain.
[Pineda, Roberto] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Yun, Seok Hyun] Harvard MIT Hlth Sci & Technol, Cambridge, MA USA.
RP Yun, SH (reprint author), 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA.
EM syun@hms.harvard.edu
OI scarcelli, giuliano/0000-0002-1736-077X
FU Harvard Clinical and Translational Science Center [NIH UL1-RR025758];
American Society for Laser Medicine and Surgery; National Institutes of
Health [P41-EB015903]; National Science of Foundation [CBET-0853773];
Spanish Government [FIS2008-02065, FIS2011-25637]; European Research
Council [ERC-AdG-294099]
FX Supported by the Harvard Clinical and Translational Science Center (NIH
UL1-RR025758), American Society for Laser Medicine and Surgery, National
Institutes of Health (P41-EB015903), National Science of Foundation
(CBET-0853773), Spanish Government (FIS2008-02065, FIS2011-25637), and
the European Research Council (ERC-AdG-294099).
NR 47
TC 72
Z9 73
U1 0
U2 30
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2013
VL 54
IS 2
BP 1418
EP 1425
DI 10.1167/iovs.12-11387
PG 8
WC Ophthalmology
SC Ophthalmology
GA 100BS
UT WOS:000315670300065
PM 23361513
ER
PT J
AU Ahluwalia, SK
Peng, R
Aloe, C
Shreffler, WG
Krevans, M
Hagberg, KA
Thorne, PS
Matsui, E
AF Ahluwalia, Sharon K.
Peng, Roger
Aloe, Charles
Shreffler, Wayne G.
Krevans, Mary
Hagberg, Karol A.
Thorne, Peter S.
Matsui, Elizabeth
TI Endotoxin Exposure May Modify the Relationship Between Mouse Allergen
Exposure and Incident Sensitization to Mouse
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Ahluwalia, Sharon K.; Aloe, Charles; Matsui, Elizabeth] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Peng, Roger] Johns Hopkins Univ, Baltimore, MD USA.
[Shreffler, Wayne G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Shreffler, Wayne G.] Harvard Univ, Sch Med, Boston, MA USA.
[Krevans, Mary; Hagberg, Karol A.] Jackson Lab, Bar Harbor, ME 04609 USA.
[Thorne, Peter S.] Univ Iowa, Iowa City, IA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB141
EP AB141
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800502
ER
PT J
AU Baxi, SN
Petty, CR
Fu, CX
Sheehan, WJ
Permaul, P
Kopel, L
Kanchongkittiphon, W
Gaffin, JM
Rogers, CA
Muilenberg, ML
Gold, DR
Phipatanakul, W
AF Baxi, Sachin N.
Petty, Carter R.
Fu, Chunxia
Sheehan, William J.
Permaul, Perdita
Kopel, Lianne
Kanchongkittiphon, Watcharoot
Gaffin, Jonathan M.
Rogers, Christine A.
Muilenberg, Michael L.
Gold, Diane R.
Phipatanakul, Wanda
TI Classroom Fungal Spore Exposure and Asthma Morbidity in Inner-City
School Children
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Baxi, Sachin N.; Petty, Carter R.; Sheehan, William J.; Kopel, Lianne; Kanchongkittiphon, Watcharoot; Gaffin, Jonathan M.; Phipatanakul, Wanda] Boston Childrens Hosp, Boston, MA USA.
[Fu, Chunxia] Harvard Univ, Sch Med, Boston, MA USA.
[Permaul, Perdita] Massachusetts Gen Hosp, Div Pediat Allergy Immunol, Boston, MA 02114 USA.
[Rogers, Christine A.; Muilenberg, Michael L.] Univ Massachusetts, Amherst, MA 01003 USA.
[Gold, Diane R.] Channing Labs, Boston, MA USA.
NR 0
TC 1
Z9 2
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB54
EP AB54
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800197
ER
PT J
AU Brennan, AK
Patil, SU
Fleming, J
Boyce, JA
Stieb, ES
Nichols, M
Iyengar, RS
Permaul, P
Walter, JE
Hesterberg, P
Shreffler, WG
AF Brennan, Alisa K.
Patil, Sarita U.
Fleming, Jude
Boyce, Joshua A.
Stieb, Elisabeth S.
Nichols, Margaux
Iyengar, Rajashri Shuba
Permaul, Perdita
Walter, Jolan E.
Hesterberg, Paul
Shreffler, Wayne G.
TI Outcomes Using a Graded Protocol for Open Food Challenges
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Brennan, Alisa K.; Patil, Sarita U.; Nichols, Margaux; Iyengar, Rajashri Shuba; Walter, Jolan E.; Hesterberg, Paul; Shreffler, Wayne G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Fleming, Jude] Brown Univ, Rhode Isl Hosp, Dept Pediat, Div Asthma & Allergy,Alpert Sch Med, Providence, RI 02903 USA.
[Boyce, Joshua A.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
[Stieb, Elisabeth S.] Massachusetts Gen Hosp, S Weymouth, MA USA.
[Permaul, Perdita] Massachusetts Gen Hosp, Div Pediat Allergy Immunol, Boston, MA 02114 USA.
[Shreffler, Wayne G.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB86
EP AB86
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800313
ER
PT J
AU Ferzacca, E
Alejos, AR
Leibowitz, R
Pistiner, M
Shreffler, WG
Sheetz, A
AF Ferzacca, Elizabeth
Alejos, Alexandra R.
Leibowitz, Robert
Pistiner, Michael
Shreffler, Wayne G.
Sheetz, Anne
TI Real-Time Surveillance of Epinephrine Administration in Schools Supports
the Argument for Stock' Epinephrine Availability
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Ferzacca, Elizabeth] Barnard, Boston, MA USA.
[Ferzacca, Elizabeth; Alejos, Alexandra R.; Shreffler, Wayne G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Leibowitz, Robert; Sheetz, Anne] Massachusetts Dept Publ Hlth, Boston, MA USA.
[Pistiner, Michael] Harvard Vanguard Med Associates, Boston, MA USA.
[Shreffler, Wayne G.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB219
EP AB219
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800779
ER
PT J
AU Fleming, J
Clark, S
Camargo, C
Rudders, SA
AF Fleming, Jude
Clark, Sunday
Camargo, Carlos, Jr.
Rudders, Susan A.
TI Early Treatment of Food-Induced Allergic Reactions with Epinephrine Is
Associated with Lower Risk of Hospital Admission
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Fleming, Jude; Rudders, Susan A.] Brown Univ, Rhode Isl Hosp, Dept Pediat, Div Asthma & Allergy,Alpert Sch Med, Providence, RI 02903 USA.
[Clark, Sunday] Weill Cornell Med Coll, Dept Emergency Med, New York, NY USA.
[Camargo, Carlos, Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB90
EP AB90
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800326
ER
PT J
AU Greenhawt, MJ
Weiss, CC
Conte, M
Doucet, M
Engler, A
Camargo, C
AF Greenhawt, Matthew J.
Weiss, Christopher C.
Conte, Marisa
Doucet, Marlie
Engler, Amy
Camargo, Carlos, Jr.
TI Racial and Ethnic Disparity in Food Allergy in the United States: A
Systematic Review
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Greenhawt, Matthew J.] Univ Michigan, Sch Med, Dept Internal Med, Div Allergy & Clin Immunol, Ann Arbor, MI USA.
[Weiss, Christopher C.] Global Food Protect Inst, Battle Creek, MI USA.
[Conte, Marisa] Univ Michigan, Taubman Hlth Sci Lib, Ann Arbor, MI 48109 USA.
[Doucet, Marlie] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA.
[Engler, Amy] Stanford Univ, EHuman Biol Dept, Palo Alto, CA 94304 USA.
[Camargo, Carlos, Jr.] Harvard Univ, Dept Emergency Med, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 2
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB58
EP AB58
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800208
ER
PT J
AU Guana, A
Simons, FERR
Wang, S
Camargo, C
AF Guana, Adriana
Simons, F. Estelle R. R.
Wang, Sheldon
Camargo, Carlos, Jr.
TI Auvi-Q Versus Epipen: Preferences of Adults, Caregivers, and Children
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Simons, F. Estelle R. R.] Univ Manitoba, Winnipeg, MB, Canada.
[Camargo, Carlos, Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB213
EP AB213
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800760
ER
PT J
AU Guyer, AC
Conroy, M
Carlos-Camargo Jr
Long, AD
Banerji, A
AF Guyer, Autumn Chandler
Conroy, Michelle
Carlos-Camargo, Jr.
Long, Aidan
Banerji, Aleena
TI Comprehensive Allergy Consultation Minimizes Risk of Hypersensitivity
Reaction During Subsequent Anesthesia
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Guyer, Autumn Chandler; Conroy, Michelle; Long, Aidan; Banerji, Aleena] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Carlos-Camargo, Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB176
EP AB176
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800624
ER
PT J
AU Harper, N
Castiblanco, J
Rather, C
Andrews, C
Ramirez, D
Jacobs, RL
He, WJ
Ahuja, S
AF Harper, Nathan
Castiblanco, John
Rather, Cynthia
Andrews, Charles
Ramirez, Daniel
Jacobs, Robert L.
He, Weijing
Ahuja, Sunil
TI RNA-Seq-Derived Whole Genome Transcriptomic Profiling Following
Challenge to Mt. Cedar in a Pollen Challenge Chamber Uncover Novel
Insights Into Allergic Rhinoconjunctivitis Pathogenesis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Harper, Nathan; Castiblanco, John; He, Weijing; Ahuja, Sunil] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA.
[Harper, Nathan; Castiblanco, John; He, Weijing; Ahuja, Sunil] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Rather, Cynthia; Andrews, Charles; Ramirez, Daniel; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA.
RI CASTIBLANCO, JOHN/B-6599-2009
OI CASTIBLANCO, JOHN/0000-0002-7965-9822
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB40
EP AB40
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800147
ER
PT J
AU He, WJ
Carrillo, A
Harper, N
Jimenez, F
Martinez, H
Ahuja, S
Rather, C
Ramirez, D
Andrews, C
Jacobs, RL
Ahuja, S
AF He, Weijing
Carrillo, Andrew
Harper, Nathan
Jimenez, Fabio
Martinez, Hernan
Ahuja, Seema
Rather, Cynthia
Ramirez, Daniel
Andrews, Charles
Jacobs, Robert L.
Ahuja, Sunil
TI Exposure to Juniperus Ashei (Mt. Cedar) Pollen in a Pollen Challenge
Chamber Elicits Changes in White Blood Cell Counts and Cytokines in
Mountain Cedar Positive and Negative Subjects
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [He, Weijing; Carrillo, Andrew; Harper, Nathan; Jimenez, Fabio; Martinez, Hernan; Ahuja, Seema; Ahuja, Sunil] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[He, Weijing; Carrillo, Andrew; Harper, Nathan; Jimenez, Fabio; Martinez, Hernan; Ahuja, Seema; Ahuja, Sunil] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA.
[Rather, Cynthia; Ramirez, Daniel; Andrews, Charles; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB45
EP AB45
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800165
ER
PT J
AU Leung, J
Katz, AJ
Yuan, Q
Iyengar, RS
Permaul, P
Walter, JE
Ramakrishna, J
Hundal, N
Swenson, T
Alejos, AR
Shreffler, WG
Hesterberg, PE
AF Leung, John
Katz, Aubrey J.
Yuan, Qian
Iyengar, Rajashri Shuba
Permaul, Perdita
Walter, Jolan E.
Ramakrishna, Jyoti
Hundal, Navneet
Swenson, Theadora
Alejos, Alexandra R.
Shreffler, Wayne G.
Hesterberg, Paul E.
TI Tolerance of Baked Milk in a Subset of Patients with Cow's Milk-Mediated
Eosinophilic Esophagitis
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Leung, John; Katz, Aubrey J.; Yuan, Qian; Iyengar, Rajashri Shuba; Walter, Jolan E.; Ramakrishna, Jyoti; Hundal, Navneet; Swenson, Theadora; Alejos, Alexandra R.; Shreffler, Wayne G.; Hesterberg, Paul E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Permaul, Perdita] Massachusetts Gen Hosp, Div Pediat Allergy Immunol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB181
EP AB181
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800643
ER
PT J
AU Ling, M
Patil, SU
Wong, JT
AF Ling, Morris
Patil, Sarita U.
Wong, Johnson T.
TI Oxaliplatin Hypersensitivity: Management and Comparison with
Carbo/Cisplatin
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Ling, Morris; Patil, Sarita U.; Wong, Johnson T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ling, Morris; Patil, Sarita U.; Wong, Johnson T.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB165
EP AB165
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800584
ER
PT J
AU Oyoshi, MK
He, R
Li, YT
Mondal, S
Yoon, J
Afshar, R
Chen, M
Lee, DM
Luo, HB
Luster, AD
Cho, J
Miller, L
Larson, A
Murphy, G
Geha, R
AF Oyoshi, Michiko K.
He, Rui
Li, Yitang
Mondal, Subhanjan
Yoon, Juhan
Afshar, Roshi
Chen, Mei
Lee, David M.
Luo, Hongbo
Luster, Andrew D.
Cho, John
Miller, Lloyd
Larson, Allison
Murphy, George
Geha, Raif
TI Leukotriene B-4 Driven Neutrophil Recruitment to the Skin Is Essential
for Allergic Skin Inflammation
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Oyoshi, Michiko K.; He, Rui; Li, Yitang; Mondal, Subhanjan; Yoon, Juhan; Luo, Hongbo; Geha, Raif] Boston Childrens Hosp, Boston, MA USA.
[Afshar, Roshi; Luster, Andrew D.] Massachusetts Gen Hosp, Charlestown, MA USA.
[Chen, Mei; Lee, David M.; Larson, Allison] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Cho, John; Miller, Lloyd] Univ Calif Los Angeles, Boston, MA USA.
[Murphy, George] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
RI Larson, Allison/N-4263-2015
OI Larson, Allison/0000-0001-8534-7078
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB102
EP AB102
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800374
ER
PT J
AU Patil, SU
Kubala, S
Brennan, AK
Ma, A
Moon, J
Shreffler, WG
AF Patil, Sarita U.
Kubala, Stephanie
Brennan, Alisa K.
Ma, Alex
Moon, James
Shreffler, Wayne G.
TI Induction of Antigen-Specific B Cells During Peanut Oral Immunotherapy
Using Novel Tetramer-Based Approach
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Patil, Sarita U.; Brennan, Alisa K.; Ma, Alex; Moon, James; Shreffler, Wayne G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kubala, Stephanie] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
[Shreffler, Wayne G.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB86
EP AB86
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800312
ER
PT J
AU Permaul, P
Petty, CR
Sheehan, WJ
Baxi, SN
Gaffin, JM
Kopel, LS
Kanchongkittiphan, W
Bailey, A
Fu, CX
Gold, DR
Phipatanakul, W
AF Permaul, Perdita
Petty, Carter R.
Sheehan, William J.
Baxi, Sachin N.
Gaffin, Jonathan M.
Kopel, Lianne S.
Kanchongkittiphan, Watcharoot
Bailey, Ann
Fu, Chunxia
Gold, Diane R.
Phipatanakul, Wanda
TI Mouse Allergen Exposure in Urban Schools and Its Effect On Childhood
Asthma Morbidity
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Permaul, Perdita] Massachusetts Gen Hosp, Div Pediat Allergy Immunol, Boston, MA 02114 USA.
[Petty, Carter R.; Sheehan, William J.; Baxi, Sachin N.; Gaffin, Jonathan M.; Kopel, Lianne S.; Kanchongkittiphan, Watcharoot; Phipatanakul, Wanda] Boston Childrens Hosp, Boston, MA USA.
[Bailey, Ann; Fu, Chunxia; Gold, Diane R.] Channing Labs, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB141
EP AB141
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800501
ER
PT J
AU Ramirez, D
Rather, C
Harper, N
Carrillo, A
He, WJ
Andrews, C
Ahuja, S
Jacobs, RL
AF Ramirez, Daniel
Rather, Cynthia
Harper, Nathan
Carrillo, Andrew
He, Weijing
Andrews, Charles
Ahuja, Sunil
Jacobs, Robert L.
TI Exposure to Juniperus Ashei (Mt. Cedar) and Virginia Live Oak Pollen in
a Pollen Challenge Chamber Elicits Similar Symptomology When Compared to
Natural Season
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Ramirez, Daniel; Rather, Cynthia; Andrews, Charles; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA.
[Harper, Nathan; Carrillo, Andrew; He, Weijing; Ahuja, Sunil] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA.
[Harper, Nathan; Carrillo, Andrew; He, Weijing; Ahuja, Sunil] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB49
EP AB49
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800178
ER
PT J
AU Rudders, SA
Clark, S
Wei, WH
Camargo, C
AF Rudders, Susan A.
Clark, Sunday
Wei, Wenhui
Camargo, Carlos, Jr.
TI A Retrospective Study of Drug-Induced Anaphylaxis Treated in the
Emergency Department (ED) or Hospital: Patients' Characteristics and
Their Receipt of Preventive Care
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Rudders, Susan A.] Brown Univ, Rhode Isl Hosp, Alpert Sch Med, Div Asthma & Allergy,Dept Pediat, Providence, RI 02903 USA.
[Clark, Sunday] Weill Cornell Med Coll, Dept Emergency Med, New York, NY USA.
[Wei, Wenhui] Sanofi US, Evidence Based Med, Bridgewater, NJ USA.
[Camargo, Carlos, Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB174
EP AB174
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800617
ER
PT J
AU Ruiter, B
Grishina, G
Jager, SD
Knol, EF
Ozias-Akins, P
Sampson, HA
Shreffler, WG
AF Ruiter, Bert
Grishina, Galina
Jager, Stans den Hartog
Knol, Edward F.
Ozias-Akins, Peggy
Sampson, Hugh A.
Shreffler, Wayne G.
TI Human Dendritic Cells Stimulated with a Novel Peanut Protein Express
High Levels of RALDH2 and Induce RA-Sensitive Genes in Naive T Cells
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Ruiter, Bert; Shreffler, Wayne G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Grishina, Galina; Sampson, Hugh A.] Mt Sinai Sch Med, New York, NY USA.
[Jager, Stans den Hartog; Knol, Edward F.] Univ Med Ctr, Utrecht, Netherlands.
[Ozias-Akins, Peggy] Univ Georgia, Tifton, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB127
EP AB127
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800457
ER
PT J
AU Viswanathan, RK
Mathur, SK
AF Viswanathan, Ravi K.
Mathur, Sameer K.
TI Autoimmune Phenotype in Refractory Chronic Urticaria Does Not Affect
Response to Omalizumab
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Viswanathan, Ravi K.; Mathur, Sameer K.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Viswanathan, Ravi K.; Mathur, Sameer K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB30
EP AB30
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800109
ER
PT J
AU Wong, JT
AF Wong, Johnson T.
TI Rapid Outpatient Aspirin Desensitization/Challenge for
Urticaria/Angioedema and AERD
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology
(AAAAI)
CY FEB 22-26, 2013
CL San Antonio, TX
SP Amer Acad Allergy, Asthma & Immunol (AAAAI)
C1 [Wong, Johnson T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wong, Johnson T.] Harvard Univ, Sch Med, Boston, MA USA.
[Wong, Johnson T.] Newton Wellesley Hosp, Newton, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2013
VL 131
IS 2
SU S
BP AB167
EP AB167
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 111WC
UT WOS:000316550800591
ER
PT J
AU Abel, BS
Shaw, ND
Brown, JM
Adams, JM
Alati, T
Martin, KA
Pitteloud, N
Seminara, SB
Plummer, L
Pignatelli, D
Crowley, WF
Welt, CK
Hall, JE
AF Abel, Brent S.
Shaw, Natalie D.
Brown, Jenifer M.
Adams, Judith M.
Alati, Teresa
Martin, Kathryn A.
Pitteloud, Nelly
Seminara, Stephanie B.
Plummer, Lacey
Pignatelli, Duarte
Crowley, William F., Jr.
Welt, Corrine K.
Hall, Janet E.
TI Responsiveness to a Physiological Regimen of GnRH Therapy and Relation
to Genotype in Women With Isolated Hypogonadotropic Hypogonadism
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID GONADOTROPIN-RELEASING-HORMONE; FOLLICLE-STIMULATING-HORMONE;
ENDOTHELIAL GROWTH-FACTOR; HUMAN MENSTRUAL-CYCLE; LUTEINIZING-HORMONE;
KALLMANN-SYNDROME; PHENOTYPIC SPECTRUM; CHARGE SYNDROME; RECEPTOR
MUTATIONS; HUMAN OVARY
AB Context: Isolated hypogonadotropic hypogonadism (IHH) is caused by defective GnRH secretion or action resulting in absent or incomplete pubertal development and infertility. Most women with IHH ovulate with physiological GnRH replacement, implicating GnRH deficiency as the etiology. However, a subset does not respond normally, suggesting the presence of defects at the pituitary or ovary.
Objectives: The objective of the study was to unmask pituitary or ovarian defects in IHH women using a physiological regimen of GnRH replacement, relating these responses to genes known to cause IHH.
Design, Setting, and Subjects: This study is a retrospective analysis of 37 IHH women treated with iv pulsatile GnRH (75 ng/kg per bolus).
Main Outcome Measures: Serum gonadotropin and sex steroid levels were measured, and 14 genes implicated in IHH were sequenced.
Results: During their first cycle of GnRH replacement, normal cycles were recreated in 60% (22 of 37) of IHH women. Thirty percent of women (12 of 37) demonstrated an attenuated gonadotropin response, indicating pituitary resistance, and 10% (3 of 37) exhibited an exaggerated FSH response, consistent with ovarian resistance. Mutations in CHD7, FGFR1, KAL1, TAC3, and TACR3 were documented in IHH women with normal cycles, whereas mutations were identified in GNRHR, PROKR2, and FGFR1 in those with pituitary resistance. Women with ovarian resistance were mutation negative.
Conclusions: Although physiological replacement with GnRH recreates normal menstrual cycle dynamics in most IHH women, hypogonadotropic responses in the first week of treatment identify a subset of women with pituitary dysfunction, only some of whom have mutations in GNRHR. IHH women with hypergonadotropic responses to GnRH replacement, consistent with an additional ovarian defect, did not have mutations in genes known to cause IHH, similar to our findings in a subset of IHH men with evidence of an additional testicular defect. (J Clin Endocrinol Metab 98: E206-E216, 2013)
C1 [Abel, Brent S.; Shaw, Natalie D.; Brown, Jenifer M.; Adams, Judith M.; Alati, Teresa; Martin, Kathryn A.; Seminara, Stephanie B.; Plummer, Lacey; Crowley, William F., Jr.; Welt, Corrine K.; Hall, Janet E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit,Dept Med, Boston, MA 02114 USA.
[Abel, Brent S.; Shaw, Natalie D.; Brown, Jenifer M.; Adams, Judith M.; Alati, Teresa; Martin, Kathryn A.; Seminara, Stephanie B.; Plummer, Lacey; Crowley, William F., Jr.; Welt, Corrine K.; Hall, Janet E.] Harvard Univ, Sch Med, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA.
[Shaw, Natalie D.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Pitteloud, Nelly] CHU Vaudois, CH-1011 Lausanne, Switzerland.
[Pignatelli, Duarte] Univ Porto, Hosp San Joao, Fac Med Porto, Dept Endocrinol,Dept Expt Biol, P-4200 Oporto, Portugal.
[Pignatelli, Duarte] Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, P-4200 Oporto, Portugal.
RP Hall, JE (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, BHX 5, 55 Fruit St, Boston, MA 02114 USA.
EM jehall@partners.org
RI PITTELOUD, Nelly/K-2709-2014;
OI Pignatelli, Duarte/0000-0002-5555-7004; Welt,
Corrine/0000-0002-8219-5504; Shaw, Natalie/0000-0002-0847-9170; Hall,
Janet/0000-0003-4644-3061
FU Eunice Kennedy Shriver National Institutes of Child Health and Human
Development/National Institutes of Health [R01 HD42708]; Specialized
Cooperative Centers Program in Reproduction and Infertility Research
[U54 HD028138]; National Institutes of Health National Center for
Research Resources, General Clinical Research Centers Program
[M01-RR-01066]; National Institutes of Health [5F32 HD062315]; Scholars
in Clinical Science program of Harvard Catalyst [The Harvard Clinical
and Translational Science Center] [UL1RR025758]; Harvard University
FX This work was supported by the Eunice Kennedy Shriver National
Institutes of Child Health and Human Development/National Institutes of
Health through R01 HD42708 and cooperative agreement U54 HD028138 as
part of the Specialized Cooperative Centers Program in Reproduction and
Infertility Research and M01-RR-01066 National Institutes of Health
National Center for Research Resources, General Clinical Research
Centers Program. N.D.S. received fellowship support from the National
Institutes of Health (Grant 5F32 HD062315) and from the Scholars in
Clinical Science program of Harvard Catalyst [The Harvard Clinical and
Translational Science Center (Award UL1RR025758) and financial
contributions from Harvard University and its affiliated academic health
care centers].
NR 62
TC 4
Z9 7
U1 1
U2 7
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD FEB
PY 2013
VL 98
IS 2
BP E206
EP E216
DI 10.1210/jc.2012-3294
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 108DE
UT WOS:000316270900002
PM 23341491
ER
PT J
AU Schult, TM
Awosika, ER
Schmunk, SK
Hodgson, MJ
Heymach, BL
Parker, CD
AF Schult, Tamara M.
Awosika, Ebi R.
Schmunk, Sandra K.
Hodgson, Michael J.
Heymach, Bria L.
Parker, Celestine Dent
TI Sitting on Stability Balls: Biomechanics Evaluation in a Workplace
Setting
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE
LA English
DT Article
DE intervention effectiveness; office ergonomics; seating; stability ball
ID LOW-BACK-PAIN; SEDENTARY TIME; EXERCISE BALL; OFFICE CHAIR; WORK;
PERFORMANCE; DISCOMFORT; COMFORT; DISEASE; HEALTH
AB Use of a stability ball alone and stability ball chair were evaluated in the Veterans Health Administration as possible alternatives to incorporate with regular office chair use. The evaluation of stability ball use was conducted under the auspices of a work site health promotion program as a cross-over trial with participants rotating through use of the stability ball, stability ball chair, and regular office chair on a monthly basis for a total duration of 3 months. Rotations on regular office chairs served as the control. Three medical facilities participated. A total of 193 employees completed a baseline questionnaire; 159 completed at least one post-rotation questionnaire. Self-reported measures included perceived posture when sitting, perceptions of overall balance, energy levels, job performance, safety, and pain. Use was associated with improvements in perceived posture (p < 0.0001) and energy levels (p = 0.007) for stability ball users compared with the office chair control, and improvements in perceived posture (p < 0.0001) and overall balance (p = 0.05) for stability ball chair users compared with the control. Use of stability balls at work decreases the likelihood of reporting pain from regular office chair use from approximately 45% to 21%. Alternatively, a high number of participants reported pain with use of the stability ball alone and stability ball chair, 42% and 45%, respectively. The perceived risks and benefits of stability ball use should be weighed when incorporating use. [Supplementary materials are available for this article. Go to the publisher's online edition of Journal of Occupational and Environmental Hygiene for the following free supplementary resource: Post-Active Sitting Device Questionnaire]
C1 [Schult, Tamara M.; Awosika, Ebi R.; Schmunk, Sandra K.] Vet Hlth Adm, Off Publ Hlth, Minneapolis, MN 55417 USA.
[Hodgson, Michael J.] Vet Hlth Adm, Off Publ Hlth, Washington, DC USA.
[Heymach, Bria L.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Parker, Celestine Dent] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Schult, TM (reprint author), Vet Hlth Adm, Off Publ Hlth, 1 Vet Dr V68, Minneapolis, MN 55417 USA.
EM tamara.schult@va.gov
NR 25
TC 6
Z9 6
U1 4
U2 48
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1545-9624
J9 J OCCUP ENVIRON HYG
JI J. Occup. Environ. Hyg.
PD FEB 1
PY 2013
VL 10
IS 2
BP 55
EP 63
DI 10.1080/15459624.2012.748324
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA 108XG
UT WOS:000316329000004
PM 23252582
ER
PT J
AU Oxnard, GR
Lo, PC
Nishino, M
Dahlberg, SE
Lindeman, NI
Butaney, M
Jackman, DM
Johnson, BE
Janne, PA
AF Oxnard, Geoffrey R.
Lo, Peter C.
Nishino, Mizuki
Dahlberg, Suzanne E.
Lindeman, Neal I.
Butaney, Mohit
Jackman, David M.
Johnson, Bruce E.
Jaenne, Pasi A.
TI Natural History and Molecular Characteristics of Lung Cancers Harboring
EGFR Exon 20 Insertions
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Non-small-cell lung cancer; Epidermal growth factor receptor mutations;
Exon 20 insertions
ID GROWTH-FACTOR-RECEPTOR; MUTATIONS; INHIBITION; ADENOCARCINOMAS;
GEFITINIB; GENE; BRAF; SENSITIVITY; MELANOMA; SURVIVAL
AB Introduction: Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies.
Methods: NSCLC patients with EGFR genotyping were studied using a mechanism approved by the Institutional Review Board. Cancers with exon 20 insertions were indentified, sequences were characterized, and effectiveness of different treatment regimens was reviewed retrospectively. Clinical characteristics and survival were compared with cancers harboring common EGFR mutations and cancers with wild-type EGFR.
Results: One thousand eighty-six patients underwent EGFR genotyping from 2004 to 2012. Twenty seven (2.5%) harbored exon 20 insertions, making up 9.2% of all cancers with documented EGFR mutations. Compared with wild-type cancers, those with exon 20 insertions were more commonly found in never-smokers and Asian patients. Insertion sequences were highly variable, with the most common variant (V769_D770insASV) making up only 22% of cases. Median survival of patients with exon 20 insertions was 16 months, similar to the survival of wild-type cancers and shorter than the survival of cancers with common EGFR mutations.
Conclusions: Patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations but a poorer prognosis. The prevalence of this subset of NSCLC is similar to that of other genotype-defined subsets of lung adenocarcinoma (e.g. those with BRAF mutations, HER2 insertions, ROS1 rearrangements) and is a population of interest for trials of new targeted therapies.
C1 [Oxnard, Geoffrey R.; Lo, Peter C.; Butaney, Mohit; Jackman, David M.; Johnson, Bruce E.; Jaenne, Pasi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02114 USA.
[Oxnard, Geoffrey R.; Jackman, David M.; Johnson, Bruce E.; Jaenne, Pasi A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Nishino, Mizuki] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02114 USA.
[Nishino, Mizuki] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Dahlberg, Suzanne E.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02114 USA.
[Lindeman, Neal I.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02114 USA.
RP Oxnard, GR (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,D1234, Boston, MA 02114 USA.
EM Geoffrey_Oxnard@DFCI.harvard.edu
FU National Cancer Institute at the National Institutes of Health
[R01-CA135257, P50-CA090578, K23-CA157631]
FX This work was supported in part by the National Cancer Institute at the
National Institutes of Health (R01-CA135257, P50-CA090578,
K23-CA157631). G.R. Oxnard is a consultant/advisory board member for
Genentech and Boehringer Ingelheim. D.M. Jackman is a
consultant/advisory board member for Genentech and Foundation Medicine.
B.E. Johnson is a consultant/advisory board member for Genentech,
Pfizer, Chugai, Astra-Zeneca, Kew and Transgenomics. P.A. Janne is a
consultant/advisory board member for Boehringer Ingelheim, Roche,
Genentech, Abbot, Teva, Astra-Zeneca, Pfizer, and Sanofi. B.E. Johnson
and P.A. Janne are coinventors on a patent held by the Dana-Farber
Cancer Institute for the use of EGFR genotyping, and receive a share of
post-market licensing revenue distributed by DFCI. Other authors have no
potential conflicts of interest to disclose.
NR 30
TC 39
Z9 39
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD FEB
PY 2013
VL 8
IS 2
BP 179
EP 184
DI 10.1097/JTO.0b013e3182779d18
PG 6
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 107HA
UT WOS:000316204900012
PM 23328547
ER
PT J
AU Malinoski, D
Ewing, T
Bhakta, A
Schutz, R
Imayanagita, B
Casas, T
Woo, N
Margulies, D
Barrios, C
Lekawa, M
Chung, R
Bukur, M
Kong, A
AF Malinoski, Darren
Ewing, Tyler
Bhakta, Akash
Schutz, Randi
Imayanagita, Bryan
Casas, Tamara
Woo, Noah
Margulies, Daniel
Barrios, Cristobal
Lekawa, Michael
Chung, Rex
Bukur, Marko
Kong, Allen
TI Which central venous catheters have the highest rate of
catheter-associated deep venous thrombosis: A prospective analysis of
2,128 catheter days in the surgical intensive care unit
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Catheter-associated deep venous thrombosis; risk factors; central venous
catheter; critical care
ID UPPER-EXTREMITY; VEIN THROMBOSIS; NATURAL-HISTORY; TRAUMA PATIENTS;
RISK-FACTORS; ANTICOAGULATION; COMPLICATIONS; TRIAL
AB BACKGROUND: Catheter-associated deep venous thromboses (CADVTs) are a common occurrence in the surgical intensive care unit (SICU), necessitating central venous catheter (CVC) removal and replacement. Previous studies evaluating risk factors for CADVT in SICU patients are limited, and most lack a true denominator of all CVC days. We sought to determine the true incidence of and risk factors for CADVT based on patient characteristics as well as CVC site, type, and duration of insertion.
METHODS: The following data from all SICU patients in two urban Level I trauma centerswere prospectively collected from 2009 to 2012: demographics, risk factors for DVT, CVC site/type/duration, and duplex results. Sites included the subclavian (SC), internal jugular (IJ), arm (for peripherally inserted central catheter [PICC] lines), and femoral. Types included multilumen (ML), introducer/hemodialysis (I/HD), and PICC. High-risk patients received weekly screening duplex examinations and a CADVT was defined as a DVT being detected on duplex with a CVC in place or within 7 days of removal. Rates of CADVT were normalized per 1,000 CVC days, and independent predictors of CADVT were determined using logistic regression.
RESULTS: Data were complete for 184 patients, 354 CVCs, and 2,128 CVC days. Fifty-nine CADVTs were diagnosed in 28% of patients. Rates of CADVT were 9 per 1,000 catheter days for SC, 61 for IJ (p < 0.01 vs. SC), 27 for arm (p < 0.01), 36 for femoral (p < 0.01), 22 for ML, 57 for I/HD (p < 0.01 vs. ML), and 27 for PICC (p = 0.24). After adjusting for patient risk factors, predictors of CADVT included the IJ and arm sites (odds ratio, 6.0 and 3.0 compared with SC) and the I/HD type (odds ratio, 2.6 compared with ML, all p < 0.05).
CONCLUSION: The IJ and arm sites and I/HD type are associated with increased CADVT. These data may be used to determine the optimal site and type of CVC for insertion. (J Trauma Acute Care Surg. 2013; 74: 454-462. Copyright (C) 2013 by Lippincott Williams & Wilkins)
C1 [Malinoski, Darren] Portland VA Med Ctr, Sect Surg Crit Care, Portland, OR USA.
[Ewing, Tyler] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA.
[Schutz, Randi; Imayanagita, Bryan; Woo, Noah; Barrios, Cristobal; Lekawa, Michael; Kong, Allen] Univ Calif Irvine, Div Trauma & Crit Care, Irvine, CA USA.
[Malinoski, Darren; Casas, Tamara; Chung, Rex; Bukur, Marko] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA.
[Bhakta, Akash] Midwestern Univ, Downers Grove, IL 60515 USA.
RP Malinoski, D (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Sect Surg Crit Care, POB 1034 P3ANES, Portland, OR 97207 USA.
EM malinosk@ohsu.edu
NR 21
TC 7
Z9 8
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD FEB
PY 2013
VL 74
IS 2
BP 454
EP 460
PG 7
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 108UH
UT WOS:000316321200029
PM 23354238
ER
PT J
AU van der Wilden, GM
Schmidt, U
Chang, YC
Bittner, EA
Cobb, JP
Velmahos, GC
Alam, HB
de Moya, MA
King, DR
AF van der Wilden, Gwendolyn M.
Schmidt, Ulrich
Chang, Yuchiao
Bittner, Edward A.
Cobb, J. Perren
Velmahos, George C.
Alam, Hasan B.
de Moya, Marc A.
King, David R.
TI Implementation of 24/7 intensivist presence in the SICU: Effect on
processes of care
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Intensive care; 24/7; Leapfrog; intensivist; surgical intensive care
unit
ID CRITICALLY-ILL PATIENTS; HOSPITAL MORTALITY; UNIT; ADMISSION; ICU;
SERVICES; RECOMMENDATIONS; ASSOCIATION; DELIVERY; WEEKENDS
AB BACKGROUND: Staffing of attending intensivists 24 hours per day, 7 days per week (24/7) in the surgical intensive care unit (SICU) has unknown benefits. We hypothesized that 24/7 attending intensivist staffing in the SICU would improve outcomes and processes of care.
METHODS: We retrospectively reviewed 26 months of admissions to our 20-bed SICU, comparing 13 months before and 13 months after addition of an in-house night intensivist to the existing day intensivist with a nighttime on-demand model. Primary outcomes were mortality, complications, SICU length of stay, and ventilator days. Secondary outcomes were use of intensivist-directed ancillary testing and therapies, as well as physician billing (relative value units per full-time equivalent [RVU/FTE]).
RESULTS: A total of 2,829 patients were included: 1,408 before and 1,421 after 24/7 staffing. Baseline characteristics, mortality, complications, ventilation days, ICU and hospital length of stay, and readmission rate were similar between groups (all p > 0.05). Use of blood products and imaging tests (computed tomographic scans) were significantly reduced. Total RVU increased, as did the RVU/FTE ratio.
CONCLUSION: Implementation of 24/7 staffing did not improve SICU morbidity or mortality but was associated with decreased blood product use and fewer axial imaging studies. The RVU/FTE ratio was improved. Overall health care value may be decreased under this model. (J Trauma Acute Care Surg. 2013;74: 563-567. Copyright (C) 2013 by Lippincott Williams & Wilkins)
C1 [van der Wilden, Gwendolyn M.; Chang, Yuchiao; Velmahos, George C.; Alam, Hasan B.; de Moya, Marc A.; King, David R.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02141 USA.
[Schmidt, Ulrich; Bittner, Edward A.; Cobb, J. Perren] Massachusetts Gen Hosp, Dept Anesthesia, Boston, MA 02141 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP King, DR (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02141 USA.
EM dking3@partners.org
OI King, David/0000-0003-1028-1478
NR 25
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD FEB
PY 2013
VL 74
IS 2
BP 563
EP 567
DI 10.1097/TA.0b013e31827880a8
PG 5
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 108UH
UT WOS:000316321200046
PM 23354251
ER
PT J
AU Katon, J
Reiber, G
Williams, MA
Yanez, D
Miller, E
AF Katon, Jodie
Reiber, Gayle
Williams, Michelle A.
Yanez, David
Miller, Edith
TI Weight Loss After Diagnosis with Gestational Diabetes and Birth Weight
Among Overweight and Obese Women
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Article
DE Gestational weight gain; Weight loss; Gestational diabetes; Birth
weight; Obesity
ID ANTEPARTUM MATERNAL METABOLISM; PREGNANCY OUTCOMES; GAIN; MELLITUS;
RISK; ASSOCIATIONS; VALIDITY; TRENDS
AB To determine if, among overweight or obese women with gestational diabetes (GDM), weight loss after GDM diagnosis is associated with lower infant birth weight within levels of overweight or obesity class. Overweight and obese women with singleton pregnancies managed for GDM at a large diabetes and pregnancy program located in Charlotte, NC between November 2000 and April 2010, were eligible for this retrospective cohort study. All were managed using a rigorous standardized clinical protocol. Clinical information including maternal pre-pregnancy body mass index, gestational weight gain, treatment, and medical and obstetric history was abstracted from medical records. The association of weight loss after GDM diagnosis and birth weight was analyzed using linear regression stratified by maternal pre-pregnancy overweight or obesity class (I, II/III). Of the 322 women in this study 19 % lost weight between diagnosis of GDM and delivery. After adjustment for maternal age, parity, race/ethnicity, gestational week at first hemoglobin A1c (A1C), A1C at diagnosis, weight gain prior to GDM, treatment with insulin or oral hypoglycemic agents, gestational age at delivery, and infant sex, weight loss was associated with 238.3 g lower mean infant birth weight among overweight women (95 % CI -393.72, -82.95 g), but was not associated with lower mean infant birth weight among obese class II/III women (95 % CI -275.61, 315.38 g). Weight loss, after diagnosis of GDM, is associated with lower infant birth weight among overweight women, but not among obese class II/III women.
C1 [Katon, Jodie; Reiber, Gayle; Williams, Michelle A.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Reiber, Gayle] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Yanez, David] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
[Miller, Edith] Carolinas Med Ctr, Diabet & Pregnancy Program, Charlotte, NC 28203 USA.
RP Katon, J (reprint author), Univ Washington, Sch Publ Hlth, Dept Epidemiol, POB 357236, Seattle, WA 98195 USA.
EM jkaton@u.washington.edu
FU NICHD NIH HHS [T32 HD052462]
NR 29
TC 2
Z9 2
U1 2
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
EI 1573-6628
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD FEB
PY 2013
VL 17
IS 2
BP 374
EP 383
DI 10.1007/s10995-012-1044-5
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 104PC
UT WOS:000316005600021
PM 22692470
ER
PT J
AU Duce, JA
Ayton, S
Miller, AA
Tsatsanis, A
Lam, LQ
Leone, L
Corbin, JE
Butzkueven, H
Kilpatrick, TJ
Rogers, JT
Barnham, KJ
Finkelstein, DI
Bush, AI
AF Duce, J. A.
Ayton, S.
Miller, A. A.
Tsatsanis, A.
Lam, L. Q.
Leone, L.
Corbin, J. E.
Butzkueven, H.
Kilpatrick, T. J.
Rogers, J. T.
Barnham, K. J.
Finkelstein, D. I.
Bush, A. I.
TI Amine oxidase activity of beta-amyloid precursor protein modulates
systemic and local catecholamine levels
SO MOLECULAR PSYCHIATRY
LA English
DT Article
DE beta-amyloid precursor protein; catecholamines; amine oxidation;
neurotransmission
ID CERULOPLASMIN-CATALYZED OXIDATION; ORTHO-DIANISIDINE DIHYDROCHLORIDE;
INTERNATIONAL ENZYME UNITS; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE;
DOWN-SYNDROME; FERROXIDASE ACTIVITY; PICHIA-PASTORIS; GROWTH-HORMONE;
ADIPOSE-TISSUE
AB The catecholamines dopamine (DA), norepinephrine (NE) and epinephrine (E) are neurotransmitters and hormones that mediate stress responses in tissues and plasma. The expression of beta-amyloid precursor protein (APP) is responsive to stress and is high in tissues rich in catecholamines. We recently reported that APP is a ferroxidase, subsuming, in neurons and other cells, the iron-export activity that ceruloplasmin mediates in glia. Here we report that, like ceruloplasmin, APP also oxidizes synthetic amines and catecholamines catalytically (K-m NE=0.27mM), through a site encompassing its ferroxidase motif and selectively inhibited by zinc. Accordingly, APP knockout mice have significantly higher levels of DA, NE and E in brain, plasma and select tissues. Consistent with this, these animals have increased resting heart rate and systolic blood pressure as well as suppressed prolactin and lymphocyte levels. These findings support a role for APP in extracellular catecholaminergic clearance. Molecular Psychiatry (2013) 18, 245-254; doi:10.1038/mp.2011.168; published online 3 January 2012
C1 [Duce, J. A.; Ayton, S.; Tsatsanis, A.; Lam, L. Q.; Barnham, K. J.; Finkelstein, D. I.; Bush, A. I.] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3052, Australia.
[Duce, J. A.; Ayton, S.; Butzkueven, H.; Kilpatrick, T. J.; Finkelstein, D. I.] Univ Melbourne, Ctr Neurosci, Parkville, Vic 3052, Australia.
[Miller, A. A.] Monash Univ, Dept Pharmacol, Clayton, Vic 3168, Australia.
[Leone, L.; Barnham, K. J.; Bush, A. I.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.
[Corbin, J. E.] PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res & Cooperat Res C, Parkville, Vic, Australia.
[Rogers, J. T.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
[Barnham, K. J.] Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3052, Australia.
RP Bush, AI (reprint author), Univ Melbourne, Mental Hlth Res Inst, 155 Oak St, Parkville, Vic 3052, Australia.
EM abush@mhri.edu.au
RI Bush, Ashley/A-1186-2007; Finkelstein, David/B-9617-2009
OI Bush, Ashley/0000-0001-8259-9069; Finkelstein, David/0000-0002-8167-4917
FU Australian Research Council; Australian National Health & Medical
Research Council; Alzheimer's Association
FX We thank Michael Cater for the generation of
FD1(E415N)-APP695 and Keyla Perez for the
generation of the FD1 peptide. This work was supported by funds from the
Australian Research Council, the Australian National Health & Medical
Research Council and the Alzheimer's Association.
NR 69
TC 4
Z9 4
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD FEB
PY 2013
VL 18
IS 2
BP 245
EP 254
DI 10.1038/mp.2011.168
PG 10
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA 112BW
UT WOS:000316567800017
PM 22212595
ER
PT J
AU Guha, M
Castellanos-Rizaldos, E
Liu, PF
Mamon, H
Makrigiorgos, GM
AF Guha, Minakshi
Castellanos-Rizaldos, Elena
Liu, Pingfang
Mamon, Harvey
Makrigiorgos, G. Mike
TI Differential strand separation at critical temperature: A minimally
disruptive enrichment method for low-abundance unknown DNA mutations
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID METASTATIC COLORECTAL-CANCER; RAS GENE-MUTATIONS; COLD-PCR; KRAS
MUTATIONS; ACQUIRED-RESISTANCE; SENSITIVE DETECTION; IDENTIFICATION;
ADENOCARCINOMA; ALLELES; SAMPLES
AB Detection of low-level DNA variations in the presence of wild-type DNA is important in several fields of medicine, including cancer, prenatal diagnosis and infectious diseases. PCR-based methods to enrich mutations during amplification have limited multiplexing capability, are mostly restricted to known mutations and are prone to polymerase or mis-priming errors. Here, we present Differential Strand Separation at Critical Temperature (DISSECT), a method that enriches unknown mutations of targeted DNA sequences purely based on thermal denaturation of DNA heteroduplexes without the need for enzymatic reactions. Target DNA is pre-amplified in a multiplex reaction and hybridized onto complementary probes immobilized on magnetic beads that correspond to wild-type DNA sequences. Presence of any mutation on the target DNA forms heteroduplexes that are subsequently denatured from the beads at a critical temperature and selectively separated from wild-type DNA. We demonstrate multiplexed enrichment by 100- to 400-fold for KRAS and TP53 mutations at multiple positions of the targeted sequence using two to four successive cycles of DISSECT. Cancer and plasma-circulating DNA samples containing traces of mutations undergo mutation enrichment allowing detection via Sanger sequencing or high-resolution melting. The simplicity, scalability and reliability of DISSECT make it a powerful method for mutation enrichment that integrates well with existing downstream detection methods.
C1 [Guha, Minakshi; Castellanos-Rizaldos, Elena; Liu, Pingfang; Makrigiorgos, G. Mike] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div DNA Repair & Genome Stabil,Dept Radiat Oncol, Boston, MA 02115 USA.
[Mamon, Harvey; Makrigiorgos, G. Mike] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Mamon, Harvey; Makrigiorgos, G. Mike] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
RP Makrigiorgos, GM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div DNA Repair & Genome Stabil,Dept Radiat Oncol, 44 Binney St, Boston, MA 02115 USA.
EM mmakrigiorgos@lroc.harvard.edu
FU NCI [R21 CA-111994, R21 CA-155615]
FX NCI [R21 CA-111994 and R21 CA-155615, in part]. The contents of this
article do not necessarily represent the official views of the National
Cancer Institute or the National Institutes of Health. Funding for open
access charge: Departmental funds.
NR 28
TC 9
Z9 9
U1 2
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB
PY 2013
VL 41
IS 3
AR e50
DI 10.1093/nar/gks1250
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 109FM
UT WOS:000316351800008
PM 23258702
ER
PT J
AU Metzger, O
de Azambuja, E
Bradbury, I
Saini, KS
Bines, J
Simon, SD
Van Dooren, V
Aktan, G
Pritchard, KI
Wolff, AC
Smith, I
Jackisch, C
Lang, I
Untch, M
Boyle, F
Xu, BH
Baselga, J
Perez, EA
Piccart-Gebhart, M
AF Metzger-Filho, Otto
de Azambuja, Evandro
Bradbury, Ian
Saini, Kamal S.
Bines, Jose
Simon, Sergio D.
Van Dooren, Veerle
Aktan, Gursel
Pritchard, Kathleen I.
Wolff, Antonio C.
Smith, Ian
Jackisch, Christian
Lang, Istvan
Untch, Michael
Boyle, Frances
Xu, Binghe
Baselga, Jose
Perez, Edith A.
Piccart-Gebhart, Martine
TI Analysis of Regional Timelines To Set Up a Global Phase III Clinical
Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab
Treatment Optimization Experience
SO ONCOLOGIST
LA English
DT Article
DE Activation; Phase III clinical trials; Ethics committee/institutional
review board
AB Purpose. This study measured the time taken for setting up the different facets of Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO), an international phase III study being conducted in 44 participating countries.
Methods. Time to regulatory authority (RA) approval, time to ethics committee/institutional review board (EC/IRB) approval, time from study approval by EC/IRB to first randomized patient, and time from first to last randomized patient were prospectively collected in the ALTTO study. Analyses were conducted by grouping countries into either geographic regions or economic classes as per the World Bank's criteria.
Results. South America had a significantly longer time to RA approval (median: 236 days, range: 21-257 days) than Europe (median: 52 days, range: 0-151 days), North America (median: 26 days, range: 22-30 days), and Asia-Pacific (median: 62 days, range: 37-75 days). Upper-middle economies had longer times to RA approval (median: 123 days, range: 21-257 days) than high-income (median: 47 days, range: 0-112 days) and lower-middle income economies (median: 57 days, range: 37-62 days). No significant difference was observed for time to EC/IRB approval across the studied regions (median: 59 days, range 0-174 days). Overall, the median time from EC/IRB approval to first recruited patient was 169 days (range: 26-412 days).
Conclusion. This study highlights the long time intervals required to activate a global phase III trial. Collaborative research groups, pharmaceutical industry sponsors, and regulatory authorities should analyze the current system and enter into dialogue for optimizing local policies. This would enable faster access of patients to innovative therapies and enhance the efficiency of clinical research. The Oncologist 2013; 18: 134-140
C1 [Metzger-Filho, Otto] Dana Farber Canc Inst, Div Womens Canc, Boston, MA 02215 USA.
[Metzger-Filho, Otto; de Azambuja, Evandro; Saini, Kamal S.; Piccart-Gebhart, Martine] Univ Libre Brussels, Brussels, Belgium.
[Metzger-Filho, Otto; de Azambuja, Evandro; Van Dooren, Veerle; Piccart-Gebhart, Martine] Breast European Adjuvant Study Team BrEAST Data C, Brussels, Belgium.
[de Azambuja, Evandro; Piccart-Gebhart, Martine] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium.
[Saini, Kamal S.; Piccart-Gebhart, Martine] Breast Int Grp, Brussels, Belgium.
[Bines, Jose; Simon, Sergio D.] Grp Brasileiro Estudos Canc Mama GBECAM Sao Paulo, Sao Paulo, Brazil.
[Bines, Jose] INCA, Inst Nacl Canc, Rio De Janeiro, Brazil.
[Simon, Sergio D.] Univ Fed Sao Paulo, Dept Oncol Clin, Sao Paulo, Brazil.
[Aktan, Gursel] GlaxoSmithKline, Collegeville, PA USA.
[Pritchard, Kathleen I.] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
[Wolff, Antonio C.] Johns Hopkins Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA.
[Smith, Ian] Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England.
[Smith, Ian] Inst Canc Res, London SW3 6JB, England.
[Lang, Istvan] Natl Inst Oncol, Dept Med Oncol, Budapest, Hungary.
[Untch, Michael] HELIOS Klin, Dept Gynecol & Obstet, Berlin, Germany.
[Untch, Michael] HELIOS Klin, Multidisciplinary Breast Canc Ctr, Berlin, Germany.
[Xu, Binghe] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China.
[Baselga, Jose] Mem Sloan Kettering Canc Ctr, Div Hematol Oncol, New York, NY 10021 USA.
[Baselga, Jose] SOLTI Breast Canc Res Grp, Barcelona, Spain.
[Perez, Edith A.] Mayo Clin, Ctr Canc, Jacksonville, FL 32224 USA.
RP Metzger, O (reprint author), Dana Farber Canc Inst, Div Womens Canc, 450 Brookline Ave,Yawkey Bldg 1238, Boston, MA 02215 USA.
EM otto_metzger@dfci.harvard.edu
OI Wolff, Antonio/0000-0003-3734-1063
FU GlaxoSmithKline
FX The ALTTO trial is sponsored by GlaxoSmithKline. Collection, analysis,
and interpretation of the current data were done independently by an
academic group of statisticians (Frontier Science), I.B., and O.M.-F.
NR 12
TC 5
Z9 5
U1 0
U2 8
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD FEB
PY 2013
VL 18
IS 2
BP 134
EP 140
DI 10.1634/theoncologist.2012-0342
PG 7
WC Oncology
SC Oncology
GA 102YJ
UT WOS:000315880300003
PM 23359433
ER
PT J
AU Khanna, G
Naranjo, A
Hoffer, F
Mullen, E
Geller, J
Gratias, EJ
Ehrlich, PF
Perlman, EJ
Rosen, N
Grundy, P
Dome, JS
AF Khanna, Geetika
Naranjo, Arlene
Hoffer, Fredric
Mullen, Elizabeth
Geller, James
Gratias, Eric J.
Ehrlich, Peter F.
Perlman, Elizabeth J.
Rosen, Nancy
Grundy, Paul
Dome, Jeffrey S.
TI Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the
Children's Oncology Group
SO RADIOLOGY
LA English
DT Article
ID PERITONEAL CARCINOMATOSIS; INTEROBSERVER AGREEMENT; QUALITY ASSESSMENT;
NEPHROBLASTOMA; CHILDHOOD; STUDY-5
AB Purpose: To retrospectively determine the diagnostic performance of computed tomography (CT) in identifying the presence or absence of preoperative Wilms tumor rupture.
Materials and Methods: The cohort was derived from the AREN03B2 study of the Children's Oncology Group. The study was approved by the institutional review board and was compliant with HIPAA. Written informed consent was obtained before enrollment. The diagnosis of Wilms tumor rupture was established by central review of notes from surgery and/or pathologic examination. Seventy Wilms tumor cases with rupture were matched to 70 Wilms tumor controls without rupture according to age and tumor weight (within 6 months and 50 g, respectively). CT scans were independently reviewed by two radiologists, and the following CT findings were assessed: poorly circumscribed mass, perinephric fat stranding, peritumoral fat planes obscured, retroperitoneal fluid (subcapsular vs extracapsular), ascites beyond the cul-de-sac, peritoneal implants, ipsilateral pleural effusion, and intratumoral hemorrhage. All fluids were classified as hemorrhagic or nonhemorrhagic by using a cutoff of 30 HU. The relationship between CT findings and rupture was assessed with logistic regression models.
Results: The sensitivity and specificity for detecting Wilms tumor rupture were 54% (36 of 67 cases) and 88% (61 of 69 cases), respectively, for reviewer 1 and 70% (47 of 67 cases) and 88% (61 of 69 cases), respectively, for reviewer 2. Interobserver agreement was substantial (kappa = 0.76). All imaging signs tested, except peritoneal implants, intratumoral hemorrhage, and subcapsular fluid, showed a significant association with rupture (P <= .02). The attenuation of ascitic fluid did not have a significant correlation with rupture (P = .9990). Ascites beyond the cul-de-sac was the single best indicator of rupture for both reviewers, followed by perinephric fat stranding and retroperitoneal fluid for reviewers 1 and 2, respectively (P < .01).
Conclusion: CT has moderate specificity but relatively low sensitivity in the detection of preoperative Wilms tumor rupture. Ascites beyond the cul-de-sac, irrespective of attenuation, is most predictive of rupture. (C) RSNA, 2012 Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12120670/-/DC1
C1 [Khanna, Geetika] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA.
[Naranjo, Arlene] Univ Florida, Dept Biostat, Gainesville, FL USA.
[Hoffer, Fredric; Rosen, Nancy] Qual Assurance Review Ctr, Providence, RI USA.
[Mullen, Elizabeth] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mullen, Elizabeth] Harvard Univ, Childrens Hosp, Boston, MA 02115 USA.
[Geller, James] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Cincinnati, OH USA.
[Gratias, Eric J.] Univ Tennessee, Coll Med, Childrens Hosp Erlanger, Div Hematol Oncol, Chattanooga, TN USA.
[Ehrlich, Peter F.] Univ Michigan, CS Mott Childrens Hosp, Dept Surg, Ann Arbor, MI 48109 USA.
[Perlman, Elizabeth J.] Childrens Mem Med Ctr, Dept Pathol, Chicago, IL USA.
[Grundy, Paul] Stollery Childrens Hosp, Dept Pediat Hematol Oncol & Palliat Care, Edmonton, AB, Canada.
[Dome, Jeffrey S.] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Washington, DC 20010 USA.
RP Khanna, G (reprint author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, 510 S Kingshighway Blvd,Campus Box 8131, St Louis, MO 63110 USA.
EM khannag@mir.wustl.edu
FU National Institutes of Health [U10 CA98543, U10 CA98413, CA29511]
FX This research was supported by the National Institutes of Health (grants
U10 CA98543, U10 CA98413, and CA29511).
NR 19
TC 7
Z9 8
U1 0
U2 2
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD FEB
PY 2013
VL 266
IS 2
BP 610
EP 617
DI 10.1148/radiol.12120670
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 080DP
UT WOS:000314221700027
PM 23192775
ER
PT J
AU Livi, CB
Hardman, RL
Christy, BA
Dodds, SG
Jones, D
Williams, C
Strong, R
Bokov, A
Javors, MA
Ikeno, Y
Hubbard, G
Hasty, P
Sharp, ZD
AF Livi, Carolina B.
Hardman, Rulon L.
Christy, Barbara A.
Dodds, Sherry G.
Jones, Diane
Williams, Charnae
Strong, Randy
Bokov, Alex
Javors, Martin A.
Ikeno, Yuji
Hubbard, Gene
Hasty, Paul
Sharp, Zelton Dave
TI Rapamycin extends life span of Rb1(+/-) mice by inhibiting
neuroendocrine tumors
SO AGING-US
LA English
DT Article
DE mTOR; rapamycin; Rb1; neuroendocrine tumors
ID GENETICALLY HETEROGENEOUS MICE; FATAL NEOPLASTIC DISEASES;
RETINOBLASTOMA GENE; CALORIC RESTRICTION; DELAYED OCCURRENCE;
GROWTH-HORMONE; CANCER; CARCINOGENESIS; RB; LONGEVITY
AB Chronic treatment of mice with an enterically released formulation of rapamycin (eRapa) extends median and maximum life span, partly by attenuating cancer. The mechanistic basis of this response is not known. To gain a better understanding of these in vivo effects, we used a defined preclinical model of neuroendocrine cancer, Rb1(+/-) mice. Previous results showed that diet restriction (DR) had minimal or no effect on the lifespan of Rb1(+/-) mice, suggesting that the beneficial response to DR is dependent on pRb1. Since long-term eRapa treatment may at least partially mimic chronic DR in lifespan extension, we predicted that it would have a minimal effect in Rb1(+/-) mice. Beginning at 9 weeks of age until death, we fed Rb1(+/-) mice a diet without or with eRapa at 14 mg/kg food, which results in an approximate dose of 2.24 mg/kg body weight per day, and yielded rapamycin blood levels of about 4 ng/ml. Surprisingly, we found that eRapa dramatically extended life span of both female and male Rb1(+/-) mice, and slowed the appearance and growth of pituitary and decreased the incidence of thyroid tumors commonly observed in these mice. In this model, eRapa appears to act differently than DR, suggesting diverse mechanisms of action on survival and anti-tumor effects. In particular the beneficial effects of rapamycin did not depend on the dose of Rb1.
C1 [Livi, Carolina B.; Christy, Barbara A.; Dodds, Sherry G.; Jones, Diane; Williams, Charnae; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
[Livi, Carolina B.; Christy, Barbara A.; Dodds, Sherry G.; Jones, Diane; Williams, Charnae; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, San Antonio, TX 78229 USA.
[Hardman, Rulon L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Javors, Martin A.; Ikeno, Yuji; Hubbard, Gene] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Livi, Carolina B.; Christy, Barbara A.; Strong, Randy; Javors, Martin A.; Ikeno, Yuji; Hubbard, Gene; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Livi, Carolina B.; Christy, Barbara A.; Strong, Randy; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
[Strong, Randy; Ikeno, Yuji] South Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Res Serv, San Antonio, TX 78229 USA.
RP Sharp, ZD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
EM sharp@uthscsa.edu
FU NIH [ISG 1RC2AG036613-01, 2P01AG017242-12, AG13319, UL1RR025767]; The
Glenn Foundation for Medical Research; Department of Veteran Affairs (VA
Merit Review Grant); Cancer Therapy Research Center [CA054174]; NCRR [UL
1RR025767]; RCMI [G12MD007591]; NIH (CTSA, Technology Transfer
Resource); NIH (CBL)
FX The authors gratefully acknowledge Gregory Friesenhahn for rapamycin
blood level measurements, Jesse Usrey and Dr. Michael Duff Davis for
technical assistance with MRI imaging. Viviane Diaz and the Nathan Shock
Animal Core staff provided expert care for our mice. This work was
supported by the following funding agencies: NIH (ISG 1RC2AG036613-01,
Project 1, ZDS and PH; 2P01AG017242-12, PH; AG13319, YI; UL1RR025767,
CTSA, Technology Transfer Resource to ZDS and CBL supported MRI imaging
costs associated with this study), The Glenn Foundation for Medical
Research (ZDS and YI), Department of Veteran Affairs (VA Merit Review
Grant, YI). We would also like to thank the Cancer Therapy Research
Center (CA054174), the NCRR (UL 1RR025767) and the RCMI (G12MD007591)
for additional support.
NR 42
TC 38
Z9 38
U1 1
U2 5
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD FEB
PY 2013
VL 5
IS 2
BP 100
EP 110
PG 11
WC Cell Biology
SC Cell Biology
GA 104HL
UT WOS:000315982700004
PM 23454836
ER
PT J
AU Brune, K
Reng, F
Ruff, CT
Renner, B
AF Brune, K.
Reng, F.
Ruff, C. T.
Renner, B.
TI Cardiovascular Risks of Cyclooxygenase Inhibitors (NSAIDs): Biomarkers
for Risk Assessment?
SO AKTUELLE RHEUMATOLOGIE
LA German
DT Article
DE NSAID; natriuretic peptide; C-reactive peptide; cardiovascular risk;
cyclooxygenase inhbitors
ID BRAIN NATRIURETIC PEPTIDE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
C-REACTIVE PROTEIN; RHEUMATOID-ARTHRITIS; NT-PROBNP; COX-2 INHIBITORS;
PAIN THERAPY; OLDER-ADULTS; PREDICT; MORTALITY
AB Non-steroidal, anti-inflammatory drugs (NSAIDs, inhibitors of cyclooxygenases) are still worldwide the most intensively used remedies. These compounds are reliable therapeutics for muscle, joint, back, and traumatic pain. They cause, however, many unwanted side effects. Recently, the propensity of these compounds to cause cardiovascular diseases has been highlighted. As there are no alternatives available, attempts are made to single out those patients who are likely to develop unwanted cardiovascular drug effects when treated with NSAIDs. 2 widely used biomarkers were investigated as predictors of cardiovascular risks aggravated by the treatment with cyclooxygenase inhibitors. We here report on positive results of such evaluations employing the biomarker NTproBNP.
C1 [Brune, K.; Renner, B.] Univ Erlangen Nurnberg, Inst Expt & Klin Pharmakol & Toxikol, D-91054 Erlangen, Germany.
[Reng, F.; Ruff, C. T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc,TIMI Study Grp, Boston, MA 02115 USA.
RP Brune, K (reprint author), Univ Erlangen Nurnberg, Inst Expt & Klin Pharmakol & Toxikol, D-91054 Erlangen, Germany.
EM kay.brune@pharmakologie.uni-erlangen.de
NR 27
TC 0
Z9 0
U1 6
U2 13
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0341-051X
J9 AKTUEL RHEUMATOL
JI Aktuelle Rheumatol.
PD FEB
PY 2013
VL 38
IS 1
BP 45
EP 49
DI 10.1055/s-0032-1301928
PG 5
WC Rheumatology
SC Rheumatology
GA 098EF
UT WOS:000315528600006
ER
PT J
AU Blumenthal, DM
Song, ZR
Jena, AB
Ferris, TG
AF Blumenthal, Daniel M.
Song, Zirui
Jena, Anupam B.
Ferris, Timothy G.
TI Guidance for Structuring Team-Based Incentives in Healthcare
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID OF-THE-LITERATURE; KAISER-PERMANENTE; ORGANIZATIONS; INNOVATION;
LEADERSHIP; MORTALITY; PROSPECTS; MEDICARE; QUALITY; SAFETY
AB New payment methods designed to incentivize more efficient care delivery are accelerating the movement of healthcare providers into organized provider groups. More efficient healthcare delivery requires explicit structuring of care delivery processes around teams of clinicians working toward common patient care goals. Provider organizations accepting new payment methods will need to design and implement compensation systems that provide incentives for team-based care. While lessons from studies performed both outside and inside healthcare provide some guidance on designing and implementing team-based incentives, organized delivery systems face several significant barriers to accomplishing this. (Am J Manag Care. 2013;19(2):e64-e70)
C1 [Blumenthal, Daniel M.; Jena, Anupam B.; Ferris, Timothy G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Song, Zirui; Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Song, Zirui] Natl Bur Econ Res, Cambridge, MA 02138 USA.
RP Blumenthal, DM (reprint author), Massachusetts Gen Hosp, Dept Internal Med, Wang Ambulatory Care Ctr, 5th Fl,Ste 535,15 Parkman St, Boston, MA 02114 USA.
EM dblumenthal1@partners.org
FU NIA NIH HHS [F30 AG039175]
NR 49
TC 7
Z9 7
U1 2
U2 12
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD FEB
PY 2013
VL 19
IS 2
BP E64
EP E70
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 099XI
UT WOS:000315657600011
PM 23448116
ER
PT J
AU Romley, JA
Jena, AB
O'Leary, JF
Goldman, DP
AF Romley, John A.
Jena, Anupam B.
O'Leary, June F.
Goldman, Dana P.
TI Spending and Mortality in US Acute Care Hospitals
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID LIFE TREATMENT INTENSITY; REGIONAL-VARIATIONS; HEALTH; VARIABLES;
OUTCOMES; QUALITY; ASSOCIATION; VALIDATION; SELECTION; SURVIVAL
AB Background: Despite evidence that greater US Medicare spending is not associated with better quality of care at a regional level, recent studies suggest that greater hospital spending is associated with lower risk-adjusted mortality. Studies have been limited to older data, specific US states and conditions, and the Medicare population.
Objectives: To analyze the association between hospital spending and risk-adjusted inpatient mortality for 6 major medical conditions in US acute care hospitals.
Study Design: Retrospective cohort study of riskadjusted inpatient mortality, with hospital spending taken from the Dartmouth Atlas of Health Care. The study population included 2,635,510 patients admitted to 1201 US hospitals between 2003 and 2007.
Methods: Patient-level logistic regression models were used to estimate the effect of hospital spending on inpatient mortality, controlling for mortality risk, comorbidities, community characteristics (eg, median household income in a patient's zip code), hospital volume and ownership, and admission year.
Results: Patients treated at hospitals in the highest spending quintile (relative to the lowest) had lower risk-adjusted inpatient mortality for acute myocardial infarction (odds ratio [OR] 0.751, 95% confidence interval [CI] 0.656-0.859), congestive heart failure (OR 0.652, 95% CI 0.560-0.759), stroke (OR 0.852, 95% Cl, 0.739-0.983), and hip fracture (OR 0.691, 95% CI 0.545-0.876). Greater spending was associated with lower mortality primarily in nonteaching hospitals, hospitals with fewer than the median number of beds, and nonprofit/public hospitals.
Conclusions: Greater hospital spending is associated with lower risk-adjusted inpatient mortality for major medical conditions in the United States. (Am J Manag Care. 2013;19(2):e46-e54)
C1 [Romley, John A.; Goldman, Dana P.] Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA.
[Romley, John A.] RAND Corp, Santa Monica, CA USA.
[Jena, Anupam B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wang Ambulatory Care Ctr, Boston, MA USA.
[O'Leary, June F.] Pomona Coll, Dept Econ, Claremont, CA 91711 USA.
RP Romley, JA (reprint author), RAND Corp, 3335 S Figueroa St,Unit A, Los Angeles, CA 90089 USA.
EM romley@healthpolicy.usc.edu
FU National Institute on Aging [1R03AG031990-A1]; Royal Center for Health
Policy Simulation [P30AG024968]
FX This research was supported by the National Institute on Aging
(1R03AG031990-A1) and the Royal Center for Health Policy Simulation
(P30AG024968).
NR 41
TC 11
Z9 11
U1 1
U2 4
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD FEB
PY 2013
VL 19
IS 2
BP E46
EP E54
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 099XI
UT WOS:000315657600009
PM 23448114
ER
PT J
AU Fiedler, SE
Dudiki, T
Vijayaraghavan, S
Carr, DW
AF Fiedler, Sarah E.
Dudiki, Tejasvi
Vijayaraghavan, Srinivasan
Carr, Daniel W.
TI Loss of R2D2 Proteins ROPN1 and ROPN1L Causes Defects in Murine Sperm
Motility, Phosphorylation, and Fibrous Sheath Integrity
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE AKAP; fibrous sheath; OmniBank; PKA; ROPN1; sperm
ID ZONA-PELLUCIDA BINDING; TYROSINE PHOSPHORYLATION; KINASE-A; EPIDIDYMAL
MATURATION; REGULATORY SUBUNIT; MOUSE SPERMATOZOA; ANCHORING PROTEIN;
MAMMALIAN SPERMATOZOA; ACROSOME REACTION; LATE STEPS
AB The fibrous sheath (FS) is a flagellar cytoskeletal structure unique to sperm that surrounds the outer dense fibers and axoneme. Its primary components are A-kinase anchoring proteins (AKAPs) 3 and 4, which suggests that the FS affects flagellar beating via the scaffolding of signaling pathways necessary for motility. Sperm proteins ROPN1 and ROPN1L bind AKAP3. To determine the role of ROPN1 and ROPN1L in sperm function, we created mice deficient in ROPN1 (RKO), mice deficient in ROPN1L (RLKO), and double knockout mice (DKO). All three strains of mice had normal testicular morphology and spermatogenesis. Only the DKOs had obvious defects in sperm morphology (thinning and shredding of the principal piece), which was accompanied by a reduction in AKAP3 levels. RLKO mice had slightly reduced sperm motility and increased levels of ROPN1. RKO mice had moderately impaired motility and increased levels of ROPN1L. DKO sperm were immotile. We have previously determined that RKO male mice are subfertile, and DKO males are infertile. Together these data indicate that ROPN1L and ROPN1 compensate for each other in the absence of the opposing protein, possibly to maintain AKAP3 incorporation in the FS. Sperm from mice lacking ROPN1L exhibited reductions in both cAMP-dependent protein kinase (PKA) phosphorylation of a 270-kDa protein (perhaps FSCB), and in capacitation-induced tyrosine phosphorylation. Sperm from mice lacking ROPN1 had reduced levels of FSCB and increased tyrosine phosphorylation of noncapacitated sperm. These data demonstrate that mutations in ROPN1 and ROPN1L can cause defects in FS integrity, sperm motility, and PKA-dependent signaling processes, leading to male infertility.
C1 [Fiedler, Sarah E.; Carr, Daniel W.] Portland VA Med Ctr, Portland, OR USA.
[Fiedler, Sarah E.; Carr, Daniel W.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Dudiki, Tejasvi; Vijayaraghavan, Srinivasan] Kent State Univ, Dept Biol Sci, Kent, OH 44242 USA.
RP Carr, DW (reprint author), Vet Affairs Med Ctr, Mail Code R&D8,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM carrd@ohsu.edu
FU Department of Veterans' Affairs Biomedical Laboratory Research and
Development Service; Eunice Kennedy Shriver National Institute of Child
Health & Human Development [R03HD068668, HD38520]
FX Supported by the Department of Veterans' Affairs Biomedical Laboratory
Research and Development Service (D. W. C.) and by grants R03HD068668
and HD38520 to D. W. C. and S. V., respectively, from the Eunice Kennedy
Shriver National Institute of Child Health & Human Development. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the Eunice Kennedy Shriver
National Institute of Child Health & Human Development or the National
Institutes of Health.
NR 51
TC 16
Z9 16
U1 0
U2 6
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD FEB
PY 2013
VL 88
IS 2
AR 41
DI 10.1095/biolreprod.112.105262
PG 10
WC Reproductive Biology
SC Reproductive Biology
GA 103ZP
UT WOS:000315958600001
PM 23303679
ER
PT J
AU Krishnan, MS
Recht, A
Bellon, JR
Punglia, RS
AF Krishnan, Monica S.
Recht, Abram
Bellon, Jennifer R.
Punglia, Rinaa S.
TI Trade-offs associated with axillary lymph node dissection with breast
irradiation versus breast irradiation alone in patients with a positive
sentinel node in relation to the risk of non-sentinel node involvement:
implications of ACOSOG Z0011
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Decision analysis; Axillary lymph node dissection; Breast cancer
ID RANDOMIZED CLINICAL-TRIAL; CANCER-PATIENTS; REGIONAL RECURRENCE; RADICAL
MASTECTOMY; BIOPSY; WOMEN; CARCINOMA; RADIATION; METASTASES; MANAGEMENT
AB Recent data suggest that axillary lymph node dissection (ALND) may be unnecessary for patients with positive sentinel lymph node biopsy (SLNB) receiving whole-breast irradiation (ACOSOG Z0011). The purpose of this study was to use decision analysis with simulated patients to determine subgroups with positive SLNB who may still benefit from ALND. We performed a decision analysis simulating axillary recurrence (ALR) risk, lymphedema, and quality of life following breast-conserving surgery (BCS) with positive SLNB and either completion ALND and whole-breast radiation (ALND + BRT) or breast radiation (BRT) alone. Simulated patients were divided into two risk groups based on the likelihood of disease in non-sentinel axillary nodes after positive SLNB: those with risk 30-60 % ("high-risk") and those with risk under 30 % ("low-risk," similar to average Z0011 patients). In simulated patients aged 55, BRT alone resulted in 1 month of additional QALE in the low-risk group versus ALND + BRT, while ALND + BRT resulted in 9.7 months of additional QALE in the high-risk group versus BRT alone. Overall survival was similar at 5 years in this simulation with either treatment in both groups, but ALND + BRT was superior to BRT alone at 20 years in the high-risk group (42 vs. 38 %). In the low-risk group, BRT alone is preferable unless ALR risk with BRT is greater than 1.6 % or lymphedema risk with ALND is under 10 %. Patients eligible for Z0011 but at a higher risk of residual nodal disease following BCS and positive SLNB may benefit from ALND + BRT, rather than BRT alone.
C1 [Krishnan, Monica S.] Harvard Radiat Oncol Program, Boston, MA USA.
[Recht, Abram] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA.
[Bellon, Jennifer R.; Punglia, Rinaa S.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02215 USA.
RP Punglia, RS (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM rpunglia@lroc.harvard.edu
NR 54
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB
PY 2013
VL 138
IS 1
BP 205
EP 213
DI 10.1007/s10549-013-2418-0
PG 9
WC Oncology
SC Oncology
GA 099CX
UT WOS:000315598200021
PM 23338762
ER
PT J
AU Carinci, AJ
Pathak, R
Young, M
Christo, PJ
AF Carinci, Adam J.
Pathak, Ravi
Young, Mark
Christo, Paul J.
TI Complementary and Alternative Treatments for Chronic Pelvic Pain
SO CURRENT PAIN AND HEADACHE REPORTS
LA English
DT Review
DE Chronic pelvic pain; Complementary and alternative treatments; Pain
ID POLLEN EXTRACT; DOUBLE-BLIND; WOMEN; ACUPUNCTURE; TRIAL
AB Chronic pelvic pain (CPP) is a significant clinical entity that affects both men and women alike. The etiologies of CPP are multifactorial, and treatments are myriad. Complementary and Alternative Medicine (CAM) refers to non-allopathic health systems, and its use is popular in the United States. In particular, several recent studies have investigated the efficacy of various CAMpractices in the treatment of CPP. The authors systematically evaluated recent literature in this area by searching the PubMed database for English-language studies published between January 2007 and August 2012.
C1 [Carinci, Adam J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pain Med,Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Pathak, Ravi; Young, Mark] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Christo, Paul J.] Johns Hopkins Univ, Sch Med, Div Pain Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.
RP Carinci, AJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pain Med,Dept Anesthesia Crit Care & Pain Med, 15 Parkman St,Room 330, Boston, MA 02114 USA.
EM acarinci@partners.org
NR 25
TC 2
Z9 2
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1531-3433
J9 CURR PAIN HEADACHE R
JI Curr. Pain Headache Rep.
PD FEB
PY 2013
VL 17
IS 2
AR 316
DI 10.1007/s11916-012-0316-5
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 099NT
UT WOS:000315629200006
PM 23315022
ER
PT J
AU Kelkar, CA
Desai, RS
Kambadakone, A
Shetty, SJ
AF Kelkar, C. A.
Desai, R. S.
Kambadakone, A.
Shetty, S. J.
TI Multidetector CT and histological features of benign mesenchymoma of the
infratemporal space: a rare case report
SO DENTOMAXILLOFACIAL RADIOLOGY
LA English
DT Article
DE head and neck; infratemporal space; mesenchymoma
ID TONGUE; NECK; HEAD
AB Benign mesenchymoma is a soft tissue neoplasm composed of an admixture of two or more benign mesenchymal components in addition to fibrous tissue. A rare case of benign mesenchymoma of the infratemporal space in a 14-year-old boy is presented. In this case report we discuss the salient imaging and histopathological features of this rare entity. Dentomaxillofacial Radiology (2013) 42, 82002914. doi: 10.1259/dmfr/82002914
C1 [Desai, R. S.; Shetty, S. J.] Nair Hosp Dent Coll, Dept Oral & Maxillofacial Pathol, Bombay 400008, Maharashtra, India.
[Kambadakone, A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Shetty, SJ (reprint author), Nair Hosp Dent Coll, Dept Oral & Maxillofacial Pathol, Dr AL Nair Rd, Bombay 400008, Maharashtra, India.
EM docsubu@yahoo.com
NR 29
TC 0
Z9 1
U1 0
U2 2
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0250-832X
J9 DENTOMAXILLOFAC RAD
JI Dentomaxillofac. Radiol.
PD FEB
PY 2013
VL 42
IS 2
AR 82002914
DI 10.1259/dmfr/82002914
PG 7
WC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine &
Medical Imaging
SC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine &
Medical Imaging
GA 102FC
UT WOS:000315829100013
PM 22282510
ER
PT J
AU Mifflin, J
AF Mifflin, Jeffrey
TI The camera as historian: amateur photographers and historical
imagination, 18851918
SO EARLY POPULAR VISUAL CULTURE
LA English
DT Book Review
C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM jmifflin@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1746-0654
J9 EARLY POPUL VIS CULT
JI Early Popul. Vis. Cult.
PD FEB 1
PY 2013
VL 11
IS 1
BP 91
EP 94
DI 10.1080/17460654.2012.757909
PG 4
WC Humanities, Multidisciplinary
SC Arts & Humanities - Other Topics
GA 098YK
UT WOS:000315584800012
ER
PT J
AU Faustman, DL
AF Faustman, Denise L.
TI EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good
cop?
SO EXPERT REVIEW OF CLINICAL IMMUNOLOGY
LA English
DT Editorial Material
ID NF-KAPPA-B; T-CELLS; TNF; AUTOIMMUNITY; ANTIBODY; GENES
C1 [Faustman, Denise L.] Massachusetts Gen Hosp, Immunobiol Labs, MGH East, Boston, MA 02129 USA.
[Faustman, Denise L.] Harvard Univ, Sch Med, Boston, MA 02129 USA.
RP Faustman, DL (reprint author), Massachusetts Gen Hosp, Immunobiol Labs, MGH East, Room 3602, Boston, MA 02129 USA.
EM faustman@helix.mgh.harvard.edu
FU NIDDK NIH HHS [P30 DK057521]
NR 17
TC 0
Z9 0
U1 0
U2 2
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1744-666X
J9 EXPERT REV CLIN IMMU
JI Expert Rev. Clin. Immunol.
PD FEB
PY 2013
VL 9
IS 2
BP 95
EP 97
DI 10.1586/ECI.12.101
PG 3
WC Immunology
SC Immunology
GA 098UP
UT WOS:000315574900001
PM 23390937
ER
PT J
AU Lindenberger, E
Lugassy, M
Clark, E
Bixby, K
Sutcliffe, N
Shah, R
AF Lindenberger, Elizabeth
Lugassy, Mara
Clark, Elizabeth
Bixby, Kathleen
Sutcliffe, Natalie
Shah, Ruchir
TI Neurodegenerative Diseases: Palliative Care From Day One
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Lindenberger, Elizabeth] Mt Sinai Sch Med, New York, NY USA.
[Lugassy, Mara] Metropolitan Jewish Hosp, New York, NY USA.
[Clark, Elizabeth] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA.
[Bixby, Kathleen] Dept Vet Affairs, Washington, DC USA.
[Sutcliffe, Natalie] James J Peters VA Med Ctr, Bronx, NY USA.
[Shah, Ruchir] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 318
EP 319
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600018
ER
PT J
AU Talebreza, S
Bernacki, R
Kamal, A
Swetz, K
Tatum, P
Stewart, T
Widera, E
Tucker, R
AF Talebreza, Shaida
Bernacki, Rachelle
Kamal, Arif
Swetz, Keith
Tatum, Paul
Stewart, Tanya
Widera, Eric
Tucker, Rodney
TI Winning! Taking Your Presentation to the Next Level: From Abstract
Submission to Magic at the Podium
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Talebreza, Shaida] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kamal, Arif] Duke Univ, Durham, NC USA.
[Swetz, Keith] Mayo Clin, Rochester, MN USA.
[Tatum, Paul] Univ Missouri, Columbia, MO USA.
[Stewart, Tanya] Evercare Oregon, Lake Oswego, OR USA.
[Widera, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Tucker, Rodney] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 321
EP 321
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600022
ER
PT J
AU Hultman, T
Moment, A
Cole, CA
AF Hultman, Todd
Moment, Amanda
Cole, Corinne Alexander
TI Conflict Resolution in the Workplace: Separated by a Common Language
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Hultman, Todd; Cole, Corinne Alexander] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Moment, Amanda] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 324
EP 324
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600027
ER
PT J
AU Periyakoil, V
O'Neill, LB
Bernacki, R
Reilly, SS
Thomas, JD
Kapo, J
Block, S
Ferrell, B
Weissman, D
von Gunten, C
AF Periyakoil, Vyjeyanthi
O'Neill, Lynn Bunch
Bernacki, Rachelle
Reilly, Sandra Sanchez
Thomas, Jane DeLima
Kapo, Jennifer
Block, Susan
Ferrell, Betty
Weissman, David
von Gunten, Charles
TI Mentoring Academy: An Immersive Learning Workshop for Interdisciplinary
Professionals
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Periyakoil, Vyjeyanthi] Stanford Univ, Palo Alto, CA 94304 USA.
[O'Neill, Lynn Bunch] Duke Univ, Durham, NC USA.
[Bernacki, Rachelle; Thomas, Jane DeLima; Block, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Reilly, Sandra Sanchez] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Thomas, Jane DeLima] Womens Hosp Med Ctr, Boston, MA USA.
[Kapo, Jennifer] Yale Univ, Sch Med, New Haven, CT USA.
[Ferrell, Betty] City Hope Natl Med Ctr, Duarte, CA USA.
[Weissman, David] Palliat Care Educ LLC, Shorewood, WI USA.
[von Gunten, Charles] Univ Calif San Diego, San Diego, CA 92103 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 324
EP 325
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600029
ER
PT J
AU Hultman, T
Cox, S
Paukstis, B
Marshall, G
AF Hultman, Todd
Cox, Susan
Paukstis, Beverly
Marshall, Ginger
TI Workforce Planning and Policy: Mind the Gap
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Hultman, Todd] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cox, Susan] Hosp & Palliat Care Greensboro, Greensboro, NC USA.
[Paukstis, Beverly] Washington Home & Community Hosp, Washington, DC USA.
[Marshall, Ginger] Carolina Palliat Care & Hosp Network, Charlotte, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 329
EP 329
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600037
ER
PT J
AU Bailey, A
Leigh, A
Redman, A
Kennemer, D
AF Bailey, Amos
Leigh, Alexandra
Redman, Amanda
Kennemer, Darren
TI Disease Update: More Deadly than AIDS, Dying of Hepatitis C Infection in
the US
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Bailey, Amos; Kennemer, Darren] Birmingham VA Med Ctr, Birmingham, AL USA.
[Leigh, Alexandra] Univ Alabama Birmingham, Birmingham Hosp, Birmingham VA Med Ctr, Birmingham, AL USA.
[Redman, Amanda] Birmingham VA Med Ctr Birmingham, Birmingham, AL USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 333
EP 333
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600044
ER
PT J
AU Schell, J
Arnold, R
Weisbord, S
Moss, A
AF Schell, Jane
Arnold, Robert
Weisbord, Steven
Moss, Alvin (Woody)
TI The ABCs of Renal Palliative Care: Tools for Decision-Making and Symptom
Management in Kidney Disease
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Schell, Jane] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Arnold, Robert] Univ Pittsburgh, Pittsburgh, PA USA.
[Weisbord, Steven] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Moss, Alvin (Woody)] W Virginia Univ, Sch Med, Morgantown, WV USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 339
EP 340
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600054
ER
PT J
AU McMichael, B
Stewart, T
Villars, P
AF McMichael, Brian
Stewart, Tanya
Villars, Patrice
TI "We Took a Sexual History, Now What Do We Do with the Answers?!"
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [McMichael, Brian] Sect Palliat Care & Med Eth, Pittsburgh, PA USA.
[Stewart, Tanya] Evercare Oregon, Lake Oswego, OR USA.
[Villars, Patrice] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 341
EP 342
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600057
ER
PT J
AU Ullrich, C
Liaw, SN
Person, JL
Warren, T
Friebert, S
AF Ullrich, Christina
Liaw, Shih-Ning
Person, Judi Lund
Warren, Terri
Friebert, Sarah
TI The Concurrent Care Requirement for Children with Life-Threatening
Illness: Challenges and Opportunities
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Ullrich, Christina] Childrens Hosp Boston, Dana Farber Canc Inst, Boston, MA USA.
[Liaw, Shih-Ning] Univ Texas Houston, Sch Med, Houston, TX USA.
[Person, Judi Lund] Natl Hosp & Palliat Care Org, Alexandria, VA USA.
[Warren, Terri] Providence TrinityCare, Torrance, CA USA.
[Friebert, Sarah] Akron Childrens Hosp, Akron, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 346
EP 346
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600064
ER
PT J
AU Bernacki, R
Billings, JA
Block, S
AF Bernacki, Rachelle
Billings, J. Andrew
Block, Susan
TI Timing and Selection of Patients for Advance Care Planning: Where is the
Most Value Added?
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Bernacki, Rachelle; Block, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Billings, J. Andrew] Harvard Univ, Sch Med, Ctr Palliat Care, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 353
EP 354
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600076
ER
PT J
AU Aziz, W
Getter, B
Ross, J
Sanchez-Reilly, S
Lee, S
AF Aziz, Wesam
Getter, Benjamin
Ross, Jeanette
Sanchez-Reilly, Sandra
Lee, Shuko
TI YouTube as a Palliative Care Source of Information to "The World"
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Aziz, Wesam; Getter, Benjamin; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Aziz, Wesam; Getter, Benjamin; Ross, Jeanette; Sanchez-Reilly, Sandra; Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 360
EP 361
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600086
ER
PT J
AU Nash, R
Bailey, A
Bishop, J
AF Nash, Ryan
Bailey, Amos
Bishop, Jeffrey
TI A Palliative Response to the Anticipatory Corpse
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Nash, Ryan] Univ Alabama Birmingham, Ctr Palliat Care, Birmingham, AL USA.
[Bailey, Amos] Birmingham VA Med Ctr, Birmingham, AL USA.
[Bishop, Jeffrey] St Louis Univ, St Louis, MO 63103 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 363
EP 364
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600091
ER
PT J
AU Bona, K
Chabot, J
Wolfe, J
AF Bona, Kira
Chabot, Joseph
Wolfe, Joanne
TI Meeting the Material Resource Needs of Families of Children With Cancer:
Lessons for the Care of Children with Serious Illness
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Bona, Kira; Chabot, Joseph; Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 366
EP 366
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600095
ER
PT J
AU Patel, C
Abel, J
Ross, J
Lee, S
Wiesenthal, A
Sanchez-Reilly, S
AF Patel, Chikal
Abel, Jordan
Ross, Jeanette
Lee, Shuko
Wiesenthal, Alison
Sanchez-Reilly, Sandra
TI Changing Practice by Changing Hearts: Medical Students Reflecting on
Their Hands-on Palliative Care Experience
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Patel, Chikal; Abel, Jordan; Ross, Jeanette; Wiesenthal, Alison; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Patel, Chikal; Abel, Jordan; Ross, Jeanette; Lee, Shuko; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 366
EP 367
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600096
ER
PT J
AU Kaiser, R
Balish, M
Bixby, K
Tillman, D
AF Kaiser, Robert
Balish, Marshall
Bixby, Kathleen
Tillman, Douglas
TI The Promise and Perils of BiPAP: Devising Effective Clinical Practice
Guidelines for ALS Patients
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Kaiser, Robert] George Washington Univ, Sch Med, DC VA Med Ctr, Washington, DC 20052 USA.
[Balish, Marshall; Tillman, Douglas] DC VA Med Ctr, Washington, DC USA.
[Bixby, Kathleen] US Dept Vet Affairs, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 377
EP 378
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600113
ER
PT J
AU Waldman, E
Tarquini, S
AF Waldman, Elisha
Tarquini, Sarah
TI When Parents Want More: Negotiating Care in Pediatric Oncology With
Palliative Chemotherapy
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Waldman, Elisha] Childrens Hosp, Boston, MA 02115 USA.
[Waldman, Elisha; Tarquini, Sarah] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 379
EP 380
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600116
ER
PT J
AU Ahluwalia, S
Luhrs, C
Cortez, T
Bailey, A
Shreve, S
Baum, H
Zuccaro, M
AF Ahluwalia, Sangeeta
Luhrs, Carol
Cortez, Therese
Bailey, Amos
Shreve, Scott
Baum, Hannah
Zuccaro, Mary
TI The Use of Toolkits for Palliative Care Quality Improvement: The VA's
"Strive for 65 Implementation Package''
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Ahluwalia, Sangeeta; Baum, Hannah] Vet Adm, Los Angeles, CA USA.
[Luhrs, Carol] VA New York Harbor Hlth Care Syst, Brooklyn, NY USA.
[Cortez, Therese] VA Vet Integrated Serv Network 3, New York, NY USA.
[Bailey, Amos] Birmingham VA Med Ctr, Birmingham, AL USA.
[Shreve, Scott; Zuccaro, Mary] US Dept Vet Affairs, Lebanon, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 391
EP 391
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600133
ER
PT J
AU Worster, B
Strand, J
Lepp, A
AF Worster, Brooke
Strand, Jacob
Lepp, Anya
TI Palliative Care "Bucket List''-Skills Learned From Difficult Cases
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Worster, Brooke] Jefferson Univ Hosp, Philadelphia, PA USA.
[Strand, Jacob] Mayo Clin, Rochester, MN USA.
[Lepp, Anya] Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 392
EP 393
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600135
ER
PT J
AU Wilson, E
AF Wilson, Erica
TI Dying Without a Home: Understanding and Responding to Palliative and
End-of-Life Care Needs of Homeless Patients
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Wilson, Erica] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 403
EP 403
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600151
ER
PT J
AU Selvaggi, K
Fitzgerald, K
Moment, A
Rickerson, E
Bernacki, R
AF Selvaggi, Kathy
Fitzgerald, Katie
Moment, Amanda
Rickerson, Elizabeth
Bernacki, Rachelle
TI If It's Not One Thing, It's Another: The Pain Is Gone but the Suffering
Continues
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Selvaggi, Kathy; Fitzgerald, Katie] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Moment, Amanda] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Rickerson, Elizabeth] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bernacki, Rachelle] Dana Farber Canc Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 407
EP 407
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600157
ER
PT J
AU Bearden, D
Patel, K
Tucker, R
Wozencraft, C
Allman, R
Ahmed, A
AF Bearden, Donna
Patel, Kanan
Tucker, Rodney
Wozencraft, Colin
Allman, Richard
Ahmed, Ali
TI Six-Month Natural History of Hospitalized Medicare Beneficiaries With
Heart Failure Referred for Hospice Care
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Bearden, Donna; Patel, Kanan; Wozencraft, Colin; Allman, Richard; Ahmed, Ali] Univ Alabama Birmingham, Birmingham, AL USA.
[Tucker, Rodney] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL USA.
[Allman, Richard] Birmingham VA Med Ctr, Birmingham, AL USA.
[Ahmed, Ali] VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 421
EP 422
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600179
ER
PT J
AU Ersek, M
Smith, D
Richardson, D
Cannuscio, C
Moore, D
AF Ersek, Mary
Smith, Dawn
Richardson, Diane
Cannuscio, Carolyn
Moore, Denise
TI A National Study Comparing End-of-life Care for Men and Women Veterans
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Ersek, Mary; Richardson, Diane; Moore, Denise] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Smith, Dawn] Univ Penn, Dept Vet Affairs, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 429
EP 430
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600191
ER
PT J
AU Jesus, OTV
Qiu, A
Carretero, E
Oliver, DC
Sanchez-Reilly, S
AF Jesus, Ortiz Ter-Veen
Qiu, Ann
Carretero, Edgar
Oliver, Dulce Cruz
Sanchez-Reilly, Sandra
TI Barriers to Quality End of Life Care for Latinos: Hospice Healthcare
Professionals' Perspective
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Jesus, Ortiz Ter-Veen; Qiu, Ann; Carretero, Edgar; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Jesus, Ortiz Ter-Veen; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA.
[Oliver, Dulce Cruz] St Louis Univ, St Louis, MO 63103 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 436
EP 437
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600202
ER
PT J
AU Riggs, J
Woodby, L
Burgio, K
Bailey, FA
Williams, B
AF Riggs, Jennifer
Woodby, Lesa
Burgio, Kathryn
Bailey, F. Amos
Williams, Beverly
TI Don't Get Weak in Your Compassion: Bereaved Next-of-Kin's Suggestions
for Improving End-of-Life Care in VA Medical Centers
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Riggs, Jennifer] Birmingham Atlanta VA Geriatr Res Educ & Clin Cnt, Birmingham, AL USA.
[Woodby, Lesa] Birmingham VA Med Ctr, Birmingham, AL USA.
[Burgio, Kathryn; Williams, Beverly] Univ Alabama Birmingham, Birmingham, AL USA.
[Bailey, F. Amos] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 450
EP 450
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600223
ER
PT J
AU Williams, B
Bailey, FA
Woodby, L
Wittich, A
Burgio, K
AF Williams, Beverly
Bailey, F. Amos
Woodby, Lesa
Wittich, Angelina
Burgio, Kathryn
TI We Thought We Had More Time: Exploring Next-of-Kin Accounts of Hospice
and Palliative Care Discussions for Veterans Who Died in VA Medical
Centers
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY MAR 13-16, 2013
CL New Orleans, LA
SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc
C1 [Williams, Beverly; Burgio, Kathryn] Univ Alabama Birmingham, Birmingham, AL USA.
[Bailey, F. Amos] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA.
[Woodby, Lesa; Wittich, Angelina] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2013
VL 45
IS 2
BP 458
EP 459
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 100GE
UT WOS:000315684600236
ER
PT J
AU Muh, SJ
Streit, JJ
Lenarz, CJ
McCrum, C
Wanner, JP
Shishani, Y
Moraga, C
Nowinski, RJ
Edwards, TB
Warner, JJP
Walch, G
Gobezie, R
AF Muh, Stephanie J.
Streit, Jonathan J.
Lenarz, Christopher J.
McCrum, Christopher
Wanner, John Paul
Shishani, Yousef
Moraga, Claudio
Nowinski, Robert J.
Edwards, T. Bradley
Warner, Jon J. P.
Walch, Gilles
Gobezie, Reuben
TI Resection arthroplasty for failed shoulder arthroplasty
SO JOURNAL OF SHOULDER AND ELBOW SURGERY
LA English
DT Article
DE Resection arthroplasty; failed shoulder arthroplasty; reverse total
shoulder; total shoulder arthroplasty; hemiarthroplasty; prosthesis
resection; shoulder pain; shoulder replacement
ID FRACTURES; INFECTION; HUMERUS; HEAD
AB Background: As shoulder arthroplasty becomes more common, the number of failed arthroplasties requiring revision is expected to increase. When revision arthroplasty is not feasible, resection arthroplasty has been used in an attempt to restore function and relieve pain. Although outcomes data for resection arthroplasty exist, studies comparing the outcomes after the removal of different primary shoulder arthroplasties have been limited.
Materials and methods: This was a retrospective multicenter reviewof 26 patients who underwent resection arthroplasty for failure of a primary arthroplasty at a mean follow-up of 41.8 months (range, 12-130 months). Resection arthroplasty was performed for 6 failed total shoulder arthroplasties (TSAs), 7 failed hemiarthroplasties, and 13 failed reverse TSAs.
Results: Patients who underwent resection arthroplasty demonstrated significant improvement in visual analog scale pain score (6 +/- 4 preoperatively to 3 +/- 2 postoperatively). Mean active forward flexion and mean active external rotation decreased, but this difference was not significant. Subgroup analysis revealed that postoperative mean active forward flexion was significantly greater in patients undergoing resection arthroplasty after failed TSA than after reverse TSA (P = .01).
Conclusions: Resection arthroplasty is effective in relieving pain, but patients have poor postoperative function. Patients with resection arthroplasty for failed reverse shoulder arthroplasty have worse function than those with failed hemiarthroplasty or TSA. Surgeons should be aware of this when assessing postoperative function. There is no difference in functional outcome between hemiarthroplasty and TSA. Level of evidence: Level IV, Case Series, Treatment Study. (C) 2013 Journal of Shoulder and Elbow Surgery Board of Trustees.
C1 [Muh, Stephanie J.; Lenarz, Christopher J.; Wanner, John Paul; Shishani, Yousef] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Case Shoulder & Elbow Serv, Cleveland, OH 44106 USA.
[Streit, Jonathan J.] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Dept Orthopaed, Cleveland, OH 44106 USA.
[McCrum, Christopher] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
[Moraga, Claudio] Clin Alemana Santiago, Dept Orthoped Surg, Santiago, Chile.
[Nowinski, Robert J.] OrthoNeuro, New Albany, IN USA.
[Edwards, T. Bradley] Fondren Orthoped Grp, Houston, TX USA.
[Warner, Jon J. P.] Massachusetts Gen Hosp, Harvard Shoulder Serv, Boston, MA 02114 USA.
[Walch, Gilles] Shoulder Unit, Ctr Orthoped Santy, Lyon, France.
[Gobezie, Reuben] Univ Hosp Cleveland, Cleveland Shoulder Inst, Cleveland, OH 44106 USA.
RP Gobezie, R (reprint author), 5885 Landerbrook Dr,Suite 150, Mayfield Hts, OH 44124 USA.
EM clevelandshoulder@gmail.com
FU University Hospitals Case Medical Center Institutional Review Board
(IRB) for Human Investigation [11-09-17]
FX This study was approved by the University Hospitals Case Medical Center
Institutional Review Board (IRB) for Human Investigation on Jan 5, 2010
(IRB grant number, 11-09-17), Joseph Gibbons, MD, Chairman.
NR 26
TC 10
Z9 10
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1058-2746
J9 J SHOULDER ELB SURG
JI J. Shoulder Elbow Surg.
PD FEB
PY 2013
VL 22
IS 2
BP 247
EP 252
DI 10.1016/j.jse.2012.05.025
PG 6
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA 100DG
UT WOS:000315675400025
PM 22938790
ER
PT J
AU Jockel, CR
Gardenal, RM
Chen, NC
Golden, RD
Jupiter, JB
Capomassi, M
AF Jockel, Christopher R.
Gardenal, R. Martin
Chen, Neal C.
Golden, Robert D.
Jupiter, Jesse B.
Capomassi, Miguel
TI Intermediate-term outcomes for floating elbow and floating elbow variant
injuries
SO JOURNAL OF SHOULDER AND ELBOW SURGERY
LA English
DT Article
DE Floating elbow fracture; outcome
ID ORTHOPEDIC TRAUMA; INTERNAL-FIXATION; DISLOCATED ELBOW; HUMERAL SHAFT;
FRACTURES; FOREARM; MANAGEMENT; EXTREMITY
AB Background: There are limited outcome studies describing floating elbow injuries. The purpose of this report is to describe patient outcomes after floating elbow injury using the American Shoulder and Elbow Surgeons (ASES) elbow assessment form.
Materials and methods: From 1994 to 2004, 19 patients were retrospectively identified at 3 Level I trauma centers and returned for follow-up evaluation after treatment of their floating elbow injury. Patient outcomes were assessed based on physical examination and the ASES elbow form.
Results: The 19 patients were evaluated at a mean of 6.7 years (range, 2.3-13.4 years) after treatment of their floating elbow injuries. The mean ASES elbow score was 89 (range, 13-99), and the mean visual analog scale satisfaction with elbow surgery was 8.7 (range, 7-10). Fifteen of 19 patients reported continued pain in the elbow. Patient age, arm dominance, type of humeral fixation, type of forearm fixation, open fracture, multiple surgeries, and fracture pattern were not significantly associated with outcomes. Nerve injury was associated with lower ASES elbow scores (P = .03). There was also a significant correlation between the ASES elbow score and follow-up time, indicating that patients with a longer duration of follow-up had better subjective outcomes (Spearman coefficient = 0.55; P = .02).
Conclusion: Floating elbow fractures represent high-energy trauma and have significant associated injuries. Nerve injury is correlated with lower subjective outcomes. Patients continue to improve for several years with acceptable mid-term results.
Level of evidence: Level IV, Case Series, Treatment Study. (C) 2013 Journal of Shoulder and Elbow Surgery Board of Trustees.
C1 [Jockel, Christopher R.; Chen, Neal C.] Philadelphia Hand Ctr, Philadelphia, PA 19107 USA.
[Gardenal, R. Martin; Capomassi, Miguel] Inst Jaime Slullitel, Rosario, Argentina.
[Gardenal, R. Martin; Capomassi, Miguel] Hosp Emergencias HECA, Rosario, Argentina.
[Golden, Robert D.; Jupiter, Jesse B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Golden, Robert D.; Jupiter, Jesse B.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Jockel, CR (reprint author), Philadelphia Hand Ctr, 834 Chestnut St,Ste G114, Philadelphia, PA 19107 USA.
EM cjockel79@gmail.com
OI Gardenal, Ricardo Martin/0000-0003-0013-9275
FU Orthopaedic Trauma Association (OTA) [6]; AO Foundation; publisher
Elsevier Thieme
FX This research was supported by the Orthopaedic Trauma Association (OTA)
research grant #6.; Neal C. Chen, MD, is an unpaid consultant for
Medartis. Jesse B. Jupiter, MD, is a paid consultant for OHK Medical
Devices Inc and an unpaid consultant for Synthes, Eisomed. He receives
research support from the AO Foundation, and receives royalties from the
publisher Elsevier Thieme. The other authors, their immediate families,
and any research foundations with which they are affiliated have not
received any financial payments or other benefits from any commercial
entity related to the subject of this article.
NR 23
TC 3
Z9 4
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1058-2746
J9 J SHOULDER ELB SURG
JI J. Shoulder Elbow Surg.
PD FEB
PY 2013
VL 22
IS 2
BP 280
EP 285
DI 10.1016/j.jse.2012.11.008
PG 6
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA 100DG
UT WOS:000315675400030
PM 23352472
ER
PT J
AU Miller, MW
Reardon, AF
Wolf, EJ
Prince, LB
Hein, CL
AF Miller, Mark W.
Reardon, Annemarie F.
Wolf, Erika J.
Prince, Lauren B.
Hein, Christina L.
TI Alcohol and Drug Abuse Among US Veterans: Comparing Associations With
Intimate Partner Substance Abuse and Veteran Psychopathology
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; VA HEALTH-CARE; RELATIONSHIP STABILITY;
PSYCHIATRIC-DISORDERS; ANXIETY DISORDERS; COMMUNITY SAMPLE; HEAVY
DRINKING; PTSD; COMORBIDITY; DEPENDENCE
AB This study examined the relative influences of posttraumatic stress disorder (PTSD), other psychopathology, and intimate partner alcohol and drug use on substance-related problems in U.S. veterans (242 couples, N = 484). Hierarchical regression analyses revealed that partner alcohol and drug use severity explained more variance in veteran alcohol use and drug use (20% and 13%, respectively) than did veteran PTSD, adult antisocial behavior, or depression symptoms combined (6% for veteran alcohol use; 7% for veteran drug use). Findings shed new light on the influence of relationship factors on veteran alcohol and drug use and underscore the importance of couples-oriented approaches to treating veterans with comorbid PTSD and substance abuse.
C1 [Miller, Mark W.; Wolf, Erika J.; Prince, Lauren B.; Hein, Christina L.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
[Miller, Mark W.; Wolf, Erika J.; Prince, Lauren B.; Hein, Christina L.] Dept Psychiat, Boston, MA USA.
[Miller, Mark W.; Wolf, Erika J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Reardon, Annemarie F.] VA Boston Healthcare Syst, Boston, MA 02130 USA.
RP Miller, MW (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 2, 150 South Huntington Ave, Boston, MA 02130 USA.
EM mark.miller5@va.gov
RI Miller, Mark/G-7322-2011;
OI Miller, Mark/0000-0001-6393-8563; Wolf, Erika/0000-0003-2666-2435
FU CSRD VA [I01 CX000431]; NIMH NIH HHS [R01 MH079806, R01MH079806]
NR 39
TC 2
Z9 2
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD FEB
PY 2013
VL 26
IS 1
BP 71
EP 76
DI 10.1002/jts.21773
PG 6
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 092CH
UT WOS:000315095900009
PM 23325433
ER
PT J
AU Iverson, KM
Litwack, SD
Pineles, SL
Suvak, MK
Vaughn, RA
Resick, PA
AF Iverson, Katherine M.
Litwack, Scott D.
Pineles, Suzanne L.
Suvak, Michael K.
Vaughn, Rachel A.
Resick, Patricia A.
TI Predictors of Intimate Partner Violence Revictimization: The Relative
Impact of Distinct PTSD Symptoms, Dissociation, and Coping Strategies
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; WOMEN; SELF;
REABUSE; TRAUMA; SCALE; RESOURCES; SURVIVORS; MEDIATOR
AB Psychological distress and coping strategies following intimate partner violence (IPV) victimization may impact survivors' risk for future IPV. The current study prospectively examined the impact of distinct posttraumatic stress disorder (PTSD) symptom clusters (reexperiencing, avoidance, numbing, and hyperarousal), dissociation, and coping strategies (engagement and disengagement coping) on IPV revictimization among recently abused women. Women (N = 69) who were seeking services for IPV and experienced their most recent episode of physical IPV between 2 weeks and 6 months prior to study enrollment completed measures of physical IPV, psychological distress, and coping strategies at baseline and at 6-month follow-up. The women averaged 36 years of age and 67% of the sample was African American. Separate Poisson regression analyses revealed that PTSD hyperarousal symptoms, dissociation, engagement coping, and disengagement coping each significantly predicted physical IPV revictimization at the 6-month follow-up (with effect sizes ranging from a 1.20-1.34 increase in the likelihood of Time 2 physical IPV with a 1 SD increase in the predictor). When these significant predictors were examined together in a single Poisson regression model, only engagement and disengagement coping were found to predict physical IPV revictimization such that disengagement coping was associated with higher revictimization risk (1.29 increase in the likelihood of Time 2 physical IPV with one SD increase in disengagement coping) and engagement coping was associated with lower revictimization risk (1.30 decrease in the likelihood of Time 2 physical IPV with one SD increase in engagement coping). The current findings suggest that coping strategies are important and potentially malleable predictors of physical IPV revictimization.
C1 [Iverson, Katherine M.; Pineles, Suzanne L.; Suvak, Michael K.; Vaughn, Rachel A.; Resick, Patricia A.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA.
[Iverson, Katherine M.; Pineles, Suzanne L.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Litwack, Scott D.] VA Boston Healthcare Syst, Behav Hlth Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA.
[Suvak, Michael K.] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA.
[Resick, Patricia A.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA.
[Resick, Patricia A.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
RP Iverson, KM (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave,116B-3, Boston, MA 02130 USA.
EM katherine.iverson@va.gov
FU NIMH NIH HHS [1-R01-MH55542]
NR 52
TC 17
Z9 18
U1 5
U2 46
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD FEB
PY 2013
VL 26
IS 1
BP 102
EP 110
DI 10.1002/jts.21781
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 092CH
UT WOS:000315095900013
PM 23417878
ER
PT J
AU Jakupcak, M
Hoerster, KD
Blais, RK
Malte, CA
Hunt, S
Seal, K
AF Jakupcak, Matthew
Hoerster, Katherine D.
Blais, Rebecca K.
Malte, Carol A.
Hunt, Stephen
Seal, Karen
TI Readiness for Change Predicts VA Mental Healthcare Utilization Among
Iraq and Afghanistan War Veterans
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; TRANSTHEORETICAL MODEL; RISK-FACTORS;
DIAGNOSES; PTSD; PSYCHOTHERAPY; ASSOCIATION; ENGAGEMENT; SERVICES;
COMBAT
AB Many veterans present to Veteran Affairs (VA) care intending to seek mental health treatment for symptoms of posttraumatic stress disorder (PTSD), depression, and/or alcohol misuse, yet most subsequently underutilize mental health care. This study examined the association of readiness for change with outpatient VA mental health care utilization in 104 treatment-seeking Iraq and Afghanistan war veterans who screened positive for PTSD, depression, and/or alcohol misuse at intake. Multivariate analyses demonstrated that readiness for change assessed at intake was positively associated (Incident Rate Ratio [IRR] = 1.22) with prospective outpatient mental health care utilization with demographic factors, military characteristics, and mental health burden in the model. Results suggest that interventions that target readiness to change, such as motivational interviewing, may improve treatment utilization in veterans presenting for mental health care.
C1 [Jakupcak, Matthew; Hoerster, Katherine D.; Blais, Rebecca K.; Malte, Carol A.; Hunt, Stephen] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA.
[Jakupcak, Matthew; Hoerster, Katherine D.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Blais, Rebecca K.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA.
[Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA USA.
[Seal, Karen] Univ Calif San Francisco, Dept Med & Psychiat, San Francisco, CA 94143 USA.
RP Jakupcak, M (reprint author), VA Puget Sound Hlth Care Syst, Deployment Hlth Serv, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM matthew.jakupcak@va.gov
NR 22
TC 4
Z9 4
U1 1
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD FEB
PY 2013
VL 26
IS 1
BP 165
EP 168
DI 10.1002/jts.21768
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 092CH
UT WOS:000315095900021
PM 23319359
ER
PT J
AU Fontana, CR
Lerman, MA
Patel, N
Grecco, C
Costa, CAD
Amiji, MM
Bagnato, VS
Soukos, NS
AF Fontana, Carla R.
Lerman, Mark A.
Patel, Niraj
Grecco, Clovis
de Souza Costa, Carlos A.
Amiji, Mansoor M.
Bagnato, Vanderlei S.
Soukos, Nikolaos S.
TI Safety assessment of oral photodynamic therapy in rats
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Photodynamic therapy; Photosensitizers; Histological analysis;
Fluorescence
ID STAPHYLOCOCCUS-AUREUS; WOUND INFECTIONS; CANDIDA-ALBICANS;
METHYLENE-BLUE; IN-VITRO; NANOPARTICLES; INACTIVATION; LIGHT;
PHOTOSENSITIZERS; PHOTOFRIN
AB Photodynamic therapy (PDT) is based on the synergism of a photosensitive drug (a photosensitizer) and visible light to destroy target cells (e.g., malignant, premalignant, or bacterial cells). The aim of this study was to investigate the response of normal rat tongue mucosa to PDT following the topical application of hematoporphyrin derivative (PhotogemA (R)), PhotodithazineA (R), methylene blue (MB), and poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with MB. One hundred and thirty three rats were randomly divided in various groups: the PDT groups were treated with the photosensitizers for 10 min followed by exposure to red light. Those in control groups received neither photosensitizer nor light, and they were subjected to light exposure alone or to photosensitizer alone. Fluorescent signals were obtained from tongue tissue immediately after the topical application of photosensitizers and 24 h following PDT. Histological changes were evaluated at baseline and at 1, 3, 7, and 15 days post-PDT treatment. Fluorescence was detected immediately after the application of the photosensitizers, but not 24 h following PDT. Histology revealed intact mucosa in all experimental groups at all evaluation time points. The results suggest that there is a therapeutic window where PDT with PhotogemA (R), PhotodithazineA (R), MB, and MB-loaded PLGA nanoparticles could safely target oral pathogenic bacteria without damaging normal oral tissue.
C1 [Fontana, Carla R.] Univ Sao Paulo State UNESP, Sch Pharmaceut Sci, Dept Clin Anal, BR-14801960 Araraquara, Sau Paulo, Brazil.
[Lerman, Mark A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Patel, Niraj; Soukos, Nikolaos S.] Forsyth Inst, Appl Mol Photomed Lab, Boston, MA 02115 USA.
[Grecco, Clovis; Bagnato, Vanderlei S.] Univ Sao Paulo, Inst Phys Sao Carlos, BR-15980900 Sao Carlos, Sau Paulo, Brazil.
[de Souza Costa, Carlos A.] Univ Sao Paulo State UNESP, Dent Sch Araraquara, BR-14801960 Araraquara, Sau Paulo, Brazil.
[Patel, Niraj; Amiji, Mansoor M.] Northeastern Univ, Bouve Coll Hlth Sci, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Fontana, CR (reprint author), Univ Sao Paulo State UNESP, Sch Pharmaceut Sci, Dept Clin Anal, 1621 Expedicionarios Brasil St, BR-14801960 Araraquara, Sau Paulo, Brazil.
EM fontanacr@fcfar.unesp.br
RI Amiji, Mansoor/A-4365-2014; Grecco, Clovis/L-2401-2014; USP,
CePOF/J-3608-2015; de Souza Costa, Carlos Alberto/C-6799-2012; Sao
Carlos Institute of Physics, IFSC/USP/M-2664-2016; Bagnato,
Vanderlei/C-3133-2012
OI Amiji, Mansoor/0000-0001-6170-881X; de Souza Costa, Carlos
Alberto/0000-0002-7455-6867;
FU FAPESP
FX This work was supported by FAPESP.
NR 38
TC 7
Z9 7
U1 0
U2 19
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-8921
J9 LASER MED SCI
JI Lasers Med. Sci.
PD FEB
PY 2013
VL 28
IS 2
BP 479
EP 486
DI 10.1007/s10103-012-1091-6
PG 8
WC Engineering, Biomedical; Surgery
SC Engineering; Surgery
GA 098WI
UT WOS:000315579400018
PM 22467011
ER
PT J
AU Priyadarshini, R
Cugini, C
Arndt, A
Chen, T
Tjokro, NO
Goodman, SD
Davey, ME
AF Priyadarshini, Richa
Cugini, Carla
Arndt, Annette
Chen, Tsute
Tjokro, Natalia O.
Goodman, Steven D.
Davey, Mary E.
TI The nucleoid-associated protein HU beta affects global gene expression
in Porphyromonas gingivalis
SO MICROBIOLOGY-SGM
LA English
DT Article
ID INTEGRATION HOST FACTOR; DNA-BINDING PROTEIN; ESCHERICHIA-COLI; HEME
UTILIZATION; INCREASED SENSITIVITY; PERIODONTAL-DISEASE;
BACILLUS-SUBTILIS; SOS INDUCTION; CRUCIFORM DNA; CELL-DIVISION
AB HU is a non-sequence-specific DNA-binding protein and one of the most abundant nucleoid-associated proteins in the bacterial cell. Like Escherichia coli, the genome of Porphyromonas gingivalis is predicted to encode both the HU alpha (PG1258) and the HU beta (PG0121) subunit. We have previously reported that PG0121 encodes a non-specific DNA-binding protein and that PG0121 is co-transcribed with the K-antigen capsule synthesis operon. We also reported that deletion of PG0121 resulted in downregulation of capsule operon expression and produced a P. gingivalis strain that is phenotypically deficient in surface polysaccharide production. Here, we show through complementation experiments in an E. coli MG1655 hupAB double mutant strain that PG0121 encodes a functional HU homologue. Microarray and quantitative RT-PCR analysis were used to further investigate global transcriptional regulation by HU beta using comparative expression profiling of the PG0121 (HU beta) mutant strain to the parent strain, W83. Our analysis determined that expression of genes encoding proteins involved in a variety of biological functions, including iron acquisition, cell division and translation, as well as a number of predicted nucleoid associated proteins were altered in the PG0121 mutant. Phenotypic and quantitative real-time-PCR (qRT-PCR) analyses determined that under iron-limiting growth conditions, cell division and viability were defective in the PG0121 mutant. Collectively, our studies show that PG0121 does indeed encode a functional HU homologue, and HU beta has global regulatory functions in P. gingivalis; it affects not only production of capsular polysaccharides but also expression of genes involved in basic functions, such as cell wall synthesis, cell division and iron uptake.
C1 [Priyadarshini, Richa; Cugini, Carla; Chen, Tsute; Davey, Mary E.] Forsyth Inst, Dept Mol Genet, Cambridge, MA USA.
[Priyadarshini, Richa; Cugini, Carla; Chen, Tsute; Davey, Mary E.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Arndt, Annette] Univ Ulm, Inst Microbiol & Biotechnol, D-89069 Ulm, Germany.
[Tjokro, Natalia O.; Goodman, Steven D.] Univ So Calif, Div Biomed Sci, Herman Ostrow Sch Dent, Los Angeles, CA USA.
RP Davey, ME (reprint author), Forsyth Inst, Dept Mol Genet, Cambridge, MA USA.
EM mdavey@forsyth.org
FU National Institute of Dental and Craniofacial Research NIDCR [DE-019117]
FX The authors wish to thank Jennifer Downey for her technical expertise
and advice. This work was supported by a grant from the National
Institute of Dental and Craniofacial Research NIDCR (DE-019117) to M. E.
D.
NR 75
TC 7
Z9 7
U1 1
U2 4
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD FEB
PY 2013
VL 159
BP 219
EP 229
DI 10.1099/mic.0.061002-0
PN 2
PG 11
WC Microbiology
SC Microbiology
GA 103QL
UT WOS:000315933900002
PM 23175503
ER
PT J
AU Cugini, C
Stephens, DN
Nguyen, D
Kantarci, A
Davey, ME
AF Cugini, Carla
Stephens, Danielle N.
Daniel Nguyen
Kantarci, Alpdogan
Davey, Mary E.
TI Arginine deiminase inhibits Porphyromonas gingivalis surface attachment
SO MICROBIOLOGY-SGM
LA English
DT Article
ID PSEUDOMONAS-AERUGINOSA; PERIODONTAL-DISEASE; ESCHERICHIA-COLI; ORAL
BACTERIA; PEPTIDYLARGININE DEIMINASE; BACTEROIDES-GINGIVALIS; CATALYTIC
MECHANISM; CRYSTAL-STRUCTURES; CARIES EXPERIENCE; BIOFILM FORMATION
AB The oral cavity is host to a complex microbial community whose maintenance depends on an array of cell-to-cell interactions and communication networks, with little known regarding the nature of the signals or mechanisms by which they are sensed and transmitted. Determining the signals that control attachment, biofilm development and outgrowth of oral pathogens is fundamental to understanding pathogenic biofilm development. We have previously identified a secreted arginine deiminase (ADI) produced by Streptococcus intermedius that inhibited biofilm development of the commensal pathogen Porphyromonas gingivalis through downregulation of genes encoding the major (fimA) and minor (mfa1) fimbriae, both of which are required for proper biofilm development. Here we report that this inhibitory effect is dependent on enzymic activity. We have successfully cloned, expressed and defined the conditions to ensure that ADI from S. intermedius is enzymically active. Along with the cloning of the wild-type allele, we have created a catalytic mutant (ADIC399S), in which the resulting protein is not able to catalyse the hydrolysis of L-arginine to L-citrulline. P. gingivalis is insensitive to the ADIC399S catalytic mutant, demonstrating that enzymic activity is required for the effects of ADI on biofilm formation. Biofilm formation is absent under L-arginine-deplete conditions, and can be recovered by the addition of the amino acid. Taken together, the results indicate that arginine is an important signal that directs biofilm formation by this anaerobe. Based on our findings, we postulate that ADI functions to reduce arginine levels and, by a yet to be identified mechanism, signals P. gingivalis to alter biofilm development. ADI release from the streptococcal cell and its cross-genera effects are important findings in understanding the nature of inter-bacterial signalling and biofilm-mediated diseases of the oral cavity.
C1 [Cugini, Carla; Davey, Mary E.] Forsyth Inst, Dept Mol Genet, Cambridge, MA USA.
[Cugini, Carla; Davey, Mary E.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Stephens, Danielle N.; Daniel Nguyen; Kantarci, Alpdogan] Forsyth Inst, Dept Periodontol, Cambridge, MA USA.
RP Davey, ME (reprint author), Forsyth Inst, Dept Mol Genet, Cambridge, MA USA.
EM mdavey@forsyth.org
FU National Institutes of Health-National Institute of Dental and
Craniofacial Research [DE022484 NIH-NIDCR, DE019117 NIH-NIDCR, DE20906
NIH-NIDCR]
FX This work was supported by National Institutes of Health-National
Institute of Dental and Craniofacial Research grants DE022484 NIH-NIDCR,
awarded to C. C., DE019117 NIH-NIDCR, awarded to M. E. D, and DE20906
NIH-NIDCR, awarded to A. K.
NR 54
TC 7
Z9 7
U1 1
U2 13
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD FEB
PY 2013
VL 159
BP 275
EP 285
DI 10.1099/mic.0.062695-0
PN 2
PG 11
WC Microbiology
SC Microbiology
GA 103QL
UT WOS:000315933900008
PM 23242802
ER
PT J
AU Molineros, JE
Maiti, AK
Sun, C
Looger, LL
Han, SZ
Kim-Howard, X
Glenn, S
Adler, A
Kelly, JA
Niewold, TB
Gilkeson, GS
Brown, EE
Alarcon, GS
Edberg, JC
Petri, M
Ramsey-Goldman, R
Reveille, JD
Vila, LM
Freedman, BI
Tsao, BP
Criswell, LA
Jacob, CO
Moore, JH
Vyse, TJ
Langefeld, CL
Guthridge, JM
Gaffney, PM
Moser, KL
Scofield, RH
Alarcon-Riquelme, ME
Williams, SM
Merrill, JT
James, JA
Kaufman, KM
Kimberly, RP
Harley, JB
Nath, SK
AF Molineros, Julio E.
Maiti, Amit K.
Sun, Celi
Looger, Loren L.
Han, Shizhong
Kim-Howard, Xana
Glenn, Stuart
Adler, Adam
Kelly, Jennifer A.
Niewold, Timothy B.
Gilkeson, Gary S.
Brown, Elizabeth E.
Alarcon, Graciela S.
Edberg, Jeffrey C.
Petri, Michelle
Ramsey-Goldman, Rosalind
Reveille, John D.
Vila, Luis M.
Freedman, Barry I.
Tsao, Betty P.
Criswell, Lindsey A.
Jacob, Chaim O.
Moore, Jason H.
Vyse, Timothy J.
Langefeld, Carl L.
Guthridge, Joel M.
Gaffney, Patrick M.
Moser, Kathy L.
Scofield, R. Hal
Alarcon-Riquelme, Marta E.
Williams, Scott M.
Merrill, Joan T.
James, Judith A.
Kaufman, Kenneth M.
Kimberly, Robert P.
Harley, John B.
Nath, Swapan K.
CA BIOLUPUS Network
TI Admixture Mapping in Lupus Identifies Multiple Functional Variants
within IFIH1 Associated with Apoptosis, Inflammation, and Autoantibody
Production
SO PLOS GENETICS
LA English
DT Article
ID CLASS-SWITCH RECOMBINATION; WHOLE-GENOME ASSOCIATION; BINDING-PROTEIN;
RIG-I; POPULATION-STRUCTURE; AFRICAN-AMERICANS; REVISED CRITERIA; GENE
DISCOVERY; DISEASE GENES; GENOTYPE DATA
AB Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease with a strong genetic component. African-Americans (AA) are at increased risk of SLE, but the genetic basis of this risk is largely unknown. To identify causal variants in SLE loci in AA, we performed admixture mapping followed by fine mapping in AA and European-Americans (EA). Through genome-wide admixture mapping in AA, we identified a strong SLE susceptibility locus at 2q22-24 (LOD = 6.28), and the admixture signal is associated with the European ancestry (ancestry risk ratio similar to 1.5). Large-scale genotypic analysis on 19,726 individuals of African and European ancestry revealed three independently associated variants in the IFIH1 gene: an intronic variant, rs13023380 [P-meta = 5.20x10(-14); odds ratio, 95% confidence interval = 0.82 (0.78-0.87)], and two missense variants, rs1990760 (Ala946Thr) [P-meta = 3.08x10(-7); 0.88 (0.84-0.93)] and rs10930046 (Arg460His) [P-dom = 1.16x10(-8); 0.70 (0.62-0.79)]. Both missense variants produced dramatic phenotypic changes in apoptosis and inflammation-related gene expression. We experimentally validated function of the intronic SNP by DNA electrophoresis, protein identification, and in vitro protein binding assays. DNA carrying the intronic risk allele rs13023380 showed reduced binding efficiency to a cellular protein complex including nucleolin and lupus autoantigen Ku70/80, and showed reduced transcriptional activity in vivo. Thus, in SLE patients, genetic susceptibility could create a biochemical imbalance that dysregulates nucleolin, Ku70/80, or other nucleic acid regulatory proteins. This could promote antibody hypermutation and auto-antibody generation, further destabilizing the cellular network. Together with molecular modeling, our results establish a distinct role for IFIH1 in apoptosis, inflammation, and autoantibody production, and explain the molecular basis of these three risk alleles for SLE pathogenesis.
C1 [Molineros, Julio E.; Maiti, Amit K.; Sun, Celi; Han, Shizhong; Kim-Howard, Xana; Glenn, Stuart; Adler, Adam; Kelly, Jennifer A.; Guthridge, Joel M.; Gaffney, Patrick M.; Moser, Kathy L.; Scofield, R. Hal; Alarcon-Riquelme, Marta E.; James, Judith A.; Kaufman, Kenneth M.; Nath, Swapan K.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA.
[Looger, Loren L.] Howard Hughes Med Inst, Ashburn, VA USA.
[Han, Shizhong] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA.
[Niewold, Timothy B.] Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA.
[Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA.
[Brown, Elizabeth E.; Alarcon, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Petri, Michelle] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Ramsey-Goldman, Rosalind] Northwestern Univ, Div Rheumatol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Dept Rheumatol & Clin Immunogenet, Houston, TX USA.
[Vila, Luis M.] Univ Puerto Rico, Div Rheumatol, Dept Med, San Juan, PR 00936 USA.
[Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA.
[Tsao, Betty P.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA.
[Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA 94143 USA.
[Jacob, Chaim O.] Univ So Calif, Dept Med, Los Angeles, CA USA.
[Moore, Jason H.] Dartmouth Med Sch, Dept Genet, Lebanon, NH USA.
[Vyse, Timothy J.] Kings Coll London, Div Genet & Mol Med, London WC2R 2LS, England.
[Vyse, Timothy J.] Kings Coll London, Div Immunol Infect & Inflammatory Dis, London WC2R 2LS, England.
[Langefeld, Carl L.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Wake Forest, NC USA.
[Moser, Kathy L.; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Oklahoma City, OK 73190 USA.
[Alarcon-Riquelme, Marta E.] Univ Granada, Ctr Genom & Invest Oncol GENyO Pfizer, Granada, Spain.
[Williams, Scott M.] Dartmouth Coll, Dept Genet, Geisel Sch Med, Hanover, NH 03755 USA.
[Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Res Program, Oklahoma City, OK 73104 USA.
[Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA.
[Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
RP Molineros, JE (reprint author), Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.
EM Swapan-Nath@omrf.org
OI Kimberly, Robert/0000-0002-5330-3086; Alarcon Riquelme, Marta
Eugenia/0000-0002-7632-4154; Niewold, Timothy/0000-0003-3532-6660
FU National Institutes of Health [AR060366, AR049084, AI094377, AR053483,
AR33062, RR020143, RR0155577, AI082714, AR058554, AI083194, AI024717,
GM103510, AR057172]; U.S. Department of Defense [AI082714, AI024717,
PR094002, AR002138, AR30692, RR025741, AR042460, AI031584, AI101934,
AR062277, AR048940, AR043814, DE018209, AI062629, DE015223, RR027190,
P60 AR053308, R01 AR44804, M01 RR-00079, UL1 TR000165]; U.S. Department
of Veterans Affairs [IMMA 9]; Alliance for Lupus Research; Swedish
Research Council; Kirkland Scholar Award; Instituto de Salud Carlos III
(European Union Fonds Europeen de Developpement Regional (FEDER))
[PS09/00129]; European Science Foundation (BIOLUPUS)
FX This work was supported by grants from the National Institutes of Health
(AR060366, AR049084, AI094377, AR053483, AR33062, RR020143, RR0155577,
AI082714, AR058554, AI083194, AI024717, GM103510, AR057172), the U.S.
Department of Defense (PR094002, AR002138, AR30692, RR025741, AR042460,
AI024717, AI031584, AI101934, AR062277, AR048940, AR043814, DE018209,
AI082714, AI062629, DE015223, RR027190, PR094002, P60 AR053308, R01
AR44804, M01 RR-00079, UL1 TR000165), the U.S. Department of Veterans
Affairs (IMMA 9), the Alliance for Lupus Research, the Swedish Research
Council, Kirkland Scholar Award, Instituto de Salud Carlos III
(PS09/00129, co-financed through the European Union Fonds Europeen de
Developpement Regional (FEDER)), and European Science Foundation
(BIOLUPUS). The funders had no role in the study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 77
TC 37
Z9 38
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD FEB
PY 2013
VL 9
IS 2
AR e1003222
DI 10.1371/journal.pgen.1003222
PG 19
WC Genetics & Heredity
SC Genetics & Heredity
GA 099RG
UT WOS:000315638300005
PM 23441136
ER
PT J
AU Shi, W
Bain, AL
Schwer, B
Al-Ejeh, F
Smith, C
Wong, L
Chai, H
Miranda, MS
Ho, U
Kawaguchi, M
Miura, Y
Finnie, JW
Wall, M
Heierhorst, J
Wicking, C
Spring, KJ
Alt, FW
Khanna, KK
AF Shi, Wei
Bain, Amanda L.
Schwer, Bjoern
Al-Ejeh, Fares
Smith, Corey
Wong, Lee
Chai, Hua
Miranda, Mariska S.
Ho, Uda
Kawaguchi, Makoto
Miura, Yutaka
Finnie, John W.
Wall, Meaghan
Heierhorst, Jorg
Wicking, Carol
Spring, Kevin J.
Alt, Frederick W.
Khanna, Kum Kum
TI Essential Developmental, Genomic Stability, and Tumour Suppressor
Functions of the Mouse Orthologue of hSSB1/NABP2
SO PLOS GENETICS
LA English
DT Article
ID REPLICATION PROTEIN-A; CLASS-SWITCH RECOMBINATION; COSTO-MANDIBULAR
SYNDROME; ABNORMAL RIB DEVELOPMENT; DNA-DAMAGE RESPONSE;
ATAXIA-TELANGIECTASIA; EPITHELIAL-CELLS; PROGENITOR CELLS;
SECKEL-SYNDROME; MICE
AB Single-stranded DNA binding proteins (SSBs) regulate multiple DNA transactions, including replication, transcription, and repair. We recently identified SSB1 as a novel protein critical for the initiation of ATM signaling and DNA double-strand break repair by homologous recombination. Here we report that germline Ssb1(-/-) embryos die at birth from respiratory failure due to severe rib cage malformation and impaired alveolar development, coupled with additional skeletal defects. Unexpectedly, Ssb1(-/-) fibroblasts did not exhibit defects in Atm signaling or gamma-H2ax focus kinetics in response to ionizing radiation (IR), and B-cell specific deletion of Ssb1 did not affect class-switch recombination in vitro. However, conditional deletion of Ssb1 in adult mice led to increased cancer susceptibility with broad tumour spectrum, impaired male fertility with testicular degeneration, and increased radiosensitivity and IR-induced chromosome breaks in vivo. Collectively, these results demonstrate essential roles of Ssb1 in embryogenesis, spermatogenesis, and genome stability in vivo.
C1 [Shi, Wei; Bain, Amanda L.; Al-Ejeh, Fares; Smith, Corey; Miranda, Mariska S.; Ho, Uda; Spring, Kevin J.; Khanna, Kum Kum] Queensland Inst Med Res, Herston, Qld 4006, Australia.
[Bain, Amanda L.; Spring, Kevin J.; Khanna, Kum Kum] Griffith Univ, Sch Biomol & Phys Sci, Nathan, Qld 4111, Australia.
[Schwer, Bjoern; Chai, Hua; Alt, Frederick W.] Childrens Hosp, Howard Hughes Med Inst, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Schwer, Bjoern; Chai, Hua; Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet & Pediat, Boston, MA USA.
[Wong, Lee] Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Melbourne, Vic 3004, Australia.
[Miranda, Mariska S.; Spring, Kevin J.; Khanna, Kum Kum] Univ Queensland, Sch Med, Herston, Qld, Australia.
[Kawaguchi, Makoto; Miura, Yutaka] Nagoya City Univ, Grad Sch Med Sci, Dept Bioregulat & Mol Neurobiol, Nagoya, Aichi, Japan.
[Finnie, John W.] SA Pathol, Inst Med & Vet Sci, Adelaide, SA, Australia.
[Wall, Meaghan] St Vincents Hosp, Victorian Canc Cytogenet Serv, Melbourne, Vic, Australia.
[Wall, Meaghan; Heierhorst, Jorg] St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
[Heierhorst, Jorg] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
[Wicking, Carol] Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia.
RP Shi, W (reprint author), Queensland Inst Med Res, Bramston Terrace, Herston, Qld 4006, Australia.
EM kumkum.khanna@qimr.edu.au
RI Bain, Amanda/B-4907-2013; Wong, Lee/H-9757-2012; Al-Ejeh,
Fares/M-7032-2016;
OI Bain, Amanda/0000-0002-4980-2114; Wong, Lee/0000-0002-4005-7330;
Al-Ejeh, Fares/0000-0002-1553-0077; Wicking, Carol/0000-0002-7225-3803;
Spring, Kevin/0000-0003-0601-924X
FU National Health and Medical Research Council (NHMRC) Project [552472,
1031327]; National Institutes of Health [5R01AI077595, 5T32CA009382];
Victorian Government's Operational Infrastructure Support Program; NHMRC
FX This work was supported by National Health and Medical Research Council
(NHMRC) Project Grants 552472 and 1031327 (KKK), National Institutes of
Health Grants 5R01AI077595 (FWA) and 5T32CA009382 (BS), and a Victorian
Government's Operational Infrastructure Support Program (JH). KKK is an
NHMRC Senior Principal Research Fellow; JH and CW are NHMRC Senior
Research Fellows. FWA is an Investigator of the Howard Hughes Medical
Institute. ALB is supported by an NHMRC Biomedical Postgraduate
Scholarship. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 58
TC 16
Z9 16
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD FEB
PY 2013
VL 9
IS 2
AR e1003298
DI 10.1371/journal.pgen.1003298
PG 19
WC Genetics & Heredity
SC Genetics & Heredity
GA 099RG
UT WOS:000315638300049
PM 23408915
ER
PT J
AU Tomlinson, M
Rotheram-Borus, MJ
Swartz, L
Tsai, AC
AF Tomlinson, Mark
Rotheram-Borus, Mary Jane
Swartz, Leslie
Tsai, Alexander C.
TI Scaling Up mHealth: Where Is the Evidence?
SO PLOS MEDICINE
LA English
DT Editorial Material
ID DEVELOPING-COUNTRIES; RANDOMIZED-TRIAL; HEALTH BEHAVIORS; ADHERENCE;
CARE; REMINDERS; INTERVENTIONS; COMMUNICATION; MESSAGES; PROGRAMS
C1 [Tomlinson, Mark; Swartz, Leslie] Univ Stellenbosch, Dept Psychol, Ctr Publ Mental Hlth, ZA-7600 Stellenbosch, South Africa.
[Rotheram-Borus, Mary Jane] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Dept Psychiat, MD Div Global Psychiat, Boston, MA 02114 USA.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
RP Tomlinson, M (reprint author), Univ Stellenbosch, Dept Psychol, Ctr Publ Mental Hlth, ZA-7600 Stellenbosch, South Africa.
EM markt@sun.ac.za
RI Swartz, Leslie/A-5168-2008;
OI Swartz, Leslie/0000-0003-1741-5897; Tsai, Alexander/0000-0001-6397-7917
FU NIMH NIH HHS [K23 MH-096620, K23 MH096620, P30 MH058107]
NR 38
TC 119
Z9 121
U1 13
U2 55
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD FEB
PY 2013
VL 10
IS 2
AR e1001382
DI 10.1371/journal.pmed.1001382
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 099BC
UT WOS:000315592800004
PM 23424286
ER
PT J
AU Vimaleswaran, KS
Berry, DJ
Lu, C
Tikkanen, E
Pilz, S
Hiraki, LT
Cooper, JD
Dastani, Z
Li, R
Houston, DK
Wood, AR
Michaelsson, K
Vandenput, L
Zgaga, L
Yerges-Armstrong, LM
McCarthy, MI
Dupuis, J
Kaakinen, M
Kleber, ME
Jameson, K
Arden, N
Raitakari, O
Viikari, J
Lohman, KK
Ferrucci, L
Melhus, H
Ingelsson, E
Byberg, L
Lind, L
Lorentzon, M
Salomaa, V
Campbell, H
Dunlop, M
Mitchell, BD
Herzig, KH
Pouta, A
Hartikainen, AL
Streeten, EA
Theodoratou, E
Jula, A
Wareham, NJ
Ohlsson, C
Frayling, TM
Kritchevsky, SB
Spector, TD
Richards, JB
Lehtimaki, T
Ouwehand, WH
Kraft, P
Cooper, C
Marz, W
Power, C
Loos, RJF
Wang, TJ
Jarvelin, MR
Whittaker, JC
Hingorani, AD
Hypponen, E
AF Vimaleswaran, Karani S.
Berry, Diane J.
Lu, Chen
Tikkanen, Emmi
Pilz, Stefan
Hiraki, Linda T.
Cooper, Jason D.
Dastani, Zari
Li, Rui
Houston, Denise K.
Wood, Andrew R.
Michaelsson, Karl
Vandenput, Liesbeth
Zgaga, Lina
Yerges-Armstrong, Laura M.
McCarthy, Mark I.
Dupuis, Josee
Kaakinen, Marika
Kleber, Marcus E.
Jameson, Karen
Arden, Nigel
Raitakari, Olli
Viikari, Jorma
Lohman, Kurt K.
Ferrucci, Luigi
Melhus, Hakan
Ingelsson, Erik
Byberg, Liisa
Lind, Lars
Lorentzon, Mattias
Salomaa, Veikko
Campbell, Harry
Dunlop, Malcolm
Mitchell, Braxton D.
Herzig, Karl-Heinz
Pouta, Anneli
Hartikainen, Anna-Liisa
Streeten, Elizabeth A.
Theodoratou, Evropi
Jula, Antti
Wareham, Nicholas J.
Ohlsson, Claes
Frayling, Timothy M.
Kritchevsky, Stephen B.
Spector, Timothy D.
Richards, J. Brent
Lehtimaki, Terho
Ouwehand, Willem H.
Kraft, Peter
Cooper, Cyrus
Maerz, Winfried
Power, Chris
Loos, Ruth J. F.
Wang, Thomas J.
Jaervelin, Marjo-Riitta
Whittaker, John C.
Hingorani, Aroon D.
Hyppoenen, Elina
CA Genetic Invest Anthropometric Trai
TI Causal Relationship between Obesity and Vitamin D Status: Bi-Directional
Mendelian Randomization Analysis of Multiple Cohorts
SO PLOS MEDICINE
LA English
DT Article
ID BODY-MASS INDEX; CARDIOVASCULAR-DISEASE RISK; GENOME-WIDE ASSOCIATION;
GENETIC-VARIANTS; INSTRUMENTAL VARIABLES; D DEFICIENCY;
25-HYDROXYVITAMIN D; D INSUFFICIENCY; COMMON OBESITY; PREVALENCE
AB Background: Obesity is associated with vitamin D deficiency, and both are areas of active public health concern. We explored the causality and direction of the relationship between body mass index (BMI) and 25-hydroxyvitamin D [25(OH) D] using genetic markers as instrumental variables (IVs) in bi-directional Mendelian randomization (MR) analysis.
Methods and Findings: We used information from 21 adult cohorts (up to 42,024 participants) with 12 BMI-related SNPs (combined in an allelic score) to produce an instrument for BMI and four SNPs associated with 25(OH) D (combined in two allelic scores, separately for genes encoding its synthesis or metabolism) as an instrument for vitamin D. Regression estimates for the IVs (allele scores) were generated within-study and pooled by meta-analysis to generate summary effects. Associations between vitamin D scores and BMI were confirmed in the Genetic Investigation of Anthropometric Traits (GIANT) consortium (n = 123,864). Each 1 kg/m(2) higher BMI was associated with 1.15% lower 25(OH) D (p = 6.52x10(-27)). The BMI allele score was associated both with BMI (p = 6.30x10(-62)) and 25(OH) D (20.06% [95% CI -0.10 to -0.02], p = 0.004) in the cohorts that underwent meta-analysis. The two vitamin D allele scores were strongly associated with 25(OH) D (p <= 8.07x10(-57) for both scores) but not with BMI (synthesis score, p = 0.88; metabolism score, p = 0.08) in the meta-analysis. A 10% higher genetically instrumented BMI was associated with 4.2% lower 25(OH) D concentrations (IV ratio: -4.2 [95% CI -7.1 to -1.3], p = 0.005). No association was seen for genetically instrumented 25(OH) D with BMI, a finding that was confirmed using data from the GIANT consortium (p >= 0.57 for both vitamin D scores).
Conclusions: On the basis of a bi-directional genetic approach that limits confounding, our study suggests that a higher BMI leads to lower 25(OH) D, while any effects of lower 25(OH) D increasing BMI are likely to be small. Population level interventions to reduce BMI are expected to decrease the prevalence of vitamin D deficiency.
C1 [Vimaleswaran, Karani S.; Berry, Diane J.; Power, Chris; Hyppoenen, Elina] UCL Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England.
[Vimaleswaran, Karani S.; Berry, Diane J.; Power, Chris; Hyppoenen, Elina] UCL Inst Child Hlth, MRC Ctr Epidemiol Child Hlth, London, England.
[Lu, Chen; Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Tikkanen, Emmi] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland.
[Tikkanen, Emmi; Salomaa, Veikko; Jula, Antti] Natl Inst Hlth & Welf, Helsinki, Finland.
[Pilz, Stefan] Med Univ Graz, Div Endocrinol & Metab, Dept Internal Med, Graz, Austria.
[Pilz, Stefan] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
[Hiraki, Linda T.; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
[Cooper, Jason D.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Juvenile Diabet Res Fdn Wellcome Trust Diabet & I, Cambridge, England.
[Dastani, Zari] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ H3T 1E2, Canada.
[Li, Rui; Richards, J. Brent] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Dept Med, Montreal, PQ H3T 1E2, Canada.
[Li, Rui; Richards, J. Brent] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Dept Human Genet, Montreal, PQ H3T 1E2, Canada.
[Li, Rui; Richards, J. Brent] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Dept Epidemiol & Biostat, Montreal, PQ H3T 1E2, Canada.
[Houston, Denise K.; Kritchevsky, Stephen B.] Wake Forest Sch Med, Sect Gerontol & Geriatr Med, Dept Internal Med, Winston Salem, NC USA.
[Wood, Andrew R.; Frayling, Timothy M.] Univ Exeter, Peninsula Coll Med & Dent, Exeter, Devon, England.
[Michaelsson, Karl; Byberg, Liisa] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden.
[Vandenput, Liesbeth; Lorentzon, Mattias; Ohlsson, Claes] Univ Gothenburg, Inst Med, Dept Internal Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden.
[Zgaga, Lina; Campbell, Harry; Theodoratou, Evropi] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland.
[Zgaga, Lina] Univ Zagreb, Sch Med, Andrija Stampar Sch Publ Hlth, Zagreb 41001, Croatia.
[Yerges-Armstrong, Laura M.; Mitchell, Braxton D.; Streeten, Elizabeth A.] Univ Maryland, Sch Med, Div Endocrinol, Baltimore, MD 21201 USA.
[McCarthy, Mark I.] Univ Oxford, Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[McCarthy, Mark I.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[McCarthy, Mark I.] Churchill Hosp, Oxford NIHR Biomed Res Ctr, Oxford OX3 7LJ, England.
[Dupuis, Josee] NHLBI, Framingham, MA USA.
[Kaakinen, Marika; Herzig, Karl-Heinz; Jaervelin, Marjo-Riitta] Univ Oulu, Inst Hlth Sci, Oulu, Finland.
[Kaakinen, Marika; Herzig, Karl-Heinz; Jaervelin, Marjo-Riitta] Univ Oulu, Bioctr Oulu, Oulu, Finland.
[Kleber, Marcus E.] LURIC Study Non Profit LLC, Freiburg, Germany.
[Kleber, Marcus E.] Heidelberg Univ, Mannheim Inst Publ Hlth, Mannheim Med Fac, Social & Prevent Med, Mannheim, Germany.
[Jameson, Karen; Cooper, Cyrus] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
[Arden, Nigel] Botnar Res Ctr, NIHR Musculoskeletal BRU, Oxford, England.
[Arden, Nigel] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
[Raitakari, Olli] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland.
[Raitakari, Olli] Univ Turku, Dept Clin Physiol & Nucl Med, Turku, Finland.
[Raitakari, Olli; Viikari, Jorma] Turku Univ Hosp, FIN-20520 Turku, Finland.
[Viikari, Jorma] Univ Turku, Dept Med, Turku, Finland.
[Lohman, Kurt K.] Wake Sch Med, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA.
[Ferrucci, Luigi] Harbor Hosp, Clin Res Branch, Baltimore, MD USA.
[Melhus, Hakan; Lind, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
[Ingelsson, Erik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Dunlop, Malcolm] Univ Edinburgh, Inst Genet & Mol Med, Colon Canc Genet Grp & Acad Coloproctol, Edinburgh EH8 9YL, Midlothian, Scotland.
[Dunlop, Malcolm] Western Gen Hosp Edinburgh, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland.
[Herzig, Karl-Heinz] Univ Oulu, Inst Biomed, Oulu, Finland.
[Herzig, Karl-Heinz] Kuopio Univ Hosp, Dept Psychiat, SF-70210 Kuopio, Finland.
[Pouta, Anneli] Univ Oulu, Dept Publ Hlth Sci & Gen Practice, Oulu, Finland.
[Hartikainen, Anna-Liisa] Univ Oulu, Dept Obstet & Gynaecol & Publ Hlth & Gen Practice, Oulu, Finland.
[Wareham, Nicholas J.; Loos, Ruth J. F.] Addenbrookes Hosp, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England.
[Spector, Timothy D.; Richards, J. Brent] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England.
[Lehtimaki, Terho] Tampere Univ Hosp, Dept Clin Chem, Fimlab Labs, FIN-33521 Tampere, Finland.
[Lehtimaki, Terho] Univ Tampere, FIN-33101 Tampere, Finland.
[Ouwehand, Willem H.] Univ Cambridge, Dept Haematol, Cambridge CB2 1TN, England.
[Ouwehand, Willem H.] Wellcome Trust Sanger Inst, Cambridge, England.
[Ouwehand, Willem H.] NHS Blood & Transplant, Cambridge, England.
[Maerz, Winfried] Synlab Acad, Mannheim, Germany.
[Maerz, Winfried] Heidelberg Univ, Mannheim Inst Publ Hlth, Mannheim Med Fac, Social & Prevent Med, Mannheim, Germany.
[Wang, Thomas J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Jaervelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Dept Biostat & Epidemiol, Sch Publ Hlth, MRC HPA Ctr Environm & Hlth,Fac Med, London, England.
[Jaervelin, Marjo-Riitta] Natl Inst Hlth & Welf, Dept Children Young People & Families, Oulu, Finland.
[Whittaker, John C.] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
[Whittaker, John C.] GlaxoSmithKline, Quantitat Sci, Stevenage, Herts, England.
[Hingorani, Aroon D.] UCL, Div Populat Hlth, Dept Epidemiol & Publ Hlth, Genet Epidemiol Grp, London, England.
[Hingorani, Aroon D.] UCL, Div Med, Ctr Clin Pharmacol, London, England.
RP Vimaleswaran, KS (reprint author), UCL Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England.
EM e.hypponen@ucl.ac.uk
RI Smith, Albert Vernon/K-5150-2015; Aben, Katja/G-9686-2016; Rudan,
Igor/I-1467-2012; kinnunen, leena/B-7059-2012; Visvikis-Siest,
Sophie/H-2324-2014; Dunlop, Malcolm/F-1973-2011; Beckmann, Jacques S
/A-9772-2008; Kolcic, Ivana/E-2713-2017; Feitosa, Mary/K-8044-2012;
Colaus, PsyColaus/K-6607-2013; Hypponen, Elina/B-2596-2014; Lu,
Chen/D-8514-2015; Gudnason, Vilmundur/K-6885-2015; Ripatti,
Samuli/H-9446-2014; Polasek, Ozren/B-6002-2011; Meitinger,
Thomas/O-1318-2015; Theodoratou, Evropi/C-3430-2014; Kiemeney,
Lambertus/D-3357-2009; Aspelund, Thor/C-5983-2008; Palmer,
Lyle/K-3196-2014; Witte, Daniel/C-1722-2008
OI Pichler, Irene/0000-0001-8251-0757; Magi, Reedik/0000-0002-2964-6011;
Lango Allen, Hana/0000-0002-7803-8688; Esko, Tonu/0000-0003-1982-6569;
Smith, Albert Vernon/0000-0003-1942-5845; Zgaga,
Lina/0000-0003-4089-9703; Dupuis, Josee/0000-0003-2871-3603;
Kritchevsky, Stephen/0000-0003-3336-6781; Luben,
Robert/0000-0002-5088-6343; Scherag, Andre/0000-0002-9406-4704;
Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Vandenput,
Liesbeth/0000-0002-1712-6131; Aben, Katja/0000-0002-0214-2147; Rudan,
Igor/0000-0001-6993-6884; kinnunen, leena/0000-0001-8739-4812;
Visvikis-Siest, Sophie/0000-0001-8104-8425; Dunlop,
Malcolm/0000-0002-3033-5851; Beckmann, Jacques S /0000-0002-9741-1900;
Kolcic, Ivana/0000-0001-7918-6052; Feitosa, Mary/0000-0002-0933-2410;
Thiering, Elisabeth/0000-0002-5429-9584; Kaakinen,
Marika/0000-0002-9228-0462; Karani, Vimal/0000-0002-8485-8930;
Jorgensen, Torben/0000-0001-9453-2830; Mitchell,
Braxton/0000-0003-4920-4744; Ouwehand, Willem/0000-0002-7744-1790;
Lawlor, Debbie A/0000-0002-6793-2262; Hattersley,
Andrew/0000-0001-5620-473X; de Geus, Eco/0000-0001-6022-2666; Kleber,
Marcus/0000-0003-0663-7275; Hypponen, Elina/0000-0003-3670-9399;
Gudnason, Vilmundur/0000-0001-5696-0084; Ripatti,
Samuli/0000-0002-0504-1202; Polasek, Ozren/0000-0002-5765-1862;
Theodoratou, Evropi/0000-0001-5887-9132; Kiemeney,
Lambertus/0000-0002-2368-1326; Aspelund, Thor/0000-0002-7998-5433;
Palmer, Lyle/0000-0002-1628-3055; Witte, Daniel/0000-0002-0769-2922
FU British Heart Foundation [PG/09/023]; UK Medical Research Council (MRC)
[G0601653]; British Heart Foundation Senior Research Fellow(Award)
[FS05/125]; MRC Centre of Epidemiology for Child Health; NHS Executive;
Canada Institute of Research (CIHR) Fellowship award; Amgen; Eli Lilly;
Medtronic; Merck; Novartis; Servier
FX The authors thank the British Heart Foundation (grant PG/09/023) and the
UK Medical Research Council (MRC; grant G0601653) for funding this work.
ADH is a British Heart Foundation Senior Research Fellow (Award
FS05/125). EH is a Department of Health (UK) Public Health Career
Scientist. This work was undertaken at the Centre for Paediatric
Epidemiology and Biostatistics, which benefits from funding support from
the MRC in its capacity as the MRC Centre of Epidemiology for Child
Health. Research at the University College London Institute of Child
Health and Great Ormond Street Hospital for Children NHS Trust benefits
from R&D funding received from the NHS Executive. No funding bodies had
any role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.; LTH is currently supported
by a Canada Institute of Research (CIHR) Fellowship award. CC has
received honoraria and consulting fees from Amgen, Eli Lilly, Medtronic,
Merck, Novartis, and Servier. WM is an employee of synlab laboratory
services GmbH. Synlab offers vitamin D testing. TJW is on the scientific
advisory board for Diasorin Inc. and has received research support from
them. JCW is 90% employed by GlaxoSmithKline (GSK) whilst maintaining a
10% appointment at London School of Hygiene & Tropical Medicine (LSHTM),
and holds GSK shares. All other authors declare that no competing
interests exist.
NR 50
TC 206
Z9 212
U1 4
U2 80
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD FEB
PY 2013
VL 10
IS 2
AR e1001383
DI 10.1371/journal.pmed.1001383
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 099BC
UT WOS:000315592800005
PM 23393431
ER
PT J
AU Eriksson, S
Graf, EH
Dahl, V
Strain, MC
Yukl, SA
Lysenko, ES
Bosch, RJ
Lai, J
Chioma, S
Emad, F
Abdel-Mohsen, M
Hoh, R
Hecht, F
Hunt, P
Somsouk, M
Wong, J
Johnston, R
Siliciano, RF
Richman, DD
O'Doherty, U
Palmer, S
Deeks, SG
Siliciano, JD
AF Eriksson, Susanne
Graf, Erin H.
Dahl, Viktor
Strain, Matthew C.
Yukl, Steven A.
Lysenko, Elena S.
Bosch, Ronald J.
Lai, Jun
Chioma, Stanley
Emad, Fatemeh
Abdel-Mohsen, Mohamed
Hoh, Rebecca
Hecht, Frederick
Hunt, Peter
Somsouk, Ma
Wong, Joseph
Johnston, Rowena
Siliciano, Robert F.
Richman, Douglas D.
O'Doherty, Una
Palmer, Sarah
Deeks, Steven G.
Siliciano, Janet D.
TI Comparative Analysis of Measures of Viral Reservoirs in HIV-1
Eradication Studies
SO PLOS PATHOGENS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; ACTIVE ANTIRETROVIRAL
THERAPY; BLOOD MONONUCLEAR-CELLS; LOW-LEVEL VIREMIA; LATENT HIV-1;
IN-VIVO; INFECTED INDIVIDUALS; PERIPHERAL-BLOOD; PLASMA VIREMIA
AB HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral therapy (HAART). The best characterized reservoir is a small, difficult-to-quantify pool of resting memory CD4(+) T cells carrying latent but replication-competent viral genomes. Because strategies targeting this latent reservoir are now being tested in clinical trials, well-validated high-throughput assays that quantify this reservoir are urgently needed. Here we compare eleven different approaches for quantitating persistent HIV-1 in 30 patients on HAART, using the original viral outgrowth assay for resting CD4(+) T cells carrying inducible, replication-competent viral genomes as a standard for comparison. PCR-based assays for cells containing HIV-1 DNA gave infected cell frequencies at least 2 logs higher than the viral outgrowth assay, even in subjects who started HAART during acute/early infection. This difference may reflect defective viral genomes. The ratio of infected cell frequencies determined by viral outgrowth and PCR-based assays varied dramatically between patients. Although strong correlations with the viral outgrowth assay could not be formally excluded for most assays, correlations achieved statistical significance only for integrated HIV-1 DNA in peripheral blood mononuclear cells and HIV-1 RNA/DNA ratio in rectal CD4(+) T cells. Residual viremia was below the limit of detection in many subjects and did not correlate with the viral outgrowth assays. The dramatic differences in infected cell frequencies and the lack of a precise correlation between culture and PCR-based assays raise the possibility that the successful clearance of latently infected cells may be masked by a larger and variable pool of cells with defective proviruses. These defective proviruses are detected by PCR but may not be affected by reactivation strategies and may not require eradication to accomplish an effective cure. A molecular understanding of the discrepancy between infected cell frequencies measured by viral outgrowth versus PCR assays is an urgent priority in HIV-1 cure research.
C1 [Eriksson, Susanne; Dahl, Viktor; Palmer, Sarah] Swedish Inst Communicable Dis, Dept Diagnost & Vaccinol, Solna, Sweden.
[Eriksson, Susanne; Dahl, Viktor; Palmer, Sarah] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Solna, Sweden.
[Graf, Erin H.; Lysenko, Elena S.; O'Doherty, Una] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
[Strain, Matthew C.; Richman, Douglas D.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Strain, Matthew C.; Richman, Douglas D.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
[Yukl, Steven A.; Wong, Joseph] San Francisco VA Med Ctr, San Francisco, CA USA.
[Yukl, Steven A.; Abdel-Mohsen, Mohamed; Hoh, Rebecca; Hecht, Frederick; Hunt, Peter; Somsouk, Ma; Wong, Joseph; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Lai, Jun; Chioma, Stanley; Emad, Fatemeh; Siliciano, Robert F.; Siliciano, Janet D.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Johnston, Rowena] Fdn AIDS Res, AmfAR, New York, NY USA.
[Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.
RP Eriksson, S (reprint author), Swedish Inst Communicable Dis, Dept Diagnost & Vaccinol, Solna, Sweden.
EM jsilicia@jhmi.edu
OI Dahl, Viktor/0000-0001-9921-5172
FU ARCHE Collaborative Research Grant from the Foundation for AIDS Research
[amFAR 108165-50-RGRL]; Martin Delaney CARE and DARE
Collaboratories(NIH) [AI096113, 1U19AI096109]; NIH [43222]; Howard
Hughes Medical Institute; Department of Veterans Affairs [1 IK2
CX000520-01]; James Pendleton Charitable Trust; National Institutes of
Health [AI 080193, AI74621, AI69432-S]; CFAR [AI306214]; NIAID
[RO1AIO87145, K24AIO69994]; UCSF/Gladstone CFAR [P30 AIO27763]; UCSF
Clinical and Translational Research Institute Clinical Research Center
[UL 1 RR024131]; Center for AIDS Prevention Studies [P30 MH62246]
FX This work was supported by an ARCHE Collaborative Research Grant from
the Foundation for AIDS Research (amFAR 108165-50-RGRL), by the Martin
Delaney CARE and DARE Collaboratories(NIH grants AI096113 and
1U19AI096109), and by NIH grant 43222 (RFS), and by the Howard Hughes
Medical Institute (RFS). For MS and DDR, this work was supported by the
Department of Veterans Affairs, the James Pendleton Charitable Trust,
National Institutes of Health (AI 080193, AI74621, AI69432-S), and CFAR
grant AI306214. For SAY, this work was supported by the Department of
Veterans Affairs (VA Career Development Award 1 IK2 CX000520-01). The
UCSF SCOPE cohort was supported in part by the NIAID (RO1AIO87145,
K24AIO69994), the UCSF/Gladstone CFAR (P30 AIO27763), the UCSF Clinical
and Translational Research Institute Clinical Research Center (UL 1
RR024131) and the Center for AIDS Prevention Studies (P30 MH62246). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 84
TC 155
Z9 156
U1 5
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD FEB
PY 2013
VL 9
IS 2
AR e1003174
DI 10.1371/journal.ppat.1003174
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 099UU
UT WOS:000315648900024
PM 23459007
ER
PT J
AU Chan, ED
Iseman, MD
AF Chan, Edward D.
Iseman, Michael D.
TI Underlying Host Risk Factors for Nontuberculous Mycobacterial Lung
Disease
SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Review
DE Marfan syndrome; environmental mycobacteria; bronchiectasis; pectus
excavatum; scoliosis; nontuberculous mycobacteria
ID PULMONARY ALVEOLAR PROTEINOSIS; ANTITUMOR NECROSIS FACTOR; RAPIDLY
GROWING MYCOBACTERIA; CHRONIC MYELOGENOUS LEUKEMIA;
WILLIAMS-CAMPBELL-SYNDROME; AVIUM COMPLEX DISEASE;
MITRAL-VALVE-PROLAPSE; MOUNIER-KUHN-SYNDROME; AFRICAN GOLD MINERS;
GROWTH-FACTOR-BETA
AB Nontuberculous mycobacteria (NTM) are environmental microbes that cause a variety of human diseases, particularly chronic lung infections. Despite the fact that NTM are widespread in the environment, relatively few people develop NTM lung disease, suggesting intrinsic vulnerability in some individuals. This paper reviews the evidence that underlying disorders predispose to NTM lung disease, in particular primary conditions that result in bronchiectasis, chronic obstructive pulmonary disease, alpha-1-antitrypsin anomalies, pneumoconiosis, pulmonary alveolar proteinosis, and frank immunosuppressive states such as that associated with the use of anti-tumor necrosis factor-alpha biologics, posttransplantation immunosuppression, and HIV infection. Over the past several decades, NTM lung disease has been increasingly identified in postmenopausal women with slender body habitus. Thus we will also review the clinical and experimental evidence which supports the observation that such individuals are predisposed to NTM lung disease.
C1 [Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Chan, Edward D.; Iseman, Michael D.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA.
[Chan, Edward D.] Natl Jewish Hlth, Cell Biol Program, Denver, CO 80206 USA.
[Chan, Edward D.; Iseman, Michael D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Denver, CO USA.
[Iseman, Michael D.] Univ Colorado Denver, Div Infect Dis, Denver, CO USA.
RP Chan, ED (reprint author), Natl Jewish Hlth, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA.
EM chane@njhealth.org
NR 139
TC 34
Z9 35
U1 0
U2 8
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1069-3424
EI 1098-9048
J9 SEMIN RESP CRIT CARE
JI Semin. Respir. Crit. Care Med.
PD FEB
PY 2013
VL 34
IS 1
BP 110
EP 123
DI 10.1055/s-0033-1333573
PG 14
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 101RY
UT WOS:000315793300011
PM 23460011
ER
PT J
AU Granda, ML
Carlin, SM
Moseley, CK
Neelamegam, R
Mandeville, JB
Hooker, JM
AF Granda, Michael L.
Carlin, Stephen M.
Moseley, Christian K.
Neelamegam, Ramesh
Mandeville, Joseph B.
Hooker, Jacob M.
TI Synthesis and Evaluation of Methylated Arylazepine Compounds for PET
Imaging of 5-HT2c Receptors
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Article
DE Serotonin; PET imaging; carbon-11; 5-HT2c agonist
ID SEROTONIN RECEPTORS; HUMAN-BRAIN; RECOGNITION SITES; LOCALIZATION;
BINDING; BEHAVIOR; AGONIST
AB The serotonin 5-HT2c receptor is implicated in a number of diseases including obesity, depression, anxiety, and schizophrenia. In order to ascribe the role of 5-HT2c in these diseases, a method for measuring 5-HT2c density and function in vivo, such as with positron emission tomography (PET), must be developed. Many high-affinity and relatively selective ligands exist for 5-HT2c but cannot be accessed with current radiosynthetic methods for use as PET radiotracers. We propose that N-methylation of an arylazepine moiety, a frequent structural feature in 5-HT2c ligands, may be a suitable method for producing new radiotracers for 5-HT2c. The impact of N-methylation has not been previously reported. For the agonists that we selected herein, N-methylation was found to increase affinity up to 8-fold without impairing selectivity. Compound 5, an N-methylated azetidine-derived arylazepine, was found to be brain penetrant and reached a brain/blood ratio of 2.05:1. However, our initial test compound was rapidly metabolized within 20 min of administration and exhibited high nonspecific binding. N-Methylation, with 16 +/- 3% isolated radiochemical yield (decay corrected), is robust and may facilitate screening other 5-HT2c ligands as radiotracers for PET.
C1 [Granda, Michael L.; Carlin, Stephen M.; Moseley, Christian K.; Neelamegam, Ramesh; Mandeville, Joseph B.; Hooker, Jacob M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02129 USA.
RP Hooker, JM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02129 USA.
EM hooker@nmr.mgh.harvard.edu
OI Hooker, Jacob/0000-0002-9394-7708
FU National Institute of Health [1R21MH093874]
FX This project was funded by a grant from the National Institute of Health
(1R21MH093874).
NR 21
TC 8
Z9 9
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD FEB
PY 2013
VL 4
IS 2
BP 261
EP 265
DI 10.1021/cn300223d
PG 5
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences
& Neurology
GA 095HT
UT WOS:000315326000007
PM 23421677
ER
PT J
AU Koido, S
Gong, JL
AF Koido, Shigeo
Gong, Jianlin
TI Characterization of Structure and Direct Antigen Presentation by
Dendritic/Tumor-fused Cells as Cancer Vaccines
SO ANTICANCER RESEARCH
LA English
DT Article
DE Dendritic cell; cancer vaccine; antigen presentation; fusion
ID CYTOTOXIC T-LYMPHOCYTES; HUMAN TUMOR-ANTIGEN; CLASS-II MOLECULES;
ANTITUMOR IMMUNITY; CARCINOMA-CELLS; IN-VIVO; FUSION CELLS; VACCINATION;
INDUCTION; ELECTROFUSION
AB Background: Previous work has shown that fusion of dendritic cells (DCs) and tumor cells induces potent antitumor immune responses. However, little is known on whether fused cells directly present tumor-associated antigens (TAAs) through major histocompatibility complex (MHC) class I and II pathways in the context of co-stimulatory molecules. Materials and Methods: Fusion cells were generated between DCs and MC38 carcinoma cells stably expressing mucin-1 (MUC1) by polyethylene glycol. The characterization of structure and antigen presentation by fused cells was examined by immunoelectron microscopic and flow cytometric analyses. Results: The cytoplasm from both cellular entities was integrated, while their nuclei were independently preserved. Short-term culture gave fused cells sufficient time to integrate and directly display MUC1 through MHC class I and II pathways in the context of co-stimulatory molecules. Conclusion: DC-derived molecules and TAAs are presumably synthesized at separate sites of fused cells, to converge and complex with each other.
C1 [Gong, Jianlin] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Koido, Shigeo] Jikei Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Kashiwa, Chiba 2778564, Japan.
[Koido, Shigeo; Gong, Jianlin] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Koido, S (reprint author), Jikei Univ, Sch Med, Dept Gastroenterol & Hepatol, 163-1 Kashiwa Shita, Kashiwa, Chiba 2778564, Japan.
EM shigeo_koido@jikei.ac.jp
FU National Cancer Institute Grant [R01 CA87057]; US Department of Defense
Breast Cancer Research programs [990344]; Susan G. Komen Breast Cancer
Foundation [9825]; Ministry of Education, Cultures, Sports, Science and
Technology of Japan
FX This work was supported by National Cancer Institute Grant R01 CA87057;
by the US Department of Defense Breast Cancer Research programs, grant
990344; by the Susan G. Komen Breast Cancer Foundation, grant 9825; and
by Grants-in-Aid for Scientific Research (C) from the Ministry of
Education, Cultures, Sports, Science and Technology of Japan.
NR 36
TC 11
Z9 11
U1 1
U2 15
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD FEB
PY 2013
VL 33
IS 2
BP 347
EP 354
PG 8
WC Oncology
SC Oncology
GA 096SG
UT WOS:000315424000001
PM 23393323
ER
PT J
AU Yasuda, Y
Fukushima, Y
Kaneki, M
Martyn, JAJ
AF Yasuda, Yoshikazu
Fukushima, Yuji
Kaneki, Masao
Martyn, J. A. Jeevendra
TI Anesthesia with propofol induces insulin resistance systemically in
skeletal and cardiac muscles and liver of rats
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Glucose output (hepatic); Hepatic glucose uptake; Hyperinsulinemic
clamp; Insulin resistance; Muscle glucose uptake; Propofol; Sedation
ID CRITICALLY-ILL PATIENTS; INFUSION SYNDROME; CRITICAL ILLNESS; GLUCOSE
CONTROL; MITOCHONDRIAL RESPIRATION; DIABETIC-PATIENTS; THERAPY;
HYPERGLYCEMIA; METABOLISM; MECHANISMS
AB Hyperglycemia together with hepatic and muscle insulin resistance are common features in critically ill patients, and these changes are associated with enhanced inflammatory response, increased susceptibility to infection, muscle wasting, and worsened prognosis. Tight blood glucose control by intensive insulin treatment may reduce the morbidity and mortality in intensive care units. Although some anesthetics have been shown to cause insulin resistance, it remains unknown how and in which tissues insulin resistance is induced by anesthetics. Moreover, the effects of propofol, a clinically relevant intravenous anesthetic, also used in the intensive care unit for sedation, on insulin sensitivity have not yet been investigated. Euglycemic hyperinsulinemic clamp study was performed in rats anesthetized with propofol and conscious unrestrained rats. To evaluate glucose uptake in tissues and hepatic glucose output [H-3]glucose and 2-deoxy[C-14]glucose were infused during the clamp study. Anesthesia with propofol induced a marked whole-body insulin resistance compared with conscious rats, as reflected by significantly decreased glucose infusion rate to maintain euglycemia. Insulin-stimulated tissue glucose uptake was decreased in skeletal muscle and heart, and hepatic glucose output was increased in propofol anesthetized rats. Anesthesia with propofol induces systemic insulin resistance along with decreases in insulin-stimulated glucose uptake in skeletal and heart muscle and attenuation of the insulin-mediated suppression of hepatic glucose output in rats. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Yasuda, Yoshikazu; Fukushima, Yuji; Kaneki, Masao; Martyn, J. A. Jeevendra] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anaesthesia Crit Care & Pain Med,Shriners Ho, Boston, MA 02114 USA.
RP Martyn, JAJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anaesthesia Crit Care & Pain Med,Shriners Ho, 51 Blossom St,Room 206, Boston, MA 02114 USA.
EM jmartyn@partners.org
FU National Institutes of Health [R01-GM 055082, P50-GM-2500]; Shriners
Hospitals for Children(R) Research Philanthropy
FX This study was supported in part by grants to JAJM from the National
Institutes of Health R01-GM 055082 and P50-GM-2500 Project I, and from
the Shriners Hospitals for Children (R) Research Philanthropy.
NR 46
TC 3
Z9 3
U1 1
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 1
PY 2013
VL 431
IS 1
BP 81
EP 85
DI 10.1016/j.bbrc.2012.12.084
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 096UC
UT WOS:000315428800015
PM 23274498
ER
PT J
AU Trivedi, MH
Morris, DW
Wisniewski, SR
Nierenberg, AA
Gaynes, BN
Kurian, BT
Warden, D
Stegman, D
Shores-Wilson, K
Rush, AJ
AF Trivedi, Madhukar H.
Morris, David W.
Wisniewski, Stephen R.
Nierenberg, Andrew A.
Gaynes, Bradley N.
Kurian, Benji T.
Warden, Diane
Stegman, Diane
Shores-Wilson, Kathy
Rush, A. John
TI Clinical and Sociodemographic Characteristics Associated With Suicidal
Ideation in Depressed Outpatients
SO CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
LA English
DT Article
DE suicidal ideation; depression; major depressive disorder; anxiety;
suicide assessment
ID SEQUENCED TREATMENT ALTERNATIVES; NATIONAL-COMORBIDITY-SURVEY;
INTERACTIVE VOICE RESPONSE; ILLNESS RATING-SCALE; STAR-ASTERISK-D;
REPORT QIDS-SR; MAJOR DEPRESSION; PSYCHIATRIC OUTPATIENTS; RISK-FACTORS;
SELF-REPORT
AB Objective: To identify clinical and sociodemographic characteristics associated with suicidal ideation (SI) among patients seeking care for depression in routine primary and psychiatric care settings.
Methods: We examined data from 4041 treatment-seeking outpatients with major depressive disorder (MDD) to compare baseline sociodemographic and clinical characteristics of those with and without SI, and the presence or absence of baseline depressive symptoms and psychiatric comorbidities in those with SI.
Results: SI was significantly (P < 0.01) associated with numerous sociodemographic characteristics (that is, lower level of education, Caucasian or African American, male, unemployed, and treated in psychiatric care) and clinical features (that is, previous suicide attempt, younger age of MDD onset, greater baseline depressive symptom severity, greater number of depressive symptoms, and presence of agoraphobia and [or] generalized anxiety disorder). Elevated levels of SI at baseline were associated with decreased remission rates.
Conclusions: Consistent with past findings, increased rates of SI were associated with greater depressive symptom severity as well as other features suggestive of severity of illness. Our results confirm previous findings of associations between SI and panic and (or) phobic symptoms and anxiety, but did not confirm previous findings of an association between SI and alcohol or drug use and (or) dependence. While selective serotonin reuptake inhibitor monotherapy appeared significantly helpful in reducing SI during the course of treatment, the presence of SI at baseline was found to be a associated with decreased treatment response, with patients reporting SI at the start of treatment being less likely to achieve remission.
C1 [Trivedi, Madhukar H.; Morris, David W.; Kurian, Benji T.; Warden, Diane; Stegman, Diane; Shores-Wilson, Kathy] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA USA.
[Nierenberg, Andrew A.] Massachusetts Gen Hosp, Clin Psychopharmacol Unit, Bipolar Clin & Res Program, Boston, MA 02114 USA.
[Nierenberg, Andrew A.] Massachusetts Gen Hosp, Clin Psychopharmacol Unit, Depress Clin & Res Program, Boston, MA 02114 USA.
[Gaynes, Bradley N.] Univ N Carolina, Chapel Hill, NC USA.
[Rush, A. John] Duke Natl Univ Singapore, Off Clin Sci, Singapore, Singapore.
RP Trivedi, MH (reprint author), Univ Texas SW Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM madhukar.trivedi@utsouthwestern.edu
OI Wisniewski, Stephen/0000-0002-3877-9860; Gaynes,
Bradley/0000-0002-8283-5030; Rush, Augustus/0000-0003-2004-2382
FU National Institute of Mental Health (NIMH); National Institutes of
Health [N01MH90003]; Agency for Healthcare Research and Quality; Corcept
Therapeutics, Inc; Cyberonics, Inc; Merck; National Alliance for
Research in Schizophrenia and Depression; NIMH; National Institute on
Drug Abuse; Novartis; Pharmacia Upjohn; Predix Pharmaceuticals (Epix);
Solvay Pharmaceuticals, Inc; Targacept; Abbott Laboratories, Inc; Abdi
Ibrahim; Akzo (Organon Pharmaceuticals Inc); Alkermes; AstraZeneca; Axon
Advisors; Bristol-Myers Squibb Company; Cephalon, Inc; Evotec; Fabre
Kramer Pharmaceuticals, Inc; Forest Pharmaceuticals; GlaxoSmithKline;
Janssen Pharmaceutica Products; Johnson Johnson PRD; Libby; LP; Eli
Lilly Company; Lundbeck; Meade Johnson; MedAvante; Medtronic; Naurex;
Neuronetics; Otsuka Pharmaceuticals, Pamlab; Parke-Davis
Pharmaceuticals, Inc; Pfizer Inc; Ppd-lealth; Rexahn Pharmaceuticals;
Sepracor; SHIRE Development; Sierra; Takeda; Tal Medical/Puretech;
Transcept; VantagePoint; Wyeth-Ayerst Laboratories; Otsuka
Pharmaceutical Co Ltd; University of Michigan; Brain Resource Ltd;
Singapore College of Family Physicians; Guilford Publications and
University of Texas Southwestern Medical Center; International College
of Neuropsychopharmacology; NEVIH; Duke-NUS; Targacept, Inc; Pfizer,
Inc; Johnson Johnson; Rexahn
FX This project was funded by the National Institute of Mental Health
(NIMH), National Institutes of Health, under Contract N01MH90003 to UT
Southwestern Medical Center at Dallas (Principal Investigator, Dr Rush).
Neither the content of this publication nor the mention of trade names,
commercial products, or organizations, necessarily reflects the views or
policies of the Department of Health and Human Services or imply
endorsement by the US Government. We acknowledge the editorial
assistance of Jon Kilner.; Dr Trivedi has received research support from
the Agency for Healthcare Research and Quality, Corcept Therapeutics,
Inc, Cyberonics, Inc, Merck, National Alliance for Research in
Schizophrenia and Depression, NIMH, National Institute on Drug Abuse,
Novartis, Pharmacia & Upjohn, Predix Pharmaceuticals (Epix), Solvay
Pharmaceuticals, Inc, and Targacept, and consulting and speaker fees
from Abbott Laboratories, Inc, Abdi Ibrahim, Akzo (Organon
Pharmaceuticals Inc), Alkermes, AstraZeneca, Axon Advisors,
Bristol-Myers Squibb Company, Cephalon, Inc, Evotec, Fabre Kramer
Pharmaceuticals, Inc, Forest Pharmaceuticals, GlaxoSmithKline, Janssen
Pharmaceutica Products, Johnson & Johnson PRD, Libby, LP, Eli Lilly &
Company, Lundbeck, Meade Johnson, MedAvante, Medtronic, Naurex,
Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis
Pharmaceuticals, Inc, Pfizer Inc, Ppd-lealth, Rexahn Pharmaceuticals,
Sepracor, SHIRE Development, Sierra, Takeda, Tal Medical/Puretech,
Transcept, VantagePoint, and Wyeth-Ayerst Laboratories. Dr Wisniewski
has been a consultant for Cyberonics, Inc, ImaRx Therapeutics, Inc,
Bristol-Myers Squibb Company, Organon, Case-Western University,
Singapore Clinical Research Institute, Dey Pharmaceuticals, and Venebio
Group LLC.; Dr Rush has received consultant fees from Otsuka
Pharmaceutical Co Ltd, University of Michigan, Brain Resource Ltd;
speaking fees from Singapore College of Family Physicians; royalties
from Guilford Publications and University of Texas Southwestern Medical
Center; travel grant from the International College of
Neuropsychopharmacology; and research support from NEVIH and Duke-NUS.;
Dr Kurian has received research support from Targacept, Inc, Pfizer,
Inc, Johnson & Johnson, Evotec, Rexahn, Naurex, Forest Pharmaceuticals,
and NIMH.
NR 52
TC 5
Z9 5
U1 3
U2 12
PU CANADIAN PSYCHIATRIC ASSOC
PI OTTAWA
PA 141 LAURIER AVENUE WEST, STE 701, OTTAWA, ONTARIO K1P 5J3, CANADA
SN 0706-7437
J9 CAN J PSYCHIAT
JI Can. J. Psychiat.-Rev. Can. Psychiat.
PD FEB
PY 2013
VL 58
IS 2
BP 113
EP 122
PG 10
WC Psychiatry
SC Psychiatry
GA 095HA
UT WOS:000315324100009
PM 23442899
ER
PT J
AU Garcia-Albeniz, X
Nan, HM
Valeri, L
Morikawa, T
Kuchiba, A
Phipps, AI
Hutter, CM
Peters, U
Newcomb, PA
Fuchs, CS
Giovannucci, EL
Ogino, S
Chan, AT
AF Garcia-Albeniz, Xabier
Nan, Hongmei
Valeri, Linda
Morikawa, Teppei
Kuchiba, Aya
Phipps, Amanda I.
Hutter, Carolyn M.
Peters, Ulrike
Newcomb, Polly A.
Fuchs, Charles S.
Giovannucci, Edward L.
Ogino, Shuji
Chan, Andrew T.
TI Phenotypic and tumor molecular characterization of colorectal cancer in
relation to a susceptibility SMAD7 variant associated with survival
SO CARCINOGENESIS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ISLAND METHYLATOR PHENOTYPE; BODY-MASS INDEX;
COLON-CANCER; MICROSATELLITE INSTABILITY; PATHOLOGICAL EPIDEMIOLOGY;
RISK; LOCI; METAANALYSIS; EXPRESSION
AB The minor allele (G) of rs4939827, a SMAD7 (18q21) intronic variant, is associated with a lower risk of developing colorectal cancer (CRC) and poorer survival after diagnosis. Our objective was to evaluate the associations of this variant with different tumor phenotype and intratumoral molecular characteristics. We evaluated 1509 CRC cases and 2307 age-matched controls nested within the Nurses' Health Study and the Health Professionals Follow-up Study. We used the TaqMan assay to genotype rs4939827 and logistic regression to assess the association of rs4939827 with risk of CRC according to different phenotypic and molecular characteristics. We found that the minor allele (G) in rs4939827 (SMAD7, 18q21) was associated with a lower risk of developing tumor stage pT1 or pT2 CRC [multivariate odds ratio (OR), 0.73; 95% confidence interval (CI) 0.62-0.87] but not tumor stage pT3 or pT4 (multivariate OR, 1.07; 95% CI 0.93-1.23, P for heterogeneity = 1.2 x 10(-4)). The association between rs4939827 and CRC also significantly differed by methylation of RUNX3 (P for heterogeneity = 0.005). Among those with CRC, the minor allele (G) in rs4939827 was significantly associated with poorer overall survival (hazards ratio, 1.20; 95% CI, 1.02-1.42). We can conclude that the minor allele (G) of the germline intronic SMAD7 variant rs4939827 is associated with a lower risk of CRC with earlier tumor stage and CRC without methylation of the tumor suppressor RUNX3. These findings suggest that individuals with this SMAD7 variant that develop CRC are more probably to have tumors with greater invasiveness and methylation of RUNX3, which potentially contributes to their poorer observed survival.
C1 [Garcia-Albeniz, Xabier; Giovannucci, Edward L.; Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Garcia-Albeniz, Xabier; Nan, Hongmei; Fuchs, Charles S.; Giovannucci, Edward L.; Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Garcia-Albeniz, Xabier; Nan, Hongmei; Morikawa, Teppei; Kuchiba, Aya; Fuchs, Charles S.; Giovannucci, Edward L.; Ogino, Shuji; Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Nan, Hongmei] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Div Canc Epidemiol, Baltimore, MD 21201 USA.
[Valeri, Linda] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Morikawa, Teppei; Ogino, Shuji] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Morikawa, Teppei; Kuchiba, Aya; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Kuchiba, Aya; Giovannucci, Edward L.] Harvard Univ, Dept Nutr, Sch Publ Hlth, Boston, MA 02115 USA.
[Phipps, Amanda I.; Hutter, Carolyn M.; Peters, Ulrike; Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Chan, AT (reprint author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
EM achan@partners.org
FU National Institutes of Health (NIH) / National Cancer Institute (NCI)
[CA137178, CA059045, CA151993, CA055075, CA087969, CA127003, CA094880,
CA154337]; 'La Caixa' fellowship
FX National Institutes of Health (NIH) / National Cancer Institute (NCI)
(grant CA137178, CA059045, CA151993, CA055075, CA087969, CA127003,
CA094880, CA154337); 'La Caixa' fellowship to X. G. A.; A. T. C. is a
Damon Runyon Cancer Foundation Clinical Investigator.
NR 39
TC 12
Z9 12
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 2013
VL 34
IS 2
BP 292
EP 298
DI 10.1093/carcin/bgs335
PG 7
WC Oncology
SC Oncology
GA 099NH
UT WOS:000315627900007
PM 23104301
ER
PT J
AU Steenkamp, MM
Litz, BT
AF Steenkamp, Maria M.
Litz, Brett T.
TI Psychotherapy for military-related posttraumatic stress disorder: Review
of the evidence
SO CLINICAL PSYCHOLOGY REVIEW
LA English
DT Review
DE PTSD; Combat; Military; War; Psychotherapy; Treatment
ID PROLONGED EXPOSURE THERAPY; COGNITIVE PROCESSING THERAPY; RANDOMIZED
CONTROLLED-TRIAL; MENTAL-HEALTH TREATMENT; PRIMARY-CARE; COMBAT
VETERANS; PSYCHOLOGICAL TREATMENTS; SERVICE MEMBERS; NATIONAL-GUARD;
BEHAVIORAL ACTIVATION
AB Approximately 20% of the two million troops who have deployed to Iraq and Afghanistan may require treatment for posttraumatic stress disorder (PTSD). We review treatment outcome studies on individual outpatient therapy for military-related PTSD, and consider the extent to which veterans initiate and complete available PTSD treatments. We conclude with considerations for future research. Published by Elsevier Ltd.
C1 [Steenkamp, Maria M.; Litz, Brett T.] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Steenkamp, Maria M.; Litz, Brett T.] Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02130 USA.
[Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Steenkamp, MM (reprint author), Boston Vet Affairs Med Ctr, 150 S Huntington Ave,13B-73, Boston, MA 02130 USA.
EM maria.steenkamp2@va.gov
NR 81
TC 44
Z9 46
U1 0
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0272-7358
J9 CLIN PSYCHOL REV
JI Clin. Psychol. Rev.
PD FEB
PY 2013
VL 33
IS 1
BP 45
EP 53
DI 10.1016/j.cpr.2012.10.002
PG 9
WC Psychology, Clinical
SC Psychology
GA 083RJ
UT WOS:000314482600004
PM 23123570
ER
PT J
AU Alcantara, C
Casement, MD
Lewis-Fernandez, R
AF Alcantara, Cantlela
Casement, Melynda D.
Lewis-Fernandez, Roberto
TI Conditional risk for PTSD among Latinos: A systematic review of
racial/ethnic differences and sociocultural explanations
SO CLINICAL PSYCHOLOGY REVIEW
LA English
DT Review
DE PTSD; Hispanics; Immigrants; Mental health; Psychosocial risk factors;
Trauma
ID POSTTRAUMATIC-STRESS-DISORDER; ATAQUES-DE-NERVIOS; NATIONAL COMORBIDITY
SURVEY; INTIMATE PARTNER VIOLENCE; UNITED-STATES; ETHNIC-DIFFERENCES;
ANXIETY SENSITIVITY; GENDER-DIFFERENCES; TERRORIST ATTACKS; VIETNAM
VETERANS
AB Conditional risk for Posttraumatic Stress Disorder (PTSD)-defined as prevalence, onset, persistence, or severity of PTSD after traumatic exposure appears to be higher among Latinos relative to non-Latinos after accounting for sociodemographic factors. This systematic review focuses on differences in conditional risk for PTSD between Latinos and non-Latinos (White, Black, or combined) and across Latino subgroups in studies that adjust for trauma exposure. We discuss methodological characteristics of existing articles and sociocultural explanatory factors. Electronic bibliographic searches were conducted for English-language articles published in peer-reviewed journals between 1991 and 2012. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Twenty-eight articles met inclusion criteria. Consistent support was found for elevated rates of PTSD onset and PTSD severity among Latinos relative to non-Latino Whites. The evidence on racial/ethnic differences in conditional risk for PTSD prevalence and PTSD persistence is mixed. Twenty-four articles evaluated sociocultural explanations, with the strongest support found for racial/ethnic variation in pen-traumatic responses and structure of PTSD. There were also consistent main effects for social disadvantage in studies that simultaneously adjusted for effects of race/ethnicity. Future research should use theoretically-driven models to formally test for interactions between sociocultural factors, race/ethnicity, and PTSD probability. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Alcantara, Cantlela] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Casement, Melynda D.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Casement, Melynda D.] Boston Univ, Med Ctr, Boston, MA USA.
[Lewis-Fernandez, Roberto] Columbia Univ, Dept Psychiat, New York, NY 10032 USA.
[Lewis-Fernandez, Roberto] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
RP Alcantara, C (reprint author), Columbia Univ, Dept Med, Med Ctr, Ctr Behav Cardiovasc Hlth, PH-9,Room 9-319,622 W 168th St, New York, NY 10032 USA.
EM ca2543@columbia.edu
OI Casement, Melynda/0000-0002-5906-0994
FU NIMH NIH HHS [T32 MH019836, T32-MH019836, R01 MH072833, R01 MH077226]
NR 67
TC 18
Z9 18
U1 6
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0272-7358
J9 CLIN PSYCHOL REV
JI Clin. Psychol. Rev.
PD FEB
PY 2013
VL 33
IS 1
BP 107
EP 119
DI 10.1016/j.cpr.2012.10.005
PG 13
WC Psychology, Clinical
SC Psychology
GA 083RJ
UT WOS:000314482600009
PM 23159328
ER
PT J
AU Marshall, J
Shapiro, GI
Uttenreuther-Fischer, M
Ould-Kaci, M
Stopfer, P
Gordon, MS
AF Marshall, John
Shapiro, Geoffrey I.
Uttenreuther-Fischer, Martina
Ould-Kaci, Mahmoud
Stopfer, Peter
Gordon, Michael S.
TI Phase I dose-escalation study of afatinib, an ErbB family blocker, plus
docetaxel in patients with advanced cancer
SO FUTURE ONCOLOGY
LA English
DT Article
DE afatinib; docetaxel; ErbB family blocker; pharmacokinetics; Phase I
ID CELL LUNG-CANCER; ADVANCED SOLID TUMORS; 1ST-LINE TREATMENT;
BREAST-CANCER; BIBW 2992; KINASE INHIBITOR; TYROSINE KINASE; OPEN-LABEL;
TRIAL; EGFR
AB Aims: To determine the maximum tolerated dose (MTD), safety and anti-tumor activity of afatinib combined with docetaxel in advanced cancer. Patients & methods: The MTD was determined from dose-limiting toxicities in the first cycle. Results: Thirty-one patients received 10, 20 and 30 mg oral afatinib, plus 60 and 75 mg/m(2) intravenous docetaxel (six cohorts; 3-week cycles). The MTD of afatinib was 20 mg/day (days 2-21) with 75 mg/m(2) docetaxel (day 1). Dose-limiting toxicities were grade 3/4 diarrhea (n = 3) and febrile neutropenia (n = 6). Most frequently occurring adverse events were diarrhea, neutropenia and rash. Disease stabilization occurred in 14 patients. Conclusion: Afatinib 20 mg/day plus docetaxel was suboptimal and the study could not yield Phase II dose recommendations. The combination resulted in a manageable safety profile.
C1 [Marshall, John] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
[Shapiro, Geoffrey I.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Uttenreuther-Fischer, Martina; Stopfer, Peter] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.
[Ould-Kaci, Mahmoud] Boehringer Ingelheim GmbH & Co KG, F-75013 Paris, France.
[Gordon, Michael S.] Pinnacle Oncol Hematol, Scottsdale, AZ 85258 USA.
RP Marshall, J (reprint author), Georgetown Univ, Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd NW, Washington, DC 20007 USA.
EM marshalj@georgetown.edu
FU Boehringer Ingelheim; Ogilvy Healthworld
FX The clinical research involved in the production of this manuscript is
sponsored by Boehringer Ingelheim. The authors have no other relevant
affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.; Writing assistance was utilized in the production of this
manuscript. Medical writing assistance, supported financially by
Boehringer Ingelheim, was provided by Ogilvy Healthworld, with edits and
suggestions by ML Hartley of the Lombardi Cancer Center, during the
preparation of this article.
NR 36
TC 16
Z9 16
U1 0
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1479-6694
J9 FUTURE ONCOL
JI Future Oncol.
PD FEB
PY 2013
VL 9
IS 2
BP 271
EP 281
DI 10.2217/FON.12.195
PG 11
WC Oncology
SC Oncology
GA 093BD
UT WOS:000315165800018
PM 23414476
ER
PT J
AU Keating, A
DaSilva, G
Perez, WS
Gupta, V
Cutler, CS
Ballen, KK
Cairo, MS
Camitta, BM
Champlin, RE
Gajewski, JL
Lazarus, HM
Lill, M
Marks, DI
Nabhan, C
Schiller, GJ
Socie, G
Szer, J
Tallman, MS
Weisdorf, DJ
AF Keating, Armand
DaSilva, Gisela
Perez, Waleska S.
Gupta, Vikas
Cutler, Corey S.
Ballen, Karen K.
Cairo, Mitchell S.
Camitta, Bruce M.
Champlin, Richard E.
Gajewski, James L.
Lazarus, Hillard M.
Lill, Michael
Marks, David I.
Nabhan, Chadi
Schiller, Gary J.
Socie, Gerald
Szer, Jeffrey
Tallman, Martin S.
Weisdorf, Daniel J.
TI Autologous blood cell transplantation versus HLA-identical sibling
transplantation for acute myeloid leukemia in first complete remission:
a registry study from the Center for International Blood and Marrow
Transplantation Research
SO HAEMATOLOGICA
LA English
DT Article
ID BONE-MARROW; COOPERATIVE-GROUP; MYELODYSPLASTIC-SYNDROME; COMPETING
RISKS; OLDER PATIENTS; AML-10 TRIAL; CHEMOTHERAPY; SURVIVAL; THERAPY;
RELAPSE
AB The optimal post-remission treatment for acute myeloid leukemia in first complete remission remains uncertain. Previous comparisons of autologous versus allogeneic hematopoietic cell transplantation noted higher relapse, but lower treatment-related mortality though using bone marrow grafts, with treatment-related mortality of 12-20%. Recognizing lower treatment-related mortality using autologous peripheral blood grafts, in an analysis of registry data from the Center for International Blood and Transplant Research, we compared treatment-related mortality, relapse, leukemia-free survival, and overall survival for patients with acute myeloid leukemia in first complete remission (median ages 36-44, range 19-60) receiving myeloablative HLA-matched sibling donor grafts (bone marrow, n=475 or peripheral blood, n=428) versus autologous peripheral blood (n=230). The 5-year cumulative incidence of treatment-related mortality was 19% (95% confidence interval, 16-23%), 20% (17-24%) and 8% (5-12%) for allogeneic bone marrow, allogeneic peripheral blood and autologous peripheral blood stem cell transplant recipients, respectively. The corresponding figures for 5-year cumulative incidence of relapse were 20% (17-24%), 26% (21-30%) and 45% (38-52%), respectively. At 5 years, leukemia-free survival and overall survival rates were similar: allogeneic bone marrow 61% (56-65%) and 64% (59-68%); allogeneic peripheral blood 54% (49-59%) and 59% (54-64%); autologous peripheral blood 47% (40-54%) and 54% (47-60%); P=0.13 and P=0.19, respectively. In multivariate analysis the incidence of treatment-related mortality was lower after autologous peripheral blood transplantation than after allogeneic bone marrow/peripheral blood transplants [relative risk 0.37 (0.20-0.69); P=0.001], but treatment failure (death or relapse) after autologous peripheral blood was significantly more likely [relative risk 1.32 (1.06-1.64); P=0.011]. The 5-year overall survival, however, was similar in patients who received autologous peripheral blood (n=230) [relative risk 1.23 (0.98-1.55); P=0.071] or allogeneic bone marrow/peripheral blood (n=903). In the absence of an HLA-matched sibling donor, autologous peripheral blood may provide acceptable alternative post-remission therapy for patients with acute myeloid leukemia in first complete remission.
C1 [Keating, Armand; Gupta, Vikas] Univ Toronto, Princess Margaret Hosp, Toronto, ON M5S 1A1, Canada.
[DaSilva, Gisela] Univ Sao Paulo, Sao Paulo, Brazil.
[Perez, Waleska S.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cairo, Mitchell S.] New York Med Coll, Valhalla, NY 10595 USA.
[Camitta, Bruce M.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA.
[Champlin, Richard E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Gajewski, James L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Lazarus, Hillard M.] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA.
[Lill, Michael] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Marks, David I.] Bristol Childrens Hosp, Bristol, Avon, England.
[Nabhan, Chadi] Adv Lutheran Gen Hosp, Park Ridge, IL USA.
[Schiller, Gary J.] Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA.
[Socie, Gerald] Hop St Louis, Paris, France.
[Szer, Jeffrey] Royal Melbourne Hosp, Melbourne, Vic, Australia.
[Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
RP Weisdorf, DJ (reprint author), Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
EM weisd001@umn.edu
OI Szer, Jeff/0000-0001-6783-2301
FU National Cancer Institute (NCI) [24-CA76518]; National Heart, Lung and
Blood Institute (NHLBI); National Institute of Allergy and Infectious
Diseases (NIAID); NHLBI [5U01HL069294]; NCI; Health Resources and
Services Administration (HRSA/DHHS) [HHSH234200637015C]; Office of Naval
Research [N00014-06-1-0704, N00014-08-1-0058]; Allos, Inc.; Amgen, Inc.;
Angioblast; Anonymous donation; Ariad; Be the Match Foundation; Blue
Cross; Blue Shield Association; Buchanan Family Foundation; CaridianBCT;
Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research
Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva
Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation;
GlaxoSmithKline; Kiadis Pharma; Leukemia & Lymphoma Society; Medical
College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman USA,
Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum
Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Seattle
Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish Orphan
Biovitrum; THERAKOS, Inc.; Wellpoint, Inc.
FX The CIBMTR is supported by Public Health Service Grant/Cooperative
Agreement 24-CA76518 from the National Cancer Institute (NCI), the
National Heart, Lung and Blood Institute (NHLBI) and the National
Institute of Allergy and Infectious Diseases (NIAID); a
Grant/Cooperative Agreement 5U01HL069294 from the NHLBI and NCI; a
contract HHSH234200637015C with Health Resources and Services
Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and
N00014-08-1-0058 from the Office of Naval Research; and grants from
Allos, Inc.; Amgen, Inc.; Angioblast; Anonymous donation to the Medical
College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and
Blue Shield Association; Buchanan Family Foundation; CaridianBCT;
Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research
Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva
Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation;
GlaxoSmithKline; Kiadis Pharma; The Leukemia & Lymphoma Society; The
Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman
USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum
Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Seattle
Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish Orphan
Biovitrum; THERAKOS, Inc.; and Wellpoint, Inc.
NR 32
TC 15
Z9 15
U1 0
U2 10
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD FEB
PY 2013
VL 98
IS 2
BP 185
EP 192
DI 10.3324/haematol.2012.062059
PG 8
WC Hematology
SC Hematology
GA 096PD
UT WOS:000315415800010
PM 22983587
ER
PT J
AU Chen, WJ
Sun, CC
Chen, SZ
Meynard, D
Babitt, JL
Lin, HY
AF Chen, Wenjie
Sun, Chia Chi
Chen, Shanzhuo
Meynard, Delphine
Babitt, Jodie L.
Lin, Herbert Y.
TI A novel validated enzyme-linked immunosorbent assay to quantify soluble
hemojuvelin in mouse serum
SO HAEMATOLOGICA
LA English
DT Article
ID IRON-REGULATORY PROTEIN; HEPCIDIN EXPRESSION; JUVENILE HEMOCHROMATOSIS;
PEPTIDE HEPCIDIN; DOWN-REGULATION; HOMEOSTASIS; OVERLOAD; ANEMIA;
TMPRSS6; BMP6
AB Hemojuvelin is a critical regulator of hepcidin expression and can be cleaved by proteases to form soluble hemojuvelin. Soluble hemojuvelin has been recently identified in human serum but the presence and quantity of soluble hemojuvelin in mouse serum is unknown. We developed a two-site enzyme-linked immunosorbent assay using a monoclonal anti-hemojuvelin as the capture antibody and a biotinylated polyclonal anti-hemojuvelin as the detection antibody to quantify the levels of soluble hemojuvelin in mouse serum. We validated this assay using cell-conditioned media and serum from Hemojuvelin-null and Bone morphogenetic protein 6-null mice. We also used this validated assay to measure serum soluble hemojuvelin concentrations in mice receiving an acute low iron or high iron treatment. This two-site enzyme-linked immunosorbent assay was highly specific for mouse hemojuvelin, with a lower limit of detection at 13.2-26.8 ng/mL of soluble hemojuvelin in mouse serum. The median serum soluble hemojuvelin concentration in wild-type C57BL/6J mice was 57.9+/-22 ng/mL, which is 4- to 20-fold less than that reported in healthy human volunteers. After acute low iron diet treatment in these mice, serum soluble hemojuvelin levels were increased and correlated with lowered serum iron levels and decreased hepatic hepcidin expression. An acute high iron diet in wild-type mice or chronically iron-overloaded Bone morphogenetic protein 6-null mice did not significantly lower serum soluble hemojuvelin concentrations. Here we report reliable quantitation of mouse serum soluble hemojuvelin using a novel and validated enzyme-linked immunosorbent assay. This assay may provide a useful tool to elucidate the source and physiological role of serum soluble hemojuvelin in hepcidin regulation and iron metabolism using well-established mouse models of iron-related disorders.
C1 [Chen, Wenjie; Sun, Chia Chi; Chen, Shanzhuo; Meynard, Delphine; Babitt, Jodie L.; Lin, Herbert Y.] Harvard Univ, Massachusetts Gen Hosp, Program Membrane Biol,Ctr Syst Biol, Program Anemia Signaling Res,Div Nephrol,Sch Med, Boston, MA 02115 USA.
RP Lin, HY (reprint author), Harvard Univ, Massachusetts Gen Hosp, Program Membrane Biol,Ctr Syst Biol, Program Anemia Signaling Res,Div Nephrol,Sch Med, Boston, MA 02115 USA.
EM Lin.Herbert@mgh.harvard.edu
RI meynard, delphine/B-4236-2014
FU Cooley's Anemia Foundation; NRSA [T32-DK7540-27]; NIH [RO1-DK087727, RO1
DK-069533, RO1 DK-071837]; Massachusetts General Hospital
FX This work was supported by a Cooley's Anemia Foundation Research
Fellowship (to WC), by a NRSA grant T32-DK7540-27 (to CCS), by a NIH
grant RO1-DK087727 and a Claflin Distinguished Scholar Award from the
Massachusetts General Hospital (to JLB), and by NIH grants RO1 DK-069533
and RO1 DK-071837 (to HYL).
NR 42
TC 9
Z9 10
U1 1
U2 9
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD FEB
PY 2013
VL 98
IS 2
BP 296
EP 304
DI 10.3324/haematol.2012.070136
PG 9
WC Hematology
SC Hematology
GA 096PD
UT WOS:000315415800025
PM 22875629
ER
PT J
AU Chinitz, JS
Chen, D
Goyal, P
Wilson, S
Islam, F
Nguyen, T
Wang, Y
Hurtado-Rua, S
Simprini, L
Cham, M
Levine, RA
Devereux, RB
Weinsaft, JW
AF Chinitz, Jason S.
Chen, Debbie
Goyal, Parag
Wilson, Sean
Islam, Fahmida
Thanh Nguyen
Wang, Yi
Hurtado-Rua, Sandra
Simprini, Lauren
Cham, Matthew
Levine, Robert A.
Devereux, Richard B.
Weinsaft, Jonathan W.
TI Mitral Apparatus Assessment by Delayed Enhancement CMR Relative Impact
of Infarct Distribution on Mitral Regurgitation
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE mitral regurgitation; myocardial infarction; papillary muscle infarction
ID ACUTE MYOCARDIAL-INFARCTION; PAPILLARY-MUSCLE DYSFUNCTION; QUANTITATIVE
DOPPLER ASSESSMENT; CARDIAC MAGNETIC-RESONANCE; VALVULAR REGURGITATION;
CLINICAL-SIGNIFICANCE; CONTRAST-ENHANCEMENT; IRREVERSIBLE INJURY;
ATRIAL-FIBRILLATION; VALVE
AB OBJECTIVES This study sought to assess patterns and functional consequences of mitral apparatus infarction after acute myocardial infarction (AMI).
BACKGROUND The mitral apparatus contains 2 myocardial components: papillary muscles and the adjacent left ventricular (LV) wall. Delayed-enhancement cardiac magnetic resonance (DE-CMR) enables in vivo study of inter-relationships and potential contributions of LV wall and papillary muscle infarction (PMI) to mitral regurgitation (MR).
METHODS Multimodality imaging was performed: CMR was used to assess mitral geometry and infarct pattern, including 3D DE-CMR for PMI. Echocardiography was used to measure MR. Imaging occurred 27 +/- 8 days after AMI (CMR, echocardiography within 1 day).
RESULTS A total of 153 patients with first AMI were studied; PMI was present in 30% (n = 46 [72% posteromedial, 39% anterolateral]). When stratified by angiographic culprit vessel, PMI occurred in 65% of patients with left circumflex, 48% with right coronary, and only 14% of patients with left anterior descending infarctions (p <0.001). Patients with PMI had more advanced remodeling as measured by LV size and mitral annular diameter (p <0.05). Increased extent of PMI was accompanied by a stepwise increase in mean infarct transmurality within regional LV segments underlying each papillary muscle (p <0.001). Prevalence of lateral wall infarction was 3-fold higher among patients with PMI compared to patients without PMI (65% vs. 22%, p <0.001). Infarct distribution also impacted MR, with greater MR among patients with lateral wall infarction (p = 0.002). Conversely, MR severity did not differ on the basis of presence (p = 0.19) or extent (p = 0.12) of PMI, or by angiographic culprit vessel. In multivariable analysis, lateral wall infarct size (odds ratio 1.20/% LV myocardium [95% confidence interval: 1.05 to 1.39], p = 0.01) was independently associated with substantial (moderate or greater) MR even after controlling for mitral annular (odds ratio 1.22/mm [1.04 to 1.43], p = 0.01), and LV end-diastolic diameter (odds ratio 1.11/mm [0.99 to 1.23], p = 0.056).
CONCLUSIONS Papillary muscle infarction is common after AMI, affecting nearly one-third of patients. Extent of PMI parallels adjacent LV wall injury, with lateral infarction-rather than PMI-associated with increased severity of post-AMI MR. (J Am Coll Cardiol Img 2013;6:220-34) (C) 2013 by the American College of Cardiology Foundation
C1 [Chinitz, Jason S.; Chen, Debbie; Goyal, Parag; Wilson, Sean; Islam, Fahmida; Devereux, Richard B.; Weinsaft, Jonathan W.] Weill Cornell Med Coll, Greenberg Cardiol Div, Dept Med, New York, NY 10021 USA.
[Thanh Nguyen; Wang, Yi; Weinsaft, Jonathan W.] Weill Cornell Med Coll, Dept Radiol, New York, NY 10021 USA.
[Hurtado-Rua, Sandra] Weill Cornell Med Coll, Dept Biostat, New York, NY 10021 USA.
[Simprini, Lauren] Mem Sloan Kettering Canc Ctr, Div Cardiol, New York, NY 10021 USA.
[Cham, Matthew] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Levine, Robert A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Weinsaft, JW (reprint author), Weill Cornell Med Coll, Starr 4,525 East 68th St, New York, NY 10021 USA.
EM jww2001@med.cornell.edu
FU Lantheus Medical Imaging; Doris Duke Clinical Scientist Development
Award [K23 HL102249-01]
FX This work was supported by Lantheus Medical Imaging, and a Doris Duke
Clinical Scientist Development Award (K23 HL102249-01) to Dr. Weinsaft.
The authors have reported they have no relationships relevant to the
contents of this paper to disclose.
NR 47
TC 22
Z9 22
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD FEB
PY 2013
VL 6
IS 2
BP 220
EP 234
DI 10.1016/j.jcmg.2012.08.016
PG 15
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 097XX
UT WOS:000315507900011
PM 23489536
ER
PT J
AU Jin, JO
Han, XZ
Yu, Q
AF Jin, Jun-O
Han, Xiaozhe
Yu, Qing
TI Interleukin-6 induces the generation of IL-10-producing Tr1 cells and
suppresses autoimmune tissue inflammation
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE Interleukin-6; Interleukin-10; Tr1 cells; Autoimmune disease;
Immune-regulatory; Inflammation
ID REGULATORY T-CELLS; ARYL-HYDROCARBON RECEPTOR; C-MAF; IL-10 PRODUCTION;
TH17 CELLS; EXPRESSION; DIFFERENTIATION; IL-27; RESPONSES; EFFECTOR
AB Compared with its pro-inflammatory function, the mechanisms underlying the anti-inflammatory effect of IL-6 are poorly understood. IL-6 can cooperate with TGF-beta to induce IL-10 production in Th17 cells in vitro. However, the effect of IL-6 on generation of Tr1 cells and the in vivo importance of this effect are mostly uncharacterized. In this study, we showed that in vitro, IL-6 can induce the generation of IL-10-producing Tr1 cells from naive CD4 T cells, independently of IL-27 and TGF-beta. IL-6 induces IL-21 production in CD4 T cells and IL-10-inducing effect of IL-6 requires both IL-21 and IL-2. Although IL-6 cannot induce IL-10 production in CD8 T cells in a cell-autonomous manner, it can do so indirectly through promoting CD4 T cell IL-21 production. The IL-10-producing T cells induced by IL-6 have phenotypic, genetic and functional traits of Tr1 cells and can suppress LPS-induced in vivo inflammatory response in an IL-10-dependent fashion. Blockade of IL-6 in two autoimmune inflammation models, induced respectively by anti-CD3 antibody or Treg-depletion, led to reduction in IL-10-producing T cells and exacerbated inflammation of lung and intestine. Thus, we delineated critical pathways involved in IL-6-induced generation of Tr1 cells and demonstrated the importance of this event in restraining autoimmune tissue inflammation. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Jin, Jun-O; Han, Xiaozhe; Yu, Qing] Forsyth Inst, Dept Immunol, Cambridge, MA 02142 USA.
RP Yu, Q (reprint author), Forsyth Inst, Dept Immunol, 245 1st St, Cambridge, MA 02142 USA.
EM qyu@forsyth.org
FU National Institutes of Health [P30DE020751]
FX We thank Drs. T. Kawai, DJ. Smith and MA. Taubman for advice and support
in this project; Drs. K. Shortman and A. Lew for critical reading of the
manuscript; and Dr. M. Kajiya and Z. Li and for technical assistance.
This entire study was supported by the National Institutes of Health
(P30DE020751).
NR 43
TC 34
Z9 37
U1 1
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
J9 J AUTOIMMUN
JI J. Autoimmun.
PD FEB
PY 2013
VL 40
BP 28
EP 44
DI 10.1016/j.jaut.2012.07.009
PG 17
WC Immunology
SC Immunology
GA 095XJ
UT WOS:000315368000004
PM 22921334
ER
PT J
AU Jeon, HJ
Bae, J
Woo, JM
AF Jeon, Hong Jin
Bae, Joomi
Woo, Jong-Min
TI Recent statistics and risk factors of suicide in children and
adolescents
SO JOURNAL OF THE KOREAN MEDICAL ASSOCIATION
LA Korean
DT Article
DE Adolescent; Suicide; Risk factors
ID PROTECTIVE FACTORS; SELF-HARM; ASSOCIATION; DEPRESSION; SAMPLE; YOUTH
AB Youth suicide is like the tip of an iceberg; while many adolescents have died from suicide, many more adolescents have been harmed by suicide attempts and self-injury. Suicide influences not only the victims, but also their family members, friends, teachers, and neighbors. Witnesses can suffer from posttraumatic stress disorder. Suicide is the second leading cause of death among adolescents worldwide and the first cause of death among Korean adolescents. The number of suicides in Korea, especially among high school students and female students, is rapidly increasing when compared with Western countries. Suicide accounted for 28.2% of deaths among Korean adolescents in 2010. There were 4.44% and 18.97% of adolescents who had attempted suicide and had experienced suicidal ideation in their lifetime, which shows that many adolescents have a potential risk for suicide. Previous studies in Western countries have revealed that risk factors for adolescent suicide consist of three categories: sociodemographic factors (male and low socioeconomic and educational status), mental health factors (depression and drug abuse), and individual negative life events and family diversity (family history of suicidal behavior, parental death, and child abuse). In conclusion, suicide is common and rapidly increasing in Korean adolescents. However, the risk factors of suicide and suicide behaviors in Korean adolescents are yet to be determined. A well-designed nationwide survey is needed to investigate the prevalence and risk factors of suicide behaviors and mental disorders among Korean adolescents.
C1 [Jeon, Hong Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Depress Ctr,Dept Psychiat, Seoul, South Korea.
[Jeon, Hong Jin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Depress Clin & Res Program,Dept Psychiat, Boston, MA 02115 USA.
[Bae, Joomi] Korea Youth Counselling & Welf Inst, Seoul, South Korea.
[Woo, Jong-Min] Inje Univ, Sch Med, Seoul Paik Hosp, Dept Psychiat, Seoul, South Korea.
[Woo, Jong-Min] Inje Univ, Stress Res Inst, Seoul, South Korea.
[Woo, Jong-Min] Natl Evidence Based Healthcare Collaborating Agcy, Seoul, South Korea.
RP Woo, JM (reprint author), Inje Univ, Sch Med, Seoul Paik Hosp, Dept Psychiat, Seoul, South Korea.
EM jongmin.woo@gmail.com
FU National Evidence-based Healthcare Collaborating Agency [NM11-003]
FX This study was fully funded by the National Evidence-based Healthcare
Collaborating Agency (NM11-003).
NR 25
TC 4
Z9 4
U1 5
U2 40
PU KOREAN MEDICAL ASSOC
PI SEOUL
PA 302-75 INCHON-1 DONG, YONGSAN-GU, SEOUL, 140-721, SOUTH KOREA
SN 1975-8456
J9 J KOREAN MED ASSOC
JI J. Korean Med. Assoc.
PD FEB
PY 2013
VL 56
IS 2
BP 93
EP 99
DI 10.5124/jkma.2013.56.2.93
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 098NC
UT WOS:000315555000003
ER
PT J
AU Meimarakis, G
Angele, M
Conrad, C
Schauer, R
Weidenhagen, R
Crispin, A
Giessen, C
Preissler, G
Wiedemann, M
Jauch, KW
Heinemann, V
Stintzing, S
Hatz, RA
Winter, H
AF Meimarakis, Georgios
Angele, Martin
Conrad, Claudius
Schauer, Rolf
Weidenhagen, Rolf
Crispin, Alexander
Giessen, Clemens
Preissler, Gerhard
Wiedemann, Max
Jauch, Karl-Walter
Heinemann, Volker
Stintzing, Sebastian
Hatz, Rudolf A.
Winter, Hauke
TI Combined resection of colorectal hepatic-pulmonary metastases shows
improved outcome over chemotherapy alone
SO LANGENBECKS ARCHIVES OF SURGERY
LA English
DT Article
DE Colorectal cancer; Prognostic factors; Pulmonary metastases; Liver
metastases; Surgical resection; Survival
ID SURGICAL-TREATMENT; PLUS OXALIPLATIN; COLON-CANCER; FINAL REPORT;
PHASE-III; CARCINOMA; FLUOROURACIL; SURVIVAL; LEUCOVORIN; RECURRENCE
AB The objective of this retrospective study was to assess the survival of patients after resection of hepatic and pulmonary colorectal metastases to identify predictors of long-term survival.
Patients receiving chemotherapy alone were compared to patients receiving surgery and chemotherapy in a matched-pair analysis with the following criteria: UICC stage, grading, and date of initial primary tumor occurrence.
A total of 30 patients with liver and lung metastases of colorectal carcinoma underwent resection. In 20 cases, complete resection was achieved (median survival, 67 months). Incomplete resection and preoperatively elevated carcinoembryonic antigen (CEA) levels are independent risk factors for reduced survival. Patients developing pulmonary metastases prior to hepatic metastases had the worst prognosis. Surgical resection significantly increased survival compared to chemotherapy alone in matched-pair analysis (65 vs. 30 months, p = 0.03).
Incomplete resection and elevated CEA levels are predictors of poor outcome. Matched-paired analysis confirmed that surgical resection in combination with chemotherapy appears to be superior to chemotherapy alone.
C1 [Meimarakis, Georgios; Angele, Martin; Weidenhagen, Rolf; Preissler, Gerhard; Jauch, Karl-Walter; Hatz, Rudolf A.; Winter, Hauke] Univ Munich Grosshadern, Dept Gen Thorac Surg, D-81377 Munich, Germany.
[Conrad, Claudius] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Schauer, Rolf] Traunstein Hosp, Dept Surg, Traunstein, Germany.
[Crispin, Alexander; Wiedemann, Max] Univ Munich, Dept Med Informat Biometry & Epidemiol, Munich, Germany.
[Giessen, Clemens; Heinemann, Volker; Stintzing, Sebastian] Univ Munich Grosshadern, Dept Oncol, D-81377 Munich, Germany.
[Giessen, Clemens; Heinemann, Volker; Stintzing, Sebastian] Univ Munich Grosshadern, Ctr Comprehens Canc, D-81377 Munich, Germany.
RP Winter, H (reprint author), Univ Munich Grosshadern, Dept Gen Thorac Surg, Marchioninistr 15, D-81377 Munich, Germany.
EM hauke.winter@med.uni-muenchen.de
RI Winter, Hauke/I-1394-2013;
OI Winter, Hauke/0000-0001-8911-6218; Stintzing, Sebastian
/0000-0002-3297-5801
FU Chiles Foundation, Portland, OR
FX This work was supported by a grant from the Chiles Foundation, Portland,
OR. The Chiles Foundation is a nonprofit research institution supporting
biomedical research. The Chiles Foundation had no influence on the
design or conduct of the study, the collection, management, analysis,
and interpretation of the data, or the preparation, review, or approval
of the manuscript.
NR 27
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1435-2443
J9 LANGENBECK ARCH SURG
JI Langenbecks Arch. Surg.
PD FEB
PY 2013
VL 398
IS 2
BP 265
EP 276
DI 10.1007/s00423-012-1046-1
PG 12
WC Surgery
SC Surgery
GA 089GX
UT WOS:000314900100010
PM 23314791
ER
PT J
AU Brown, JR
Kim, HT
Armand, P
Cutler, C
Fisher, DC
Ho, V
Koreth, J
Ritz, J
Wu, C
Antin, JH
Soiffer, RJ
Gribben, JG
Alyea, EP
AF Brown, J. R.
Kim, H. T.
Armand, P.
Cutler, C.
Fisher, D. C.
Ho, V.
Koreth, J.
Ritz, J.
Wu, C.
Antin, J. H.
Soiffer, R. J.
Gribben, J. G.
Alyea, E. P.
TI Long-term follow-up of reduced-intensity allogeneic stem cell
transplantation for chronic lymphocytic leukemia: prognostic model to
predict outcome
SO LEUKEMIA
LA English
DT Article
DE CLL; RIC; myeloablative; SCT; prognostic model
ID BONE-MARROW-TRANSPLANTATION; PROGRESSION-FREE SURVIVAL;
VERSUS-HOST-DISEASE; POOR-PROGNOSIS; MATCHED ANALYSIS; INITIAL THERAPY;
FLUDARABINE; RITUXIMAB; CYCLOPHOSPHAMIDE; TRIAL
AB Chronic lymphocytic leukemia (CLL) remains incurable with chemoimmunotherapy, and allogeneic hematopoietic stem cell transplantation (HSCT) offers the potential for cure. We assessed the outcomes of 108 CLL patients undergoing first allogeneic HSCTs, 76 with reduced-intensity (RIC) and 32 with myeloablative conditioning (MAC) between 1998 and 2009 at Dana-Farber Cancer Institute. With median follow-up of 5.9 years in surviving patients, the 5-year overall survival (OS) for the entire cohort is 63% for RIC regimens and 49% for MAC regimens (P=0.18). The risk of death declined significantly starting in 2004, and we found that 5-year OS for HSCT between 2004 and 2009 was 83% for RIC regimens compared with 47% for MAC regimens (P=0.003). For RIC transplantation, we developed a prognostic model based on predictors of progression-free survival (PFS), specifically remission status, lactate dehydrogenase, comorbidity score and lymphocyte count, and found 5-year PFS to be 83% for Score 0, 63% for Score 1, 24% for Score 2 and 6% for Score >= 3 (P<0.0001). We conclude that RIC HSCT for CLL in the current era is associated with excellent long-term PFS and OS, and, as potentially curative therapy, should be considered early in the disease course of relapsed high-risk CLL patients. Leukemia (2013) 27, 362-369; doi:10.1038/leu.2012.228
C1 [Brown, J. R.; Kim, H. T.; Armand, P.; Cutler, C.; Fisher, D. C.; Ho, V.; Koreth, J.; Ritz, J.; Wu, C.; Antin, J. H.; Soiffer, R. J.; Gribben, J. G.; Alyea, E. P.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Brown, J. R.; Armand, P.; Cutler, C.; Fisher, D. C.; Ho, V.; Koreth, J.; Ritz, J.; Wu, C.; Antin, J. H.; Soiffer, R. J.; Gribben, J. G.; Alyea, E. P.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Brown, J. R.; Armand, P.; Cutler, C.; Fisher, D. C.; Ho, V.; Koreth, J.; Ritz, J.; Wu, C.; Antin, J. H.; Soiffer, R. J.; Gribben, J. G.; Alyea, E. P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Brown, JR (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM jbrown2@partners.org
OI Ritz, Jerome/0000-0001-5526-4669
FU NIH [K23 CA115682-01, PO1 HL070149, PO1 CA81538, A129530, P01 CA142106];
Jock and Bunny Adams Research and Education Endowment; Ted and Eileen
Pasquarello Research Fund
FX We are indebted to the nurses, medical oncology fellows, house staff and
social workers of the Dana-Farber Cancer Institute and Brigham and
Women's Hospital for their excellent care of these patients. We thank
the staff of the Connell-O'Reilly Cell Manipulation Laboratory and the
Blood Component Laboratory of the Dana-Farber Cancer Institute for
processing stem cells for these patients, and the data management staff
for their tireless work in maintaining the DFCI BMT clinical data
repository, without which this project would not be possible. This work
was supported by NIH Grants K23 CA115682-01 to JRB, PO1 HL070149, PO1
CA81538 to JGG, A129530 to FLIS, P01 CA142106 to JHA, and by the Jock
and Bunny Adams Research and Education Endowment and the Ted and Eileen
Pasquarello Research Fund. JRB is a Scholar of the American Society of
Hematology as well as a Scholar in Clinical Research of the Leukemia and
Lymphoma Society.
NR 38
TC 44
Z9 44
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD FEB
PY 2013
VL 27
IS 2
BP 362
EP 369
DI 10.1038/leu.2012.228
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA 098MO
UT WOS:000315553600013
PM 22955330
ER
PT J
AU Magrangeas, F
Avet-Loiseau, H
Gouraud, W
Lode, L
Decaux, O
Godmer, P
Garderet, L
Voillat, L
Facon, T
Stoppa, AM
Marit, G
Hulin, C
Casassus, P
Tiab, M
Voog, E
Randriamalala, E
Anderson, KC
Moreau, P
Munshi, NC
Minvielle, S
AF Magrangeas, F.
Avet-Loiseau, H.
Gouraud, W.
Lode, L.
Decaux, O.
Godmer, P.
Garderet, L.
Voillat, L.
Facon, T.
Stoppa, A. M.
Marit, G.
Hulin, C.
Casassus, P.
Tiab, M.
Voog, E.
Randriamalala, E.
Anderson, K. C.
Moreau, P.
Munshi, N. C.
Minvielle, S.
TI Minor clone provides a reservoir for relapse in multiple myeloma
SO LEUKEMIA
LA English
DT Article
DE multiple myeloma; genomic analysis; nonlinear evolution
ID STEM-CELL TRANSPLANTATION; LYMPHOBLASTIC-LEUKEMIA; COPY-NUMBER;
EVOLUTION; ABNORMALITIES; THALIDOMIDE; DYSCRASIAS; PREDNISONE;
MECHANISMS; MELPHALAN
AB Recent studies have provided direct evidence for genetic variegation in subclones for various cancer types. However, little is known about subclonal evolutionary processes according to treatment and subsequent relapse in multiple myeloma (MM). This issue was addressed in a cohort of 24 MM patients treated either with conventional chemotherapy or with the proteasome inhibitor, bortezomib. As MM is a highly heterogeneous disease associated with a large number of chromosomal abnormalities, a subset of secondary genetic events that seem to reflect progression, 1q21 gain, NF-kappa B-activating mutations, RB1 and TP53 deletions, was examined. By using high-resolution single-nucleotide polymorphism arrays, subclones were identified with nonlinear complex evolutionary histories. Such reordering of the spectrum of genetic lesions, identified in a third of MM patients during therapy, is likely to reflect the selection of genetically distinct subclones, not initially competitive against the dominant population but which survived chemotherapy, thrived and acquired new anomalies. In addition, the emergence of minor subclones at relapse appeared to be significantly associated with bortezomib treatment. These data support the idea that new strategies for future clinical trials in MM should combine targeted therapy and subpopulations' control to eradicate all myeloma subclones in order to obtain long-term remission. Leukemia (2013) 27, 473-481; doi:10.1038/leu.2012.226
C1 [Magrangeas, F.; Gouraud, W.; Decaux, O.; Moreau, P.; Minvielle, S.] Univ Nantes, CNRS, INSERM, UMR 892,UMR 6299, F-44007 Nantes 01, France.
[Magrangeas, F.; Avet-Loiseau, H.; Lode, L.; Moreau, P.; Minvielle, S.] CHU Nantes, F-44007 Nantes 01, France.
[Gouraud, W.] Inst Cancerol Ouest, Nantes, France.
[Decaux, O.] Ctr Hosp Univ, Rennes, France.
[Godmer, P.] Ctr Hosp, Vannes, France.
[Garderet, L.] Hop St Antoine, F-75571 Paris, France.
[Voillat, L.] Ctr Hosp, Chalon Sur Saone, France.
[Facon, T.] CHU Lille, F-59037 Lille, France.
[Stoppa, A. M.] Inst J Paoli I Calmettes, F-13009 Marseille, France.
[Marit, G.] Ctr Hosp Univ, Bordeaux, France.
[Hulin, C.] Ctr Hosp Univ, Nancy, France.
[Casassus, P.] Hop Avicenne, F-93009 Bobigny, France.
[Tiab, M.] Ctr Hosp, La Roche Sur Yon, France.
[Voog, E.] Ctr Jean Bernard, Le Mans, France.
[Randriamalala, E.] Ctr Hosp Mileterie, Poitiers, France.
[Anderson, K. C.; Munshi, N. C.] Dana Farber Canc Harvard Med Sch, Leebow Inst Myeloma Therapeut, Boston, MA 02115 USA.
[Anderson, K. C.; Munshi, N. C.] Dana Farber Canc Harvard Med Sch, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA.
[Munshi, N. C.] Boston VA Healthcare Syst, Boston, MA USA.
RP Minvielle, S (reprint author), Univ Nantes, CNRS, INSERM, UMR 892,UMR 6299, 8 Quai Moncousu BP 70721, F-44007 Nantes 01, France.
EM stephane.minvielle@inserm.fr
RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015; Magrangeas,
Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015
OI FACON, THIERRY/0000-0001-7705-8460;
FU IFM; French National Research Agency [R08079NS]; French Institute
National du Cancer [R09076NN]; National Institutes of Health [PO1
CA155258-01, RO1-124929, P50-100007, PO1-78378]; Department of Veterans
Affairs Merit Review Awards
FX This study was supported by IFM; the French National Research Agency,
Grant R08079NS (to SM); the French Institute National du Cancer, Grant
R09076NN (to HA-L); the National Institutes of Health, Grants PO1
CA155258-01 (to NCM, SM, HA-L and KCA), RO1-124929 (to NCM), P50-100007
and PO1-78378 (to NCM and KCA), and Department of Veterans Affairs Merit
Review Awards. We thank Elise Douillard, Magali Devic, Emilie Maurenton
and Nathalie Roi for excellent technical expertise. We also thank Marie
C Bene for critical reading of the manuscript
NR 33
TC 42
Z9 44
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD FEB
PY 2013
VL 27
IS 2
BP 473
EP 481
DI 10.1038/leu.2012.226
PG 9
WC Oncology; Hematology
SC Oncology; Hematology
GA 098MO
UT WOS:000315553600025
PM 22874878
ER
PT J
AU Mata, IF
Alvarez, V
Ribacoba, R
Infante, J
Sierra, M
Gomez-Garre, P
Mir, P
Waldherr, S
Yearout, D
Zabetian, CP
AF Mata, Ignacio F.
Alvarez, Victoria
Ribacoba, Renee
Infante, Jon
Sierra, Maria
Gomez-Garre, Pilar
Mir, Pablo
Waldherr, Sarah
Yearout, Dora
Zabetian, Cyrus P.
CA Latin Amer Res Consortium Genetics
TI Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's
disease in Spain
SO MOVEMENT DISORDERS
LA English
DT Letter
C1 [Mata, Ignacio F.; Waldherr, Sarah; Yearout, Dora; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Mata, Ignacio F.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
[Alvarez, Victoria] Hosp Univ Cent Asturias, Lab Genet Mol, Inst Invest Nefrol, Oviedo, Spain.
[Ribacoba, Renee] Hosp Univ Cent Asturias, Dept Neurol, Oviedo, Spain.
[Infante, Jon; Gomez-Garre, Pilar; Mir, Pablo] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Barcelona, Spain.
[Infante, Jon; Sierra, Maria] Marques de Valdecilla Univ Hosp, Dept Neurol, Santander, Spain.
[Gomez-Garre, Pilar; Mir, Pablo] Univ Seville, Hosp Univ Virgen del Rocio, Unidad Trastornos Movimiento, CSIC,Serv Neurol & Neurofisiol Clin,Inst Biomed S, Seville, Spain.
RP Mata, IF (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S182, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM nachofm@u.washington.edu
RI IBIS, MOVIMIENTO/P-3309-2015; Mir, Pablo/C-8662-2013;
OI Mir, Pablo/0000-0003-1656-302X; Fernandez Mata,
Ignacio/0000-0003-1198-0633; Gomez-Garre, Pilar/0000-0002-0437-6182;
Zabetian, Cyrus/0000-0002-7739-4306
FU BLRD VA [I01 BX000531]; FIC NIH HHS [R25 TW009345]; NINDS NIH HHS [P50
NS062684, R01 NS065070]
NR 3
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD FEB
PY 2013
VL 28
IS 2
BP 248
EP 248
DI 10.1002/mds.25293
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 096JF
UT WOS:000315399300026
PM 23389884
ER
PT J
AU Cai, XM
Han, S
Feske, SK
Chou, SHY
AF Cai, Xuemei
Han, Steve
Feske, Steven K.
Chou, Sherry H. -Y.
TI Pearls and Oy-sters: Small but consequential Intracerebral hemorrhage
caused by lenticulostriate artery aneurysm
SO NEUROLOGY
LA English
DT Editorial Material
ID SUBARACHNOID HEMORRHAGE; ANGIOGRAPHY
C1 [Cai, Xuemei; Feske, Steven K.; Chou, Sherry H. -Y.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Cai, Xuemei; Han, Steve] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Cai, Xuemei; Han, Steve; Feske, Steven K.; Chou, Sherry H. -Y.] Harvard Univ, Sch Med, Boston, MA USA.
RP Cai, XM (reprint author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.
EM xcai@partners.org
RI Chou, Sherry/G-5779-2015
FU NINDS NIH HHS [K23 NS073806]
NR 10
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD FEB
PY 2013
VL 80
IS 9
BP E89
EP E91
DI 10.1212/WNL.0b013e31828406a2
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 097CI
UT WOS:000315451200002
PM 23439707
ER
PT J
AU Joseph, J
Loscalzo, J
AF Joseph, Jacob
Loscalzo, Joseph
TI Selenistasis: Epistatic Effects of Selenium on Cardiovascular Phenotype
SO NUTRIENTS
LA English
DT Review
DE selenium; cardiovascular disease; redox balance; methylation;
epigenesis; gene expression; heart failure; fibrosis; methionine;
homocysteine
ID CHRONIC HEART-FAILURE; ABERRANT CRYPT FORMATION; DIETARY SELENIUM; DNA
METHYLATION; VITAMIN-E; COXSACKIEVIRUS B3; SERUM SELENIUM; DEFICIENT
MICE; GLUTATHIONE-PEROXIDASE; MYOCARDIAL-INFARCTION
AB Although selenium metabolism is intricately linked to cardiovascular biology and function, and deficiency of selenium is associated with cardiac pathology, utilization of selenium in the prevention and treatment of cardiovascular disease remains an elusive goal. From a reductionist standpoint, the major function of selenium in vivo is antioxidant defense via its incorporation as selenocysteine into enzyme families such as glutathione peroxidases and thioredoxin reductases. In addition, selenium compounds are heterogeneous and have complex metabolic fates resulting in effects that are not entirely dependent on selenoprotein expression. This complex biology of selenium in vivo may underlie the fact that beneficial effects of selenium supplementation demonstrated in preclinical studies using models of oxidant stress-induced cardiovascular dysfunction, such as ischemia-reperfusion injury and myocardial infarction, have not been consistently observed in clinical trials. In fact, recent studies have yielded data that suggest that unselective supplementation of selenium may, indeed, be harmful. Interesting biologic actions of selenium are its simultaneous effects on redox balance and methylation status, a combination that may influence gene expression. These combined actions may explain some of the biphasic effects seen with low and high doses of selenium, the potentially harmful effects seen in normal individuals, and the beneficial effects noted in preclinical studies of disease. Given the complexity of selenium biology, systems biology approaches may be necessary to reach the goal of optimization of selenium status to promote health and prevent disease.
C1 [Joseph, Jacob] VA Boston Healthcare Syst, Dept Med, Boston, MA 02132 USA.
[Joseph, Jacob; Loscalzo, Joseph] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Loscalzo, J (reprint author), VA Boston Healthcare Syst, Dept Med, Boston, MA 02132 USA.
EM Jacob.joseph@va.gov; jloscalzo@partners.org
FU National Institutes of Health [HL89734, HL061795, HL107192, HL070819,
HL048743, HL108630]
FX This work presented in this article was supported by the National
Institutes of Health grant number HL89734 (J.J.), and National
Institutes of Health grant numbers HL061795, HL107192, HL070819,
HL048743, and HL108630 (J.L.).
NR 96
TC 17
Z9 17
U1 0
U2 27
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD FEB
PY 2013
VL 5
IS 2
BP 340
EP 358
DI 10.3390/nu5020340
PG 19
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 096JW
UT WOS:000315401100002
PM 23434902
ER
PT J
AU Harden, RN
Oaklander, AL
Burton, AW
Perez, RSGM
Richardson, K
Swan, M
Barthel, J
Costa, B
Graciosa, JR
Bruehl, S
AF Harden, R. Norman
Oaklander, Ann Louise
Burton, Allen W.
Perez, Roberto S. G. M.
Richardson, Kathryn
Swan, Melanie
Barthel, Jennifer
Costa, Brienne
Graciosa, Joseph R.
Bruehl, Stephen
TI Complex Regional Pain Syndrome: Practical Diagnostic and Treatment
Guidelines, 4th Edition
SO PAIN MEDICINE
LA English
DT Review
DE Complex Regional Pain Syndrome; Reflex Sympathetic Dystrophy;
Guidelines; Diagnosis; Therapy
ID REFLEX SYMPATHETIC DYSTROPHY; SYNDROME TYPE-I; SPINAL-CORD STIMULATION;
RANDOMIZED CONTROLLED-TRIAL; LOW-BACK-PAIN; CONCENTRATION CAPSAICIN
PATCH; DOUBLE-BLIND CROSSOVER; FACILITATED NEUROGENIC INFLAMMATION;
RECEPTOR ANTAGONIST AMANTADINE; CHRONIC POSTHERPETIC NEURALGIA
AB Objective This is the fourth edition of diagnostic and treatment guidelines for complex regional pain syndrome (CRPS; aka reflex sympathetic dystrophy). Methods Expert practitioners in each discipline traditionally utilized in the treatment of CRPS systematically reviewed the available and relevant literature; due to the paucity of levels 1 and 2 studies, less rigorous, preliminary research reports were included. The literature review was supplemented with knowledge gained from extensive empirical clinical experience, particularly in areas where high-quality evidence to guide therapy is lacking. Results The research quality, clinical relevance, and state of the art of diagnostic criteria or treatment modalities are discussed, sometimes in considerable detail with an eye to the expert practitioner in each therapeutic area. Levels of evidence are mentioned when available, so that the practitioner can better assess and analyze the modality under discussion, and if desired, to personally consider the citations. Tables provide details on characteristics of studies in different subject domains described in the literature. Conclusions In the humanitarian spirit of making the most of all current thinking in the area, balanced by a careful case-by-case analysis of the risk/cost vs benefit analysis, the authors offer these practical guidelines.
C1 [Harden, R. Norman; Graciosa, Joseph R.] Rehabil Inst Chicago, Ctr Pain Studies, Chicago, IL 60611 USA.
[Richardson, Kathryn] Rehabil Inst Chicago, Ctr Pain Management, Chicago, IL 60611 USA.
[Barthel, Jennifer] Rehabil Inst Chicago, Vocat Rehabil Serv, Chicago, IL 60611 USA.
[Harden, R. Norman] Northwestern Univ, Dept Phys Med, Chicago, IL 60611 USA.
[Harden, R. Norman] Northwestern Univ, Dept Rehabil, Chicago, IL 60611 USA.
[Harden, R. Norman] Northwestern Univ, Chicago, IL 60611 USA.
[Oaklander, Ann Louise] Massachusetts Gen Hosp, Dept Neurol & Pathol, Boston, MA 02114 USA.
[Oaklander, Ann Louise] Harvard Univ, Sch Med, Boston, MA USA.
[Burton, Allen W.] Houston Pain Associates PLLC, Houston, TX USA.
[Swan, Melanie] Ohio State Univ, Wexner Med Ctr, Inpatient Rehabil Serv, Acquired Brain Injury Team, Columbus, OH 43210 USA.
[Costa, Brienne] Snoqualmie Valley Hosp, Rehabil Dept, Snoqualmie, WA USA.
[Bruehl, Stephen] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA.
[Perez, Roberto S. G. M.] Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, Amsterdam, Netherlands.
RP Harden, RN (reprint author), Rehabil Inst Chicago, Ctr Pain Studies, 345 E Super St, Chicago, IL 60611 USA.
EM nharden@ric.org
FU Reflex Sympathetic Dystrophy Syndrome Association (RSDSA); Dutch
Alliance for Improvement of Paincare (DALI); Pfizer; Board of the Reflex
Sympathetic Dystrophy Syndrome Association
FX This work was sponsored by the Reflex Sympathetic Dystrophy Syndrome
Association (RSDSA), on which Dr. Harden currently serves as the
Chairman of the Research Committee and is on the Board of Directors. Dr.
Bruehl serves on the RSDSA Scientific Advisory Board. Dr. Burton
consults for Medtronic, Inc. and Boston Scientific. Dr. Perez has
received consultancy fees and an unrestricted research grant from the
Dutch Alliance for Improvement of Paincare (DALI), which is funded by
Pfizer. All other authors have no conflicts of interest to disclose.;
The authors would like to extend their gratitude to James Broatch and
the Board of the Reflex Sympathetic Dystrophy Syndrome Association for
their sponsorship, guidance, and continued support of this project.
NR 343
TC 87
Z9 92
U1 3
U2 41
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD FEB
PY 2013
VL 14
IS 2
BP 180
EP 229
DI 10.1111/pme.12033
PG 50
WC Medicine, General & Internal
SC General & Internal Medicine
GA 099TL
UT WOS:000315644800002
PM 23331950
ER
PT J
AU Schneider, JC
Gerrard, P
Goldstein, R
Divita, MA
Niewczyk, P
Ryan, CM
Kowalske, K
Zafonte, R
AF Schneider, Jeffrey C.
Gerrard, Paul
Goldstein, Richard
Divita, Margaret A.
Niewczyk, Paulette
Ryan, Colleen M.
Kowalske, Karen
Zafonte, Ross
TI The Impact of Comorbidities and Complications on Burn Injury Inpatient
Rehabilitation Outcomes
SO PM&R
LA English
DT Article
ID SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; LENGTH-OF-STAY; STROKE
REHABILITATION; RISK-FACTORS; ADMINISTRATIVE DATABASES; ACUTE-CARE;
MEDICAL REHABILITATION; ADULT PATIENTS; MORTALITY
AB Objective: To examine the impact of comorbidities and complications on burn inpatient rehabilitation facilities (IRE) outcomes.
Design: A retrospective cross-sectional study.
Setting: Inpatient rehabilitation hospitals.
Patients: A total of 4572 patients with a primary diagnosis of burn injury from the Uniform Data System for Medical Rehabilitation database from 2002 to 2010.
Methods or Interventions: Regression analyses were used to determine whether 3 different comorbidity measures (Charlson Comorbidity Index, Elixhauser Comoribidity Index, Centers for Medicare and Medicaid Services Comorbidity Tiers) and 1 complication measure improved the predictive model (c-statistic) for each outcome measure.
Main Outcome Measurements: Community discharge, Functional Independence Measure (FIM) gain, length of stay efficiency, transfer to acute care within the first 3 days of IRE stay, and transfer to acute care for all time periods.
Results: For all outcomes, there was no difference between the Standard Model and the models that include the comorbidity and complication variables as measured by the c-statistic confidence intervals.
Conclusions: Comorbidities and complications did not significantly affect burn IRE outcomes. Future research is needed to examine the impact of comorbidities and complications on outcomes of other IRE populations to better understand the implications for current and future health care policy. PM R2013;5:114-121
C1 [Schneider, Jeffrey C.; Gerrard, Paul; Goldstein, Richard; Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA 02114 USA.
[Divita, Margaret A.; Niewczyk, Paulette] Uniform Data Syst Med Rehabilitat, Amherst, NY USA.
[Niewczyk, Paulette] Daemen Coll, Hlth Care Studies Dept, Amherst, NY USA.
[Ryan, Colleen M.] Shriners Hosp Children Boston, Dept Surg, Boston, MA USA.
[Ryan, Colleen M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Sumner Redstone Burn Ctr,Surg Serv, Boston, MA 02114 USA.
[Kowalske, Karen] Univ Texas SW Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA.
RP Schneider, JC (reprint author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, 125 Nashua St, Boston, MA 02114 USA.
EM jcschneider@partners.org
OI Gerrard, Paul/0000-0003-0654-5354; DiVita, Margaret/0000-0002-4878-2959
FU Department of Defense
FX grant, Department of Defense
NR 46
TC 11
Z9 11
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD FEB
PY 2013
VL 5
IS 2
BP 114
EP 121
DI 10.1016/j.pmrj.2012.07.014
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 095VP
UT WOS:000315363400005
PM 22981003
ER
PT J
AU Murray, AL
Morgenroth, DC
Czerniecki, JM
AF Murray, Andrew L.
Morgenroth, David C.
Czerniecki, Joseph M.
TI Residual Limb Claudication in a Traumatic Transtibial Amputee
SO PM&R
LA English
DT Article
ID BACK-PAIN; PHANTOM PAIN; AMPUTATION
AB Residual limb pain is a common symptom in the lower extremity amputee population with a fairly broad differential diagnosis. One etiology of residual limb pain that has previously received limited discussion in the literature is that of vascular claudication. Increased awareness of this etiology is important given the prevalence of vascular disease in both the general population and in lower extremity amputees. This article discusses a presentation of residual limb vascular claudication, describes a clinical approach to the problem, and discusses a potential pathophysiologic mechanism for vascular claudication in the amputee that differs from the nonamputee. PM R 2013;5:152-154
C1 [Murray, Andrew L.; Morgenroth, David C.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Morgenroth, David C.; Czerniecki, Joseph M.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA.
RP Morgenroth, DC (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, 1660 S Columbian Way,RCS 117, Seattle, WA 98108 USA.
EM dmorgen@uw.edu
OI Morgenroth, David/0000-0002-0226-7775
NR 15
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD FEB
PY 2013
VL 5
IS 2
BP 152
EP 154
DI 10.1016/j.pmrj.2012.08.003
PG 3
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 095VP
UT WOS:000315363400011
PM 23415251
ER
PT J
AU Mishra, RK
Li, YM
Ricardo, AC
Yang, W
Keane, M
Cuevas, M
Christenson, R
DeFilippi, C
Chen, J
He, J
Kallem, RR
Raj, DS
Schelling, JR
Wright, J
Go, AS
Shlipak, MG
AF Mishra, Rakesh K.
Li, Yongmei
Ricardo, Ana C.
Yang, Wei
Keane, Martin
Cuevas, Magdalena
Christenson, Robert
DeFilippi, Christopher
Chen, Jing
He, Jiang
Kallem, Radhakrishna R.
Raj, Dominic S.
Schelling, Jeffrey R.
Wright, Jackson
Go, Alan S.
Shlipak, Michael G.
CA Chronic Renal Insufficiency Cohort
TI Association of N-Terminal Pro-B-Type Natriuretic Peptide With Left
Ventricular Structure and Function in Chronic Kidney Disease (from the
Chronic Renal Insufficiency Cohort [CRIC])
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID HEART-FAILURE; CARDIOVASCULAR EVENTS; DIASTOLIC FUNCTION; MORTALITY;
BNP; HEMODIALYSIS; HYPERTROPHY; MASS; CKD; ECHOCARDIOGRAPHY
AB We evaluated the cross-sectional associations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) with cardiac structural and functional abnormalities in a cohort of patients with chronic kidney disease without clinical heart failure, the Chronic Renal Insufficiency Cohort (n = 3,232). The associations of NT-proBNP with echocardiographically determined left ventricular (LV) mass and LV systolic and diastolic function were evaluated using multivariate logistic and linear regression models. Reclassification of participants' predicted risk of LV hypertrophy (LVH), systolic and diastolic dysfunction was performed using a category-free net reclassification improvement index that compared a clinical model with and without NT-proBNP. The median NT-proBNP was 126.6 pg/ml (interquartile range 55.5 to 303.7). The greatest quartile of NT-proBNP was associated with a nearly threefold odds of LVH (odds ratio 2.7, 95% confidence interval [CI] 1.8 to 4.0) and LV systolic dysfunction (odds ratio 2.7, 95% CI 1.7 to 4.5) and a twofold odds of diastolic dysfunction (odds ratio 2.0, 95% CI 1.3 to 2.9) in the fully adjusted models. When evaluated alone as a screening test, NT-proBNP functioned modestly for the detection of LVH (area under the curve 0.66) and LV systolic dysfunction (area under the curve 0.62) and poorly for the detection of diastolic dysfunction (area under the curve 0.51). However, when added to the clinical model, NT-proBNP significantly reclassified participants' likelihood of having LVH (net reclassification improvement 0.14, 95% CI 0.13-0.15; p < 0.001) and LV systolic dysfunction (net reclassification improvement 0.28, 95% CI 0.27 to 0.30; p < 0.001) but not diastolic dysfunction (net reclassification improvement 0.10, 95% CI 0.10 to 0.11; p = 0.07). In conclusion, in this large chronic kidney disease cohort without heart failure, NT-proBNP had strong associations with prevalent LVH and LV systolic dysfunction. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:432-438)
C1 [Mishra, Rakesh K.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Mishra, Rakesh K.; Li, Yongmei; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ricardo, Ana C.] Univ Illinois, Chicago, IL USA.
[Yang, Wei] Univ Penn, Sci & Data Coordinating Ctr, Philadelphia, PA 19104 USA.
[Keane, Martin; Cuevas, Magdalena] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Christenson, Robert; DeFilippi, Christopher] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
[Chen, Jing; He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA.
[Kallem, Radhakrishna R.] Univ Penn, Philadelphia, PA 19104 USA.
[Raj, Dominic S.] George Washington Univ, Washington, DC USA.
[Schelling, Jeffrey R.] MetroHlth Med Ctr, Cleveland, OH USA.
[Schelling, Jeffrey R.; Wright, Jackson] Case Western Univ, Cleveland, OH USA.
[Go, Alan S.] Kaiser Permanente Div Res, Oakland, CA USA.
RP Mishra, RK (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.
EM rakesh.mishra@ucsf.edu
RI Yang, Wei/A-9223-2009
OI Yang, Wei/0000-0001-8984-4389
FU Chronic Renal Insufficiency Cohort General Clinical Research Center and
Clinical and Translational Science Award [UL1 RR-024134, UL1 RR-025005,
M01RR-16500, UL1 RR-024989, M01 RR-000042, UL1 RR-024986, UL1 RR-029879,
2 U01 DK060902]; [R01 DK066488]
FX This project was supported by R01 DK066488 award (to principal
investigator M. G. Shlipak); and in part by the Chronic Renal
Insufficiency Cohort General Clinical Research Center and Clinical and
Translational Science Award grants: UL1 RR-024134 to the University of
Pennsylvania (Philadelphia, Pennsylvania), UL1 RR-025005 to Johns
Hopkins University (Baltimore, Maryland), M01RR-16500 to University of
Maryland (College Park, Maryland), UL1 RR-024989 to Case Western Reserve
University (Cleveland, Ohio), M01 RR-000042 and UL1 RR-024986 to
University of Michigan (Ann Arbor, Michigan), UL1 RR-029879 to
University of Illinois at Chicago (Chicago, Illinois), and 2 U01
DK060902 to the Kaiser Permanente Division of Research in Oakland
(Oakland, California).
NR 28
TC 16
Z9 18
U1 0
U2 3
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD FEB 1
PY 2013
VL 111
IS 3
BP 432
EP 438
DI 10.1016/j.amjcard.2012.10.019
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 083BM
UT WOS:000314437700022
PM 23178053
ER
PT J
AU Yo, K
Yu, YM
Zhao, GZ
Bonab, AA
Aikawa, N
Tompkins, RG
Fischman, AJ
AF Yo, Kikuo
Yu, Yong-Ming
Zhao, Gaofeng
Bonab, Ali A.
Aikawa, Naoki
Tompkins, Ronald G.
Fischman, Alan J.
TI Brown adipose tissue and its modulation by a mitochondria-targeted
peptide in rat burn injury-induced hypermetabolism
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE brown adipose tissue; burn injury-induced hypermetabolism; mitochondria
dysfunction
ID HUMAN SKELETAL-MUSCLE; ADULT HUMANS; NONSHIVERING THERMOGENESIS;
UNCOUPLING PROTEINS; ANTIOXIDANT PEPTIDE; ENERGY-EXPENDITURE;
REPERFUSION INJURY; OBESITY; STRESS; UCP1
AB Yo K, Yu YM, Zhao G, Bonab AA, Aikawa N, Tompkins RG, Fischman AJ. Brown adipose tissue and its modulation by a mitochondria-targeted peptide in rat burn injury-induced hypermetabolism. Am J Physiol Endocrinol Metab 304: E331-E341, 2013. First published November 20, 2012; doi:10.1152/ajpendo.00098.2012.-Hypermetabolism is a prominent feature of burn injury, and altered mitochondria function is presumed to contribute to this state. Recently, brown adipose tissue (BAT) was found to be present not only in rodents but also in humans, and its activity is associated with resting metabolic rate. In this report, we elucidate the relationship between burn injury-induced hypermetabolism and BAT activity and the possible role of the mitochondria-targeted peptide SS31 in attenuating burn injury-induced hypermetabolism by using a rat burn injury model. We demonstrate that burn injury induces morphological changes in interscapular BAT (iBAT). Burn injury was associated with iBAT activation, and this effect was positively correlated with increased energy expenditure. BAT activation was associated with augmentation of mitochondria biogenesis, and UCP1 expression in the isolated iBAT mitochondria. In addition, the mitochondria-targeted peptide SS31 attenuated burn injury-induced hypermetabolism, which was accompanied by suppression of UCP1 expression in isolated mitochondria. Our results suggest that BAT plays an important role in burn injury-induced hypermetabolism through its morphological changes and expression of UCP1.
C1 [Yo, Kikuo; Yu, Yong-Ming; Zhao, Gaofeng; Bonab, Ali A.; Tompkins, Ronald G.; Fischman, Alan J.] Shriners Hosp Children, Boston, MA 02114 USA.
[Yo, Kikuo; Yu, Yong-Ming; Zhao, Gaofeng; Bonab, Ali A.; Tompkins, Ronald G.; Fischman, Alan J.] Massachusetts Gen Hosp, Burn Unit, Boston, MA 02114 USA.
[Yo, Kikuo; Yu, Yong-Ming; Zhao, Gaofeng; Bonab, Ali A.; Tompkins, Ronald G.; Fischman, Alan J.] Harvard Univ, Sch Med, Boston, MA USA.
[Aikawa, Naoki] Keio Univ, Sch Med, Dept Emergency & Crit Care Med, Tokyo, Japan.
RP Fischman, AJ (reprint author), Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA.
EM aajjff@gmail.com
FU National Institutes of Health [2P50 GM-21700-27A, P30 DK-004056];
Shriners Hospitals for Children [84050]; Morningside Technology
Advisory, Inc.
FX This study was supported in part by grants from the National Institutes
of Health (2P50 GM-21700-27A, P30 DK-004056), Shriners Hospitals for
Children (no. 84050), and Morningside Technology Advisory, Inc.
NR 47
TC 6
Z9 7
U1 0
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD FEB
PY 2013
VL 304
IS 4
BP E331
EP E341
DI 10.1152/ajpendo.00098.2012
PG 11
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 092SI
UT WOS:000315141900001
PM 23169784
ER
PT J
AU Shao, RX
Zhang, LL
Hong, Z
Goto, K
Cheng, D
Chen, WC
Jilg, N
Kumthip, K
Fusco, DN
Peng, LF
Chung, RT
AF Shao, Run-Xuan
Zhang, Leiliang
Hong, Zhi
Goto, Kaku
Cheng, Du
Chen, Wen-Chi
Jilg, Nikolaus
Kumthip, Kattareeya
Fusco, Dahlene N.
Peng, Lee F.
Chung, Raymond T.
TI SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Hepatitis C virus; SOCS1; Interferon; ISG; JFH1
ID JAK-STAT PATHWAY; INTERFERON-ALPHA; RIBAVIRIN; CYTOKINE; ACTIVATION;
SUPPRESSOR; EXPRESSION; INHIBITOR; INFECTION; PROTEINS
AB Suppressor of cytokine signaling 1 (SOCS1) and suppressor of cytokine signaling 3 (SOCS3) have been thought to block type I interferon (IFN) signaling. We have previously reported that SOCS3 suppresses HCV replication in an mTOR-dependent manner. However, the relationship between SOCS1 and HCV replication remains unclear. Here, we found that overexpression of SOCS1 alone did not have an effect on HCV RNA replication. However, suppression of HCV replication by IFN-alpha, was rescued by SOCS1 overexpression. The upregulation of HCV replication by SOCS1 overexpression in the presence of IFN is likely a result of the impairment of IFN signaling by SOCS1 and subsequent induction of ISGs. Knockdown of SOCS1 alone with specific shRNA enhanced the antiviral effect of IFN compared with negative control. Thus, SOCS1 acts as a suppressor of type I IFN function against HCV. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zhang, Leiliang; Hong, Zhi] Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Beijing 100730, Peoples R China.
[Zhang, Leiliang; Hong, Zhi] Peking Union Med Coll, Beijing 100730, Peoples R China.
[Shao, Run-Xuan; Zhang, Leiliang; Goto, Kaku; Cheng, Du; Chen, Wen-Chi; Jilg, Nikolaus; Kumthip, Kattareeya; Fusco, Dahlene N.; Peng, Lee F.; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Dept Med, Boston, MA 02114 USA.
RP Chung, RT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Dept Med, Boston, MA 02114 USA.
EM rtchung@partners.org
FU National Institutes of Health [AI069939, AI082630, DK078772]; Intramural
Research Program of the Institute of Pathogen Biology, Chinese Academy
of Medical Sciences [2012IPB101]
FX This work was supported by Grants AI069939, AI082630 and DK078772
(R.T.C.) from the National Institutes of Health, 2012IPB101 from
Intramural Research Program of the Institute of Pathogen Biology,
Chinese Academy of Medical Sciences (to L.Z.). We thank Drs. Nobuyuki
Kato and Masanori Ikeda for the gift of OR6 cells; Dr. Francis Chisari
for the Huh7.5.1 cell line; Dr. Takaji Wakita for the infectious HCV
virus JFH1 DNA construct; Dr. Christoph J. Auernhammer for pCR3.1/SOCS1
construct.
NR 27
TC 7
Z9 7
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD FEB
PY 2013
VL 97
IS 2
BP 101
EP 107
DI 10.1016/j.antiviral.2012.12.001
PG 7
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 095FG
UT WOS:000315319500003
PM 23237992
ER
PT J
AU Lee, J
AF Lee, Jongsoon
TI Adipose tissue macrophages in the development of obesity-induced
inflammation, insulin resistance and type 2 Diabetes
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Review
DE Adipose tissue macrophage (ATM); Insulin resistance; Obesity;
Inflammation
ID DIET-INDUCED OBESITY; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN;
FACTOR-KAPPA-B; INDUCED HEPATIC STEATOSIS; FREE FATTY-ACIDS;
SKELETAL-MUSCLE; IKK-BETA; SYSTEMIC INFLAMMATION; 3T3-L1 ADIPOCYTES
AB It has been increasingly accepted that chronic subacute inflammation plays an important role in the development of insulin resistance and type 2 Diabetes in animals and humans. Particularly supporting this is that suppression of systemic inflammation in type 2 Diabetes improves glycemic control; this also points to a new potential therapeutic target for the treatment of type 2 Diabetes. Recent studies strongly suggest that obesity-induced inflammation is mainly mediated by tissue resident immune cells, with particular attention being focused on adipose tissue macrophages (ATMs). This review delineates the current progress made in understanding obesity-induced inflammation and the roles ATMs play in this process.
C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Lee, J (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02115 USA.
EM jongsoon.lee@joslin.harvard.edu
FU American Diabetes Association [RA 110BS97]; Boston Obesity Nutrition
Research Center (NIDDK) [DK046200]; NIH/NIDDK [DK80380]
FX The author was supported by grants from the American Diabetes
Association (RA 110BS97), Pilot and Feasibility awards from the Boston
Obesity Nutrition Research Center (DK046200, NIDDK) and NIH/NIDDK
(DK80380).
NR 143
TC 36
Z9 41
U1 3
U2 51
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD FEB
PY 2013
VL 36
IS 2
BP 208
EP 222
DI 10.1007/s12272-013-0023-8
PG 15
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 093BZ
UT WOS:000315168000009
PM 23397293
ER
PT J
AU Mikuls, TR
Padala, PR
Sayles, HR
Yu, F
Michaud, K
Caplan, L
Kerr, GS
Reimold, A
Cannon, GW
Richards, JS
Lazaro, D
Thiele, GM
Boscarino, JA
AF Mikuls, Ted R.
Padala, Prasad R.
Sayles, Harlan R.
Yu, Fang
Michaud, Kaleb
Caplan, Liron
Kerr, Gail S.
Reimold, Andreas
Cannon, Grant W.
Richards, J. Steuart
Lazaro, Deana
Thiele, Geoffrey M.
Boscarino, Joseph A.
TI Prospective study of posttraumatic stress disorder and disease activity
outcomes in US veterans with rheumatoid arthritis
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID GULF-WAR VETERANS; CHRONIC PAIN; ANXIETY DISORDERS; VIETNAM VETERANS;
PTSD SYMPTOMS; CARE; ASSOCIATION; MORTALITY; EXPOSURE; ILLNESS
AB Objective To examine the relationship between posttraumatic stress disorder (PTSD) and disease activity in US veterans with rheumatoid arthritis (RA). Methods US veterans with RA were enrolled in a longitudinal observational study and were categorized as having PTSD, other anxiety/depression disorders, or neither of these psychiatric diagnoses using administrative codes. Generalized linear mixed-effects models were used to examine the associations of the diagnostic groups with outcomes measured over a mean followup period of 3.0 years. Results At enrollment, 1,522 patients had a mean age of 63 years, they were primarily men (91%), and a majority (78%) reported white race. A diagnosis of PTSD was observed in 178 patients (11.7%), and other anxiety/depression diagnoses (excluding PTSD) were found in 360 patients (23.7%). The presence of a PTSD diagnosis was independently associated with higher values of self-reported pain, physical impairment, tender joint count, and worse patient global well-being scores compared to patients with no psychiatric diagnosis. There were no significant group differences in swollen joint count, erythrocyte sedimentation rate, or Disease Activity Score in 28 joints. There were no differences between any outcomes comparing those with PTSD and those with other anxiety/depression diagnoses. Conclusion In this RA cohort, the diagnosis of PTSD was associated with worse patient-reported outcomes and tender joint counts, but not with other physician- or laboratory-based measures of disease activity. These results suggest that PTSD, along with other anxiety/depression disorders, may affect RA disease activity assessments that rely on patient-reported outcomes and the resulting treatment decisions.
C1 [Mikuls, Ted R.; Thiele, Geoffrey M.] Omaha VAMC, Omaha, NE 68198 USA.
[Mikuls, Ted R.; Sayles, Harlan R.; Yu, Fang; Michaud, Kaleb; Thiele, Geoffrey M.] Univ Nebraska Med Ctr, Omaha, NE 68198 USA.
[Padala, Prasad R.] Little Rock VAMC, Little Rock, AR USA.
[Caplan, Liron] Denver VAMC, Denver, CO USA.
[Caplan, Liron] Univ Colorado, Sch Med, Denver, CO USA.
[Kerr, Gail S.; Richards, J. Steuart] DC VAMC, Washington, DC USA.
[Kerr, Gail S.] Georgetown Univ Hosp, Washington, DC 20007 USA.
[Reimold, Andreas] Dallas VAMC, Dallas, TX USA.
[Reimold, Andreas] Univ Texas SW, Dallas, TX USA.
[Cannon, Grant W.] George E Wahlen VAMC, Salt Lake City, UT USA.
[Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[Lazaro, Deana] Brooklyn VAMC, Brooklyn, NY USA.
[Boscarino, Joseph A.] Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA.
RP Mikuls, TR (reprint author), Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
EM tmikuls@unmc.edu
RI Yu, Fang/B-9874-2013;
OI Thiele, Geoffrey/0000-0001-5688-8596
FU Nebraska Arthritis Outcomes Research Center at the University of
Nebraska Medical Center; Veterans Health Administration; Abbott
Laboratories; Bristol-Myers Squibb; Veterans Affairs Health Services
Research and Development Program Career Development Award [CDA 07-221]
FX Supported by the Nebraska Arthritis Outcomes Research Center at the
University of Nebraska Medical Center. The Veterans Affairs Rheumatoid
Arthritis registry is supported by the Veterans Affairs Health Services
Research and Development Program of the Veterans Health Administration
and unrestricted research grants from Abbott Laboratories and
Bristol-Myers Squibb. Dr. Mikuls' work was supported by the Veterans
Health Administration (Veterans Affairs Merit award). Dr. Caplan's work
was supported by a Veterans Affairs Health Services Research and
Development Program Career Development Award (CDA 07-221).
NR 36
TC 9
Z9 9
U1 4
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD FEB
PY 2013
VL 65
IS 2
BP 227
EP 234
DI 10.1002/acr.21778
PG 8
WC Rheumatology
SC Rheumatology
GA 083LW
UT WOS:000314466600008
PM 22740431
ER
PT J
AU Fryer, SL
Jorgensen, KW
Yetter, EJ
Daurignac, EC
Watson, TD
Shanbhag, H
Krystal, JH
Mathalon, DH
AF Fryer, Susanna L.
Jorgensen, Kasper W.
Yetter, Elizabeth J.
Daurignac, Elsa C.
Watson, Todd D.
Shanbhag, Harshad
Krystal, John H.
Mathalon, Daniel H.
TI Differential brain response to alcohol cue distractors across stages of
alcohol dependence
SO BIOLOGICAL PSYCHOLOGY
LA English
DT Article
DE Abstinence; Alcoholism; Amygdala; Anterior cingulate; Cognitive control;
Distraction; Inferior parietal lobule
ID ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; ABSTINENT ALCOHOLICS;
VENTRAL STRIATUM; ODDBALL TASK; ACTIVATION; FMRI; AMYGDALA; STIMULI;
EMOTION
AB Altered attention to alcohol-related cues is implicated in the craving and relapse cycle characteristic of alcohol dependence (ALC). Prior cue reactivity studies typically invoke explicit attention to alcohol cues, so the neural response underlying incidental cue exposure remains unclear. Here, we embed infrequent, task-irrelevant alcohol and non-alcohol cues in an attention-demanding task, enabling evaluation of brain responses to distracting alcohol cues. Alcohol dependent individuals, across illness phase (n = 44), and controls (n = 20) performed a cue-reactivity fMRI target detection task. Significant Group-by-Distractor effects were observed in dorsal anterior cingulate cortex (ACC), inferior parietal lobule, and amygdala. Controls and long-term abstainers increased recruitment of attention and cognitive control regions, while recent and long-term abstainers decreased limbic recruitment to alcohol distractors. Across phases of ALC, self-reported craving positively correlated with cue-related activations in ventral ACC, medial prefrontal cortex, and cerebellum. Results indicate that brain responses elicited by incidental alcohol cues differentiate phases of ALC. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Fryer, Susanna L.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Fryer, Susanna L.; Jorgensen, Kasper W.; Yetter, Elizabeth J.; Shanbhag, Harshad; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Daurignac, Elsa C.] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14260 USA.
[Watson, Todd D.] Lewis & Clark Coll, Dept Psychol, Portland, OR 97219 USA.
[Krystal, John H.; Mathalon, Daniel H.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA.
EM daniel.mathalon@ucsf.edu
OI Mathalon, Daniel/0000-0001-6090-4974
FU NIAAA [P50-AA-12870]; Alcohol Beverage Medical Research Foundation; NIMH
[T32 MH089920]
FX This work was supported by grants from NIAAA P50-AA-12870 (to J.H.
Krystal), the Alcohol Beverage Medical Research Foundation (to D.H.
Mathalon), and NIMH T32 MH089920 (to J.M. Ford). The authors thank Drs.
Mark George and Andreas Heinz for facilitating access to stimulus sets
developed in their laboratories.
NR 63
TC 10
Z9 10
U1 7
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-0511
J9 BIOL PSYCHOL
JI Biol. Psychol.
PD FEB
PY 2013
VL 92
IS 2
BP 282
EP 291
DI 10.1016/j.biopsycho.2012.10.004
PG 10
WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology,
Experimental
SC Psychology; Behavioral Sciences
GA 095DU
UT WOS:000315315700025
PM 23131612
ER
PT J
AU Micallef, IN
Jacobsen, ED
Shaughnessy, P
Gandhi, PJ
Calandra, G
van Rhee, F
Uberti, J
AF Micallef, I. N.
Jacobsen, E. D.
Shaughnessy, P.
Gandhi, P. J.
Calandra, G.
van Rhee, F.
Uberti, J.
TI G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in
patients with thrombocytopenia or leukopenia prior to auto-SCT
SO BONE MARROW TRANSPLANTATION
LA English
DT Letter
ID NON-HODGKINS-LYMPHOMA; MULTIPLE-MYELOMA; AMD3100
C1 [Micallef, I. N.] Mayo Clin, Dept Med, Div Hematol, Rochester, MN 55905 USA.
[Jacobsen, E. D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Shaughnessy, P.] Texas Transplant Inst, San Antonio, TX USA.
[Gandhi, P. J.; Calandra, G.] Sanofi Oncol, Cambridge, MA USA.
[van Rhee, F.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA.
[Uberti, J.] Karmanos Canc Inst, Detroit, MI USA.
RP Micallef, IN (reprint author), Mayo Clin, Dept Med, Div Hematol, Rochester, MN 55905 USA.
EM micallef.ivana@mayo.edu
NR 9
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD FEB
PY 2013
VL 48
IS 2
BP 303
EP 304
DI 10.1038/bmt.2012.125
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 094BY
UT WOS:000315239200029
PM 22773123
ER
PT J
AU Uchida, Y
Raina, D
Kharbanda, S
Kufe, D
AF Uchida, Yasumitsu
Raina, Deepak
Kharbanda, Surender
Kufe, Donald
TI Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic
agents in the treatment of breast cancer cells
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE MUC1; GO-203; doxorubicin; taxol; synergy; breast cancer
ID TRANSCRIPTION FACTOR; APOPTOTIC RESPONSE; SURVIVAL RESPONSE; ACTIVATION;
PROTEIN; STRESS; GENE
AB Mucin 1 (MUC1) is a heterodimeric glycoprotein that is aberrantly overexpressed in most human breast cancers. The oncogenic MUC1-C subunit promotes survival and blocks the apoptotic response to genotoxic anticancer agents. In the present studies, human MCF-7 and ZR-75-1 breast cancer cells were treated with the MUC1-C inhibitor, GO-203, a cell-penetrating peptide that blocks MUC1-C homodimerization and thereby its oncogenic function. Treatment with GO-203 was found to promote the apoptotic response of MCF-7 and ZR-75-1 cells to the therapeutic drugs taxol and doxorubicin (DOX). This effect was (1) attenuated by a pan-caspase inhibitor and (2) mediated, at least in part, by activation of the effector caspase-7 and cleavage of the downstream substrate PARP. Further analysis of the interaction between GO-203 and taxol using isobolograms, which evaluate the nature of the interaction of two drugs, demonstrated that the combination is highly synergistic. These results were supported by combination index (CI) analysis with values of less than 1. GO-203 was also highly synergistic with DOX in studies of both MCF-7 and ZR-75-1 breast cancer cells. These findings indicate that blocking MUC1-C function could be effective in combination with taxol and DOX for the treatment of breast cancer.
C1 [Uchida, Yasumitsu; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Raina, Deepak; Kharbanda, Surender] Genus Oncol, Boston, MA USA.
RP Kufe, D (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM Donald_Kufe@dfci.harvard.edu
FU National Cancer Institute of the National Institutes of Health [CA97098,
CA166480]
FX Research reported in this publication was supported by the National
Cancer Institute of the National Institutes of Health under award
numbers CA97098 and CA166480.
NR 26
TC 10
Z9 10
U1 0
U2 11
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4047
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD FEB
PY 2013
VL 14
IS 2
BP 127
EP 134
DI 10.4161/cbt.22634
PG 8
WC Oncology
SC Oncology
GA 083MP
UT WOS:000314468700009
PM 23114713
ER
PT J
AU Lee, HJ
Schaefer, G
Heffron, TP
Shao, L
Ye, XF
Sideris, S
Malek, S
Chan, E
Merchant, M
La, H
Ubhayakar, S
Yauch, RL
Pirazzoli, V
Politi, K
Settleman, J
AF Lee, Ho-June
Schaefer, Gabriele
Heffron, Timothy P.
Shao, Lily
Ye, Xiaofen
Sideris, Steve
Malek, Shiva
Chan, Emily
Merchant, Mark
La, Hank
Ubhayakar, Savita
Yauch, Robert L.
Pirazzoli, Valentina
Politi, Katerina
Settleman, Jeff
TI Noncovalent Wild-type-Sparing Inhibitors of EGFR T790M
SO CANCER DISCOVERY
LA English
DT Article
ID TYROSINE KINASE INHIBITOR; CELL LUNG-CANCER; ACUTE MYELOID-LEUKEMIA;
ACQUIRED-RESISTANCE; INCREASED SENSITIVITY; POTENT INHIBITOR; FLT3
INHIBITORS; GEFITINIB; RECEPTOR; PKC412
AB Approximately half of EGFR-mutant non-small cell lung cancer (NSCLC) patients treated with small-molecule EGFR kinase inhibitors develop drug resistance associated with the EGF receptor (EGFR) T790M "gatekeeper" substitution, prompting efforts to develop covalent EGFR inhibitors, which can effectively suppress EGFR T790M in preclinical models. However, these inhibitors have yet to prove clinically efficacious, and their toxicity in skin, reflecting activity against wild-type EGFR, may limit dosing required to effectively suppress EGFR T790M in vivo. While profiling sensitivity to various kinase inhibitors across a large cancer cell line panel, we identified indolocarbazole compounds, including a clinically well-tolerated FLT3 inhibitor, as potent and reversible inhibitors of EGFR T790M that spare wild-type EGFR. These findings show the use of broad cancer cell profiling of kinase inhibitor efficacy to identify unanticipated novel applications, and they identify indolocarbazole compounds as potentially effective EGFR inhibitors in the context of T790M-mediated drug resistance in NSCLC.
SIGNIFICANCE: EGFR-mutant lung cancer patients who respond to currently used EGFR kinase inhibitors invariably develop drug resistance, which is associated with the EGFR T790M resistance mutation in about half these cases. We unexpectedly identified a class of reversible potent inhibitors of EGFR T790M that do not inhibit wild-type EGFR, revealing a promising therapeutic strategy to overcome T790M-associated drug-resistant lung cancers. Cancer Discov; 3(2); 168-81. (C) 2012 AACR. See related commentary by Brewer and Pao, p. 138.
C1 [Lee, Ho-June; Ye, Xiaofen; Yauch, Robert L.; Settleman, Jeff] Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA.
[Schaefer, Gabriele; Shao, Lily] Genentech Inc, Dept Res Oncol, San Francisco, CA 94080 USA.
[Heffron, Timothy P.] Genentech Inc, Dept Discovery Chem, San Francisco, CA 94080 USA.
[Sideris, Steve; Malek, Shiva] Genentech Inc, Dept Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA.
[Chan, Emily; Merchant, Mark] Genentech Inc, Dept Canc Signaling & Translat Oncol, San Francisco, CA 94080 USA.
[La, Hank; Ubhayakar, Savita] Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA.
[Lee, Ho-June; Settleman, Jeff] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.
[Politi, Katerina] Yale Univ, Sch Med, New Haven, CT USA.
RP Settleman, J (reprint author), Genentech Inc, Discovery Oncol, 1 DNA Way, San Francisco, CA 94080 USA.
EM settleman.jeffrey@gene.com
RI Lee, Ho-June/D-8855-2014;
OI Lee, Ho-June/0000-0002-7019-2533; Merchant, Mark/0000-0003-0690-8581
FU National Institutes of Health [R00CA131488, R01CA120247]; Uniting
Against Lung Cancer; Labrecque Foundation; American Italian Cancer
Foundation
FX This study was supported by grants R00CA131488 and R01CA120247 from the
National Institutes of Health (to K. Politi). Additional support was
received from Uniting Against Lung Cancer (to K. Politi), the Labrecque
Foundation (to K. Politi), and the American Italian Cancer Foundation
(to V. Pirazzoli).
NR 39
TC 40
Z9 40
U1 2
U2 20
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
J9 CANCER DISCOV
JI Cancer Discov.
PD FEB
PY 2013
VL 3
IS 2
BP 168
EP 181
DI 10.1158/2159-8290.CD-12-0357
PG 14
WC Oncology
SC Oncology
GA 088IA
UT WOS:000314826300023
PM 23229345
ER
PT J
AU Theodos, G
Raymond, C
Becker, MC
Thornton, J
Ellis, SG
Bhatt, DL
Raymond, RE
AF Theodos, Gus
Raymond, Chad
Becker, Matthew C.
Thornton, Julie
Ellis, Stephen G.
Bhatt, Deepak L.
Raymond, Russell E.
TI Arteriotomy closure device safety after percutaneous coronary
intervention in the direct thrombin inhibitor era: A comparative study
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE bivalirudin; angio-seal; perclose; manual compression
ID CARDIAC-CATHETERIZATION; VASCULAR COMPLICATIONS; RANDOMIZED-TRIAL;
MANUAL COMPRESSION; MYOCARDIAL-INFARCTION; HEART-ASSOCIATION;
CLINICAL-TRIALS; FEMORAL-ARTERY; ANGIO-SEAL; REGISTRY
AB Objectives To investigate the safety and risk of vascular complications of arteriotomy closure devices (ACD) with the direct thrombin inhibitor bivalirudin in patients undergoing percutaneous coronary intervention (PCI). Background ACDs and manual compression have been shown to have a similar risk of complications in the setting of PCI with heparin +/- glycoprotein (GP) IIb/IIIa inhibitor usage. In many centers bivalirudin is becoming the most frequent type of anticoagulation used during PCI. We sought to determine the risk of vascular complications using Angio-Seal, Perclose, and manual compression for groin hemostasis using predominantly bivalirudin. Methods Our institution's interventional database retrospectively identified 14,354 consecutive patients undergoing PCI from 2000 to 2008. Patients were grouped by the adjunctive anticoagulation used (bivalirudin vs. heparin + GP IIb/IIIa inhibitors) as well as ACD employed. The incidence of complications was evaluated using multivariable analysis to account for baseline differences between groups. Results Patients undergoing PCI with adjunctive bivalirudin had significantly fewer complications overall, regardless of closure method (2.9% vs. 8.7%, P < 0.001). The Perclose group had significantly fewer complications than the Angio-Seal and manual compression groups (3.9% vs. 5.6% vs. 9.0%, P < 0.001) respectively; the Angio-Seal group had significantly fewer complications than manual compression. Multivariable analysis also identified age 65, female gender, BMI 26, and operator as independent predictors of complications. Conclusions The use of adjunctive bivalirudin during PCI was associated with fewer vascular complications. In addition, the Perclose and Angio-Seal devices had significantly fewer complications than manual compression and women 65 are at highest risk. (c) 2012 Wiley Periodicals, Inc.
C1 [Theodos, Gus; Raymond, Chad; Thornton, Julie; Ellis, Stephen G.; Raymond, Russell E.] Cleveland Clin, Cleveland, OH 44106 USA.
[Becker, Matthew C.] St Vincent Heart & Vasc Ctr, Erie, PA USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Raymond, RE (reprint author), Cleveland Clin Fdn, 9500 Euclid Ave,J2-03, Cleveland, OH 44195 USA.
EM raymonr@ccf.org
NR 29
TC 4
Z9 5
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD FEB
PY 2013
VL 81
IS 2
BP 294
EP 300
DI 10.1002/ccd.24393
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 093UO
UT WOS:000315218400015
PM 22826017
ER
PT J
AU Jama, A
Schainfeld, RM
AF Jama, Abdi
Schainfeld, Robert M.
TI Filling the void: "She's Got Gaps, I've Got Gaps. Together, We Fill
Gaps." Rocky Balboa (1976)
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
ID POSTCATHETERIZATION PSEUDOANEURYSMS; INJECTION
C1 [Jama, Abdi; Schainfeld, Robert M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Sect Vasc Med,Div Cardiol, Boston, MA USA.
RP Schainfeld, RM (reprint author), Massachusetts Gen Hosp, Sect Vasc Med, 55 Fruit St, Boston, MA 02114 USA.
EM rschainfeld@partners.org
NR 5
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD FEB
PY 2013
VL 81
IS 2
BP 308
EP 309
DI 10.1002/ccd.24787
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 093UO
UT WOS:000315218400018
PM 23423925
ER
PT J
AU Bhatt, DL
AF Bhatt, Deepak L.
TI Pushing the boundaries of renal denervation for resistant hypertension
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
ID TRIAL
C1 [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA 02132 USA.
RP Bhatt, DL (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, 1400 VFW Pkwy, Boston, MA 02132 USA.
EM dlbhattmd@post.harvard.edu
NR 5
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD FEB
PY 2013
VL 81
IS 2
BP 340
EP 341
DI 10.1002/ccd.24785
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 093UO
UT WOS:000315218400024
PM 23423926
ER
PT J
AU Fox, ER
Musani, SK
Barbalic, M
Lin, HH
Yu, B
Ogunyankin, KO
Smith, NL
Kutlar, A
Glazer, NL
Post, WS
Paltoo, DN
Dries, DL
Farlow, DN
Duarte, CW
Kardia, SL
Meyers, KJ
Sun, YV
Arnett, DK
Patki, AA
Sha, J
Cui, XQ
Samdarshi, TE
Penman, AD
Bibbins-Domingo, K
Buzkova, P
Benjamin, EJ
Bluemke, DA
Morrison, AC
Heiss, G
Carr, JJ
Tracy, RP
Mosley, TH
Taylor, HA
Psaty, BM
Heckbert, SR
Cappola, TP
Vasan, RS
AF Fox, Ervin R.
Musani, Solomon K.
Barbalic, Maja
Lin, Honghuang
Yu, Bing
Ogunyankin, Kofo O.
Smith, Nicholas L.
Kutlar, Abdullah
Glazer, Nicole L.
Post, Wendy S.
Paltoo, Dina N.
Dries, Daniel L.
Farlow, Deborah N.
Duarte, Christine W.
Kardia, Sharon L.
Meyers, Kristin J.
Sun, Yan V.
Arnett, Donna K.
Patki, Amit A.
Sha, Jin
Cui, Xiangqui
Samdarshi, Tandaw E.
Penman, Alan D.
Bibbins-Domingo, Kirsten
Buzkova, Petra
Benjamin, Emelia J.
Bluemke, David A.
Morrison, Alanna C.
Heiss, Gerardo
Carr, J. Jeffrey
Tracy, Russell P.
Mosley, Thomas H.
Taylor, Herman A.
Psaty, Bruce M.
Heckbert, Susan R.
Cappola, Thomas P.
Vasan, Ramachandran S.
TI Genome-Wide Association Study of Cardiac Structure and Systolic Function
in African Americans The Candidate Gene Association Resource (CARe)
Study
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE echocardiography; ethnic; genome-wide association studies; left atrium
genetics; left ventricular mass genetics
ID LEFT-VENTRICULAR MASS; COMMON DISEASES; HYPERTROPHY; VARIANTS;
SUSCEPTIBILITY; CONTRACTILITY; HYPERTENSION; HYPERGEN; LINKAGE; MARKERS
AB Background-Using data from 4 community-based cohorts of African Americans, we tested the association between genome-wide markers (single-nucleotide polymorphisms) and cardiac phenotypes in the Candidate-gene Association Resource study.
Methods and Results-Among 6765 African Americans, we related age, sex, height, and weight-adjusted residuals for 9 cardiac phenotypes (assessed by echocardiogram or magnetic resonance imaging) to 2.5 million single-nucleotide polymorphisms genotyped using Genome-wide Affymetrix Human SNP Array 6.0 (Affy6.0) and the remainder imputed. Within the cohort, genome-wide association analysis was conducted, followed by meta-analysis across cohorts using inverse variance weights (genome-wide significance threshold=4.0x10(-7)). Supplementary pathway analysis was performed. We attempted replication in 3 smaller cohorts of African ancestry and tested lookups in 1 consortium of European ancestry (EchoGEN). Across the 9 phenotypes, variants in 4 genetic loci reached genome-wide significance: rs4552931 in UBE2V2 (P=1.43x10(-7)) for left ventricular mass, rs7213314 in WIPI1 (P=1.68x10(-7)) for left ventricular internal diastolic diameter, rs1571099 in PPAPDC1A (P=2.57x10(-8)) for interventricular septal wall thickness, and rs9530176 in KLF5 (P=4.02x10(-7)) for ejection fraction. Associated variants were enriched in 3 signaling pathways involved in cardiac remodeling. None of the 4 loci replicated in cohorts of African ancestry was confirmed in lookups in EchoGEN.
Conclusions-In the largest genome-wide association study of cardiac structure and function to date in African Americans, we identified 4 genetic loci related to left ventricular mass, interventricular septal wall thickness, left ventricular internal diastolic diameter, and ejection fraction, which reached genome-wide significance. Replication results suggest that these loci may be unique to individuals of African ancestry. Additional large-scale studies are warranted for these complex phenotypes. (Circ Cardiovasc Genet. 2013;6:37-46.)
C1 [Fox, Ervin R.; Musani, Solomon K.; Yu, Bing; Samdarshi, Tandaw E.; Penman, Alan D.; Mosley, Thomas H.; Taylor, Herman A.] Univ Mississippi, Sch Med, Dept Med, Jackson, MS 39216 USA.
[Barbalic, Maja; Morrison, Alanna C.] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX USA.
[Lin, Honghuang; Glazer, Nicole L.; Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Ogunyankin, Kofo O.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Sch Med, Seattle, WA 98195 USA.
[Smith, Nicholas L.] US Dept Vet Affairs, Seattle Epidemiol Res & Informat Ctr, Off Res & Dev, Grp Hlth Res Inst,Grp Hlth Cooperat, Seattle, WA USA.
[Kutlar, Abdullah] Georgia Hlth Sci Univ, Dept Med, Augusta, GA USA.
[Post, Wendy S.] Johns Hopkins Sch Med, Dept Med, Div Cardiol, Baltimore, MD USA.
[Paltoo, Dina N.] NHLBI, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Dries, Daniel L.] Yale Univ, Sch Med, Dept Med, Div Cardiovasc, New Haven, CT 06510 USA.
[Farlow, Deborah N.] Broad Inst Massachusetts Inst Technol & Harvard U, Boston, MA USA.
[Duarte, Christine W.; Patki, Amit A.; Cui, Xiangqui] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA.
[Arnett, Donna K.; Sha, Jin] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Kardia, Sharon L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Meyers, Kristin J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
[Sun, Yan V.] Emory Univ, Sch Med, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA USA.
[Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Buzkova, Petra] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Bluemke, David A.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
[Heiss, Gerardo] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
[Carr, J. Jeffrey] Wake Forest Univ, Sch Med Publ Hlth & Translat Sci, Salem, NC USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT 05405 USA.
[Psaty, Bruce M.; Heckbert, Susan R.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce M.; Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Psaty, Bruce M.; Heckbert, Susan R.] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Carr, J. Jeffrey] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
RP Fox, ER (reprint author), Univ Mississippi, Med Ctr, Dept Med, 2500 North State St, Jackson, MS 39216 USA.
EM efox@medicine.umsmed.edu
RI Carr, John/A-1938-2012;
OI Carr, John/0000-0002-4398-8237; Lin, Honghuang/0000-0003-3043-3942;
Ramachandran, Vasan/0000-0001-7357-5970; Benjamin,
Emelia/0000-0003-4076-2336; Bluemke, David/0000-0002-8323-8086
FU National Institutes of Health (NIH)/National Institute on Minority
Health and Health Disparities (NIMHD) [P20]; Novartis; Celgene Corp;
Global Iron Summit; NIH [HL 100245, R01 HL09257, RC1 HD101056, R01
HL102214, R01 AG028321]; Candidate Gene Association Resource Study,
Exome Sequencing Project; ARIC, NIH; NIH; National Heart, Lung, and
Blood Institute [HL 087652]; University of North Carolina at Chapel Hill
[N01-HC-55015]; Baylor Medical College [N01-HC-55016]; University of
Mississippi Medical Center [N01-HC-55021]; University of Minnesota
[N01-HC-55019, N01-HC-48048]; Johns Hopkins University [N01-HC-55020,
N01-HC-85081, N01 HC-15103]; University of Texas, Houston
[N01-HC-55017]; University of North Carolina, Forsyth County
[N01-HC-55018]; University of Washington [N01-HC-85079, N01 HC-55222,
U01 HL080295, N01-HC-95159]; Wake Forest University [N01-HC-85080,
N01-HC-45205]; University of Pittsburgh [N01-HC-85082]; University of
California, Davis [N01-HC-85083]; University of California, Irvine
[N01-HC-85084, N01-HC-45134, N01-HC-95100]; New England Medical Center
[N01-HC-85085]; University of Vermont [N01-HC-85086]; Georgetown
University [N01-HC-35129]; University of Wisconsin [N01-HC-75150];
Geisinger Clinic [N01-HC-45133]; Case Western Reserve University [RO1
HL46380-01-16]; University of Illinois [N01-HB-72982, N01-HB-97062];
Howard University [N01-HB-72991, N01-HB-97061]; University of Miami
[N01-HB-72992, N01-HB-97064]; Duke University [N01-HB-72993]; George
Washington University [N01-HB-72994]; University of Tennessee
[N01-HB-72995, N01-HB-97070]; Yale University [N01-HB-72996,
N01-HB-97072]; Children's Hospital-Philadelphia [N01-HB-72997,
N01-HB-97056]; University of Chicago [N01-HB-72998, N01-HB-97053];
Medical College of Georgia [N01-HB-73000, N01-HB-97060]; Washington
University [N01-HB-73001, N01-HB-97071]; Jewish Hospital and Medical
Center of Brooklyn [N01-HB-73002]; Trustees of Health and Hospitals of
the City of Boston, Inc. [N01-HB-73003]; Children's Hospital-Oakland
[N01-HB-73004, N01-HB-97054]; University of Mississippi [N01-HB-73005,
N01-HC-95171]; St. Luke's Hospital-New York [N01-HB-73006]; Alta
Bates-Herrick Hospital [N01-HB-97051]; Columbia University
[N01-HB-97058]; St. Jude's Children's Research Hospital [N01-HB-97066];
Research Foundation, State University of New York-Albany [N01-HB-97068,
N01-HB-97069]; New England Research Institute [N01-HB-97073]; Interfaith
Medical Center-Brooklyn [N01-HB-97085]; University of Alabama at
Birmingham [N01-HC-48047, N01-HC-95095]; Northwestern University
[N01-HC-48049]; Kaiser Foundation Research Institute [N01-HC-48050];
Tufts-New England Medical Center [N01-HC-45204]; Harbor-UCLA Research
and Education Institute [N01-HC-05187]; Boston University
[N01-HC-25195]; Jackson State University [N01-HC-95170]; Tougaloo
College [N01-HC-95172]; Regents of the University of California
[N01-HC-95160]; [R01 HD067264]; [RC4 AG039029]; [R01 HL101161-01-A1];
[R01 DK077950-03]; [RC1 HL100185]; [P60 MD002249]
FX Dr Kutlar received research grants from National Institutes of Health
(NIH)/National Institute on Minority Health and Health Disparities
(NIMHD)-P20, Novartis, Celgene Corp. (>=$10000), and Global Iron Summit
(<$10000). Dr Paltoo has ownership interest in a 529 College Plan and a
Thrift Saving Plan (>$10000). Dr Kardia received research grants from
R01 HD067264, RC4 AG039029, R01 HL101161-01-A1, R01 DK077950-03, RC1
HL100185, and P60 MD002249 (>$10000). Dr Sun received research grants
from NIH HL 100245, Genetics of Hypertension Risk Factors, and Sequela
in African Americans (>$10000). Dr Benjamin received research grants
from R01 HL09257, RC1 HD101056, R01 HL102214, and R01 AG028321 (all NIH
grants >$10000). Dr Tracy received research grants from Candidate Gene
Association Resource Study, Exome Sequencing Project (>$10000). Dr
Mosley received research grants from ARIC, ARIC-Neurocognitive Study,
Predictors of Coronary Artery Calcification in an African American
Cohort, GWAS of Ischemic Brain Vascular Injury, ARIC PET Amyloid Imaging
Study, the Intracranial Atherosclerosis Disease and Cognitive Impairment
Study, Parkinson Disease and Olfactory Function in the ARIC Study, and
Identify Epidemiological Risk Factors for Abdominal Aortic Aneurysm
Study (all NIH grants >$10000). Dr Taylor received research grants for
the Jackson Heart Study (NIH grant >$10000). Dr Psaty received NIH
grants (<$10000); he serves on the Data and Safety Monitoring Board for
a clinical trial for a device (Zoll Life Cor <$10000) and service on the
Steering Committee for Yale Open Data Project (Medtronic <$10000). Dr
Heckbert received research grants from HL 087652 Whole Genome
Association Study in the Cardiovascular Health Study (National Heart,
Lung, and Blood Institute >$10000). Dr Vasan received an NIH grant
(>$10000). The other authors report no conflicts.; Atherosclerotic Risk
in Communities: University of North Carolina at Chapel Hill
(N01-HC-55015), Baylor Medical College (N01-HC-55016), University of
Mississippi Medical Center (N01-HC-55021), University of Minnesota
(N01-HC-55019), Johns Hopkins University (N01-HC-55020), University of
Texas, Houston (N01-HC-55017), and University of North Carolina, Forsyth
County (N01-HC-55018); Cardiovascular Health Study: University of
Washington (N01-HC-85079), Wake Forest University (N01-HC-85080), Johns
Hopkins University (N01-HC-85081), University of Pittsburgh
(N01-HC-85082), University of California, Davis (N01-HC-85083),
University of California, Irvine (N01-HC-85084), New England Medical
Center (N01-HC-85085), University of Vermont (N01-HC-85086), Georgetown
University (N01-HC-35129), Johns Hopkins University (N01 HC-15103),
University of Wisconsin (N01-HC-75150), Geisinger Clinic (N01-HC-45133),
and University of Washington (N01 HC-55222, U01 HL080295); Cleveland
Family Study: Case Western Reserve University (RO1 HL46380-01-16);
Cooperative Study of Sickle Cell Disease: University of Illinois
(N01-HB-72982, N01-HB-97062), Howard University (N01-HB-72991,
N01-HB-97061), University of Miami (N01-HB-72992, N01-HB-97064), Duke
University (N01-HB-72993), George Washington University (N01-HB-72994),
University of Tennessee (N01-HB-72995, N01-HB-97070), Yale University
(N01-HB-72996, N01-HB-97072), Children's Hospital-Philadelphia
(N01-HB-72997, N01-HB-97056), University of Chicago (N01-HB-72998,
N01-HB-97053), Medical College of Georgia (N01-HB-73000, N01-HB-97060),
Washington University (N01-HB-73001, N01-HB-97071), Jewish Hospital and
Medical Center of Brooklyn (N01-HB-73002), Trustees of Health and
Hospitals of the City of Boston, Inc. (N01-HB-73003), Children's
Hospital-Oakland (N01-HB-73004, N01-HB-97054), University of Mississippi
(N01-HB-73005), St. Luke's Hospital-New York (N01-HB-73006), Alta
Bates-Herrick Hospital (N01-HB-97051), Columbia University
(N01-HB-97058), St.; Jude's Children's Research Hospital (N01-HB-97066),
Research Foundation, State University of New York-Albany (N01-HB-97068,
N01-HB-97069), New England Research Institute (N01-HB-97073), and
Interfaith Medical Center-Brooklyn (N01-HB-97085); Coronary Artery Risk
in Young Adults: University of Alabama at Birmingham (N01-HC-48047),
University of Minnesota (N01-HC-48048), Northwestern University
(N01-HC-48049), Kaiser Foundation Research Institute (N01-HC-48050),
University of Alabama at Birmingham (N01-HC-95095), Tufts-New England
Medical Center (N01-HC-45204), Wake Forest University (N01-HC-45205),
Harbor-UCLA Research and Education Institute (N01-HC-05187), and
University of California, Irvine (N01-HC-45134, N01-HC-95100);
Framingham Heart Study: Boston University (N01-HC-25195); Jackson Heart
Study: Jackson State University (N01-HC-95170), University of
Mississippi (N01-HC-95171), and Tougaloo College (N01-HC-95172);
Multi-Ethnic Study of Atherosclerosis: University of Washington
(N01-HC-95159), Regents of the University of California (N01-HC-95160),
Columbia University (N01-HC-95161), Johns Hopkins University
(N01-HC-95162), University of Minnesota (N01-HC-95163), Northwestern
University (N01-HC-95164), Wake Forest University (N01-HC-95165),
University of Vermont (N01-HC-95166), New England Medical Center
(N01-HC-95167), Johns Hopkins University (N01-HC-95168), and Harbor-UCLA
Research and Education Institute (N01-HC-95169); Sleep Heart Health
Study: Johns Hopkins University (U01 HL064360), Case Western University
(U01 HL063463), University of California, Davis (U01 HL053916),
University of Arizona (U01 HL053938), University of Minnesota
(relocating in 2006 to University Arizona) (U01 HL053934), University of
Pittsburgh (U01 HL077813), Boston University (U01 HL053941), MedStar
Research Institute (U01 HL063429), and Johns Hopkins University (U01
HL053937).
NR 28
TC 15
Z9 15
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD FEB
PY 2013
VL 6
IS 1
BP 37
EP 46
DI 10.1161/CIRCGENETICS.111.962365
PG 10
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA 094YL
UT WOS:000315301500008
PM 23275298
ER
PT J
AU Yu, B
Barbalic, M
Brautbar, A
Nambi, V
Hoogeveen, RC
Tang, WH
Mosley, TH
Rotter, JI
deFilippi, CR
O'Donnell, CJ
Kathiresan, S
Rice, K
Heckbert, SR
Ballantyne, CM
Psaty, BM
Boerwinkle, E
AF Yu, Bing
Barbalic, Maja
Brautbar, Ariel
Nambi, Vijay
Hoogeveen, Ron C.
Tang, Weihong
Mosley, Thomas H.
Rotter, Jerome I.
deFilippi, Christopher R.
O'Donnell, Christopher J.
Kathiresan, Sekar
Rice, Ken
Heckbert, Susan R.
Ballantyne, Christie M.
Psaty, Bruce M.
Boerwinkle, Eric
CA CARDIoGRAM Consortium
TI Association of Genome-Wide Variation With Highly Sensitive Cardiac
Troponin-T Levels in European Americans and Blacks A Meta-Analysis From
Atherosclerosis Risk in Communities and Cardiovascular Health Studies
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE genetics; genome-wide association study; troponin
ID CORONARY-ARTERY-DISEASE; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; SARCOMERE
PROTEIN GENES; DILATED CARDIOMYOPATHY; MYOCARDIAL-INFARCTION;
ALPHA-TROPOMYOSIN; HEART-FAILURE; MUTATIONS; ASSAY; MORTALITY
AB Background-High levels of cardiac troponin T, measured by a highly sensitive assay (hs-cTnT), are strongly associated with incident coronary heart disease and heart failure. To date, no large-scale genome-wide association study of hs-cTnT has been reported. We sought to identify novel genetic variants that are associated with hs-cTnT levels.
Methods and Results-We performed a genome-wide association in 9491 European Americans and 2053 blacks free of coronary heart disease and heart failure from 2 prospective cohorts: the Atherosclerosis Risk in Communities Study and the Cardiovascular Health Study. Genome-wide association studies were conducted in each study and race stratum. Fixed-effect meta-analyses combined the results of linear regression from 2 cohorts within each race stratum and then across race strata to produce overall estimates and probability values. The meta-analysis identified a significant association at chromosome 8q13 (rs10091374; P=9.06x10(-9)) near the nuclear receptor coactivator 2 (NCOA2) gene. Overexpression of NCOA2 can be detected in myoblasts. An additional analysis using logistic regression and the clinically motivated 99th percentile cut point detected a significant association at 1q32 (rs12564445; P=4.73x10(-8)) in the gene TNNT2, which encodes the cardiac troponin T protein itself. The hs-cTnT-associated single-nucleotide polymorphisms were not associated with coronary heart disease in a large case-control study, but rs12564445 was significantly associated with incident heart failure in Atherosclerosis Risk in Communities Study European Americans (hazard ratio=1.16; P=0.004).
Conclusions-We identified 2 loci, near NCOA2 and in the TNNT2 gene, at which variation was significantly associated with hs-cTnT levels. Further use of the new assay should enable replication of these results. (Circ Cardiovasc Genet. 2013;6:82-88.)
C1 [Yu, Bing; Barbalic, Maja; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX USA.
[Brautbar, Ariel; Nambi, Vijay; Hoogeveen, Ron C.; Ballantyne, Christie M.] Baylor Coll Med, Deptartment Med, Houston, TX 77030 USA.
[Boerwinkle, Eric] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Tang, Weihong] Univ Minnesota, Deptartment Epidemiol, Minneapolis, MN USA.
[Mosley, Thomas H.] Univ Mississippi, Med Ctr, Div Geriatr, Jackson, MS 39216 USA.
[Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[deFilippi, Christopher R.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[O'Donnell, Christopher J.] NHLBI, Bethesda, MD 20892 USA.
[O'Donnell, Christopher J.] NIH, Framingham Heart Study, Bethesda, MD 20892 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Kathiresan, Sekar] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Rice, Ken] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Heckbert, Susan R.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
RP Boerwinkle, E (reprint author), Univ Texas Sch Publ Hlth, Ctr Human Genet, 1200 Herman Pressler E-447, Houston, TX 77030 USA.
EM Eric.Boerwinkle@uth.tmc.edu
FU National Heart, Lung, and Blood Institute [HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN2682011000 08C,
HHSN268201100009C, HHSN268201100010C, HHSN2682 01100011C,
HHSN268201100012C, R01HL087641, R01HL59 367, R01HL086694]; National
Human Genome Research Institute [U01HG004402]; National Institutes of
Health [HHSN268200625226C, UL1RR025005]; National Institute on Aging
[AG-023629, AG-15928, AG-20098, AG-027058]; National Center for Research
Resources CTSI [UL 1RR033176]; National Institute of Diabetes and
Digestive and Kidney Diseases [DK063491]; Burroughs Wellcome Fund;
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
Consortium; National Heart, Lung, and Blood Institute. [N01-HC-85239,
N01-HC-85079, N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222,
N01-HC-75150, N01-HC-45133, HL080295, HL075366, HL085251, HL087652,
HL105756]
FX The Atherosclerosis Risk in Communities Study is carried out as a
collaborative study supported by National Heart, Lung, and Blood
Institute contracts (HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HHSN2682011000 08C, HHSN268201100009C,
HHSN268201100010C, HHSN2682 01100011C, and HHSN268201100012C),
R01HL087641, R01HL59 367, and R01HL086694; National Human Genome
Research Institute contract U01HG004402; and National Institutes of
Health contract HHSN268200625226C. Infrastructure was partly supported
by Grant Number UL1RR025005, a component of the National Institutes of
Health, and NIH Roadmap for Medical Research. This Cardiovascular Health
Study research was supported by the National Heart, Lung, and Blood
Institute contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086;
N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, and
N01-HC-45133,; and National Heart, Lung, and Blood Institute grants
HL080295, HL075366, HL085251, HL087652, and HL105756, with additional
contributions from National Institute of Neurological Disorders and
Stroke. Additional support was provided through AG-023629, AG-15928,
AG-20098, and AG-027058 from the National Institute on Aging. See also
http://www.chs-nhlbi.org/pi.htm. DNA handling and genotyping was
supported in part by National Center for Research Resources CTSI grant
UL 1RR033176 and National Institute of Diabetes and Digestive and Kidney
Diseases grant DK063491 to the Southern California Diabetes
Endocrinology Research Center and the Cedars-Sinai Board of Governors'
Chair in Medical Genetics (to Dr Rotter).; We acknowledge the essential
role of The Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) Consortium in developing and supporting this article. CHARGE
members include the ARIC, the CHS, Framingham Heart Study (FHS) and
Rotterdam Study (RS), and Age, Gene/Environment Susceptibility. The
authors also thank the staff and participants of the ARIC and CHS study
for their important contributions. Dr Yu is supported in part by the
Burroughs Wellcome Fund.
NR 30
TC 8
Z9 8
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD FEB
PY 2013
VL 6
IS 1
BP 82
EP 88
DI 10.1161/CIRCGENETICS.112.963058
PG 7
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA 094YL
UT WOS:000315301500013
PM 23247143
ER
PT J
AU Baffy, G
AF Baffy, Gyoergy
TI Allostasis in Nonalcoholic Fatty Liver Disease: Implications for Risk
Assessment
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Review
DE Allostasis; Allostatic load; Outcomes; Risk prediction; Allostatic
score; Nonalcoholic fatty liver disease; Hepatocellular carcinoma
ID UNFOLDED PROTEIN RESPONSE; HEPATOCELLULAR-CARCINOMA; METABOLIC-SYNDROME;
NONCIRRHOTIC LIVERS; INSULIN-RESISTANCE; STRESS; LIPOTOXICITY; OBESITY;
LOAD; STEATOHEPATITIS
AB Allostasis, a concept of anticipatory physiological regulation in response to external and internal challenges, was originally developed in the context of neuroendocrinology and behavioral medicine. Allostasis preserves function under changing conditions by abandoning physiological set points and developing new ones. Allostatic load refers to the aggregate effect of adaptation throughout life, and corresponds to the wear and tear associated with this process. In response to chronic stress, allostatic load may accumulate faster than expected if sustained activation of regulatory systems exceeds optimum operating ranges; this results in increased risk of disease. Used in a broader sense, the allostatic model of adaptive responses, trade-offs, feed-forward cycles, and collateral damage provides a framework for assessing the involvement of environmental-genetic interactions and co-morbidities in the course of chronic disease and developing a comprehensive score for personalized risk prediction. The utility of this approach is illustrated for nonalcoholic fatty liver disease, a prevalent condition with common and less common outcomes.
C1 [Baffy, Gyoergy] VA Boston Healthcare Syst, Dept Med, Boston, MA 02130 USA.
[Baffy, Gyoergy] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Baffy, Gyoergy] VA Boston Healthcare Syst, Gastroenterol Sect, Boston, MA 02130 USA.
RP Baffy, G (reprint author), VA Boston Healthcare Syst, Gastroenterol Sect, 150 S Huntington Ave,Room 6A-46, Boston, MA 02130 USA.
EM gbaffy@partners.org
NR 50
TC 1
Z9 1
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD FEB
PY 2013
VL 58
IS 2
BP 302
EP 308
DI 10.1007/s10620-012-2344-8
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 094UZ
UT WOS:000315291100006
PM 22886595
ER
PT J
AU Hermos, JA
Altincatal, A
Weber, HC
Grotzinger, K
Smoot, KJ
Cho, K
Gagnon, DR
Lawler, EV
AF Hermos, John A.
Altincatal, Arman
Weber, H. Christian
Grotzinger, Kelly
Smoot, Kyle J.
Cho, Kelly
Gagnon, David R.
Lawler, Elizabeth V.
TI Thrombocytopenia and Bleeding in Veterans with Non-hepatitis C-related
Chronic Liver Disease
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Chronic liver disease; Thrombocytopenia; Hemorrhage; Veterans
ID CIRRHOSIS; ARTICLE; SURVIVAL; COHORT; PREVALENCE; DRINKING
AB Thrombocytopenia in chronic liver disease (CLD) typically reflects disease severity and may indicate an increased risk for bleeding.
To describe the longitudinal course of thrombocytopenia and risks for bleeding in veteran patients with non-hepatitis C-related CLD.
We identified 2,349 patients with non-hepatitis C-related CLD from databases of the New England Veterans Healthcare System between 1999 and 2008. The cohort was stratified by baseline platelet counts of < 50,000, 50-100,000, > 100,000-150,000, and > 150,000/mu l. Primary outcomes were the incidence and hazard rates for bleeding episodes requiring hospitalization and incident severe thrombocytopenia (< 50,000/mu l).
Over a median follow-up of 3.3 years (IQR 1.2, 6.3), incident major bleeds, predominantly gastrointestinal, occurred in 254 patients (10.8 % of the cohort) and in 19.9 % of those with baseline platelets < 50,000/mu l. Incident severe thrombocytopenia occurred in 315 patients (13.4 % of cohort) and in 40.7 % of those with baseline platelet counts between 50,000 and 100,000/mu l. Baseline platelet counts between 50,000 and 100,000/mu l independently predicted bleeding [adjusted HR 2.89 (1.76, 4.73) p < 0.001] as did esophageal varices, hemoglobin a parts per thousand currency sign9.9 g %, and INR 1.4-2.0. Incident severe thrombocytopenia and minimum platelet counts < 25,000/mu l each associated with bleeding episodes, but the average of minimum platelet counts recorded for those who bled was 76,000/mu l.
Among veteran patients with non-hepatitis C-related CLD, baseline platelet counts of 50,000 to 100,000/mu l increased subsequent risks for both incident severe thrombocytopenia and major bleeding events. Whereas associations between severe thrombocytopenia and bleeding most likely reflect CLD severity, liver-related coagulopathies, and co-morbid bleeding risks, interventions to enhance platelet production may be beneficial for such patients.
C1 [Hermos, John A.; Altincatal, Arman; Smoot, Kyle J.; Cho, Kelly; Gagnon, David R.; Lawler, Elizabeth V.] VA Boston Healthcare Syst 151MAV, Massachusetts Vet Epidemiol Res & Informat Ctr MA, VA Cooperat Studies Program, Boston, MA 02130 USA.
[Hermos, John A.; Weber, H. Christian] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Weber, H. Christian] VA Boston Healthcare Syst, Dept Med, Gastroenterol Sect, Boston, MA USA.
[Grotzinger, Kelly] GlaxoSmithKline, Philadelphia, PA USA.
[Cho, Kelly; Lawler, Elizabeth V.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Gagnon, David R.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
RP Hermos, JA (reprint author), VA Boston Healthcare Syst 151MAV, Massachusetts Vet Epidemiol Res & Informat Ctr MA, VA Cooperat Studies Program, 150 S Huntington Ave, Boston, MA 02130 USA.
EM john.hermos@va.gov; aa2228@caa.columbia.edu; christian.weber@va.gov;
kelly.m.grotzinger@gsk.com; kyle.smoot@va.gov; kelly.cho@va.gov;
david.gagnon@va.gov; elizabeth.lawler@gmail.com
OI Gagnon, David/0000-0002-6367-3179
FU VA Cooperative Studies Program, Massachusetts Veterans Epidemiologic
Research and Information Center (MAVERIC); VA Boston Healthcare System,
Boston, MA; GlaxoSmithKline, Philadelphia, PA
FX The authors acknowledge the programming support of Galena Sokolovskaya.
The study was supported by core funds of the VA Cooperative Studies
Program, Massachusetts Veterans Epidemiologic Research and Information
Center (MAVERIC), VA Boston Healthcare System, Boston, MA, and from
GlaxoSmithKline, Philadelphia, PA.
NR 25
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD FEB
PY 2013
VL 58
IS 2
BP 562
EP 573
DI 10.1007/s10620-012-2404-0
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 094UZ
UT WOS:000315291100038
PM 23010745
ER
PT J
AU Wu, Y
Ahmed, A
Kamal, A
AF Wu, Ying
Ahmed, Aijaz
Kamal, Ahmad
TI Donor Diabetes Mellitus Is an Independent Risk Factor for Graft Loss in
HCV Positive but Not HCV Negative Liver Transplant Recipients
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Liver transplantation; Hepatitis C; Liver donor; Diabetes mellitus type
II
ID INFECTION
AB Graft survival in HCV (hepatitis C virus) infected recipients is worse than those transplanted for other liver diseases. We studied whether several donor cardiovascular risk factors (including advanced age, smoking, hypertension, and diabetes mellitus) contribute to worse outcomes for HCV positive and HCV negative liver transplant recipients.
We obtained data from the United Network for Organ Sharing on all adult liver transplants performed in the United States between January 1, 1998 and December 31, 2003. In total, 27,033 transplant cases were evaluated. Independent predictors of graft survival were determined using Cox proportional hazards regression analysis after controlling for factors previously found to be associated with differences in transplant outcomes.
Donor diabetes was a strong independent risk factor for graft failure [hazard ratio (HR) = 1.20, p = 0.006] only in HCV positive recipients. Neither donor smoking status nor hypertension predicted graft loss in either cohort. Consistent with previous studies, advanced donor age, donation after cardiac death, height, and African American donor all predicted graft loss amongst both cohorts.
Accounting for donor diabetes in relation to recipient HCV status in the selection of liver recipients may result in improved graft survival.
C1 [Wu, Ying] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Ahmed, Aijaz; Kamal, Ahmad] Stanford Univ, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA.
[Kamal, Ahmad] Santa Clara Valley Med Ctr, Div Gastroenterol, San Jose, CA 95128 USA.
RP Wu, Y (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St,Blake 4, Boston, MA 02114 USA.
EM yingny@gmail.com
FU Health Resources and Services Administration [234-2005-370011C];
Stanford University Gastroenterology Division
FX This work was also supported by the Health Resources and Services
Administration (contract 234-2005-370011C). There was no pharmaceutical
and industry support. The funding source was Stanford University
Gastroenterology Division.
NR 11
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD FEB
PY 2013
VL 58
IS 2
BP 574
EP 578
DI 10.1007/s10620-012-2345-7
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 094UZ
UT WOS:000315291100039
PM 22923335
ER
PT J
AU Pennathur, PR
Thompson, D
Abernathy, JH
Martinez, EA
Pronovost, PJ
Kim, GR
Bauer, LC
Lubomski, LH
Marsteller, JA
Gurses, AP
AF Pennathur, Priyadarshini R.
Thompson, David
Abernathy, James H., III
Martinez, Elizabeth A.
Pronovost, Peter J.
Kim, George R.
Bauer, Laura C.
Lubomski, Lisa H.
Marsteller, Jill A.
Gurses, Ayse P.
TI Technologies in the wild (TiW): human factors implications for patient
safety in the cardiovascular operating room
SO ERGONOMICS
LA English
DT Article
DE patient safety; technology; hazards; cognition; cardiac operating room
ID CARDIAC-SURGERY; HEALTH-CARE; EQUIPMENT; CONSEQUENCES; INFORMATION;
HAZARDS; SYSTEM; ERRORS; COMMUNICATION; FAILURES
AB We describe different sources of hazards from cardiovascular operating room (CVOR) technologies, how hazards propagate in the CVOR and their impact on cognitive processes. Previous studies have examined hazards from poor design of a specific CVOR technology. However, the impact of different CVOR technologies functioning in context is not clearly understood. In addition, the impact of non-design hazards in technology devices is unclear. Our study identified hazards from organisational, physical/environmental elements, in addition to design of technology in a CVOR. We used observations, follow-up interviews and photographs. With qualitative analyses, we categorised the different hazard sources and their potential impact on cognitive processes. Patient safety can be built into technologies by incorporating user needs in design, decision-making and implementation of medical technologies. Practitioner summary: Effective design and implementation of technology in a safety-critical system requires prospective understanding of technology-related hazards. Our research fills this gap by studying different technologies in context of a CVOR using observations. Qualitative analyses identified different sources for technology-related hazards besides design, and their impact on cognitive processes.
C1 [Pennathur, Priyadarshini R.] Univ Iowa, Dept Mech & Ind Engn, Iowa City, IA 52242 USA.
[Thompson, David; Pronovost, Peter J.; Bauer, Laura C.; Lubomski, Lisa H.; Marsteller, Jill A.; Gurses, Ayse P.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.
[Thompson, David; Martinez, Elizabeth A.; Pronovost, Peter J.; Kim, George R.; Lubomski, Lisa H.; Marsteller, Jill A.; Gurses, Ayse P.] Johns Hopkins Univ, Sch Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD USA.
[Abernathy, James H., III] Med Univ S Carolina, Div Cardiothorac Anesthesiol, Charleston, SC 29425 USA.
[Martinez, Elizabeth A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Pronovost, Peter J.; Marsteller, Jill A.; Gurses, Ayse P.] Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
[Pronovost, Peter J.; Kim, George R.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA.
[Kim, George R.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA.
[Kim, George R.; Gurses, Ayse P.] Johns Hopkins Univ, Sch Med, Div Hlth Sci Informat, Baltimore, MD USA.
RP Pennathur, PR (reprint author), Univ Iowa, Dept Mech & Ind Engn, Iowa City, IA 52242 USA.
EM prp.uiowa@gmail.com
FU Society of Cardiovascular Anesthesiologists (SCA) Foundation; SCA
Foundation; Agency for Healthcare Research and Quality [K01HS018762]
FX This study was supported by the Society of Cardiovascular
Anesthesiologists (SCA) Foundation for the LENS Project. The FOCUS
Initiative is a collaborative project of the Society of Cardiovascular
Anesthesiologists, the SCA Foundation and the Johns Hopkins University
Quality and Safety Research Group. FOCUS is funded exclusively by the
SCA Foundation. Dr. Gurses was partially supported by a grant from the
Agency for Healthcare Research and Quality (K01HS018762). We thank Ms.
Christine Holzmueller for her assistance in editing this manuscript.
NR 46
TC 12
Z9 12
U1 3
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0014-0139
J9 ERGONOMICS
JI Ergonomics
PD FEB 1
PY 2013
VL 56
IS 2
BP 205
EP 219
DI 10.1080/00140139.2012.757655
PG 15
WC Engineering, Industrial; Ergonomics; Psychology, Applied; Psychology
SC Engineering; Psychology
GA 092WZ
UT WOS:000315155000005
PM 23384283
ER
PT J
AU Sommers, R
Goold, SD
McGlynn, EA
Pearson, SD
Danis, M
AF Sommers, Roseanna
Goold, Susan Dorr
McGlynn, Elizabeth A.
Pearson, Steven D.
Danis, Marion
TI Focus Groups Highlight That Many Patients Object To Clinicians' Focusing
On Costs
SO HEALTH AFFAIRS
LA English
DT Article
ID HEALTH-CARE; PHYSICIANS; DECISIONS
AB Having patients weigh costs when making medical decisions has been proposed as a way to rein in health care spending. We convened twenty-two focus groups of people with insurance to examine their willingness to discuss health care costs with clinicians and consider costs when deciding among nearly comparable clinical options. We identified the following four barriers to patients' taking cost into account: a preference for what they perceive as the best care, regardless of expense; inexperience with making trade-offs between health and money; a lack of interest in costs borne by insurers and society as a whole; and noncooperative behavior characteristic of a "commons dilemma," in which people act in their own self-interest although they recognize that by doing so, they are depleting limited resources. Surmounting these barriers will require new research in patient education, comprehensive efforts to shift public attitudes about health care costs, and training to prepare clinicians to discuss costs with their patients.
C1 [Sommers, Roseanna] Yale Univ, Sch Law, New Haven, CT 06520 USA.
[Goold, Susan Dorr] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Goold, Susan Dorr] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
[McGlynn, Elizabeth A.] Kaiser Permanente Ctr Effectiveness & Safety Res, Oakland, CA USA.
[Pearson, Steven D.] Massachusetts Gen Hosp, Inst Clin & Econ Review, Boston, MA 02114 USA.
[Danis, Marion] NIH, Sect Eth & Hlth Policy, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA.
[Danis, Marion] NIH, Eth Consultat Serv, Ctr Clin, Bethesda, MD 20892 USA.
RP Sommers, R (reprint author), Yale Univ, Sch Law, New Haven, CT 06520 USA.
EM mdanis@nih.gov
OI Goold, Susan Dorr/0000-0002-0258-9774
FU Office of the Director; Department of Bioethics at the National
Institutes of Health
FX An earlier version of this article was presented at the 2012 annual
meeting of the American Society for Bioethics and Humanities,
Washington, D. C., October 21, 2012. This project was funded by the
Office of the Director and the Department of Bioethics at the National
Institutes of Health. The authors thank Beverly Weidmer, Shirley Chen,
Jean Logan, and Greer Donley for assistance with the survey design, data
collection, and data coding. The views expressed here are those of the
authors and do not necessarily reflect the policies of the American
Medical Association, the National Institutes of Health, or the
Department of Health and Human Services.
NR 23
TC 20
Z9 20
U1 0
U2 13
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD FEB
PY 2013
VL 32
IS 2
BP 338
EP 346
DI 10.1377/hlthaff.2012.0686
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 093QQ
UT WOS:000315206900019
PM 23381527
ER
PT J
AU Halpern, SD
Loewenstein, G
Volpp, KG
Cooney, E
Vranas, K
Quill, CM
McKenzie, MS
Harhay, MO
Gabler, NB
Silva, T
Arnold, R
Angus, DC
Bryce, C
AF Halpern, Scott D.
Loewenstein, George
Volpp, Kevin G.
Cooney, Elizabeth
Vranas, Kelly
Quill, Caroline M.
McKenzie, Mary S.
Harhay, Michael O.
Gabler, Nicole B.
Silva, Tatiana
Arnold, Robert
Angus, Derek C.
Bryce, Cindy
TI Default Options In Advance Directives Influence How Patients Set Goals
For End-Of-Life Care
SO HEALTH AFFAIRS
LA English
DT Article
ID TREATMENT PREFERENCES; DECISION-MAKING; MEDICAL-CARE; HEALTH-CARE;
CARDIOPULMONARY-RESUSCITATION; ASYMMETRIC PATERNALISM; BEHAVIORAL
ECONOMICS; FAMILY; OUTCOMES; SATISFACTION
AB Although decisions regarding end-of-life care are personal and important, they may be influenced by the ways in which options are presented. To test this hypothesis, we randomly assigned 132 seriously ill patients to complete one of three types of advance directives. Two types had end-of-life care options already checked-a default choice-but one of these favored comfort-oriented care, and the other, life-extending care. The third type was a standard advance directive with no options checked. We found that most patients preferred comfort-oriented care, but the defaults influenced those choices. For example, 77 percent of patients in the comfort-oriented group retained that choice, while 43 percent of those in the life-extending group rejected the default choice and selected comfort-oriented care instead. Among the standard advance directive group, 61 percent of patients selected comfort-oriented care. Our findings suggest that patients may not hold deep-seated preferences regarding end-of-life care. The findings provide motivation for future research examining whether using default options in advance directives may improve important outcomes, including patients' receipt of wanted and unwanted services, resource use, survival, and quality of life.
C1 [Halpern, Scott D.] Univ Penn, Fostering Improvement End Of Life Decis Sci Progr, Philadelphia, PA 19104 USA.
[Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
[Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Wharton Sch, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Vranas, Kelly] Philadelphia Vet Affairs Med Ctr, Med Intens Care Unit, Philadelphia, PA USA.
[Quill, Caroline M.; McKenzie, Mary S.] Hosp Univ Penn, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA.
[Harhay, Michael O.] Univ Penn, Philadelphia, PA 19104 USA.
[Gabler, Nicole B.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Silva, Tatiana] Univ Mannheim, Mannheim, Germany.
[Arnold, Robert] Univ Pittsburgh, Inst Doctor Patient Commun, Pittsburgh, PA 15260 USA.
[Angus, Derek C.] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness, Pittsburgh, PA 15260 USA.
[Bryce, Cindy] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
RP Halpern, SD (reprint author), Univ Penn, Fostering Improvement End Of Life Decis Sci Progr, Philadelphia, PA 19104 USA.
EM shalpern@exchange.upenn.edu
RI Angus, Derek/E-9671-2012;
OI Bryce, Cindy/0000-0001-6356-6675
FU Greenwall Foundation; Kornfeld Foundation; Leonard Davis Institute of
Health Economics at the University of Pennsylvania; Center for
Excellence in Cancer Communication Research of the University of
Michigan; Center for Excellence in Cancer Communication Research of the
University of Pennsylvania
FX This work was supported by research grants from the Greenwall
Foundation, Kornfeld Foundation, Leonard Davis Institute of Health
Economics at the University of Pennsylvania, and Center for Excellence
in Cancer Communication Research of the Universities of Michigan and
Pennsylvania. The authors thank Susan Metzger for her assistance with
patient recruitment.
NR 45
TC 28
Z9 28
U1 2
U2 23
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD FEB
PY 2013
VL 32
IS 2
BP 408
EP 417
DI 10.1377/hlthaff.2012.0895
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 093QQ
UT WOS:000315206900027
PM 23381535
ER
PT J
AU Prabhakar, S
Taherian, M
Gianni, D
Conlon, TJ
Fulci, G
Brockmann, J
Stemmer-Rachamimov, A
Sena-Esteves, M
Breakefield, XO
Brenner, GJ
AF Prabhakar, Shilpa
Taherian, Mehran
Gianni, Davide
Conlon, Thomas J.
Fulci, Giulia
Brockmann, Jillian
Stemmer-Rachamimov, Anat
Sena-Esteves, Miguel
Breakefield, Xandra O.
Brenner, Gary J.
TI Regression of Schwannomas Induced by Adeno-Associated Virus-Mediated
Delivery of Caspase-1
SO HUMAN GENE THERAPY
LA English
DT Article
ID SELF-COMPLEMENTARY VECTORS; NF2 TUMOR-SUPPRESSOR; CELL-DEATH; PHASE-I;
MOLECULAR CHARACTERIZATION; NEUROFIBROMATOSIS TYPE-2; NERVOUS-SYSTEM;
GENE-THERAPY; DISEASE; AAV
AB Schwannomas are tumors formed by proliferation of dedifferentiated Schwann cells. Patients with neurofibromatosis 2 (NF2) and schwannomatosis develop multiple schwannomas in peripheral and cranial nerves. Although benign, these tumors can cause extreme pain and compromise sensory/motor functions, including hearing and vision. At present, surgical resection is the main treatment modality, but it can be problematic because of tumor inaccessibility and risk of nerve damage. We have explored gene therapy for schwannomas, using a model in which immortalized human NF2 schwannoma cells expressing a fluorescent protein and luciferase are implanted in the sciatic nerve of nude mice. Direct injection of an adeno-associated virus (AAV) serotype 1 vector encoding caspase-1 (ICE) under the Schwann-cell specific promoter, P0, leads to regression of these tumors with essentially no vector-mediated neuropathology, and no changes in sensory or motor function. In a related NF2 xenograft model designed to cause measurable pain behavior, the same gene therapy leads to tumor regression and concordant resolution of tumor-associated pain. This AAV1-P0-ICE vector holds promise for clinical treatment of schwannomas by direct intratumoral injection to achieve reduction in tumor size and normalization of neuronal function.
C1 [Prabhakar, Shilpa; Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Neurol, Ctr Neurosci, Boston, MA 02114 USA.
[Prabhakar, Shilpa; Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Radiol, Ctr Mol Imaging Res, Boston, MA 02114 USA.
[Prabhakar, Shilpa; Breakefield, Xandra O.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA.
[Taherian, Mehran; Brenner, Gary J.] Massachusetts Gen Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02114 USA.
[Gianni, Davide; Sena-Esteves, Miguel] Univ Massachusetts, Dept Neurol, Worcester, MA 01655 USA.
[Gianni, Davide; Sena-Esteves, Miguel] Univ Massachusetts, Gene Therapy Ctr, Worcester, MA 01655 USA.
[Conlon, Thomas J.] Univ Florida, Dept Pediat, Gainesville, FL 32611 USA.
[Conlon, Thomas J.] Univ Florida, Powell Gene Therapy Ctr, Gainesville, FL 32611 USA.
[Fulci, Giulia] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Brockmann, Jillian; Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Brenner, GJ (reprint author), MGH Ctr Pain Med, WAC 334,15 Parkman St, Boston, MA 02114 USA.
EM gjbrenner@partners.org
FU NIH/NINDS [NS24279]; DOD [NF060106]
FX The authors thank Dr. Okay Saydam, Ozlem Senol, Arda Mirzak, and Mehmet
Fatih Bolukbasi for help in generating the HEI-193FC line; Hae-Sook Shin
for assistance with behavioral testing; and Ahmed Hassad for general
technical assistance. The authors thank Kirsten E. Erger at the
University of Florida Gene Therapy Center Toxicology Core for work on
the DNA isolation and real-time PCR for vector biodistribution. The
authors thank Leora Cramer at the Pathology Laboratory for work on the
histology. The authors thank Ms. Suzanne McDavitt for skilled editorial
assistance. This work was supported by NIH/NINDS grant NS24279 (X.O.B.,
A. S.) and DOD NF060106 (M. S. and G.J.B.).
NR 47
TC 2
Z9 2
U1 1
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD FEB
PY 2013
VL 24
IS 2
BP 152
EP 162
DI 10.1089/hum.2012.094
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 093MS
UT WOS:000315196600005
PM 23140466
ER
PT J
AU Win, AK
Lindor, NM
Winship, I
Tucker, KM
Buchanan, DD
Young, JP
Rosty, C
Leggett, B
Giles, GG
Goldblatt, J
Macrae, FA
Parry, S
Kalady, MF
Baron, JA
Ahnen, DJ
Le Marchand, L
Gallinger, S
Haile, RW
Newcomb, PA
Hopper, JL
Jenkins, MA
AF Win, Aung Ko
Lindor, Noralane M.
Winship, Ingrid
Tucker, Katherine M.
Buchanan, Daniel D.
Young, Joanne P.
Rosty, Christophe
Leggett, Barbara
Giles, Graham G.
Goldblatt, Jack
Macrae, Finlay A.
Parry, Susan
Kalady, Matthew F.
Baron, John A.
Ahnen, Dennis J.
Le Marchand, Loic
Gallinger, Steven
Haile, Robert W.
Newcomb, Polly A.
Hopper, John L.
Jenkins, Mark A.
TI Risks of Colorectal and Other Cancers After Endometrial Cancer for Women
With Lynch Syndrome
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID DNA MISMATCH REPAIR; GERMLINE MUTATIONS; MOLECULAR ANALYSIS; FAMILY
REGISTRY; MSH6 MUTATION; COLON-CANCER; CARRIERS; HNPCC; NONCARRIERS;
GUIDELINES
AB Background Lynch syndrome is an autosomal dominantly inherited disorder caused by germline mutations in DNA mismatch repair (MMR) genes. Previous studies have shown that MMR gene mutation carriers are at increased risk of colorectal, endometrial, and several other cancers following an initial diagnosis of colorectal cancer. We estimated cancer risks following an endometrial cancer diagnosis for women carrying MMR gene mutations.
Methods We obtained data from the Colon Cancer Family Registry for a cohort of 127 women who had a diagnosis of endometrial cancer and who carried a mutation in one of four MMR genes (30 carried a mutation in MLH1, 72 in MSH2, 22 in MSH6, and 3 in PMS2). We used the Kaplan-Meier method to estimate 10- and 20-year cumulative risks for each cancer. We estimated the age-, country-, and calendar period-specific standardized incidence ratios (SIRs) for each cancer, compared with the general population.
Results Following endometrial cancer, women carrying MMR gene mutations had the following 20-year risks of other cancer cancers: colorectal cancer (48%, 95% confidence interval [CI] = 35% to 62%); cancer of the kidney, renal pelvis, or ureter (11%, 95% CI = 3% to 20%); urinary bladder cancer (9%, 95% CI = 2% to 17%); and breast cancer (11%, 95% CI = 4% to 19%). Compared with the general population, these women were at statistically significantly elevated risks of colorectal cancer (SIR = 39.9, 95% CI = 27.2 to 58.3), cancer of the kidney, renal pelvis, or ureter (SIR = 28.3, 95% CI = 11.9 to 48.6), urinary bladder cancer (SIR = 24.3, 95% CI = 8.56 to 42.9), and breast cancer (SIR = 2.51, 95% CI = 1.17 to 4.14).
Conclusions Women with Lynch syndrome who are diagnosed with endometrial cancer have increased risks of several cancers, including breast cancer. J Natl Cancer Inst;2013;105:274-279
C1 [Win, Aung Ko; Hopper, John L.; Jenkins, Mark A.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3010, Australia.
[Winship, Ingrid] Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia.
[Lindor, Noralane M.] Mayo Clin Arizona, Dept Hlth Sci Res, Scottsdale, AZ USA.
[Winship, Ingrid; Macrae, Finlay A.] Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
[Tucker, Katherine M.] Prince Wales Hosp, Hereditary Canc Clin, Randwick, NSW 2031, Australia.
[Buchanan, Daniel D.; Young, Joanne P.; Rosty, Christophe] Queensland Inst Med Res, Canc & Populat Studies Grp, Herston, Qld 4006, Australia.
[Leggett, Barbara] Royal Brisbane & Womens Hosp Res Fdn, Queensland Inst Med Res, Clin Res Ctr, Conjoint Gastroenterol Lab,Pathol Queensland, Herston, Qld, Australia.
[Rosty, Christophe] Univ Queensland, Dept Mol & Cellular Pathol, Herston, Qld, Australia.
[Leggett, Barbara] Univ Queensland, Sch Med, Herston, Qld, Australia.
[Leggett, Barbara] Royal Brisbane & Womens Hosp, Dept Gastroenterol & Hepatol, Brisbane, Qld, Australia.
[Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia.
[Goldblatt, Jack] Univ Western Australia, Genet Serv Western Australia, Perth, WA 6009, Australia.
[Goldblatt, Jack] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia.
[Parry, Susan] Auckland City Hosp, New Zealand Familial Gastrointestinal Canc Regist, Auckland, New Zealand.
[Parry, Susan] Middlemore Hosp, Dept Gastroenterol, Auckland 6, New Zealand.
[Kalady, Matthew F.] Cleveland Clin, Dept Colorectal Surg, Inst Digest Dis, Cleveland, OH 44106 USA.
[Kalady, Matthew F.] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44106 USA.
[Baron, John A.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
[Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver VA Med Ctr, Denver, CO USA.
[Le Marchand, Loic] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
[Gallinger, Steven] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Gallinger, Steven] Canc Care Ontario, Toronto, ON, Canada.
[Haile, Robert W.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA.
RP Jenkins, MA (reprint author), Univ Melbourne, Melbourne Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Level 3,207 Bouverie St, Parkville, Vic 3010, Australia.
EM m.jenkins@unimelb.edu.au
RI Gallinger, Steven/E-4575-2013; Rosty, Christophe/F-1796-2010; Jenkins,
Mark/P-7803-2015; Leggett, Barbara/D-3579-2011;
OI Jenkins, Mark/0000-0002-8964-6160; Giles, Graham/0000-0003-4946-9099;
Win, Aung Ko/0000-0002-2794-5261; Buchanan, Daniel/0000-0003-2225-6675;
Winship, Ingrid/0000-0001-8535-6003
FU National Cancer Institute, National Institutes of Health under RFA
[CA-95-011]; Picchi Brothers Foundation Cancer Council Victoria Cancer
Research Scholarship, Australia
FX This work was supported by the National Cancer Institute, National
Institutes of Health under RFA CA-95-011, and through cooperative
agreements with members of the Colon Cancer Family Registry and
principal investigators. AKW is supported by the Picchi Brothers
Foundation Cancer Council Victoria Cancer Research Scholarship,
Australia. JLH is a National Health and Medical Research Council
Australia Fellow. MAJ is a National Health and Medical Research Council
Senior Research Fellow. JPY is a Cancer Council Queensland Senior
Research Fellow. CR is a Jass Pathology Fellow.
NR 34
TC 36
Z9 39
U1 0
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 JNCI-J NATL CANCER I
JI JNCI-. Natl. Cancer Inst.
PD FEB
PY 2013
VL 105
IS 4
BP 274
EP 279
DI 10.1093/jnci/djs525
PG 6
WC Oncology
SC Oncology
GA 093PD
UT WOS:000315202900008
PM 23385444
ER
PT J
AU Gamazon, ER
Pinto, N
Konkashbaev, A
Im, HK
Diskin, SJ
London, WB
Maris, JM
Dolan, ME
Cox, NJ
Cohn, SL
AF Gamazon, Eric R.
Pinto, Navin
Konkashbaev, Anuar
Im, Hae Kyung
Diskin, Sharon J.
London, Wendy B.
Maris, John M.
Dolan, M. Eileen
Cox, Nancy J.
Cohn, Susan L.
TI Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in
Neuroblastoma Survival
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COPY NUMBER; CANCER; LOCUS
AB Background Black patients with neuroblastoma have a higher prevalence of high-risk disease and worse outcome than white patients. We sought to investigate the relationship between genetic variation and the disparities in survival observed in neuroblastoma.
Methods The analytic cohort was composed of 2709 patients. Principal components were used to assign patients to genomic ethnic clusters for survival analyses. Locus-specific ancestry was calculated for use in association analysis. The shorter spans of linkage disequilibrium in African populations may facilitate the fine mapping of causal variants in regions previously implicated by genome-wide association studies conducted primarily in patients of European descent. Thus, we evaluated 13 single nucleotide polymorphisms known to be associated with susceptibility to high-risk neuroblastoma from genome-wide association studies and all variants with highly divergent allele frequencies in reference African and European populations near the known susceptibility loci. All statistical tests were two-sided.
Results African genomic ancestry was associated with high-risk neuroblastoma (P = .007) and lower event-free survival (P = .04, hazard ratio = 1.4, 95% confidence interval = 1.05 to 1.80). rs1033069 within SPAG16 (sperm associated antigen 16) was determined to have higher risk allele frequency in the African reference population and statistically significant association with high-risk disease in patients of European and African ancestry (P = 6.42 x 10(-5), false discovery rate < 0.0015) in the overall cohort. Multivariable analysis using an additive model demonstrated that the SPAG16 single nucleotide polymorphism contributes to the observed ethnic disparities in high-risk disease and survival.
Conclusions Our study demonstrates that common genetic variation influences neuroblastoma phenotype and contributes to the ethnic disparities in survival observed and illustrates the value of trans-population mapping. J Natl Cancer Inst;2013;105:302-309
C1 [Gamazon, Eric R.; Konkashbaev, Anuar; Cox, Nancy J.] Univ Chicago, Dept Med, Med Genet Sect, Chicago, IL 60637 USA.
[Pinto, Navin; Cohn, Susan L.] Univ Chicago, Dept Pediat, Sect Pediat Hematol Oncol, Chicago, IL 60637 USA.
[Im, Hae Kyung] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA.
[Dolan, M. Eileen] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA.
[Diskin, Sharon J.; Maris, John M.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.
[Diskin, Sharon J.; Maris, John M.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA.
[Diskin, Sharon J.; Maris, John M.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[London, Wendy B.] Harvard Univ, Dana Farber Harvard Canc Ctr, Boston Childrens Hosp, Boston, MA 02115 USA.
[London, Wendy B.] Childrens Oncol Grp Stat & Data Ctr, Arcadia, CA USA.
RP Cox, NJ (reprint author), Univ Chicago, Med Genet Sect, 900 E 57th St,Rm 3220F, Chicago, IL 60637 USA.
EM ncox@medicine.bsd.uchicago.edu; scohn@peds.bsd.uchicago.edu
OI Cohn, Susan/0000-0001-5749-7650; Gamazon, Eric/0000-0003-4204-8734
FU National Institutes of Health [U01 GM61393, R01 MH090937, U01 HG005773,
R01 CA078545]; Alex's Lemonade Stand; Children's Neuroblastoma Cancer
Foundation; Elise Anderson Fund; Neuroblastoma Children's Cancer
Society; Little Heroes Cancer Research Foundation; St. Baldrick's
Foundation; Cancer Research Foundation
FX This research was funded by the National Institutes of Health (U01
GM61393 [to MED and NJC], R01 MH090937 [to MED], U01 HG005773 [to NJC],
R01 MH090937 [to NJC], and R01 CA078545 [to JMM]; Alex's Lemonade Stand
(to SLC); Children's Neuroblastoma Cancer Foundation (to SLC); Elise
Anderson Fund (to SLC); Neuroblastoma Children's Cancer Society (to
SLC); Little Heroes Cancer Research Foundation(to SLC); St. Baldrick's
Foundation (to NP); and Cancer Research Foundation (to NP).
NR 34
TC 13
Z9 13
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 JNCI-J NATL CANCER I
JI JNCI-. Natl. Cancer Inst.
PD FEB
PY 2013
VL 105
IS 4
BP 302
EP 309
DI 10.1093/jnci/djs503
PG 8
WC Oncology
SC Oncology
GA 093PD
UT WOS:000315202900011
PM 23243203
ER
PT J
AU Kandala, J
Upadhyay, GA
Altman, RK
Bose, A
Heist, EK
Mela, T
Singh, JP
AF Kandala, Jagdesh
Upadhyay, Gaurav A.
Altman, Robert K.
Bose, Abhishek
Heist, E. Kevin
Mela, Theofanie
Singh, Jagmeet P.
TI Electrical Delay in Apically Positioned Left Ventricular Leads and
Clinical Outcome After Cardiac Resynchronization Therapy
SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
LA English
DT Article
DE cardiac resynchronization therapy; heart failure; lead electrical delay;
LV lead position; LV remodeling
ID CHRONIC HEART-FAILURE; BUNDLE-BRANCH BLOCK; ACTIVATION
AB Electrical Delay in Apically Positioned LV Leads.Introduction: In recent studies, an anatomical apical left ventricular (LV) lead pacing location has been associated with deleterious outcome after cardiac resynchronization therapy (CRT). The differential impact of the LV lead electrical location in these patients remains unknown. Methods and Results: Thirty-one consecutive CRT patients (mean age 71.7 +/- 12.7 years, 55% left bundle-branch block [LBBB] morphology) with an apical LV lead and LV lead electrical delay (LVLED) were studied. Anatomical LV lead location was determined via review of coronary venography and chest radiographs. Electrical location was assessed through intraprocedural LVLED measurement. Patients were dichotomized into either long LVLED (LVLED 50% of QRS) or short LVLED groups (LVLED < 50%). Patients in the long LVLED group demonstrated significantly greater freedom from a primary composite endpoint of all-cause death, heart failure hospitalization, and cardiac transplantation at 2 years (81% vs 30%, P = 0.007 vs short LVLED patients). Longer LVLED was also associated with more favorable LV remodeling (LV end-systolic volume 41.9 +/- 10.3 mL vs 4.3 +/- 17.2 mL; P = 0.05), and greater improvement in LV ejection fraction (+9.4 +/- 2.9% vs +2.3 +/- 7.5%; P = 0.04). Even after multivariate adjustment, LVLED remained an independent predictor of the primary composite endpoint (HR 0.47, P = 0.031). Conclusions: Electrical lead localization, as estimated by LVLED 50%, is associated with improved long-term clinical outcome and measures of LV remodeling in patients with apical LV leads. Intraprocedural LVLED assessment may provide incremental utility in targeting lead placement even in conventionally unfavorable anatomical segments.(J Cardiovasc Electrophysiol, Vol. 24, pp. 182-187, February 2013)
C1 [Kandala, Jagdesh; Upadhyay, Gaurav A.; Altman, Robert K.; Bose, Abhishek; Heist, E. Kevin; Mela, Theofanie; Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol,Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
RP Singh, JP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv,Heart Ctr, Boston, MA 02114 USA.
EM jsingh@partners.org
OI Altman, Robert/0000-0002-1612-3561
FU Max Schaldach Fellowship in Cardiac Pacing and Electrophysiology of the
Heart Rhythm Society; Biotronik; Boston Scientific Corp.; Sorin; St.
Jude Medical; Medtronic Inc.
FX J. Kandala, R. K. Altman, and A. Bose report no significant financial
disclosures. G. A. Upadhyay received salary support from the Max
Schaldach Fellowship in Cardiac Pacing and Electrophysiology of the
Heart Rhythm Society. E. K. Heist reports Biotronik (honoraria/research
grants), Boston Scientific Corp. (consultant/honoraria/research grants),
Sorin (consultant/honoraria/research grants), and St. Jude Medical
(consultant/honoraria/research grants). T. Mela reports Boston
Scientific Corp. (honoraria), Medtronic Inc. (honoraria), and St Jude
Medical (honoraria). J. P. Singh reports St. Jude Medical
(consultant/honoraria/research grants), Medtronic Inc.
(consultant/honoraria/research grants), Boston Scientific Corp.
(consultant/honoraria/research grants), Biotronik
(consultant/honoraria/research grants), Sorin Group
(consultant/honoraria), CardioInsight Inc. (consultant), and Respicardia
Inc. (consultant).
NR 25
TC 6
Z9 6
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-3873
J9 J CARDIOVASC ELECTR
JI J. Cardiovasc. Electrophysiol.
PD FEB
PY 2013
VL 24
IS 2
BP 182
EP 187
DI 10.1111/j.1540-8167.2012.02428.x
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 083NF
UT WOS:000314470500014
PM 22966852
ER
PT J
AU Dhanani, NM
Jiang, YD
AF Dhanani, Nadya M.
Jiang, Yandong
TI Olfactory disorders after general anesthesia Reply
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Letter
C1 [Dhanani, Nadya M.; Jiang, Yandong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Dhanani, NM (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM yjiang@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD FEB
PY 2013
VL 25
IS 1
BP 73
EP 74
DI 10.1016/j.jclinane.2012.10.002
PG 2
WC Anesthesiology
SC Anesthesiology
GA 091RM
UT WOS:000315067500017
PM 23246498
ER
PT J
AU Cather, C
Dyer, MA
Burrell, HA
Hoeppner, B
Goff, DC
Evins, AE
AF Cather, Corinne
Dyer, Michael A.
Burrell, Heather A.
Hoeppner, Bettina
Goff, Donald C.
Evins, A. Eden
TI An Open Trial of Relapse Prevention Therapy for Smokers With
Schizophrenia
SO JOURNAL OF DUAL DIAGNOSIS
LA English
DT Article
DE schizophrenia; severe mental illness; smoking cessation; nicotine
replacement therapy; bupropion; cognitive behavioral therapy; relapse
prevention
ID PLACEBO-CONTROLLED TRIAL; BUPROPION SUSTAINED-RELEASE;
SMOKING-CESSATION; CIGARETTE-SMOKING; DOUBLE-BLIND; NICOTINE; MORTALITY;
NORMALIZATION; NONSMOKERS; DISORDERS
AB Objective: Following successful smoking cessation, smokers with schizophrenia are vulnerable to relapse shortly after treatment discontinuation. Our objective was to assess the feasibility and effectiveness of a 12-month relapse prevention intervention in recently abstinent smokers with schizophrenia. Method: Adult outpatient smokers with schizophrenia received weekly cognitive-behavioral therapy groups, bupropion slow-release, transdermal nicotine patch, and nicotine gum or lozenge for 3 months. Subjects with 7-day point prevalence abstinence at month 3 received an additional 12 months (months 4 through 15) of therapy with bupropion, transdermal nicotine patch, and nicotine gum/lozenge in conjunction with relapse preventionbased cognitive-behavioral therapy groups that were held weekly in month 4, biweekly in months 5 and 6, and monthly in months 7 through 15. Results: Seventeen of 41 participants (41.5%) attained biochemically verified self-report of 7-day point prevalence abstinence at the end of 3 months of treatment and entered relapse prevention treatment. There was an 81% attendance rate at relapse prevention groups. At the end of the 12-month relapse prevention phase (month 15 overall), 11 of 17 (64.7%) demonstrated biochemically verified 7-day point prevalence abstinence, and 10 of 17 (58.8%) reported 4-week continuous abstinence. Almost one-quarter of the sample (23.5%) demonstrated long-term prolonged abstinence through the end of the trial. There were no clinically detected cases of psychiatric symptom exacerbation. One participant, who was managed as an outpatient, self-reported psychiatric symptom exacerbation in the interim period between study visits. Conclusions: Extended-duration smoking cessation treatment is well tolerated and may improve smoking outcomes for recently abstinent smokers with schizophrenia. Controlled trials are warranted.
C1 [Cather, Corinne; Dyer, Michael A.; Burrell, Heather A.; Goff, Donald C.; Evins, A. Eden] Massachusetts Gen Hosp, Schizophrenia Program, Dept Psychiat, Boston, MA 02114 USA.
[Cather, Corinne; Hoeppner, Bettina; Evins, A. Eden] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA.
[Cather, Corinne; Dyer, Michael A.; Burrell, Heather A.; Goff, Donald C.; Evins, A. Eden] Harvard Univ, Sch Med, Boston, MA USA.
RP Cather, C (reprint author), Massachusetts Gen Hosp, Schizophrenia Program, Freedom Trail Clin, 25 Staniford St, Boston, MA 02114 USA.
EM ccather@partners.org
FU NIDA NIH HHS [K01 DA027097, K23 DA000510, K24 DA030443, L30 DA025511];
NIMH NIH HHS [K24 MH002025]
NR 38
TC 10
Z9 11
U1 2
U2 7
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1550-4263
J9 J DUAL DIAGN
JI J. Dual Diagn.
PD FEB 1
PY 2013
VL 9
IS 1
BP 87
EP 93
DI 10.1080/15504263.2012.749559
PG 7
WC Psychology, Clinical; Substance Abuse; Psychiatry
SC Psychology; Substance Abuse; Psychiatry
GA 092XP
UT WOS:000315156600011
PM 23750123
ER
PT J
AU Shin, SS
Bales, JW
Yan, HQ
Kline, AE
Wagner, AK
Lyons-Weiler, J
Dixon, CE
AF Shin, Samuel S.
Bales, James W.
Yan, Hong Q.
Kline, Anthony E.
Wagner, Amy K.
Lyons-Weiler, James
Dixon, C. Edward
TI The Effect of Environmental Enrichment on Substantia Nigra Gene
Expression after Traumatic Brain Injury in Rats
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE dopamine; EE; microarray; TBI
ID CLOSED HEAD-INJURY; MEDIATED FUNCTIONAL IMPROVEMENT; RANDOMIZED
CONTROLLED-TRIAL; CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE;
LONG-TERM POTENTIATION; PARKINSONS-DISEASE; MESSENGER-RNA; AXONAL
INJURY; NEUROBEHAVIORAL RECOVERY
AB Experimental investigations into the effects of traumatic brain injury (TBI) have demonstrated significant alterations in dopaminergic systems. Dopaminergic fibers originating within the substantia nigra and ventral tegmental area (VTA) are important for reward learning, addiction, movement, and behavior. However, little is known about the effect of TBI on substantia nigra and VTA function. Environmental enrichment (EE) has been shown to improve functional outcome after TBI, and a number of studies suggest that it may exert some benefits via dopaminergic signaling. To better understand the role of dopamine in chronic TBI pathophysiology and the effect of EE, we examined the mRNA expression profile within the substantia nigra and VTA at 4 weeks post-injury. Specifically, three comparisons were made: 1) TBI versus sham, 2) sham + EE versus sham + standard (STD) housing, and 3) TBI + EE versus TBI + STD. There were differential expressions of 25, 4, and 40 genes in these comparisons, respectively. Chronic alterations in genes post-injury within the substantia nigra and VTA included genes important for cellular membrane homeostasis and transcription. EE-induced gene alterations after TBI included genes important for signal transduction, in particular calcium signaling pathways, membrane homeostasis, and metabolism. Elucidation of these alterations in gene expression within the substantia nigra and VTA provides new insights into chronic changes in dopamine signaling post-TBI, and the potential role of EE in TBI rehabilitation.
C1 [Shin, Samuel S.; Bales, James W.; Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA.
[Shin, Samuel S.; Bales, James W.; Yan, Hong Q.; Kline, Anthony E.; Wagner, Amy K.; Dixon, C. Edward] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA.
[Shin, Samuel S.; Bales, James W.; Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA.
[Shin, Samuel S.; Bales, James W.; Yan, Hong Q.; Kline, Anthony E.; Wagner, Amy K.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.
[Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
[Kline, Anthony E.; Wagner, Amy K.; Dixon, C. Edward] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.
[Lyons-Weiler, James] Univ Pittsburgh, Genom & Prote Core Labs Bioinformat Anal Core, Pittsburgh, PA 15260 USA.
[Dixon, C. Edward] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Dixon, CE (reprint author), Univ Pittsburgh, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA.
EM dixonec@upmc.edu
OI Lyons-Weiler, James/0000-0001-9343-7508
FU National Institutes of Health (NIH) [R21NS047919, P01NS030318,
R01NS060672, 5F30NS067731-03]; Pittsburgh Copeland Foundation;
[R01NS060005]
FX This research was supported by National Institutes of Health (NIH)
grants R21NS047919, P01NS030318, R01NS060672, NIH F30 grant
5F30NS067731-03, and the Pittsburgh Copeland Foundation (CED), and
R01NS060005 (AEK).
NR 92
TC 9
Z9 10
U1 1
U2 12
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD FEB
PY 2013
VL 30
IS 4
BP 259
EP 270
DI 10.1089/neu.2012.2462
PG 12
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 093CM
UT WOS:000315169300003
PM 23094804
ER
PT J
AU Plank, RM
Kubiak, DW
Abdullahi, RB
Ndubuka, N
Nkgau, MM
Dapaah-Siakwan, F
Powis, KM
Lockman, S
AF Plank, Rebeca M.
Kubiak, David W.
Abdullahi, Rasak Bamidele
Ndubuka, Nnamdi
Nkgau, Maggie M.
Dapaah-Siakwan, Fredrick
Powis, Kathleen M.
Lockman, Shahin
TI Loss of anatomical landmarks with eutectic mixture of local anesthetic
cream for neonatal male circumcision
SO JOURNAL OF PEDIATRIC UROLOGY
LA English
DT Article
DE Male circumcision; Neonatal; EMLA; Eutectic mixture of local anesthetic;
Adverse events; Edema
ID RANDOMIZED CONTROLLED-TRIAL; PENILE NERVE BLOCK; LIDOCAINE-PRILOCAINE
CREAM; TOPICAL ANESTHESIA; HIV PREVENTION; EMLA CREAM;
METHEMOGLOBINEMIA; PAIN; INFECTION; ANALGESIA
AB We report two cases of newborns who developed marked local edema after application of a eutectic mixture of local anesthetic (EMLA) topical anesthetic cream for neonatal male circumcision (NMC). Although local edema and erythema are known potential side effects of EMLA cream, a common anesthetic used for NMC, the loss of landmarks precluding safe NMC has not previously been reported, and is described here. Although we cannot recommend an alternate local anesthetic for neonates with this reaction to EMLA, based on a review of the published data we think that serious systemic adverse events related to EMLA are extremely rare. (C) 2012 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
C1 [Plank, Rebeca M.; Kubiak, David W.; Lockman, Shahin] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Plank, Rebeca M.; Powis, Kathleen M.; Lockman, Shahin] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Plank, Rebeca M.; Abdullahi, Rasak Bamidele; Ndubuka, Nnamdi; Nkgau, Maggie M.; Powis, Kathleen M.; Lockman, Shahin] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana.
[Kubiak, David W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dapaah-Siakwan, Fredrick] Scottish Livingstone Hosp, Molepolole, Botswana.
[Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Dapaah-Siakwan, Fredrick] Albert Einstein Med Ctr, Dept Pediat, Philadelphia, PA 19141 USA.
RP Plank, RM (reprint author), 15 Francis St PBB A-4, Boston, MA 02115 USA.
EM rplank@partners.org
FU NIH from the National Institutes of Allergy and Infectious Diseases
[5K23AI084579]; President's Emergency Plan for AIDS Relief (PEPFAR)
[U2GPS000941-01, 08-P0157]
FX Supported by NIH 5K23AI084579 from the National Institutes of Allergy
and Infectious Diseases (Dr. Plank). The larger study was supported
through the President's Emergency Plan for AIDS Relief (PEPFAR) grant
U2GPS000941-01, Program No. 08-P0157. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of PEPFAR or the National Institutes of Health. The study
sponsors had no role in the study design, in the collection, analysis
and interpretation of data; in the writing of the manuscript; or in the
decision to submit the manuscript for publication.
NR 29
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-5131
J9 J PEDIATR UROL
JI J. Pediatr. Urol
PD FEB
PY 2013
VL 9
IS 1
BP E86
EP E90
DI 10.1016/j.jpurol.2012.09.013
PG 5
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 094SU
UT WOS:000315284900026
PM 23102766
ER
PT J
AU Villamar, MF
Fregni, F
AF Villamar, Mauricio F.
Fregni, Felipe
TI ON THE INSUFFICIENCY OF REPORTING MASKING RESPONSE
SO JOURNAL OF REHABILITATION MEDICINE
LA English
DT Letter
ID TRIALS
C1 [Villamar, Mauricio F.; Fregni, Felipe] Spaulding Rehabil Hosp, Lab Neuromodulat, Dept Phys Med & Rehabil, Boston, MA 02114 USA.
[Villamar, Mauricio F.; Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Villamar, Mauricio F.] Pontifical Catholic Univ Ecuador, Sch Med, Quito, Ecuador.
[Villamar, Mauricio F.] Spaulding Rehabil Hosp, Boston, MA 02114 USA.
RP Villamar, MF (reprint author), Spaulding Rehabil Hosp, Lab Neuromodulat, Dept Phys Med & Rehabil, Boston, MA 02114 USA.
EM Fregni.Felipe@mgh.harvard.edu
NR 5
TC 0
Z9 0
U1 0
U2 1
PU FOUNDATION REHABILITATION INFORMATION
PI UPPSALA
PA TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN
SN 1650-1977
J9 J REHABIL MED
JI J. Rehabil. Med.
PD FEB
PY 2013
VL 45
IS 2
BP 221
EP 222
PG 2
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 093GM
UT WOS:000315179700020
PM 23495381
ER
PT J
AU Schoenborn, NL
Arbaje, AI
Eubank, KJ
Maynor, K
Carrese, JA
AF Schoenborn, Nancy L.
Arbaje, Alicia I.
Eubank, Kathryn J.
Maynor, Kenric
Carrese, Joseph A.
TI Clinician Roles and Responsibilities During Care Transitions of Older
Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE care transitions; older adults; qualitative study; clinician roles;
healthcare professionals
ID HOSPITAL DISCHARGE; FOLLOW-UP; COMMUNICATION; PHYSICIANS; CONTINUITY;
TRIAL; OPPORTUNITIES; INTERVENTION; READMISSION; INFECTIONS
AB OBJECTIVES: To identify the perceived roles and responsibilities of clinicians during care transitions of older adults.
DESIGN: Qualitative study involving 1-hour in-depth semistructured interviews. Audiotapes of interviews were transcribed, coded, and analyzed, and themes and sub-themes were generated.
SETTING: An acute care hospital, a skilled nursing facility, two community-based outpatient practices, and one home healthcare agency.
PARTICIPANTS: Forty healthcare professionals directly involved in care transitions of older adults (18 physicians, 11 home healthcare administrative and field staff, four social workers, three nurse practitioners, three physician assistants, and one hospital case manager).
MEASUREMENTS: Perspectives of healthcare professionals regarding clinicians' roles and responsibilities during care transitions were examined and described.
RESULTS: Content analysis revealed several themes: components of clinicians' roles during care transitions; congruence between self- and others' perceived ideal roles but incongruence between ideal and routine roles; ambiguity in accountability in the postdischarge period; factors prompting clinicians to act closer to ideal roles; and barriers to performing ideal roles. A conceptual framework was created to summarize clinicians' roles during care transitions.
CONCLUSION: This study reports differences between what healthcare professionals perceive as ideal roles of clinicians during care transitions and what clinicians actually do routinely. Certain patient and clinician factors prompt clinicians to act closer to the ideal roles. Multiple barriers interfere with consistent practice of ideal roles. Future investigations could evaluate interventions targeting various components of the conceptual framework and relevant outcomes. J Am Geriatr Soc 61:231-236, 2013.
C1 [Schoenborn, Nancy L.; Arbaje, Alicia I.] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA.
[Eubank, Kathryn J.] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA USA.
[Maynor, Kenric] Geisinger Hlth Syst, Wyoming Valley Med Ctr, Dept Hospitalist Med, Wilkes Barre, PA USA.
[Carrese, Joseph A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
RP Schoenborn, NL (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Div Geriatr Med & Gerontol, 5200 Eastern Ave,Mason F Lord Bldg,Ctr Tower,Suit, Baltimore, MD 21224 USA.
EM nancyli@jhmi.edu
FU Robert Wood Johnson Foundation Clinical Scholars Program; Harold Amos
Medical Faculty Development Program
FX This project was supported by the Robert Wood Johnson Foundation
Clinical Scholars Program and Harold Amos Medical Faculty Development
Program.
NR 30
TC 9
Z9 9
U1 2
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2013
VL 61
IS 2
BP 231
EP 236
DI 10.1111/jgs.12084
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 094HY
UT WOS:000315254800008
PM 23320747
ER
PT J
AU Brown, AF
Vassar, SD
Connor, KI
Vickrey, BG
AF Brown, Arleen F.
Vassar, Stefanie D.
Connor, Karen I.
Vickrey, Barbara G.
TI Collaborative Care Management Reduces Disparities in Dementia Care
Quality for Caregivers with Less Education
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE dementia; caregivers; care management
ID NURSING-HOME PLACEMENT; ALZHEIMERS-DISEASE; OF-CARE; INTERVENTION;
OUTCOMES; HEALTH; PATIENT; BURDEN; INSTITUTIONALIZATION; PREDICTORS
AB OBJECTIVES: To examine educational gradients in dementia care and whether the effect of a dementia collaborative care management intervention varied according to the educational attainment of the informal caregiver,
DESIGN: Analysis of data from a cluster-randomized controlled trial.
SETTING: Eighteen clinics in three healthcare organizations in southern California.
PARTICIPANTS: Dyads of Medicare recipients aged 65 and older with a diagnosis of dementia and an eligible caregiver.
INTERVENTION: Collaborative care management for dementia.
MEASUREMENTS: Caregiver educational attainment, adherence to four dimensions of guideline-recommended processes of dementia care (assessment, treatment, education and support, and safety) before and after the intervention, and the adjusted intervention effect (IE) for each dimension stratified according to caregiver education. Each IE, was estimated by subtracting the difference between pre- and postintervention scores for the usual care participants from the difference between pre- and postintervention scores in the intervention participants.
RESULTS: At baseline, caregivers with lower educational attainment provided poorer quality of dementia care for the Treatment and Education dimensions than those with more education, but less-educated caregivers had significantly more improvement after the intervention on the assessment, treatment, and safety dimensions. The IEs for those who had not graduated from high school were 44.4 for the assessment dimension, 36.9 for the treatment dimension, and 52.7 for the safety dimension, versus 29.5, 15.7, and 40.9 respectively, for college graduates (P < .001 for all three).
CONCLUSIONS: Collaborative care management was associated with smaller disparities in dementia care quality between caregivers with lower educational attainment and those with more education. J Am Geriatr Soc 61:243-251, 2013.
C1 [Brown, Arleen F.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA.
[Vassar, Stefanie D.; Connor, Karen I.; Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Vassar, Stefanie D.; Connor, Karen I.; Vickrey, Barbara G.] Greater Los Angeles Vet Affairs Hlth Care Syst, Los Angeles, CA USA.
RP Brown, AF (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Plaza,Room 205, Los Angeles, CA 90024 USA.
EM abrown@mednet.ucla.edu
FU California Healthcare Foundation [99-3020]; State of California
Department of Aging [IG-0001-22]; State of California Department of
Health Services; Alzheimer's Disease Education Initiative [00-91, 316];
Archstone Foundation [00-04-37]; University of California at Los Angeles
(UCLA) Resource Centers for Minority Aging Research Center for Health
Improvement of Minority Elderly under National Institutes of Health,
National Institute on Aging [P30-AG021684]; UCLA/Drew Project EXPORT;
National Center on Minority Health and Health Disparities
[2P20MD000182]; National Center for Advancing Clinical Sciences; UCLA
Clinical and Translational Research Institute [UL1TR000124]
FX Funding for the original study was provided by the California Healthcare
Foundation (99-3020), the State of California Department of Aging
(IG-0001-22), the State of California Department of Health Services, the
Alzheimer's Disease Education Initiative (00-91,316), and the Archstone
Foundation (00-04-37). Dr. Brown received support from the University of
California at Los Angeles (UCLA) Resource Centers for Minority Aging
Research Center for Health Improvement of Minority Elderly under
National Institutes of Health, National Institute on Aging Grant
P30-AG021684, from UCLA/Drew Project EXPORT, National Center on Minority
Health and Health Disparities, 2P20MD000182, and from the National
Center for Advancing Clinical Sciences, UCLA Clinical and Translational
Research Institute, UL1TR000124. The content does not necessarily
represent the official views of the sponsoring organizations.
NR 28
TC 4
Z9 4
U1 2
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2013
VL 61
IS 2
BP 243
EP 251
DI 10.1111/jgs.12079
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 094HY
UT WOS:000315254800010
PM 23320655
ER
PT J
AU Koyama, A
Steinman, M
Ensrud, K
Hillier, TA
Yaffe, K
AF Koyama, Alain
Steinman, Michael
Ensrud, Kristine
Hillier, Teresa A.
Yaffe, Kristine
TI Ten-Year Trajectory of Potentially Inappropriate Medications in Very Old
Women: Importance of Cognitive Status
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE cognitive function; dementia; potentially inappropriate medication;
anticholinergic
ID CHOLINESTERASE-INHIBITORS; BENZODIAZEPINE USE; ELDERLY-PATIENTS;
CONTROLLED-TRIAL; BEERS CRITERIA; RISK-FACTORS; DRUG-USE;
ANTICHOLINERGICS; IMPAIRMENT; DEMENTIA
AB OBJECTIVES: To determine which older adults tend to receive potentially inappropriate medications (PIMs), how this may differ according to cognitive status, and how the trajectories of PIM use change over time.
DESIGN: Ten-year longitudinal cohort study.
SETTING: Three clinical sites in the United States.
PARTICIPANTS: One thousand four hundred eighty-four community-dwelling women aged 75 and older.
MEASUREMENTS: At follow-up, cognitive status was ascertained and classified as normal, mild cognitive impairment (MCI), or dementia. Beers 2003 criteria and other literature were used to identify PIMs from,detailed medication inventory performed at three time points. Anticholinergic load was measured using the Anticholinergic Cognitive Burden Scale (ACB), which assigns medications a value from 0 to 3 depending on anticholinergic properties.
RESULTS: At baseline, 23.9% of women were taking at least one PIM and the mean +/- SD ACB score was 1.41 +/- 1.69. The most frequently reported PIMs were anticholinergics (15.2%), benzodiazepines (8.6%), and antispasmodics (8.0%). Over 10 years, PIM use increased for women with dementia (24.9-33.1%; P = .02) but remained fairly constant for women with MCI (23.9-23.0%; P = .84) and normal cognitive status (22.2-19.8%; P = .17). Mean ACB score increased significantly (P < .001) over time for all groups (dementia: 1.28-2.05; MCI: 0.98-1.66; normal: 0.99-1.48).
CONCLUSION: PIM use and anticholinergic load in a community-dwelling population of older women was high, especially in women who later developed dementia. Future guidelines should limit PIM use and seek safer alternatives. J Am Geriatr Soc 61:258-263, 2013.
C1 [Koyama, Alain] No Calif Inst Res & Educ, San Francisco, CA USA.
[Koyama, Alain; Steinman, Michael; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Steinman, Michael] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Ensrud, Kristine] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Ensrud, Kristine] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Ensrud, Kristine] Minneapolis Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Hillier, Teresa A.] Kaiser Permanente Northwest Hawaii, Ctr Hlth Res, Honolulu, HI USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Koyama, A (reprint author), 4150 Clement St,VAMC 116H, San Francisco, CA 94121 USA.
EM alain.koyama@va.gov
FU National Institute of Aging (NIA) [K24 AG 031155, R01 AG 026720];
Alzheimer's Association [IIRG-08-88872]; National Institutes of Health
(NIH); NIA [R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01
AG005394, R01 AG027574, R01 AG027576]
FX Funded in part by Grants K24 AG 031155 and R01 AG 026720 from the
National Institute of Aging (NIA) and Grant IIRG-08-88872 from the
Alzheimer's Association. The Study of Osteoporotic Fractures is
supported by the National Institutes of Health (NIH). NIA provides
support under Grants R01 AG005407, R01 AR35582, R01 AR35583, R01
AR35584, R01 AG005394, R01 AG027574, and R01 AG027576.
NR 30
TC 16
Z9 16
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2013
VL 61
IS 2
BP 258
EP 263
DI 10.1111/jgs.12093
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 094HY
UT WOS:000315254800012
PM 23320787
ER
PT J
AU Thai, JN
Walter, LC
Eng, C
Smith, AK
AF Thai, Julie N.
Walter, Louise C.
Eng, Catherine
Smith, Alexander K.
TI Every Patient Is an Individual: Clinicians Balance Individual Factors
When Discussing Prognosis with Diverse Frail Elderly Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE prognosis; geriatrics; end of life
ID DECISION-MAKING; OLDER; LIFE; END; COMMUNICATION; MAMMOGRAPHY; BURDENS;
WOMEN; CARE; AGE
AB BACKGROUND: To explore clinician choice of whether to discuss prognosis with their frail older patients.
DESIGN: Qualitative interview study.
SETTING: Primary care clinicians were recruited from nursing homes, community-based clinics, and academic medical centers.
PARTICIPANTS: Three geriatric nurse practitioners, nine geriatricians, five general internists, and three family medicine physicians with a mean age of 44 and a mean 12 years in practice. Seventeen clinicians had patient panels with 80% or more community-dwelling outpatients, 13 had patient panels with 50% or more patients aged 85 and older, and 16 had patient panels with 25% or more of patients in a minority group (Asian, African American, Hispanic).
MEASUREMENTS: Clinicians were asked to describe their practice of discussing long-term (<5-year) and short-term (<1-year and 3-month) prognosis. Responses were analyzed qualitatively using constant comparison until thematic saturation was reached.
RESULTS: Clinicians reported individualizing the decision to discuss prognosis with their frail older patients based on clinical circumstances. Common reasons for discussing prognosis included patient had a specific condition with a limited prognosis, to give patients time to prepare, to promote informed medical decision-making, and when patients or families prompted the conversation. Common reasons not to discuss included maintaining hope and avoiding anxiety, cognitive impairment or patient unable to understand prognosis, respect for patients' cultural values, and long-term prognosis too uncertain to be useful.
CONCLUSION: Clinicians caring for frail older adults are generally willing to discuss short- but not long-term prognosis. Clinicians balance individual factors when deciding whether to discuss prognosis. J Am Geriatr Soc 61:264-269, 2013.
C1 [Thai, Julie N.; Walter, Louise C.; Eng, Catherine; Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94121 USA.
[Thai, Julie N.; Walter, Louise C.; Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Eng, Catherine] On Lok Lifeways, San Francisco, CA USA.
RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 4150 Clement St 181G, San Francisco, CA 94121 USA.
EM aksmith@ucsf.edu
FU Center for Aging in Diverse Communities of the Resource Centers for
Minority Aging Research program [P30-AG15272]; National Institute on
Aging, National Institutes of Health; National Center for Research
Resources UCSF-CTSI [UL1 RR024131]; Atlantic Philanthropies; Society of
General Internal Medicine; John A. Hartford Foundation; Association of
Specialty Professors
FX Dr. Smith was supported by pilot Grant P30-AG15272 from the Center for
Aging in Diverse Communities of the Resource Centers for Minority Aging
Research program funded by the National Institute on Aging, National
Institutes of Health. The National Center for Research Resources
UCSF-CTSI (UL1 RR024131), Atlantic Philanthropies, the Society of
General Internal Medicine, the John A. Hartford Foundation, and the
Association of Specialty Professors provided additional support.
NR 17
TC 8
Z9 8
U1 0
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2013
VL 61
IS 2
BP 264
EP 269
DI 10.1111/jgs.12098
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 094HY
UT WOS:000315254800013
PM 23320808
ER
PT J
AU Vorasubin, N
Wu, AW
Day, C
Suh, JD
AF Vorasubin, Nopawan
Wu, Arthur W.
Day, Christina
Suh, Jeffrey D.
TI Invasive sinonasal actinomycosis: Case Report and Literature Review
SO LARYNGOSCOPE
LA English
DT Article
DE sinonasal actinomycosis; cervicofacial actinomycosis
ID SINUS ACTINOMYCOSIS; MAXILLARY SINUS; MANAGEMENT; INFECTION
AB Actinomycosis is a rare anaerobic bacterial infection typically caused by Actinomyces israelii. Although part of normal flora in the oral cavity, and respiratory and digestive tracts, A israelii can give rise to pathologic infections most commonly reported in the oral cavity from odontogenic causes. We present a rare case of invasive actinomycosis presenting with extensive midface destruction involving the maxilla and paranasal sinuses, with mucosal necrosis mimicking an aggressive neoplasm. The diagnosis is usually reached only after histopathologic analysis showing characteristic sulfur granules with filamentous gram-positive, nonacid-fast bacteria. We review the literature on its epidemiology, clinical presentation, diagnosis, treatment, and prognosis.
C1 [Vorasubin, Nopawan; Wu, Arthur W.; Suh, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.
[Day, Christina] W Los Angeles Vet Affairs Hosp, Dept Pathol, Los Angeles, CA USA.
RP Vorasubin, N (reprint author), 10833 Le Conte Ave,62-132 CHS, Los Angeles, CA 90095 USA.
EM nvorasubin@mednet.ucla.edu
NR 24
TC 5
Z9 5
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD FEB
PY 2013
VL 123
IS 2
BP 334
EP 338
DI 10.1002/lary.23477
PG 5
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 090NH
UT WOS:000314985400009
PM 23008010
ER
PT J
AU Lakhani, KR
Boudreau, KJ
Loh, PR
Backstrom, L
Baldwin, C
Lonstein, E
Lydon, M
MacCormack, A
Arnaout, RA
Guinan, EC
AF Lakhani, Karim R.
Boudreau, Kevin J.
Loh, Po-Ru
Backstrom, Lars
Baldwin, Carliss
Lonstein, Eric
Lydon, Mike
MacCormack, Alan
Arnaout, Ramy A.
Guinan, Eva C.
TI Prize-based contests can provide solutions to computational biology
problems
SO NATURE BIOTECHNOLOGY
LA English
DT Letter
ID FOLDING GAME PLAYERS; INNOVATION CONTESTS; SEARCH; SYSTEM
C1 [Lakhani, Karim R.; Baldwin, Carliss; Lonstein, Eric; MacCormack, Alan] Harvard Univ, Sch Business, Boston, MA 02163 USA.
[Lakhani, Karim R.; Boudreau, Kevin J.] Harvard NASA Tournament Lab, Inst Quantitat Social Sci, Boston, MA USA.
[Boudreau, Kevin J.] London Business Sch, London NW1 4SA, England.
[Loh, Po-Ru] MIT, Dept Math & Comp Sci, Cambridge, MA 02139 USA.
[Loh, Po-Ru] MIT, Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Backstrom, Lars; Lydon, Mike] TopCoder Com, Glastonbury, CT USA.
[Arnaout, Ramy A.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
[Arnaout, Ramy A.] Beth Israel Deaconess Med Ctr, Div Clin Informat, Dept Med, Boston, MA 02215 USA.
[Arnaout, Ramy A.; Guinan, Eva C.] Harvard Univ, Sch Med, Boston, MA USA.
[Guinan, Eva C.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Lakhani, KR (reprint author), Harvard Univ, Sch Business, Boston, MA 02163 USA.
EM eva_guinan@dfci.harvard.edu
RI Boudreau, Kevin/A-1036-2015
OI Boudreau, Kevin/0000-0002-9029-8247
FU NCRR NIH HHS [5UL1RR025758, 5UL1RR025758-S, UL1 RR025758]
NR 27
TC 41
Z9 41
U1 1
U2 35
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD FEB
PY 2013
VL 31
IS 2
BP 108
EP 111
DI 10.1038/nbt.2495
PG 4
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 095GG
UT WOS:000315322100014
PM 23392504
ER
PT J
AU Weiner, MW
AF Weiner, Michael W.
TI Further insights into Alzheimer disease pathogenesis
SO NATURE REVIEWS NEUROLOGY
LA English
DT Editorial Material
ID PRIONS; TAU
AB In 2012, studies of autosomal dominant Alzheimer disease (AD), late-onset AD, and a rare genetic mutation of amyloid precursor protein provided support for the critical role of amyloid in AD pathogenesis. Increasing evidence implicated cell-to-cell transmission in the spread of tau and amyloid, highlighting novel targets for therapeutic intervention. Weiner, M. W. Nat. Rev. Neurol. 9, 65-66 (2013); published online 22 January 2013; doi:10.1038/nrneurol.2012.275
C1 Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, Dept Radiol, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Weiner, MW (reprint author), Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, Dept Radiol, San Francisco VA Med Ctr, 4150 Clement St 114M, San Francisco, CA 94121 USA.
EM michael.weiner@ucsf.edu
NR 8
TC 17
Z9 19
U1 1
U2 25
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD FEB
PY 2013
VL 9
IS 2
BP 65
EP 66
DI 10.1038/nrneurol.2012.275
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 094GG
UT WOS:000315250400002
PM 23338285
ER
PT J
AU Kenton, K
Mueller, ER
Tarnay, C
Brubaker, L
Rosenman, A
Smith, B
Stroupe, K
Bresee, C
Anger, JT
AF Kenton, Kimberly
Mueller, Elizabeth R.
Tarnay, Christopher
Brubaker, Linda
Rosenman, Amy
Smith, Bridget
Stroupe, Kevin
Bresee, Catherine
Anger, Jennifer T.
TI COMPARATIVE EFFECTIVENESS OF ROBOTIC AND LAPAROSCOPIC SACROCOLPOPEXY FOR
APICAL VAGINAL PROLAPSE: ONE YEAR OUTCOMES
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU)
CY FEB 26-MAR 02, 2013
CL Las Vegas, NV
SP Soc Urodynam & Female Urol (SUFU)
C1 [Kenton, Kimberly; Mueller, Elizabeth R.; Brubaker, Linda] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
[Tarnay, Christopher; Rosenman, Amy] UCLA Med Ctr, Los Angeles, CA USA.
[Smith, Bridget; Stroupe, Kevin] US Dept Vet Affairs, Hines, IL USA.
[Bresee, Catherine; Anger, Jennifer T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
RI Bresee, Catherine/A-9148-2015
OI Bresee, Catherine/0000-0002-5710-4906
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2013
VL 32
IS 2
BP 112
EP 113
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 093WG
UT WOS:000315223200016
ER
PT J
AU Cristofaro, V
Yalla, SV
Sullivan, MP
AF Cristofaro, Vivian
Yalla, Subbarao V.
Sullivan, Maryrose P.
TI REGULATION OF BLADDER SPONTANEOUS ACTIVITY BY INTERACTION OF CAVEOLAE
AND PURINERGIC (P2X) RECEPTORS
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU)
CY FEB 26-MAR 02, 2013
CL Las Vegas, NV
SP Soc Urodynam & Female Urol (SUFU)
C1 [Cristofaro, Vivian; Yalla, Subbarao V.; Sullivan, Maryrose P.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2013
VL 32
IS 2
BP 124
EP 125
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 093WG
UT WOS:000315223200044
ER
PT J
AU Wang, ZW
Cheng, ZY
Cristofaro, V
Sullivan, M
White, M
Olumi, A
AF Wang, Zongwei
Cheng, Zhiyong
Cristofaro, Vivian
Sullivan, Maryrose
White, Morris
Olumi, Aria
TI UROTHELIUM RELEASED ATP CONTRIBUTES TO BLADDER DYSFUNCTION IN TYPE 2
DIABETES
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU)
CY FEB 26-MAR 02, 2013
CL Las Vegas, NV
SP Soc Urodynam & Female Urol (SUFU)
C1 [Wang, Zongwei; Olumi, Aria] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cheng, Zhiyong; White, Morris] Childrens Hosp Boston, Div Endocrinol, Howard Hughes Med Inst, Boston, MA USA.
[Cristofaro, Vivian; Sullivan, Maryrose] VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2013
VL 32
IS 2
BP 127
EP 127
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 093WG
UT WOS:000315223200049
ER
PT J
AU Munoz, A
Boone, TB
Smith, CP
Salas, NA
Somogyi, GT
AF Munoz, Alvaro
Boone, Timothy B.
Smith, Christopher P.
Salas, Nilson A.
Somogyi, George T.
TI BLADDER OVERACTIVITY FOLLOWING SPINAL CORD INJURY IS IMPROVED BY
INCREASING NITRIC OXIDE LEVELS
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU)
CY FEB 26-MAR 02, 2013
CL Las Vegas, NV
SP Soc Urodynam & Female Urol (SUFU)
C1 [Munoz, Alvaro; Boone, Timothy B.; Salas, Nilson A.] Methodist Hosp, Res Inst, Houston, TX 77030 USA.
[Munoz, Alvaro; Smith, Christopher P.; Salas, Nilson A.; Somogyi, George T.] Baylor Coll Med, Houston, TX 77030 USA.
[Boone, Timothy B.; Smith, Christopher P.] VA Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2013
VL 32
IS 2
BP 128
EP 129
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 093WG
UT WOS:000315223200053
ER
PT J
AU Munoz, A
Boone, TB
Sun, YX
AF Munoz, Alvaro
Boone, Timothy B.
Sun, Yuxiang
TI GHRELIN-SIGNALING AFFECTS NEURALLY EVOKED BLADDER CONTRACTIONS BUT NOT
DETRUSOR PERFORMANCE
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU)
CY FEB 26-MAR 02, 2013
CL Las Vegas, NV
SP Soc Urodynam & Female Urol (SUFU)
C1 [Munoz, Alvaro; Boone, Timothy B.] Methodist Hosp, Res Inst, Houston, TX 77030 USA.
[Munoz, Alvaro; Sun, Yuxiang] Baylor Coll Med, Houston, TX 77030 USA.
[Boone, Timothy B.] VA Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2013
VL 32
IS 2
BP 134
EP 134
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 093WG
UT WOS:000315223200064
ER
PT J
AU Cristofaro, V
Chaudhury, A
Goyal, RK
Sullivan, MP
AF Cristofaro, Vivian
Chaudhury, Arun
Goyal, Raj K.
Sullivan, Maryrose P.
TI IMPAIRED PURINERGIC NEUROTRANSMISSION IN MYOSINVA DEFICIENT MOUSE
BLADDERS
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU)
CY FEB 26-MAR 02, 2013
CL Las Vegas, NV
SP Soc Urodynam & Female Urol (SUFU)
C1 [Cristofaro, Vivian; Chaudhury, Arun; Goyal, Raj K.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Cambridge, MA 02138 USA.
[Sullivan, Maryrose P.] VA Boston Healthcare, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2013
VL 32
IS 2
BP 136
EP 137
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 093WG
UT WOS:000315223200069
ER
PT J
AU Polland, A
Meckel, K
Trop, C
AF Polland, Allison
Meckel, Katherine
Trop, Cynthia
TI INCIDENCE OF PLACEMENT AND REMOVAL OR REVISION OF TRANSVAGINAL MESH FOR
PROLAPSE AND STRESS URINARY INCONTINENCE BEFORE AND AFTER THE 2011 FDA
NOTIFICATION
SO NEUROUROLOGY AND URODYNAMICS
LA English
DT Meeting Abstract
CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU)
CY FEB 26-MAR 02, 2013
CL Las Vegas, NV
SP Soc Urodynam & Female Urol (SUFU)
C1 [Polland, Allison] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Meckel, Katherine] Columbia Univ, New York, NY USA.
[Trop, Cynthia] James J Peters VA Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2467
J9 NEUROUROL URODYNAM
JI Neurourol. Urodyn.
PD FEB
PY 2013
VL 32
IS 2
BP 200
EP 200
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 093WG
UT WOS:000315223200215
ER
PT J
AU Shen, C
Kaelin, WG
AF Shen, Chuan
Kaelin, William G., Jr.
TI The VHL/HIF axis in clear cell renal carcinoma
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Review
DE Kidney cancer; von Hippel-Lindau; Hypoxia; Angiogenesis; VEGF
ID HYPOXIA-INDUCIBLE FACTOR; EPIDERMAL-GROWTH-FACTOR;
HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR GENE; PHASE-II TRIAL;
OXYGEN-SENSING PATHWAY; MYELOID-LEUKEMIC-CELLS; PAS DOMAIN PROTEIN;
FACTOR RECEPTOR; FACTOR-ALPHA
AB Inactivation of the VHL tumor suppressor protein (pVHL) is a common event in clear cell renal carcinoma, which is the most common form of kidney cancer. pVHL performs many functions, including serving as the substrate recognition module of an ubiquitin ligase complex that targets the alpha subunits of the heterodimeric HIF transcription factor for proteasomal degradation. Deregulation of HIF2 alpha appears to be a driving force in pVHL-defective clear cell renal carcinomas. In contrast, genetic and functional studies suggest that HIFI a serves as a tumor suppressor and is a likely target of the 14q deletions that are characteristic of this tumor type. Drugs that inhibit HIF2 alpha, or its downstream targets such as VEGF, are in various stages of clinical testing. Indeed, clear cell renal carcinomas are exquisitely sensitive to VEGF deprivation and four VEGF inhibitors have now been approved for the treatment of this disease. (C) 2012 Elsevier Ltd. All rights reserved.
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02215 USA.
RP Kaelin, WG (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Mayer 457, Boston, MA 02215 USA.
EM William_kaelin@dfci.harvard.edu
FU NIH; HHMI; Doris Duke Foundation
FX Funding; NIH, HHMI, Doris Duke Foundation.
NR 144
TC 90
Z9 93
U1 8
U2 23
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044-579X
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD FEB
PY 2013
VL 23
IS 1
BP 18
EP 25
DI 10.1016/j.semcancer.2012.06.001
PG 8
WC Oncology
SC Oncology
GA 094CI
UT WOS:000315240200004
PM 22705278
ER
PT J
AU Gunn, AJ
Iqbal, SI
Kalva, SP
Walker, TG
Ganguli, S
Salazar, GM
Oklu, R
Wicky, S
AF Gunn, Andrew J.
Iqbal, Shams I.
Kalva, Sanjeeva P.
Walker, T. Gregory
Ganguli, Suvranu
Salazar, Gloria M.
Oklu, Rahmi
Wicky, Stephan
TI Intravascular Ultrasound-Guided Inferior Vena Cava Filter Placement
Using a Single-Puncture Technique in 99 Patients
SO VASCULAR AND ENDOVASCULAR SURGERY
LA English
DT Article
DE IVC filter; intravascular ultrasound; deep vein thrombosis; pulmonary
embolism
ID INTENSIVE-CARE-UNIT; TRAUMA PATIENTS; PULMONARY-EMBOLISM; BEDSIDE
INSERTION; MULTIPLE-TRAUMA; RENAL VEINS; CAVOGRAPHY; EXPERIENCE;
PREVENTION; GUIDELINES
AB Purpose: To assess the feasibility and safety of intravascular ultrasound (IVUS) to guide inferior vena cava (IVC) filter placement using a single venous puncture technique. Materials and Methods: Medical records of all patients who had IVC filters placed under IVUS guidance between January 1, 2005 and December 31, 2011 were retrospectively reviewed for pertinent history, results, and complications. All filters were placed using a single venous puncture technique. Results: Filters were successfully placed within the IVC in 94% of the patients with 6 malpositioned filters (4 in the iliac veins and 2 in the suprarenal IVC). Complications included groin hematoma (4%), deep venous thrombosis at the site of vascular access (2%), and filter tilt >15 degrees along the long axis of the IVC (2%). Conclusions: The IVUS-guided IVC filter placement using a single venous puncture technique is technically feasible and safe when compared to case series using a double venous puncture technique.
C1 [Gunn, Andrew J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Gunn, Andrew J.; Kalva, Sanjeeva P.; Walker, T. Gregory; Ganguli, Suvranu; Salazar, Gloria M.; Oklu, Rahmi; Wicky, Stephan] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Iqbal, Shams I.] Lahey Clin Fdn, Dept Radiol, Burlington, MA USA.
[Kalva, Sanjeeva P.; Walker, T. Gregory; Ganguli, Suvranu; Salazar, Gloria M.; Oklu, Rahmi; Wicky, Stephan] Massachusetts Gen Hosp, Div Vasc Imaging & Intervent, Dept Radiol, Boston, MA 02114 USA.
RP Gunn, AJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, FND 216,55 Fruit St, Boston, MA 02114 USA.
EM agunn@partners.org
NR 22
TC 2
Z9 3
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1538-5744
J9 VASC ENDOVASC SURG
JI Vasc. Endovasc. Surg.
PD FEB
PY 2013
VL 47
IS 2
BP 97
EP 101
DI 10.1177/1538574412473186
PG 5
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 094SY
UT WOS:000315285300003
PM 23315196
ER
PT J
AU Reisner, AT
Heldt, T
AF Reisner, Andrew T.
Heldt, Thomas
TI A computational model of hemorrhage and dehydration suggests a
pathophysiological mechanism: Starling-mediated protein trapping
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE circulation; computer model; interstitial fluid; lymphatics; hemorrhage
ID BLOOD-VOLUME; MATHEMATICAL-MODEL; UNCONTROLLED HEMORRHAGE;
HEMODYNAMIC-RESPONSE; FLUID RESUSCITATION; PLASMA-VOLUME; TRAUMA DEATHS;
RESTITUTION; SHOCK; EPIDEMIOLOGY
AB Reisner AT, Heldt T. A computational model of hemorrhage and dehydration suggests a pathophysiological mechanism: Starling-mediated protein trapping. Am J Physiol Heart Circ Physiol 304: H620-H631, 2013. First published November 30, 2012; doi:10.1152/ajpheart.00621.2012.-We sought to understand the degree to which a single computational cardiovascular model could replicate the typical responses of healthy subjects through a breadth of blood loss patterns and whether such a model could illuminate the cause-effect relationships that underlie the observed responses. The model consisted of compartments for the upper body, lower body, viscera, and kidneys as well as a four-chambered heart and a pulmonary compartment. Transcapillary fluid flux was governed by Starling forces, whereas lymphatic flow was driven by hydrostatic tissue pressure and scaled by a lymphatic activation term. We adjusted parameters based on results from one protocol involving moderate continual blood loss in a canine model. Next, we simulated six additional protocols spanning euvolemic and dehydrated subjects and compared in silico behavior with in vivo hemodynamic responses and fluid shifts. The model was able to replicate group-averaged behavior (i.e., within 1 or 2 SEs) of the rate and quantity of vascular refill and the associated cardiac output during slow, moderate, and rapid ongoing blood losses, the restitution after the cessation of blood loss, and the absence of restitution in dehydrated subjects. The model suggested that the earlier phase of restitution, i.e., transcapillary fluid shifts, was antagonistic to the later phase of restitution, i.e., protein return via lymphatics. This phenomenon was termed "interstitial protein trapping." In conclusion, the model appears valid for a range of blood loss patterns and prehydration states. Further investigation into the in vivo relevance of interstitial protein trapping is justified.
C1 [Reisner, Andrew T.] MIT, Div Hlth Sci & Technol, Boston, MA USA.
[Reisner, Andrew T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Reisner, Andrew T.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Heldt, Thomas] MIT, Elect Res Lab, Computat Physiol & Clin Inference Grp, Cambridge, MA 02139 USA.
RP Reisner, AT (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA.
EM Areisner@partners.org
NR 39
TC 0
Z9 0
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD FEB
PY 2013
VL 304
IS 4
BP H620
EP H631
DI 10.1152/ajpheart.00621.2012
PG 12
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA 092SE
UT WOS:000315141500013
PM 23203962
ER
PT J
AU Krishnan, JA
Lindenauer, PK
Au, DH
Carson, SS
Lee, TA
McBurnie, MA
Naureckas, ET
Vollmer, WM
Mularski, RA
AF Krishnan, Jerry A.
Lindenauer, Peter K.
Au, David H.
Carson, Shannon S.
Lee, Todd A.
McBurnie, Mary Ann
Naureckas, Edward T.
Vollmer, William M.
Mularski, Richard A.
TI Stakeholder Priorities for Comparative Effectiveness Research in Chronic
Obstructive Pulmonary Disease A Workshop Report
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE health services research; research priorities; care coordination;
stakeholders
ID COPD
AB Comparative effectiveness research (CER) is intended to address the expressed needs of patients, clinicians, and other stakeholders. Representatives of 54 stakeholder groups with an interest in chronic obstructive pulmonary disease (COPD) participated in workshops convened by the COPD Outcomes-based Network for Clinical Effectiveness and Research Translation (CONCERT) over a 2-year period. Year 1 focused on chronic care and care coordination. Year 2 focused on acute care and transitions in care between healthcare settings. Discussions and provisional voting were conducted via teleconferences and e-mail exchanges before the workshop. Final prioritization votes occurred after in-person discussions at the workshop. We used a modified Delphi approach to facilitate discussions and consensus building. To more easily quantify preferences and to evaluate the internal consistency of rankings, the Analytic Hierarchy Process was incorporated in Year 2. Results of preworkshop and final workshop voting often differed, suggesting that prioritization efforts relying solely on requests for topics from stakeholder groups without in-person discussion may provide different research priorities. Research priorities varied across stakeholder groups, but generally focused on studies to evaluate different approaches to healthcare delivery (e.g., spirometry for diagnosis and treatment, integrated healthcare strategies during transitions in care) rather than head-to-head comparisons of medications. This research agenda may help to inform groups intending to respond to CER funding opportunities in COPD. The methodologies used, detailed in the online supplement, may also help to inform prioritization efforts for CER in other health conditions.
C1 [Krishnan, Jerry A.; Lee, Todd A.] Univ Illinois, Chicago, IL 60612 USA.
[Lindenauer, Peter K.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA USA.
[Lindenauer, Peter K.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Au, David H.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Au, David H.] Univ Washington, Seattle, WA 98195 USA.
[Carson, Shannon S.] Univ N Carolina, Div Pulm & Crit Care Med, Chapel Hill, NC USA.
[McBurnie, Mary Ann; Vollmer, William M.; Mularski, Richard A.] Kaiser Permanente Ctr Hlth Res, Ctr Hlth Res, Portland, OR USA.
[Naureckas, Edward T.] Univ Illinois, Sect Pulm & Crit Care, Chicago, IL 60612 USA.
RP Krishnan, JA (reprint author), Univ Illinois, Hosp & Hlth Sci Syst, Med Ctr Adm Bldg,MC 973,914 S Wood St, Chicago, IL 60612 USA.
EM jakris@uic.edu
FU Agency for Healthcare Research and Quality [AHRQ R13 HS017894]; National
Institutes of Health/National Heart, Lung, and Blood Institute
[NIH/NHLBI RC2 HL1011618]; Health Services Research and Development,
Department of Veterans Affairs
FX Supported by Agency for Healthcare Research and Quality grant AHRQ R13
HS017894 and National Institutes of Health/National Heart, Lung, and
Blood Institute grant NIH/NHLBI RC2 HL1011618. D.H.A. is supported
through Health Services Research and Development, Department of Veterans
Affairs.
NR 16
TC 15
Z9 17
U1 0
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 1
PY 2013
VL 187
IS 3
BP 320
EP 326
DI 10.1164/rccm.201206-0994WS
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 088TT
UT WOS:000314860700014
PM 23155144
ER
PT J
AU Miller, YE
Karoor, V
Dempsey, EC
AF Miller, York E.
Karoor, Vijaya
Dempsey, Edward C.
TI Sleep-disordered Breathing, Hypoxemia, and Cancer Mortality
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Letter
ID DISEASE; MECHANISM; APNEA
C1 [Miller, York E.] Denver Vet Affairs Med Ctr, Denver, CO USA.
Univ Colorado Denver, Aurora, CO USA.
RP Miller, YE (reprint author), Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 6
TC 4
Z9 4
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD FEB 1
PY 2013
VL 187
IS 3
BP 330
EP 331
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 088TT
UT WOS:000314860700021
PM 23378442
ER
PT J
AU Dording, CM
LaRocca, RA
Hails, KA
Vitolo, OV
Wisniewski, SR
Balasubramani, GK
Trivedi, M
Fava, M
Mischoulon, D
AF Dording, Christina M.
LaRocca, Rachel A.
Hails, Katherine A.
Vitolo, Ottavio V.
Wisniewski, Stephen R.
Balasubramani, Goundappa K.
Trivedi, Madhukar
Fava, Maurizio
Mischoulon, David
TI The effect of sildenafil on quality of life
SO ANNALS OF CLINICAL PSYCHIATRY
LA English
DT Article
DE major depressive disorder; sexual dysfunction; antidepressant; libido;
sildenafil; quality of life
ID INDUCED SEXUAL DYSFUNCTION; ERECTILE DYSFUNCTION; DOUBLE-BLIND;
QUESTIONNAIRE; OUTPATIENTS; TRIAL
AB BACKGROUND: Antidepressant-induced sexual dysfunction affects approximately 50% of patients taking antidepressants. Previous research has explored sildenafil's effectiveness in treating various forms of erectile dysfunction, but there is no research supporting sildenafil's use for improving the quality of life for patients with sexual dysfunction linked to antidepressant use. The authors of this article aimed to assess the improvements in quality of life in patients taking sildenafil to treat antidepressant-induced sexual dysfunction.
METHODS: One hundred and two out of 2,239 male and female patients in the follow-up phase of the Sequenced Treatment Alternatives to Relieve Depression antidepressant trials who complained of sexual dysfunction were given sildenafil, 50 to 100 mg, as needed. After 12 months, we measured patients' change in libido, sexual drive, family relationships, overall well-being, satisfaction with treatment, and overall contentment with items on the 17-item Hamilton Depression Rating Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, 30-item Inventory of Depressive Symptoms, and 12-item Short Form Health Survey.
RESULTS: There was a significant association between sildenafil use and improvement in libido and sexual drive by month 6. There was no significant improvement in the quality-of-life scores we examined, but treatment satisfaction and overall contentment increased over time.
CONCLUSIONS: Despite no direct association with sildenafil use and quality-of-life scores, sildenafil may be a beneficial treatment for antidepressant-induced sexual dysfunction. A double-blind, placebo-controlled study of sildenafil in antidepressant-induced sexual dysfunction is needed to further explore its potential benefits.
C1 [Dording, Christina M.; LaRocca, Rachel A.; Hails, Katherine A.; Vitolo, Ottavio V.; Fava, Maurizio; Mischoulon, David] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
[Wisniewski, Stephen R.; Balasubramani, Goundappa K.] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA USA.
[Trivedi, Madhukar] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
RP Dording, CM (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM cdording@partners.org
OI Wisniewski, Stephen/0000-0002-3877-9860; Goundappa K,
Balasubramani/0000-0001-7221-1825
FU Abbott Laboratories; Alkermes, Inc.; Aspect Medical Systems;
AstraZeneca; BioResearch; BrainCells, Inc.; Bristol-Myers Squibb; CeNeRx
BioPharma; Cephalon; Clinical Trials Solutions; Clintara; Covance;
Covidien; Eli Lilly and Company; ElMindA; EnVivo Pharmaceuticals;
Euthymics Bioscience; Forest Pharmaceuticals; Ganeden Biotech;
GlaxoSmithKline; Icon Clinical Research; i3 Innovus/Ingenix; Johnson &
Johnson Pharmaceutical Research and Development; Lichtwer Pharma; Lorex
Pharmaceuticals; National Alliance for Research on Schizophrenia and
Depression (NARSAD); National Center for Complementary and Alternative
Medicine (NCCAM); National Institute on Drug Abuse (NIDA); National
Institute of Mental Health (NIMH); Novartis; Organon Pharmaceuticals;
PamLab, LLC; Pfizer, Inc.; Pharmavite; Photothera; Roche
Pharmaceuticals; RCT Logic; sanofi-aventis; Shire; Solvay
Pharmaceutical; Synthelabo; Wyeth-Ayerst Laboratories; Clinical
Investigator Training Program at Beth Israel Deaconess Medical Center,
Harvard Medical School; Merck; Ibdi Ibrahim; Agency for Healthcare
Research and Quality; Akzo (Organon Pharmaceuticals); Axon Advisors;
Corcept Therapeutics; Cyberonics; Evotek; Fabre-Kramer Pharmaceuticals;
Janssen Pharmaceutica; Libby; Lundbeck, Inc.; Meade Johnson; MedAvante;
Medtronic; NARSAD; Naurex; Neuronetics; NIDA; NIMH; Otsuka
Pharmaceuticals; Parke-Davis Pharmaceuticals; PgxHealth; Pharmacia
Upjohn; Predix Pharmaceuticals; Rexahn Pharmaceuticals; Sepracor; Shire
Development; Sierra; SK Life and Science; Solvay Pharmaceuticals; Takeda
Pharmaceutical Company Limited; Tai Medical/Puretech Venture; Targacept;
Transcept; Valient; VantagePoint; BrainCells Inc.; CeNeRx Bio Pharma;
Clinical Trials Solutions, LLC; Clintara, LLC; ElMindA, Ltd.; EnVivo
Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest
Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; Johnson & Johnson
Pharmaceutical Research Development; Lichtwer Pharma GmbH; NCCAM;
Novartis AG; Pharmavite LLC; RCT Logic, LLC; Solvay Pharmaceuticals,
Inc.; Bowman Family Foundation; FisherWallace; Nordic Naturals;
NIMH/National Institutes of Health [N01MH90003]
FX Dr. Dording has received research support from Abbott Laboratories,
Alkermes, Inc., Aspect Medical Systems, AstraZeneca, BioResearch,
BrainCells, Inc., Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon,
Clinical Trials Solutions, Clintara, Covance, Covidien, Eli Lilly and
Company, ElMindA, EnVivo Pharmaceuticals, Euthymics Bioscience, Forest
Pharmaceuticals, Ganeden Biotech, GlaxoSmithKline, Icon Clinical
Research, i3 Innovus/Ingenix, Johnson & Johnson Pharmaceutical Research
and Development, Lichtwer Pharma, Lorex Pharmaceuticals, National
Alliance for Research on Schizophrenia and Depression (NARSAD), National
Center for Complementary and Alternative Medicine (NCCAM), National
Institute on Drug Abuse (NIDA), National Institute of Mental Health
(NIMH), Novartis, Organon Pharmaceuticals, PamLab, LLC, Pfizer, Inc.,
Pharmavite, Photothera, Roche Pharmaceuticals, RCT Logic,
sanofi-aventis, Shire, Solvay Pharmaceutical, Synthelabo, and
Wyeth-Ayerst Laboratories; has served as an advisor or consultant to
Takeda; and has been a speaker for Wyeth-Ayerst Laboratories. Dr. Vitolo
receives grant or research support from the Clinical Investigator
Training Program at Beth Israel Deaconess Medical Center, Harvard
Medical School, funded in part by an unrestricted educational grant from
Merck and Pfizer, Inc. Dr. Wisniewski is a consultant to Bristol-Myers
Squibb, Case Western Reserve University, Cyberonic, Dey Pharmaceuticals,
ImaRx Therapeutics, Organon Pharmaceuticals, Singapore Clinical Research
Institute, and Venebio. Dr. Trivedi received research support from or
has been a consultant or speaker for Abbott Laboratories, Ibdi Ibrahim,
Agency for Healthcare Research and Quality, Akzo (Organon
Pharmaceuticals), Alkermes, Inc., AstraZeneca, Axon Advisors,
Bristol-Myers Squibb, Cephalon, Corcept Therapeutics, Cyberonics, Eli
Lilly and Company, Evotek, Fabre-Kramer Pharmaceuticals, Forest
Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Johnson &
Johnson Pharmaceutical Research and Development, Libby, Lundbeck, Inc.,
Meade Johnson, MedAvante, Medtronic, Merck, NARSAD, Naurex, Neuronetics,
NIDA, NIMH, Novartis, Otsuka Pharmaceuticals, PamLab, LLC, Parke-Davis
Pharmaceuticals, Pfizer, Inc., PgxHealth, Pharmacia & Upjohn, Predix
Pharmaceuticals, Rexahn Pharmaceuticals, Sepracor, Shire Development,
Sierra, SK Life and Science, Solvay Pharmaceuticals, Takeda
Pharmaceutical Company Limited, Tai Medical/Puretech Venture, Targacept,
Transcept, Valient, VantagePoint, and Wyeth-Ayerst Laboratories. Dr.
Fava receives research support from Abbott Laboratories, Alkermes, Inc.,
Aspect Medical Systems, AstraZeneca, BioResearch, BrainCells Inc.,
Bristol-Myers Squibb, CeNeRx Bio Pharma, Cephalon, Clinical Trials
Solutions, LLC, Clintara, LLC, Covance, Covidien, Eli Lilly and Company,
ElMindA, Ltd., EnVivo Pharmaceuticals, Inc., Euthymics Bioscience, Inc.,
Forest Pharmaceuticals, Inc., Ganeden Biotech, Inc., GlaxoSmithKline, i3
Innovus/Ingenix, Icon Clinical Research, Johnson & Johnson
Pharmaceutical Research & Development, Lichtwer Pharma GmbH, Lorex
Pharmaceuticals, NARSAD, NCCAM, NIMH, NIDA, Novartis AG, Organon
Pharmaceuticals, PamLab, LLC, Pfizer Inc., Pharmavite LLC, Photothera,
RCT Logic, LLC, Roche Pharmaceuticals, sanofi-aventis, Shire, Solvay
Pharmaceuticals, Inc., Synthelabo, and Wyeth-Ayerst Laboratories; is an
advisor or consultant to Abbott Laboratories, Affectis Pharmaceuticals
AG, Alkermes, Inc., Amarin Pharma, Inc., Aspect Medical Systems,
AstraZeneca, Auspex Pharmaceuticals, Bayer AG, Best Practice Project
Management, Inc.; , BioMarin Pharmaceuticals, Inc., Biovail Corporation,
BrainCells Inc., Bristol-Myers Squibb, CeNeRx Bio Pharma, Cephalon,
Clinical Trials Solutions, LLC, CNS Response, Inc., Compellis
Pharmaceutics, Cypress Pharmaceutical, Inc., DiagnoSearch Life Sciences
(P) Ltd., Dainippon Sumitomo Pharma Co. Inc., Dov Pharmaceuticals, Inc.,
Edgemont Pharmaceuticals, Inc., Eisai, Inc., Eli Lilly and Company,
EnVivo Pharmaceuticals, Inc., ePharmaSolutions, EPIX Pharmaceuticals,
Euthymics Bioscience, Inc., Fabre-Kramer Pharmaceuticals, Forest
Pharmaceuticals, Inc., GenOmind, LLC, GlaxoSmithKline, Grunenthal GmbH,
i3 Innovus/Ingenix, Janssen Pharmaceutica, Jazz Pharmaceuticals, Inc.,
Johnson & Johnson Pharmaceutical Research & Development, Knoll
Pharmaceuticals Corp., Labopharm, Inc., Lorex Pharmaceuticals, Lundbeck,
Inc., MedAvante, Inc., Merck, MSI Methylation Sciences, Inc., Naurex,
Inc., Neuronetics, Inc., NextWave Pharmaceuticals, Novartis AG,
Nutrition 21, Orexigen Therapeutics, Inc., Organon Pharmaceuticals,
Otsuka Pharmaceuticals, PamLab, LLC, Pfizer, Inc., PharmaStar,
Pharmavite LLC, PharmoRx Therapeutics, Precision Human Biolaboratory,
Prexa Pharmaceuticals, Inc., PsychoGenics, Psylin Neurosciences, Inc.,
Puretech Ventures, RCT Logic, LLC, Rexahn Pharmaceuticals, Inc., Ridge
Diagnostics, Inc., Roche Pharmaceuticals, sanofi-aventis,
Schering-Plough Corporation, Sepracor, Inc., Servier Laboratories,
Solvay Pharmaceuticals, Inc., Somaxon Pharmaceuticals, Inc., Somerset
Pharmaceuticals, Inc., Sunovion Pharmaceuticals, Supernus
Pharmaceuticals, Inc., Synthelabo, Takeda Pharmaceutical Company
Limited, Tal Medical, Inc., Tetragenex Pharmaceuticals, Inc., Transcept
Pharmaceuticals, Inc., TransForm Pharmaceuticals, Inc., and Vanda
Pharmaceuticals, Inc.; is a speaker for or has been published by:
Adamed, Co., Advanced Meeting Partners, American Psychiatric
Association, American Society of Clinical Psychopharmacology,
AstraZeneca, Belvoir Media Group, Boehringer Ingelheim GmbH,
Bristol-Myers Squibb, Cephalon, Inc., CME Institute/Physicians
Postgraduate Press, Inc., Eli Lilly and Company, Forest Pharmaceuticals,
Inc., GlaxoSmithKline, Imedex, LLC, MGH Psychiatry Academy/Primedia, MGH
Psychiatry Academy/Reed Elsevier, Novartis AG, Organon Pharmaceuticals,
Pfizer, Inc., PharmaStar, United BioSource Corp., and Wyeth-Ayerst
Laboratories; has equity holdings with Compellis; has a patent for
Sequential Parallel Comparison Design (SPCD) and a patent application
for a combination of azapirones and bupropion in major depressive
disorder, for research and licensing of SPCD with RCP Logic; and has a
copyright for the MGH Cognitive & Physical Functioning Questionnaire,
Sexual Functioning Inventory, Antidepressant Treatment Response
Questionnaire, Discontinuation-Emergent Signs & Symptoms, and SAFER;
Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific
Publishing Co. Pte. Ltd. Dr. Mischoulon receives grant or research
support from the Bowman Family Foundation, FisherWallace, and Nordic
Naturals; is a speaker for MGH Psychiatry Academy; and received
royalties from Lippincott Williams & Wilkins. Ms. LaRocca, Ms. Hails,
and Dr. Balasubramani report no financial relationship with any company
whose products are mentioned in this article or with manufacturers of
competing products.; The initial STAR*D project was supported with
federal funds from the NIMH/National Institutes of Health under contract
N01MH90003 to the University of Texas Southwestern Medical Center,
Dallas (PI: Dr. A.J. Rush). The content of this publication does not
necessarily reflect the views or policies of the US Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US government. The
NIMH approved the design of the overall study and reviewed its conduct
but performed no role in the collection, management, or interpretation
of the data analyzed for this report or in the preparation, review, or
approval of the manuscript. We appreciate the support of Bristol-Myers
Squibb, Forest Laboratories, GlaxoSmithKline, King Pharmaceuticals,
Organon, Pfizer, Inc., and Wyeth for providing medications at no cost
for the original STAR*D trial. None of these entities had a role in any
part of the study (eg, design, execution, data collection, analysis, or
interpretation of the data), nor in writing any report, including this
one.
NR 12
TC 4
Z9 4
U1 0
U2 2
PU QUADRANT HEALTHCOM INC
PI PARSIPPANY
PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA
SN 1040-1237
J9 ANN CLIN PSYCHIATRY
JI Ann. Clin. Psychiatry
PD FEB
PY 2013
VL 25
IS 1
BP 3
EP 10
PG 8
WC Psychiatry
SC Psychiatry
GA 091UF
UT WOS:000315074600002
PM 23376864
ER
PT J
AU Nyer, M
Holt, DJ
Pedrelli, P
Fava, M
Ameral, V
Cassiello, CF
Nock, MK
Ross, M
Hutchinson, D
Farabaugh, A
AF Nyer, Maren
Holt, Daphne J.
Pedrelli, Paola
Fava, Maurizio
Ameral, Victoria
Cassiello, Clair F.
Nock, Matthew K.
Ross, Margaret
Hutchinson, Dori
Farabaugh, Amy
TI Factors that distinguish college students with depressive symptoms with
and without suicidal thoughts
SO ANNALS OF CLINICAL PSYCHIATRY
LA English
DT Article
DE suicide; depression; college students; anxiety; undergraduate;
hopelessness
ID IDEATION; HOPELESSNESS; QUESTIONNAIRE; PREVALENCE; PREDICTORS; BEHAVIOR;
RISK
AB BACKGROUND: Suicide among college students is a significant public health concern. Although suicidality is linked to depression, not all depressed college students experience suicidal ideation (SI). The primary aim of this study was to determine potential factors that may distinguish college students with depressive symptoms with and without SI.
METHODS: A total of 287 undergraduate college students with substantial depressive symptoms (Beck Depression Inventory [BDI] total score >13) with and without SI were compared across psychiatric and functional outcome variables. Independent sample t tests were conducted for each outcome variable using the suicide item of the BDI as a dichotomous (ie, zero vs nonzero score) grouping variable.
RESULTS: Relative to students with substantial depressive symptoms without SI, those with SI were more symptomatic overall, having significantly higher levels of depressive symptoms, hopelessness, and anxiety. However, contrary to our expectations, nonsuicidal and suicidal students did not differ on measures of everyday functioning (ie, cognitive and physical functioning and grade point average).
CONCLUSIONS: Our findings suggest that SI among college students is associated with increased subjective distress but may not adversely impact physical or cognitive functioning or academic performance.
C1 [Nyer, Maren; Holt, Daphne J.; Pedrelli, Paola; Fava, Maurizio; Ameral, Victoria; Cassiello, Clair F.; Farabaugh, Amy] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
[Nock, Matthew K.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Ross, Margaret] Boston Univ, Student Hlth Serv, Boston, MA 02215 USA.
[Hutchinson, Dori] Boston Univ, Ctr Psychiat Rehabil, Boston, MA 02215 USA.
RP Nyer, M (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM mnyer@partners.org
FU Harvard Medical School; Kaplen Fellowship; Abbott Laboratories;
Alkermes, Inc.; Aspect Medical Systems; AstraZeneca; BioResearch;
BrainCells Inc.; Bristol-Myers Squibb; CeNeRx Bio Pharma; Cephalon;
Clinical Trials Solutions, LLC; Clintara, LLC; Covance; Covidien; Eli
Lilly and Company; ElMindA Ltd.; EnVivo Pharmaceuticals, Inc.; Euthymics
Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.;
GlaxoSmithKline; i3 Innovus/Ingenix; Icon Clinical Research; Johnson &
Johnson Pharmaceutical Research Development; Lichtwer Pharma GmbH; Lorex
Pharmaceuticals; NARSAD; National Center for Complementary and
Alternative Medicine; National Institute of Mental Health; National
Institute on Drug Abuse; Novartis AG; Organon Pharmaceuticals; PamLab,
LLC; Pfizer, Inc.; Pharmavite LLC; Photothera; RCT Logic, LLC; Roche
Pharmaceuticals; sanofi-aventis; Shire; Solvay Pharmaceuticals, Inc.;
Synthelabo; Wyeth-Ayerst Laboratories; Jed Foundation
FX Dr. Nyer receives grant or research support from Harvard Medical School
and the Kaplen Fellowship. Dr. Fava receives research support from
Abbott Laboratories, Alkermes, Inc., Aspect Medical Systems,
AstraZeneca, BioResearch, BrainCells Inc., Bristol-Myers Squibb, CeNeRx
Bio Pharma, Cephalon, Clinical Trials Solutions, LLC, Clintara, LLC,
Covance, Covidien, Eli Lilly and Company, ElMindA Ltd., EnVivo
Pharmaceuticals, Inc., Euthymics Bioscience, Inc., Forest
Pharmaceuticals, Inc., Ganeden Biotech, Inc., GlaxoSmithKline, i3
Innovus/Ingenix, Icon Clinical Research, Johnson & Johnson
Pharmaceutical Research & Development, Lichtwer Pharma GmbH, Lorex
Pharmaceuticals, NARSAD, National Center for Complementary and
Alternative Medicine, National Institute of Mental Health, National
Institute on Drug Abuse, Novartis AG, Organon Pharmaceuticals, PamLab,
LLC, Pfizer, Inc., Pharmavite LLC, Photothera, RCT Logic, LLC, Roche
Pharmaceuticals, sanofi-aventis, Shire, Solvay Pharmaceuticals, Inc.,
Synthelabo, and Wyeth-Ayerst Laboratories; is an advisor or consultant
to Abbott Laboratories, Affectis Pharmaceuticals AG, Alkermes, Inc.,
Amarin Pharma, Inc., Aspect Medical Systems, AstraZeneca, Auspex
Pharmaceuticals, Bayer AG, Best Practice Project Management, Inc.,
BioMarin Pharmaceuticals, Inc., Biovail Corporation, Brain Cells Inc.,
Bristol-Myers Squibb, CeNeRx Bio Pharma, Cephalon, Clinical Trials
Solutions, LLC, CNS Response, Inc., Compellis Pharmaceutics, Cypress
Pharmaceutical, Inc., DiagnoSearch Life Sciences (P) Ltd., Dainippon
Sumitomo Pharma Co. Inc., Dov Pharmaceuticals, Inc., Edgemont
Pharmaceuticals, Inc., Eisai, Inc., Eli Lilly and Company, En Vivo
Pharmaceuticals, Inc., ePharmaSolutions, EPIX Pharmaceuticals, Euthymics
Bioscience, Inc., Fabre-Kramer Pharmaceuticals, Forest Pharmaceuticals,
Inc., GenOmind, LLC, GlaxoSmithKline, Grunenthal GmbH, i3
Innovus/Ingenix, Janssen Pharmaceutica, Jazz Pharmaceuticals, Inc.,
Johnson & Johnson Pharmaceutical Research & Development, Knoll
Pharmaceuticals Corp., Labopharm Inc., Lorex Pharmaceuticals, Lundbeck
Inc., MedAvante, Inc., Merck, MSI Methylation Sciences, Inc., Naurex,
Inc., Neuronetics, Inc., Next Wave Pharmaceuticals, Novartis AG,
Nutrition 21, Orexigen Therapeutics, Inc., Organon Pharmaceuticals,
Otsuka Pharmaceuticals, PamLab, LLC, Pfizer, Inc., PharmaStar,
Pharmavite LLC, PharmoRx Therapeutics, Precision Human Biolaboratory,
Prexa Pharmaceuticals, Inc., PsychoGenics, Psylin Neurosciences, Inc.,
Puretech Ventures, RCT Logic, LLC, Rexahn Pharmaceuticals, Inc., Ridge
Diagnostics, Inc., Roche Pharmaceuticals, sanofi-aventis,
Schering-Plough Corporation, Sepracor, Inc., Servier Laboratories,
Solvay Pharmaceuticals, Inc., Somaxon Pharmaceuticals, Inc., Somerset
Pharmaceuticals, Inc., Sunovion Pharmaceuticals, Supernus
Pharmaceuticals, Inc., Synthelabo, Takeda Pharmaceutical Company
Limited, Tal Medical, Inc., Tetragenex Pharmaceuticals, Inc., Transcept
Pharmaceuticals, Inc., Trans Form Pharmaceuticals, Inc., and Vanda
Pharmaceuticals, Inc.; is a speaker for or has been published by:
Adamed, Co., Advanced Meeting Partners, American Psychiatric
Association, American Society of Clinical Psychopharmacology,
AstraZeneca, Belvoir Media Group, Boehringer Ingelheim GmbH,
Bristol-Myers Squibb, Cephalon, Inc., CME Institute/Physicians
Postgraduate Press, Inc., Eli Lilly and Company, Forest Pharmaceuticals,
Inc., GlaxoSmithKline, Imedex, LLC, MGH Psychiatry Academy/Primedia, MGH
Psychiatry Academy/Reed Elsevier, Novartis AG, Organon Pharmaceuticals,
Pfizer, PharmaStar, United BioSource Corp.; , and Wyeth-Ayerst
Laboratories; has equity holdings with Compellis; has a patent for
Sequential Parallel Comparison Design (SPCD) and a patent application
for a combination of azapirones and bupropion in major depressive
disorder, for research and licensing of SPCD with RCP Logic; and has a
copyright for the MGH Cognitive & Physical Functioning Questionnaire
(CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment
Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms
(DESS), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World
Scientific Publishing Co. Pte. Ltd. Drs. Holt, Pedrelli, Nock, Ross,
Hutchinson, and Farabaugh, Ms. Ameral, and Ms. Cassiello report no
financial relationships with any products are mentioned in this article
or with manufacturers of competing products. This study was supported by
a grant from The Jed Foundation.
NR 33
TC 11
Z9 11
U1 2
U2 21
PU QUADRANT HEALTHCOM INC
PI PARSIPPANY
PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA
SN 1040-1237
J9 ANN CLIN PSYCHIATRY
JI Ann. Clin. Psychiatry
PD FEB
PY 2013
VL 25
IS 1
BP 41
EP 49
PG 9
WC Psychiatry
SC Psychiatry
GA 091UF
UT WOS:000315074600007
PM 23376869
ER
PT J
AU Wilcox, SR
Brown, DFM
Elmer, J
AF Wilcox, Susan R.
Brown, David F. M.
Elmer, Jonathan
TI Video Laryngoscopy Is a Valuable Adjunct in Emergency Airway Management
but Is Not Sufficient as an Exclusive Method of Training Residents
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Letter
ID TRACHEAL INTUBATIONS
C1 [Wilcox, Susan R.; Brown, David F. M.] Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA 02115 USA.
[Wilcox, Susan R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Elmer, Jonathan] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA.
RP Wilcox, SR (reprint author), Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA 02115 USA.
OI Wilcox, Susan/0000-0001-7477-7531
NR 5
TC 3
Z9 3
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD FEB
PY 2013
VL 61
IS 2
BP 252
EP 253
DI 10.1016/j.annemergmed.2012.07.127
PG 2
WC Emergency Medicine
SC Emergency Medicine
GA 086FJ
UT WOS:000314669200020
PM 23331650
ER
PT J
AU Pak, TR
Roth, FP
AF Pak, Theodore R.
Roth, Frederick P.
TI ChromoZoom: a flexible, fluid, web-based genome browser
SO BIOINFORMATICS
LA English
DT Article
ID DATABASE
AB A: Current web-based genome browsers require repetitious user input to scroll over long distances, alter the drawing density of elements or zoom through multiple orders of magnitude. Generally, either the server or the client is responsible for the majority of data processing, resulting in either servers having to receive and handle data relevant only to one user, or clients redundantly processing widely viewed data. ChromoZoom pre-renders and caches general-use tracks into tiled images on the server and serves them in an interactive web interface with inertial scrolling and precise, fluent zooming via the mouse wheel or trackpad. Custom tracks in several formats can be rendered by client-side code alongside the pre-rendered tracks, minimizing server load because of user-specific rendering and eliminating the need to transmit private data. ChromoZoom thereby enables rapid and simultaneous exploration of curated, experimental and personal genomic datasets.
C1 [Pak, Theodore R.; Roth, Frederick P.] Univ Toronto, Donnelly Ctr, Toronto, ON M5S 3E1, Canada.
[Pak, Theodore R.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Roth, Frederick P.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 3E1, Canada.
[Roth, Frederick P.] Univ Toronto, Dept Comp Sci, Toronto, ON M5S 3E1, Canada.
[Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
RP Roth, FP (reprint author), Univ Toronto, Donnelly Ctr, Toronto, ON M5S 3E1, Canada.
EM fritz.roth@utoronto.ca
RI Roth, Frederick/H-6308-2011;
OI Roth, Frederick/0000-0002-6628-649X
FU National Institutes of Health [HG004233, HL107440]; Ontario Research
Fund-Research Excellence Award; Canadian Institute for Advanced Research
Fellowship; Canada Excellence Research Chair
FX National Institutes of Health (HG004233, HL107440); Ontario Research
Fund-Research Excellence Award; Canadian Institute for Advanced Research
Fellowship; Canada Excellence Research Chair (to F.P.R.).
NR 11
TC 3
Z9 3
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
J9 BIOINFORMATICS
JI Bioinformatics
PD FEB 1
PY 2013
VL 29
IS 3
BP 384
EP 386
DI 10.1093/bioinformatics/bts695
PG 3
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Computer Science, Interdisciplinary Applications; Mathematical &
Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Computer Science; Mathematical & Computational Biology; Mathematics
GA 089EI
UT WOS:000314892000012
PM 23220575
ER
PT J
AU Yaseen, MA
Sakadzic, S
Wu, WC
Becker, W
Kasischke, KA
Boas, DA
AF Yaseen, Mohammad A.
Sakadzic, Sava
Wu, Weicheng
Becker, Wolfgang
Kasischke, Karl A.
Boas, David A.
TI In vivo imaging of cerebral energy metabolism with two-photon
fluorescence lifetime microscopy of NADH
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID NICOTINAMIDE ADENINE-DINUCLEOTIDE; TIME-RESOLVED FLUORESCENCE;
PYRIDINE-NUCLEOTIDES; CELLULAR-METABOLISM; INTRACELLULAR NADH; RESPONSE
FUNCTION; LIVE TISSUE; REVEALS; BRAIN; CELLS
AB Minimally invasive, specific measurement of cellular energy metabolism is crucial for understanding cerebral pathophysiology. Here, we present high-resolution, in vivo observations of autofluorescence lifetime as a biomarker of cerebral energy metabolism in exposed rat cortices. We describe a customized two-photon imaging system with time correlated single photon counting detection and specialized software for modeling multiple-component fits of fluorescence decay and monitoring their transient behaviors. In vivo cerebral NADH fluorescence suggests the presence of four distinct components, which respond differently to brief periods of anoxia and likely indicate different enzymatic formulations. Individual components show potential as indicators of specific molecular pathways involved in oxidative metabolism. (c) 2013 Optical Society of America
C1 [Yaseen, Mohammad A.; Sakadzic, Sava; Wu, Weicheng; Boas, David A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Opt Div, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA.
[Becker, Wolfgang] Becker & Hickl GmbH, D-12277 Berlin, Germany.
[Kasischke, Karl A.] Univ Ulm, Med Ctr, Dept Neurol, D-89075 Ulm, Germany.
RP Yaseen, MA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Opt Div, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA.
EM dboas@nmr.mgh.harvard.edu
FU NIH [R01-NS057476, P50-NS010828, P01-NS055104, R01-EB000790]; AHA
[11SDG7600037]
FX This work was supported by NIH R01-NS057476, P50-NS010828, and
P01-NS055104, R01-EB000790 and AHA 11SDG7600037. We gratefully
acknowledge Boston Electronics for their generous support with the TCSPC
equipment and software. Dr. Becker has a financial interest in Becker &
Hickl GmbH, which did not support this work.
NR 53
TC 30
Z9 30
U1 2
U2 37
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2013
VL 4
IS 2
BP 307
EP 321
PG 15
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA 088AQ
UT WOS:000314806600013
PM 23412419
ER
PT J
AU Chew, S
Balasubramanian, R
Chan, WM
Kang, PB
Andrews, C
Webb, BD
MacKinnon, SE
Oystreck, DT
Rankin, J
Crawford, TO
Geraghty, M
Pomeroy, SL
Crowley, WF
Jabs, EW
Hunter, DG
Grant, PE
Engle, EC
AF Chew, Sheena
Balasubramanian, Ravikumar
Chan, Wai-Man
Kang, Peter B.
Andrews, Caroline
Webb, Bryn D.
MacKinnon, Sarah E.
Oystreck, Darren T.
Rankin, Jessica
Crawford, Thomas O.
Geraghty, Michael
Pomeroy, Scott L.
Crowley, William F., Jr.
Jabs, Ethylin Wang
Hunter, David G.
Grant, Patricia E.
Engle, Elizabeth C.
TI A novel syndrome caused by the E410K amino acid substitution in the
neuronal beta-tubulin isotype 3
SO BRAIN
LA English
DT Article
DE Kallmann syndrome; cyclic vomiting; peripheral neuropathy; CFEOM; TUBB3
ID CYCLIC VOMITING SYNDROME; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM;
MOEBIUS SYNDROME; PERIPHERAL NEUROPATHY; KALLMANN-SYNDROME; TUBB3
MUTATIONS; GNRH DEFICIENCY; DISEASE-MODEL; MIGRATION; SEQUENCE
AB Missense mutations in TUBB3, the gene that encodes the neuronal-specific protein beta-tubulin isotype 3, can cause isolated or syndromic congenital fibrosis of the extraocular muscles, a form of complex congenital strabismus characterized by cranial nerve misguidance. One of the eight TUBB3 mutations reported to cause congenital fibrosis of the extraocular muscles, c.1228G>A results in a TUBB3 E410K amino acid substitution that directly alters a kinesin motor protein binding site. We report the detailed phenotypes of eight unrelated individuals who harbour this de novo mutation, and thus define the 'TUBB3 E410K syndrome'. Individuals harbouring this mutation were previously reported to have congenital fibrosis of the extraocular muscles, facial weakness, developmental delay and possible peripheral neuropathy. We now confirm by electrophysiology that a progressive sensorimotor polyneuropathy does indeed segregate with the mutation, and expand the TUBB3 E410K phenotype to include Kallmann syndrome (hypogonadotropic hypogonadism and anosmia), stereotyped midface hypoplasia, intellectual disabilities and, in some cases, vocal cord paralysis, tracheomalacia and cyclic vomiting. Neuroimaging reveals a thin corpus callosum and anterior commissure, and hypoplastic to absent olfactory sulci, olfactory bulbs and oculomotor and facial nerves, which support underlying abnormalities in axon guidance and maintenance. Thus, the E410K substitution defines a new genetic aetiology for Moebius syndrome, Kallmann syndrome and cyclic vomiting. Moreover, the c.1228G>A mutation was absent in DNA from similar to 600 individuals who had either Kallmann syndrome or isolated or syndromic ocular and/or facial dysmotility disorders, but who did not have the combined features of the TUBB3 E410K syndrome, highlighting the specificity of this phenotype-genotype correlation. The definition of the TUBB3 E410K syndrome will allow clinicians to identify affected individuals and predict the mutation based on clinical features alone.
C1 [Chew, Sheena; Chan, Wai-Man; Kang, Peter B.; Andrews, Caroline; Rankin, Jessica; Pomeroy, Scott L.; Engle, Elizabeth C.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Chew, Sheena; Chan, Wai-Man; Andrews, Caroline; Pomeroy, Scott L.; Engle, Elizabeth C.] Boston Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA.
[Chew, Sheena; Kang, Peter B.; Andrews, Caroline; Pomeroy, Scott L.; Engle, Elizabeth C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Chew, Sheena; Rankin, Jessica] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Chew, Sheena; Chan, Wai-Man; Andrews, Caroline; Engle, Elizabeth C.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Balasubramanian, Ravikumar; Crowley, William F., Jr.] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA.
[Balasubramanian, Ravikumar; Crowley, William F., Jr.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA.
[Balasubramanian, Ravikumar; Crowley, William F., Jr.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Chan, Wai-Man; Andrews, Caroline; Engle, Elizabeth C.] Boston Childrens Hosp, Program Genom, Boston, MA 02115 USA.
[Webb, Bryn D.; Jabs, Ethylin Wang] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Webb, Bryn D.; Jabs, Ethylin Wang] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
[MacKinnon, Sarah E.; Oystreck, Darren T.; Hunter, David G.; Engle, Elizabeth C.] Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
[Crawford, Thomas O.] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA.
[Geraghty, Michael] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Paediat, Ottawa, ON K1N 6N5, Canada.
[Pomeroy, Scott L.; Engle, Elizabeth C.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Jabs, Ethylin Wang] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA.
[Grant, Patricia E.] Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Engle, Elizabeth C.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA.
[Engle, Elizabeth C.] Boston Childrens Hosp, Dept Med Genet, Boston, MA 02115 USA.
RP Engle, EC (reprint author), Boston Childrens Hosp, CLS14074,300 Longwood Ave, Boston, MA 02115 USA.
EM Elizabeth.engle@childrens.harvard.edu
FU National Eye Institute of the National Institutes of Health
[R01EY12498]; Boston Children's Hospital Intellectual and Developmental
Disabilities Research Centre [HD018655]; National Institute of Child
Health & Human Development of the National Institutes of Health [U54
HD28138, T32 HD07396]; Children's Hospital Ophthalmology Foundation;
Moebius Syndrome Foundation; HHMI Medical Fellowship; Harvard Medical
School
FX National Eye Institute of the National Institutes of Health [R01EY12498
to E.C.E.]; the Boston Children's Hospital Intellectual and
Developmental Disabilities Research Centre [HD018655 to S.L.P., E.C.E.];
the National Institute of Child Health & Human Development of the
National Institutes of Health [U54 HD28138 and T32 HD07396 to W.F.C.];
Children's Hospital Ophthalmology Foundation [to E.C.E., D.G.H.]; the
Moebius Syndrome Foundation [to E.C.E.]. S.C is funded by the HHMI
Medical Fellowship and Harvard Medical School. E.C.E. is a Howard Hughes
Medical Institute Investigator.
NR 47
TC 27
Z9 30
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD FEB
PY 2013
VL 136
BP 522
EP 535
DI 10.1093/brain/aws345
PN 2
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 090QX
UT WOS:000314995200021
PM 23378218
ER
PT J
AU Pitman, MB
AF Pitman, Martha Bishop
TI Pancreatic cyst fluid triage A Critical Component of the Preoperative
Evaluation of Pancreatic Cysts
SO CANCER CYTOPATHOLOGY
LA English
DT Editorial Material
ID PAPILLARY-MUCINOUS NEOPLASMS; ENDOSCOPIC ULTRASOUND; MOLECULAR ANALYSIS;
ADDS VALUE; DIAGNOSIS; LESIONS; MANAGEMENT; CYTOLOGY; MALIGNANCY;
ACCURATE
C1 Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Pitman, MB (reprint author), Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02115 USA.
EM mpitman@partners.org
NR 40
TC 9
Z9 9
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-662X
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD FEB
PY 2013
VL 121
IS 2
BP 57
EP 60
DI 10.1002/cncy.21227
PG 4
WC Oncology; Pathology
SC Oncology; Pathology
GA 090NQ
UT WOS:000314986300002
PM 22961913
ER
PT J
AU Kulu, Y
Kawasaki, H
Donahue, JM
Kasuya, H
Cusack, JC
Choi, EW
Kuruppu, DK
Fuchs, BC
Tanabe, KK
AF Kulu, Y.
Kawasaki, H.
Donahue, J. M.
Kasuya, H.
Cusack, J. C.
Choi, E. W.
Kuruppu, D. K.
Fuchs, B. C.
Tanabe, K. K.
TI Concurrent chemotherapy inhibits herpes simplex virus-1 replication and
oncolysis
SO CANCER GENE THERAPY
LA English
DT Article
DE Herpes simplex virus; oncolytic HSV; viral oncolysis; combination
therapy; chemotherapeutics
ID NF-KAPPA-B; VIRAL RIBONUCLEOTIDE REDUCTASE; DIFFUSE LIVER METASTASES;
DOUBLE-STRANDED-RNA; CELL LUNG-CANCER; COLORECTAL-CANCER; MALIGNANT
GLIOMA; COLON-CARCINOMA; PHASE I/II; INDUCIBLE CHEMORESISTANCE
AB Herpes simplex virus-1 (HSV-1) replication in cancer cells leads to their destruction (viral oncolysis) and has been under investigation as an experimental cancer therapy in clinical trials as single agents, and as combinations with chemotherapy. Cellular responses to chemotherapy modulate viral replication, but these interactions are poorly understood. To investigate the effect of chemotherapy on HSV-1 oncolysis, viral replication in cells exposed to 5-fluorouracil (5-FU), irinotecan (CPT-11), methotrexate (MTX) or a cytokine (tumor necrosis factor-alpha (TNF-alpha)) was examined. Exposure of colon and pancreatic cancer ceIIS to 5-FU, CPT-11 or MTX in vitro significantly antagonizes both HSV-1 replication and lytic oncolysis. Nuclear factor-kappa B (NF-kappa B) activation is required for efficient viral replication, and experimental inhibition of this response with an I kappa B alpha donninant-negative repressor significantly antagonizes HSV-1 replication. Nonetheless, cells exposed to 5-FU, CPT-11, TNF-alpha or HSV-1 activate NF-kappa B. Cells exposed to MTX do not activate NF-kappa B, suggesting a possible role for NF-kappa B inhibition in the decreased viral replication observed following exposure to MTX. The role of eukaryotic initiation factor 2 alpha (eIF-2 alpha) dephosphorylation was examined; HSV-1-mediated eIF-2 alpha dephosphorylation proceeds normally in HT29 cells exposed to 5-FU, CPT-11 or MTX. This report demonstrates that cellular responses to chemotherapeutic agents provide an unfavorable environment for HSV-1-mediated oncolysis, and these observations are relevant to the design of both preclinical and clinical studies of HSV-1 oncolysis. Cancer Gene Therapy (2013) 20, 133-140; doi:10.1038/cgt.2012.97; published online 25 January 2013
C1 [Tanabe, K. K.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
RP Tanabe, KK (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, Yawkey 7-924,55 Fruit St, Boston, MA 02114 USA.
EM KTanabe@partners.org
RI Kasuya, hideki/I-7278-2014
FU NIH [CA64454, CA76183, DK43352, CA71345, CA077278]; DFG [KU 1989/1-1]
FX This work is supported by NIH Grants CA64454 and CA76183 (KK Tanabe),
DK43352 (core facilities), CA71345 (JM Donahue) and CA077278 (JC Cusack)
and DFG Grant KU 1989/1-1 (YKulu).
NR 65
TC 3
Z9 3
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD FEB
PY 2013
VL 20
IS 2
BP 133
EP 140
DI 10.1038/cgt.2012.97
PG 8
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
Research & Experimental Medicine
GA 091RV
UT WOS:000315068400011
PM 23348635
ER
PT J
AU Marais, R
Sellers, W
Livingston, D
Mihich, E
AF Marais, Richard
Sellers, William
Livingston, David
Mihich, Enrico
TI Twenty-fourth Annual Pezcoller Symposium: Molecular Basis for Resistance
to Targeted Agents
SO CANCER RESEARCH
LA English
DT Editorial Material
AB The mechanisms of genetically determined mechanisms of resistance to several target drugs were discussed in breast cancer, melanoma, colorectal and prostate cancers, chronic myelogenous leukemia, small cell lung cancer, and medulloblastoma. In each case, heterogeneity of mechanisms was emphasized. In melanoma, therapeutic interference with the effects of BRAF mutations was repeatedly discussed. It was also reported that anti-CTLA4 antibodies provided the first treatment improving survival of patients with stage IV melanoma. Epithelial-mesenchymal transition (EMT) was introduced as a mechanism of resistance, particularly in lung and pancreatic cancer, where the role of microenvironment factors was also indicated. In colorectal and prostate cancers, the use of liquid biopsies, namely, measurements of tumor nucleic acid in blood, were indicated as a way to obtain whole-tumor assessment instead of the partial assessment obtainable with traditional biopsies. Knowledge of the mechanisms of drug action and resistance was stressed to be essential for the design of new agents and combination of agents aimed at increasing antitumor effectiveness and overcoming resistance. Cancer Res; 73(3); 1046-9. (C) 2012 AACR.
C1 [Marais, Richard] Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England.
[Sellers, William] Novartis Inst Biomed Res, Cambridge, England.
[Livingston, David; Mihich, Enrico] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Mihich, E (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.
EM enrico_mihich@dfci.harvard.edu
OI Marais, Richard/0000-0001-7484-4183
NR 0
TC 4
Z9 4
U1 2
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2013
VL 73
IS 3
BP 1046
EP 1049
DI 10.1158/0008-5472.CAN-12-3236
PG 4
WC Oncology
SC Oncology
GA 091DD
UT WOS:000315028300002
PM 23222297
ER
PT J
AU Chau, NG
Haddad, RI
AF Chau, Nicole G.
Haddad, Robert I.
TI Vandetanib for the Treatment of Medullary Thyroid Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MALIGNANT-TUMORS; PHASE-II; KINASE INHIBITORS; ZD6474; MUTATIONS
AB Vandetanib (ZD6474, Caprelsa, AstraZeneca), an oral small-molecule tyrosine kinase inhibitor (TKI) that targets the rearranged during transfection receptor (RET), VEGF receptor (VEGFR2-3), and EGF receptor (EGFR), is the first systemic therapy approved by the U. S. Food and Drug Administration (FDA) for the treatment of symptomatic or progressive advanced medullary thyroid cancer (MTC). In a randomized phase III trial of patients with unresectable, locally advanced, or metastatic MTC, vandetanib improved progression-free survival compared with placebo [HR, 0.46; 95% confidence interval (CI), 0.31-0.69; P < 0.001]. However, the benefits in delaying disease progression need to be balanced against the associated and potentially serious toxicities, including diarrhea, hypertension, and QTc prolongation. Here, we review the clinical development of vandetanib leading to its integration into the current treatment paradigm and highlight the ongoing and future challenges in TKI use in MTC. Clin Cancer Res; 19(3); 524-9. (C) 2012 AACR.
C1 [Chau, Nicole G.; Haddad, Robert I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Head & Neck Oncol Program, Boston, MA 02115 USA.
RP Haddad, RI (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,SW430, Boston, MA 02215 USA.
EM robert_haddad@dfci.harvard.edu
FU Astra Zeneca
FX R.I. Haddad has a commercial research grant from Astra Zeneca and is a
consultant/advisory board member for Exelixis. No potential conflicts of
interest were disclosed by N.G. Chau.
NR 25
TC 20
Z9 21
U1 0
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 1
PY 2013
VL 19
IS 3
BP 524
EP 529
DI 10.1158/1078-0432.CCR-12-2353
PG 6
WC Oncology
SC Oncology
GA 088UQ
UT WOS:000314863000004
PM 23231950
ER
PT J
AU Jiang, XF
Zhou, J
Giobbie-Hurder, A
Wargo, J
Hodi, FS
AF Jiang, Xiaofeng
Zhou, Jun
Giobbie-Hurder, Anita
Wargo, Jennifer
Hodi, F. Stephen
TI The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition
Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID METASTATIC MELANOMA; B7-H1 EXPRESSION; ACQUIRED-RESISTANCE; RAF
INHIBITION; CANCER; PATHWAY; KINASE; BRAF(V600E); IMMUNORESISTANCE;
VEMURAFENIB
AB Purpose: Selective BRAF inhibition (BRAFi) provides a paradigm shift for melanoma treatment. The duration of benefit is typically limited before resistance develops. Interest remains in combining targeted and immune therapies to overcome resistance and improve durability of clinical benefit. One mechanism of evading immune destruction is programmed death-1-ligand 1 (PD-L1) expression by tumors that results in potent antitumor immune suppression.
Experimental Design: BRAFi-resistant melanoma cells were examined for changes in PD-L1 expression by immunoblot and flow cytometry. Signaling pathways involved in altering PD-L1 expression were examined. Strategies to maximize the effect of the BRAFi therapy were studied including MEKi, MEKi combinations, and additional pathways including phosphoinositide-3 kinase (PI3K).
Results: Melanoma cells resistant to BRAFi exhibit increased MAPK signaling and promotion of PD-L1 expression. PD-L1 expression is transcriptionally modulated by c-Jun and augmented by STAT3. MEK inhibition (MEKi) regains downregulation of MAPK signaling and suppresses the production of PD-L1. MEKi in melanoma cells shows dual therapeutic effects with simultaneous suppression of PD-L1 expression and induction of apoptosis. By combining MEKi with BRAFi, an additive effect on the inhibition of PD-L1 expression results.
Conclusions: We report a novel mechanism that suppresses preexisting immune responses in patients with melanoma receiving BRAFi therapy. BRAFi resistance leads to increased expression of PD-L1 in melanoma cells, mediated by c-Jun and STAT3. MEKi may be feasible to counteract BRAFi resistance of MAPK reactivation and also for the additive effect of PD-L1 suppression. Potential therapeutic benefits of combining targeted inhibitors and immune modulation to improve patient outcomes should be investigated. Clin Cancer Res; 19(3); 598-609. (C) 2012 AACR.
C1 [Jiang, Xiaofeng; Zhou, Jun; Hodi, F. Stephen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Giobbie-Hurder, Anita] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Wargo, Jennifer] Harvard Univ, Sch Med, Boston, MA USA.
[Jiang, Xiaofeng; Zhou, Jun; Hodi, F. Stephen] Dana Farber Brigham & Womens Canc Ctr, Melanoma Dis Ctr, Boston, MA USA.
[Zhou, Jun; Giobbie-Hurder, Anita; Hodi, F. Stephen] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02215 USA.
[Wargo, Jennifer] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Hodi, FS (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM stephen_hodi@dfci.harvard.edu
FU Sharon Crowley Martin Memorial Fund for Melanoma Research; Malcolm and
Emily Mac Naught Fund for Melanoma Research at Dana-Farber Cancer
Institute
FX This work was supported in part by the Sharon Crowley Martin Memorial
Fund for Melanoma Research (F. S. Hodi) and Malcolm and Emily Mac Naught
Fund for Melanoma Research (F. S. Hodi) at Dana-Farber Cancer Institute.
NR 46
TC 112
Z9 114
U1 3
U2 25
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 1
PY 2013
VL 19
IS 3
BP 598
EP 609
DI 10.1158/1078-0432.CCR-12-2731
PG 12
WC Oncology
SC Oncology
GA 088UQ
UT WOS:000314863000012
PM 23095323
ER
PT J
AU Dogliotti, A
Paolasso, E
Giugliano, RP
AF Dogliotti, Ariel
Paolasso, Ernesto
Giugliano, Robert P.
TI Novel Oral Anticoagulants in Atrial Fibrillation: A Meta-analysis of
Large, Randomized, Controlled Trials vs Warfarin
SO CLINICAL CARDIOLOGY
LA English
DT Review
ID STROKE PREVENTION; ELDERLY-PATIENTS; CLINICAL-TRIALS; DABIGATRAN;
THERAPY; XIMELAGATRAN; RIVAROXABAN; QUALITY; RISK
AB Background: Warfarin reduces ischemic stroke in atrial fibrillation, but has numerous limitations. Novel oral anticoagulants provide more predictable anticoagulation with fewer shortcomings. Hypothesis: Novel oral anticoagulants are superior to warfarin to prevent stroke or systemic embolism. Methods: Phase III randomized warfarin-controlled trials enrolling >3000 patients that reported clinical efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation were identified from MEDLINE, Embase, and Cochrane Central Register of Controlled Trials through October 2012. Two reviewers extracted data; differences were resolved by consensus. The end points analyzed were stroke or systemic embolism (primary efficacy composite); all-cause mortality, ischemic stroke, systemic embolism (individually, secondary efficacy); and hemorrhagic stroke, major bleeding (individually, safety). The Mantel-Haenszel method was used to calculate pooled relative risk (RR) and 95% confidence intervals (CI) from fixed-effects (if homogenous) or random-effects models (if heterogeneous). Results: In 5 studies of 51895 patients, the composite of stroke or systemic embolism (RR: 0.82; 95% CI: 0.690.98; P = 0.03) and all-cause mortality (RR: 0.91; 95% CI: 0.85-0.96; P = 0.0026, respectively) were reduced with the novel agents. Factor Xa inhibitors significantly reduced the primary composite (RR: 0.84; 95% CI: 0.74-0.94; P = 0.004) and all-cause mortality (RR: 0.91; 95% CI: 0.84 - 0.98; P = 0.01). Direct thrombin inhibitor achieved results similar to the overall meta-analysis (drug classoutcome interactions P = 0.47 for primary outcome, P = 1.00 for mortality). Compared with warfarin, novel anticoagulants markedly reduced hemorrhagic stroke (RR: 0.51; 95% CI: 0.41-0.64; P < 0.0001). Conclusions: Novel oral anticoagulants may be superior to warfarin in patients with atrial fibrillation, reducing the composite of stroke or systemic embolism and lowering all-cause mortality. The benefit is largely due to fewer hemorrhagic strokes. Ernesto Paolasso, MD, is a national lead investigator for a clinical trial sponsored by Daiichi-Sankyo investigating a novel oral anticoagulant. Robert Giugliano, MD, SM, is a member of the TIMI Study Group, which has received research grant support from Johnson & Johnson and from Daiichi-Sankyo related to clinical trials of anticoagulants. Dr. Giugliano has received honoraria for consultation/lectures from Bristol-Myers Squibb, Daiichi-Sankyo, Johnson & Johnson, and Sanofi-Aventis. The authors have no other funding, financial relationships, or conflicts of interest to disclose.
C1 [Dogliotti, Ariel] Orono Grp, Clin Epidemiol & Stat Unit, Rosario, Santa Fe, Argentina.
[Paolasso, Ernesto] Inst Invest Clin, Rosario, Santa Fe, Argentina.
[Dogliotti, Ariel; Paolasso, Ernesto] Inst Cardiovasc Rosario, Rosario, Santa Fe, Argentina.
[Giugliano, Robert P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
RP Giugliano, RP (reprint author), TIMI Study Grp, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA.
EM rgiugliano@partners.org
FU Daiichi-Sankyo; Johnson Johnson
FX Ernesto Paolasso, MD, is a national lead investigator for a clinical
trial sponsored by Daiichi-Sankyo investigating a novel oral
anticoagulant. Robert Giugliano, MD, SM, is a member of the TIMI Study
Group, which has received research grant support from Johnson & Johnson
and from Daiichi-Sankyo related to clinical trials of anticoagulants.
Dr. Giugliano has received honoraria for consultation/lectures from
Bristol-Myers Squibb, Daiichi-Sankyo, Johnson & Johnson, and
Sanofi-Aventis.
NR 28
TC 35
Z9 38
U1 0
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD FEB
PY 2013
VL 36
IS 2
BP 61
EP 67
DI 10.1002/clc.22081
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 090KA
UT WOS:000314976700001
PM 23338902
ER
PT J
AU O'Hare, AM
Vig, EK
Hebert, PL
AF O'Hare, Ann M.
Vig, Elizabeth K.
Hebert, Paul L.
TI Initiation of Dialysis at Higher Levels of Estimated GFR and Subsequent
Withdrawal
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; UNITED-STATES;
ELDERLY-PATIENTS; KIDNEY-FUNCTION; OLDER-ADULTS; END; LIFE;
DISCONTINUATION; INTENSITY
C1 VA Puget Sound Healthcare Syst, Seattle, WA USA.
Univ Washington, Seattle, WA 98195 USA.
RP O'Hare, AM (reprint author), VA Med Ctr, 1160 S Columbian Way, Seattle, WA 98108 USA.
EM ann.ohare@va.gov
NR 29
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD FEB
PY 2013
VL 8
IS 2
BP 179
EP 181
DI 10.2215/CJN.12841212
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 083TT
UT WOS:000314488800003
PM 23349332
ER
PT J
AU Alge, JL
Karakala, N
Neely, BA
Janech, MG
Tomlin, JA
Chawla, LS
Shaw, AD
Arthur, JM
AF Alge, Joseph L.
Karakala, Nithin
Neely, Benjamin A.
Janech, Michael G.
Tomlin, James A.
Chawla, Lakhmir S.
Shaw, Andrew D.
Arthur, John M.
CA SAKInet Investigators
TI Urinary Angiotensinogen and Risk of Severe AKI
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; GELATINASE-ASSOCIATED
LIPOCALIN; ADULT CARDIAC-SURGERY; POOR OUTCOMES; OBSERVATIONAL COHORT;
STATISTICAL-MODEL; CYSTATIN-C; BIOMARKERS; SYSTEM
AB Background Biomarkers of AKI that can predict which patients will develop severe renal disease at the time of diagnosis will facilitate timely intervention in populations at risk of adverse outcomes.
Design, setting, participants, & measurements Liquid chromatography/tandem mass spectrometry was used to identify 30 potential prognostic urinary biomarkers of severe AKI in a group of patients that developed AKI after cardiac surgery. Angiotensinogen had the best discriminative characteristics. Urinary angiotensinogen was subsequently measured by ELISA and its prognostic predictive power was verified in 97 patients who underwent cardiac surgery between August 1, 2008 and October 6, 2011.
Results The urine angiotensinogen/creatinine ratio (uAnCR) predicted worsening of AKI, Acute Kidney Injury Network (AKIN) stage 3, need for renal replacement therapy, discharge >7 days from sample collection, and composite outcomes of AKIN stage 2 or 3, AKIN stage 3 or death, and renal replacement therapy or death. The prognostic predictive power of uAnCR was improved when only patients classified as AKIN stage 1 at the time of urine sample collection (n=79) were used in the analysis, among whom it predicted development of stage 3 AKI or death with an area under the curve of 0.81. Finally, category free net reclassification improvement showed that the addition of uAnCR to a clinical model to predict worsening of AM improved the predictive power.
Conclusions Elevated uAnCR is associated with adverse outcomes inpatients with AKI. These data are the first to demonstrate the utility of angiotensinogen as a prognostic biomarker of AKI after cardiac surgery. Clin J Am Soc Nephrol 8: 184-193, 2013. doi: 10.2215/CJN.06280612
C1 [Alge, Joseph L.; Karakala, Nithin; Neely, Benjamin A.; Janech, Michael G.; Arthur, John M.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Karakala, Nithin; Janech, Michael G.; Arthur, John M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Tomlin, James A.] Univ Tennessee, Coll Med, Chattanooga, TN USA.
[Chawla, Lakhmir S.] George Washington Univ, Washington, DC USA.
[Shaw, Andrew D.] Duke Univ, Durham, NC USA.
[Shaw, Andrew D.] Durham Vet Affairs Med Ctr, Durham, NC USA.
RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA.
EM arthurj@musc.edu
RI Velez, Juan Carlos/N-3782-2016;
OI Janech, Michael/0000-0002-3202-4811; Neely,
Benjamin/0000-0001-6120-7695; Alge, Joseph/0000-0002-2491-1066
FU National Institutes of Health [R01 DK080234, UL1 RR029882]; Department
of Veterans Affairs; Nephcure Foundation
FX This study was supported by the National Institutes of Health (Grants
R01 DK080234 and UL1 RR029882) and by a Merit Review award from the
Biomedical Laboratory Research and Development Program of the Department
of Veterans Affairs. M.J. was supported by the Nephcure Foundation as a
young investigator. The contents do not necessarily represent the views
of the Department of Veterans Affairs or the US Government.
NR 36
TC 24
Z9 25
U1 0
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD FEB
PY 2013
VL 8
IS 2
BP 184
EP 193
DI 10.2215/CJN.06280612
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 083TT
UT WOS:000314488800005
PM 23143504
ER
PT J
AU Johansen, KL
Kaysen, GA
Dalrymple, LS
Grimes, BA
Glidden, DV
Anand, S
Chertow, GM
AF Johansen, Kirsten L.
Kaysen, George A.
Dalrymple, Lorien S.
Grimes, Barbara A.
Glidden, David V.
Anand, Shuchi
Chertow, Glenn M.
TI Association of Physical Activity with Survival among Ambulatory Patients
on Dialysis: The Comprehensive Dialysis Study
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID STAGE RENAL-DISEASE; DOSE-RESPONSE; MORTALITY; METAANALYSIS; COHORT;
HEMODIALYSIS
AB Background and objectives Despite high mortality and low levels of physical activity (PA) among patients starting dialysis, the link between low PA and mortality has not been carefully evaluated.
Design, setting, participants, & measurements The Comprehensive Dialysis Study was a prospective cohort study that enrolled patients who started dialysis between June 2005 and June 2007 in a random sample of dialysis facilities in the United States. The Human Activity Profile (HAP) was administered to estimate PA among 1554 ambulatory enrolled patients in the Comprehensive Dialysis Study. Patients were followed until death or September 30, 2009, and the major outcome was all-cause mortality.
Results The average age was 59.8 (14.2) years; 55% of participants were male, 28% were black, and 56% had diabetes mellitus. The majority (57.3%) had low fitness estimated from the HAP score. The median follow-up was 2.6 (interquartile range, 2.2-3.1) years. The association between PA and mortality was linear across the range of scores (1-94). After multivariable adjustment, lower adjusted activity score on the HAP was associated with higher mortality (hazard ratio, 1.30; 95% confidence interval, 1.23-1.39 per 10 points). Patients in the lowest level of fitness experienced a 3.5-fold (95% confidence interval, 2.54-4.89) increase in risk of death compared with those with average or above fitness.
Conclusions Low levels of PA are strongly associated with mortality among patients new to dialysis. Interventions aimed to preserve or enhance PA should be prospectively tested. Clin J Am Soc Nephrol 8: 248-253, 2013. doi: 10.2215/CJN.08560812
C1 [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA.
[Kaysen, George A.; Dalrymple, Lorien S.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA.
[Grimes, Barbara A.; Glidden, David V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Anand, Shuchi; Chertow, Glenn M.] Stanford Univ, Div Nephrol, Stanford, CA 94305 USA.
RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA.
EM Kirsten.johansen@ucsf.edu
FU National Institutes of Health [N01-DK-1-2450, N01-DK-7-0005]; Abbott
Laboratories Inc
FX This study was supported by the National Institutes of Health (Contracts
N01-DK-1-2450 to G.M.C. and N01-DK-7-0005 to K.L.J.). The interpretation
and reporting of the data presented here are the responsibility of the
authors and in no way should be seen as an official policy or
interpretation of the US government.; K.L.J. has received grant support
from Abbott Laboratories Inc and has served on Amgen's National
Nephrology Advisory Board.
NR 21
TC 26
Z9 27
U1 2
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD FEB
PY 2013
VL 8
IS 2
BP 248
EP 253
DI 10.2215/CJN.08560812
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 083TT
UT WOS:000314488800013
PM 23124787
ER
PT J
AU Soscia, SJ
Fitzgerald, ML
AF Soscia, Stephanie J.
Fitzgerald, Michael L.
TI The ABCA7 transporter, brain lipids and Alzheimer's disease
SO CLINICAL LIPIDOLOGY
LA English
DT Review
DE ABCAI; ABCA7; Alzheimer's disease; amyloid-beta; ApoE; ApoJ; brain;
cholesterol homeostasis; genome-wide association study; lipid
ID AMYLOID-BETA-PEPTIDE; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM;
HIGH-DENSITY-LIPOPROTEIN; TRANSGENIC MOUSE MODEL; APOLIPOPROTEIN-E;
A-BETA; CHOLESTEROL EFFLUX; III HYPERLIPOPROTEINEMIA; PROTEOLYTIC
DEGRADATION
AB ABCA7 is part of the ABCA superfamily of cholesterol and phospholipid transporters that move lipids and other molecules across membranes. The ABCA7 locus was one of four loci implicated in Alzheimer's disease (AD) susceptibility in a recent genome-wide association study. It is also one of three loci involved in both lipid homeostasis and increased risk for AD. The link between AD and altered brain lipid metabolism is reviewed here, with particular emphasis on the roles of ApoE, ApoJ and ABCA7. Advances in genome-wide studies have allowed researchers to explore the relationships between common sequence variations and disease predisposition. Investigating a link between the biological function of genetic variants and underlying disease pathology may be key to understanding AD cause, progression and treatment.
C1 [Soscia, Stephanie J.; Fitzgerald, Michael L.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
RP Soscia, SJ (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, 185 Cambridge St, Boston, MA 02114 USA.
EM ssoscia@gmail.com
NR 138
TC 1
Z9 1
U1 1
U2 14
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-4299
J9 CLIN LIPIDOL
JI Clin. Lipidol.
PD FEB
PY 2013
VL 8
IS 1
BP 97
EP 108
DI 10.2217/CLP.12.91
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 087VP
UT WOS:000314792600016
ER
PT J
AU Ferris, M
Norwood, V
Radeva, M
Gassman, JJ
Al-Uzri, A
Askenazi, D
Matoo, T
Pinsk, M
Sharma, A
Smoyer, W
Stults, J
Vyas, S
Weiss, R
Gipson, D
Kaskel, F
Friedman, A
Moxey-Mims, M
Trachtman, H
AF Ferris, Maria
Norwood, Victoria
Radeva, Milena
Gassman, Jennifer J.
Al-Uzri, Amira
Askenazi, David
Matoo, Tej
Pinsk, Maury
Sharma, Amita
Smoyer, William
Stults, Jenna
Vyas, Shefali
Weiss, Robert
Gipson, Debbie
Kaskel, Frederick
Friedman, Aaron
Moxey-Mims, Marva
Trachtman, Howard
TI Patient Recruitment into a Multicenter Randomized Clinical Trial for
Kidney Disease: Report of the Focal Segmental Glomerulosclerosis
Clinical Trial (FSGS CT)
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
DE clinical trials; kidney; nephrology; pediatrics
ID RARE DISEASES; ENROLLMENT; CHILDREN
AB We describe the experience of the focal segmental glomerulosclerosis clinical trial (FSGS CT) in the identification and recruitment of participants into the study. This National Institutes of Health funded study, a multicenter, open-label, randomized comparison of cyclosporine versus oral dexamethasone pulses plus mycophenolate mofetil, experienced difficulty and delays meeting enrollment goals. These problems occurred despite the support of patient advocacy groups and aggressive recruitment strategies. Multiple barriers were identified including: (1) inaccurate estimates of the number of potential incident FSGS patients at participating centers; (2) delays in securing one of the test agents; (3) prolonged time between IRB approval and execution of a subcontract (mean 7.5 +/- 0.8 months); (4) prolonged time between IRB approval and enrollment of the first patient at participating sites (mean 19.6 +/- 1.4 months); and (5) reorganization of clinical coordinating core infrastructure to align resources with enrollment. A Web-based anonymous survey of site investigators revealed site-related barriers to patient recruitment. The value of a variety of recruitment tools was of marginal utility in facilitating patient enrollment. We conclude that improvements in the logistics of study approval and regulatory start-up and testing of promising novel agents are important factors in promoting enrollment into randomized clinical trials in nephrology. Clin Trans Sci 2013; Volume 6: 1320
C1 [Ferris, Maria] Univ N Carolina, Chapel Hill, NC USA.
[Norwood, Victoria] Univ Virginia, Charlottesville, VA USA.
[Radeva, Milena; Gassman, Jennifer J.] Cleveland Clin, Cleveland, OH 44106 USA.
[Al-Uzri, Amira] Doernbecher Childrens Hosp, Portland, OR USA.
[Askenazi, David] Univ Alabama Birmingham, Birmingham, AL USA.
[Matoo, Tej] Childrens Hosp Michigan, Detroit, MI 48201 USA.
[Pinsk, Maury] Univ Alberta, Edmonton, AB, Canada.
[Sharma, Amita] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Smoyer, William] Nationwide Childrens Hosp, Columbus, OH USA.
[Stults, Jenna] Seattle Childrens Hosp, Seattle, WA USA.
[Vyas, Shefali] St Barnabas Hosp, Livingston, NJ USA.
[Weiss, Robert] New York Med Coll, Valhalla, NY 10595 USA.
[Gipson, Debbie] Univ Michigan, Ann Arbor, MI 48109 USA.
[Kaskel, Frederick] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Friedman, Aaron] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
[Moxey-Mims, Marva] NIDDK, NIH, Bethesda, MD USA.
[Trachtman, Howard] NYU Langone Med Ctr, New York, NY USA.
RP Trachtman, H (reprint author), NYU Langone Med Ctr, New York, NY USA.
EM howard.trachtman@nyumc.org
OI Pinsk, Maury/0000-0001-7668-665X; Trachtman, Howard/0000-0001-7447-9489
FU NIH-NIDDK [U01-DK063385, DK063490, DK063455, DK063549]; National Center
for Research Resources: University of North Carolina [UL1 RR025747];
National Center for Research Resources: University of Michigan [UL1
RR0249860]; National Center for Research Resources: Harvard University
[UL1 RR05758]; National Center for Research Resources: Albert Einstein
College of Medicine [UL1 RR025750]; National Center for Research
Resources: Medical University of South Carolina [UL1 RR029882]
FX This study was sponsored by the NIH-NIDDK Grants U01-DK063385, DK063490,
DK063455, and DK063549. In addition, the trial was supported by the
following Clinical and Translational Science Awards from the National
Center for Research Resources: University of North Carolina (UL1
RR025747), University of Michigan (UL1 RR0249860), Harvard University
(UL1 RR05758), Albert Einstein College of Medicine (UL1 RR025750), and
Medical University of South Carolina (UL1 RR029882). The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Center for Research
Resources or the National Institutes of Health. Th e authors thank
Edward Iglesia for his assistance in preparing Figure 2.
NR 21
TC 5
Z9 5
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD FEB
PY 2013
VL 6
IS 1
BP 13
EP 20
DI 10.1111/cts.12003
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 089OK
UT WOS:000314919700007
PM 23399084
ER
PT J
AU Sharon, VR
Armstrong, AW
On, SCJ
Ibrahimi, OA
Eisen, DB
AF Sharon, Victoria R.
Armstrong, April W.
On, Shelbi C. Jim
Ibrahimi, Omar A.
Eisen, Daniel B.
TI Separate- Versus Same-Day Preoperative Consultation in Dermatologic
Surgery: A Patient-Centered Investigation in an Academic Practice
SO DERMATOLOGIC SURGERY
LA English
DT Article
ID MOHS MICROGRAPHIC SURGERY; CUTANEOUS SURGERY; WARFARIN; STROKE
AB Background Little is known about patient preferences for preoperative consultation in dermatologic surgery. Objective To determine patient preferences for separate- versus same-day preoperative consultation and factors that may be associated with these preferences. Methods and Materials Patients who underwent Mohs micrographic surgery (MMS) or excision at our institution within 24months were retrospectively surveyed regarding their preferences for a separate- or same-day preoperative consultation. Procedure, tumor attributes, complications, and medications were recorded. Results Sixty-seven percent of patients preferred same-day preoperative consultation and surgery. Patients preferring same-day surgery were more likely to have a larger preoperative tumor size, whereas those preferring separate-day surgery were more likely to have had a history of complications. Limitations This was a retrospective study performed at a single academic center. Conclusion A majority of patients preferred same-day preoperative consultation and surgery. Tumor size and prior complications should be considered in preoperative planning for dermatologic surgery.
C1 [Sharon, Victoria R.; Armstrong, April W.; Eisen, Daniel B.] Univ Calif Davis, Dept Dermatol, Davis, CA 95616 USA.
[On, Shelbi C. Jim] Mt Sinai Sch Med, Dept Dermatol, New York, NY USA.
[Ibrahimi, Omar A.] Connecticut Skin Inst, Stamford, CT USA.
[Ibrahimi, Omar A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
RP Eisen, DB (reprint author), 3301 C St,Suite 1400, Sacramento, CA 95816 USA.
EM dbeisen@ucdavis.edu
OI Sharon, Victoria/0000-0002-5108-8757; Eisen, Daniel/0000-0001-6741-3182
NR 10
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1076-0512
EI 1524-4725
J9 DERMATOL SURG
JI Dermatol. Surg.
PD FEB
PY 2013
VL 39
IS 2
BP 240
EP 247
DI 10.1111/dsu.12083
PG 8
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 086CV
UT WOS:000314661700009
PM 23279092
ER
PT J
AU Damiano, ER
El-Khatib, FH
Zheng, H
Nathan, DM
Russell, SJ
AF Damiano, Edward R.
El-Khatib, Firas H.
Zheng, Hui
Nathan, David M.
Russell, Steven J.
TI A Comparative Effectiveness Analysis of Three Continuous Glucose
Monitors
SO DIABETES CARE
LA English
DT Article
ID DIABETIC-PATIENTS; INSULIN DELIVERY; TYPE-1; PANCREAS
AB OBJECTIVE-To compare three continuous glucose monitoring (CGM) devices in subjects with type 1 diabetes under closed-loop blood glucose (BG) control.
RESEARCH DESIGN AND METHODS-Six subjects with type 1 diabetes (age 52 +/- 14 years, diabetes duration 32 +/- 14 years) each participated in two 51-h closed-loop BG control experiments in the hospital. Venous plasma glucose (PG) measurements (GlucoScout, International Biomedical) obtained every 15 min (2,360 values) were paired in time with corresponding CGM glucose (CGMG) measurements obtained from three CGM devices, the Navigator (Abbott Diabetes Care), the Seven Plus (DexCom), and the Guardian (Medtronic), worn simultaneously by each subject. Errors in paired PG-CGMG measurements and data reporting percentages were obtained for each CGM device.
RESULTS-The Navigator had the best overall accuracy, with an aggregate mean absolute relative difference (MARD) of all paired points of 11.8 +/- 11.1% and an average MARD across all 12 experiments of 11.8 +/- 3.8%. The Seven Plus and Guardian produced aggregate MARDs of all paired points of 16.5 +/- 17.8% and 20.3 +/- 18.0%, respectively, and average MARDs across all 12 experiments of 16.5 +/- 6.7% and 20.2 +/- 6.8%, respectively. Data reporting percentages, a measure of reliability, were 76% for the Seven Plus and nearly 100% for the Navigator and Guardian.
CONCLUSIONS-A comprehensive head-to-head-to-head comparison of three CGM devices for BG values from 36 to 563 mg/dL revealed marked differences in performance characteristics that include accuracy, precision, and reliability. The Navigator outperformed the other two in these areas. Diabetes Care 36:251-259, 2013
C1 [Damiano, Edward R.; El-Khatib, Firas H.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Nathan, David M.; Russell, Steven J.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
[Nathan, David M.; Russell, Steven J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Nathan, David M.; Russell, Steven J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Russell, SJ (reprint author), Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
EM sjrussell@partners.org
FU National Institutes of Health (NIH); General Clinical Research Center
and Clinical and Translational Science Center programs from the NIH
National Center for Research Resources [M01-RR01066, UL1-RR025758];
Juvenile Diabetes Research Foundation [22-2009-798]; Charlton Fund for
Innovative Research in Diabetes
FX This study was supported by National Institutes of Health (NIH) Grant
R01-DK085633 to E.R.D., grants M01-RR01066 and UL1-RR025758 through the
General Clinical Research Center and Clinical and Translational Science
Center programs from the NIH National Center for Research Resources,
Clinical Investigations Research Grant 22-2009-798 to E.R.D. from the
Juvenile Diabetes Research Foundation, and a grant to D.M.N. from the
Charlton Fund for Innovative Research in Diabetes.
NR 9
TC 34
Z9 34
U1 0
U2 22
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2013
VL 36
IS 2
BP 251
EP 259
DI 10.2337/dc12-0070
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 083MA
UT WOS:000314467100021
PM 23275350
ER
PT J
AU Pomeroy, J
Renstrom, F
Gradmark, AM
Mogren, I
Persson, M
Bluck, L
Wright, A
Kahn, SE
Domellof, M
Franks, PW
AF Pomeroy, Jeremy
Renstrom, Frida
Gradmark, Anna M.
Mogren, Ingrid
Persson, Margareta
Bluck, Les
Wright, Antony
Kahn, Steven E.
Domellof, Magnus
Franks, Paul W.
TI Maternal Physical Activity and Insulin Action in Pregnancy and Their
Relationships With Infant Body Composition
SO DIABETES CARE
LA English
DT Article
ID SENSITIVITY; WOMEN; SECRETION
AB OBJECTIVE-We sought to assess the association between maternal gestational physical activity and insulin action and body composition in early infancy.
RESEARCH DESIGN AND METHODS-At 28-32 weeks' gestation, pregnant women participating in an observational study in Sweden underwent assessments of height, weight, and body composition, an oral glucose tolerance test, and 10 days of objective physical activity assessment. Thirty mothers and infants returned at 11-19 weeks postpartum. Infants underwent assessments of weight, length, and body composition.
RESULTS-Early insulin response was correlated with total physical activity (r = 0.47; P = 0.007). Early insulin response (r = -0.36; P = 0.045) and total physical activity (r = 0.52; P = 0.037) were also correlated with infant fat-free mass. No maternal variable was significantly correlated with infant adiposity.
CONCLUSIONS-The relationships between maternal physical activity, insulin response, and infant fat-free mass suggest that physical activity during pregnancy may affect metabolic outcomes in the mother and her offspring. Diabetes Care 36:267-269, 2013
C1 [Pomeroy, Jeremy; Renstrom, Frida; Franks, Paul W.] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden.
[Pomeroy, Jeremy] NIH, Phoenix Epidemiol & Clin Res Branch, Phoenix, AZ USA.
[Renstrom, Frida; Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Renstrom, Frida; Gradmark, Anna M.; Franks, Paul W.] Umea Univ, Med Sect, Genet Epidemiol & Clin Res Grp, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Mogren, Ingrid; Persson, Margareta] Umea Univ, Dept Clin Sci, Obstet & Gynecol Unit, Umea, Sweden.
[Persson, Margareta] Dalarna Univ, Sch Hlth & Social Studies, Falun, Sweden.
[Bluck, Les; Wright, Antony] MRC Human Nutr Res, Cambridge, England.
[Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
[Domellof, Magnus] Umea Univ, Dept Pediat, Umea, Sweden.
RP Franks, PW (reprint author), Lund Univ, Skane Univ Hosp, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden.
EM jeremy.pomeroy@nih.gov; paul.franks@med.lu.se
RI Domellof, Magnus/E-5307-2011;
OI Domellof, Magnus/0000-0002-0726-7029; Mogren,
Ingrid/0000-0003-2985-1135; Franks, Paul/0000-0002-0520-7604; Kahn,
Steven/0000-0001-7307-9002
FU Torsten Soderberg foundation; Ragnar Soderberg foundation; Fredrik and
Ingrid Thurings Foundation; Vasterbotten regional health authority;
Medical Research Council Unit [U1059]; National Institute of Diabetes
and Digestive and Kidney Diseases; U.S. Department of Veterans Affairs
FX This study was a preparatory project for the LifeGene Study
(www.lifegene.se) and was funded by the Torsten and Ragnar Soderberg
foundations, Fredrik and Ingrid Thurings Foundation, and Vasterbotten
regional health authority (all grants to P.W.F.). The stable isotope
measurements were conducted under the Medical Research Council Unit
Program U1059. J.P. was supported by the National Institute of Diabetes
and Digestive and Kidney Diseases Intramural Research Program. S.E.K.
was supported in part by the U.S. Department of Veterans Affairs.
NR 9
TC 8
Z9 8
U1 0
U2 11
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2013
VL 36
IS 2
BP 267
EP 269
DI 10.2337/dc12-0885
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 083MA
UT WOS:000314467100023
PM 22966095
ER
PT J
AU Wander, PL
Boyko, EJ
Leonetti, DL
McNeely, MJ
Kahn, SE
Fujimoto, WY
AF Wander, Pandora L.
Boyko, Edward J.
Leonetti, Donna L.
McNeely, Marguerite J.
Kahn, Steven E.
Fujimoto, Wilfred Y.
TI Change in Visceral Adiposity Independently Predicts a Greater Risk of
Developing Type 2 Diabetes Over 10 Years in Japanese Americans
SO DIABETES CARE
LA English
DT Article
ID BODY-FAT DISTRIBUTION; IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE;
LIFETIME RISK; MELLITUS; OBESITY; MEN; CLASSIFICATION; DISEASE; WEIGHT
AB OBJECTIVE-Visceral adiposity is an important risk factor for cardiovascular disease and type 2 diabetes. We sought to determine whether change in intraabdominal fat area (IAF) over time predicts subsequent development of diabetes.
RESEARCH DESIGN AND METHODS-We followed up 436 nondiabetic Japanese-American subjects (mean age 51.9 years, mean BMI 24.2 kg/m(2), 54% male) for development of diabetes. We fit a logistic regression model to examine the association over a 10-year follow-up between change in IAF at 5-year follow-up and other fat areas (measured by computed tomography) and development of incident diabetes, adjusted for age, sex, family history of diabetes in a first-degree relative, second-generation versus third-generation Japanese American (Nisei vs. Sansei), baseline IAF, BMI, weight change over time, smoking status, physical activity level, and subcutaneous fat (SCF) depot areas.
RESULTS-Cumulative incidence of diabetes was 20.4% at 10 years. Mean change in IAF was 10.9 cm(2). An increase of 1 SD in IAF was associated with a 1.65-fold increase in the odds of diabetes over 10 years (OR = 1.65, 95% CI 1.21-2.25) after adjusting for the above covariates. This association was also independent of changes in thoracic, thigh, and abdominal SCF, as well as change in weight.
CONCLUSIONS-We conclude that baseline IAF and accumulation of fat in this area over time are independent predictors of the development of type 2 diabetes in Japanese Americans. Diabetes Care 36:289-293, 2013
C1 [Wander, Pandora L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Boyko, Edward J.; McNeely, Marguerite J.; Kahn, Steven E.; Fujimoto, Wilfred Y.] Univ Washington, Dept Med, Seattle, WA USA.
[Boyko, Edward J.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA.
RP Wander, PL (reprint author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
EM lwander@u.washington.edu
OI Wander, Pandora/0000-0003-3671-1464; Kahn, Steven/0000-0001-7307-9002
FU National Institutes of Health [DK-31170, HL-49293, DK-02654]; Diabetes
Research Center [DK-17047]; Clinical Nutrition Research Unit [DK-35816];
General Clinical Research Center at the University of Washington
[RR-00037]
FX This work was supported by National Institutes of Health grants
DK-31170, HL-49293, and DK-02654 and by facilities and services provided
by the Diabetes Research Center (DK-17047), Clinical Nutrition Research
Unit (DK-35816), and the General Clinical Research Center (RR-00037) at
the University of Washington. VA Puget Sound Health Care System provides
support for the involvement of E.J.B. and S.E.K. in this research.
NR 33
TC 21
Z9 21
U1 0
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2013
VL 36
IS 2
BP 289
EP 293
DI 10.2337/dc12-0198
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 083MA
UT WOS:000314467100028
PM 22966093
ER
PT J
AU Willette, AA
Xu, GF
Johnson, SC
Birdsill, AC
Jonaitis, EM
Sager, MA
Hermann, BP
La Rue, A
Asthana, S
Bendlin, BB
AF Willette, Auriel A.
Xu, Guofan
Johnson, Sterling C.
Birdsill, Alex C.
Jonaitis, Erin M.
Sager, Mark A.
Hermann, Bruce P.
La Rue, Asenath
Asthana, Sanjay
Bendlin, Barbara B.
TI Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late
Middle-Aged Adults
SO DIABETES CARE
LA English
DT Article
ID GRAY-MATTER VOLUME; ALZHEIMERS-DISEASE; RHESUS-MONKEYS; DYSFUNCTION;
RECEPTOR; GLUCOSE; BETA; MORPHOMETRY; METABOLISM; MECHANISMS
AB OBJECTIVE-Insulin resistance dysregulates glucose uptake and other functions in brain areas affected by Alzheimer disease. Insulin resistance may play a role in Alzheimer disease etiopathogenesis. This longitudinal study examined whether insulin resistance among late middle-aged, cognitively healthy individuals was associated with 1) less gray matter in Alzheimer disease-sensitive brain regions and 2) worse cognitive performance.
RESEARCH DESIGN AND METHODS-Homeostasis model assessment of insulin resistance, gray matter volume, and the Rey Auditory Verbal Learning Test (RAVLT) were acquired in 372 participants at baseline and a consecutive subset of 121 individuals similar to 4 years later. Voxel-based morphometry and tensor-based morphometry were used, respectively, to test the association of insulin resistance with baseline brain volume and progressive gray matter atrophy.
RESULTS-Higher insulin resistance predicted less gray matter at baseline and 4 years later in medial temporal lobe, prefrontal cortices, precuneus, and other parietal gyri. A region-of-interest analysis, independent of the voxel-wise analyses, confirmed that higher insulin resistance was related to medial temporal lobe atrophy. Atrophy itself corresponded to cognitive deficits in the RAVLT. Temporal lobe atrophy that was predicted by higher insulin resistance significantly mediated worse RAVLT encoding performance.
CONCLUSIONS-These results suggest that insulin resistance in an asymptomatic, late middle-aged cohort is associated with progressive atrophy in regions affected by early Alzheimer disease. Insulin resistance may also affect the ability to encode episodic information by negatively influencing gray matter volume in medial temporal lobe. Diabetes Care 36:443-449, 2013
C1 [Willette, Auriel A.; Xu, Guofan; Johnson, Sterling C.; Birdsill, Alex C.; Asthana, Sanjay; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Willette, Auriel A.; Johnson, Sterling C.] Univ Wisconsin, Waisman Lab Brain Imaging & Behav, Madison, WI USA.
[Willette, Auriel A.; Xu, Guofan; Johnson, Sterling C.; Birdsill, Alex C.; Jonaitis, Erin M.; Sager, Mark A.; Hermann, Bruce P.; La Rue, Asenath; Asthana, Sanjay; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA.
[Xu, Guofan] Univ Wisconsin, Dept Nucl Med, Madison, WI USA.
[Jonaitis, Erin M.; Sager, Mark A.; Hermann, Bruce P.; La Rue, Asenath; Asthana, Sanjay] Wisconsin Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA.
RP Bendlin, BB (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
EM bbb@medicine.wisc.edu
OI Bendlin, Barbara/0000-0002-0580-9875
FU National Institutes of Health [R01AG21155, R01AG027161, P50AG033514]
FX This study was supported by National Institutes of Health grants
R01AG21155, R01AG027161, and P50AG033514. Portions of data collection
and analysis were facilitated by resources from the Veterans
Administration at the William S. Middleton Memorial Veterans Hospital
and Geriatric Research Education and Clinical Center in Madison,
Wisconsin.
NR 40
TC 48
Z9 48
U1 1
U2 12
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2013
VL 36
IS 2
BP 443
EP 449
DI 10.2337/dc12-0922
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 083MA
UT WOS:000314467100050
PM 23069842
ER
PT J
AU Shameli, A
Yamanouchi, J
Tsai, S
Yang, Y
Clemente-Casares, X
Moore, A
Serra, P
Santamaria, P
AF Shameli, Afshin
Yamanouchi, Jun
Tsai, Sue
Yang, Yang
Clemente-Casares, Xavier
Moore, Anna
Serra, Pau
Santamaria, Pere
TI IL-2 promotes the function of memory-like autoregulatory CD8+T cells but
suppresses their development via FoxP3+Treg cells
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Autoregulatory T-cell memory; CD122; FoxP3+CD25+Treg cells; IL-2; Type 1
diabetes
ID CD8(+) T-CELLS; NONOBESE DIABETIC MICE; SECONDARY EXPANSION; AVIDITY
MATURATION; CD8-T-CELL MEMORY; CD4-T-CELL HELP; BONE-MARROW; RESPONSES;
PROLIFERATION; AUTOIMMUNITY
AB IL-2 plays a critical role in both effector T-cell development and FoxP3+CD4+ Treg-cell homeostasis. A reduction in Il2 transcription results in impaired FoxP3+CD4+ Treg-cell recruitment and function, and accounts for the association between murine Il2 and type 1 diabetes (T1D). The progression of T1D elicits a disease-countering negative feedback regulatory loop that involves the differentiation of low-avidity autoreactive CD8+ T cells into memory-like autoregulatory T cells in a CD4+ Th-dependent manner. Since these auto-regulatory T cells express IL-2R (CD122), we hypothesized that their development might also be regulated by IL-2. Here, we investigate the effects of differences in IL-2 expression on this autoregulatory subset. We show that decreased IL-2 production impairs the regulatory capacity of memory-like autoregulatory CD8+CD122+ T cells. Surprisingly, we also find that a reduction in IL-2 production capacity increases memory autoregulatory CD8+ T-cell formation indirectly, by decreasing the development and function of FoxP3+ Treg cells in nonobese diabetic mice. These results illustrate a complex homeostatic interplay between IL-2, CD4+ Th cells, FoxP3+CD4+ Treg cells and autoregulatory CD8+ T-cell memory whereby IL-2 controls the function of both Treg-cell subsets, but IL-2-potentiation of FoxP3+CD4+ Treg-cell function results in the suppression of CD4+ Th-cell activation and autoregulatory memory CD8+ T-cell formation.
C1 [Shameli, Afshin; Yamanouchi, Jun; Tsai, Sue; Yang, Yang; Clemente-Casares, Xavier; Santamaria, Pere] Univ Calgary, JMDRC, Calgary, AB T2N 4N1, Canada.
[Shameli, Afshin; Yamanouchi, Jun; Tsai, Sue; Yang, Yang; Clemente-Casares, Xavier; Santamaria, Pere] Univ Calgary, Dept Microbiol, Snyder Inst Chron Dis, Calgary, AB T2N 4N1, Canada.
[Shameli, Afshin; Yamanouchi, Jun; Tsai, Sue; Yang, Yang; Clemente-Casares, Xavier; Santamaria, Pere] Univ Calgary, Dept Immunol, Snyder Inst Chron Dis, Calgary, AB T2N 4N1, Canada.
[Shameli, Afshin; Yamanouchi, Jun; Tsai, Sue; Yang, Yang; Clemente-Casares, Xavier; Santamaria, Pere] Univ Calgary, Dept Infect Dis, Snyder Inst Chron Dis, Calgary, AB T2N 4N1, Canada.
[Yang, Yang] Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.
[Moore, Anna] Massachusetts Gen Hosp, Mol Imaging Lab, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Dept Radiol, Charlestown, MA USA.
[Serra, Pau; Santamaria, Pere] Hosp Clin Barcelona, Ctr Esther Koplowitz, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain.
RP Santamaria, P (reprint author), Univ Calgary, Dept Microbiol Immunol & Infect Dis, HRIC 4A22,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM psantama@ucalgary.ca
FU Canadian Institutes of Health Research; Alberta Innovates-Health
Solutions (AIHS); Diabetes Association (Foothills); Canadian Diabetes
Association
FX We thank J. Luces and R. Barasi for technical assistance, and L. Kennedy
and L. Robertson for flow cytometry. This work was supported by the
Canadian Institutes of Health Research. A. S. and S. T. were supported
by studentships from Alberta Innovates-Health Solutions (AIHS). P.
Santamaria is a Scientist of AIHS and a Scholar of the Juvenile Diabetes
Research Foundation and Instituto de Investigaciones Sanitarias Carlos
III. P. Serra is an investigator of the Ramon y Cajal re-integration
program of the Ministerio de Economia y Competitividad of Spain. The
JMDRC was supported by the Diabetes Association (Foothills) and the
Canadian Diabetes Association.
NR 40
TC 12
Z9 13
U1 0
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD FEB
PY 2013
VL 43
IS 2
BP 394
EP 403
DI 10.1002/eji.201242845
PG 10
WC Immunology
SC Immunology
GA 091LN
UT WOS:000315051100013
PM 23180662
ER
PT J
AU Gurol, ME
AF Gurol, M. E.
TI Cerebral hypoperfusion and white matter disease in healthy elderly and
patients with Alzheimer's disease
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Editorial Material
ID AMYLOID ANGIOPATHY; HYPERINTENSITIES; FLOW
C1 [Gurol, M. E.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Gurol, M. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Gurol, ME (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA.
EM megurol@partners.org
RI Gurol, Edip/J-2279-2014
OI Gurol, Edip/0000-0002-2169-4457
FU NIA NIH HHS [R01 AG026484, R01 AG26484]; NINDS NIH HHS [T32 NS048005]
NR 11
TC 4
Z9 4
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD FEB
PY 2013
VL 20
IS 2
BP 214
EP 215
DI 10.1111/j.1468-1331.2012.03865.x
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 090RO
UT WOS:000314997200005
PM 22958114
ER
PT J
AU Kumar, KR
Ramirez, A
Gobel, A
Kresojevic, N
Svetel, M
Lohmann, K
Sue, CM
Rolfs, A
Mazzulli, JR
Alcalay, RN
Krainc, D
Klein, C
Kostic, V
Grunewald, A
AF Kumar, K. R.
Ramirez, A.
Goebel, A.
Kresojevic, N.
Svetel, M.
Lohmann, K.
Sue, C. M.
Rolfs, A.
Mazzulli, J. R.
Alcalay, R. N.
Krainc, D.
Klein, C.
Kostic, V.
Gruenewald, A.
TI Glucocerebrosidase mutations in a Serbian Parkinson's disease population
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE Gaucher disease; GBA; glucocerebrosidase; Parkinson's disease; Serbian
ID GAUCHER-DISEASE; N370S; GENE; HAPLOTYPE
AB Background and purpose: To screen for glucocerebrosidase (GBA) mutations in a Serbian Parkinson's disease (PD) population.
Methods: Glucocerebrosidase exons 8-11 harbouring the most common mutations were sequenced in 360 patients with PD and 348 controls from Serbia. Haplotype analysis was performed for the N370S mutation and compared with German and Ashkenazi Jewish carriers.
Results: Glucocerebrosidase mutations were significantly more frequent in patients with PD (21/360; 5.8%) vs. controls (5/348; 1.4%; OR = 4.25; CI, 1.58-11.40; P = 0.0041). Two patients with PD carried homozygous or compound heterozygous mutations in GBA. The N370S mutation accounted for about half of the mutated alleles in patients (10/23) but was absent amongst controls. Three novel variants were detected including two non-synonymous variants (D380V, N392S) in the patient group and one synonymous change (V459V) in a control. Carriers of the D409H mutation were also sequenced for H255Q, and all were found to carry the [D409H; H255Q] double-mutant allele. Genotyping suggested a common haplotype for all N370S carriers.
Conclusion: Glucocerebrosidase mutations represent a PD risk factor in the Serbian population.
C1 [Kumar, K. R.; Ramirez, A.; Goebel, A.; Lohmann, K.; Klein, C.; Gruenewald, A.] Med Univ Lubeck, Dept Neurol, Sect Clin & Mol Neurogenet, D-23538 Lubeck, Germany.
[Kumar, K. R.; Sue, C. M.] Royal N Shore Hosp, Kolling Inst Med Res, Dept Neurogenet, Sydney, NSW, Australia.
[Kumar, K. R.; Sue, C. M.] Univ Sydney, Sydney, NSW 2006, Australia.
[Ramirez, A.] Univ Hosp Bonn, Dept Psychiat, Bonn, Germany.
[Kresojevic, N.; Svetel, M.; Kostic, V.] Univ Belgrade, Sch Med, Inst Neurol CCS, Belgrade, Serbia.
[Rolfs, A.] Univ Rostock, Albrecht Kossel Inst Neuroregenerat, D-18055 Rostock, Germany.
[Mazzulli, J. R.; Krainc, D.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,MassGen Inst Neurodegenera, Charlestown, MA USA.
[Alcalay, R. N.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
RP Klein, C (reprint author), Med Univ Lubeck, Dept Neurol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM Christine.klein@neuro.uni-luebeck.de
FU Dora Lush National Health and Medical Research Council of Australia;
Ministry of Education and Science of the Republic of Serbia [175090];
Australian Brain Foundation; Parkinson's NSW Foundation; Australian
Department of Health and Aging; National Health and Medical Research
Council of Australia [1010839]; National Institutes of Health
[F32NS066730, R01NS051303]; Parkinson's Disease Foundation; Brookdale
Foundation; National Parkinson Foundation; GENE-PARK [EU-LSHB-CT-.
2006-037544]; Novartis Pharma; Volkswagen Foundation; Hermann and Lilly
Schilling Foundation; BMBF [01GI0201]; Boehringer Ingelheim; Centogene;
Fritz Thyssen Foundation; Dystonia Medical Research Foundation
FX Kishore R. Kumar receives funding from the Dora Lush National Health and
Medical Research Council of Australia postgraduate scholarship. Alfredo
Ramirez and Anna Gobel report no disclosures. Nikola Kresojevic and
Marina Svetel are supported by a scientific grant from the Ministry of
Education and Science of the Republic of Serbia (Grant #175090). Carolyn
M. Sue receives support from the Australian Brain Foundation, the
Parkinson's NSW Foundation, the Australian Department of Health and
Aging and the National Health and Medical Research Council of Australia
(Grant #1010839). Joseph R. Mazzulli has received support from the
National Institutes of Health (Grant F32NS066730). Roy N. Alcalay
receives support from the Parkinson's Disease Foundation H. Houston
Merritt Fellowship in Movement Disorders and has also received
publishing royalties for Early Onset Parkinson's Disease (Cyberounds,
2010) and research support from the Brookdale Foundation. Dimitri Krainc
has received support from the National Institutes of Health (Grant
R01NS051303), the National Parkinson Foundation, and a GENE-PARK
(EU-LSHB-CT-. 2006-037544) grant and research support from Novartis
Pharma. Christine Klein is supported by grants from the Volkswagen
Foundation (Lichtenberg Grant), the Hermann and Lilly Schilling
Foundation and from the BMBF (01GI0201) and has also received consulting
fees from Boehringer Ingelheim and Centogene and speaker honoraria from
Boehringer Ingelheim and Merz Pharma. Vladimir S. Kostic is supported by
a scientific grant from the Ministry of Education and Science of the
Republic of Serbia (Grant #175090) and has served on a scientific
advisory board for Boehringer Ingelheim and received speaker honoraria
from Novartis, Boehringer Ingelheim, Libra (Merck Serono), Lundbeck Inc.
and GlaxoSmithKline. Anne Grunewald receives funding from the Fritz
Thyssen Foundation and the Dystonia Medical Research Foundation. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 13
TC 18
Z9 18
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD FEB
PY 2013
VL 20
IS 2
BP 402
EP 405
DI 10.1111/j.1468-1331.2012.03817.x
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 090RO
UT WOS:000314997200033
PM 22812582
ER
PT J
AU Schon, K
Ross, RS
Hasselmo, ME
Stern, CE
AF Schon, Karin
Ross, Robert S.
Hasselmo, Michael E.
Stern, Chantal E.
TI Complementary roles of medial temporal lobes and mid-dorsolateral
prefrontal cortex for working memory for novel and familiar trial-unique
visual stimuli
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE familiarity monitoring; hippocampus; human; parahippocampal cortex;
retrieval success
ID LONG-TERM-MEMORY; LATERAL FRONTAL-CORTEX; EVENT-RELATED FMRI; PARIETAL
CORTEX; EPISODIC MEMORY; RECOGNITION MEMORY; ENTORHINAL CORTEX; DELAYED
MATCH; RELATIONAL INFORMATION; LOCATION ASSOCIATIONS
AB It has been suggested that working memory (WM) for novel information requires the medial temporal lobes (MTL), but is not necessary for WM for familiar stimuli. In previous studies that directly compared WM for novel and familiar stimuli, only the novel stimuli were trial-unique. Here, 16 young human subjects performed a Sternberg WM task with visual scenes while in a functional magnetic resonance imaging scanner. All task stimuli were trial-unique, but were either new (Novel condition) or previously learned (Familiar condition). This design allowed investigation of whether MTL and prefrontal cortex (PFC) activity is related specifically to the novelty/familiarity of the stimuli or to their trial-unique status during WM. We observed greater hippocampal and parahippocampal activity during encoding and maintenance for novel than for familiar stimuli. In contrast, right mid-dorsolateral PFC (dlPFC) activity was greater during encoding of familiar than novel stimuli. The mid-dlPFC was not recruited during maintenance or for retrieval when the Familiar condition was contrasted with the Novel condition. However, left mid-dlPFC activity was present at retrieval when correct Match trials (i.e. hits) were contrasted with correct Non-match trials (i.e. correct rejections) for the Novel condition. The results support the hypothesis that MTL regions are required for the encoding and maintenance of novel stimuli during WM, demonstrating that the observed MTL activity is not related to the trial-uniqueness of the stimuli per se. Furthermore, the observed activation pattern in mid-dlPFC suggests a role for the mid-dlPFC in executive control-associated processes related to monitoring of scene familiarity at encoding and retrieval during WM.
C1 [Schon, Karin; Ross, Robert S.; Hasselmo, Michael E.; Stern, Chantal E.] Boston Univ, Dept Psychol, CELEST, Boston, MA 02215 USA.
[Schon, Karin; Ross, Robert S.; Hasselmo, Michael E.; Stern, Chantal E.] Boston Univ, Ctr Memory & Brain, CELEST, Boston, MA 02215 USA.
[Schon, Karin; Ross, Robert S.; Stern, Chantal E.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
RP Schon, K (reprint author), Boston Univ, Dept Psychol, CELEST, 64 Cummington St, Boston, MA 02215 USA.
EM kschon@bu.edu
OI Schon, Karin/0000-0003-2963-8449; Ross, Robert/0000-0002-3987-881X;
Hasselmo, Michael/0000-0002-9925-6377
FU CELEST, an NSF Science of Learning Center [SBE 0354278]; Silvio O. Conte
Center for Neuroscience Research [NIH P50 MH094263]; Boston University
Undergraduate Research Opportunities Program; [P41RR14075]
FX This work was supported by CELEST, an NSF Science of Learning Center
(SBE 0354278), by the Silvio O. Conte Center for Neuroscience Research
(NIH P50 MH094263) and by the Boston University Undergraduate Research
Opportunities Program (Julie Olofson). Imaging data were collected at
the Athinoula A. Martinos Center for Biomedical Imaging in Charlestown,
MA, USA (supported by P41RR14075). We would like to thank Yakeel Quiroz
and Julie Olofson for help with data collection and preprocessing, and
Julie Olofson and Friederike Thiel for help with collecting stimuli,
putting together the behavioral tasks and for initial behavioral
piloting. The authors declare that they have no conflict of interest.
NR 93
TC 7
Z9 7
U1 1
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD FEB
PY 2013
VL 37
IS 4
BP 668
EP 678
DI 10.1111/ejn.12062
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 091YM
UT WOS:000315085700017
PM 23167976
ER
PT J
AU Parikh, RB
Alba, GA
Zukerberg, LR
AF Parikh, Ravi B.
Alba, George A.
Zukerberg, Lawrence R.
TI Tense Ascites in a Postpartum Woman
SO GASTROENTEROLOGY
LA English
DT Editorial Material
C1 [Parikh, Ravi B.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Alba, George A.; Zukerberg, Lawrence R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Parikh, RB (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 2013
VL 144
IS 2
BP 272
EP 467
DI 10.1053/j.gastro.2012.08.025
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 086VL
UT WOS:000314716300016
PM 23253295
ER
PT J
AU Wong, GS
Habibollahi, P
Heidari, P
Lee, JS
Klein-Szanto, AJ
Waldron, TJ
Gimotty, P
Nakagawa, H
Taylor, PR
Wang, TC
Mahmood, U
Rustgi, AK
AF Wong, Gabrielle S.
Habibollahi, Peiman
Heidari, Pedram
Lee, Ju-Seog
Klein-Szanto, Andres J.
Waldron, Todd J.
Gimotty, Phyllis
Nakagawa, Hiroshi
Taylor, Philip R.
Wang, Timothy C.
Mahmood, Umar
Rustgi, Anil K.
TI Optical Imaging of Periostin Enables Early Endoscopic Detection and
Characterization of Esophageal Cancer in Mice
SO GASTROENTEROLOGY
LA English
DT Article
DE Mouse Model; Esophageal Cancer; Extracellular; Matrix; POSTN; Tumor
Microenvironment
ID TUMOR MICROENVIRONMENT; CELL; IDENTIFICATION; INVASION
AB Imaging strategies that detect early stage esophageal squamous cell carcinoma (ESCC) could improve clinical outcomes, when combined with endoscopic approaches. Periostin is an integrin-binding protein that is important in the tumor microenvironment. We created a fluorescent-labeled antibody that recognizes periostin and binds specifically to ESCC xenograft tumors in mice. In L2-cre; p120ctnLoxP/LoxP mice, which develop squamous cell cancers that resemble human ESCC, we visualized the probe in preneoplastic and neoplastic esophageal lesions using near-infrared fluorescent imaging with upper-gastrointestinal endoscopy. Periostin might be a biomarker of the esophageal tumor microenvironment that can be used to detect preneoplastic lesions.
C1 [Wong, Gabrielle S.; Waldron, Todd J.; Nakagawa, Hiroshi; Rustgi, Anil K.] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
[Wong, Gabrielle S.; Waldron, Todd J.; Nakagawa, Hiroshi; Rustgi, Anil K.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Wong, Gabrielle S.; Waldron, Todd J.; Gimotty, Phyllis; Nakagawa, Hiroshi; Rustgi, Anil K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Gimotty, Phyllis] Univ Penn, Ctr Clin Epidemiol & Biostat, Div Biostat, Philadelphia, PA 19104 USA.
[Rustgi, Anil K.] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
[Habibollahi, Peiman; Heidari, Pedram; Mahmood, Umar] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Lee, Ju-Seog] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
[Klein-Szanto, Andres J.] Fox Chase Canc Ctr, Dept Pathol & Canc Biol, Philadelphia, PA 19111 USA.
[Taylor, Philip R.] NCI, Genet Epidemiol Branch, DCEG, NIH, Bethesda, MD 20892 USA.
[Wang, Timothy C.] Columbia Univ, Med Ctr, Dept Med, Div Digest & Liver Dis, New York, NY USA.
[Wang, Timothy C.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
RP Rustgi, AK (reprint author), Univ Penn, 951 BRB,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM anil2@mail.med.upenn.edu
FU National Institutes of Health/NCI [P01-CA098101, U01-CA14305603];
National Institutes of Health [T32-CA115299, F32-CA162719]; National
Institutes of Health/NIDDK [T32-DK007066]; National Institutes of
Health/NIDDK Center for Molecular Studies in Digestive and Liver
Diseases [P30DK050306]; American Cancer Society [RP-10-033-01-CCE];
Intramural Research Program of the US National Institutes of Health,
NCI; Division of Cancer Epidemiology and Genetics
FX Supported by National Institutes of Health/NCI grant P01-CA098101,
National Institutes of Health grant T32-CA115299, National Institutes of
Health/NIDDK (T32-DK007066), National Institutes of Health
(F32-CA162719), National Institutes of Health/NCI grant U01-CA14305603,
National Institutes of Health/NIDDK Center for Molecular Studies in
Digestive and Liver Diseases (P30DK050306), American Cancer Society
(RP-10-033-01-CCE), and the Intramural Research Program of the US
National Institutes of Health, NCI, and the Division of Cancer
Epidemiology and Genetics.
NR 15
TC 11
Z9 12
U1 1
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 2013
VL 144
IS 2
BP 294
EP 297
DI 10.1053/j.gastro.2012.10.030
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 086VL
UT WOS:000314716300022
PM 23085486
ER
PT J
AU Dominitz, JA
Baldwin, LM
Green, P
Kreuter, WI
Ko, CW
AF Dominitz, Jason A.
Baldwin, Laura-Mae
Green, Pamela
Kreuter, William I.
Ko, Cynthia W.
TI Regional Variation in Anesthesia Assistance During Outpatient
Colonoscopy Is Not Associated With Differences in Polyp Detection or
Complication Rates
SO GASTROENTEROLOGY
LA English
DT Article
DE Colorectal Cancer Screening; Cost Efficacy; Quality; Pain
ID DEEP SEDATION; UNITED-STATES; GI ENDOSCOPY; PROPOFOL; POPULATION;
MEDICARE; ECONOMICS; SERVICES; QUALITY; SYSTEM
AB BACKGROUND & AIMS: We investigated the rate and predictors of anesthesia assistance during outpatient colonoscopy and whether anesthesia assistance is associated with colonoscopy interventions and outcomes. METHODS: We performed a retrospective cohort study using a 20% sample of Medicare administrative claims submitted during the 2003 calendar year. We analyzed data from 328,177 adults, 66 years old or older, who underwent outpatient colonoscopy examinations. RESULTS: Overall, 8.7% of outpatient colonoscopies were performed with anesthesia assistance. In multivariate analysis, independent predictors of anesthesia assistance included black race, female sex, and a nonscreening indication; anesthesia assistance increased with median income and comorbidities. General and colorectal surgeons, fewer years in their practice, and nonhospital site of service were also significantly associated with anesthesia assistance. The strongest predictor of anesthesia assistance was the Medicare carrier, with odds ratios ranging from 0.22 (95% confidence interval: 0.12-0.43) for the Arkansas carrier (crude rate 0.9%) to 9.90 (95% confidence interval: 7.92-12.39) for the Empire carrier in New York area (crude rate 35.3%) compared with the Wisconsin carrier (crude rate 4.3%). There was also considerable variation among endoscopists; 75% of providers had no colonoscopies with anesthesia assistance recorded in their dataset, and 4.5% of providers had anesthesia assistance in at least three quarters of their examinations. Anesthesia assistance was not associated with the diagnosis of polyps, the performance of biopsy or polypectomy, or complications in multivariate analyses. CONCLUSIONS: There are significant variations among regions and sites of service in anesthesia assistance during outpatient colonoscopies of Medicare beneficiaries. Although this variation has considerable economic implications, it was not associated with measures of patient risk or outcomes, such as polyp detection or procedure-related complications.
C1 [Dominitz, Jason A.; Green, Pamela] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA.
[Dominitz, Jason A.; Ko, Cynthia W.] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA.
[Baldwin, Laura-Mae] Univ Washington, Sch Med, Dept Family Med, Seattle, WA 98195 USA.
[Kreuter, William I.] Univ Washington, Dept Hlth Serv, Sch Med, Seattle, WA 98195 USA.
RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst S111 GI, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM Jason.Dominitz@va.gov
OI Dominitz, Jason/0000-0002-8070-7086
FU American College of Gastroenterology; NIH [CA127659]; American Society
for Gastrointestinal Endoscopy Endoscopic Research Career Development
Award; VA Puget Sound Health Care System, Department of Veterans Affairs
FX This material is based on work supported by the VA Puget Sound Health
Care System, Department of Veterans Affairs. The views expressed in this
article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs.; Support was
received from the American College of Gastroenterology (CWK), NIH
CA127659 (CWK), and American Society for Gastrointestinal Endoscopy
Endoscopic Research Career Development Award (JAD).
NR 30
TC 14
Z9 14
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 2013
VL 144
IS 2
BP 298
EP 306
DI 10.1053/j.gastro.2012.10.038
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 086VL
UT WOS:000314716300023
PM 23103615
ER
PT J
AU Shalbueva, N
Mareninova, OA
Gerloff, A
Yuan, JZ
Waldron, RT
Pandol, SJ
Gukovskaya, AS
AF Shalbueva, Natalia
Mareninova, Olga A.
Gerloff, Andreas
Yuan, Jingzhen
Waldron, Richard T.
Pandol, Stephen J.
Gukovskaya, Anna S.
TI Effects of Oxidative Alcohol Metabolism on the Mitochondrial
Permeability Transition Pore and Necrosis in a Mouse Model of Alcoholic
Pancreatitis
SO GASTROENTEROLOGY
LA English
DT Article
DE Tissue Damage; Ethanol Toxicity; Cell Death; Exocrine Pancreas
ID KAPPA-B ACTIVATION; ACINAR-CELLS; CYCLOPHILIN-D; ACETALDEHYDE
METABOLISM; MOLECULAR-MECHANISMS; CYCLOSPORINE-A; ETHANOL; CALCIUM;
DEATH; APOPTOSIS
AB BACKGROUND & AIMS: Opening of the mitochondrial permeability transition pore (MPTP) causes loss of the mitochondrial membrane potential (Delta Psi m) and, ultimately, adenosine triphosphate depletion and necrosis. Cells deficient in cyclophilin D (CypD), a component of the MPTP, are resistant to MPTP opening, loss of Delta Psi m, and necrosis. Alcohol abuse is a major risk factor for pancreatitis and is believed to sensitize the pancreas to stressors, by poorly understood mechanisms. We investigated the effects of ethanol on the pancreatic MPTP, the mechanisms of these effects, and their role in pancreatitis. METHODS: We measured Delta Psi m in mouse pancreatic acinar cells incubated with ethanol alone and in combination with physiologic and pathologic concentrations of cholecystokinin-8 (CCK). To examine the role of MPTP, we used ex vivo and in vivo models of pancreatitis, induced in wild-type and CypD(-/-) mice by a combination of ethanol and CCK. RESULTS: Ethanol reduced basal Delta Psi m and converted a transient depolarization, induced by physiologic concentrations of CCK, into a sustained decrease in Delta Psi m, resulting in reduced cellular adenosine triphosphate and increased necrosis. The effects of ethanol and CCK were mediated by MPTP because they were not observed in CypD(-/-) acinar cells. Ethanol and CCK activated MPTP through different mechanisms-ethanol by reducing the ratio of oxidized nicotinamide adenine dinucleotide to reduced nicotinamide adenine dinucleotide, as a result of oxidative metabolism, and CCK by increasing cytosolic Ca2+. CypD(-/-) mice developed a less-severe form of pancreatitis after administration of ethanol and CCK. CONCLUSIONS: Oxidative metabolism of ethanol sensitizes pancreatic mitochondria to activate MPTP, leading to mitochondrial failure; this makes the pancreas susceptible to necrotizing pancreatitis.
C1 [Shalbueva, Natalia; Mareninova, Olga A.; Gerloff, Andreas; Yuan, Jingzhen; Waldron, Richard T.; Pandol, Stephen J.; Gukovskaya, Anna S.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, So Calif Res Ctr Alcohol Liver & Pancreat Dis & C, Los Angeles, CA 90073 USA.
[Shalbueva, Natalia] Russian Acad Sci, Inst Gen & Expt Biol, Siberian Branch, Ulan Ude, Russia.
RP Gukovskaya, AS (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd,Bldg 258,Room 340, Los Angeles, CA 90073 USA.
EM agukovsk@ucla.edu
FU Southern California Research Center for ALPD and Cirrhosis (National
Institutes of Health) [P50AA11999]; Department of Veterans Affairs;
National Institutes of Health [R01 DK59936, R01 AA19730]
FX Supported by the Southern California Research Center for ALPD and
Cirrhosis (National Institutes of Health grant P50AA11999), Department
of Veterans Affairs, and in part by the National Institutes of Health
(R01 grants DK59936 and AA19730).
NR 42
TC 13
Z9 13
U1 2
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB
PY 2013
VL 144
IS 2
BP 437
EP +
DI 10.1053/j.gastro.2012.10.037
PG 16
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 086VL
UT WOS:000314716300037
PM 23103769
ER
PT J
AU Fitzgerald, DC
Fonseca-Kelly, Z
Cullimore, ML
Safabakhsh, P
Saris, CJM
Zhang, GX
Rostami, AM
AF Fitzgerald, Denise C.
Fonseca-Kelly, Zoe
Cullimore, Melissa L.
Safabakhsh, Pegah
Saris, Christiaan J. M.
Zhang, Guang-Xian
Rostami, A. M.
TI Independent and inter-dependent immunoregulatory effects of IL-27,
IFN-beta eta and IL-10 in the suppression of human Th17 cells and murine
Experimental Autoimmune Encephalomyelitis
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Meeting Abstract
C1 [Fitzgerald, Denise C.] Queens Univ Belfast, Ctr Infect & Immun, Belfast BT7 1NN, Antrim, North Ireland.
[Fonseca-Kelly, Zoe] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Cullimore, Melissa L.; Safabakhsh, Pegah; Zhang, Guang-Xian; Rostami, A. M.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.
[Saris, Christiaan J. M.] Amgen Inc, Dept Inflammat Res, Thousand Oaks, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD FEB
PY 2013
VL 182
SU 1
BP S7
EP S7
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 092AG
UT WOS:000315090600011
ER
PT J
AU Wongviriyawong, C
Harris, RS
Greenblatt, E
Winkler, T
Venegas, JG
AF Wongviriyawong, C.
Harris, R. S.
Greenblatt, E.
Winkler, T.
Venegas, J. G.
TI Peripheral resistance: a link between global airflow obstruction and
regional ventilation distribution
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE distal lung; peripheral airway; structure and function; modeling; asthma
ID HYPERPOLARIZED HE-3 MRI; LUNG-MECHANICS; BRONCHIAL TREE; AIRWAYS;
ASTHMA; CT; PET; BRONCHOCONSTRICTION; HETEROGENEITY; METHACHOLINE
AB Wongviriyawong C, Harris RS, Greenblatt E, Winkler T, Venegas JG. Peripheral resistance: a link between global airflow obstruction and regional ventilation distribution. J Appl Physiol 114: 504-514, 2013. First published November 1, 2012; doi: 10.1152/japplphysiol.00273.2012.-Airflow obstruction and heterogeneities in airway constriction and ventilation distribution are well-described prominent features of asthma. However, the mechanistic link between these global and regional features has not been well defined. We speculate that peripheral airway resistance (R-p) may provide such a link. Structural and functional parameters are estimated from PET and HRCT images of asthmatic (AS) and nonasthmatic (NA) subjects measured at baseline (BASE) and post-methacholine challenge (POST). Conductances of 35 anatomically defined proximal airways are estimated from airway geometry obtained from high-resolution computed tomography (HRCT) images. Compliances of sublobar regions subtended by 19 most distal airways are estimated from changes in regional gas volume between two lung volumes. Specific ventilations (s(V) over dot) of these sublobar regions are evaluated from (NN)-N-13-washout PET scans. For each pathway connecting the trachea to sublobar region, values of R-p required to explain the s(V) over dot distribution and global airflow obstruction are computed. Results show that R-p is highly heterogeneous within each subject, but has average values consistent with global values in the literature. The contribution of R-p to total pathway resistance (R-T) increased substantially for POST (P < 0.0001). The fraction R-p/R-T was higher in AS than NA at POST (P < 0.0001) but similar at BASE (range: 0.960-0.997, median: 0.990). For POST, R-p/R-T range was 0.979-0.999 (NA) and 0.981-0.995 (AS). This approach allows for estimations of peripheral airway resistance within anatomically defined sublobar regions in vivo human lungs and may be used to evaluate peripheral effects of therapy in a subject specific manner.
C1 [Wongviriyawong, C.; Greenblatt, E.; Winkler, T.; Venegas, J. G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Harris, R. S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Pulm & Crit Care Unit, Boston, MA USA.
[Greenblatt, E.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
RP Wongviriyawong, C (reprint author), 114 Thailand Sci Pk,Paholyothin Rd,Klong 1, Klongluang 12120, Pathumthani, Thailand.
EM mint.wongviriyawong@gmail.com
RI Winkler, Tilo/B-5337-2009
OI Winkler, Tilo/0000-0002-7276-5550
FU National Institutes of Health [R01-HL-068011]
FX This work was supported by National Institutes of Health Grant
R01-HL-068011.
NR 40
TC 10
Z9 10
U1 0
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD FEB
PY 2013
VL 114
IS 4
BP 504
EP 514
DI 10.1152/japplphysiol.00273.2012
PG 11
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 092KA
UT WOS:000315118300010
PM 23123354
ER
PT J
AU Kalwani, NM
Ong, CA
Lysaght, AC
Haward, SJ
McKinley, GH
Stankovic, KM
AF Kalwani, Neil M.
Ong, Cheng Ai
Lysaght, Andrew C.
Haward, Simon J.
McKinley, Gareth H.
Stankovic, Konstantina M.
TI Quantitative polarized light microscopy of unstained mammalian cochlear
sections
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE quantitative polarized light microscopy; cochlea; birefringence;
retardance; collagen; myelin
ID OPTICAL COHERENCE TOMOGRAPHY; INNER-EAR; ARTICULAR-CARTILAGE; RAT
COCHLEA; BASILAR-MEMBRANE; COLLAGEN NETWORK; BIREFRINGENCE; ORIENTATION;
PATHOLOGY; DISEASES
AB Hearing loss is the most common sensory deficit in the world, and most frequently it originates in the inner ear. Yet, the inner ear has been difficult to access for diagnosis because of its small size, delicate nature, complex three-dimensional anatomy, and encasement in the densest bone in the body. Evolving optical methods are promising to afford cellular diagnosis of pathologic changes in the inner ear. To appropriately interpret results from these emerging technologies, it is important to characterize optical properties of cochlear tissues. Here, we focus on that characterization using quantitative polarized light microscopy (qPLM) applied to unstained cochlear sections of the mouse, a common animal model of human hearing loss. We find that the most birefringent cochlear materials are collagen fibrils and myelin. Retardance of the otic capsule, the spiral ligament, and the basilar membrane are substantially higher than that of other cochlear structures. Retardance of the spiral ligament and the basilar membrane decrease from the cochlear base to the apex, compared with the more uniform retardance of other structures. The intricate structural details revealed by qPLM of unstained cochlear sections ex vivo strongly motivate future application of polarization-sensitive optical coherence tomography to human cochlea in vivo. (C) 2013 Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10.1117/1.JBO.18.2.026021]
C1 [Kalwani, Neil M.; Ong, Cheng Ai; Lysaght, Andrew C.; Stankovic, Konstantina M.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Kalwani, Neil M.; Ong, Cheng Ai; Lysaght, Andrew C.; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Ong, Cheng Ai] Queen Elizabeth Hosp, ENT Dept, Kota Kinabalu 88586, Sabah, Malaysia.
[Lysaght, Andrew C.; Stankovic, Konstantina M.] Harvard Massachusetts Inst Technol Joint Div Hlth, Program Speech & Hearing Biosci & Technol, Cambridge, MA 02139 USA.
[Haward, Simon J.; McKinley, Gareth H.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Haward, Simon J.] Univ Porto, Fac Engn, Ctr Estudos Fenomenos Transporte, P-4200465 Oporto, Portugal.
RP Stankovic, KM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM Konstantina_Stankovich@meei.harvard.edu
RI Haward, Simon/H-8700-2013
OI Haward, Simon/0000-0002-1884-4100
FU National Institute on Deafness and other Communication Disorders [K08
DC010419, T32 DC00038]; Bertarelli Foundation; Harvard Medical School
Scholars in Medicine Office; Malaysian Federal Training Scholarship;
NASA Microgravity Fluid Sciences [NNX09AV99G]
FX We are grateful for the support of the National Institute on Deafness
and other Communication Disorders Grants K08 DC010419 (K. M. S.) and T32
DC00038 (A. C. L.), the Bertarelli Foundation (K. M. S.), the Harvard
Medical School Scholars in Medicine Office (N.M.K.) and the Malaysian
Federal Training Scholarship (C.A.O.). S.J.H. and G. H. M. gratefully
acknowledge financial support from NASA Microgravity Fluid Sciences
(Code UG) Grant NNX09AV99G. We thank Drs. Deborah Perez Fernandez and
Johannes Soulages for preliminary studies.
NR 50
TC 3
Z9 3
U1 0
U2 16
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD FEB
PY 2013
VL 18
IS 2
AR 026021
DI 10.1117/1.JBO.18.2.026021
PG 6
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA 092YW
UT WOS:000315159900035
PM 23407909
ER
PT J
AU Gillman, J
Davila, J
Sansgiry, S
Parkinson-Windross, D
Miertschin, N
Mitts, B
Henley, C
Giordano, TP
AF Gillman, Jason
Davila, Jessica
Sansgiry, Shubhada
Parkinson-Windross, Diana
Miertschin, Nancy
Mitts, Beau
Henley, Charles
Giordano, Thomas P.
TI The Effect of Conspiracy Beliefs and Trust on HIV Diagnosis, Linkage,
and Retention in Young MSM with HIV
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE HIV/AIDS; adolescent; race/ethnicity; linkage to care; retention in care
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL ADHERENCE; CARE PROVIDERS;
HIV/AIDS; ADOLESCENTS; PREVENTION; GOVERNMENT; INFECTION; BARRIER;
ADULTS
AB Conspiracy beliefs about HIV may result in delayed diagnosis, medication non-adherence, and low retention in care. The impact of such beliefs is not well described for minority youth. We assessed conspiracy beliefs, trust in physicians, and trust in the health care system in 47 HIV-infected, minority, adolescent men who have sex with men (MSM). We identified correlations of these factors with two intermediate outcomes (general self-efficacy and medication attitudes) and with three clinical outcomes (CD4 cell count at diagnosis, linkage to care, and retention in care). Greater conspiracy beliefs were associated with negative medication attitudes (r = -0.37, p = .01), while trust in physicians was correlated with positive medication attitudes (r = 0.42, p = .003). Neither conspiracy beliefs nor trust was correlated with self-efficacy, nor were they correlated with any of the three clinical outcomes. Conspiracy beliefs and lack of trust did not predict delayed diagnosis or poor linkage and retention in this population of young, minority MSM.
C1 [Gillman, Jason] Baylor Univ, Methodist Hosp, Dept Med, Houston, TX 77030 USA.
[Davila, Jessica; Sansgiry, Shubhada; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Davila, Jessica; Sansgiry, Shubhada; Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA.
[Parkinson-Windross, Diana; Miertschin, Nancy; Giordano, Thomas P.] Harris Cty Hosp Dist, Thomas St Hlth Ctr, Houston, TX USA.
[Mitts, Beau] City Houston Dept Hlth & Human Serv, Houston, TX USA.
[Henley, Charles] Harris Cty Publ Hlth & Environm Serv, Houston, TX USA.
RP Giordano, TP (reprint author), Michael E DeBakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM tpg@bcm.tmc.edu
FU PHS HHS [H97HA03786]
NR 22
TC 4
Z9 4
U1 2
U2 10
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD FEB
PY 2013
VL 24
IS 1
BP 36
EP 45
PG 10
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 087AZ
UT WOS:000314734900008
PM 23377715
ER
PT J
AU Allen, JD
Mars, DR
Tom, L
Apollon, G
Hilaire, D
Iralien, G
Cloutier, LB
Sheets, MM
Zamor, R
AF Allen, Jennifer D.
Mars, Dana R.
Tom, Laura
Apollon, Guy
Hilaire, Dany
Iralien, Gerald
Cloutier, Lindsay B.
Sheets, Margaret M.
Zamor, Riche
TI Health Beliefs, Attitudes and Service Utilization among Haitians
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Health; health beliefs; Haitian; cancer screening
ID GREEN TEA CONSUMPTION; PROSTATE-CANCER; PREVENTION; MORTALITY;
COMMUNITY; KNOWLEDGE; WOMEN; DISPARITIES; SUBGROUPS; CATECHINS
AB Understanding the factors that influence health beliefs, attitudes, and service use among Haitians in the United States is increasingly important for this growing population. We undertook a qualitative analysis to explore the factors related to cancer screening and utilization of health services among Haitians in Boston. Key informant interviews (n = 42) and nine focus groups (n = 78) revealed that Haitians experience unique barriers to health services. These include language barriers, unfamiliarity with preventive care, confidentiality concerns, mistrust and stigma concerning Western medicine, and a preference for natural remedies. Results suggest that many Haitians could benefit from health system navigation assistance, and highlight the need for comprehensive, rather than disease-focused programs, to decrease stigma and increase programmatic reach. Faith-based organizations, social service agencies, and Haitian media were identified as promising channels for disseminating health information. Leveraging positive cultural traditions and existing communication networks could increase the impact of Haitian health initiatives.
C1 [Allen, Jennifer D.; Mars, Dana R.; Tom, Laura; Iralien, Gerald; Cloutier, Lindsay B.; Sheets, Margaret M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
[Allen, Jennifer D.] Dana Farber Canc Inst, Cantor Ctr Nursing & Patient Care Serv, Boston, MA 02215 USA.
[Apollon, Guy] Haitian Multi Serv Ctr, Dorchester, MA USA.
[Hilaire, Dany] Univ Massachusetts, Boston, MA 02125 USA.
[Zamor, Riche] Romaz Consulting, Boston, MA USA.
RP Allen, JD (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM Jennifer_allen@dfci.harvard.edu
RI Allen, Jennifer/M-2113-2015
FU NCCDPHP CDC HHS [1U48DP001946-01]; NCI NIH HHS [3U56CA118641-05S1,
5U56CA118641-03]
NR 55
TC 11
Z9 11
U1 4
U2 18
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD FEB
PY 2013
VL 24
IS 1
BP 106
EP 119
PG 14
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 087AZ
UT WOS:000314734900015
PM 23377722
ER
PT J
AU Frakt, AB
Carroll, AE
AF Frakt, Austin B.
Carroll, Aaron E.
TI Sound Policy Trumps Politics: States Should Expand Medicaid
SO JOURNAL OF HEALTH POLITICS POLICY AND LAW
LA English
DT Article
ID AFFORDABLE CARE ACT; MORTALITY; INSURANCE; COVERAGE; EXPANSIONS
AB By virtue of the Supreme Court's decision on the constitutionality of the Patient Protection and Affordable Care Act, states may reject the law's expansion of Medicaid without losing all Medicaid funding from the federal government. The Court's ruling potentially permits a range of Medicaid options for states, including some that may be very attractive from state officials' political perspectives. In the context of the presidential campaign, the uncompensated care problem, and their concerns about costs of expansion, state officials are weighing their options, and some have already pledged to opt out of expansion. We argue that despite the politics, expansion is in fact good for patients, providers, and taxpayers, and states should therefore comply.
C1 [Frakt, Austin B.] VA Boston Healthcare Syst, Boston, MA USA.
Indiana Univ, Bloomington, IN 47405 USA.
RP Frakt, AB (reprint author), VA Boston Healthcare Syst, Boston, MA USA.
NR 43
TC 6
Z9 7
U1 0
U2 10
PU DUKE UNIV PRESS
PI DURHAM
PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA
SN 0361-6878
J9 J HEALTH POLIT POLIC
JI J. Health Polit. Policy Law
PD FEB
PY 2013
VL 38
IS 1
BP 165
EP 178
DI 10.1215/03616878-1898839
PG 14
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
Legal; Social Issues; Social Sciences, Biomedical
SC Health Care Sciences & Services; Legal Medicine; Social Issues;
Biomedical Social Sciences
GA 078YF
UT WOS:000314136300008
PM 23052687
ER
PT J
AU Davidson, M
Liu, SX
Barter, P
Brinton, EA
Cannon, CP
Gotto, AM
Leary, ET
Shah, S
Stepanavage, M
Mitchel, Y
Dansky, HM
AF Davidson, Michael
Liu, Sherry Xueyu
Barter, Philip
Brinton, Eliot A.
Cannon, Christopher P.
Gotto, Antonio M., Jr.
Leary, Elizabeth T.
Shah, Sukrut
Stepanavage, Michael
Mitchel, Yale
Dansky, Hayes M.
TI Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE Friedewald formula; beta quantification; VLDL cholesterol; HDL
cholesterol; direct method; low density lipoprotein cholesterol;
cholesteryl ester transfer protein
ID DENSITY-LIPOPROTEIN CHOLESTEROL; INTEGRATED APPROACH; FAT TRANSPORT;
HEALTHY-INDIVIDUALS; MECHANISMS; DISORDERS; DISEASE; RISK; GUIDELINES;
HDL
AB Estimation of low-density lipoprotein cholesterol (LDL-C) using the Friedewald (FR) formula is often inaccurate when triglycerides are elevated or VLDL particle composition is altered. We hypothesized that LDL-C estimation by the FR formula and other measurement methods might also be inaccurate in individuals treated with a cholesteryl ester transfer protein (CETP) inhibitor. An assay comparison study was conducted using pre and posttreatment serum samples from 280 of the 811 patients treated with the CETP inhibitor anacetrapib in the DEFINE study (determining the efficacy and tolerability of CETP inhibition with anacetrapib). After 24 weeks of treatment with anacetrapib, mean LDL-C values by FR formula, Roche direct method (RDM) and Genzyme direct method (GDM) deviated from that measured by the beta-quantification (BQ) reference method by -12.2 +/- 7.5, -10.2 +/- 6.6, -10.8 +/- 8.8 mg/dl, respectively.(jlr) After treatment with anacetrapib, the FR formula and detergent-based direct methods provided lower LDL-C values than those obtained by the BQ reference method. The bias by the FR formula appeared to be due to an overestimation of VLDL-C by the TG/5 component of the formula. Evaluation of the clinical significance of these findings awaits comprehensive lipid and cardiovascular outcome data from ongoing Phase III clinical studies of anacetrapib.-Davidson, M., S. X. Liu, P. Barter, E. A. Brinton, C. P. Cannon, A. M. Gotto, Jr., E. T. Leary, S. Shah, M. Stepanavage, Y. Mitchel, and H. M. Dansky. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J. Lipid Res. 2013. 54: 467-472.
C1 [Davidson, Michael] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
[Liu, Sherry Xueyu; Shah, Sukrut; Stepanavage, Michael; Mitchel, Yale; Dansky, Hayes M.] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA.
[Barter, Philip] Heart Res Inst, Sydney, NSW, Australia.
[Brinton, Eliot A.] Utah Fdn Biomed Res, Salt Lake City, UT USA.
[Brinton, Eliot A.] Univ Utah, Salt Lake City, UT USA.
[Cannon, Christopher P.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Gotto, Antonio M., Jr.] Weill Cornell Med Coll, New York, NY USA.
[Leary, Elizabeth T.] Pacific Biomarkers, Seattle, WA USA.
RP Davidson, M (reprint author), Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
EM mdavidso@medicine.bsd.uchicago.edu
FU Merck & Co., Inc., Whitehouse Station, NJ
FX This study was funded by Merck & Co., Inc., Whitehouse Station, NJ.
NR 24
TC 21
Z9 21
U1 1
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD FEB
PY 2013
VL 54
IS 2
BP 467
EP 472
DI 10.1194/jlr.M032615
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 088ZH
UT WOS:000314876400016
PM 23172660
ER
PT J
AU Kim, DS
Burt, AA
Crosslin, DR
Robertson, PD
Ranchalis, JE
Boyko, EJ
Nickerson, DA
Furlong, CE
Jarvik, GP
AF Kim, Daniel S.
Burt, Amber A.
Crosslin, David R.
Robertson, Peggy D.
Ranchalis, Jane E.
Boyko, Edward J.
Nickerson, Deborah A.
Furlong, Clement E.
Jarvik, Gail P.
TI Novel common and rare genetic determinants of paraoxonase activity: FTO,
SERPINA12, and ITGAL
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE exome chip; atherosclerosis; diabetes
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; LOW-DENSITY-LIPOPROTEIN; GENOME-WIDE
ASSOCIATION; CAROTID-ARTERY-DISEASE; SERUM PARAOXONASE;
PARKINSONS-DISEASE; MISSING HERITABILITY; ADIPOSE-TISSUE; PON1 STATUS;
CARDIOVASCULAR-DISEASE
AB HDL-associated paraoxonase 1 (PON1) activity is associated with cardiovascular and other human diseases. As the role of genetic variants outside of the PON gene cluster on PON1 activity is unknown, we sought to identify common and rare variants in such loci. We typed 33,057 variants on the CVD chip in 1,362 subjects to test for their effects on adjusted-PON1 activity. Three novel genes (FTO, ITGAL, and SERPINA12) and the PON gene cluster had SNPs associated with PON1 arylesterase (AREase) activity. These loci were carried forward for rare-variant analysis using Exome chip genotypes in an overlapping subset of 1,051 subjects using sequence kernel association testing. PON1 (P = 2.24 x 10=(-4)), PON3 (P = 0.022), FTO (P = 0.019), and SERPINA12 (P = 0.039) had both common and rare variants associated with PON1 AREase. ITGAL variants were associated with PON1 activity when using weighted sequence kernel association testing (SKAT) analysis (P = 2.63 x 10(-3)). When adjusting for the initial common variants, SERPINA12 became marginally significant (P = 0.09), whereas all other findings remained significant (P < 0.05), suggesting independent rare-variant effects. We present novel findings that common and rare variants in FTO, SERPINA12, and ITGAL predict PON1 activity. These results further link PON1 to diabetes and inflammation and may inform the role of HDL in human disease.-Kim, D. S., A. A. Burt, D. R. Crosslin, P. D. Robertson, J. E. Ranchalis, E. J. Boyko, D. A. Nickerson, C. E. Furlong, and G. P. Jarvik. Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J. Lipid Res. 2013. 54: 552-560.
C1 [Kim, Daniel S.; Burt, Amber A.; Crosslin, David R.; Ranchalis, Jane E.; Furlong, Clement E.; Jarvik, Gail P.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Kim, Daniel S.; Crosslin, David R.; Robertson, Peggy D.; Nickerson, Deborah A.; Furlong, Clement E.; Jarvik, Gail P.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA.
[Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
RP Jarvik, GP (reprint author), Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
EM pair@u.washington.edu
RI Jarvik, Gail/N-6476-2014
OI Jarvik, Gail/0000-0002-6710-8708
FU National Institutes of Health [RO1 HL-67406]; State of Washington Life
Sciences Discovery Award; Sarnoff Cardiovascular Research Fellowship for
Medical Students Award; Veteran Affairs Epidemiologic Research and
Information Center Award [CSP 701S]
FX This work was funded by National Institutes of Health Grant RO1 HL-67406
and a State of Washington Life Sciences Discovery Award to the Northwest
Institute of Genetic Medicine. D.S.K. was supported in part by a Sarnoff
Cardiovascular Research Fellowship for Medical Students Award. This work
utilized resources of National Heart, Lung, and Blood Institute (NHLBI)
Program for Genomic Applications, SeattleSNPs, Seattle, WA
(http://pga.gs.washington.edu). Past work in this cohort and
specifically E.J.B.'s involvement, was supported in part by resources
from the VA Puget Sound Health Care System, Seattle, WA, including the
Veteran Affairs Epidemiologic Research and Information Center Award CSP
701S. The contents of this article are solely the responsibility of the
authors and do not necessarily represent the official views of the
National Institutes of Health.
NR 75
TC 12
Z9 12
U1 2
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD FEB
PY 2013
VL 54
IS 2
BP 552
EP 560
DI 10.1194/jlr.P033266
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 088ZH
UT WOS:000314876400026
PM 23160181
ER
PT J
AU Habibollahi, P
van den Berg, NS
Kuruppu, D
Loda, M
Mahmood, U
AF Habibollahi, Peiman
van den Berg, Nynke S.
Kuruppu, Darshini
Loda, Massimo
Mahmood, Umar
TI Metformin-an Adjunct Antineoplastic Therapy-Divergently Modulates Tumor
Metabolism and Proliferation, Interfering with Early Response Prediction
by F-18-FDG PET Imaging
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE metformin; AMPK; tumor metabolic imaging; proliferation imaging
ID ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; IN-VIVO;
DIABETIC-PATIENTS; CELL-GROWTH; CANCER; ENERGY; RISK; DRUG; VITRO
AB Over the last several years, epidemiologic data have suggested that the antidiabetes drug metformin (MET), an adenosine monophosphate-activated protein kinase (AMPK) activator, improves progression-free survival of patients with multiple cancers; more than 30 clinical trials are under way to confirm this finding. We postulated that the role of AMPK as a central cellular energy sensor would result in opposite effects on glucose uptake and proliferation, suggesting different roles for F-18-FDG and 3'deoxy-3'-F-18-fluorothymidine (F-18-FLT) in assessing its effectiveness as an antineoplastic agent. Methods: Colon cancer cell lines HT29 (human) and MC26 (murine) were treated for 24 or 72 h with a range of MET concentrations (0-10 mM). Western blotting was used to study the activation of AMPK after MET treatment. Glucose uptake and cell proliferation were measured by cell retention studies with either F-18-FDG or F-18-FLT. EdU (ethynyl deoxyuridine, a thymidine analog) and annexin-propidium iodide flow cytometry was performed to determine cell cycle S-phase and apoptotic changes. In vivo F-18-FDG and F-18-FLT PET images were acquired before and 24 h after MET treatment of HT29 tumor-bearing mice. Results: After 24 h of MET incubation, phosphorylated AMPK levels increased severalfold in both cell lines, whereas total AMPK levels remained unchanged. In cell retention studies, F-18-FDG uptake increased but F-18-FLT retention decreased significantly in both cell lines. The numbers of HT29 and MC26 cells in the S phase decreased 36% and 33%, respectively, after MET therapy. Apoptosis increased 10.5-fold and 5.8-fold in HT29 and MC26 cells, respectively, after 72 h of incubation with MET. PET imaging revealed increased F-18-FDG uptake (mean +/- SEM standardized uptake values were 0.71 +/- 0.03 before and 1.29 +/- 0.11 after MET therapy) (P < 0.05) and decreased (FFLT)-F-18 uptake (mean +/- SEM standardized uptake values were 1.18 +/- 0.05 before and 0.89 +/- 0.01 after MET therapy) (P < 0.05) in HT29 tumor-bearing mice. Conclusion: MET, through activation of the AMPK pathway, produces a dose-dependent increase in tumor glucose uptake while decreasing cell proliferation in human and murine colon cancer cells. Thus, changes in F-18-FDG uptake after MET treatment may be misleading. F-18-FLT imaging is a promising alternative that correlates with the tumor response.
C1 [Habibollahi, Peiman; van den Berg, Nynke S.; Kuruppu, Darshini; Mahmood, Umar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Loda, Massimo] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02114 USA.
RP Mahmood, U (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Nucl Med & Mol Imaging, 55 Fruit St, Boston, MA 02114 USA.
EM umahmood@mgh.harvard.edu
FU National Institutes of Health grants [U01CA143056, U01CA084301,
P50CA127003]
FX The costs of publication of this article were defrayed in part by the
payment of page charges. Therefore, and solely to indicate this fact,
this article is hereby marked "advertisement" in accordance with 18 USC
section 1734. This research was supported in part by National Institutes
of Health grants U01CA143056, U01CA084301, and P50CA127003. No other
potential conflict of interest relevant to this article was reported.
NR 32
TC 12
Z9 14
U1 0
U2 12
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
J9 J NUCL MED
JI J. Nucl. Med.
PD FEB 1
PY 2013
VL 54
IS 2
BP 252
EP 258
DI 10.2967/jnumed.112.107011
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 086NI
UT WOS:000314691200026
PM 23376854
ER
PT J
AU Gao, J
Dizon, DS
AF Gao, Jennifer
Dizon, Don S.
TI Preparing for Survivorship: Quality of Life in Breast Cancer Survivors
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Article
DE Quality of Life; Breast Cancer; Cancer Therapy
ID DISTRESS
AB Introduction. Breast cancer affects over 200,000 women each year; however, with earlier diagnosis and more effective treatment, patients are living longer, even in the presence of metastatic disease. Current estimates place patients with breast cancer as the largest population of cancer survivors in the United States. Given the successes in treatment, quality of life (QOL) of breast cancer survivors has become a more important consideration. Aim. The aim of this study is to examine QOL throughout the cancer journey. Methods. The cancer journey will be conceptualized across disease states. Main Outcome Measures. Understanding of the longitudinal journey associated with dynamic changes in physical, mental, and psychosocial spheres that occur with cancer, cancer treatment, and the sequelae of both. Conceptualization of changes is shown through the QOL as the survivor moves through the phases of cancer. Results. QOL is not a static concept, and breast cancer survivors undergo dynamic changes in QOL starting at diagnosis, as they progress through treatment and enter posttreatment. Some domains that make up QOL (i.e., sexual functioning and role functioning) can show persistent detriments related to cancer and its treatment. Conclusions. In this article, we will provide a snapshot of some research performed to better understand the QOL of breast cancer survivors using a disease states model of breast cancer. Gao J and Dizon DS. Preparing for survivorship: quality of life in breast cancer survivors. J Sex Med 2013;10(suppl 1):16-20.
C1 [Gao, Jennifer] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Dizon, Don S.] Massachusetts Gen Canc Ctr, Gillette Ctr Womens Canc, Boston, MA 02114 USA.
RP Dizon, DS (reprint author), Massachusetts Gen Canc Ctr, Gillette Ctr Womens Canc, Boston, MA 02114 USA.
EM donstevendizon@gmail.com
NR 17
TC 2
Z9 2
U1 1
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-6095
J9 J SEX MED
JI J. Sex. Med.
PD FEB
PY 2013
VL 10
SU 1
SI SI
BP 16
EP 20
DI 10.1111/jsm.12029
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 088XM
UT WOS:000314871200004
PM 23387908
ER
PT J
AU Bober, SL
Carter, J
Falk, S
AF Bober, Sharon L.
Carter, Jeanne
Falk, Sandy
TI Addressing Female Sexual Function after Cancer by Internists and Primary
Care Providers
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Article
DE Female Sexual Function; Survivorship; Cancer; Primary Care
ID LOW-DOSE ESTRADIOL; QUALITY-OF-LIFE; BREAST-CANCER; POSTMENOPAUSAL
WOMEN; VAGINAL ATROPHY; OVARIAN-CANCER; THERAPY; COMMUNICATION;
DYSFUNCTION; PHYSICIANS
AB Introduction. There are now almost 14 million cancer survivors in the United States, and for the majority of survivors, the bulk of post-cancer medical care is provided by community primary care providers (PCPs). Sexual dysfunction is one of the most common and distressing quality of life issues facing female cancer survivors yet it has become increasingly evident that women's cancer-related sexual dysfunction often goes unaddressed, including in primary care treatment setting. Aim. Building on a model that calls for an integrative approach to treatment, the aim is to concisely review barriers and challenges of managing cancer-related female sexual dysfunction for PCPs and to offer specific and effective strategies that PCPs may use to treat common sexual problems in their female cancer survivors. Methods. Literature was reviewed for relevant publications on the topic of treating cancer-related sexual dysfunction and primary care, and interviews were conducted with experts on state-of-the-art methods for treating cancer-related sexual dysfunction. Main Outcome Measure. Clinical evidence that demonstrates the effectiveness of simple strategies to manage cancer-related female sexual dysfunction. Results. Cancer-related female sexual dysfunction does not seem to be appropriately acknowledged and addressed in primary care treatment settings. There is evidence to show that simple and effective strategies exist to ameliorate many of these problems. Conclusions. PCPs provide the bulk of survivorship care and are therefore in a critical position to initiate assessment and treatment for female survivors with cancer-related sexual dysfunction. Although PCPs are in need of increased support and preparation to manage this aspect of survivorship care, simple and effective strategies are available for PCPs to offer women as part of their clinical practice. Bober SL, Carter J, and Falk S. Addressing female sexual function after cancer by internists and primary care providers. J Sex Med 2013;10(suppl 1):112-119.
C1 [Bober, Sharon L.; Falk, Sandy] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bober, Sharon L.; Falk, Sandy] Harvard Univ, Sch Med, Boston, MA USA.
[Carter, Jeanne] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RP Bober, SL (reprint author), Dana Farber Canc Inst Psychooncol, 44 Binney St Dana 321, Boston, MA 02115 USA.
EM sharon_bober@dfci.harvard.edu
NR 61
TC 10
Z9 10
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-6095
J9 J SEX MED
JI J. Sex. Med.
PD FEB
PY 2013
VL 10
SU 1
SI SI
BP 112
EP 119
DI 10.1111/jsm.12027
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 088XM
UT WOS:000314871200013
PM 23387916
ER
PT J
AU Eberhardt, SC
Carter, S
Casalino, DD
Merrick, G
Frank, SJ
Gottschalk, AR
Leyendecker, JR
Nguyen, PL
Oto, A
Porter, C
Remer, EM
Rosenthal, SA
AF Eberhardt, Steven C.
Carter, Scott
Casalino, David D.
Merrick, Gregory
Frank, Steven J.
Gottschalk, Alexander R.
Leyendecker, John R.
Nguyen, Paul L.
Oto, Aytekin
Porter, Christopher
Remer, Erick M.
Rosenthal, Seth A.
TI ACR Appropriateness Criteria Prostate Cancer-Pretreatment Detection,
Staging, and Surveillance
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Appropriateness Criteria; prostate cancer; imaging; detection; staging
ID DIGITAL RECTAL EXAMINATION; RADICAL RETROPUBIC PROSTATECTOMY;
POSITRON-EMISSION-TOMOGRAPHY; SEMINAL-VESICLE INVASION;
CONTRAST-ENHANCED MRI; ENDORECTAL MR; ACTIVE SURVEILLANCE; GLEASON
SCORE; TRANSRECTAL ULTRASONOGRAPHY; EXTRACAPSULAR EXTENSION
AB Prostate cancer is the most common noncutaneous male malignancy in the United States. The use of serum prostate-specific antigen as a screening tool is complicated by a significant fraction of nonlethal cancers diagnosed by biopsy. Ultrasound is used predominately as a biopsy guidance tool. Combined rectal examination, prostate-specific antigen testing, and histology from ultrasound-guided biopsy provide risk stratification for locally advanced and metastatic disease. Imaging in low-risk patients is unlikely to guide management for patients electing up-front treatment. MRI, CT, and bone scans are appropriate in intermediate-risk to high-risk patients to better assess the extent of disease, guide therapy decisions, and predict outcomes. MRI (particularly with an endorectal coil and multiparametric functional imaging) provides the best imaging for cancer detection and staging. There may be a role for prostate MRI in the context of active surveillance for low-risk patients and in cancer detection for undiagnosed clinically suspected cancer after negative biopsy results.
The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
C1 [Eberhardt, Steven C.; Carter, Scott] Univ New Mexico, Albuquerque, NM 87131 USA.
[Casalino, David D.] Northwestern Univ, Chicago, IL 60611 USA.
[Merrick, Gregory] Schiffler Canc Ctr, Wheeling, WV USA.
[Merrick, Gregory] Wheeling Jesuit Univ, Wheeling, WV USA.
[Frank, Steven J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Gottschalk, Alexander R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Leyendecker, John R.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
[Nguyen, Paul L.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Oto, Aytekin] Univ Chicago, Chicago, IL 60637 USA.
[Porter, Christopher] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
[Porter, Christopher] Amer Urol Assoc, Linthicum, MD USA.
[Remer, Erick M.] Cleveland Clin, Cleveland, OH 44106 USA.
[Rosenthal, Seth A.] Radiol Associates Sacramento, Sacramento, CA USA.
RP Eberhardt, SC (reprint author), Amer Coll Radiol, 1891 Preston White Dr, Reston, VA 20191 USA.
EM seberhardt@salud.unm.edu
NR 115
TC 33
Z9 33
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2013
VL 10
IS 2
BP 83
EP 92
DI 10.1016/j.jacr.2012.10.021
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 090VM
UT WOS:000315008100009
PM 23374687
ER
PT J
AU Gunn, AJ
Sahani, DV
Bennett, SE
Choy, G
AF Gunn, Andrew J.
Sahani, Dushyant V.
Bennett, Susan E.
Choy, Garry
TI Recent Measures to Improve Radiology Reporting: Perspectives From
Primary Care Physicians
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Radiology reporting; primary care physicians; quality improvement
ID REFERRING PHYSICIANS; CONSULTANT; STYLE; THINK
AB Purpose: There is considerable interest in improving radiology reporting practices. It has been suggested recently that reporting practices could be improved by more direct involvement of radiologists in delivering results to patients and by making clear recommendations within the radiology report. The opinions of primary care physicians about these initiatives are not well known. The authors surveyed primary care physicians to better understand their views.
Methods: An online survey was distributed to 229 primary care physicians through an internal list sewer, and responses were collected confidentially.
Results: There were 100 responses (a 43.6% response rate). The majority of respondents were satisfied with radiology reporting and recommendations in general. Ninety-five percent of respondents felt that ordering physicians should deliver the results of examinations. No respondents felt that radiologists should deliver results directly to patients. Ninety-four percent of respondents felt medicolegally obligated by recommendations made by radiologists within their reports. Twenty-three percent of respondents felt more medicolegally obligated if the recommendation is set apart from the clinical impression, while 58% of respondents felt less medicolegally obligated if qualifying language is added to the recommendation.
Conclusions: Primary care physicians prefer to deliver the results of examinations themselves and feel medicolegally obligated by recommendations within radiology reports, even though this seems to be influenced by the wording and location of the recommendations within reports. Radiologists should consider these factors when contemplating changes in reporting practices.
C1 [Gunn, Andrew J.; Sahani, Dushyant V.; Choy, Garry] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Gunn, Andrew J.; Sahani, Dushyant V.; Bennett, Susan E.; Choy, Garry] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Sahani, Dushyant V.] Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent, Dept Radiol, Boston, MA 02114 USA.
[Bennett, Susan E.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Choy, Garry] Massachusetts Gen Hosp, Dept Radiol, Div Emergency Radiol & Teleradiol, Boston, MA 02114 USA.
RP Gunn, AJ (reprint author), Massachusetts Gen Hosp, FND 216,55 Fruit St, Boston, MA 02114 USA.
EM agunn@partners.org
NR 26
TC 19
Z9 19
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2013
VL 10
IS 2
BP 122
EP 127
DI 10.1016/j.jacr.2012.08.013
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 090VM
UT WOS:000315008100015
PM 23228373
ER
PT J
AU Thrall, JH
AF Thrall, James H.
TI Residents' and Fellows' Column: The Invisible Radiologist: An Address to
a Residency Graduating Class
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Thrall, JH (reprint author), Massachusetts Gen Hosp, Dept Radiol, 32 Fruit St,Room 216, Boston, MA 02114 USA.
EM jthrall@partners.org
NR 0
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2013
VL 10
IS 2
BP 153
EP 155
DI 10.1016/j.jacr.2012.07.020
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 090VM
UT WOS:000315008100022
PM 23374696
ER
PT J
AU Benson, AB
Bekaii-Saab, T
Chan, E
Chen, YJ
Choti, MA
Cooper, HS
Engstrom, PF
Enzinger, PC
Fakih, MG
Fenton, MJ
Fuchs, CS
Grem, JL
Hunt, S
Kamel, A
Leong, LA
Lin, E
May, KS
Mulcahy, MF
Murphy, K
Rohren, E
Ryan, DP
Saltz, L
Sharma, S
Shibata, D
Skibber, JM
Small, W
Sofocleous, CT
Venook, AP
Willett, CG
Gregory, KM
Freedman-Cass, DA
AF Benson, Al B., III
Bekaii-Saab, Tanios
Chan, Emily
Chen, Yi-Jen
Choti, Michael A.
Cooper, Harry S.
Engstrom, Paul F.
Enzinger, Peter C.
Fakih, Marwan G.
Fenton, Moon J.
Fuchs, Charles S.
Grem, Jean L.
Hunt, Steven
Kamel, Ahmed
Leong, Lucille A.
Lin, Edward
May, Kilian Salerno
Mulcahy, Mary F.
Murphy, Kate
Rohren, Eric
Ryan, David P.
Saltz, Leonard
Sharma, Sunil
Shibata, David
Skibber, John M.
Small, William, Jr.
Sofocleous, Constantinos T.
Venook, Alan P.
Willett, Christopher G.
Gregory, Kristina M.
Freedman-Cass, Deborah A.
TI Metastatic Colon Cancer, Version 3.2013
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID ADVANCED COLORECTAL-CANCER; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY;
HIGH-DOSE LEUCOVORIN; PHASE-III TRIAL; FLUOROURACIL PLUS LEUCOVORIN;
RANDOMIZED-TRIAL; PERITONEAL CARCINOMATOSIS; CYTOREDUCTIVE SURGERY;
1ST-LINE TREATMENT; SYSTEMIC CHEMOTHERAPY
AB The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, patient surveillance, management of recurrent and metastatic disease, and survivorship. The NCCN Colon Cancer Panel meets annually to review comments from reviewers within their institutions and to reevaluate and update their recommendations. In addition, the panel has interim conferences as new data necessitate. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel's discussions surrounding metastatic colorectal cancer for the 2013 update of the guidelines. Importantly, changes were made to the continuum of care for patients with advanced or metastatic disease, including new drugs and an additional line of therapy. (JNCCN 2013;11:141-152)
C1 [Benson, Al B., III; Mulcahy, Mary F.; Small, William, Jr.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Bekaii-Saab, Tanios] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Bekaii-Saab, Tanios] Solove Res Inst, Columbus, OH USA.
[Chan, Emily] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Choti, Michael A.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Cooper, Harry S.; Engstrom, Paul F.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Fakih, Marwan G.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Fenton, Moon J.] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Grem, Jean L.] UNMC Eppley Canc Ctr, Nebraska Med Ctr, Omaha, NE USA.
[Hunt, Steven] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Hunt, Steven] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Kamel, Ahmed] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Lin, Edward] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Alliance, OH USA.
[May, Kilian Salerno] Roswell Pk Canc Inst, Buffalo, NY USA.
[Rohren, Eric; Skibber, John M.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Ryan, David P.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Saltz, Leonard; Sofocleous, Constantinos T.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Sharma, Sunil] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Shibata, David] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Venook, Alan P.] UCSF Helen Diller Family, Ctr Comprehens Canc, San Francisco, CA USA.
[Willett, Christopher G.] Duke Canc Inst, Durham, NC USA.
[Gregory, Kristina M.; Freedman-Cass, Deborah A.] Natl Comprehens Canc Network, Toronto, ON, Canada.
RP Benson, AB (reprint author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
RI Bekaii-Saab, Tanios/E-2733-2011
NR 71
TC 57
Z9 58
U1 1
U2 14
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD FEB
PY 2013
VL 11
IS 2
BP 141
EP 152
PG 12
WC Oncology
SC Oncology
GA 087WN
UT WOS:000314795200005
PM 23411381
ER
PT J
AU Kornstein, SG
Toups, M
Rush, AJ
Wisniewski, SR
Thase, ME
Luther, J
Warden, D
Fava, M
Trivedi, MH
AF Kornstein, Susan G.
Toups, Marisa
Rush, A. John
Wisniewski, Stephen R.
Thase, Michael E.
Luther, James
Warden, Diane
Fava, Maurizio
Trivedi, Madhukar H.
TI Do Menopausal Status and Use of Hormone Therapy Affect Antidepressant
Treatment Response? Findings from the Sequenced Treatment Alternatives
to Relieve Depression (STAR*D) Study
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID INTERACTIVE VOICE RESPONSE; MEASUREMENT-BASED CARE; REPORT QIDS-SR;
GENDER-DIFFERENCES; MAJOR DEPRESSION; PSYCHOMETRIC EVALUATION;
SYMPTOMATOLOGY IDS; CLINICAL-PRACTICE; QUICK INVENTORY; SEX-DIFFERENCES
AB Background: Menopausal status and use of hormonal contraception or menopausal hormone therapy (HT) may affect treatment response to selective serotonin reuptake inhibitors (SSRIs). This report evaluates whether menopausal status and use of hormonal contraceptives or menopausal HT affect outcome in women treated with citalopram.
Methods: In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 896 premenopausal and 544 postmenopausal women were treated with citalopram for 12-14 weeks. Baseline demographic and clinical characteristics were used in adjusted analysis of the effect of menopausal status and use of hormonal contraceptives or menopausal HT on outcomes. Remission was defined as final Hamilton Rating Scale for Depression-17 (HRSD17) <= 7 or Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16)score <= 5 and response as >= 50% decrease from the baseline QIDS-SR16 score.
Results: Premenopausal and postmenopausal women differed in multiple clinical and demographic baseline variables but did not differ in response or remission rates. Premenopausal women taking hormonal contraceptives had significantly greater unadjusted remission rates on the HRSD17 and the QIDS-SR16 than women not taking contraception. Response and remission rates were not different between postmenopausal women taking vs. not taking HT. Adjusted results showed no significant difference in any outcome measure across menopause status in women who were not taking contraception/HT. There were no significant differences in adjusted results across HT status in premenopausal or postmenopausal women.
Conclusions: In this study, citalopram treatment outcome was not affected by menopausal status. Hormonal contraceptives and HT also did not affect probability of good outcome.
C1 [Kornstein, Susan G.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA.
[Kornstein, Susan G.] Virginia Commonwealth Univ, Inst Womens Hlth, Richmond, VA 23298 USA.
[Toups, Marisa; Rush, A. John; Warden, Diane; Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Rush, A. John] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
[Rush, A. John] Duke Natl Univ Singapore, Singapore, Singapore.
[Wisniewski, Stephen R.; Luther, James] Univ Pittsburgh, GSPH, Epidemiol Data Ctr, Pittsburgh, PA USA.
[Thase, Michael E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Kornstein, SG (reprint author), Virginia Commonwealth Univ, Sch Med, Dept Psychiat, POB 980710, Richmond, VA 23298 USA.
EM skornste@vcu.edu
OI Wisniewski, Stephen/0000-0002-3877-9860; Rush,
Augustus/0000-0003-2004-2382
FU National Institute of Mental Health [N01MH90003]; Bristol-Myers Squibb;
Lilly; Euthymics; Forest Laboratories; Wyeth; Novartis;
Boehringer-Ingelheim; Pfizer; Otsuka; Rexahn; Guilford Press; Advanced
Neuromodulation Systems; AstraZeneca; Best Practice Project Management;
Brain Resource Inc.; Bristol-Myers Squibb/Otsuka; Cyberonics; Forest
Pharmaceuticals; Gerson Lehrman Group; GlaxoSmithKline; Jazz
Pharmaceuticals; Magellan Health Services; Merck Company; Neuronetics;
Novartis Pharmaceuticals; Ono Pharmaceuticals; Organon; Otsuka
Pharmaceuticals; Pamlab; University of Michigan; Transcept
Pharmaceuticals; Urban Institute; Wyeth Ayerst; Cyberonics Inc.;
Guilford Publications; Healthcare Technology Systems; University of
Texas Southwestern Medical Center; Stanley Medical Research Institute
FX This project was funded by the National Institute of Mental Health under
Contract No. N01MH90003 to UT Southwestern Medical Center at Dallas
(Pls: A. J. R. and M. H. T.). The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the U. S. Government. We
appreciate the support of Bristol-Myers Squibb, Forest Laboratories,
GlaxoSmithKline, King Pharmaceuticals, Organon, Pfizer, and Wyeth for
providing medications at no cost for this trial.; M. T. and J. L. have
no conflicts of interest to report. S. G. K. has received
grants/research support from the National Institute of Mental Health;
Bristol-Myers Squibb; Lilly; Euthymics; Forest Laboratories; Wyeth;
Novartis; Boehringer-Ingelheim; Pfizer; Otsuka; Rexahn. She has been on
the advisory board or received honoraria from Pfizer; Lilly;
Bristol-Myers Squibb; Forest Laboratories; Dey Pharma; Rexahn;
PGxHealth; Wyeth; Takeda; Trovis; Lundbeck. She has also received book
royalties from Guilford Press.; A. J. R. has received consultant fees
from Advanced Neuromodulation Systems; AstraZeneca; Best Practice
Project Management; Brain Resource Inc.; Bristol-Myers Squibb/Otsuka;
Cyberonics; Forest Pharmaceuticals; Gerson Lehrman Group;
GlaxoSmithKline; Jazz Pharmaceuticals; Magellan Health Services; Merck &
Company; Neuronetics; Novartis Pharmaceuticals; Ono Pharmaceuticals;
Organon; Otsuka Pharmaceuticals; Pamlab; Pfizer; The University of
Michigan; Transcept Pharmaceuticals; Urban Institute; and Wyeth Ayerst;
speaking fees from Cyberonics Inc.; Forest Laboratories;
GlaxoSmithKline; and Otsuka; royalties from Guilford Publications;
Healthcare Technology Systems; and The University of Texas Southwestern
Medical Center; and research support from National Institute of Mental
Health and the Stanley Medical Research Institute. He has owned shares
of stock in Pfizer.; M. E. T. has provided scientific consultation to
AstraZeneca; Bristol-Myers Squibb; Dey Pharma, L. P.; Eli Lilly &
Company; Forest Pharmaceuticals, Inc.; Gerson Lehman Group;
GlaxoSmithKline; Guidepoint Global; H. Lundbeck A/S; MedAvante, Inc.;
Merck and Company; Neuronetics, Inc.; Novartis; Otsuka; Ortho-McNeil
Pharmaceuticals; PamLab; Pfizer (formerly Wyeth-Ayerst Laboratories);
ScheringPlough (formerly Organon, Inc.); Shire US Inc.; Supernus
Pharmaceuticals; Takeda (Lundbeck); and Transcept Pharmaceuticals. He
has been a member of the speakers' bureaus for AstraZeneca;
Bristol-Myers Squibb; Eli Lilly & Company; Merck and Company; and Pfizer
(formerly Wyeth-Ayerst Laboratories). He receives grant funding from Eli
Lilly & Company; GlaxoSmithKline; National Institute of Mental Health;
and Agency for Healthcare Research and Quality, Sepracor, Inc. He has
equity holdings in MedAvante, Inc., and receives royalty income from
American Psychiatric Foundation, Inc.; Guilford Publications; Herald
House; Oxford University Press; and W. W. Norton & Company. His wife is
employed as the Group Scientific Director for Embryon, formerly
Advogent, which does business with BMS and Pfizer/Wyeth. D. W. has owned
stock in Pfizer, Inc. and Bristol-Myers Squibb within the last 5 years.
She has also received funding from National Alliance for Research on
Schizophrenia & Depression (NARSAD).; M. F. has received research
support from Abbott Laboratories; Alkermes, Inc.; Aspect Medical
Systems; AstraZeneca; BioResearch; BrainCells Inc.; Bristol-Myers
Squibb; Cephalon, Inc.; CeNeRx BioPharma; Clinical Trials Solutions,
LLC; Clintara, LLC; Covidien; Eli Lilly and Company; EnVivo
Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest
Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Icon
Clinical Research; i3 Innovus/Ingenix; Johnson & Johnson Pharmaceutical
Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals;
NARSAD; National Center for Complementary and Alternative Medicine
(NCCAM); National Institute of Drug Abuse (NIDA); National Institute of
Mental Health (NIMH); Novartis AG; Organon Pharmaceuticals; PamLab,
LLC.; Pfizer Inc.; Pharmavite LLC; Photothera; Roche; RCT Logic, LLC;
SanofiAventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Synthelabo;
Wyeth-Ayerst Laboratories. He has provided advisory/ consulting services
to Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.;
Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex
Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc.;
BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc;
Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Clinical Trials
Solutions, LLC; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress
Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon
Sumitomo Pharma Co., Inc.; Dov Pharmaceuticals, Inc.; Edgemont
Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company;
ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience,
Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.;
GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis;
Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson
Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.;
Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.;
Merck & Company; MSI Methylation Sciences, Inc.; Naurex, Inc.;
Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG; Nutrition 21;
Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka
Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite ~
LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa
Pharmaceuticals, Inc.; Puretech Ventures; PsychoGenics; Psylin
Neurosciences, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics,
Inc.; Roche; RCT Logic, LLC; Sanofi-Aventis US LLC.; Sepracor Inc.;
Servier Laboratories; Schering-Plough Corporation; Solvay
Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset
Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus
Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company
Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm
Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda
Pharmaceuticals, Inc. He has speaking/publishing relationships with
Adamed, Co; Advanced Meeting Partners; American Psychiatric Association;
American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir
Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon,
Inc.; CME Institute/ Physicians Postgraduate Press, Inc.; Eli Lilly and
Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH
Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier;
Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United
BioSource, Corp.; Wyeth-Ayerst Laboratories. He has equity holdings
(excluding mutual funds/blinded trusts) with Compellis.; He has received
royalty/patent or other income for Sequential Parallel Comparison Design
(SPCD) and patent application for a combination of azapirones and
bupropion in Major Depressive Disorder; has received copyright royalties
for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ),
Sexual Functioning Inventory (SFI), Antidepressant Treatment Response
Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS),
and SAFER; and has received a patent for research and licensing of SPCD
with RCT Logic; Lippincott, Williams & Wilkins; World Scientific
Publishing Co. Pte. Ltd.; M. H. T. has been a consultant for Abbott
Laboratories, Inc.; Akzo (Organon Pharmaceuticals Inc.); AstraZeneca;
Bayer; Bristol-Myers Squibb Company; Cephalon, Inc.; Cyberonics, Inc.;
Eli Lilly & Company; Fabre-Kramer Pharmaceuticals, Inc.; Forest
Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica Products, LP;
Johnson & Johnson PRD; Eli Lilly & Company; Meade Johnson; Neuronetics;
Parke-Davis Pharmaceuticals, Inc.; Pfizer, Inc.; Pharmacia & Upjohn;
Sepracor; Solvay Pharmaceuticals, Inc.; VantagePoint; and Wyeth-Ayerst
Laboratories. He has served on speakers bureaus for Abdi Brahim; Akzo
(Organon Pharmaceuticals Inc.); Bristol-Myers Squibb Company; Cephalon,
Inc.; Cyberonics, Inc.; Forest Pharmaceuticals; GlaxoSmithKline; Janssen
Pharmaceutica Products, LP; Eli Lilly & Company; Pharmacia & Upjohn;
Solvay Pharmaceuticals, Inc.; and Wyeth-Ayerst Laboratories. He has also
received grant support from BristolMyers Squibb; Cephalon, Inc.; Corcept
Therapeutics, Inc.; Cyberonics, Inc.; Eli Lilly & Company; Forest
Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica; Merck; National
Institute of Mental Health; NARSAD; Novartis; Pfizer Inc.; Pharmacia &
Upjohn; Predix Pharmaceuticals; Solvay Pharmaceuticals, Inc.; and
Wyeth-Ayerst Laboratories.
NR 39
TC 10
Z9 11
U1 2
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD FEB
PY 2013
VL 22
IS 2
BP 121
EP 131
DI 10.1089/jwh.2012.3479
PG 11
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA 088XJ
UT WOS:000314870900003
PM 23398127
ER
PT J
AU Cipriani, NA
Kurzawa, P
Mullen, J
Deshpande, V
Ahmad, R
Nielsen, GP
AF Cipriani, N. A.
Kurzawa, P.
Mullen, J.
Deshpande, V.
Ahmad, R.
Nielsen, G. P.
TI Prognostic Value of Subclassification of Pleomorphic Soft Tissue Sarcoma
(STS): Myogenic Versus Non-Myogenic Differentiation
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Greater Poland Canc Ctr, Poznan, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 31
BP 10A
EP 11A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300032
ER
PT J
AU Cipriani, NA
McLaughlin, PJ
Borger, DR
Nielsen, GP
AF Cipriani, N. A.
McLaughlin, P. J.
Borger, D. R.
Nielsen, G. P.
TI BRAF Mutation in "Sarcomas": A Possible Method To Detect Melanomas
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Cipriani, N. A.; McLaughlin, P. J.; Borger, D. R.; Nielsen, G. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 30
BP 10A
EP 10A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300031
ER
PT J
AU Kerr, DA
Deshpande, V
Kurzawa, P
Nielsen, GP
AF Kerr, D. A.
Deshpande, V.
Kurzawa, P.
Nielsen, G. P.
TI Chondroid Chordoma: A Chordoma Subtype with Worse Prognosis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Greater Poland Canc Ctr, Poznan, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 47
BP 14A
EP 14A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300048
ER
PT J
AU Lee, YD
Nardi, V
Le, LP
Deshpande, V
Hornicek, FJ
Lafrate, AJ
Nielsen, GP
AF Lee, Y. D.
Nardi, V.
Le, L. P.
Deshpande, V.
Hornicek, F. J.
Lafrate, A. J.
Nielsen, G. P.
TI Array Comparative Genomic Hybridization Analysis of a Conventional
Chordoma and an Adjacent Benign Notochordal Tumor Shows No Direct
Lineage Relationship
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Lee, Y. D.; Nardi, V.; Le, L. P.; Deshpande, V.; Hornicek, F. J.; Lafrate, A. J.; Nielsen, G. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 56
BP 16A
EP 17A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300057
ER
PT J
AU Shah, K
Zhang, Y
Nielsen, GP
Rosenberg, AE
AF Shah, K.
Zhang, Y.
Nielsen, G. P.
Rosenberg, A. E.
TI Primary Myoepithelioma of the Orbit
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Univ Miami, Miller Sch Med, Jackson Mem Hosp, Miami, FL 33136 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 71
BP 20A
EP 20A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300072
ER
PT J
AU Zhang, Y
Nielsen, GP
Raskin, K
Cipriani, N
Rosenberg, AE
AF Zhang, Y.
Nielsen, G. P.
Raskin, K.
Cipriani, N.
Rosenberg, A. E.
TI Primary Malignant Myoepithelial Tumor of Bone
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Univ Miami, Miller Sch Med, Jackson Mem Hosp, Miami, FL 33136 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 94
BP 25A
EP 25A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300095
ER
PT J
AU Brachtel, EF
Kerr, SE
Anderson, J
Zhang, Y
Singh, V
Erlander, MG
Carey, B
Highsmith, WE
Schnabel, CA
Dry, SM
Sullivan, PS
AF Brachtel, E. F.
Kerr, S. E.
Anderson, J.
Zhang, Y.
Singh, V.
Erlander, M. G.
Carey, B.
Highsmith, W. E.
Schnabel, C. A.
Dry, S. M.
Sullivan, P. S.
TI Diagnostic Utility of a 92-Gene Classifier in Triple-Negative Breast
Carcinomas
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Mayo Clin, Rochester, MN USA.
BioTheranostics Inc, San Diego, CA USA.
Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 121
BP 31A
EP 31A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300123
ER
PT J
AU Marques, RC
Lerwill, MF
AF Canas Marques, R.
Lerwill, M. F.
TI Incidence of Carcinoma and Atypia in Breast Reduction Mammoplasty
Specimens
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 EPE, Inst Portugues Oncol Lisboa Francisco Gentil, Lisbon, Portugal.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 126
BP 32A
EP 32A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300128
ER
PT J
AU Auger, M
Nayar, R
Khalbuss, WE
Barkan, GA
Benedict, C
Tambouret, R
Schwartz, MR
Howell, L
Souers, R
Hartley, A
Thomas, N
Moriarty, AT
AF Auger, M.
Nayar, R.
Khalbuss, W. E.
Barkan, G. A.
Benedict, C.
Tambouret, R.
Schwartz, M. R.
Howell, L.
Souers, R.
Hartley, A.
Thomas, N.
Moriarty, A. T.
TI Implementation of the Bethesda System for Reporting Thyroid
Cytopathology: Observations from the 2011 Thyroid Supplemental
Questionnaire of the College of American Pathologists
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 McGill Univ, Montreal, PQ, Canada.
McGill Unvers Hlth Ctr, Montreal, PQ, Canada.
Northwestern Univ, Chicago, IL 60611 USA.
NW Mem Hosp, Chicago, IL 60611 USA.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Loyola Univ, Maywood, IL 60153 USA.
Loyola Univ, Med Ctr Bedside Test, Maywood, IL 60153 USA.
DCL Pathol LLC, Indianapolis, IN USA.
Harvard Univ, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Methodist Hosp, Phys Org, Houston, TX 77030 USA.
Calif State Univ Sacramento, Sacramento, CA 95819 USA.
Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA.
Coll Amer Pathologists, Northfield, MN USA.
AmeriPath Indiana, Indianapolis, IN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 338
BP 83A
EP 83A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300341
ER
PT J
AU Balassanian, R
Ono, JC
Wool, GD
Olejnik-Nave, J
Mah, MM
Sweeney, BJ
Ljung, BM
Pitman, MB
AF Balassanian, R.
Ono, J. C.
Wool, G. D.
Olejnik-Nave, J.
Mah, M. M.
Sweeney, B. J.
Ljung, B-M
Pitman, M. B.
TI A Superior Technique for Cell Block Preparation for Fine Needle
Aspiration
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Lab Med Consultants, Las Vegas, NV USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 340
BP 83A
EP 83A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300343
ER
PT J
AU Linskey, K
Kay, J
Duncan, LM
Nazarian, RM
AF Linskey, K.
Kay, J.
Duncan, L. M.
Nazarian, R. M.
TI Wnt and Hedgehog Signaling Pathway Activation in Cutaneous Fibrosing
Disorders: A Tissue Microarray Study
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
UMass Mem Med Ctr, Worcester, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 479
BP 116A
EP 117A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300481
ER
PT J
AU Mochel, M
Arakaki, R
Wang, G
Kroshinsky, D
Hoang, M
AF Mochel, M.
Arakaki, R.
Wang, G.
Kroshinsky, D.
Hoang, M.
TI A Retrospective Histologic and Histochemical Evaluation of Cutaneous
Calciphylaxis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Mochel, M.; Arakaki, R.; Wang, G.; Kroshinsky, D.; Hoang, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 482
BP 117A
EP 117A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300484
ER
PT J
AU Prieto-Granada, CN
Lezcano, C
Piris, A
Scoyler, R
Mihm, M
AF Prieto-Granada, C. N.
Lezcano, C.
Piris, A.
Scoyler, R.
Mihm, M.
TI Lethal Childhood Melanoma: A Clinicopathological Study of 12 Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Baystate Med Ctr, Springfield, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Sydney Med Sch, Sydney, NSW, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 489
BP 119A
EP 119A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300491
ER
PT J
AU Cipriani, NA
Faquin, WC
Sadow, PM
AF Cipriani, N. A.
Faquin, W. C.
Sadow, P. M.
TI Clear Cell Variant of Thyroid Carcinoma: A Clinicopathologic Study
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Cipriani, N. A.; Faquin, W. C.; Sadow, P. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 542
BP 131A
EP 131A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300544
ER
PT J
AU Agoston, AT
Zheng, Y
Bueno, R
Lauwers, GY
Odze, RD
Srivastava, A
AF Agoston, A. T.
Zheng, Y.
Bueno, R.
Lauwers, G. Y.
Odze, R. D.
Srivastava, A.
TI Clinicopathologic Predictors of Long Term and Disease-Free Survival in
Esophageal Adenocarcinomas with Complete Pathologic Response to
Neoadjuvant Chemoradiation
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 592
BP 142A
EP 142A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300594
ER
PT J
AU Arnason, T
Pino, MS
Chung, DC
Sapp, HL
Rayson, D
Deshpande, V
Zukerberg, LR
AF Arnason, T.
Pino, M. S.
Chung, D. C.
Sapp, H. L.
Rayson, D.
Deshpande, V.
Zukerberg, L. R.
TI Loss of Cables Expression in Neuroendocrine Tumors (NETs) of the
Gastrointestinal Tract, Pancreas, and Lung
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Queen Elizabeth II HSC, Halifax, NS, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 600
BP 143A
EP 144A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300602
ER
PT J
AU Arnason, T
Brown, I
O'Brien, B
Wilson, C
Winter, H
Lauwers, GY
AF Arnason, T.
Brown, I.
O'Brien, B.
Wilson, C.
Winter, H.
Lauwers, G. Y.
TI Collagenous Gastritis: A Morphologic and Immunohistochemical Study of 27
Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia.
Sullivan Nicolaides Pathol, Brisbane, Qld, Australia.
RI Brown, Ian/R-7763-2016
OI Brown, Ian/0000-0001-6329-2547
NR 0
TC 1
Z9 1
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 601
BP 144A
EP 144A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300603
ER
PT J
AU Bandla, S
Peters, JH
Ruff, D
Chen, SM
Li, CY
Song, K
Thoms, K
Litle, VR
Watson, T
Chapurin, N
Pennathur, A
Luketich, JD
Peterson, D
Dulak, A
Lin, L
Bass, A
Beer, DG
Godfrey, TE
Zhou, Z
AF Bandla, S.
Peters, J. H.
Ruff, D.
Chen, S-M
Li, C-Y
Song, K.
Thoms, K.
Litle, V. R.
Watson, T.
Chapurin, N.
Pennathur, A.
Luketich, J. D.
Peterson, D.
Dulak, A.
Lin, L.
Bass, A.
Beer, D. G.
Godfrey, T. E.
Zhou, Z.
TI Analysis of Columnar Lined Esophagus Reveals Less Frequent Mutations In
Non-Goblet Cell Metaplasia Than intestinal Metaplasia
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 URMC, Rochester, NY USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Life Technol, Foster City, CA USA.
Dana Farber Canc Ctr, Boston, MA USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 604
BP 145A
EP 145A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300606
ER
PT J
AU Bledsoe, JR
Kamionek, M
Shvetz, DE
Mino-Kenudson, M
AF Bledsoe, J. R.
Kamionek, M.
Shvetz, D. E.
Mino-Kenudson, M.
TI Loss of Expression of ARID1A and BRG1 in Colorectal Cancer Occurs
Infrequently and Is Associated with BRAF Mutation and Microsatellite
Instability
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Bledsoe, J. R.; Kamionek, M.; Shvetz, D. E.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 608
BP 145A
EP 146A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300610
ER
PT J
AU Bledsoe, JR
Shvetz, DE
Mino-Kenudson, M
AF Bledsoe, J. R.
Shvetz, D. E.
Mino-Kenudson, M.
TI Phosphorylation of EGFR in Colorectal Cancer
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Bledsoe, J. R.; Shvetz, D. E.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 607
BP 145A
EP 145A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300609
ER
PT J
AU Deshpande, A
Deshpande, V
O'Brien, MJ
AF Deshpande, A.
Deshpande, V.
O'Brien, M. J.
TI Interstitial Cells of Cajal in Gastrointestinal Leiomyoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Boston Med Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 621
BP 149A
EP 149A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300623
ER
PT J
AU Huang, Q
Shi, J
Sun, Q
Yu, H
Chen, J
Wu, H
Gold, JK
Mashimo, H
Yu, C
Lauwers, GY
AF Huang, Q.
Shi, J.
Sun, Q.
Yu, H.
Chen, J.
Wu, H.
Gold, J. K.
Mashimo, H.
Yu, C.
Lauwers, G. Y.
TI Small (<= 2 cm) Carcinomas in the Proximal Stomach Demonstrate Distinct
Clinicopathologic Features from Those in the Distal and Corpus: A
Proposal for Classification of Gastric Cancer by Location
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
VA Boston Healthcare Syst, W Roxbury, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 648
BP 155A
EP 155A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300650
ER
PT J
AU Imamura, Y
Fuchs, C
Ogino, S
AF Imamura, Y.
Fuchs, C.
Ogino, S.
TI KRAS c.35G > T (p.G12V) and c.34G > C (p.G12R) Mutations Predict Shorter
Survival in 1925 Colorectal Cancers
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 651
BP 156A
EP 157A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300653
ER
PT J
AU Kuchiba, A
Lochhead, P
Ogino, S
AF Kuchiba, A.
Lochhead, P.
Ogino, S.
TI Colon Cancer Nodal Staging Score: A Tool To Assess Adequacy of Nodal
Harvesting in Pathology Practice
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 672
BP 161A
EP 162A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789300674
ER
PT J
AU Liang, WY
Hsu, CY
Arnason, T
Hawkins, AT
Sylla, P
Lauwers, GY
AF Liang, W. Y.
Hsu, C. Y.
Arnason, T.
Hawkins, A. T.
Sylla, P.
Lauwers, G. Y.
TI Retrospective Evaluation of Elastic Stain in the Assessment of Serosal
Invasion of pT3N0Mx Colorectal Cancers
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Vet Gen Hosp Taipei, Taipei, Taiwan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 683
BP 164A
EP 165A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301008
ER
PT J
AU Liang, WY
Arnason, T
Alfaro, E
Kelly, P
Genevay, M
Odze, RD
Lauwers, GY
AF Liang, W. Y.
Arnason, T.
Alfaro, E.
Kelly, P.
Genevay, M.
Odze, R. D.
Lauwers, G. Y.
TI Morphology and Natural History of Familial Adenomatous Polyposis
(FAP)-Associated Dysplastic Fundic Gland Polyps (FGPs)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 684
BP 165A
EP 165A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301009
ER
PT J
AU Liao, X
Imamura, Y
Ogino, S
AF Liao, X.
Imamura, Y.
Ogino, S.
TI KRAS Codon 12, 13, 61 and 146 Mutations in 1267 Colorectal Cancers:
Clinicopathological, Molecular, and Survival Analyses
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 685
BP 165A
EP 165A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301010
ER
PT J
AU Lochhead, P
Fuchs, C
Ogino, S
AF Lochhead, P.
Fuchs, C.
Ogino, S.
TI Microsatellite Instability (MSI) and BRAF Mutation Tests Jointly Provide
Useful Prognostic Information in 1861 Colorectal Cancers
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 688
BP 166A
EP 166A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301013
ER
PT J
AU Masia, R
Peyton, S
Lauwers, GY
Brown, I
AF Masia, R.
Peyton, S.
Lauwers, G. Y.
Brown, I.
TI Gastrointestinal Biopsy Findings of Autoimmune Enteropathy - A Review of
20 Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Pathol Queensland, Herston, Qld, Australia.
RI Brown, Ian/R-7763-2016
OI Brown, Ian/0000-0001-6329-2547
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 690
BP 167A
EP 167A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301015
ER
PT J
AU Nishihara, R
Fuchs, C
Ogino, S
AF Nishihara, R.
Fuchs, C.
Ogino, S.
TI Hereditary Predisposition to LINE-1 Hypomethylated Colorectal Cancer:
Potential Clinical Utility of Tumor LINE-1 Methylation Test for Familial
Cancer Risk Assessment
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 698
BP 169A
EP 169A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301023
ER
PT J
AU Ogino, S
Imamura, Y
Fuchs, C
AF Ogino, S.
Imamura, Y.
Fuchs, C.
TI LINE-1 Hypomethylation and Patient Prognosis in 1253 Colorectal Cancers
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 702
BP 170A
EP 170A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301027
ER
PT J
AU Primiani, A
Shahid, M
Yilmaz, O
Ferrone, CR
Borger, DR
Iafrate, AJ
Zhu, AX
Deshpande, V
AF Primiani, A.
Shahid, M.
Yilmaz, O.
Ferrone, C. R.
Borger, D. R.
Iafrate, A. J.
Zhu, A. X.
Deshpande, V.
TI Microsatellite Instability in Gallbladder Carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Primiani, A.; Shahid, M.; Yilmaz, O.; Ferrone, C. R.; Borger, D. R.; Iafrate, A. J.; Zhu, A. X.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 713
BP 172A
EP 173A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301038
ER
PT J
AU Primiani, A
Nazarian, RM
Linskey, K
Doyle, LA
Duncan, LM
Odze, R
Zukerberg, LR
AF Primiani, A.
Nazarian, R. M.
Linskey, K.
Doyle, L. A.
Duncan, L. M.
Odze, R.
Zukerberg, L. R.
TI CK17: An Adjunctive Marker of Invasion in Squamous Neoplastic Lesions of
the Anus
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womans Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 714
BP 173A
EP 173A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301039
ER
PT J
AU Primiani, A
Shahid, M
Yilmaz, O
Ferrone, CR
Borger, DR
Iafrate, AJ
Zhu, AX
Deshpande, V
AF Primiani, A.
Shahid, M.
Yilmaz, O.
Ferrone, C. R.
Borger, D. R.
Iafrate, A. J.
Zhu, A. X.
Deshpande, V.
TI The PI3K/mTOR Pathway in Gallbladder Carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Primiani, A.; Shahid, M.; Yilmaz, O.; Ferrone, C. R.; Borger, D. R.; Iafrate, A. J.; Zhu, A. X.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 715
BP 173A
EP 173A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301040
ER
PT J
AU Schulte, S
Khor, T
Hagen, C
Najarian, R
Lauwers, G
Odze, R
Srivastava, A
AF Schulte, S.
Khor, T.
Hagen, C.
Najarian, R.
Lauwers, G.
Odze, R.
Srivastava, A.
TI Long Term Outcome Study of Patients with Both Inflammatory Bowel Disease
and Microscopic Colitis during the Course of Illness
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dartmouth Hitchcock Med Ctr, Dover, NH USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 734
BP 178A
EP 178A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301059
ER
PT J
AU Shen, J
Najarian, RM
Dessauvagie, B
Deshpande, V
Kumarasinghe, MP
Hamilton, M
Shahid, M
Lauwers, G
Odze, RD
Srivastava, A
AF Shen, J.
Najarian, R. M.
Dessauvagie, B.
Deshpande, V.
Kumarasinghe, M. P.
Hamilton, M.
Shahid, M.
Lauwers, G.
Odze, R. D.
Srivastava, A.
TI Isolated Ileitis May Be a Manifestation of Crohn's Disease, but Only in
Symptomatic Patients: A Multi-Institution Study of 131 Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
PathWest, Perth, WA, Australia.
UWA, Perth, WA, Australia.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 738
BP 179A
EP 179A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301063
ER
PT J
AU Tse, JY
Riggi, N
Ting, DT
Stone, JH
Rivera, M
Deshpande, V
AF Tse, J. Y.
Riggi, N.
Ting, D. T.
Stone, J. H.
Rivera, M.
Deshpande, V.
TI Diagnosis of IgG4-Related Disease: No Longer an IS(H)-Sue?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Tse, J. Y.; Riggi, N.; Ting, D. T.; Stone, J. H.; Rivera, M.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 758
BP 184A
EP 184A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301083
ER
PT J
AU Ushiku, T
Moran, CJ
Lauwers, GY
AF Ushiku, T.
Moran, C. J.
Lauwers, G. Y.
TI Focally Enhanced Gastritis in Pediatric Inflammatory Bowel Disease:
Patterns, Associations and Significance
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Ushiku, T.; Moran, C. J.; Lauwers, G. Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 760
BP 184A
EP 184A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301085
ER
PT J
AU Ushiku, T
Ban, S
Arnason, T
Hishima, T
Fukayama, M
Lauwers, GY
AF Ushiku, T.
Ban, S.
Arnason, T.
Hishima, T.
Fukayama, M.
Lauwers, G. Y.
TI Very Well Differentiated Gastric Cancer of Intestinal Metaplasia-Type: A
Systemic Analysis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Tokyo, Tokyo, Japan.
Saiseikai Kawaguchi Gen Hosp, Saitama, Japan.
Tokyo Metropolitan Komagome Hosp, Tokyo, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 761
BP 185A
EP 185A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301086
ER
PT J
AU Ananthanarayanan, V
Pan, Y
Kocherginsky, M
Tretiakova, M
Amin, MB
Cheng, L
Epstein, JI
Grignon, DJ
Hansel, DE
Jimenez, RE
McKenney, JK
Montironi, R
Oliva, E
Osunkoya, AO
Rao, P
Reuter, VE
Ro, JY
Shen, SS
Srigley, JR
Tsuzuki, T
Yao, JL
Antic, T
Haber, M
Taxy, JB
Paner, GP
AF Ananthanarayanan, V.
Pan, Y.
Kocherginsky, M.
Tretiakova, M.
Amin, M. B.
Cheng, L.
Epstein, J. I.
Grignon, D. J.
Hansel, D. E.
Jimenez, R. E.
McKenney, J. K.
Montironi, R.
Oliva, E.
Osunkoya, A. O.
Rao, P.
Reuter, V. E.
Ro, J. Y.
Shen, S. S.
Srigley, J. R.
Tsuzuki, T.
Yao, J. L.
Antic, T.
Haber, M.
Taxy, J. B.
Paner, G. P.
TI Influence of Histologic Criteria and Confounding Factors (CFs) in
Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion
(MPVI or pT3a): An Interobserver Study among Expert GU Pathologists
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Univ Chicago, Chicago, IL 60637 USA.
Emory Univ, Atlanta, GA USA.
Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
Indiana Univ, Indianapolis, IN 46204 USA.
Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Mayo Clin, Rochester, MN USA.
Polytech Univ Marche Reg, Ancona, Italy.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Methodist Hosp, Houston, TX 77030 USA.
McMaster Univ, Hamilton, ON, Canada.
Nagoya Daini Red Cross Hosp, Nagoya, Aichi, Japan.
Univ Rochester, Rochester, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 802
BP 194A
EP 195A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301126
ER
PT J
AU Dong, F
Ping, Y
Wang, C
Wu, S
Xiao, Y
McDougal, WS
Young, RH
Wu, CL
AF Dong, F.
Ping, Y.
Wang, C.
Wu, S.
Xiao, Y.
McDougal, W. S.
Young, R. H.
Wu, C-L
TI Architectural Heterogeneity and Cribriform Pattern Predict Adverse
Clinical Outcome for Gleason Grade 4 Prostatic Adenocarcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Dong, F.; Ping, Y.; Wang, C.; Wu, S.; Xiao, Y.; McDougal, W. S.; Young, R. H.; Wu, C-L] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 852
BP 206A
EP 206A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301176
ER
PT J
AU Flynn, L
Sheils, O
O'Leary, JJ
Finn, SP
Watson, W
Loda, M
Mucci, L
AF Flynn, L.
Sheils, O.
O'Leary, J. J.
Finn, S. P.
Watson, W.
Loda, M.
Mucci, L.
TI miRNA Signatures of Indolent and Aggressive Prostate Cancer
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Univ Dublin, Trinity Coll, Dublin, Ireland.
Univ Coll Dublin, Dublin 2, Ireland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 875
BP 211A
EP 211A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301199
ER
PT J
AU Mason, EF
Sadow, PM
Wagner, AJ
Remillard, SP
Flood, TA
Belanger, EC
Hornick, JL
Barletta, JA
AF Mason, E. F.
Sadow, P. M.
Wagner, A. J.
Remillard, S. P.
Flood, T. A.
Belanger, E. C.
Hornick, J. L.
Barletta, J. A.
TI Identification of Succinate Dehydrogenase-Deficient Bladder
Paragangliomas
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Ottawa Hosp, Ottawa, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 966
BP 233A
EP 233A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301290
ER
PT J
AU Ali, RH
Kurihara, S
Endo, M
Rouzbahman, M
Hoang, LN
Melnyk, N
Marino-Enriquez, A
Dal Cin, P
Fletcher, JA
Oliva, E
Huntsman, DG
Oda, Y
Nucci, MR
Lee, CH
AF Ali, R. H.
Kurihara, S.
Endo, M.
Rouzbahman, M.
Hoang, L. N.
Melnyk, N.
Marino-Enriquez, A.
Dal Cin, P.
Fletcher, J. A.
Oliva, E.
Huntsman, D. G.
Oda, Y.
Nucci, M. R.
Lee, C-H
TI Genetic Reclassification of Undifferentiated Endometrial Sarcoma:
Clinical Relevance
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
Kyushu Univ, Fukuoka 812, Japan.
Univ Toronto, Toronto, ON, Canada.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1096
BP 263A
EP 263A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301421
ER
PT J
AU Bandyopadhyay, S
Winer, I
Mert, I
Oliva, E
Nucci, M
Al-Wahab, Z
Guan, H
Arabi, H
Alosh, B
Van de Vijver, KK
Ali-Fehmi, R
AF Bandyopadhyay, S.
Winer, I.
Mert, I.
Oliva, E.
Nucci, M.
Al-Wahab, Z.
Guan, H.
Arabi, H.
Alosh, B.
Van de Vijver, K. K.
Ali-Fehmi, R.
TI Clinical Significance of Lymphovascular Space Invasion in Uterine Serous
Carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Wayne State Univ, Detroit, MI USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
King Abdul Aziz Med City, Jeddah, Saudi Arabia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1106
BP 266A
EP 266A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301431
ER
PT J
AU Hoang, LN
McConechy, MK
Koebel, M
Han, G
Rouzbahman, M
Davidson, B
Irving, J
Ali, R
Leung, S
Oliva, E
Nucci, MR
Soslow, RA
Huntsman, DG
Gilks, CB
Lee, CH
AF Hoang, L. N.
McConechy, M. K.
Koebel, M.
Han, G.
Rouzbahman, M.
Davidson, B.
Irving, J.
Ali, R.
Leung, S.
Oliva, E.
Nucci, M. R.
Soslow, R. A.
Huntsman, D. G.
Gilks, C. B.
Lee, C-H
TI Histotype-Genotype Correlation in 36 High-Grade Endometrial Carcinomas
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
Univ Calgary, Calgary, AB, Canada.
Univ Toronto, Toronto, ON, Canada.
Norwegian Radium Hosp, Oslo, Norway.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1160
BP 278A
EP 278A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301485
ER
PT J
AU Lee, CH
Hoang, LN
Reyes, C
Soslow, RA
Nucci, MR
Oliva, E
AF Lee, C-H
Hoang, L. N.
Reyes, C.
Soslow, R. A.
Nucci, M. R.
Oliva, E.
TI Frequent Immunohistochemical Expression of KIT in YWHAE-FAM22
Endometrial Stromal Sarcoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1192
BP 285A
EP 285A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301517
ER
PT J
AU Zane, NA
Kraft, S
Faquin, W
Stone, JH
Deshpande, V
AF Zane, N. A.
Kraft, S.
Faquin, W.
Stone, J. H.
Deshpande, V.
TI IgG4-Related Disease Is a Rare Cause of Recurrent Mastoiditis and Can Be
Mimicked by Severe Otitis Media
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Zane, N. A.; Kraft, S.; Faquin, W.; Stone, J. H.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1317
BP 315A
EP 315A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301642
ER
PT J
AU Boyer, DF
Lindeman, NI
Harris, NL
Ferry, JA
AF Boyer, D. F.
Lindeman, N. I.
Harris, N. L.
Ferry, J. A.
TI Peripheral T-Cell Lymphomas with Cytotoxic Phenotype in Patients with
Nodal SLL/CLL
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1341
BP 321A
EP 321A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301666
ER
PT J
AU Chen, BJ
Ouyang, J
Xu, ML
Yu, H
Fletcher, CDM
Sun, H
Shipp, MA
Rodig, SJ
AF Chen, B. J.
Ouyang, J.
Xu, M. L.
Yu, H.
Fletcher, C. D. M.
Sun, H.
Shipp, M. A.
Rodig, S. J.
TI Expression of the Immunosuppressive Molecules PD-L1 and Galectin-1 by
EBV+ Lymphoproliferative Disorders: Novel Candidates for Targeted
Immunotherapy
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
DFCI, Boston, MA USA.
Yale Univ, Sch Med, New Haven, CT USA.
UMass Mem Hosp, Worcester, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1351
BP 323A
EP 323A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789301676
ER
PT J
AU Huck, A
Fathi, A
Hasserjian, R
AF Huck, A.
Fathi, A.
Hasserjian, R.
TI Cytopenia Prior to AML Diagnosis Predicts Aggressive Behavior Even in
the Absence of Antecedent MDS: Another Diagnostic Criterion for AML with
Myelodysplasia-Related Changes?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Huck, A.; Fathi, A.; Hasserjian, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1395
BP 333A
EP 333A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302012
ER
PT J
AU Hwang, DG
Dorfman, DM
Briggs, DA
Silverio, R
Pozdnyakova, O
AF Hwang, D. G.
Dorfman, D. M.
Briggs, D. A.
Silverio, R.
Pozdnyakova, O.
TI Detecting Myelodysplastic Syndromes on Peripheral Blood Using a Machine
Learning Approach To Analyze Multiparameter Hematology Analyzer Data
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Virginia Mason Med Ctr, Seattle, WA 98101 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1399
BP 334A
EP 334A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302016
ER
PT J
AU Klepeis, V
Hasserjian, RP
AF Klepeis, V.
Hasserjian, R. P.
TI Refractory Anemia with Excess Blasts in Transformation Exhibits
Clinicopathologic Features and Clinical Behavior Similar to AML with >=
30% Blasts
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Klepeis, V.; Hasserjian, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1410
BP 336A
EP 336A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302027
ER
PT J
AU Klepeis, VE
Zukerberg, LR
Hasserjian, RP
AF Klepeis, V. E.
Zukerberg, L. R.
Hasserjian, R. P.
TI Genetic Subtypes of Acute Myeloid Leukemia Are Associated with
Distinctive Features of the Bone Marrow Microenvironment
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Klepeis, V. E.; Zukerberg, L. R.; Hasserjian, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1411
BP 336A
EP 337A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302028
ER
PT J
AU Nicolae, A
Huppmann, AR
Slack, GW
Ferry, JA
Harris, NL
Pittaluga, S
Jaffe, ES
Hasserjian, RP
AF Nicolae, A.
Huppmann, A. R.
Slack, G. W.
Ferry, J. A.
Harris, N. L.
Pittaluga, S.
Jaffe, E. S.
Hasserjian, R. P.
TI EBV Is Infrequently Expressed in the LP Cells of Nodular Lymphocyte
Predominant Hodgkin Lymphoma (NLPHL) in Both Children and Adults
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 NCI, Bethesda, MD 20892 USA.
BC Canc Agcy, Vancouver, BC, Canada.
Massachusetts Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1473
BP 352A
EP 352A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302090
ER
PT J
AU O'Malley, DP
Kim, YS
Sohani, A
Weiss, L
Perkins, S
Burke, JS
Fisher, C
Orazi, A
AF O'Malley, D. P.
Kim, Y. S.
Sohani, A.
Weiss, L.
Perkins, S.
Burke, J. S.
Fisher, C.
Orazi, A.
TI Immunohistochemical Characterization of Vascular and Stromal
Proliferations of Spleen
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Clarient Inc GE Healthcare, Aliso Viejo, CA USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Utah, Salt Lake City, UT USA.
Alta Bates Med Ctr, Berkeley, CA USA.
Royal Marsden Hosp, London SW3 6JJ, England.
Weill Cornell Med Coll, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1475
BP 352A
EP 352A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302092
ER
PT J
AU O'Malley, DP
Zuckerberg, L
Smith, L
Barry, TS
Gunn, S
Tam, W
Orazi, A
Kim, YS
Weiss, L
AF O'Malley, D. P.
Zuckerberg, L.
Smith, L.
Barry, T. S.
Gunn, S.
Tam, W.
Orazi, A.
Kim, Y. S.
Weiss, L.
TI The Genetics of Interdigitating Dendritic Cell Tumors Shares Some
Changes with Langerhans Cell Histiocytosis in Select Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Clarient Inc GE Healthcare, Aliso Viejo, CA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Spectrum Pathol, Mission Viejo, CA USA.
PathCentral, Irvine, CA USA.
Weill Comell Med Ctr, New York, NY USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1476
BP 353A
EP 353A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302093
ER
PT J
AU Pozdnyakova, O
Shahsafaei, A
Freeman, G
Dorfman, D
AF Pozdnyakova, O.
Shahsafaei, A.
Freeman, G.
Dorfman, D.
TI A Panel of Follicular Helper T-Cell (T-FH) Immunophenotypic Markers
Identifies and Differentiates T-FH-Derived Neoplasms from Other T-Cell
Neoplasms
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1486
BP 355A
EP 355A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302103
ER
PT J
AU Rogers, HJ
Vardiman, JW
Anastasi, J
Raca, G
Savage, NM
Cherry, AM
Arber, D
Moore, E
Morrissette, JJD
Bagg, A
Liu, YC
Mathew, S
Orazi, A
Lin, P
Wang, SA
Bueso-Ramos, CE
Foucar, K
Hasserjian, RP
Hsi, ED
AF Rogers, H. J.
Vardiman, J. W.
Anastasi, J.
Raca, G.
Savage, N. M.
Cherry, A. M.
Arber, D.
Moore, E.
Morrissette, J. J. D.
Bagg, A.
Liu, Y-C
Mathew, S.
Orazi, A.
Lin, P.
Wang, S. A.
Bueso-Ramos, C. E.
Foucar, K.
Hasserjian, R. P.
Hsi, E. D.
TI Complex Karyotype but Not Blast Percentage Is Associated with Poor
Survival in Acute Myeloid Leukemia and Myelodysplastic Syndrome with
Inv(3)(q21q26.2)/t(3;3)(q21;q26.2); a Bone Marrow Pathology Group Study
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Cleveland Clin, Cleveland, OH 44106 USA.
Univ Chicago, Chicago, IL 60637 USA.
Stanford Univ, Stanford, CA 94305 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ New Mexico, Albuquerque, NM 87131 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1498
BP 358A
EP 358A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302115
ER
PT J
AU Ryan, RJH
Akin, C
Castells, M
Selig, MK
Nielsen, GP
Ferry, JA
Hornick, JL
AF Ryan, R. J. H.
Akin, C.
Castells, M.
Selig, M. K.
Nielsen, G. P.
Ferry, J. A.
Hornick, J. L.
TI Mast Cell Sarcoma: An Aggressive and Potentially Under-Diagnosed
Neoplasm That May Be Responsive to Targeted Therapy
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1501
BP 359A
EP 359A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302118
ER
PT J
AU Tandon, B
Swerdlow, SH
Hasserjian, RP
Gibson, SE
AF Tandon, B.
Swerdlow, S. H.
Hasserjian, R. P.
Gibson, S. E.
TI Is Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) a
Lymphoma of Mantle Zone B-Cells?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1522
BP 364A
EP 364A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302139
ER
PT J
AU Yagi, Y
Qureshi, I
Malik, AZ
Wilbur, DC
AF Yagi, Y.
Qureshi, I.
Malik, A. Z.
Wilbur, D. C.
TI Challenges in Establishing the WSI Based Digital Pathology Facility and
Telepathology Network between Pakistna and USA
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Holy Family Hosp, Rawalpindi, Pakistan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1598
BP 382A
EP 383A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302214
ER
PT J
AU Fazlollahi, L
Dias-Santagata, D
Sahora, K
Morales-Oyarvide, V
Bernardo, LA
Iafrate, AJ
Pitman, MB
Fernandez-del Castillo, C
Mino-Kenudson, M
AF Fazlollahi, L.
Dias-Santagata, D.
Sahora, K.
Morales-Oyarvide, V.
Bernardo, L. A.
Iafrate, A. J.
Pitman, M. B.
Fernandez-del Castillo, C.
Mino-Kenudson, M.
TI GNAS Mutations in Concomitant Pancreatic Ductal Adenocarcinoma: A Pilot
Study
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Fazlollahi, L.; Dias-Santagata, D.; Sahora, K.; Morales-Oyarvide, V.; Bernardo, L. A.; Iafrate, A. J.; Pitman, M. B.; Fernandez-del Castillo, C.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1765
BP 424A
EP 424A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302381
ER
PT J
AU Shahid, M
Zukerberg, LR
Deshpande, V
AF Shahid, M.
Zukerberg, L. R.
Deshpande, V.
TI Is Investing AdditionalTime on Mitotic Counts in Neuroendocrine Neoplasm
Clinically Relevant?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Shahid, M.; Zukerberg, L. R.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1791
BP 430A
EP 430A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302407
ER
PT J
AU Sous, JF
Sahora, K
Shvetz, D
Fernandez-del-Castillo, C
Pitman, MB
Mino-Kenudson, M
AF Sous, J. F.
Sahora, K.
Shvetz, D.
Fernandez-del-Castillo, C.
Pitman, M. B.
Mino-Kenudson, M.
TI Protein Expression of the SWI/SNF Chromatin Remolding Subunits in
Intraductal Papillary Mucinous Neoplasm (IPMN) and Pancreatic Ductal
Adenocarcinoma (PDAC)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Sous, J. F.; Sahora, K.; Shvetz, D.; Fernandez-del-Castillo, C.; Pitman, M. B.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1796
BP 431A
EP 431A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302412
ER
PT J
AU Wang, JL
Shvetz, D
Sahora, K
Fernandez-del Castillo, C
Pitman, M
Mino-Kenudson, M
AF Wang, J. L.
Shvetz, D.
Sahora, K.
Fernandez-del Castillo, C.
Pitman, M.
Mino-Kenudson, M.
TI Activation of Src and STAT3 in Intraductal Papillary Mucinous Neoplasm
of the Pancreas (IPMN)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1800
BP 432A
EP 432A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302416
ER
PT J
AU Lindeman, NI
MacConaill, LE
Garcia, E
Kuo, FC
Longtine, JA
Hahn, WC
Kantoff, PW
Rollins, BJ
AF Lindeman, N. I.
MacConaill, L. E.
Garcia, E.
Kuo, F. C.
Longtine, J. A.
Hahn, W. C.
Kantoff, P. W.
Rollins, B. J.
TI Profile: Results from Multiplexed Mass Spectrometric Genotyping of 2178
Cancer Patients
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Harvard Univ, Sch Med, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Mt Sinai Hosp, New York, NY 10029 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1816
BP 436A
EP 436A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302431
ER
PT J
AU Waldron, L
Parmigiani, G
Fuchs, C
Huttenhower, C
Ogino, S
AF Waldron, L.
Parmigiani, G.
Fuchs, C.
Huttenhower, C.
Ogino, S.
TI Expression Profiling and Molecular Classification of Colorectal Cancer:
Meta-Analysis of 8 Independent mRNA Expression Datasets across the Globe
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1830
BP 439A
EP 439A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302445
ER
PT J
AU Pessarakli, MM
Phan, RT
AF Pessarakli, M. M.
Phan, R. T.
TI Association between Methylenetetrahydrofolate Reductase (MTHFR) Gene
Variants and Hyperhomocysteinemia in United States Veterans
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 USC, Keck Sch Med, Los Angeles, CA USA.
Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1853
BP 444A
EP 445A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302468
ER
PT J
AU Matsubara, O
Miyai, K
Ishikawa, V
Nakatani, Y
Mark, EJ
AF Matsubara, O.
Miyai, K.
Ishikawa, V.
Nakatani, Y.
Mark, E. J.
TI Epithelial-Mesenchymal Transition (EMT) in Active Fibroblastic Foci in
IPF/UIP
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan.
Japanese Fdn Canc Res, Inst Canc, Koto Ku, Tokyo 170, Japan.
Chiba Univ, Chiba, Japan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1911
BP 459A
EP 459A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302526
ER
PT J
AU Miyamoto, A
Sharma, A
Nishino, M
Mino-Kenudson, M
Mark, EJ
AF Miyamoto, A.
Sharma, A.
Nishino, M.
Mino-Kenudson, M.
Mark, E. J.
TI Acute Exacerbation of Non-Specific Interstitial Pneumonia Compared to
That of Usual Interstitial Pneumonia
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Toranomon Gen Hosp, Tokyo, Japan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1915
BP 460A
EP 460A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302530
ER
PT J
AU Nishino, M
Mathai, SK
O'Donnell, WJ
Kradin, RL
AF Nishino, M.
Mathai, S. K.
O'Donnell, W. J.
Kradin, R. L.
TI Intraalveolar Fibrin Is Associated with Poor Outcomes in Cryptogenic
Organizing Pneumonia
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 [Nishino, M.; Mathai, S. K.; O'Donnell, W. J.; Kradin, R. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1921
BP 462A
EP 462A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302536
ER
PT J
AU Setia, N
Janne, PA
Sholl, LM
AF Setia, N.
Janne, P. A.
Sholl, L. M.
TI Long Term Effects of EGFR Tyrosine Kinase Inhibitor Therapy on the
Non-Neoplastic Lung
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1939
BP 466A
EP 466A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302554
ER
PT J
AU Sholl, L
Sun, H
Ligon, A
Butaney, M
Janne, PA
Rodig, S
AF Sholl, L.
Sun, H.
Ligon, A.
Butaney, M.
Janne, P. A.
Rodig, S.
TI MET Copy Number by Dual Color Brightfield In Situ Hybridization and
Fluorescence In Situ Hybridization Correlates with Met Protein
Expression in Lung Adenocarcinomas
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1942
BP 467A
EP 467A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302557
ER
PT J
AU Sholl, L
Sun, H
Butaney, M
Lee, C
Janne, PA
Rodig, S
AF Sholl, L.
Sun, H.
Butaney, M.
Lee, C.
Janne, P. A.
Rodig, S.
TI ROS Immunohistochemistry Is a Sensitive and Specific Tool for Detection
of ROS Rearrangements in Lung Adenocarcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 102nd Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 02-08, 2013
CL Baltimore, MD
SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2013
VL 93
SU 1
MA 1943
BP 467A
EP 467A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 087UL
UT WOS:000314789302558
ER
PT J
AU Ackerley, EJ
Cavan, AE
Wilson, PL
Berbeco, RI
Meyer, J
AF Ackerley, E. J.
Cavan, A. E.
Wilson, P. L.
Berbeco, R. I.
Meyer, J.
TI Application of a spring-dashpot system to clinical lung tumor motion
data
SO MEDICAL PHYSICS
LA English
DT Article
DE spring-dashpot model; radiotherapy; lung tumor modeling; respiration;
differential equation
ID REAL-TIME; TRACKING SYSTEM; RESPIRATORY MOTION; GATED RADIOTHERAPY;
COMPENSATION; MOVEMENT; FEASIBILITY; SURROGATES; PREDICTION; LOCATION
AB Purpose: The treatment efficacy of radiation therapy for lung tumors can be increased by compensating for breath-induced tumor motion. In this study, we quantitatively examine a mathematical model of pseudomechanical linkages between an external surrogate signal and lung tumor motion.
Methods: A spring-dashpot system based on the Voigt model was developed to model the correlation between abdominal respiratory motion and tumor motion during lung radiotherapy. The model was applied to clinical data obtained from 52 treatments ("beams") from 10 patients, treated on the Mitsubishi Real-Time Radiation Therapy system, Sapporo, Japan. In Stage 1, model parameters were optimized for individual patients and beams to determine reference values and to investigate how well the model can describe the data. In Stage 2, for each patient the optimal parameters determined for a single beam were applied to data from other beams to investigate whether a beam-specific set of model parameters is sufficient to model tumor motion over a course of treatment.
Results: In Stage 1, the baseline root mean square (RMS) residual error for all individually optimized beam data was 0.90 +/- 0.40 mm (mean +/- 1 standard deviation). In Stage 2, patient-specific model parameters based on a single beam were found to model the tumor position closely, even for irregular beam data, with a mean increase with respect to Stage 1 values in RMS error of 0.37 mm. On average, the obtained model output for the tumor position was 95% of the time within an absolute bound of 2.0 and 2.6 mm in Stages 1 and 2, respectively. The model was capable of dealing with baseline, amplitude and frequency variations of the input data, as well as phase shifts between the input abdominal and output tumor signals.
Conclusions: These results indicate that it may be feasible to collect patient-specific model parameters during or prior to the first treatment, and then retain these for the rest of the treatment period. The model has potential for clinical application during radiotherapy treatment of lung tumors. (c) 2013 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4788643]
C1 [Ackerley, E. J.; Wilson, P. L.] Univ Canterbury, Dept Math & Stat, Christchurch 8140, New Zealand.
[Cavan, A. E.; Meyer, J.] Univ Canterbury, Dept Phys & Astron, Christchurch 8140, New Zealand.
[Cavan, A. E.] Christchurch Hosp, Dept Med Phys & Bioengn, Christchurch, New Zealand.
[Berbeco, R. I.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Berbeco, R. I.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Meyer, J.] Univ Washington, Med Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA.
RP Wilson, PL (reprint author), Univ Canterbury, Dept Math & Stat, Private Bag 4800, Christchurch 8140, New Zealand.
EM phillip.wilson@canterbury.ac.nz
OI Meyer, Juergen/0000-0003-4350-2222
FU Canterbury Medical Research Foundation
FX The authors would like to thank Dr. Seiko Nishioka and Dr. Hiroki
Shirato, for the clinical data provided from the Nippon Telegraph and
Telephone Corporation Hospital in Sapporo, Japan. Thanks also to the
Canterbury Medical Research Foundation for financial support for Alicia
Cavan.
NR 38
TC 2
Z9 2
U1 0
U2 4
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD FEB
PY 2013
VL 40
IS 2
AR 021713
DI 10.1118/1.4788643
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 086YZ
UT WOS:000314727700017
PM 23387736
ER
PT J
AU Zygmanski, P
Hoegele, W
Tsiamas, P
Cifter, F
Ngwa, W
Berbeco, R
Makrigiorgos, M
Sajo, E
AF Zygmanski, Piotr
Hoegele, Wolfgang
Tsiamas, Panagiotis
Cifter, Fulya
Ngwa, Wil
Berbeco, Ross
Makrigiorgos, Mike
Sajo, Erno
TI A stochastic model of cell survival for high-Z nanoparticle radiotherapy
SO MEDICAL PHYSICS
LA English
DT Article
DE gold; nanoparticle; LEM; RBE
ID LOCAL EFFECT MODEL; MONTE-CARLO-SIMULATION; GOLD NANOPARTICLES; DOSE
ENHANCEMENT; RADIATION-THERAPY; CLINICAL SCENARIO; MAMMALIAN-CELLS;
PHOTON ENERGY; X-RAY; DNA
AB Purpose: The authors present a stochastic framework for the assessment of cell survival in gold nanoparticle radiotherapy.
Methods: The authors derive the equations for the effective macroscopic dose enhancement for a population of cells with nonideal distribution of gold nanoparticles (GNP), allowing different number of GNP per cell and different distances with respect to the cellular target. They use the mixed Poisson distribution formalism to model the impact of the aforementioned physical factors on the effective dose enhancement.
Results: The authors show relatively large differences in the estimation of cell survival arising from using approximated formulae. They predict degeneration of the cell killing capacity due to different number of GNP per cell and different distances with respect to the cellular target.
Conclusions: The presented stochastic framework can be used in interpretation of experimental cell survival or tumor control probability studies. c 2013 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4773885]
C1 [Zygmanski, Piotr; Tsiamas, Panagiotis; Ngwa, Wil; Berbeco, Ross; Makrigiorgos, Mike] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zygmanski, Piotr; Tsiamas, Panagiotis; Ngwa, Wil; Berbeco, Ross; Makrigiorgos, Mike] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Hoegele, Wolfgang] Univ Regensburg, Dept Radiat Oncol, D-93053 Regensburg, Germany.
[Cifter, Fulya; Sajo, Erno] Univ Massachusetts, Dept Phys & Appl Phys, Med Phys Program, Lowell, MA 01854 USA.
RP Zygmanski, P (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM pzygmanski@lroc.harvard.edu
RI Hoegele, Wolfgang/A-2575-2013
OI Hoegele, Wolfgang/0000-0002-5303-9334
NR 47
TC 6
Z9 6
U1 0
U2 19
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD FEB
PY 2013
VL 40
IS 2
AR 024102
DI 10.1118/1.4773885
PG 16
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 086YZ
UT WOS:000314727700062
PM 23387781
ER
PT J
AU Galanakos, SP
Zoubos, AB
Mourouzis, I
Ignatiadis, I
Bot, AGJ
Soucacos, PN
AF Galanakos, Spyridon P.
Zoubos, Aristides B.
Mourouzis, Iordanis
Ignatiadis, Ioannis
Bot, Arjan G. J.
Soucacos, Panayotis N.
TI Prognostic scoring system for peripheral nerve repair in the upper
extremity
SO MICROSURGERY
LA English
DT Article
ID FUNCTIONAL ASSESSMENT; INJURIES; ULNAR; HAND; SURGERY; OUTCOMES;
PREDICTORS; RECOVERY; FOREARM; TRAUMA
AB So far, predictive models with individualized estimates of prognosis for patients with peripheral nerve injuries are lacking. Our group has previously shown the prognostic value of a standardized scoring system by examining the functional outcome after acute, sharp complete laceration and repair of median and/or ulnar nerves at various levels in the forearm. In the present study, we further explore the potential mathematical model in order to devise an effective prognostic scoring system. We retrospectively collected medical record data of 73 cases with a peripheral nerve injury in the upper extremity in order to estimate which patients would return to work, and what time was necessary to return to the pre-injury work. Postoperative assessment followed the protocol described by Rosen and Lundborg. We found that return to pre-injury work can be predicted with high sensitivity (100%) and specificity (95%) using the total numerical score of the Rosen and Lundborg protocol at the third follow-up interval (TS3) as well as the difference between the TS3 and the total score at second follow-up interval (TS2). In addition, the factors age and type of injured nerve (median, ulnar, or combined) can determine the time of return to work based on a mathematical model. This prognostic protocol can be a useful tool to provide information about the functional and social prospects of the patients with these types of injuries. (c) 2012 Wiley Periodicals, Inc. Microsurgery, 2013.
C1 [Galanakos, Spyridon P.; Zoubos, Aristides B.; Mourouzis, Iordanis; Ignatiadis, Ioannis; Soucacos, Panayotis N.] Univ Athens, Dept Orthopaed Surg 1, ATTIKON Univ Hosp, Athens 12462, Greece.
[Bot, Arjan G. J.] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA.
RP Galanakos, SP (reprint author), Univ Athens, Dept Orthopaed Surg 1, ATTIKON Univ Hosp, 1 Rimini St, Athens 12462, Greece.
EM spyros_galanakos@yahoo.gr
NR 33
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0738-1085
J9 MICROSURG
JI Microsurgery
PD FEB
PY 2013
VL 33
IS 2
BP 105
EP 111
DI 10.1002/micr.22000
PG 7
WC Surgery
SC Surgery
GA 089GH
UT WOS:000314898400003
PM 22707451
ER
PT J
AU Yang, XY
Kallarakal, A
Saptharishi, N
Jiang, HG
Yang, ZW
Xie, YQ
Mitra, G
Zheng, XX
Strom, TB
Soman, G
AF Yang, Xiaoyi
Kallarakal, Abraham
Saptharishi, Nirmala
Jiang, Hengguang
Yang, Zhiwen
Xie, Yueqing
Mitra, George
Zheng, Xin Xiao
Strom, Terry B.
Soman, Gopalan
TI Molecular Characterization and Functional Activity of an IL-15
Antagonist MutIL-15/Fc Human Fusion Protein
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE fusion protein; bioactivity; SEC-MALS; N-glycoprofiling; Fc receptor
binding; surface plasmon resonance
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; SENSITIVE FLUORESCENCE DETECTION;
T-CELLS; QUANTITATIVE-DETERMINATION; MONOCLONAL-ANTIBODIES; THERAPEUTIC
PROTEINS; GROWTH-FACTOR; FC DOMAIN; RECEPTOR; INTERLEUKIN-15
AB Fc fusion proteins are a new emerging class of molecules for immune-targeted delivery of therapeutic proteins. Biophysical and bioanalytical characterization is critical for clinical development and delivery of therapeutic proteins. Here we report molecular and functional characterization of a recombinant human fusion protein Mutant IL-15/Fc. MutIL-15/Fc has a molecular weight of similar to 95 kDa as determined by multiangle laser light scattering with online size exclusion chromatography and migrated at a faster rate (lower retention time) in gel filtration column. The kinetics of binding of MutIL-15/Fc to Fc gamma receptor is best fitted in a bivalent modal with K-D1 5 mu M and K-D2 9 mu M determined by surface plasmon resonance (BIAcore). N-Glycoprofiling analysis revealed extensive glycosylation of MutIL-15/Fc. The Fc and IL-15 components in the MutIL-15/Fc are detected using the dual mode ELISA. The HT-2 cell proliferation inhibition assay is qualified as a quantitative in vitro marker functional assay. Molecular state changes associated with forced stress analyzed by SEC-MALS resulted in changes in bioactivity and Fc:Fc gamma receptor interaction affinity. These data provide a systematic approach to molecular and functional characterization of the MutIL-15/Fc to establish product consistency and stability monitoring during storage and under drug delivery conditions.
C1 [Yang, Xiaoyi; Kallarakal, Abraham; Saptharishi, Nirmala; Jiang, Hengguang; Yang, Zhiwen; Xie, Yueqing; Mitra, George; Soman, Gopalan] SAIC Frederick Inc, Biopharmaceut Dev Program, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
[Zheng, Xin Xiao] Univ Pittsburgh, Med Ctr, Thomas Starzl Transplant Inst, Pittsburgh, PA 15261 USA.
[Strom, Terry B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Gen Hosp, Med Sch,Dept Surg & Med,Transplant Inst, Boston, MA 02215 USA.
RP Soman, G (reprint author), SAIC Frederick Inc, Biopharmaceut Dev Program, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
EM somang@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]; NIDDK; NIAID; Developmental Therapeutics Program in
the Division of Cancer Treatment and Diagnosis of the National Cancer
Institute
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
Contract No. HHSN261200800001E and funding from NIDDK and NIAID. The
content of this publication does not necessarily reflect the views or
policies of the Department of Health and Human Services, nor does
mention of trade names, commercial products, or organizations imply
endorsement by the U.S. government. This research was supported [in
part] by the Developmental Therapeutics Program in the Division of
Cancer Treatment and Diagnosis of the National Cancer Institute. Our
sincere thanks are due to Drs. Jason Yovandich and Stephen P. Creekmore
of the Biological Resources Branch, DTP, NCI for the support of this
work and review of this manuscript. We would like to acknowledge the
technical support from Dr. Hong Chen during the early stages of this
work. Mr. Trevor Broadt of Process Analytics is acknowledged for helpful
review of the manuscript. The support and encouragement from Dr. Steve
Giardina and the process analytics staff are also acknowledged. Thanks
are also due to Dr. Jianwei Zhu of Early Stage Process Development in
BDP.
NR 41
TC 0
Z9 0
U1 1
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD FEB
PY 2013
VL 10
IS 2
BP 717
EP 727
DI 10.1021/mp300513j
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 085PT
UT WOS:000314627400031
PM 23311475
ER
PT J
AU Tremblay, JP
Xiao, X
Aartsma-Rus, A
Barbas, C
Blaus, HM
Bogdanove, AJ
Boycott, K
Brauns, S
Breakefield, XO
Bueren, JA
Buschmann, M
Byrne, BJ
Calos, M
Cathomen, T
Chamberlain, J
Chuah, M
Cornetta, K
Davies, KE
Dickson, JG
Duchateau, P
Flotte, TR
Gaudet, D
Gersbach, CA
Gilbert, R
Glorioso, J
Herzog, RW
High, KA
Huang, WL
Huard, J
Joung, JK
Liu, DP
Liu, DX
Lochmuller, H
Lustig, L
Martens, J
Massie, B
Mavilio, F
Mendell, JR
Nathwani, A
Ponder, K
Porteus, M
Puymirat, J
Samulski, J
Takeda, S
Thrasher, A
VandenDriessche, T
Wei, YQ
Wilson, JM
Wilton, SD
Wolfe, JH
Gao, GP
AF Tremblay, Jacques P.
Xiao, Xiao
Aartsma-Rus, Annemieke
Barbas, Carlos
Blaus, Helen M.
Bogdanove, Adam J.
Boycott, Kym
Brauns, Serge
Breakefield, Xandra O.
Bueren, Juan A.
Buschmann, Michael
Byrne, Barry J.
Calos, Michele
Cathomen, Toni
Chamberlain, Jeffrey
Chuah, Marinee
Cornetta, Kenneth
Davies, Kay E.
Dickson, J. George
Duchateau, Philippe
Flotte, Terence R.
Gaudet, Daniel
Gersbach, Charles A.
Gilbert, Renald
Glorioso, Joseph
Herzog, Roland W.
High, Katherine A.
Huang, Wenlin
Huard, Johnny
Joung, J. Keith
Liu, Depei
Liu, Dexi
Lochmueller, Hanns
Lustig, Lawrence
Martens, Jeffrey
Massie, Bernard
Mavilio, Fulvio
Mendell, Jerry R.
Nathwani, Amit
Ponder, Katherine
Porteus, Matthew
Puymirat, Jack
Samulski, Jude
Takeda, Shin'ichi
Thrasher, Adrian
VandenDriessche, Thierry
Wei, Yuquan
Wilson, James M.
Wilton, Steve D.
Wolfe, John H.
Gao, Guangping
TI Translating the Genomics Revolution: The Need for an International Gene
Therapy Consortium for Monogenic Diseases
SO MOLECULAR THERAPY
LA English
DT Letter
C1 [Tremblay, Jacques P.; Puymirat, Jack] Univ Laval, Ctr Rech CHU, Quebec City, PQ, Canada.
[Tremblay, Jacques P.; Puymirat, Jack] Univ Laval, Dept Mol Med, Quebec City, PQ, Canada.
[Xiao, Xiao] Univ N Carolina, Sch Pharm, Chapel Hill, NC USA.
[Aartsma-Rus, Annemieke] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands.
[Barbas, Carlos] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
[Barbas, Carlos] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
[Barbas, Carlos] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
[Blaus, Helen M.] Stanford Univ, Sch Med, Baxter Lab Stem Cell Biol, Stanford, CA 94305 USA.
[Bogdanove, Adam J.] Cornell Univ, Dept Plant Pathol & Plant Microbe Biol, Ithaca, NY USA.
[Boycott, Kym] Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada.
[Brauns, Serge] AFM Telethon, Paris, France.
[Breakefield, Xandra O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Breakefield, Xandra O.] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA.
[Bueren, Juan A.] Ctr Invest Energet Medioambientales & Tecnol, Hematopoiet Innovat Therapies Div, Madrid, Spain.
[Bueren, Juan A.] Ctr Invest Red Enfermedades Raras CIEMAT CIBERER, Madrid, Spain.
[Buschmann, Michael] Ecole Polytech, Dept Chem Engn, Montreal, PQ H3C 3A7, Canada.
[Buschmann, Michael] Ecole Polytech, Inst Biomed Engn, Montreal, PQ H3C 3A7, Canada.
[Byrne, Barry J.; Herzog, Roland W.] Univ Florida, Dept Pediat, Gainesville, FL USA.
[Calos, Michele] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.
[Cathomen, Toni] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Lab Cell & Gene Therapy, Freiburg, Germany.
[Chamberlain, Jeffrey] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
[Chamberlain, Jeffrey] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Chamberlain, Jeffrey] Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA.
[Chuah, Marinee; VandenDriessche, Thierry] Vrije Univ Brussel, Dept Gene Therapy & Regenerat Med, Louvain, Belgium.
[Chuah, Marinee; VandenDriessche, Thierry] Katholieke Univ Leuven, Dept Cardiovasc Sci, Ctr Mol & Vasc Biol, Louvain, Belgium.
[Cornetta, Kenneth] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN USA.
[Davies, Kay E.] Univ Oxford, MRC Funct Genom Unit, Oxford, England.
[Dickson, J. George] Royal Holloway Univ London, Sch Biol Sci, Egham, Surrey, England.
[Duchateau, Philippe] Cellectis, Paris, France.
[Flotte, Terence R.] Univ Massachusetts, Sch Med, Gene Therapy Ctr, Worcester, MA USA.
[Flotte, Terence R.] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA USA.
[Gaudet, Daniel] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
[Gersbach, Charles A.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
[Gersbach, Charles A.] Duke Univ, Inst Genome Sci & Policy, Durham, NC USA.
[Gilbert, Renald; Massie, Bernard] Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada.
[Glorioso, Joseph] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
[High, Katherine A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[High, Katherine A.] Childrens Hosp Philadelphia, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.
[Huang, Wenlin] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China.
[Huard, Johnny] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA.
[Joung, J. Keith] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA USA.
[Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Liu, Depei] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, Dept Biochem & Mol Biol, Beijing 100730, Peoples R China.
[Liu, Depei] Peking Union Med Coll, Beijing 100021, Peoples R China.
[Liu, Dexi] Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.
[Lochmueller, Hanns] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Lustig, Lawrence] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA.
[Martens, Jeffrey] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.
[Mavilio, Fulvio] Genethon, Evry, France.
[Mendell, Jerry R.] Nationwide Childrens Hosp, Paul D Wellstone Ctr, Columbus, OH USA.
[Mendell, Jerry R.] Ohio State Univ, Columbus, OH 43210 USA.
[Nathwani, Amit] UCL Canc Inst, Dept Haematol, London, England.
[Ponder, Katherine] Washington Univ, Dept Internal Med, St Louis, MO USA.
[Porteus, Matthew] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.
[Samulski, Jude] Duke Univ, Med Ctr, Dept Surg, Cardiothorac Div, Durham, NC 27710 USA.
[Takeda, Shin'ichi] Natl Ctr Neurol & Psychiat, Tokyo, Japan.
[Thrasher, Adrian] UCL Inst Child Hlth, London, England.
[Wei, Yuquan] Natl Key Lab Biotherapy, Natl Gene Therapy Program, Chengdu, Peoples R China.
[Wei, Yuquan] Sichuan Univ, Chengdu 610064, Peoples R China.
[Wilson, James M.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
[Wilton, Steve D.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Crawley, WA, Australia.
[Wolfe, John H.] Univ Penn, Philadelphia, PA 19104 USA.
[Wolfe, John H.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Gao, Guangping] Univ Massachusetts, Sch Med, Worcester, MA USA.
RP Tremblay, JP (reprint author), Univ Laval, Ctr Rech CHU, Quebec City, PQ, Canada.
EM Jacques-P.Tremblay@crchul.ulaval.ca
RI MAVILIO, Fulvio/J-6125-2013; Bueren, Juan/L-6112-2014; Wilson,
James/F-9220-2011;
OI Bueren, Juan/0000-0002-3228-7013; Wilson, James/0000-0002-9630-3131;
Lochmuller, Hanns/0000-0003-2324-8001; Buschmann,
Michael/0000-0002-2242-6198; Mavilio, Fulvio/0000-0003-0459-4320;
Cathomen, Toni/0000-0002-7757-4630
FU Howard Hughes Medical Institute; Medical Research Council [G0801763,
G0902219, MC_UU_12021/2, MR/K000608/1]; NCATS NIH HHS [UL1 TR000161];
NHLBI NIH HHS [P40 HL116242]; NIAMS NIH HHS [R01 AR040864, R01
AR056394]; NIDDK NIH HHS [P30 DK079312]; NIH HHS [P40 OD010939];
Wellcome Trust [090233]
NR 4
TC 9
Z9 9
U1 0
U2 23
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD FEB
PY 2013
VL 21
IS 2
BP 266
EP 268
DI 10.1038/mt.2013.4
PG 3
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 083AH
UT WOS:000314434600002
PM 23369965
ER
PT J
AU Goldberg, MS
Hook, SS
Wang, AZ
Bulte, JWM
Patri, AK
Uckun, FM
Cryns, VL
Hanes, J
Akin, D
Hall, JB
Gharkholo, N
Mumper, RJ
AF Goldberg, Michael S.
Hook, Sara S.
Wang, Andrew Z.
Bulte, Jeff W. M.
Patri, Anil K.
Uckun, Fatih M.
Cryns, Vincent L.
Hanes, Justin
Akin, Demir
Hall, Jennifer B.
Gharkholo, Nastaran
Mumper, Russell J.
TI Biotargeted nanomedicines for cancer: six tenets before you begin
SO NANOMEDICINE
LA English
DT Article
DE cost-effectiveness analysis; good manufacturing practice; ligand;
nanoparticle; receptor targeted
ID IN-VITRO; NANOPARTICLE INTERACTION; DELIVERY-SYSTEM; DRUG-RELEASE;
THERAPY; BIODISTRIBUTION; TUMORS; VIVO; CONJUGATION; BIOMARKERS
AB Biotargeted nanomedicines have captured the attention of academic and industrial scientists who have been motivated by the theoretical possibilities of the 'magic bullet' that was first conceptualized by Paul Ehrlich at the beginning of the 20th century. The Biotargeting Working Group, consisting of more than 50 pharmaceutical scientists, engineers, biologists and clinicians, has been formed as part of the National Cancer Institute's Alliance for Nanotechnology in Cancer to harness collective wisdom in order to tackle conceptual and practical challenges in developing biotargeted nanomedicines for cancer. In modern science and medicine, it is impossible for any individual to be an expert in every aspect of biology, chemistry, materials science, pharmaceutics, toxicology, chemical engineering, imaging, physiology, oncology and regulatory affairs. Drawing on the expertise of leaders from each of these disciplines, this commentary highlights six tenets of biotargeted cancer nanomedicines in order to enable the translation of basic science into clinical practice.
C1 [Goldberg, Michael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Hook, Sara S.] NCI, Ctr Strateg Sci Initiat, Off Director, NIH, Bethesda, MD 20892 USA.
[Wang, Andrew Z.] Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27514 USA.
[Bulte, Jeff W. M.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA.
[Patri, Anil K.; Hall, Jennifer B.] NCI, Nanotechnol Characterizat Lab, Frederick, MD 21702 USA.
[Uckun, Fatih M.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033 USA.
[Uckun, Fatih M.] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90033 USA.
[Cryns, Vincent L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA.
[Akin, Demir] Stanford Univ, Sch Med, Dept Radiol, Palo Alto, CA 94305 USA.
[Gharkholo, Nastaran; Mumper, Russell J.] Univ N Carolina, UNC Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Div Mol Pharmaceut, Chapel Hill, NC 27514 USA.
RP Mumper, RJ (reprint author), Univ N Carolina, UNC Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Div Mol Pharmaceut, Chapel Hill, NC 27514 USA.
EM mumper@email.unc.edu
RI Bulte, Jeff/A-3240-2008; Wang, Andrew /F-9719-2011; Nanotechnology
Characterization Lab, NCL/K-8454-2012;
OI Bulte, Jeff/0000-0003-1202-1610; Wang, Andrew/0000-0002-9781-4494
FU National Cancer Institute (NCI)-NIH [HHSN261200800001E]; NCI Alliance
for Nanotechnology in Cancer; Center of Cancer Nanotechnology Excellence
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute (NCI)-NIH under contract number
HHSN261200800001E. All authors are part of the NCI Alliance for
Nanotechnology in Cancer and hold either Center of Cancer Nanotechnology
Excellence or Cancer Nanotechnology Platform Partnership grants. The
authors have no other relevant affiliations or financial involvement
with any organization or entity with a financial interest in or
financial conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 63
TC 16
Z9 16
U1 1
U2 76
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD FEB
PY 2013
VL 8
IS 2
BP 299
EP 308
DI 10.2217/NNM.13.3
PG 10
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
Topics
GA 087VD
UT WOS:000314791200022
PM 23394158
ER
PT J
AU Torosean, S
Flynn, B
Axelsson, J
Gunn, J
Samkoe, KS
Hasan, T
Doyley, MM
Pogue, BW
AF Torosean, Sason
Flynn, Brendan
Axelsson, Johan
Gunn, Jason
Samkoe, Kimberley S.
Hasan, Tayyaba
Doyley, Marvin M.
Pogue, Brian W.
TI Nanoparticle uptake in tumors is mediated by the interplay of vascular
and collagen density with interstitial pressure
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Fluorescence; Pressure; Collagen; Cancer; Microenvironment
ID EXTRACELLULAR-MATRIX; SOLID TUMORS; FLUID PRESSURE; DRUG-DELIVERY;
BREAST-CANCER; TRANSPORT; HYPERTENSION; GROWTH; CONVECTION
AB Nanoparticle delivery into solid tumors is affected by vessel density, interstitial fluid pressure (IFP) and collagen, as shown in this article by contrasting the in vivo macroscopic quantitative uptake of 40 nm fluorescent beads in three tumor types. The fluorescence uptake was quantified on individual animals by normalization with the transmitted light and then normalized to normal tissue uptake in each mouse. Mean data for uptake in individual tumor lines then showed expected trends with the largest uptake in the most vascularized tumor line. Tumor lines with increased collagen were also consistent with highest interstitial fluid pressure and correlated with lowest uptake of nanoparticles. The data is consistent with a delivery model indicating that while vascular permeability is maximized by neovascular growth, it is inhibited by collagen content and the resulting interstitial pressure. Imaging of these parameters in vivo can lead to better individual noninvasive methods to assess drug penetration in situ.
C1 [Torosean, Sason; Pogue, Brian W.] Dartmouth Coll, Dept Phys & Astron, Hanover, NH 03755 USA.
[Flynn, Brendan; Axelsson, Johan; Gunn, Jason; Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
[Samkoe, Kimberley S.; Pogue, Brian W.] Geisel Sch Med Dartmouth, Dept Surg, Lebanon, NH USA.
[Hasan, Tayyaba; Pogue, Brian W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Doyley, Marvin M.] Univ Rochester, Dept Elect & Comp Engn, Rochester, NY USA.
RP Pogue, BW (reprint author), 14 Engn Dr, Hanover, NH 03755 USA.
EM brian.w.pogue@dartmouth.edu
RI Doyley, Marvin/N-3765-2013
FU NIH [PO1CA084203, RO1CA109558, RO1CA156177, R01CA10998]
FX This work has been financially supported by NIH research grants
PO1CA084203, RO1CA109558, RO1CA156177 and R01CA10998.
NR 42
TC 20
Z9 20
U1 2
U2 43
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD FEB
PY 2013
VL 9
IS 2
BP 151
EP 158
DI 10.1016/j.nano.2012.07.002
PG 8
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 088YL
UT WOS:000314873700001
PM 22841910
ER
PT J
AU Waldman, E
Wolfe, J
AF Waldman, Elisha
Wolfe, Joanne
TI Palliative care for children with cancer
SO NATURE REVIEWS CLINICAL ONCOLOGY
LA English
DT Review
ID OF-LIFE CARE; PEDIATRIC ONCOLOGY; YOUNG-ADULTS; INCURABLE CANCER;
DECISION-MAKING; ALTERNATIVE THERAPIES; HEALTH-PROFESSIONALS;
DEVELOPING-COUNTRIES; CLINICAL ONCOLOGY; AMERICAN SOCIETY
AB Over the past two decades, paediatric palliative care has emerged as both a primary approach and as its own medical subspecialty, the overall aim of which is to ease suffering for children with life-threatening illness and their families through a concurrent model of care. However, most discussions have been focused on the transition to palliative care when no realistic hope for cure exists. We believe that, because the course of cancer is so unpredictable, this idea is misleading. Indeed, palliative care is increasingly being recognized as being about not just how to cope with the process of dying, but also about how to engage in living when faced with a life-threatening illness. This article will examine our current understanding of several areas of palliative care, with the ultimate message that palliative care is simply a novel term for the total care of a child and family, an approach that should be applied consistently and concurrently regardless of disease status. By improving familiarity with palliative care and building relationships with palliative care specialists, the paediatric oncology clinician will ensure that the best care possible for children and families is provided, regardless of outcome. Waldman, E. & Wolfe, J. Nat. Rev. Clin. Oncol. 10,100-107 (2013); published online 22 January 2013; doi:10.1038/nrclinonc.2012.238
C1 [Waldman, Elisha; Wolfe, Joanne] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02215 USA.
RP Wolfe, J (reprint author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave, Boston, MA 02215 USA.
EM joanne_wolfe@dfci.harvard.edu
NR 97
TC 16
Z9 17
U1 3
U2 20
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4774
J9 NAT REV CLIN ONCOL
JI Nat. Rev. Clin. Oncol.
PD FEB
PY 2013
VL 10
IS 2
BP 100
EP 107
DI 10.1038/nrclinonc.2012.238
PG 8
WC Oncology
SC Oncology
GA 088TF
UT WOS:000314859300009
PM 23337915
ER
PT J
AU Wechsler, LR
Tsao, JW
Levine, SR
Swain-Eng, RJ
Adams, RJ
Demaerschalk, BM
Hess, DC
Moro, E
Schwamm, LH
Steffensen, S
Stern, BJ
Zuckerman, SJ
Bhattacharya, P
Davis, LE
Yurkiewicz, IR
Alphonso, AL
AF Wechsler, Lawrence R.
Tsao, Jack W.
Levine, Steven R.
Swain-Eng, Rebecca J.
Adams, Robert J.
Demaerschalk, Bart M.
Hess, David C.
Moro, Elena
Schwamm, Lee H.
Steffensen, Steve
Stern, Barney J.
Zuckerman, Steven J.
Bhattacharya, Pratik
Davis, Larry E.
Yurkiewicz, Ilana R.
Alphonso, Aimee L.
TI Teleneurology applications Report of the Telemedicine Work Group of the
American Academy of Neurology
SO NEUROLOGY
LA English
DT Article
ID DEEP BRAIN-STIMULATION; ACUTE STROKE; COST-ANALYSIS; CARE; TELESTROKE;
FEASIBILITY; EXPERIENCE; TELEPHONE
AB Objective: To review current literature on neurology telemedicine and to discuss its application to patient care, neurology practice, military medicine, and current federal policy.
Methods: Review of practice models and published literature on primary studies of the efficacy of neurology telemedicine.
Results: Teleneurology is of greatest benefit to populations with restricted access to general and subspecialty neurologic care in rural areas, those with limited mobility, and those deployed by the military. Through the use of real-time audio-visual interaction, imaging, and store-and-forward systems, a greater proportion of neurologists are able to meet the demand for specialty care in underserved communities, decrease the response time for acute stroke assessment, and expand the collaboration between primary care physicians, neurologists, and other disciplines. The American Stroke Association has developed a defined policy on teleneurology, and the American Academy of Neurology and federal health care policy are beginning to follow suit.
Conclusions: Teleneurology is an effective tool for the rapid evaluation of patients in remote locations requiring neurologic care. These underserved locations include geographically isolated rural areas as well as urban cores with insufficient available neurology specialists. With this technology, neurologists will be better able to meet the burgeoning demand for access to neurologic care in an era of declining availability. An increase in physician awareness and support at the federal and state level is necessary to facilitate expansion of telemedicine into further areas of neurology. Neurology (R) 2013;80:670-676
C1 [Wechsler, Lawrence R.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Tsao, Jack W.] USN, Bur Med & Surg, Falls Church, VA USA.
[Levine, Steven R.] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA.
[Levine, Steven R.] Suny Downstate Med Ctr, Downstate Stroke Ctr, Brooklyn, NY 11203 USA.
[Swain-Eng, Rebecca J.] Amer Acad Neurol, Minneapolis, MN USA.
[Adams, Robert J.] Med Univ S Carolina, Stroke Ctr, Charleston, SC USA.
[Demaerschalk, Bart M.] Mayo Clin, Dept Neurol, Phoenix, AZ USA.
[Hess, David C.] Georgia Hlth Sci Univ, Augusta, GA USA.
[Moro, Elena] Univ Toronto, Toronto Western Hosp, Div Neurol, Movement Disorders Ctr,UHN, Toronto, ON M5T 2S8, Canada.
[Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Steffensen, Steve] Johns Hopkins Univ, Dept Neurol, Baltimore, MD USA.
[Stern, Barney J.] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA.
[Zuckerman, Steven J.] Neurol Inst, Baton Rouge, LA USA.
[Bhattacharya, Pratik] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA.
[Davis, Larry E.] New Mexico VA Hlth Care Syst, Albuquerque, NM USA.
[Yurkiewicz, Ilana R.] Harvard Univ, Sch Med, Boston, MA USA.
[Alphonso, Aimee L.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA.
RP Wechsler, LR (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
OI Schwamm, Lee/0000-0003-0592-9145
FU Telemedicine; Advanced Technology Research Center, United States Army;
NIH; Arizona Department of Health Services; Athersys, Inc.; Lundbeck;
St. Jude Medical; Medtronic; Remedy Pharmaceuticals
FX L. Wechsler has served as a consultant for Abbott Vascular, Lunbeck, and
Ferrer; is on the Data and Safety Monitoring Board for DIAS 3/4/J and
the steering committee for CLOSURE, ACT I; and owns stock in
Neurointerventional Therapeutics. J. Tsao has received funding from the
Telemedicine and Advanced Technology Research Center, United States
Army, to develop a military neurology telemedicine system. S. Levine has
given expert review and testimony on medical legal cases and has
received research funding from the NIH. R. Swain-Eng is a full-time
employee of the American Academy of Neurology. R. J. Adams is cofounder
of REACHCall Inc., a for-profit telemedicine platform provider. He is
also a co-owner of the company with <5% of outstanding stock. He is
employed by Medical University of South Carolina, which offers
telestroke consultation for fair market value to hospitals in South
Carolina. He also is a speaker for Genentech, which makes tPA, but owns
no stock. B. Demaerschalk has received telemedicine research grant
funding from the Arizona Department of Health Services. Dr. Hess is a
cofounder of REACHCall Inc., a for-profit telemedicine platform
provider. He is also a co-owner of the company with <5% of outstanding
stock. He is employed by Georgia Health Sciences University, which
offers telestroke consultation for fair market value to hospitals in
Georgia. He also has research contracts with Athersys, Inc., and
Lundbeck. E. Moro has received honoraria from Medtronic for consulting
services and speaking. She has received research grant support from St.
Jude Medical and educational grants from Medtronic and St. Jude Medical.
L. Schwamm serves as a consultant to LifeImage, a teleradiology company,
and on the International Steering Committee for the DIAS3/4 trial. His
employer, The Massachusetts General Hospital, offers an array of
telehealth services at fair market value to many area hospitals,
including telestroke. He has also given expert review and testimony on
medical legal cases and has received research funding from the NIH on
thrombolysis and HRSA on telemedicine. S. Steffensen reports no
disclosures. B. Stern has received research support from Remedy
Pharmaceuticals per patient research costs and research grants from the
NIH. He has also received compensation for expert witness testimony. S.
Zuckerman and P. Bhattacharya report no disclosures. L. Davis is a part
of the VA Teleneurology group for which the VA pays part of the research
costs for the nursing staff. I. Yurkiewicz and A. Alphonso report no
disclosures. The opinions or assertions contained herein are the private
views of the authors and are not to be construed as official or as
reflecting the views of the Department of the Navy, the Department of
Defense, or the Department of Veterans Affairs. Go to Neurology.org for
full disclosures.
NR 39
TC 28
Z9 28
U1 0
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD FEB
PY 2013
VL 80
IS 7
BP 670
EP 676
DI 10.1212/WNL.0b013e3182823361
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 088ZY
UT WOS:000314878500015
PM 23400317
ER
PT J
AU Greenberg, SM
AF Greenberg, Steven M.
TI Stroke after Alzheimer disease I have more bad news
SO NEUROLOGY
LA English
DT Editorial Material
ID DEMENTIA; RISK; INFARCTS
C1 [Greenberg, Steven M.] Massachusetts Gen Hosp, Dept Neurol, Hemorrhag Stroke Res Program, Boston, MA 02114 USA.
[Greenberg, Steven M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Greenberg, SM (reprint author), Massachusetts Gen Hosp, Dept Neurol, Hemorrhag Stroke Res Program, Boston, MA 02114 USA.
EM sgreenberg@partners.org
NR 10
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD FEB
PY 2013
VL 80
IS 8
BP 695
EP 696
DI 10.1212/WNL.0b013e3182825196
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 092ZN
UT WOS:000315161600005
PM 23303845
ER
PT J
AU Kimberly, WT
Lima, FO
O'Connor, S
Furie, KL
AF Kimberly, W. Taylor
Lima, Fabricio O.
O'Connor, Sydney
Furie, Karen L.
TI Sex differences and hemoglobin levels in relation to stroke outcomes
SO NEUROLOGY
LA English
DT Article
ID ISCHEMIC-STROKE; CLINICAL PRESENTATION; CEREBRAL-ISCHEMIA;
BLOOD-VISCOSITY; REGISTRY; CARE; AGE; HYPERGLYCEMIA; EPIDEMIOLOGY;
VALIDATION
AB Objective: Women have worse outcomes after stroke compared to men. Since women have lower hemoglobin values, we examined whether hemoglobin levels may associate with worse stroke outcomes in women.
Methods: We retrospectively studied 274 patients enrolled in a prospective multicenter study. We explored the relationship of hemoglobin with clinical outcome at 6 months, as measured by the modified Rankin Scale (mRS). Ordinal logistic regression was used to evaluate the independent effect of hemoglobin on clinical outcome, and to explore the influence of sex on that association.
Results: Women had a lower mean hemoglobin level (11.7 +/- 1.8 g/dL) compared to men (13.3 +/- 1.7 g/dL). Low hemoglobin was associated with worse 6-month mRS outcomes in univariate analysis (p < 0.001). Lower hemoglobin remained independently associated with poor outcome after adjustment for comorbid disease, stroke severity, age, and sex. The inclusion of hemoglobin in the model attenuated the independent effect of sex on outcome.
Conclusions: Sex differences in stroke outcome are linked to lower hemoglobin level, which is more prevalent in women. Further examination of this potentially modifiable predictor is warranted. Neurology (R) 2013;80:719-724
C1 [Kimberly, W. Taylor; Lima, Fabricio O.; Furie, Karen L.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,Stroke Serv, Boston, MA 02115 USA.
[Kimberly, W. Taylor; O'Connor, Sydney] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,Div Neurocrit Care & Emerg, Boston, MA 02115 USA.
RP Kimberly, WT (reprint author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,Stroke Serv, Boston, MA 02115 USA.
EM wtkimberly@partners.org
FU American Academy of Neurology Foundation; Clinical Investigator Training
Program: Beth Israel Deaconess Medical Center-Harvard Medical School;
Pfizer Inc.; Merck Co.; NIH [1K23NS076597, 5P50NS051343-07, 1R01
NS064905-01A1, 1K23NS076597-01, 5P50 NS051343-07]; [R01HS011392-01A2]
FX Supported by American Academy of Neurology Foundation clinical training
research fellowship (W. T. K.), the Clinical Investigator Training
Program: Beth Israel Deaconess Medical Center-Harvard Medical School, in
collaboration with Pfizer Inc. and Merck & Co. (W. T. K.), and by NIH
1K23NS076597 (W. T. K.) and NIH 5P50NS051343-07 and 1R01 NS064905-01A1
(K. L. F.). The original STOPStroke study was sponsored by
R01HS011392-01A2.; W.T. Kimberly reports funding from American Academy
of Neurology Foundation clinical training research fellowship, the
Clinical Investigator Training Program: Beth Israel Deaconess Medical
Center-Harvard Medical School, in collaboration with Pfizer Inc. and
Merck & Co., and by NIH 1K23NS076597-01. F. Lima reports a fellowship
funded by 5P50 NS051343-07. S. O'Connor reports no disclosures. K. Furie
reports funding by 5P50 NS051343-07 and 1R01 NS064905-01A1. Go to
Neurology.org for full disclosures.
NR 32
TC 7
Z9 7
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD FEB
PY 2013
VL 80
IS 8
BP 719
EP 724
DI 10.1212/WNL.0b013e31828250ff
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 092ZN
UT WOS:000315161600010
PM 23365064
ER
PT J
AU Zhang, Z
Zhang, L
Yang, X
Li, Y
Duan, Z
AF Zhang, Z.
Zhang, L.
Yang, X.
Li, Y.
Duan, Z.
TI Construction and validation of a placental tissue microarray from
specimens of well-documented preeclampsia patients
SO PLACENTA
LA English
DT Article
DE Tissue microarray; Preeclampsia; Villous cytotrophoblast; Extravillous
cytotrophoblast
ID EXTRAVILLOUS TROPHOBLASTS; HODGKINS LYMPHOMA; G EXPRESSION;
INVASIVENESS; TECHNOLOGY; CANCER; STAT3; FETAL
AB Construction of tissue microarray (TMA) to validate the very large number of molecular targets of gene microarray data may provide a high throughput approach in preeclampsia study. However, the intricate structure of the placenta has limited this technique's application. In this study, 80 preeclampsia and 58 normal placental specimens were selected for constructing TMA from 400 donor block according to strict criteria. Each specimen with enough tissue area was punched 3 cores (0.6 mm in diameter each). Two pathologists marked the representative area exactly on H&E stained slide of each donor block. Then, the target tissues on the donor block were marked carefully along with the marked area on the slide. The TMA of preeclampsia were successfully constructed. H&E staining showed 98.97% (97/98) of villous cytotrophoblast (VCT) samples and 86.36% (76/88) of extravillous cytotrophoblast (EVCT) samples retained target tissue in TMA. In all cores, the area stained positive for cytokeratin was negative for vimentin, which is the characteristic of cytotrophoblast. For EVCT TMA, the expression of HLA-G in preeclampsia was significantly lower than that of normal pregnancy (p = 0.008), which was consistent with previously reports. This study showed that it is feasible to construct high quality of placental TMA for preeclampsia study. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Zhang, Z.; Zhang, L.; Yang, X.; Li, Y.] Zhengzhou Univ, Dept Clin Lab, Affiliated Hosp 3, Zhengzhou, Henan Province, Peoples R China.
[Zhang, Z.; Yang, X.; Li, Y.] Zhengzhou Univ, Dept Obstet & Gynaecol, Affiliated Hosp 3, Zhengzhou, Henan Province, Peoples R China.
[Duan, Z.] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.
[Duan, Z.] Harvard Univ, Sch Med, Boston, MA USA.
RP Zhang, Z (reprint author), Dept Clin Lab, 7 KangfuQian Rd, Zhengzhou 450052, Henan Province, Peoples R China.
EM zhangzhanmd@yahoo.com.cn
FU Natural Science Foundation of China [30872316]; Henan science research
plan [102300410005]; scientific and technical fund of the health bureau
[201002011]
FX This work was supported by grants from the Natural Science Foundation of
China (30872316), Henan science research plan (102300410005) and the
scientific and technical fund of the health bureau (201002011).
NR 29
TC 4
Z9 5
U1 0
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0143-4004
J9 PLACENTA
JI Placenta
PD FEB
PY 2013
VL 34
IS 2
BP 187
EP 192
DI 10.1016/j.placenta.2012.11.023
PG 6
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA 088SJ
UT WOS:000314857100016
PM 23267778
ER
PT J
AU Patenaude, A
AF Patenaude, Andrea
TI Psycho-oncology Consultation to Genetic Counselors: New Fields, New
Roles
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Patenaude, Andrea] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Patenaude, Andrea] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 4
EP 4
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700007
ER
PT J
AU Meyer, F
AF Meyer, Fremonta
TI Tamoxifen, Mood and Antidepressants: Cases Requiring Management
Decisions in the Face of Uncertain Evidence
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Meyer, Fremonta] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 19
EP 19
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700033
ER
PT J
AU Trevino, K
Fasciano, K
Prigerson, H
AF Trevino, Kelly
Fasciano, Karen
Prigerson, Holly
TI The Relationship Between the Patient-Oncologist Alliance and Treatment
Adherence among Young Adults With Cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Trevino, Kelly; Fasciano, Karen; Prigerson, Holly] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Trevino, Kelly; Fasciano, Karen; Prigerson, Holly] Harvard Univ, Sch Med, Boston, MA USA.
[Trevino, Kelly; Fasciano, Karen; Prigerson, Holly] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 23
EP 23
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700041
ER
PT J
AU Braun, I
Rao, S
Meyer, F
Fedele, G
AF Braun, Ilana
Rao, Sowmya
Meyer, Fremonta
Fedele, Giuseppe
TI Comparison of Psychiatric Medication Use Among Nationally Representative
Long-Term Cancer Survivors and Controls
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Braun, Ilana; Meyer, Fremonta; Fedele, Giuseppe] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Braun, Ilana; Meyer, Fremonta; Fedele, Giuseppe] Harvard Univ, Sch Med, Boston, MA USA.
[Rao, Sowmya] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Rao, Sowmya] Vet Adm Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 32
EP 33
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700057
ER
PT J
AU Walling, A
Dy, S
Mack, J
Malin, J
Kim, B
Pantoja, P
Tisnado, D
AF Walling, Anne
Dy, Sydney
Mack, Jennifer
Malin, Jennifer
Kim, Ben
Pantoja, Philip
Tisnado, Diana
TI Evaluating the Quality of Information and Care Planning in Advanced
Cancer Patients
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Walling, Anne; Malin, Jennifer; Tisnado, Diana] Univ Calif Los Angeles, Los Angeles, CA USA.
[Dy, Sydney] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Mack, Jennifer] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
[Malin, Jennifer; Pantoja, Philip; Tisnado, Diana] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kim, Ben] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 40
EP 40
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700069
ER
PT J
AU Trevino, K
Gosian, J
Herman, L
Moye, J
AF Trevino, Kelly
Gosian, Jeffrey
Herman, Levi
Moye, Jennifer
TI Spiritual Disruption and Psychological Distress in Cancer Survivors
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Trevino, Kelly] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Trevino, Kelly; Moye, Jennifer] Harvard Univ, Sch Med, Boston, MA USA.
[Gosian, Jeffrey; Moye, Jennifer] Boston Healthcare Syst, Brockton, MA USA.
[Herman, Levi] Michael E DeBakey VA Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 50
EP 50
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700085
ER
PT J
AU Traeger, L
Eusebio, J
Park, E
Repper-Delisi, J
Jacobo, M
Convery, MS
Pirl, W
AF Traeger, Lara
Eusebio, Justin
Park, Elyse
Repper-Delisi, Jennifer
Jacobo, Michelle
Convery, Mary Susan
Pirl, William
TI Psychological Skills Training for Managing Difficult Patient Encounters:
Results of a Pilot Randomized Controlled Trial for Oncology Nurses
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Traeger, Lara; Eusebio, Justin; Park, Elyse; Repper-Delisi, Jennifer; Jacobo, Michelle; Convery, Mary Susan; Pirl, William] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 80
EP 81
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700139
ER
PT J
AU Traeger, L
Jacobo, M
Pirl, W
AF Traeger, Lara
Jacobo, Michelle
Pirl, William
TI Psychosocial Care of Patients With Borderline Personality Features:
Balancing Change and Acceptance Oriented Approaches in Oncology Settings
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Traeger, Lara; Jacobo, Michelle; Pirl, William] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 81
EP 81
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700140
ER
PT J
AU Muriel, A
AF Muriel, Anna
TI The Value of Psychosocial Oncology: A Survey of Pediatric Oncology
Providers
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 93
EP 94
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700162
ER
PT J
AU Muriel, A
AF Muriel, Anna
TI Developing an Integrated Service Model of Pediatric Psychosocial
Oncology
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 94
EP 94
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700163
ER
PT J
AU Cooley, M
Abrahm, J
Braun, I
Rabin, MS
Fox, E
Yeh, YT
Halpenny, B
Johns, E
McCorkle, R
Berry, D
Finn, K
Lobach, D
AF Cooley, Mary
Abrahm, Janet
Braun, Ilana
Rabin, Michael S.
Fox, Erica
Yeh, Yating
Halpenny, Barbara
Johns, Ellis
McCorkle, Ruth
Berry, Donna
Finn, Kathleen
Lobach, David
TI Evaluation of a Web Service-Based Decision Support System Report Using
Algorithms for Symptom Management
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Cooley, Mary; Abrahm, Janet; Braun, Ilana; Rabin, Michael S.; Fox, Erica; Yeh, Yating; Halpenny, Barbara; Berry, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Johns, Ellis; Lobach, David] Duke Univ Med Ctr, Durham, NC USA.
[McCorkle, Ruth] Yale Univ, New Haven, CT USA.
[Finn, Kathleen] Boston Med Ctr, Boston, MA USA.
[Lobach, David] Religent Hlth, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2013
VL 22
SU 2
SI SI
BP 144
EP 144
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 089KZ
UT WOS:000314910700246
ER
PT J
AU Blue-Howells, JH
Clark, SC
van den Berk-Clark, C
McGuire, JF
AF Blue-Howells, Jessica H.
Clark, Sean C.
van den Berk-Clark, Carissa
McGuire, James F.
TI The US Department of Veterans Affairs Veterans Justice Programs and the
Sequential Intercept Model: Case Examples in National Dissemination of
Intervention for Justice-Involved Veterans
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE veterans justice programs; criminal justice intervention; Sequential
Intercept Model; community psychology; program implementation
ID SUBSTANCE USE DISORDERS; SERIOUS MENTAL-ILLNESS
AB Veterans are a significant subpopulation in criminal justice populations, comprising between 9% and 10% of arrestee, jail, prison, and community-supervision populations. In order to address the needs of justice-involved veterans, the U.S. Department of Veterans Affairs (VA) Veterans Justice Programs (VJP) offer services to veterans at multiple points in their involvement in the criminal justice system. Within the context of the VA's national mandate to develop VJP, this article presents best practice case examples using the Sequential Intercept Model as the intervention frame, and discusses each in context of a community psychology framework for innovation dissemination. The case examples demonstrate how central program guidance is adapted locally to meet the national mandate using strategies that fit the local environment, illustrating the innovations in action orientation, boundary spanning, and flexibility of organizations. This review provides examples of creative reinvention that expand on the mandate and work to meet local needs. To optimize services to veterans released from custody or supervised in the community, future study of the implementation of this national mandate should examine all VJP sites to identify the full range of best practices in local program implementation.
C1 [Blue-Howells, Jessica H.; Clark, Sean C.; van den Berk-Clark, Carissa; McGuire, James F.] US Dept Vet Affairs, Vet Hlth Adm, Homeless Programs Off, Washington, DC USA.
RP Blue-Howells, JH (reprint author), Hlth Care Reentry Vet Program, 11301 Wilshire Blvd,Mail Code W10H5, Los Angeles, CA 90073 USA.
EM Jessica.Blue-Howells@va.gov
OI van den Berk-Clark, Carissa/0000-0001-7712-3787
NR 21
TC 13
Z9 13
U1 2
U2 9
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD FEB
PY 2013
VL 10
IS 1
BP 48
EP 53
DI 10.1037/a0029652
PG 6
WC Psychology, Clinical
SC Psychology
GA 090TI
UT WOS:000315002500005
PM 22924802
ER
PT J
AU Weaver, CM
Joseph, D
Dongon, SN
Fairweather, A
Ruzek, JI
AF Weaver, Christopher M.
Joseph, David
Dongon, Shara N.
Fairweather, Amy
Ruzek, Josef I.
TI Enhancing Services Response to Crisis Incidents Involving Veterans: A
Role for Law Enforcement and Mental Health Collaboration
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE veterans; offending; police; PTSD; crisis
ID POSTTRAUMATIC-STRESS-DISORDER; POLICE OFFICERS; INTERVENTION; IRAQ;
COMBAT; RISK; WAR; AGGRESSION; DIVERSION; HOSTILITY
AB When crisis situations involving veterans occur, responding police officers find themselves playing an important role in the spectrum of health and mental health services for those veterans. Crisis response training can help officers respond in a manner that increases safety and optimizes outcomes for all people involved. Yet, current crisis response police training models are only accessible to select officers. Nor do they emphasize the unique challenges and strengths that impact veterans who experience acute symptoms of mental illness. In the current study, we report the results from the first generation of training, collaboratively designed to enhance officers' (a) knowledge of relevant topics, including posttraumatic stress disorder and traumatic brain injury, (b) attitudes about veterans, and (c) and skills helpful in identifying and deescalating veterans and referring them to treatment Officers completed in-class evaluations (N = 314), and a subsample (n = 53) completed 3-month follow-up evaluations. Pre- versus posttest comparisons indicated significant improvements in total score, and individually in knowledge, attitudes, and skills. Consistent with previous literature, the specific in-class gains were not retained on follow-up. However, responding officers widely endorsed use of de-escalation techniques during, and a positive impact of the training on, their interactions with veterans in the 3 months following the training. Implications for future training and policy are discussed.
C1 [Weaver, Christopher M.; Dongon, Shara N.] Palo Alto Univ, Clin Psychol PhD Program, Palo Alto, CA 94143 USA.
[Weaver, Christopher M.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr Postraumat Stress Disorder, Palo Alto, CA USA.
[Joseph, David] US Dept Vet Affairs, No Calif Hlth Care Syst, Oakland, CA USA.
[Fairweather, Amy] Swords Plowshares, Coalit Iraq & Afghanistan Vet, San Francisco, CA USA.
[Ruzek, Josef I.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA.
RP Weaver, CM (reprint author), Palo Alto Univ, Forens Psychol Program, 1791 Arastradero Rd, Palo Alto, CA 94143 USA.
EM cweaver@paloaltou.edu
NR 26
TC 0
Z9 0
U1 4
U2 20
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD FEB
PY 2013
VL 10
IS 1
BP 66
EP 72
DI 10.1037/a0029651
PG 7
WC Psychology, Clinical
SC Psychology
GA 090TI
UT WOS:000315002500007
PM 23088401
ER
PT J
AU Kulke, MH
AF Kulke, Matthew H.
TI Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors
SO SEMINARS IN ONCOLOGY
LA English
DT Review
ID ISLET-CELL-CARCINOMA; ENDOCRINE TUMORS; PHASE-II; LOW-GRADE;
ANTITUMOR-ACTIVITY; MTOR PATHWAY; TEMOZOLOMIDE; OCTREOTIDE; EFFICACY;
METHYLTRANSFERASE
C1 [Kulke, Matthew H.] Dana Farber Brigham & Womens Canc Ctr, Program Neuroendocrine & Carcinoid Tumors, Boston, MA USA.
RP Kulke, MH (reprint author), Dana Farber Canc Inst, Dana 1220, Boston, MA 02115 USA.
EM Matthew_Kulke@dfci.harvard.edu
FU NIH [R01 CA151532]; Dana Farber/Harvard Cancer Center SPORE in
Gastrointestinal Cancer [P50 CA127003]; Saul and Gitta Kurlat fund for
neuroendocrine tumor research; Robert and Ann Ramsey
FX M.H. Kulke is supported in part by NIH Grant No. R01 CA151532 and the
Dana Farber/Harvard Cancer Center SPORE in Gastrointestinal Cancer P50
CA127003.; The author gratefully acknowledges additional support from
the Saul and Gitta Kurlat fund for neuroendocrine tumor research and
from Robert and Ann Ramsey. Editorial support for the manuscript was
provided by Lindy Morde.
NR 67
TC 6
Z9 8
U1 0
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
EI 1532-8708
J9 SEMIN ONCOL
JI Semin. Oncol.
PD FEB
PY 2013
VL 40
IS 1
BP 75
EP 83
DI 10.1053/j.seminoncol.2012.11.010
PG 9
WC Oncology
SC Oncology
GA 089IT
UT WOS:000314904900008
PM 23391115
ER
PT J
AU Calhoun, AW
Boone, MC
Miller, KH
Pian-Smith, MCM
AF Calhoun, Aaron W.
Boone, Megan C.
Miller, Karen H.
Pian-Smith, May C. M.
TI Case and Commentary Using Simulation to Address Hierarchy Issues During
Medical Crises
SO SIMULATION IN HEALTHCARE-JOURNAL OF THE SOCIETY FOR SIMULATION IN
HEALTHCARE
LA English
DT Article
DE Hierarchy; Teamwork; Crisis resource management; Dysrhythmia;
Hyperkalemia; Medical error; Patient simulation; Medical education;
Multidisciplinary simulation; Error avoidance; Ethics; Misdirection;
Simulator death; Psychological safety in simulation
ID RESOURCE-MANAGEMENT; PERFORMANCE; RESIDENTS; EDUCATION; FEEDBACK;
STUDENTS; STRESS; DEATH; 1ST
AB Medicine is hierarchical, and both positive and negative effects of this can be exposed and magnified during a crisis. Ideally, hierarchies function in an orderly manner, but when an inappropriate directive is given, the results can be disastrous unless team members are empowered to challenge the order. This article describes a case that uses misdirection and the possibility of simulated "death" to facilitate learning among experienced clinicians about the potentially deadly effects of an unchallenged, inappropriate order. The design of this case, however, raises additional questions regarding both ethics and psychological safety. The ethical concerns that surround the use of misdirection in simulation and the psychological ramifications of incorporating patient death in this context are explored in the commentary. We conclude with a discussion of debriefing strategies that can be used to promote psychological safety during potentially emotionally charged simulations and possible directions for future research. (Sim Healthcare 8:13-19, 2013)
C1 [Calhoun, Aaron W.] Univ Louisville, Sch Med, Dept Pediat, Louisville, KY 40202 USA.
[Boone, Megan C.] Kosair Childrens Hosp Norton Healthcare, Just Kids Crit Care Ctr, Louisville, KY USA.
[Miller, Karen H.] Univ Louisville, Coll Educ & Human Dev, Louisville, KY 40202 USA.
[Miller, Karen H.] Univ Louisville, Sch Med, Louisville, KY 40202 USA.
[Pian-Smith, May C. M.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA.
[Pian-Smith, May C. M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Calhoun, AW (reprint author), Univ Louisville, Sch Med, Dept Pediat, Div Pediat Crit Care, 571 S Floyd St,STE 332, Louisville, KY 40202 USA.
EM aaron.calhoun@louisville.edu
NR 35
TC 11
Z9 11
U1 3
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1559-2332
J9 SIMUL HEALTHC
JI Simul. Healthc.
PD FEB
PY 2013
VL 8
IS 1
BP 13
EP 19
DI 10.1097/SIH.0b013e318280b202
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 088AZ
UT WOS:000314807500004
PM 23343842
ER
PT J
AU Keung, EZ
Nelson, PJ
Conrad, C
AF Keung, Emily Z.
Nelson, Peter J.
Conrad, Claudius
TI Concise Review: Genetically Engineered Stem Cell Therapy Targeting
Angiogenesis and Tumor Stroma in Gastrointestinal Malignancy
SO STEM CELLS
LA English
DT Review
DE Mesenchymal stem cell; Genetic engineering; Gene therapy;
Gastrointestinal malignancy; Angiogenesis; Stroma
ID CANCER GENE-THERAPY; TRAIL-INDUCED APOPTOSIS; BONE-MARROW;
PANCREATIC-CARCINOMA; BREAST-CANCER; IN-VITRO; INFARCTED MYOCARDIUM;
ANTITUMOR-ACTIVITY; ENDOTHELIAL-CELLS; ADIPOSE-TISSUE
AB Cell-based gene therapy holds considerable promise for the treatment of human malignancy. Genetically engineered cells if delivered to sites of disease could alleviate symptoms or even cure cancer through expression of therapeutic or suicide transgene products. Mesenchymal stem cells (MSCs), nonhematopoietic multipotent cells found primarily in bone marrow, have garnered particular interest as potential tumor-targeting vehicles due to their innate tumortropic homing properties. However, recent strategies go further than simply using MSCs as vehicles and use the stem cell-specific genetic make-up to restrict transgene expression to tumorigenic environments using tumor-tissue specific promoters. This addresses one of the concerns with this novel therapy that nonselective stem cell-based therapy could induce cancer rather than treat it. Even minimal off-target effects can be deleterious, motivating recent strategies to not only enhance MSC homing but also engineer them to make their antitumor effect selective to sites of malignancy. This review will summarize the advances made in the past decade toward developing novel cell-based cancer therapies using genetically engineered MSCs with a focus on strategies to achieve and enhance tumor specificity and their application to targeting gastrointestinal malignancies such as hepatocellular carcinoma and pancreatic adenocarcinoma. STEM CELLS 2013;31:227-235
C1 [Keung, Emily Z.; Conrad, Claudius] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Nelson, Peter J.] Univ Munich, Med Klin & Poliklin 4, AG Clin Biochem, Munich, Germany.
RP Conrad, C (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Harvard Stem Cell Inst, 55 Fruit St, Boston, MA 02114 USA.
EM cconrad1@partners.org
NR 82
TC 25
Z9 28
U1 1
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD FEB
PY 2013
VL 31
IS 2
BP 227
EP 235
DI 10.1002/stem.1269
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 088YE
UT WOS:000314873000003
PM 23132810
ER
PT J
AU Fang, Y
Cho, KS
Tchedre, K
Lee, SW
Guo, CY
Kinouchi, H
Fried, S
Sun, XH
Chen, DF
AF Fang, Yuan
Cho, Kin-Sang
Tchedre, Kissaou
Lee, Seung Woo
Guo, Chenying
Kinouchi, Hikaru
Fried, Shelley
Sun, Xinghuai
Chen, Dong Feng
TI Ephrin-A3 Suppresses Wnt Signaling to Control Retinal Stem Cell Potency
SO STEM CELLS
LA English
DT Article
DE Adult stem cells; Cell signaling; Neural differentiation; Retina; Stem
cell plasticity
ID CILIARY EPITHELIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; PROGENITOR CELLS;
GLUTAMATE TRANSPORT; ROD PHOTORECEPTORS; MARGINAL ZONE; PARS-PLANA;
NEUROGENESIS; MOUSE; BODY
AB The ciliary epithelium (CE) of adult mammals has been reported to provide a source of retinal stem cells (RSCs) that can give rise to all retinal cell types in vitro. A recent study, however, suggests that CE-derived cells possess properties of pigmented ciliary epithelial cells and display little neurogenic potential. Here we show that the neurogenic potential of CE-derived cells is negatively regulated by ephrin-A3, which is upregulated in the CE of postnatal mice and presents a strong prohibitory niche for adult RSCs. Addition of ephrin-A3 inhibits proliferation of CE-derived RSCs and increases pigment epithelial cell fate. In contrast, absence of ephrin-A3 promotes proliferation and increases expression of neural progenitor cell markers and photoreceptor progeny. The negative effects of ephrin-A3 on CE-derived RSCs are mediated through activation of an EphA4 receptor and suppression of Wnt3a/beta-catenin signaling. Together, our data suggest that CE-derived RSCs contain the intrinsic machinery to generate photoreceptors and other retinal neurons, while the CE of adult mice expresses negative regulators that prohibit the proliferation and neural differentiation of RSCs. Manipulating ephrin and Wnt/beta-catenin signaling may, thus, represent a viable approach in activating the endogenous neurogenic potential of CE-derived RSCs for treating photoreceptor damage and retinal degenerative disorders. STEM CELLS 2013;31:349-359
C1 [Fang, Yuan; Sun, Xinghuai] Fudan Univ, Eye & ENT Hosp, Shanghai Med Coll, Dept Ophthalmol & Visual Sci, Shanghai 200433, Peoples R China.
[Fang, Yuan; Cho, Kin-Sang; Tchedre, Kissaou; Guo, Chenying; Kinouchi, Hikaru; Chen, Dong Feng] Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA USA.
[Lee, Seung Woo; Fried, Shelley; Chen, Dong Feng] Boston VA Healthcare Syst, Boston, MA USA.
[Lee, Seung Woo; Fried, Shelley] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA.
RP Chen, DF (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM dongfeng.chen@schepens.harvard.edu
FU NIH/NEI [R01EY017641]; NIDA [R21DA024803]; Department of Veterans
Affairs [1I01RX000110]; Department of Defense [W81XWH-09-2-0091]; Lion's
Foundation; National Basic Research Program of China [2007CB512204];
National Natural Science Foundation [NSFC81100667]
FX The project was supported by grants from NIH/NEI (R01EY017641), NIDA
(R21DA024803), Department of Veterans Affairs (1I01RX000110), Department
of Defense (W81XWH-09-2-0091) to D.F.C., Lion's Foundation Grant to
K.-S.C., the National Basic Research Program of China (No. 2007CB512204)
to X.S., and National Natural Science Foundation (NSFC81100667) to Y.F.
NR 45
TC 14
Z9 15
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD FEB
PY 2013
VL 31
IS 2
BP 349
EP 359
DI 10.1002/stem.1283
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 088YE
UT WOS:000314873000014
PM 23165658
ER
PT J
AU Davies, TF
AF Davies, Terry F.
TI Is Thyroid Transplantation on the Distant Horizon?
SO THYROID
LA English
DT Editorial Material
ID PLURIPOTENT STEM-CELLS; DIFFERENTIATION; PRESERVATION; GENERATION;
ORGANOIDS; MOUSE; GLAND
C1 [Davies, Terry F.] Icahn Sch Med Mt Sinai, Dept Med, Thyroid Res Unit, New York, NY USA.
[Davies, Terry F.] James J Peters Vet Adm Med Ctr, Dept Med, New York, NY USA.
RP Davies, TF (reprint author), Mt Sinai Med Ctr, Box 1055,I Gustave L Levy Pl, New York, NY 10029 USA.
EM terry.davies@mssm.edu
FU NIDDK NIH HHS [DK080459, DK052464, DK069713]
NR 17
TC 1
Z9 1
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD FEB
PY 2013
VL 23
IS 2
BP 139
EP 141
DI 10.1089/thy.2013.2302.ed2
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 088WB
UT WOS:000314867300004
PM 23398160
ER
PT J
AU Ichinose, F
AF Ichinose, Fumito
TI Improving outcomes after cardiac arrest using NO inhalation
SO TRENDS IN CARDIOVASCULAR MEDICINE
LA English
DT Review
ID NITRIC-OXIDE SYNTHASE; ISCHEMIA-REPERFUSION INJURY;
AMERICAN-HEART-ASSOCIATION; EMERGENCY CARDIOVASCULAR CARE; DECREASES
INFARCTION SIZE; CARDIOPULMONARY-RESUSCITATION; MYOCARDIAL-ISCHEMIA;
INHALED NO; S-NITROSYLATION; MODEL
AB Despite advances in cardiopulmonary resuscitation (CPR) methods including therapeutic hypothermia (TH), long-term neurological outcomes and survival after sudden cardiac arrest (CA) remains to be dismal. While nitric oxide (NO) prevents organ injury induced by ischemia and reperfusion (I/R), systemic vasodilation induced by intravenous NO-donor compounds typically precludes its use in post-CA patients in whom blood pressure is often low and unstable. Although developed as a selective pulmonary vasodilator, inhaled NO has systemic benefits in a variety of pre-clinical and clinical studies without causing potentially harmful systemic vasodilation. Breathing NO after CPR may prevent post-CA brain injury and improve long-term outcomes after CA and CPR. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Ichinose, Fumito] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, Charlestown, MA 02129 USA.
[Ichinose, Fumito] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Ichinose, F (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, 149 13th St,4315, Charlestown, MA 02129 USA.
EM fichinose@partners.org
FU NIH [HL101930, HL110378]; IKARIA Inc.
FX This work was supported by funding from NIH R01 grants HL101930 and
HL110378 and a sponsored research agreement from IKARIA Inc.
NR 43
TC 5
Z9 5
U1 2
U2 6
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1050-1738
J9 TRENDS CARDIOVAS MED
JI Trends Cardiovasc. Med.
PD FEB
PY 2013
VL 23
IS 2
BP 52
EP 58
DI 10.1016/j.tcm.2012.08.011
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 090YP
UT WOS:000315016200005
PM 23291033
ER
PT J
AU Tsai, M
Mori, AM
Forsberg, CW
Waiss, N
Sporleder, JL
Smith, NL
Goldberg, J
AF Tsai, Melyssa
Mori, Alaina M.
Forsberg, Christopher W.
Waiss, Nicole
Sporleder, Jennifer L.
Smith, Nicholas L.
Goldberg, Jack
TI The Vietnam Era Twin Registry: A Quarter Century of Progress
SO TWIN RESEARCH AND HUMAN GENETICS
LA English
DT Article
DE twins; Veterans; Vietnam; aging; repository; epidemiology; genetics
AB Now celebrating its 26th year of existence, the Vietnam Era Twin Registry continues to be one of the largest national samples of adult twins in the United States. The Registry twin member population is composed of 7,369 US male-male twin pair Veterans (14,738 total individuals) who served on active duty in the military during the Vietnam conflict (1964-1975). The Registry also maintains a register, data repository, and a biospecimen repository. Details on the operations of the Registry are described, as well as an overview of specific studies. Registry maintenance activities are also described, including the updating of contact information and vital status. Future plans include expanding the biospecimen repository and obtaining input from twins about study methods and diseases and conditions they would like to see investigated.
C1 [Tsai, Melyssa; Mori, Alaina M.; Forsberg, Christopher W.; Waiss, Nicole; Sporleder, Jennifer L.; Smith, Nicholas L.; Goldberg, Jack] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, VET Registry, Seattle, WA USA.
[Smith, Nicholas L.; Goldberg, Jack] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Smith, Nicholas L.] Grp Hlth Res Inst, Grp Hlth Cooperat, Seattle, WA USA.
RP Mori, AM (reprint author), VA Puget Sound Hlth Care Syst, VET Registry, VA MS S-152-E,1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Alaina.Mori@va.gov
FU Cooperative Studies Program of the Office of Research & Development of
the United States Department of Veterans Affairs; National Institutes of
Health [DA14363, DA014363, MH60426, AA11667, AA016402, AG018386,
AG022381, AA010586, AG18384, MH054636, MH055704, AA010339, AA11822,
DA04604, DA009447, HL068630, HL078224, AG022982]; VA Merit Review
funding; VA Cooperative Studies [256, 569]; Seattle Epidemiologic
Research and Information Center; Medical College of Pennsylvania
FX The Cooperative Studies Program of the Office of Research & Development
of the United States Department of Veterans Affairs has provided
financial support for the development and maintenance of the Vietnam Era
Twin (VET) Registry. All statements, opinions, or views are solely of
the authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States Government.; The
authors acknowledge the work of the following people: (1) VET Registry
staff; (2) Current and past VET Registry Scientific Ethics and Oversight
Committee members: J. C. Breitner, MD, MPH; E. F. Coccaro, MD; T.
Colton, ScD, MS; P. Concannon, PhD; J. Harris, PhD; W. E. Nance, MD,
PhD; W. True, PhD, MPH; J. S. Dorman, PhD; R. S. Paffenbarger, Jr., MD,
PhD; M. M. Weissman, PhD; R. R. Williams, MD; G. Chase, PhD; and A.
Bearn, MD; and (3) the many research investigators who have helped
expand the VET Registry repositories. In particular, we want to
acknowledge DA14363, DA014363, MH60426, AA11667, AA016402, AG018386,
AG022381, AA010586, AG18384, MH054636, MH055704, AA010339, AA11822,
DA04604, DA009447, HL068630, HL078224, AG022982 from the National
Institutes of Health; VA Merit Review funding awarded to Drs J. Douglas
Bremner, Mark Gilbertson, and Theodore Jacob; VA Cooperative Studies
funding of protocols #256 and #569, and core funding for the Seattle
Epidemiologic Research and Information Center; and Medical College of
Pennsylvania funding awarded Dr Emil F. Coccaro.
NR 9
TC 5
Z9 5
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1832-4274
J9 TWIN RES HUM GENET
JI Twin Res. Hum. Genet.
PD FEB
PY 2013
VL 16
IS 1
BP 429
EP 436
DI 10.1017/thg.2012.122
PG 8
WC Genetics & Heredity; Obstetrics & Gynecology
SC Genetics & Heredity; Obstetrics & Gynecology
GA 087YD
UT WOS:000314799700064
PM 23177374
ER
PT J
AU Graff, JN
Drake, CG
Beer, TM
AF Graff, Julie N.
Drake, Charles G.
Beer, Tomasz M.
TI Complete Biochemical (Prostate-specific Antigen) Response to
Sipuleucel-T With Enzalutamide in Castration-resistant Prostate Cancer:
A Case Report With Implications for Future Research
SO UROLOGY
LA English
DT Article
ID COMBINATION THERAPY; CELL INFILTRATION; IMMUNOTHERAPY; MITOXANTRONE;
PREDNISONE; DOCETAXEL; VACCINE
AB OBJECTIVE To describe the case of a patient with castration-resistant, metastatic prostate cancer who achieved a complete and durable biochemical response after treatment with sipuleucel-T while continuing with enzalutamide and to explore the immunologic basis for such a response.
MATERIALS AND METHODS We obtained serial prostate-specific antigen (PSA) measurements and bone scans to assess the patient's response to enzalutamide followed by the addition of sipuleucel-T. Using preclinical and clinical data, we describe his response through known immunobiologic mechanisms.
RESULTS This patient's PSA level became undetectable during treatment with enzalutamide and began to increase again after 14 months. He opted for treatment with sipuleucel-T, while continuing with the enzalutamide. This resulted in another complete PSA response 6 months after exposure to sipuleucel-T.
CONCLUSION Sipuleucel-T typically does not produce significant PSA reductions, and, to the best of our knowledge, only 1 previous report of a durable complete PSA response in a patient with metastatic disease has been published. The timing of this response supports an immune mechanism. The biologic rationale for the combination, coupled with the clinical result observed in our patient, provides a basis for studies of the combination of sipuleucel-T and enzalutamide. UROLOGY 81: 381-383, 2013. Published by Elsevier Inc.
C1 [Graff, Julie N.] Portland VA Med Ctr, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Urol, Baltimore, MD USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Immunol, Baltimore, MD USA.
RP Graff, JN (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,MC P3CHEMO, Portland, OR 97239 USA.
EM graffj@ohsu.edu
FU Dendreon, the maker of sipuleucel-T
FX T. M. Beer is a consultant to and receives funding from Dendreon, the
maker of sipuleucel-T; C. G. Drake is a consultant to Dendreon.
NR 14
TC 11
Z9 11
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
J9 UROLOGY
JI Urology
PD FEB
PY 2013
VL 81
IS 2
BP 381
EP 383
DI 10.1016/j.urology.2012.10.044
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 086LT
UT WOS:000314686000056
PM 23374810
ER
PT J
AU Yalla, SV
AF Yalla, Subbarao V.
TI Thulium Laser Enucleation Versus Plasmakinetic Resection of the
Prostate: A Randomized Prospective Trial With 18-Month Follow-up
EDITORIAL COMMENT
SO UROLOGY
LA English
DT Editorial Material
ID DYSFUNCTION
C1 Harvard Univ, Sch Med, Dept Urol, VA Boston Healthcare Syst, Boston, MA 02114 USA.
RP Yalla, SV (reprint author), Harvard Univ, Sch Med, Dept Urol, VA Boston Healthcare Syst, Boston, MA 02114 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
J9 UROLOGY
JI Urology
PD FEB
PY 2013
VL 81
IS 2
BP 400
EP 401
DI 10.1016/j.urology.2012.08.093
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 086LT
UT WOS:000314686000062
PM 23374816
ER
PT J
AU O'Neil, ML
Beckwith, LE
Kincaid, CL
Rasmussen, DD
AF O'Neil, Meghan L.
Beckwith, Lauren E.
Kincaid, Carrie L.
Rasmussen, Dennis D.
TI The 1-Adrenergic Receptor Antagonist, Doxazosin, Reduces Alcohol
Drinking in Alcohol-Preferring (P) Rats
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Noradrenergic; Doxazosin; Alcohol; Alcohol-Preferring; P Rats
ID POSITIVE REINFORCING PROPERTIES; DOPAMINE-BETA-HYDROXYLASE;
ALPHA-1-ADRENOCEPTOR ANTAGONIST; NORADRENERGIC MEDIATION; STARTLE
RESPONSE; LABORATORY RATS; DEPENDENCE; PRAZOSIN; NEURONS; ETHANOL
AB Background Evidence supports a role for the noradrenergic system in alcohol drinking in animals and humans. Our previous studies demonstrated the efficacy of prazosin, an 1-adrenergic antagonist, in decreasing alcohol drinking in rat models of alcohol dependence. Prazosin has also been shown to decrease alcohol drinking in treatment-seeking alcohol-dependent men. Clinically, the use of prazosin is limited by the requirement for multiple daily administrations, whereas doxazosin, a structurally similar 1-adrenergic antagonist, requires only once-daily dosing. In this study, we tested the hypothesis that doxazosin, like prazosin, would decrease alcohol drinking in rats selectively bred for alcohol preference (P line). Methods Adult male P rats were given 2h/d scheduled access to a 2-bottle choice (15% v/v alcohol vs. water) session 5d/wk (MF), with food and water available ad libitum 24h/d. Rats were injected with doxazosin (0 to 10mg/kg, IP) 40minutes prior to initiation of the alcohol access session in 3 trials (of 3, 5, and 5 consecutive days) each separated by 5 to 8weeks. The third trial included 1day without alcohol access (for locomotor testing), and 1day of a single hour of alcohol access (for plasma alcohol determination). Results Doxazosin significantly reduced alcohol intake in all 3 trials. The 5mg/kg dose consistently reduced alcohol intake, increased water drinking, did not affect locomotor activity, and resulted in lower plasma alcohol concentrations, suggesting that the doxazosin-induced reduction in alcohol drinking was not dependent on a motor impairment or an alteration in alcohol clearance. Conclusions Doxazosin decreases voluntary alcohol consumption by male alcohol-preferring (P) rats, supporting a role for the noradrenergic system in alcohol drinking in P rats and suggesting that doxazosin could potentially be an effective once-daily pharmacotherapeutic agent for the treatment of alcohol use disorders.
C1 [O'Neil, Meghan L.; Beckwith, Lauren E.; Kincaid, Carrie L.; Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[O'Neil, Meghan L.; Beckwith, Lauren E.; Kincaid, Carrie L.; Rasmussen, Dennis D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Rasmussen, Dennis D.] VISN 20 Mental Illness Res, Educ & Clin Ctr, Seattle, WA USA.
RP Rasmussen, DD (reprint author), VA Puget Sound Hlth Care Syst, Med Ctr, MIRECC 116, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM drasmuss@u.washington.edu
FU NIH [P20 AA017839, R24 AA015512]
FX This material is based upon work supported in part by resources from the
VA Puget Sound Health Care System, Seattle, Washington, and by NIH Grant
P20 AA017839. P rats were provided by the Indiana Alcohol Research
Resource Center, supported by NIH Grant R24 AA015512.
NR 48
TC 11
Z9 11
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD FEB
PY 2013
VL 37
IS 2
BP 202
EP 212
DI 10.1111/j.1530-0277.2012.01884.x
PG 11
WC Substance Abuse
SC Substance Abuse
GA 083ON
UT WOS:000314474400005
PM 22758213
ER
PT J
AU Kamine, TH
Barron, RJ
Lesicka, A
Galbraith, JD
Millham, FH
Larson, J
AF Kamine, Tovy Haber
Barron, Rebecca J.
Lesicka, Agnieszka
Galbraith, John D.
Millham, Frederick H.
Larson, Janet
TI Effects of the new Accreditation Council for Graduate Medical Education
work hour rules on surgical interns: a prospective study in a community
teaching hospital
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Accreditation Council for Graduate Medical Education; Resident work
hours; Resident exhaustion
ID GENERAL-SURGERY; NIGHT-SHIFT; RESIDENTS; SLEEP; MOOD; PERFORMANCE;
ATTITUDES; ALERTNESS; ROTATION; IMPACT
AB BACKGROUND: On July 1, 2011, the Accreditation Council for Graduate Medical Education (ACGME) eliminated 30-hour call in an attempt to improve resident wakefulness. We surveyed interns on the Newton Wellesley Hospital (NWH) surgery service before and after the transition from Q4 overnight call to a night float schedule.
METHODS: For 15 weeks, interns completed weekly surveys including the Epworth Sleepiness Scale (ESS). The service changed to a night float schedule after 3 weeks (ie, first to 3-4 and then to 6 nights in a row).
RESULTS: The average ESS score rose from 9.8 +/- 5.2 to 14.9 +/- 3.1 and 14.4 +/- 4.5 (P = .042) on the 3/4 and 6/1 schedules, respectively. Interns were more likely to be abnormally tired on either night float schedule (relative risk 5 2.86; 95% confidence interval, 1.17-6.97, P = .029).
CONCLUSIONS: The new ACGME work hours increased the ESS scores among interns at NWH and caused interns to be more tired than interns on the Q4 schedule. This is likely caused by the multiple nights of poor sleep without a post-call day to make up sleep. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Kamine, Tovy Haber; Lesicka, Agnieszka; Millham, Frederick H.] Newton Wellesley Hosp, Dept Surg, Newton, MA 02462 USA.
[Larson, Janet] Newton Wellesley Hosp, Dept Med, Newton, MA 02462 USA.
[Kamine, Tovy Haber; Galbraith, John D.] BIDMC, Dept Surg, Boston, MA 02215 USA.
[Barron, Rebecca J.] Brown Univ, Dept Emergency Med, Providence, RI 02903 USA.
RP Kamine, TH (reprint author), Newton Wellesley Hosp, Dept Surg, 2014 Washington St, Newton, MA 02462 USA.
EM tkamine@bidmc.harvard.edu
NR 22
TC 10
Z9 10
U1 0
U2 5
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD FEB
PY 2013
VL 205
IS 2
BP 163
EP 168
DI 10.1016/j.amjsurg.2012.10.006
PG 6
WC Surgery
SC Surgery
GA 086US
UT WOS:000314713800009
PM 23331981
ER
PT J
AU LaRocque, RC
Deshpande, BR
Rao, SR
Brunette, GW
Sotir, MJ
Jentes, ES
Ryan, ET
AF LaRocque, Regina C.
Deshpande, Bhushan R.
Rao, Sowmya R.
Brunette, Gary W.
Sotir, Mark J.
Jentes, Emily S.
Ryan, Edward T.
CA Global TravEpiNet Consortium
TI Pre-Travel Health Care of Immigrants Returning Home to Visit Friends and
Relatives
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID GEOSENTINEL SURVEILLANCE NETWORK; US INTERNATIONAL TRAVELERS;
UNITED-STATES; ILLNESS; KNOWLEDGE; ATTITUDES; DISEASES; CLINICS;
AIRPORT; RISK
AB Immigrants returning home to visit friends and relatives (VFR travelers) are at higher risk of travel-associated illness than other international travelers. We evaluated 3,707 VFR and 17,507 non-VFR travelers seen for pre-travel consultation in Global TravEpiNet during 2009-2011; all were traveling to resource-poor destinations. VFR travelers more commonly visited urban destinations than non-VFR travelers (42% versus 30%, P < 0.0001); 54% of VFR travelers were female, and 18% of VFR travelers were under 6 years old. VFR travelers sought health advice closer to their departure than non-VFR travelers (median days before departure was 17 versus 26, P < 0.0001). In multivariable analysis, being a VFR traveler was an independent predictor of declining a recommended vaccine. Missed opportunities for vaccination could be addressed by improving the timing of pre-travel health care and increasing the acceptance of vaccines. Making pre-travel health care available in primary care settings may be one step to this goal.
C1 [LaRocque, Regina C.; Ryan, Edward T.] Massachusetts Gen Hosp, Travelers Advice & Immunizat Ctr, Boston, MA 02114 USA.
[LaRocque, Regina C.; Ryan, Edward T.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA.
[Deshpande, Bhushan R.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Deshpande, Bhushan R.] Tufts Univ, Dept Econ, Medford, MA USA.
[Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Rao, Sowmya R.] Bedford Vet Affairs Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Brunette, Gary W.; Jentes, Emily S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
[Sotir, Mark J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
RP LaRocque, RC (reprint author), Massachusetts Gen Hosp, Travelers Advice & Immunizat Ctr, 55 Fruit St, Boston, MA 02114 USA.
EM rclarocque@partners.org; bdeshpande@partners.org;
Sowmya.Rao@umassmed.edu; fvd3@cdc.gov; mps6@cdc.gov; ejentes@cdc.gov;
etryan@partners.org
FU US Centers for Disease Control and Prevention [U19CI000514, U01CK000175]
FX This work was supported by US Centers for Disease Control and Prevention
Grants U19CI000514 and U01CK000175.
NR 22
TC 17
Z9 17
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD FEB
PY 2013
VL 88
IS 2
BP 376
EP 380
DI 10.4269/ajtmh.2012.12-0460
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 082ZG
UT WOS:000314431900029
PM 23149585
ER
PT J
AU Rice, IM
Pohlig, RT
Gallagher, JD
Boninger, ML
AF Rice, Ian M.
Pohlig, Ryan T.
Gallagher, Jerri D.
Boninger, Michael. L.
TI Handrim Wheelchair Propulsion Training Effect on Overground Propulsion
Using Biomechanical Real-Time Visual Feedback
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article; Proceedings Paper
CT Washington University Program in Occupational Therapy
CY JUL 06, 2010
CL St Louis, MO
DE Biomechanics; Feedback; Kinetics; Rehabilitation; Wheelchairs
ID SPINAL-CORD-INJURY; CARPAL-TUNNEL SYNDROME; UPPER EXTREMITY; MECHANICAL
EFFICIENCY; PUSHRIM BIOMECHANICS; PARAPLEGIC PATIENTS; EXTERNAL-FOCUS;
AXLE POSITION; SHOULDER PAIN; 2 SPEEDS
AB Objective: To compare the effects of 2 manual wheelchair propulsion training programs on handrim kinetics, contact angle, and stroke frequency collected during overground propulsion.
Design: Randomized controlled trial comparing handrim kinetics between 3 groups: a control group that received no training, an instruction-only group that reviewed a multimedia presentation, and a feedback group that reviewed the multimedia presentation and real-time visual feedback.
Setting: Research laboratory. Participants: Full-time manual wheelchair users (N=27) with spinal cord injury living in the Pittsburgh area.
Interventions: Propulsion training was given 3 times over 3 weeks, and data were collected at baseline, immediately after training, and at 3 months.
Main Outcome Measures: Contact angle, stroke frequency, peak resultant force, and peak rate of rise of resultant force.
Results: Both feedback and instruction-only groups improved their propulsion biomechanics across all surfaces (carpet, tile, and ramp) at both target and self-selected speeds compared with the control group. While controlling for velocity, both intervention groups showed long-term reductions in the peak rate or rise of resultant force, stroke frequency, and increased contact angle.
Conclusions: Long-term wheelchair users in both intervention groups significantly improved many aspects of their propulsion technique immediately after training and 3 months from baseline. Furthermore, training with a low-cost instructional video and slide presentation was an effective training tool alone. Archives of Physical Medicine and Rehabilitation 2013;94:256-63 (C) 2013 by the American Congress of Rehabilitation Medicine
C1 [Rice, Ian M.] Univ Illinois, Dept Kinesiol & Community Hlth, Champaign, IL 61820 USA.
[Pohlig, Ryan T.; Gallagher, Jerri D.] Univ Pittsburgh, Dept Educ Psychol, Pittsburgh, PA USA.
[Boninger, Michael. L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA USA.
[Boninger, Michael. L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Boninger, Michael. L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Boninger, Michael. L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
RP Rice, IM (reprint author), Univ Illinois, Coll Appl Hlth Sci, Dept Kinesiol & Community Hlth, Huff Hall,1206 S 4th St, Champaign, IL 61820 USA.
EM ianrice@illinois.edu
OI Boninger, Michael/0000-0001-6966-919X
FU NICHD NIH HHS [1-R03-HD049735-01A1]
NR 45
TC 10
Z9 10
U1 3
U2 17
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD FEB
PY 2013
VL 94
IS 2
BP 256
EP 263
DI 10.1016/j.apmr.2012.09.014
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 084TZ
UT WOS:000314563300005
PM 23022092
ER
PT J
AU Holt, NE
Percac-Lima, S
Kurlinski, LA
Thomas, JC
Landry, PM
Campbell, B
Latham, N
Ni, PS
Jette, A
Leveille, SG
Bean, JF
AF Holt, Nicole E.
Percac-Lima, Sanja
Kurlinski, Laura A.
Thomas, Julia C.
Landry, Paige M.
Campbell, Braidie
Latham, Nancy
Ni, Pengsheng
Jette, Alan
Leveille, Suzanne G.
Bean, Jonathan F.
TI The Boston Rehabilitative Impairment Study of the Elderly: A Description
of Methods
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Aged; Mobility limitation; Primary health care; Rehabilitation
ID LOWER-EXTREMITY FUNCTION; LATE-LIFE FUNCTION; PHYSICAL PERFORMANCE
BATTERY; FUNCTIONING OLDER-ADULTS; DISABILITY INSTRUMENT; LEG POWER;
GERIATRIC REHABILITATION; SUBSEQUENT DISABILITY; RISK-ASSESSMENT; HEALTH
ABC
AB Objectives: To describe the methods of a longitudinal cohort study among older adults with preclinical disability. The study aims to address the lack of evidence guiding mobility rehabilitation for older adults by identifying those impairments and impairment combinations that are most responsible for mobility decline and disability progression over 2 years of follow-up.
Design: Longitudinal cohort study.
Setting: Metropolitan-based health care system.
Participants: Community-dwelling primary care patients aged >= 65 years (N=430), with self-reported modification of mobility tasks because of underlying health conditions.
Interventions: Not applicable.
Main Outcome Measures: Late Life Function and Disability Instrument (LLFDI) (primary outcome); Short Physical Performance Battery and 400-m walk test (secondary outcomes).
Results: Among 7403 primary care patients identified as being potentially eligible for participation, 430 were enrolled. Participants have a mean age of 76.5 years, are 68% women, and have on average 4.2 chronic conditions. Mean LLFDI scores are 55.5 for Function and 68.9 and 52.3 for the Disability Limitation and Frequency domains, respectively.
Conclusions: Completion of our study aims will inform development of primary care based rehabilitative strategies to prevent disability. Additionally, data generated in this investigation can also serve as a vital resource for ancillary studies addressing important questions in rehabilitative science relevant to geriatric care. Archives of Physical Medicine and Rehabilitation 2013;94:347-55 (C) 2013 by the American Congress of Rehabilitation Medicine
C1 [Holt, Nicole E.; Kurlinski, Laura A.; Landry, Paige M.; Campbell, Braidie; Bean, Jonathan F.] Spaulding Rehabil Hosp, Boston, MA USA.
[Percac-Lima, Sanja] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Thomas, Julia C.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
[Latham, Nancy; Ni, Pengsheng; Jette, Alan] Boston Univ, Boston, MA 02215 USA.
[Leveille, Suzanne G.] Univ Massachusetts, Boston, MA 02125 USA.
RP Bean, JF (reprint author), Spaulding Cambridge Outpatient Ctr, 1575 Cambridge St, Cambridge, MA 02138 USA.
EM jfbean@partners.org
RI Bean, Jonathan/F-5798-2017;
OI Bean, Jonathan/0000-0001-8385-8210; Jette, Alan/0000-0002-2117-9973; Ni,
Pengsheng/0000-0003-1774-2185; Holt, Nicole/0000-0002-2483-7767
FU National Institute on Aging [5 R01 AG032052-03]; National Center for
Research Resources [1 UL1 RR025758-01]
FX Supported by the National Institute on Aging (grant no. 5 R01
AG032052-03) and the National Center for Research Resources in a grant
to the Harvard Clinical and Translational Science Center (grant no. 1
UL1 RR025758-01).
NR 65
TC 14
Z9 14
U1 4
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD FEB
PY 2013
VL 94
IS 2
BP 347
EP 355
DI 10.1016/j.apmr.2012.08.217
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 084TZ
UT WOS:000314563300014
PM 22989700
ER
PT J
AU Mitchell, T
Chacko, B
Ballinger, SW
Bailey, SM
Zhang, JH
Darley-Usmar, V
AF Mitchell, Tanecia
Chacko, Balu
Ballinger, Scott W.
Bailey, Shannon M.
Zhang, Jianhua
Darley-Usmar, Victor
TI Convergent mechanisms for dysregulation of mitochondrial quality control
in metabolic disease: implications for mitochondrial therapeutics
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article
DE alcoholic liver disease; cellular bioenergetics; diabetes; metabolic
syndrome; mitochondria; mitoquinone (MitoQ); reserve respiratory
capacity; steatosis
ID ALCOHOLIC LIVER-DISEASE; ANTIOXIDANT MITOQ PROTECTS;
HEPATOCELLULAR-CARCINOMA; REACTIVE OXYGEN; NITRIC-OXIDE; RAT-LIVER;
DEPENDENT HEPATOTOXICITY; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS;
RISK-FACTORS
AB Mitochondrial dysfunction is associated with a broad range of pathologies including diabetes, ethanol toxicity, metabolic syndrome and cardiac failure. It is now becoming clear that maintaining mitochondrial quality through a balance between biogenesis, reserve capacity and mitophagy is critical in determining the response to metabolic or xenobiotic stress. In diseases associated with metabolic stress, such as Type II diabetes and non-alcoholic and alcoholic steatosis, the mitochondria are subjected to multiple 'hits' such as hypoxia and oxidative and nitrative stress, which can overwhelm the mitochondrial quality control pathways. In addition, the underlying mitochondrial genetics that evolved to accommodate high-energy demand, low-calorie supply environments may now be maladapted to modern lifestyles (low-energy demand, high-calorie environments). The pro-oxidant and pro-inflammatory environment of a sedentary western lifestyle has been associated with modified redox cell signalling pathways such as steatosis, hypoxic signalling, inflammation and fibrosis. These data suggest that loss of mitochondrial quality control is intimately associated with the aberrant activation of redox cell signalling pathways under pathological conditions. In the present short review, we discuss evidence from alcoholic liver disease supporting this concept, the insights obtained from experimental models and the application of bioenergetic-based therapeutics in the context of maintaining mitochondrial quality.
C1 [Mitchell, Tanecia; Chacko, Balu; Ballinger, Scott W.; Bailey, Shannon M.; Zhang, Jianhua; Darley-Usmar, Victor] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Mitchell, Tanecia; Chacko, Balu; Ballinger, Scott W.; Bailey, Shannon M.; Zhang, Jianhua; Darley-Usmar, Victor] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
[Zhang, Jianhua] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Darley-Usmar, V (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM darley@uab.edu
FU National Institutes of Health [T32 DK007545, HL 94518, HL 103859,
DK073775, AA015172, AA018841, NS064090, AA13395]; VA merit award
FX This work was supported by National Institutes of Health [grant numbers
T32 DK007545 (to T. M.), HL 94518 and HL 103859 (to S. B.), DK073775,
AA015172 and AA018841 (to S. B.), NS064090 (to J.Z.), and AA13395 (to
V.D.-U.)]. J.Z. was supported, in part, by a VA merit award.
NR 61
TC 22
Z9 23
U1 2
U2 10
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0300-5127
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD FEB
PY 2013
VL 41
BP 127
EP 133
DI 10.1042/BST20120231
PN 1
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 080EB
UT WOS:000314222900020
PM 23356271
ER
PT J
AU Bajwa, R
McArthur, J
Talano, JA
Fitzgerald, J
Duncan, C
Margossian, S
Yates, A
Hall, M
Cunnigham, S
Spear, D
Luther, K
Tamburro, R
AF Bajwa, Rajinder
McArthur, Jennifer
Talano, Julie-An
Fitzgerald, Julie
Duncan, Christine
Margossian, Steven
Yates, Andrew
Hall, Mark
Cunnigham, Susan
Spear, Debbie
Luther, Katherine
Tamburro, Robert
TI Assessment of Brain Natriuretic Peptide in Patients Undergoing
Hematopoietic Stem Cell Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Bajwa, Rajinder] Nationwide Childrens, Columbus, OH USA.
[McArthur, Jennifer; Luther, Katherine] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Talano, Julie-An] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA.
[Fitzgerald, Julie] Childrens Hosp Pittsburgh, Boston, MA USA.
[Duncan, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Margossian, Steven] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yates, Andrew; Hall, Mark] Nationwide Childrens Hosp, Intens Care Unit, Columbus, OH USA.
[Cunnigham, Susan] Nationwide Childrens Hosp, Columbus, OH USA.
[Spear, Debbie; Tamburro, Robert] Penn State Univ, Hershey Med Ctr, University Pk, PA 16802 USA.
RI Bajwa, Rajinder/E-2685-2011; Yates, Andrew/E-4344-2011
NR 0
TC 0
Z9 0
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 291
BP S257
EP S258
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900289
ER
PT J
AU Bhatt, AS
Freeman, S
Herrera, A
Pedamallu, CS
Gevers, D
Jung, J
Duke, F
Young, S
Earl, A
Kostic, A
Ojesina, A
Soriano, G
Walker, BJ
Soiffer, RJ
Antin, JH
Baden, L
Hornick, J
Marty, F
Meyerson, M
AF Bhatt, Ami S.
Freeman, Sam
Herrera, Alex
Pedamallu, Chandra Sekhar
Gevers, Dirk
Jung, Joonil
Duke, Fujiko
Young, Sarah
Earl, Ashlee
Kostic, Aleksandar
Ojesina, Akinyemi
Soriano, Gabriela
Walker, Bruce J.
Soiffer, Robert J.
Antin, Joseph H.
Baden, Lindsey
Hornick, Jason
Marty, Francisco
Meyerson, Matthew
TI Sequence-Based Discovery of Novel Bacteria, Bradyrhizobium Enterica, in
Cord Colitis Syndrome
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Bhatt, Ami S.; Herrera, Alex; Pedamallu, Chandra Sekhar; Kostic, Aleksandar; Ojesina, Akinyemi; Soiffer, Robert J.; Antin, Joseph H.; Marty, Francisco; Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Soriano, Gabriela] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Baden, Lindsey; Hornick, Jason] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 344
BP S281
EP S282
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900341
ER
PT J
AU Bolanos-Meade, J
Logan, BR
Alousi, AM
Antin, JH
Barowski, K
Carter, SL
Hexner, EO
Horowitz, MM
Levine, JE
MacMillan, ML
Martin, PJ
Nakamura, R
Pasquini, MC
Weisdorf, DJ
Westervelt, P
Ho, VT
AF Bolanos-Meade, Javier
Logan, Brent R.
Alousi, Amin M.
Antin, Joseph H.
Barowski, Kate
Carter, Shelly L.
Hexner, Elizabeth O.
Horowitz, Mary M.
Levine, John E.
MacMillan, Margaret L.
Martin, Paul J.
Nakamura, Ryotaro
Pasquini, Marcelo C.
Weisdorf, Daniel J.
Westervelt, Peter
Ho, Vincent T.
TI A Multi-Center, Randomized, Double Blind, Phase III Clinical Trial
Comparing Steroids/Placebo Vs. Steroids/Mycophenolate Mofetil As Initial
Therapy for Acute Graft-Versus-Host Disease. Blood and Marrow Transplant
Clinical Trials Network Study 0802
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Bolanos-Meade, Javier] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Logan, Brent R.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.
[Alousi, Amin M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Carter, Shelly L.] EMMES Corp, Rockville, MD USA.
[Hexner, Elizabeth O.] Univ Penn, Philadelphia, PA 19104 USA.
[Horowitz, Mary M.; Pasquini, Marcelo C.] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
[Levine, John E.] Univ Michigan, Ann Arbor, MI 48109 USA.
[MacMillan, Margaret L.] Univ Minnesota, Pediat Blood & Marrow Transplant Program, Minneapolis, MN USA.
[Martin, Paul J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Nakamura, Ryotaro] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA.
[Westervelt, Peter] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA.
[Ho, Vincent T.] Dana Farber Canc Inst, Dept Pediat Oncol & Stem Cell Transplant, Boston, MA 02115 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 50
BP S137
EP S137
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900051
ER
PT J
AU Bredeson, C
Le-Rademacher, J
Zhu, XC
Burkart, J
Kato, K
Armstrong, E
Sun, YP
Smith, A
Ho, VT
McCarthy, PL
Cooke, KR
Rizzo, JD
Pasquini, MC
AF Bredeson, Chris
Le-Rademacher, Jennifer
Zhu, Xiaochun
Burkart, Jeanne
Kato, Kazunobu
Armstrong, Elizabeth
Sun, Yiping
Smith, Angela
Ho, Vincent T.
McCarthy, Philip L.
Cooke, Kenneth R.
Rizzo, J. Douglas
Pasquini, Marcelo C.
TI Improved Survival with Intravenous Busulfan (IV BU) Compared to Total
Body Irradiation (TBI)-Based Myeloablative Conditioning Regimens: A
CIBMTR Prospective Study
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Bredeson, Chris] Univ Ottawa, Ottawa, ON, Canada.
[Le-Rademacher, Jennifer] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Zhu, Xiaochun; Burkart, Jeanne] CIBMTR, Milwaukee, WI USA.
[Kato, Kazunobu; Armstrong, Elizabeth; Sun, Yiping; Smith, Angela] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA.
[Ho, Vincent T.] Dana Farber Canc Inst, Dept Pediat Oncol & Stem Cell Transplant, Boston, MA 02115 USA.
[McCarthy, Philip L.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Cooke, Kenneth R.] Univ Hosp Case Western Reserve, Cleveland, OH USA.
[Rizzo, J. Douglas; Pasquini, Marcelo C.] CIBMTR Med Coll Wisconsin, Dept Med, Milwaukee, WI USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 4
BP S110
EP S111
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900005
ER
PT J
AU Brunner, AM
Chen, YB
Kim, H
Coughlin, E
Alyea, EP
Armand, P
Ballen, K
Cutler, C
Dey, BR
Glotzbecker, B
Koreth, J
McAfee, SL
Spitzer, TR
Soiffer, RJ
Antin, JH
Ho, VT
AF Brunner, Andrew M.
Chen, Yi-Bin
Kim, Haesook
Coughlin, Erin
Alyea, Edwin P., III
Armand, Philippe
Ballen, Karen
Cutler, Corey
Dey, Bimalangshu R.
Glotzbecker, Brett
Koreth, John
McAfee, Steven L.
Spitzer, Thomas R.
Soiffer, Robert J.
Antin, Joseph H.
Ho, Vincent T.
TI Outcomes of Patients Older Than Age 70 Undergoing Allogeneic
Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Brunner, Andrew M.; Chen, Yi-Bin; Coughlin, Erin; Ballen, Karen; Dey, Bimalangshu R.; McAfee, Steven L.; Spitzer, Thomas R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kim, Haesook; Alyea, Edwin P., III; Armand, Philippe; Cutler, Corey; Koreth, John; Soiffer, Robert J.; Antin, Joseph H.; Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Glotzbecker, Brett] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 10
BP S114
EP S114
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900011
ER
PT J
AU Chen, YB
Batchelor, T
Hochberg, E
Brezina, M
Coughlin, E
Jones, S
Del Rio, C
Duong, A
Ballen, K
Barnes, J
Chi, A
Driscoll, J
Hochberg, F
LaCasce, A
McAfee, SL
Nayak, L
Armand, P
AF Chen, Yi-Bin
Batchelor, Tracy
Hochberg, Ephraim
Brezina, Mark
Coughlin, Erin
Jones, SooAe
Del Rio, Candice
Duong, Amanda
Ballen, Karen
Barnes, Jeffrey
Chi, Andrew
Driscoll, Jessica
Hochberg, Fred
LaCasce, Ann
McAfee, Steven L.
Nayak, Lakshmi
Armand, Philippe
TI Phase II Trial of High-Dose Rituximab with
Thiotepa/Busulfan/Cyclophosphamide (TBC) Autologous Stem Cell
Transplantation for Patients with CNS Involvement by Non-Hodgkin
Lymphoma
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Chen, Yi-Bin; Coughlin, Erin; Del Rio, Candice; Duong, Amanda; Driscoll, Jessica; McAfee, Steven L.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
[LaCasce, Ann; Nayak, Lakshmi; Armand, Philippe] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 37
BP S129
EP S130
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900038
ER
PT J
AU Chen, YB
Coughlin, E
Cutler, C
Kennedy, K
Alyea, EP
Armand, P
Attar, EC
Ballen, K
Dey, BR
Koreth, J
McAfee, SL
Spitzer, TR
Antin, JH
Soiffer, RJ
Ho, VT
AF Chen, Yi-Bin
Coughlin, Erin
Cutler, Corey
Kennedy, Kevin
Alyea, Edwin P., III
Armand, Philippe
Attar, Eyal C.
Ballen, Karen
Dey, Bimalangshu R.
Koreth, John
McAfee, Steven L.
Spitzer, Thomas R.
Antin, Joseph H.
Soiffer, Robert J.
Ho, Vincent T.
TI Busulfan Does Intensity and Outcomes in Reduced Intensity Allogeneic
Stem Cell Transplantation for MDS/AML
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Chen, Yi-Bin; Coughlin, Erin; Attar, Eyal C.; Spitzer, Thomas R.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
[Cutler, Corey] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Alyea, Edwin P., III; Armand, Philippe; Koreth, John; Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ballen, Karen; Dey, Bimalangshu R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[McAfee, Steven L.] Massachusetts Gen Hosp, Dept Med, BMT Program, Boston, MA 02114 USA.
[Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ho, Vincent T.] Dana Farber Canc Inst, Dept Pediat Oncol & Stem Cell Transplant, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 11
BP S114
EP S115
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900012
ER
PT J
AU Cuccovia, BA
Lehmann, L
Margossian, S
Buia-Amport, S
Rosati, C
AF Cuccovia, Barbara Ann
Lehmann, Leslie
Margossian, Steven
Buia-Amport, Stephanie
Rosati, Christine
TI What Tools are in Your Toolbox to Promote Change?
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Cuccovia, Barbara Ann; Buia-Amport, Stephanie] Boston Childrens Hosp, Boston, MA USA.
[Lehmann, Leslie; Rosati, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Margossian, Steven] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 485
BP S351
EP S351
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900482
ER
PT J
AU Duran-Struuck, R
Climov, M
Gusha, A
Harrington, E
Matar, AJ
Crepeau, RL
Spitzer, TR
Sachs, DH
Huang, CA
AF Duran-Struuck, Raimon
Climov, Mihail
Gusha, Ashley
Harrington, Edward
Matar, Abraham J.
Crepeau, Rebecca L.
Spitzer, Thomas R.
Sachs, David H.
Huang, Christene A.
TI Immune Modulation of Antibody Responses Induced Through Allogeneic Cell
Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Duran-Struuck, Raimon; Climov, Mihail; Gusha, Ashley; Harrington, Edward; Matar, Abraham J.; Crepeau, Rebecca L.; Sachs, David H.; Huang, Christene A.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
[Duran-Struuck, Raimon; Climov, Mihail; Sachs, David H.; Huang, Christene A.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Matar, Abraham J.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA.
[Spitzer, Thomas R.] Massachusetts Gen Hosp, Bone Marrow Transplantat Unit, Boston, MA 02114 USA.
[Spitzer, Thomas R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 354
BP S286
EP S287
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900351
ER
PT J
AU Duran-Struuck, R
Murphy, GE
Bronson, RT
Sachs, DH
Huang, CA
Spitzer, TR
AF Duran-Struuck, Raimon
Murphy, George E.
Bronson, Roderick T.
Sachs, David H.
Huang, Christene A.
Spitzer, Thomas R.
TI The MGH Miniature Swine as a Large Animal Model of HCT and Graft Versus
Host Disease
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Duran-Struuck, Raimon; Sachs, David H.; Huang, Christene A.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
[Duran-Struuck, Raimon; Sachs, David H.; Huang, Christene A.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Murphy, George E.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Bronson, Roderick T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Spitzer, Thomas R.] Massachusetts Gen Hosp, Bone Marrow Transplantat Unit, Boston, MA 02114 USA.
[Spitzer, Thomas R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 355
BP S287
EP S287
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900352
ER
PT J
AU Fackler, LS
Tilearcio, MC
Yoon, C
Phillips, KS
AF Fackler, Lauren S.
Tilearcio, Marion C.
Yoon, Clara
Phillips, Kimberly S.
TI A Comprehensive Review of DFCI's Adult HSCT Data
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Fackler, Lauren S.; Tilearcio, Marion C.; Yoon, Clara; Phillips, Kimberly S.] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 326
BP S274
EP S274
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900324
ER
PT J
AU King, B
Geary, J
Crown, D
Sturtevant, O
Anderson, S
Stasko, K
Emmert, A
Luckey, CJ
AF King, Bethany
Geary, Joshua
Crown, Donna
Sturtevant, Olive
Anderson, Sharon
Stasko, Karl
Emmert, Amy
Luckey, C. John
TI Implementing Novel Predictive Parameters in Apheresis
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [King, Bethany; Sturtevant, Olive; Luckey, C. John] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Geary, Joshua; Anderson, Sharon; Stasko, Karl] Dana Farber Canc Inst, Cell Manipulat Core Facil, Boston, MA 02115 USA.
[Crown, Donna; Luckey, C. John] Brigham & Womens Hosp, Kraft Family Blood Donor Ctr, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 490
BP S353
EP S354
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900487
ER
PT J
AU Krajewski, J
Radhakrishnan, K
Chen, N
Ricci, A
Geyer, M
Harrison, L
Ozkaynak, MF
Satwani, P
Cheerva, A
Talano, JA
Moore, TB
Gillio, AP
Baxter-Lowe, LA
Cairo, MS
AF Krajewski, Jennifer
Radhakrishnan, Kavita
Chen, Nan
Ricci, Angela
Geyer, Mark
Harrison, Lauren
Ozkaynak, M. Fevzi
Satwani, Prakash
Cheerva, Alexandra
Talano, Julie-An
Moore, Theodore B.
Gillio, Alfred P.
Baxter-Lowe, Lee Ann
Cairo, Mitchell S.
TI Low Day 100 Transplant-Related Mortality (TRM) and Relapse Rate
Following Clofarabine in Combination With Cytarabine, Total Body
Irradiation and Allogeneic Stem Cell Transplantation in Children,
Adolescents and Young Adults with Poor-Risk Acute Leukemia
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Krajewski, Jennifer] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Radhakrishnan, Kavita; Chen, Nan; Ricci, Angela; Harrison, Lauren; Ozkaynak, M. Fevzi; Cairo, Mitchell S.] New York Med Coll, Valhalla, NY 10595 USA.
[Geyer, Mark] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Satwani, Prakash] Columbia Univ, New York, NY USA.
[Cheerva, Alexandra] Univ Louisville, Louisville, KY 40292 USA.
[Talano, Julie-An] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA.
[Moore, Theodore B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Gillio, Alfred P.] HUMC, Hackensack, NJ USA.
[Baxter-Lowe, Lee Ann] UCSF, Immunogent & Transplantat Lab, San Francsico, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 278
BP S251
EP S251
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900276
ER
PT J
AU Li, LQ
Nellore, A
McDonough, SM
Politikos, I
Kim, H
Nikiforow, S
Soiffer, RJ
Antin, JH
Ballen, K
Cutler, C
Ritz, J
Boussiotis, VA
AF Li, Lequn
Nellore, Anoma
McDonough, Sean M.
Politikos, Ioannis
Kim, Haesook
Nikiforow, Sarah
Soiffer, Robert J.
Antin, Joseph H.
Ballen, Karen
Cutler, Corey
Ritz, Jerome
Boussiotis, Vassiliki A.
TI Ex Vivo Treatment of Umbilical Cord Blood with Prostaglandin E2 Alters
the Molecular and Functional Properties of T Cells Via Modulating
Wnt/beta-Catenin Signaling
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Li, Lequn; Nellore, Anoma; Politikos, Ioannis; Boussiotis, Vassiliki A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Sch Med, Boston, MA 02215 USA.
[McDonough, Sean M.; Kim, Haesook; Nikiforow, Sarah; Antin, Joseph H.; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ballen, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cutler, Corey] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 70
BP S148
EP S148
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900071
ER
PT J
AU Lill, M
Costa, LJ
Yeh, RF
Lim, S
Stuart, R
Waller, EK
Shore, T
Craig, M
Freytes, CO
Shea, TC
Rodriguez, TE
Flinn, IW
Comeau, T
Yeager, AM
Pulsipher, MA
Bence-Bruckler, I
Laneuville, P
Bierman, PJ
Chen, AI
Yu, LH
Patil, S
Sun, YP
Armstrong, E
Smith, A
Elekes, A
Kato, K
Vaughan, W
AF Lill, Michael
Costa, Luciano J.
Yeh, Rosa F.
Lim, Stephen
Stuart, Robert
Waller, Edmund K.
Shore, Tsiporah
Craig, Michael
Freytes, Cesar O.
Shea, Thomas C.
Rodriguez, Tulio E.
Flinn, Ian W.
Comeau, Terrance
Yeager, Andrew M.
Pulsipher, Michael A.
Bence-Bruckler, Isabelle
Laneuville, Pierre
Bierman, Philip J.
Chen, Andy I.
Yu, Louie H.
Patil, Shiva
Sun, Yiping
Armstrong, Elizabeth
Smith, Angela
Elekes, Agnes
Kato, Kazunobu
Vaughan, William
TI Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous
Busulfan Exposure Optimization: Findings From a Multi-Center Phase II
Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma
in North America
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Lill, Michael; Lim, Stephen] Cedars Sinai Med Ctr, Blood & Marrow Transplant Program, Los Angeles, CA 90048 USA.
[Costa, Luciano J.; Stuart, Robert] Med Univ S Carolina, Charleston, SC 29425 USA.
[Yeh, Rosa F.; Yu, Louie H.] Seattle Canc Care Alliance, Seattle, WA USA.
[Waller, Edmund K.] Emory Univ, Bone Marrow & Stem Cell Transplant Program, Atlanta, GA 30322 USA.
[Shore, Tsiporah] Cornell Univ, Weill Med Coll, Bone Marrow & Stem Cell Transplantat Program, New York, NY 10021 USA.
[Shore, Tsiporah] New York Presbyterian Hosp, New York, NY USA.
[Craig, Michael] W Virginia Univ, Osborn Heme Malignancy & Transplant Serv, Morgantown, WV 26506 USA.
[Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, Hematopoiet Stem Cell Transplant Program, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Shea, Thomas C.] Univ N Carolina, Dept Med, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
[Rodriguez, Tulio E.] Loyola Univ, Chicago Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.
[Flinn, Ian W.] Sarah Cannon Sarah Cannon Res Inst, Nashville, TN USA.
[Comeau, Terrance] New Brunswick Stem Cell Transplant Program, St John, NB, Canada.
[Yeager, Andrew M.] Blood & Marrow Transplantat Program, Tucson, AZ USA.
[Pulsipher, Michael A.] Univ Utah, Sch Med, Huntsman Canc Inst, Div Hematol & Hematol Malignancies,Primary Childr, Salt Lake City, UT USA.
[Bence-Bruckler, Isabelle] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada.
[Laneuville, Pierre] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada.
[Bierman, Philip J.] Univ Nebraska Med Ctr, Dept Internal Med, BMT, Omaha, NE USA.
[Chen, Andy I.] Oregon Hlth & Sci, Hematol Malignancies, Portland, OR USA.
[Patil, Shiva; Sun, Yiping; Armstrong, Elizabeth; Smith, Angela; Elekes, Agnes; Kato, Kazunobu] Otsuka Pharmaceutical Dev & Commercializat Inc, Princeton, NJ USA.
[Vaughan, William] Univ Alabama Birmingham, Bone Marrow Transplantat Program, Birmingham, AL USA.
NR 0
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 41
BP S132
EP S132
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900042
ER
PT J
AU Murase, K
Kawano, Y
Ryan, J
Matsuoka, KI
Bascug, G
McDonough, SM
Smith, R
Lazo-Kallanian, S
Daley, J
Koreth, J
Soiffer, RJ
Letai, A
Ritz, J
AF Murase, Kazuyuki
Kawano, Yutaka
Ryan, Jeremy
Matsuoka, Ken-ichi
Bascug, Gregory
McDonough, Sean M.
Smith, Robert
Lazo-Kallanian, Suzan
Daley, John
Koreth, John
Soiffer, Robert J.
Letai, Anthony
Ritz, Jerome
TI Regulation of Apoptotic Pathways in Human Regulatory T Cells in Chronic
Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem
Cell Transplantation (HSCT)
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Murase, Kazuyuki; Kawano, Yutaka; Ryan, Jeremy; Matsuoka, Ken-ichi; Bascug, Gregory; McDonough, Sean M.; Smith, Robert; Lazo-Kallanian, Suzan; Daley, John; Koreth, John; Soiffer, Robert J.; Letai, Anthony; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 56
BP S140
EP S141
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900057
ER
PT J
AU Nikiforow, S
McDonough, SM
Emerson, RO
Hamm, D
Kim, H
Ballen, K
Boussiotis, VA
Soiffer, RJ
Antin, JH
Ritz, J
Cutler, C
AF Nikiforow, Sarah
McDonough, Sean M.
Emerson, Ryan O.
Hamm, David
Kim, Haesook
Ballen, Karen
Boussiotis, Vassiliki A.
Soiffer, Robert J.
Antin, Joseph H.
Ritz, Jerome
Cutler, Corey
TI Evolution of T Cell Repertoire Diversity After Reduced-Intensity
Conditioning and Double Umbilical Cord Blood Transplantation with or
without Exposure to FT1050 (16,16-dimethyl Prostaglandin E2)
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Nikiforow, Sarah; McDonough, Sean M.; Kim, Haesook; Soiffer, Robert J.; Antin, Joseph H.; Ritz, Jerome; Cutler, Corey] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ballen, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Boussiotis, Vassiliki A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 187
BP S206
EP S207
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900185
ER
PT J
AU Nikiforow, S
Kim, H
Kao, G
Sainvil, MM
McDonough, SM
Armand, P
Ho, VT
Alyea, EP
Cutler, C
Ritz, J
Antin, JH
Soiffer, RJ
Koreth, J
AF Nikiforow, Sarah
Kim, Haesook
Kao, Grace
Sainvil, Marie-Michele
McDonough, Sean M.
Armand, Philippe
Ho, Vincent T.
Alyea, Edwin P., III
Cutler, Corey
Ritz, Jerome
Antin, Joseph H.
Soiffer, Robert J.
Koreth, John
TI CD25+ Regulatory T CELL-Depleted Donor Lymphocyte Infusion for Relapse
After Allogeneic Transplantation - A PHASE 1 Study
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Nikiforow, Sarah; Kao, Grace; Armand, Philippe; Ho, Vincent T.; Alyea, Edwin P., III; Cutler, Corey; Ritz, Jerome; Antin, Joseph H.; Soiffer, Robert J.; Koreth, John] Harvard Univ, Sch Med, Boston, MA USA.
[Nikiforow, Sarah; Kim, Haesook; Kao, Grace; Sainvil, Marie-Michele; McDonough, Sean M.; Armand, Philippe; Ho, Vincent T.; Alyea, Edwin P., III; Cutler, Corey; Ritz, Jerome; Antin, Joseph H.; Soiffer, Robert J.; Koreth, John] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 48
BP S135
EP S136
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900049
ER
PT J
AU Palmer, J
Chai, XY
Martin, PJ
Kurland, BF
Pavletic, SZ
Inamoto, Y
Arora, M
Cutler, C
Weisdorf, DJ
Flowers, MED
Jagasia, MH
Arai, S
Pidala, J
Lee, SJ
AF Palmer, Jeanne
Chai, Xiaoyu
Martin, Paul J.
Kurland, Brenda F.
Pavletic, Steven Z.
Inamoto, Yoshihiro
Arora, Mukta
Cutler, Corey
Weisdorf, Daniel J.
Flowers, Mary E. D.
Jagasia, Madan H.
Arai, Sally
Pidala, Joseph
Lee, Stephanie J.
TI Pulmonary Symptoms Measured by the NIH Lung Score Predict Overall
Survival and Non-Relapse Mortality in Chronic GVHD
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Palmer, Jeanne] Med Coll Wisconsin, Dept Hematol & Oncol, Milwaukee, WI 53226 USA.
[Chai, Xiaoyu; Inamoto, Yoshihiro] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Martin, Paul J.; Kurland, Brenda F.; Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Arora, Mukta] Univ Minnesota, Minneapolis, MN USA.
[Cutler, Corey] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
[Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Arai, Sally] Stanford Univ, Stanford, CA 94305 USA.
[Pidala, Joseph] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 456
BP S336
EP S337
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900453
ER
PT J
AU Pidala, J
Chai, XY
Martin, PJ
Inamoto, Y
Flowers, MED
Cutler, C
Palmer, J
Weisdorf, DJ
Pavletic, SZ
Arora, M
Arai, S
Lee, SJ
AF Pidala, Joseph
Chai, Xiaoyu
Martin, Paul J.
Inamoto, Yoshihiro
Flowers, Mary E. D.
Cutler, Corey
Palmer, Jeanne
Weisdorf, Daniel J.
Pavletic, Steven Z.
Arora, Mukta
Arai, Sally
Lee, Stephanie J.
TI Utility of Grip Strength and 2 Minute Walk Test in Chronic GVHD
Assessment: An Analysis From the Chronic GVHD Consortium
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Pidala, Joseph] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Chai, Xiaoyu; Inamoto, Yoshihiro] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Martin, Paul J.; Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Cutler, Corey] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Palmer, Jeanne] Med Coll Wisconsin, Dept Hematol & Oncol, Milwaukee, WI 53226 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
[Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Arora, Mukta] Univ Minnesota, Minneapolis, MN USA.
[Arai, Sally] Stanford Univ, Stanford, CA 94305 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 458
BP S338
EP S338
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900455
ER
PT J
AU Politikos, I
Kim, H
Brown, J
McDonough, SM
Li, LQ
Cutler, C
Soiffer, RJ
Antin, JH
Ballen, K
Ritz, J
Boussiotis, VA
AF Politikos, Ioannis
Kim, Haesook
Brown, Julia
McDonough, Sean M.
Li, Lequn
Cutler, Corey
Soiffer, Robert J.
Antin, Joseph H.
Ballen, Karen
Ritz, Jerome
Boussiotis, Vassiliki A.
TI Markers of Angiogenesis and Neovascularization Correlate with Functional
Recovery of Thymic Epithelial Cells and T Cell Immune Reconstitution
After Cord Blood Transplantation in Adults
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Politikos, Ioannis; Brown, Julia; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA.
[Kim, Haesook; McDonough, Sean M.; Antin, Joseph H.; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cutler, Corey] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ballen, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
OI Politikos, Ioannis/0000-0002-8925-2399
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 72
BP S149
EP S149
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900073
ER
PT J
AU Radhakrishnan, K
Geyer, M
Morris, E
Baxter-Lowe, LA
Cairo, MS
AF Radhakrishnan, Kavita
Geyer, Mark
Morris, Erin
Baxter-Lowe, Lee Ann
Cairo, Mitchell S.
TI Reduced Toxicity Conditioning with Busulfan, Fludarabine, Alemtuzumab
and Allogeneic Stem Cell Transplantation From HLA-Matched Sibling Donors
in Children with High Risk Sickle Cell Disease Results in Long Term
Donor Chimerism and Low Incidence of aGVHD
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Radhakrishnan, Kavita] Yale Univ, Sch Med, New Haven, CT USA.
[Geyer, Mark] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Morris, Erin; Cairo, Mitchell S.] New York Med Coll, Valhalla, NY 10595 USA.
[Baxter-Lowe, Lee Ann] UCSF, Immunogent & Transplantat Lab, San Francsico, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 100
BP S164
EP S165
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900101
ER
PT J
AU Raley, DY
Glotzbecker, B
Deangelo, D
Stone, R
Soiffer, RJ
Alyea, EP
AF Raley, Deborah Yolin
Glotzbecker, Brett
Deangelo, Daniel
Stone, Richard
Soiffer, Robert J.
Alyea, Edwin P., III
TI A Retrospective Review Comparing Outcomes of Patients Receiving
Reinduction Therapy on House Staff and PA Services
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Raley, Deborah Yolin; Deangelo, Daniel; Stone, Richard; Alyea, Edwin P., III] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Glotzbecker, Brett] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 240
BP S232
EP S232
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900238
ER
PT J
AU Ratanatharathorn, V
Stadtmauer, EA
Yeh, RF
Freytes, CO
Toro, JJ
Akpek, G
Sahovic, E
Tricot, GJ
Shaughnessy, PJ
White, DJ
Rodriguez, TE
Solomon, SR
Yu, LH
Patil, S
Sun, YP
Armstrong, E
Smith, A
Elekes, A
Kato, K
Reece, DE
AF Ratanatharathorn, Voravit
Stadtmauer, Edward A.
Yeh, Rosa F.
Freytes, Cesar O.
Toro, Juan J.
Akpek, Gorgun
Sahovic, Entezam
Tricot, Guido J.
Shaughnessy, Paul J.
White, Darrell J.
Rodriguez, Tulio E.
Solomon, Scott R.
Yu, Louie H.
Patil, Shiva
Sun, Yiping
Armstrong, Elizabeth
Smith, Angela
Elekes, Agnes
Kato, Kazunobu
Reece, Donna E.
TI Safety and Efficacy From Intravenous Busulfan with PLC-Directed Dosed
Adjustment and Bortezomib Conditioning Regimen in Relapsed Multiple
Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell
Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Ratanatharathorn, Voravit] Karmanos Canc Inst, Detroit, MI USA.
[Stadtmauer, Edward A.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Yeh, Rosa F.; Yu, Louie H.] Seattle Canc Care Alliance, Seattle, WA USA.
[Freytes, Cesar O.; Toro, Juan J.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Akpek, Gorgun] Univ Maryland, Med Ctr, Med Greenebaum Canc Ctr BMT, Baltimore, MD 21201 USA.
[Sahovic, Entezam] Western Pennsylvania Canc Inst, Pittsburgh, PA USA.
[Tricot, Guido J.] Univ Utah, Sch Med, Div Hematol, BMT & Myeloma Program, Salt Lake City, UT USA.
[Shaughnessy, Paul J.] Texas Transplant Inst, San Antonio, TX USA.
[White, Darrell J.] Queen Elizabeth 2 Hlth Sci Ctr, Dept Med, Div Hematol, Halifax, NS, Canada.
[White, Darrell J.] Dalhousie Univ, Halifax, NS B3H 3J5, Canada.
[Rodriguez, Tulio E.] Loyola Univ Chicago, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.
[Solomon, Scott R.] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA.
[Patil, Shiva; Sun, Yiping; Armstrong, Elizabeth; Smith, Angela; Elekes, Agnes; Kato, Kazunobu] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA.
[Reece, Donna E.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 146
BP S186
EP S187
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900146
ER
PT J
AU Rosenblatt, J
Avivi, I
Vasir, D
Uhl, L
Katz, T
Somaiya, P
Mills, H
Joyce, R
Levine, JD
Boussiotis, VA
Luptakova, K
Arnason, J
Drummy, N
Delaney, C
Breault, E
Held, V
Bisharat, L
Giallombardo, N
Mortellite, J
Wagoner, J
Schickler, M
Rotem-Yehudar, R
Richardson, PG
Laubach, J
Anderson, K
Munshi, N
Rowe, J
Kufe, D
Avigan, D
AF Rosenblatt, Jacalyn
Avivi, Irit
Vasir, David
Uhl, Lynne
Katz, Tami
Somaiya, Poorvi
Mills, Heidi
Joyce, Robin
Levine, James D.
Boussiotis, Vassiliki A.
Luptakova, Katarina
Arnason, Jon
Drummy, Natalie
Delaney, Carol
Breault, Emma
Held, Viki
Bisharat, Lina
Giallombardo, Nancy
Mortellite, Jamie
Wagoner, Judith
Schickler, Michael
Rotem-Yehudar, Rinat
Richardson, Paul G.
Laubach, Jacob
Anderson, Kenneth
Munshi, Nikhil
Rowe, Jacob
Kufe, Donald
Avigan, David
TI Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell
Vaccination Following Autologous Stem Cell Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Rosenblatt, Jacalyn; Uhl, Lynne; Somaiya, Poorvi; Mills, Heidi; Joyce, Robin; Levine, James D.; Boussiotis, Vassiliki A.; Luptakova, Katarina; Drummy, Natalie; Delaney, Carol; Breault, Emma; Giallombardo, Nancy; Mortellite, Jamie; Wagoner, Judith; Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Avivi, Irit; Katz, Tami; Held, Viki; Bisharat, Lina; Rowe, Jacob] Rambam Med Ctr, Haifa, Israel.
[Vasir, David; Richardson, Paul G.; Laubach, Jacob; Anderson, Kenneth; Munshi, Nikhil; Kufe, Donald] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 1
BP S109
EP S109
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900002
ER
PT J
AU Stadtmauer, EA
Sullivan, K
Marty, F
Dadwa, SS
Papanicoleau, GA
Shea, TC
Mossad, SB
Andreadis, C
Young, JA
Buadi, F
Schuster, MG
Idrissi, M
Heineman, T
Berkowitz, EM
AF Stadtmauer, Edward A.
Sullivan, Keith
Marty, Francisco
Dadwa, Sanjeet S.
Papanicoleau, Genovefa A.
Shea, Thomas C.
Mossad, Sherif B.
Andreadis, Charalambos
Young, Jo-Anne
Buadi, Francis
Schuster, Mindy G.
Idrissi, Mohamed
Heineman, Thomas
Berkowitz, Elchonon M.
TI One-Year Safety and Immunogenicity of Two Formulations of an Adjuvanted
Varicella-Zoster Virus (VZV) Subunit Candidate Vaccine in Adult
Autologous Hematopoietic Cell Transplant (HCT) Recipients
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Stadtmauer, Edward A.; Schuster, Mindy G.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Sullivan, Keith] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Marty, Francisco] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dadwa, Sanjeet S.] City Hope Natl Med Ctr, Duarte, CA USA.
[Papanicoleau, Genovefa A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Shea, Thomas C.] Univ N Carolina, Dept Med, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
[Mossad, Sherif B.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Andreadis, Charalambos] UCSF, BMT, San Francisco, CA USA.
[Young, Jo-Anne] Univ Minnesota, Minneapolis, MN USA.
[Buadi, Francis] UT Blood & Marrow Transplant Ctr, Memphis, TN USA.
[Idrissi, Mohamed] GlaxoSmithKline Vaccines, Wavre, Belgium.
[Heineman, Thomas; Berkowitz, Elchonon M.] GlaxoSmithKline Vaccines, King Of Prussia, PA USA.
RI Young, Jo-Anne/G-2617-2013
OI Young, Jo-Anne/0000-0003-4182-341X
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 107
BP S168
EP S169
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900108
ER
PT J
AU Toro, JJ
Schneider, D
Lee, S
Smith, GM
Gushiken, F
Haile, DJ
Freytes, CO
AF Toro, Juan J.
Schneider, Deanna
Lee, Shuko
Smith, Gregory M.
Gushiken, Francisco
Haile, David J.
Freytes, Cesar O.
TI Is Edentulism Associated with Lower Bacteremia and Transplant-Associated
Toxicities in Patients with Multiple Myeloma?
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Toro, Juan J.; Schneider, Deanna; Lee, Shuko; Smith, Gregory M.; Gushiken, Francisco; Haile, David J.; Freytes, Cesar O.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 322
BP S272
EP S272
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900320
ER
PT J
AU Vander Lugt, M
Braun, T
Hanash, S
Ferrara, JLM
Ritz, J
Ho, VT
Antin, JH
Zhang, Q
Chin, A
Gomez, A
Harris, AC
Levine, JE
Choi, SW
Couriel, DR
Reddy, P
Paczesny, S
AF Vander Lugt, Mark
Braun, Thomas
Hanash, Samir
Ferrara, James L. M.
Ritz, Jerome
Ho, Vincent T.
Antin, Joseph H.
Zhang, Qing
Chin, Alice
Gomez, Aurelie
Harris, Andrew C.
Levine, John E.
Choi, Sung Won
Couriel, Daniel R.
Reddy, Pavan
Paczesny, Sophie
TI Plasma ST2 Concentrations Predict Acute Gvhd Development and Non-Relapse
Mortality
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Vander Lugt, Mark; Ferrara, James L. M.; Gomez, Aurelie; Harris, Andrew C.; Levine, John E.; Choi, Sung Won; Reddy, Pavan] Univ Michigan, Ann Arbor, MI 48109 USA.
[Braun, Thomas; Couriel, Daniel R.; Paczesny, Sophie] Univ Michigan, Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA.
[Hanash, Samir; Zhang, Qing; Chin, Alice] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Ritz, Jerome; Ho, Vincent T.; Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 60
BP S142
EP S143
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900061
ER
PT J
AU Wood, WA
Chai, XY
Weisdorf, DJ
Martin, PJ
Cutler, C
Inamoto, Y
Wolff, D
Pavletic, SZ
Pidala, J
Palmer, J
Arora, M
Arai, S
Jagasia, MH
Storer, B
Lee, SJ
Mitchell, S
AF Wood, William A.
Chai, Xiaoyu
Weisdorf, Daniel J.
Martin, Paul J.
Cutler, Corey
Inamoto, Yoshihiro
Wolff, Daniel
Pavletic, Steven Z.
Pidala, Joseph
Palmer, Jeanne
Arora, Mukta
Arai, Sally
Jagasia, Madan H.
Storer, Barry
Lee, Stephanie J.
Mitchell, Sandra
TI Association of Comorbidity Scoring with Outcome in Patients with Chronic
Graft Versus Host Disease
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Wood, William A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA.
[Chai, Xiaoyu; Inamoto, Yoshihiro; Storer, Barry] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
[Martin, Paul J.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Cutler, Corey] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Wolff, Daniel] Univ Regensburg, Dept Hematol & Clin Oncol, D-93053 Regensburg, Germany.
[Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Pidala, Joseph] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Palmer, Jeanne] Med Coll Wisconsin, Dept Hematol & Oncol, Milwaukee, WI 53226 USA.
[Arora, Mukta] Univ Minnesota, Minneapolis, MN USA.
[Arai, Sally] Stanford Univ, Stanford, CA 94305 USA.
[Jagasia, Madan H.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Mitchell, Sandra] NIH, Res & Practice Dev Serv, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 463
BP S340
EP S341
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900460
ER
PT J
AU Yanik, G
Ho, VT
Horowitz, M
Weisdorf, DJ
Logan, BR
Wu, J
Soiffer, RJ
Wingard, JR
Levine, JE
Ferrara, JLM
Giralt, SA
White, E
Carter, SL
DiFronzo, N
Cooke, KR
AF Yanik, Gregory
Ho, Vincent T.
Horowitz, Mary
Weisdorf, Daniel J.
Logan, Brent R.
Wu, Juan
Soiffer, Robert J.
Wingard, John R.
Levine, John E.
Ferrara, James L. M.
Giralt, Sergio A.
White, Eric
Carter, Shelly L.
DiFronzo, Nancy
Cooke, Kenneth R.
TI Randomized, Double Blind, Placebo-Controlled Trial of a TNF Inhibitor
(ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS)
After Allogeneic Stem Cell Transplant (SCT). A Blood and Marrow
Transplant Clinical Trials Network (BMT CTN) Study
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Yanik, Gregory] Univ Michigan, Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA.
[Ho, Vincent T.] Dana Farber Canc Inst, Dept Pediat Oncol & Stem Cell Transplant, Boston, MA 02115 USA.
[Horowitz, Mary] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA.
[Logan, Brent R.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.
[Wu, Juan; Carter, Shelly L.] EMMES Corp, Rockville, MD USA.
[Soiffer, Robert J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wingard, John R.] Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA.
[Levine, John E.; Ferrara, James L. M.; White, Eric] Univ Michigan, Ann Arbor, MI 48109 USA.
[Giralt, Sergio A.] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY 10021 USA.
[DiFronzo, Nancy] NHLBI, Div Blood Dis & Resources, NIH, Bethesda, MD 20892 USA.
[Cooke, Kenneth R.] Case Western Reserve Univ Hosp, Cleveland, OH 44106 USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 108
BP S169
EP S169
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900109
ER
PT J
AU Yeh, AC
Brunner, AM
Spitzer, TR
Chen, YB
Coughlin, E
McAfee, SL
Ballen, K
Attar, EC
Caron, ML
Preffer, F
Yeap, B
Dey, BR
AF Yeh, Albert C.
Brunner, Andrew M.
Spitzer, Thomas R.
Chen, Yi-Bin
Coughlin, Erin
McAfee, Steven L.
Ballen, Karen
Attar, Eyal C.
Caron, Martin L.
Preffer, Frederick
Yeap, Beow
Dey, Bimalangshu R.
TI Lower Uric Acid Level At the Time of Allogeneic Hematopoietic Cell
Transplantation (HCT) Is Protective Against Acute Graft-Vs-Host-Disease
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Yeh, Albert C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Brunner, Andrew M.; Coughlin, Erin; Ballen, Karen; Preffer, Frederick; Dey, Bimalangshu R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Spitzer, Thomas R.] Massachusetts Gen Hosp, Bone Marrow Transplantat Unit, Boston, MA 02114 USA.
[Chen, Yi-Bin; Attar, Eyal C.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
[McAfee, Steven L.] Massachusetts Gen Hosp, Dept Med, BMT Program, Boston, MA 02114 USA.
[Caron, Martin L.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Yeap, Beow] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 62
BP S143
EP S144
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900063
ER
PT J
AU Yolin, D
Glotzbecker, B
Soiffer, RJ
Antin, J
Alyea, EP
AF Yolin, Deborah
Glotzbecker, Brett
Soiffer, Robert J.
Antin, Joseph
Alyea, Edwin P., III
TI Reducing Inappropriate Testing Following NCCN and IDSA Guidelines in
Autologous Stem Cell Transplant (SCT) Patients
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 13-17, 2013
CL Salt Lake City, UT
C1 [Yolin, Deborah; Glotzbecker, Brett; Soiffer, Robert J.; Alyea, Edwin P., III] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Antin, Joseph] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD FEB
PY 2013
VL 19
IS 2
SU 2
MA 159
BP S193
EP S193
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 083DC
UT WOS:000314441900159
ER
PT J
AU Hendricks, AM
Amara, J
Baker, E
Charns, MP
Gardner, JA
Iverson, KM
Kimerling, R
Krengel, M
Meterko, M
Pogoda, TK
Stolzmann, KL
Lew, HL
AF Hendricks, Ann M.
Amara, Jomana
Baker, Errol
Charns, Martin P.
Gardner, John A.
Iverson, Katherine M.
Kimerling, Rachel
Krengel, Maxine
Meterko, Mark
Pogoda, Terri K.
Stolzmann, Kelly L.
Lew, Henry L.
TI Screening for mild traumatic brain injury in OEF-OIF deployed US
military: An empirical assessment of VHA's experience
SO BRAIN INJURY
LA English
DT Article
DE Afghanistan; blast injuries; brain injuries; depression; Iraq; non-blast
injuries; post-traumatic stress disorder; screening; Veterans
ID POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS;
POLYTRAUMA CLINICAL TRIAD; MENTAL-HEALTH PROBLEMS; VETERANS; IRAQ;
AFGHANISTAN; CARE; TBI; CHALLENGES
AB Background: VHA screens for traumatic brain injury (TBI) among patients formerly deployed to Afghanistan or Iraq, referring those who screen positive for a Comprehensive TBI Evaluation (CTBIE).
Methods: To assess the programme, rates were calculated of positive screens for potential TBI in the population of patients screened in VHA between October 2007 through March 2009. Rates were derived of TBI confirmed by comprehensive evaluations from October 2008 through July 2009. Patient characteristics were obtained from Department of Defense and VHA administrative data.
Results: In the study population, 21.6% screened positive for potential TBI and 54.6% of these had electronic records of a CTBIE. Of those with CTBIE records, evaluators confirmed TBI in 57.7%, yielding a best estimate that 6.8% of all those screened were confirmed to have TBI. Three quarters of all screened patients and virtually all those evaluated (whether TBI was confirmed or not) had VHA care the following year.
Conclusions: VHA's TBI screening process is inclusive and has utility in referring patients with current symptoms to appropriate care. More than 90% of those evaluated received further VHA care and confirmatory evaluations were associated with significantly higher average utilization. Generalizability is limited to those who seek VHA healthcare.
C1 [Hendricks, Ann M.; Baker, Errol; Charns, Martin P.; Gardner, John A.; Iverson, Katherine M.; Krengel, Maxine; Meterko, Mark; Pogoda, Terri K.; Stolzmann, Kelly L.] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Hendricks, Ann M.; Charns, Martin P.; Meterko, Mark; Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Amara, Jomana] USN, Postgrad Sch, DRMI, Monterey, CA USA.
[Iverson, Katherine M.; Krengel, Maxine] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Kimerling, Rachel] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
[Lew, Henry L.] Def & Vet Brain Injury Ctr, Richmond, VA USA.
[Lew, Henry L.] Univ Hawaii Manoa, Honolulu, HI 96822 USA.
RP Hendricks, AM (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave,152 H, Boston, MA 02130 USA.
EM ahendricksphd@gmail.com
OI Charns, Martin/0000-0002-7102-5331; Krengel, Maxine/0000-0001-7632-590X;
Kimerling, Rachel/0000-0003-0996-4212
FU Office of Research and Development, Health Services R&D Service,
Department of Veterans Affairs [SDR 08-405]
FX This paper is based on work supported by the Office of Research and
Development, Health Services R&D Service, Department of Veterans
Affairs, through SDR 08-405. The opinions expressed in this article are
the authors' and do not reflect those of the Department of Veterans
Affairs, the Veterans Health Administration, Health Services Research
and Development, the Defense and Veterans Brain Injury Center or the
Department of Defense. We thank Douglas Bidelspach, David Cifu, Carlos
Tun and three anonymous reviewers for comments on prior versions of this
paper.
NR 41
TC 14
Z9 14
U1 1
U2 11
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
J9 BRAIN INJURY
JI Brain Inj.
PD FEB
PY 2013
VL 27
IS 2
BP 125
EP 134
DI 10.3109/02699052.2012.729284
PG 10
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 083PX
UT WOS:000314478500001
PM 23384211
ER
PT J
AU Drezner, JA
Ackerman, MJ
Anderson, J
Ashley, E
Asplund, CA
Baggish, AL
Borjesson, M
Cannon, BC
Corrado, D
DiFiori, JP
Fischbach, P
Froelicher, V
Harmon, KG
Heidbuchel, H
Marek, J
Owens, DS
Paul, S
Pelliccia, A
Prutkin, JM
Salerno, JC
Schmied, CM
Sharma, S
Stein, R
Vetter, VL
Wilson, MG
AF Drezner, Jonathan A.
Ackerman, Michael John
Anderson, Jeffrey
Ashley, Euan
Asplund, Chad A.
Baggish, Aaron L.
Borjesson, Mats
Cannon, Bryan C.
Corrado, Domenico
DiFiori, John P.
Fischbach, Peter
Froelicher, Victor
Harmon, Kimberly G.
Heidbuchel, Hein
Marek, Joseph
Owens, David S.
Paul, Stephen
Pelliccia, Antonio
Prutkin, Jordan M.
Salerno, Jack C.
Schmied, Christian M.
Sharma, Sanjay
Stein, Ricardo
Vetter, Victoria L.
Wilson, Mathew G.
TI Electrocardiographic interpretation in athletes: the 'Seattle Criteria'
SO BRITISH JOURNAL OF SPORTS MEDICINE
LA English
DT Article
ID ECG INTERPRETATION; ACCURACY
AB Sudden cardiac death (SCD) is the leading cause of death in athletes during sport. Whether obtained for screening or diagnostic purposes, an ECG increases the ability to detect underlying cardiovascular conditions that may increase the risk for SCD. In most countries, there is a shortage of physician expertise in the interpretation of an athlete's ECG. A critical need exists for physician education in modern ECG interpretation that distinguishes normal physiological adaptations in athletes from abnormal findings suggestive of pathology. On 13-14 February 2012, an international group of experts in sports cardiology and sports medicine convened in Seattle, Washington, to define contemporary standards for ECG interpretation in athletes. The objective of the meeting was to develop a comprehensive training resource to help physicians distinguish normal ECG alterations in athletes from abnormal ECG findings that require additional evaluation for conditions associated with SCD.
C1 [Drezner, Jonathan A.; Harmon, Kimberly G.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA.
[Ackerman, Michael John] Mayo Clin, Dept Med, Div Cardiovasc Dis, Rochester, MN USA.
[Ackerman, Michael John] Mayo Clin, Dept Pediat, Div Cardiovasc Dis, Rochester, MN USA.
[Ackerman, Michael John] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Div Cardiovasc Dis, Rochester, MN USA.
[Ackerman, Michael John] Mayo Clin, Div Pediat Cardiol, Rochester, MN USA.
[Anderson, Jeffrey] Univ Connecticut, Dept Athlet, Storrs, CT USA.
[Ashley, Euan; Froelicher, Victor] Stanford Univ, Sch Med, Div Cardiovasc Med, Palo Alto, CA 94304 USA.
[Asplund, Chad A.] Eisenhower Army Med Ctr, Dept Family Med, Ft Gordon, GA USA.
[Baggish, Aaron L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Borjesson, Mats] Karolinska Univ Hosp, Swedish Sch Sports & Hlth Sci, Dept Cardiol, Stockholm, Sweden.
[Cannon, Bryan C.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA.
[Corrado, Domenico] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy.
[DiFiori, John P.] Univ Calif Los Angeles, Dept Family Med, Div Sports Med, Los Angeles, CA USA.
[Fischbach, Peter] Emory Univ, Sch Med, Dept Pediat, Childrens Healthcare Atlanta, Atlanta, GA USA.
[Heidbuchel, Hein] Univ Louvain, Dept Cardiovasc Sci, Louvain, Belgium.
[Marek, Joseph] Midwest Heart Fdn, Oak Brook Terrace, IL USA.
[Owens, David S.; Prutkin, Jordan M.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Paul, Stephen] Univ Arizona, Dept Family & Community Med, Tucson, AZ USA.
[Pelliccia, Antonio] Inst Sport Med & Sci, Dept Med, Rome, Italy.
[Salerno, Jack C.] Seattle Childrens Hosp, Div Cardiol, Seattle, WA USA.
[Schmied, Christian M.] Univ Zurich Hosp, Ctr Cardiovasc, Div Cardiol, CH-8091 Zurich, Switzerland.
[Sharma, Sanjay] St Georges Univ London, Dept Cardivasc Sci, London, England.
[Stein, Ricardo] Hosp Clin Porto Alegre, Dept Cardiol, Porto Alegre, RS, Brazil.
[Vetter, Victoria L.] Childrens Hosp Philadelphia, Div Cardiol, Philadelphia, PA 19104 USA.
[Wilson, Mathew G.] Qatar Orthoped & Sports Med Hosp, ASPETAR, Dept Sports Med, Doha, Qatar.
RP Drezner, JA (reprint author), Univ Washington, Dept Family Med, 1959 NE Pacific St,Box 356390, Seattle, WA 98195 USA.
EM jdrezner@uw.edu
OI Borjesson, Mats/0000-0002-8786-0438; Owens, David/0000-0002-7293-9688
NR 11
TC 166
Z9 169
U1 4
U2 34
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-3674
J9 BRIT J SPORT MED
JI Br. J. Sports Med.
PD FEB
PY 2013
VL 47
IS 3
BP 122
EP 124
DI 10.1136/bjsports-2012-092067
PG 3
WC Sport Sciences
SC Sport Sciences
GA 081VE
UT WOS:000314349700002
PM 23303758
ER
PT J
AU Drezner, JA
Fischbach, P
Froelicher, V
Marek, J
Pelliccia, A
Prutkin, JM
Schmied, CM
Sharma, S
Wilson, MG
Ackerman, MJ
Anderson, J
Ashley, E
Asplund, CA
Baggish, AL
Borjesson, M
Cannon, BC
Corrado, D
DiFiori, JP
Harmon, KG
Heidbuchel, H
Owens, DS
Paul, S
Salerno, JC
Stein, R
Vetter, VL
AF Drezner, Jonathan A.
Fischbach, Peter
Froelicher, Victor
Marek, Joseph
Pelliccia, Antonio
Prutkin, Jordan M.
Schmied, Christian M.
Sharma, Sanjay
Wilson, Mathew G.
Ackerman, Michael John
Anderson, Jeffrey
Ashley, Euan
Asplund, Chad A.
Baggish, Aaron L.
Borjesson, Mats
Cannon, Bryan C.
Corrado, Domenico
DiFiori, John P.
Harmon, Kimberly G.
Heidbuchel, Hein
Owens, David S.
Paul, Stephen
Salerno, Jack C.
Stein, Ricardo
Vetter, Victoria L.
TI Normal electrocardiographic findings: recognising physiological
adaptations in athletes
SO BRITISH JOURNAL OF SPORTS MEDICINE
LA English
DT Article
ID EARLY REPOLARIZATION PATTERN; HYPERTROPHIC CARDIOMYOPATHY;
CLINICAL-SIGNIFICANCE; ECG; PREVALENCE; HEART; CRITERIA; POPULATION;
CARDIOLOGY; CONDUCTION
AB Electrocardiographic changes in athletes are common and usually reflect benign structural and electrical remodelling of the heart as a physiological adaptation to regular and sustained physical training (athlete's heart). The ability to identify an abnormality on the 12-lead ECG, suggestive of underlying cardiac disease associated with sudden cardiac death (SCD), is based on a sound working knowledge of the normal ECG characteristics within the athletic population. This document will assist physicians in identifying normal ECG patterns commonly found in athletes. The ECG findings presented as normal in athletes were established by an international consensus panel of experts in sports cardiology and sports medicine.
C1 [Drezner, Jonathan A.; Fischbach, Peter; Harmon, Kimberly G.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA.
[Fischbach, Peter] Emory Univ, Sch Med, Dept Pediat, Childrens Healthcare Atlanta, Atlanta, GA USA.
[Froelicher, Victor; Ashley, Euan] Stanford Univ, Sch Med, Div Cardiovasc Med, Palo Alto, CA 94304 USA.
[Marek, Joseph] Midwest Heart Fdn, Oak Brook Terrace, IL USA.
[Pelliccia, Antonio] Inst Sport Med & Sci, Dept Med, Rome, Italy.
[Prutkin, Jordan M.; Owens, David S.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Schmied, Christian M.] Univ Zurich Hosp, Div Cardiol, CH-8091 Zurich, Switzerland.
[Sharma, Sanjay] St Georges Univ London, Dept Cardivasc Sci, London, England.
[Wilson, Mathew G.] Qatar Orthoped & Sports Med Hosp, ASPETAR, Dept Sports Med, Doha, Qatar.
[Ackerman, Michael John] Mayo Clin, Dept Med, Div Cardiovasc Dis, Rochester, MN USA.
[Ackerman, Michael John] Mayo Clin, Dept Med, Dept Pediat Cardiol, Rochester, MN USA.
[Ackerman, Michael John] Mayo Clin, Dept Pediat, Rochester, MN USA.
[Ackerman, Michael John] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA.
[Anderson, Jeffrey] Univ Connecticut, Dept Athlet, Storrs, CT USA.
[Asplund, Chad A.] Eisenhower Army Med Ctr, Dept Family Med, Ft Gordon, GA USA.
[Baggish, Aaron L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Borjesson, Mats] Karolinska Univ Hosp, Swedish Sch Sports & Hlth Sci, Dept Cardiol, Stockholm, Sweden.
[Cannon, Bryan C.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA.
[Corrado, Domenico] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy.
[DiFiori, John P.] Univ Calif Los Angeles, Div Sports Med, Los Angeles, CA USA.
[Heidbuchel, Hein] Univ Louvain, Dept Cardiovasc Sci, Louvain, Belgium.
[Paul, Stephen] Univ Arizona, Dept Family & Community Med, Tucson, AZ USA.
[Salerno, Jack C.] Seattle Childrens Hosp, Div Cardiol, Seattle, WA USA.
[Stein, Ricardo] Hosp Clin Porto Alegre, Dept Cardiol, Porto Alegre, RS, Brazil.
[Vetter, Victoria L.] Childrens Hosp Philadelphia, Div Cardiol, Philadelphia, PA 19104 USA.
RP Drezner, JA (reprint author), Univ Washington, Dept Family Med, 1959 NE Pacific St,Box 356390, Seattle, WA 98195 USA.
EM jdrezner@uw.edu
OI Borjesson, Mats/0000-0002-8786-0438; Owens, David/0000-0002-7293-9688
NR 35
TC 48
Z9 50
U1 0
U2 19
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-3674
J9 BRIT J SPORT MED
JI Br. J. Sports Med.
PD FEB
PY 2013
VL 47
IS 3
BP 125
EP +
DI 10.1136/bjsports-2012-092068
PG 13
WC Sport Sciences
SC Sport Sciences
GA 081VE
UT WOS:000314349700003
PM 23303759
ER
PT J
AU Drezner, JA
Ashley, E
Baggish, AL
Borjesson, M
Corrado, D
Owens, DS
Patel, A
Pelliccia, A
Vetter, VL
Ackerman, MJ
Anderson, J
Asplund, CA
Cannon, BC
DiFiori, J
Fischbach, P
Froelicher, V
Harmon, KG
Heidbuchel, H
Marek, J
Paul, S
Prutkin, JM
Salerno, JC
Schmied, CM
Sharma, S
Stein, R
Wilson, M
AF Drezner, Jonathan A.
Ashley, Euan
Baggish, Aaron L.
Borjesson, Mats
Corrado, Domenico
Owens, David S.
Patel, Akash
Pelliccia, Antonio
Vetter, Victoria L.
Ackerman, Michael J.
Anderson, Jeff
Asplund, Chad A.
Cannon, Bryan C.
DiFiori, John
Fischbach, Peter
Froelicher, Victor
Harmon, Kimberly G.
Heidbuchel, Hein
Marek, Joseph
Paul, Stephen
Prutkin, Jordan M.
Salerno, Jack C.
Schmied, Christian M.
Sharma, Sanjay
Stein, Ricardo
Wilson, Mathew
TI Abnormal electrocardiographic findings in athletes: recognising changes
suggestive of cardiomyopathy
SO BRITISH JOURNAL OF SPORTS MEDICINE
LA English
DT Article
ID LEFT-VENTRICULAR NONCOMPACTION; PRIMARY PULMONARY-HYPERTENSION;
BUNDLE-BRANCH BLOCK; DISTINGUISHING HYPERTROPHIC CARDIOMYOPATHY;
CARDIOVASCULAR MAGNETIC-RESONANCE; FAMILIAL DILATED CARDIOMYOPATHY;
ST-SEGMENT ELEVATION; SUDDEN-DEATH; NON-COMPACTION; SYSTOLIC DYSFUNCTION
AB Cardiomyopathies are a heterogeneous group of heart muscle diseases and collectively are the leading cause of sudden cardiac death (SCD) in young athletes. The 12-lead ECG is utilised as both a screening and diagnostic tool for detecting conditions associated with SCD. Fundamental to the appropriate evaluation of athletes undergoing ECG is an understanding of the ECG findings that may indicate the presence of an underlying pathological cardiac disorder. This article describes ECG findings present in cardiomyopathies afflicting young athletes and outlines appropriate steps for further evaluation of these ECG abnormalities. The ECG findings defined as abnormal in athletes were established by an international consensus panel of experts in sports cardiology and sports medicine.
C1 [Drezner, Jonathan A.; Harmon, Kimberly G.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA.
[Ashley, Euan; Froelicher, Victor] Stanford Univ, Sch Med, Div Cardiovasc Med, Palo Alto, CA 94304 USA.
[Baggish, Aaron L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Borjesson, Mats] Karolinska Univ Hosp, Swedish Sch Sports & Hlth Sci, Dept Cardiol, Stockholm, Sweden.
[Corrado, Domenico] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy.
[Owens, David S.; Prutkin, Jordan M.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Patel, Akash; Vetter, Victoria L.] Childrens Hosp Philadelphia, Div Cardiol, Philadelphia, PA 19104 USA.
[Pelliccia, Antonio] Inst Sport Med & Sci, Dept Med, Rome, Italy.
[Ackerman, Michael J.] Mayo Clin, Dept Med, Rochester, MN USA.
[Ackerman, Michael J.] Mayo Clin, Dept Pediat, Rochester, MN USA.
[Ackerman, Michael J.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA.
[Ackerman, Michael J.; Cannon, Bryan C.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA.
[Ackerman, Michael J.] Mayo Clin, Div Pediat Cardiol, Rochester, MN USA.
[Anderson, Jeff] Univ Connecticut, Dept Athlet, Storrs, CT USA.
[Asplund, Chad A.] Eisenhower Army Med Ctr, Dept Family Med, Ft Gordon, GA USA.
[DiFiori, John] Univ Calif Los Angeles, Div Sports Med, Los Angeles, CA USA.
[Fischbach, Peter] Emory Univ, Sch Med, Dept Pediat, Childrens Healthcare Atlanta, Atlanta, GA USA.
[Heidbuchel, Hein] Univ Louvain, Dept Cardiovasc Sci, Louvain, Belgium.
[Marek, Joseph] Midwest Heart Fdn, Oak Brook Terrace, IL USA.
[Paul, Stephen] Univ Arizona, Dept Family & Community Med, Tucson, AZ USA.
[Salerno, Jack C.] Seattle Childrens Hosp, Div Cardiol, Seattle, WA USA.
[Schmied, Christian M.] Univ Zurich Hosp, Div Cardiol, CH-8091 Zurich, Switzerland.
[Sharma, Sanjay] St Georges Univ London, Dept Cardiovasc Sci, London, England.
[Stein, Ricardo] Hosp Clin Porto Alegre, Dept Cardiol, Porto Alegre, RS, Brazil.
[Wilson, Mathew] Qatar Orthoped & Sports Med Hosp, ASPETAR, Dept Sports Med, Doha, Qatar.
RP Drezner, JA (reprint author), Univ Washington, Dept Family Med, 1959 NE Pacific St,Box 356390, Seattle, WA 98195 USA.
EM jdrezner@uw.edu
OI Borjesson, Mats/0000-0002-8786-0438; Owens, David/0000-0002-7293-9688
NR 91
TC 46
Z9 46
U1 0
U2 22
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-3674
J9 BRIT J SPORT MED
JI Br. J. Sports Med.
PD FEB
PY 2013
VL 47
IS 3
BP 137
EP +
DI 10.1136/bjsports-2012-092069
PG 18
WC Sport Sciences
SC Sport Sciences
GA 081VE
UT WOS:000314349700004
PM 23303760
ER
PT J
AU Drezner, JA
Ackerman, MJ
Cannon, BC
Corrado, D
Heidbuchel, H
Prutkin, JM
Salerno, JC
Anderson, J
Ashley, E
Asplund, CA
Baggish, AL
Borjesson, M
DiFiori, JP
Fischbach, P
Froelicher, V
Harmon, KG
Marek, J
Owens, DS
Paul, S
Pelliccia, A
Schmied, CM
Sharma, S
Stein, R
Vetter, VL
Wilson, MG
AF Drezner, Jonathan A.
Ackerman, Michael J.
Cannon, Bryan C.
Corrado, Domenico
Heidbuchel, Hein
Prutkin, Jordan M.
Salerno, Jack C.
Anderson, Jeffrey
Ashley, Euan
Asplund, Chad A.
Baggish, Aaron L.
Borjesson, Mats
DiFiori, John P.
Fischbach, Peter
Froelicher, Victor
Harmon, Kimberly G.
Marek, Joseph
Owens, David S.
Paul, Stephen
Pelliccia, Antonio
Schmied, Christian M.
Sharma, Sanjay
Stein, Ricardo
Vetter, Victoria L.
Wilson, Mathew G.
TI Abnormal electrocardiographic findings in athletes: recognising changes
suggestive of primary electrical disease
SO BRITISH JOURNAL OF SPORTS MEDICINE
LA English
DT Article
ID LONG-QT-SYNDROME; PARKINSON-WHITE-SYNDROME; POLYMORPHIC
VENTRICULAR-TACHYCARDIA; SUDDEN UNEXPLAINED DEATH; HEART-RHYTHM-SOCIETY;
PROPOSED DIAGNOSTIC-CRITERIA; EXPERT CONSENSUS STATEMENT; OF-CARDIOLOGY
FOUNDATION; BRUGADA-SYNDROME; CARDIAC DEATH
AB Cardiac channelopathies are potentially lethal inherited arrhythmia syndromes and an important cause of sudden cardiac death (SCD) in young athletes. Other cardiac rhythm and conduction disturbances also may indicate the presence of an underlying cardiac disorder. The 12-lead ECG is utilised as both a screening and a diagnostic tool for detecting conditions associated with SCD. Fundamental to the appropriate evaluation of athletes undergoing ECG is an understanding of the ECG findings that may indicate the presence of a pathological cardiac disease. This article describes ECG findings present in primary electrical diseases afflicting young athletes and outlines appropriate steps for further evaluation of these ECG abnormalities. The ECG findings defined as abnormal in athletes were established by an international consensus panel of experts in sports cardiology and sports medicine.
C1 [Drezner, Jonathan A.; Harmon, Kimberly G.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA.
[Ackerman, Michael J.] Mayo Clin, Dept Med, Rochester, MN USA.
[Ackerman, Michael J.] Mayo Clin, Dept Pediat, Rochester, MN USA.
[Ackerman, Michael J.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA.
[Ackerman, Michael J.; Cannon, Bryan C.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA.
[Ackerman, Michael J.] Mayo Clin, Div Pediat Cardiol, Rochester, MN USA.
[Corrado, Domenico] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy.
[Heidbuchel, Hein] Univ Louvain, Dept Cardiovasc Sci, Louvain, Belgium.
[Prutkin, Jordan M.; Owens, David S.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Salerno, Jack C.] Seattle Childrens Hosp, Div Cardiol, Seattle, WA USA.
[Anderson, Jeffrey] Univ Connecticut, Dept Athlet, Storrs, CT USA.
[Ashley, Euan; Froelicher, Victor] Stanford Univ, Sch Med, Div Cardiovasc Med, Palo Alto, CA 94304 USA.
[Asplund, Chad A.] Eisenhower Army Med Ctr, Dept Family Med, Ft Gordon, GA USA.
[Baggish, Aaron L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Borjesson, Mats] Karolinska Univ Hosp, Swedish Sch Sports & Hlth Sci, Stockholm, Sweden.
[Borjesson, Mats] Karolinska Univ Hosp, Dept Cardiol, Stockholm, Sweden.
[DiFiori, John P.] Univ Calif Los Angeles, Div Sports Med, Los Angeles, CA USA.
[Fischbach, Peter] Emory Univ, Sch Med, Dept Pediat, Childrens Healthcare Atlanta, Atlanta, GA USA.
[Marek, Joseph] Midwest Heart Fdn, Oak Brook Terrace, IL USA.
[Paul, Stephen] Univ Arizona, Dept Family & Community Med, Tucson, AZ USA.
[Pelliccia, Antonio] Inst Sport Med & Sci, Dept Med, Rome, Italy.
[Schmied, Christian M.] Univ Zurich Hosp, Div Cardiol, CH-8091 Zurich, Switzerland.
[Sharma, Sanjay] St Georges Univ London, Dept Cardiovasc Sci, London, England.
[Stein, Ricardo] Hosp Clin Porto Alegre, Dept Cardiol, Porto Alegre, RS, Brazil.
[Vetter, Victoria L.] Childrens Hosp Philadelphia, Div Cardiol, Philadelphia, PA 19104 USA.
[Wilson, Mathew G.] Qatar Orthoped & Sports Med Hosp, ASPETAR, Dept Sports Med, Doha, Qatar.
RP Drezner, JA (reprint author), Univ Washington, Dept Family Med, 1959 NE Pacific St,Box 356930, Seattle, WA 98195 USA.
EM jdrezner@uw.edu
OI Borjesson, Mats/0000-0002-8786-0438; Owens, David/0000-0002-7293-9688
NR 67
TC 42
Z9 43
U1 0
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-3674
J9 BRIT J SPORT MED
JI Br. J. Sports Med.
PD FEB
PY 2013
VL 47
IS 3
BP 153
EP +
DI 10.1136/bjsports-2012-092070
PG 17
WC Sport Sciences
SC Sport Sciences
GA 081VE
UT WOS:000314349700005
PM 23303761
ER
PT J
AU Dhar, DK
Damink, SWMO
Brindley, JH
Godfrey, A
Chapman, MH
Sandanayake, NS
Andreola, F
Mazurek, S
Hasan, T
Malago, M
Pereira, SP
AF Dhar, Dipok Kumar
Damink, Steven W. M. Olde
Brindley, James Hal
Godfrey, Andrew
Chapman, Michael H.
Sandanayake, Neomal S.
Andreola, Fausto
Mazurek, Sybille
Hasan, Tayyaba
Malago, Massimo
Pereira, Stephen P.
TI Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor
progression in human biliary tract cancer
SO CANCER
LA English
DT Article
DE pyruvate kinase M2; cholangiocarcinoma; invasion; angiogenesis;
diagnosis
ID INTRAHEPATIC CHOLANGIOCARCINOMA; HEPATOCELLULAR-CARCINOMA; PLASMA;
CELLS; SERUM; IDENTIFICATION; METABOLISM; EXPRESSION; DISEASES; TUM2-PK
AB BACKGROUND: The early diagnosis of biliary tract cancer (BTC) remains challenging, and there are few effective therapies. This study investigated whether the M2 isotype of pyruvate kinase (M2-PK), which serves as the key regulator of cellular energy metabolism in proliferating cells, could play a role in the diagnosis and therapy of BTC. METHODS: Plasma and bile M2-PK concentrations were measured by enzyme-linked immunosorbent assay in 88 patients with BTC, 79 with benign biliary diseases, and 17 healthy controls. M2-PK expression was assayed in a BTC tissue array by immunohistochemistry. The role of M2-PK in tumor growth, invasion, and angiogenesis was evaluated in BTC cell lines by retrovirus-mediated M2-PK transfection and short hairpin RNA silencing techniques. RESULTS: Sensitivity (90.3%) and specificity (84.3%) of bile M2-PK for malignancy were significantly higher than those for plasma M2-PK and serum carbohydrate antigen 19-9. M2-PK expression was specific for cancer cells and correlated with microvessel density. M2-PK positivity was a significant independent prognostic factor by multivariable analysis. Transfection of M2-PK in a negatively expressed cell line (HuCCT-1 cells) increased cell invasion, whereas silencing in an M2-PKpositive cell line (TFK cells) decreased tumor nodule formation and cellular invasion. A significant increase in endothelial tube formation was noted when supernatants from M2-PKtransfected cells were added to an in vitro angiogenesis assay, whereas supernatants from silenced cells negated endothelial tube formation. CONCLUSIONS: Bile M2-PK is a novel tumor marker for BTC and correlates with tumor aggressiveness and poor outcome. Short hairpin RNAmediated inhibition of M2-PK indicates the potential of M2-PK as a therapeutic target. Cancer 2013. (C) 2012 American Cancer Society.
C1 [Dhar, Dipok Kumar; Brindley, James Hal; Godfrey, Andrew; Chapman, Michael H.; Sandanayake, Neomal S.; Andreola, Fausto; Pereira, Stephen P.] UCL, Sch Med, UCL Inst Liver & Digest Hlth, London NW3 2PF, England.
[Dhar, Dipok Kumar; Damink, Steven W. M. Olde; Malago, Massimo] UCL, Sch Med, Acad Dept Surg, London NW3 2PF, England.
[Damink, Steven W. M. Olde] Maastricht Univ, Dept Surg, Med Ctr, Maastricht, Netherlands.
[Damink, Steven W. M. Olde] Maastricht Univ, Nutr & Toxicol Res Inst NUTRIM, Maastricht, Netherlands.
[Mazurek, Sybille] Univ Giessen, Inst Vet Physiol & Biochem, D-35390 Giessen, Germany.
[Hasan, Tayyaba] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Pereira, SP (reprint author), UCL, Sch Med, UCL Inst Liver & Digest Hlth, Royal Free Campus, London NW3 2PF, England.
EM stephen.pereira@ucl.ac.uk
FU US National Institutes of Health [PO1CA84203]; UK Medical Research
Council [G0801588]; Charitable Research Fund East and North Herts
National Health Service Trust; Jason Boas Charitable Fund; UK Department
of Health's National Institute for Health Research Biomedical Research
Centres
FX This study was supported in part by US National Institutes of Health
grant PO1CA84203, UK Medical Research Council grant (G0801588), and
Charitable Research Fund East and North Herts National Health Service
Trust. Dipok Kumar Dhar is a Jason Boas Research Fellow, and this work
was partly funded by the Jason Boas Charitable Fund. The work was
undertaken at UCL Hospital/UCL, which receives a proportion of funding
from the UK Department of Health's National Institute for Health
Research Biomedical Research Centres funding scheme.
NR 27
TC 11
Z9 11
U1 1
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 1
PY 2013
VL 119
IS 3
BP 575
EP 585
DI 10.1002/cncr.27611
PG 11
WC Oncology
SC Oncology
GA 075IN
UT WOS:000313878500018
PM 22864959
ER
PT J
AU Lennes, IT
Temel, JS
Hoedt, C
Meilleur, A
Lamont, EB
AF Lennes, Inga T.
Temel, Jennifer S.
Hoedt, Christen
Meilleur, Ashley
Lamont, Elizabeth B.
TI Predictors of newly diagnosed cancer patients' understanding of the
goals of their care at initiation of chemotherapy
SO CANCER
LA English
DT Article
DE elderly; chemotherapy; treatment understanding; limited English
speakers; chemotherapy
ID OF-LIFE CONVERSATIONS; EARLY PALLIATIVE CARE; CELL LUNG-CANCER; HEALTH
LITERACY; COLORECTAL-CANCER; PROGNOSTIC DISCLOSURE; TREATMENT
PREFERENCES; PATIENTS PERCEPTIONS; COMMUNICATION; END
AB BACKGROUND: The American Society of Clinical Oncology Quality Oncology Practice Initiative endorses in their core measures that providers should discuss the goals of care (GOC) at the time of chemotherapy consent. GOC refers to chemotherapy treatment intent: cure versus noncure. In this study, the authors sought to determine whether attributes of patients and initial patient-physician encounters were associated with patients' understanding of their GOC. METHODS: In total, the authors surveyed 125 consecutive, newly diagnosed patients who were receiving chemotherapy for solid malignancies at a single academic cancer center and performed a medical record review for additional data. Patient understanding of their oncologist's GOC and oncologist's reported GOC were compared. The primary outcome was concordance of patient-physician dyads regarding the GOC (cure vs noncure). RESULTS: One hundred twenty-five of 137 of eligible patients (91%) completed the survey. Only 95 of 125 patient-physician pairs (75%) patient-physician pairs were concordant regarding the GOC. In a multivariable logistic regression, both older patients (odds ratio, 0.21; 95% confidence interval, 0.08-0.57) and non-native English speakers had an almost 80% lower odds (odds ratio, 0.23; 95% confidence interval, 0.05-0.93) of GOC concordance compared with younger patients and native English speakers. Patients who received printed chemotherapy information during the patient-physician consent process had almost 3 times greater odds (odds ratio, 2.88; 95% confidence interval, 1.24-6.68) of GOC concordance with their physician compared with those who did not receive materials. CONCLUSIONS: Patient misunderstanding of GOC was substantial, with 25% of cancer patients misunderstanding the goal of their chemotherapy treatment. Key predictors of GOC misunderstanding included factors that potentially were amenable to interventions at the time of chemotherapy consent. Cancer 2013. (C) 2012 American Cancer Society.
C1 [Lennes, Inga T.; Temel, Jennifer S.; Lamont, Elizabeth B.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Lennes, Inga T.; Temel, Jennifer S.; Lamont, Elizabeth B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Meilleur, Ashley; Lamont, Elizabeth B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Hoedt, Christen] Eastern Virginia Med Sch, Norfolk, VA 23501 USA.
RP Lennes, IT (reprint author), Massachusetts Gen Hosp, Ctr Canc, Profess Off Bldg,55 Fruit St, Boston, MA 02114 USA.
EM ilennes@partners.org
FU Cancer Center Program in Cancer Outcomes Research Training (PCORT)
Fellowship (National Institutes of Health) [R25CA092203]
FX This study was supported by a Cancer Center Program in Cancer Outcomes
Research Training (PCORT) Fellowship (National Institutes of Health
grant R25CA092203).
NR 38
TC 6
Z9 6
U1 2
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 1
PY 2013
VL 119
IS 3
BP 691
EP 699
DI 10.1002/cncr.27787
PG 9
WC Oncology
SC Oncology
GA 075IN
UT WOS:000313878500031
PM 23011902
ER
PT J
AU Naito, M
Hainz, U
Burkhardt, UE
Fu, BY
Ahove, D
Stevenson, KE
Rajasagi, M
Zhu, BG
Alonso, A
Witten, E
Matsuoka, KI
Neuberg, D
Duke-Cohan, JS
Wu, CJ
Freeman, GJ
AF Naito, Masayasu
Hainz, Ursula
Burkhardt, Ute E.
Fu, Buyin
Ahove, Deborah
Stevenson, Kristen E.
Rajasagi, Mohini
Zhu, Baogong
Alonso, Anselmo
Witten, Elizabeth
Matsuoka, Ken-ichi
Neuberg, Donna
Duke-Cohan, Jonathan S.
Wu, Catherine J.
Freeman, Gordon J.
TI CD40L-Tri, a novel formulation of recombinant human CD40L that
effectively activates B cells
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE CD40; CD40L; B lymphocytes; Immunotherapy; Antigen-presenting cell
ID HIGH-LEVEL EXPRESSION; T-CELLS; MAMMALIAN-CELLS; GITR LIGAND; IN-VITRO;
PROTEINS; IMMUNITY; IMMUNOTHERAPY; VECTORS; ANTIBODIES
AB CD40L has a well-established role in enhancing the immunostimulatory capacity of normal and malignant B cells, but a formulation suitable for clinical use has not been widely available. Like other TNF family members, in vivo and in vitro activity of CD40L requires a homotrimeric configuration, and growing evidence suggests that bioactivity depends on higher-order clustering of CD40. We generated a novel formulation of human recombinant CD40L (CD40L-Tri) in which the CD40L extracellular domain and a trimerization motif are connected by a long flexible peptide linker. We demonstrate that CD40L-Tri significantly expands normal CD19+ B cells by over 20- to 30-fold over 14 days and induces B cells to become highly immunostimulatory antigen-presenting cells (APCs). Consistent with these results, CD40L-Tri-activated B cells could effectively stimulate antigen-specific T responses (against the influenza M1 peptide) from normal volunteers. In addition, CD40L-Tri could induce malignant B cells to become effective APCs, such that tumor-directed immune responses could be probed. Together, our studies demonstrate the potent immune-stimulatory effects of CD40L-Tri on B cells that enable their expansion of antigen-specific human T cells. The potent bioactivity of CD40L-Tri is related to its ability to self-multimerize, which may be facilitated by its long peptide linker.
C1 [Naito, Masayasu; Hainz, Ursula; Burkhardt, Ute E.; Ahove, Deborah; Rajasagi, Mohini; Alonso, Anselmo; Witten, Elizabeth; Duke-Cohan, Jonathan S.; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Naito, Masayasu; Hainz, Ursula; Burkhardt, Ute E.; Fu, Buyin; Ahove, Deborah; Rajasagi, Mohini; Zhu, Baogong; Alonso, Anselmo; Witten, Elizabeth; Matsuoka, Ken-ichi; Duke-Cohan, Jonathan S.; Wu, Catherine J.; Freeman, Gordon J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Stevenson, Kristen E.; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Duke-Cohan, Jonathan S.; Wu, Catherine J.; Freeman, Gordon J.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA.
RP Freeman, GJ (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA.
EM cwu@partners.org; gordon_freeman@dfci.harvard.edu
OI Duke-Cohan, Jonathan/0000-0002-9478-9609
FU Early Career Physician-Scientist Award of the Howard Hughes Medical
Institute; Blavatnik Family Foundation; Innovative Research Grant of
SU2C/AACR; Leukemia and Lymphoma Translational Research Program;
Damon-Runyon Clinical Investigator award [CI-3807]; NIH [P01 AI056299,
R01-AI089955, P01-AI1054456, 5HSSN266200500030C]; [R01-ITL102532];
[R01-CA155010]
FX We would like especially to thank Drs. Richard Kornbluth, Teru
Hideshima, Tetsuro Sasada, Yutaka Kawano, and Jerome Ritz for their
insightful suggestions. CJW acknowledges support from R01-ITL102532,
R01-CA155010, the Early Career Physician-Scientist Award of the Howard
Hughes Medical Institute, the Blavatnik Family Foundation, an Innovative
Research Grant of SU2C/AACR, the Leukemia and Lymphoma Translational
Research Program, and a Damon-Runyon Clinical Investigator award
(CI-3807). GF is supported by NIH grants P01 AI056299, R01-AI089955,
P01-AI1054456, and 5HSSN266200500030C.
NR 27
TC 8
Z9 9
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD FEB
PY 2013
VL 62
IS 2
BP 347
EP 357
DI 10.1007/s00262-012-1331-4
PG 11
WC Oncology; Immunology
SC Oncology; Immunology
GA 087NN
UT WOS:000314768500013
PM 22926059
ER
PT J
AU Mascaux, C
Feser, WJ
Lewis, MT
Baron, AE
Coldren, CD
Merrick, DT
Kennedy, TC
Eckelberger, JI
Rozeboom, LM
Franklin, WA
Minna, JD
Bunn, PA
Miller, YE
Keith, RL
Hirsch, FR
AF Mascaux, Celine
Feser, William J.
Lewis, Marina T.
Baron, Anna E.
Coldren, Christopher D.
Merrick, Daniel T.
Kennedy, Timothy C.
Eckelberger, John I.
Rozeboom, Leslie M.
Franklin, Wilbur A.
Minna, John D.
Bunn, Paul A.
Miller, York E.
Keith, Robert L.
Hirsch, Fred R.
TI Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; MICRORNA EXPRESSION; DNA HYPERMETHYLATION;
COLORECTAL-CANCER; GENE-EXPRESSION; CIGARETTE-SMOKE; CARCINOGENESIS;
ADENOCARCINOMA; METHYLATION; METASTASIS
AB Lung cancers express lower levels of prostacyclin than normal lung tissues. Prostacyclin prevents lung cancer in a variety of mouse models. A randomized phase II trial comparing oral iloprost (a prostacyclin analog) with placebo in high-risk subjects showed improvement in bronchial histology in former, but not current, smokers. This placebo-controlled study offered the opportunity for investigation of other potential intermediate endpoint and predictive biomarkers to incorporate into chemoprevention trials.
Matched bronchial biopsies were obtained at baseline and at 6-month follow-up from 125 high-risk individuals who completed the trial: 31/29 and 37/28 current/former smokers in the iloprost and placebo arm, respectively. We analyzed the expression of 14 selected miRNAs by Real Time PCR in 496 biopsies.
The expression of seven miRNAs was significantly correlated with histology at baseline. The expression of miR-34c was inversely correlated with histology at baseline (P < 0.0001) and with change in histology at follow-up (P = 0.0003), independent of treatment or smoking status. Several miRNAs were also found to be differentially expressed in current smokers as compared with former smokers. In current smokers, miR-375 was upregulated at baseline (P < 0.0001) and downregulated after treatment with iloprost (P = 0.0023). No miRNA at baseline reliably predicted a response to iloprost.
No biomarker predictive of response to iloprost was found. MiR-34c was inversely correlated with baseline histology and with histology changes. Mir-34c changes at follow-up could be used as a quantitative biomarker that parallels histologic response in formalin-fixed bronchial biopsies in future lung cancer chemoprevention studies. Cancer Prev Res; 6(2); 100-8. (C)2012 AACR.
C1 [Mascaux, Celine; Eckelberger, John I.; Rozeboom, Leslie M.; Bunn, Paul A.; Hirsch, Fred R.] Colorado Sch Publ Hlth, Dept Med, Div Med Oncol, Aurora, CO USA.
[Feser, William J.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
[Lewis, Marina T.; Baron, Anna E.; Merrick, Daniel T.; Franklin, Wilbur A.; Hirsch, Fred R.] Colorado Sch Publ Hlth, Dept Pathol, Aurora, CO USA.
[Coldren, Christopher D.; Kennedy, Timothy C.; Miller, York E.; Keith, Robert L.] Colorado Sch Publ Hlth, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
Univ Colorado, Sch Med, Aurora, CO USA.
[Merrick, Daniel T.; Miller, York E.; Keith, Robert L.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Coldren, Christopher D.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Minna, John D.] Univ Texas SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, Dallas, TX USA.
[Minna, John D.] Univ Texas SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Pharmacol, Dallas, TX USA.
RP Mascaux, C (reprint author), Univ Colorado Denver, Div Med Oncol, 12801 E 17th Ave,Mail Stop 8177, Aurora, CO 80045 USA.
EM celinejmmascaux@gmail.com
FU Specialized Program of Research Excellence (SPORE) Career Development
Award; Lung Cancer Biomarkers and Chemoprevention Consortium (LCBCC);
International Association for the Study of Lung Cancer (IASLC);
Louisiana Chapter of the National Lung Cancer Partnership (NLCP); Gary
L. and Thelissa Zollinger Early Detection of Lung Cancer Endowment Fund;
Colorado SPORE in Lung Cancer [NCI P50 CA58187, NCI RO1 CA164780]; Texas
SPORE in Lung Cancer [P50 CA070907]; Department of Veterans Affairs
Merit Review Program
FX This work was financially supported by a Specialized Program of Research
Excellence (SPORE) Career Development Award (C. Mascaux) and by Lung
Cancer Biomarkers and Chemoprevention Consortium (LCBCC) funds (C.
Mascaux and F.R. Hirsch). C. Mascaux was also supported by a fellowship
from the International Association for the Study of Lung Cancer (IASLC),
a grant from the Louisiana Chapter of the National Lung Cancer
Partnership (NLCP), and a grant from the Gary L. and Thelissa Zollinger
Early Detection of Lung Cancer Endowment Fund. Additional support was
provided from the Colorado SPORE in Lung Cancer NCI P50 CA58187, NCI RO1
CA164780, Texas SPORE in Lung Cancer (P50 CA070907), Department of
Veterans Affairs Merit Review Program (to R.L. Keith).
NR 36
TC 4
Z9 4
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD FEB
PY 2013
VL 6
IS 2
BP 100
EP 108
DI 10.1158/1940-6207.CAPR-12-0382
PG 9
WC Oncology
SC Oncology
GA 086IF
UT WOS:000314676600005
PM 23268837
ER
EF